<SEC-DOCUMENT>0001493152-23-021994.txt : 20230621
<SEC-HEADER>0001493152-23-021994.hdr.sgml : 20230621
<ACCEPTANCE-DATETIME>20230621160149
ACCESSION NUMBER:		0001493152-23-021994
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		15
FILED AS OF DATE:		20230621
DATE AS OF CHANGE:		20230621

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Azitra Inc
		CENTRAL INDEX KEY:			0001701478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				464478536
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-269876
		FILM NUMBER:		231029768

	BUSINESS ADDRESS:	
		STREET 1:		21 BUSINESS PARK DRIVE, SUITE 6
		CITY:			BRANFORD
		STATE:			CT
		ZIP:			06405
		BUSINESS PHONE:		(203) 489-0183

	MAIL ADDRESS:	
		STREET 1:		21 BUSINESS PARK DRIVE, SUITE 6
		CITY:			BRANFORD
		STATE:			CT
		ZIP:			06405
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>form424b4.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
Pursuant to Rule 424(b)(4)<BR>
Registration No. 333-269876</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>1,500,000</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>
Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Common
Stock</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="logo_002.jpg" ALT="" STYLE="height: 84px; width: 370px"></B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Azitra,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="font-family: Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font: 1pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This is a firm commitment initial public offering
of shares of common stock of Azitra, Inc. Prior to this offering, there has been no public market for our common stock. The initial
public offering price of our shares is $5.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock has been approved
for listing on the NYSE American, under the symbol &ldquo;AZTR.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &ldquo;emerging growth company&rdquo; under the federal securities laws and have elected to comply with certain reduced public
company reporting requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our common stock involves a high degree of risk. See the section titled &ldquo;<I><A HREF="#ps_002">Risk Factors</A></I>&rdquo;
beginning on page 11. Neither the Securities and Exchange Commission, or the SEC, nor any state securities commission has approved or
disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal
offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per
                                            Share</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Initial
    public offering price</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">5.00</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">7,500,000</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting
    discounts and commissions<SUP>(1)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">0.375</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">562,500</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds
    to us, before expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">4.625</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">6,937,500</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Underwriting
                                            discounts and commissions do not include a non-accountable expense allowance equal to 1.0%
                                            of the initial public offering price payable to the underwriters. We refer you to &ldquo;<I>Underwriting</I>&rdquo;
                                            beginning on page 105 for additional information regarding underwriters&rsquo; compensation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted a 45-day option to the representative of the underwriters to purchase up to 225,000 additional shares of common stock
solely to cover over-allotments, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters expect to deliver the shares to purchasers on or about, June 21, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>ThinkEquity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus is June 15, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="form424b4_005.jpg" ALT="" STYLE="height: 867px; width: 670px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PAGE</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#ds_001">INDUSTRY AND MARKET DATA</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">ii</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ps_001">PROSPECTUS
    SUMMARY</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#ds_002">SUMMARY RISK FACTORS</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#ds_003">SUMMARY FINANCIAL DATA</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ps_002">RISK
    FACTORS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ps_003">CAUTIONARY
    NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#ds_004">TRADEMARKS, SERVICE MARKS AND TRADE NAMES</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">38</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ps_004">USE
    OF PROCEEDS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ps_005">DIVIDEND
    POLICY</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">40</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ps_006">CAPITALIZATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ps_007">DILUTION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ps_008">MANAGEMENT&rsquo;S
    DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ka_002">BUSINESS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ka_003">MANAGEMENT</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ka_004">PRINCIPAL
    STOCKHOLDERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ka_005">DESCRIPTION
    OF SECURITIES</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">95</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ah_001">SHARES ELIGIBLE FOR FUTURE SALE</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ah_002">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES FOR NON-U.S. HOLDERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ah_003">UNDERWRITING</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ah_004">LEGAL MATTERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">113</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ah_005">EXPERTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">113</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ah_006">WHERE YOU CAN FIND MORE INFORMATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">113</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ah_015">INDEX TO FINANCIAL STATEMENTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">114</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information contained in this prospectus. We have not authorized any other person to provide you with information
different from or in addition to that contained in this prospectus, and we take no responsibility for any other information others may
give you. If anyone provides you with different or inconsistent information, you should not rely on it. We are not making an offer to
sell these securities in any jurisdiction where an offer or sale is not permitted. You should assume that the information appearing in
this prospectus is accurate only as of the date on the front cover of this prospectus. Our business, financial condition, results of
operations and prospects may have changed since that date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
action is being taken in any jurisdiction outside the United States to permit a public offering of our common stock or possession or
distribution of this prospectus in that jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the
United States are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this
prospectus applicable to that jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this prospectus, unless the context indicates or otherwise requires, &ldquo;the Company,&rdquo; &ldquo;our Company,&rdquo; &ldquo;we,&rdquo;
&ldquo;us,&rdquo; and &ldquo;our&rdquo; refer to Azitra, Inc., a Delaware corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="ds_001"></A>INDUSTRY
AND MARKET DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus, particularly the section &ldquo;Business,&rdquo; contains observations, statistical data, estimates, and forecasts that are
based on independent industry, government and non-government organization publications or other publicly available information, as well
as other information based on our internal sources. Although we believe that the third-party sources referred to in this prospectus are
reliable, estimates as they relate to projections involve numerous assumptions, are subject to risks and uncertainties, and are subject
to change based on various factors, including those discussed under the section titled &ldquo;<I>Risk Factors</I>&rdquo; and elsewhere
in this prospectus. These and other factors could cause results to differ materially from those expressed in the estimates made by the
independent parties and by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
information in the text of this prospectus is contained in independent industry government and non-governmental organizational publications.
The sources of these publications are provided below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stacy
    and Belkaid Study<I>, Apollo Stacy and Yasmine </I>Belkaid, Microbial Guardians of Skin Health. Science, 2019 Jan 18;363(6424):227-228.
    Doi: 10.1126/science.aat4326. PMID: 30655428</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oh
    Study, Zhou W, Spoto M, Hardy R, Guan C, Fleming E, Larson PJ, Brown JS, Oh J. Host-Specific Evolutionary and Transmission Dynamics
    Shape the Functional Diversification of Staphylococcus epidermidis in Human Skin. Cell. 2020 Feb 6;180(3):454-470.e18. doi: 10.1016/j.cell.2020.01.006.
    Epub 2020 Jan 30. PMID: 32004459; PMCID</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Satoh
    Study, Satoh TK, Mellett M, Meier-Schiesser B, Fenini G, Otsuka A, Beer HD, Rordorf T, Maul JT, Hafner J, Navarini AA, Contassot
    E, French LE. IL-36&gamma; drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes. J Clin Invest.
    2020 Mar 2;130(3):1417-1430. doi: 10.1172/JCI128678. PMID: 31805013; PMCID: PMC7269569</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Barbati
    Study, Netherton Syndrome in Children: Management and Future Perspectives, Federica Barbati, Mattia Giovannini Teresa Oranges, Lorenzo
    Lodi, Simona Barni, Elio Novembre, Ermanno Baldo, Mario Cristofolini, Stefano Stagi, Silvia Ricci, Francesca Mori, Cesare Filippeschi,
    Chiara Azzari and Giuseppe Indol; Frontiers in Pediatrics, May 2021</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sun
    Study, Netherton syndrome: A case report and review of the literature, Joannie D. Sun, MD, and Kenneth G. Linden, PhD, MD, International
    Journal of Dermatology 2006</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orphanet,
    Netherton Syndrome, &zwnj;Orphanet: Netherton syndrome</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<DIV STYLE="font: 10pt Times New Roman, Times, Serif; border: Black 1.5pt solid; padding-right: 0.1in; padding-left: 0.1in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="ps_001"></A>PROSPECTUS
SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
summary highlights certain information appearing elsewhere in this prospectus. Investing in our common stock involves a high degree of
risk. Because it is only a summary, it does not contain all of the information that you should consider before investing in our common
stock and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere
in this prospectus. Before you decide to invest in our common stock, you should read the entire prospectus carefully, including &ldquo;Risk
Factors&rdquo; beginning on page 11 and the financial statements and related notes included in this prospectus.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>On
May 17, 2023,</I></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I> we effected a forward
stock split at a ratio of 7.1-for-1. All share and share price information in this prospectus have been adjusted to give effect
to the forward stock split.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered
proteins and topical live biotherapeutic products. We have built a
proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened
for unique therapeutic characteristics. The platform is augmented by an artificial intelligence and machine learning technology that
analyzes, predicts and helps screen our library of strains for drug like molecules. The platform also utilizes a licensed genetic engineering
technology, which can enable the transformation of previously genetically intractable strains. Our initial focus is on the development
of genetically engineered strains of <I>Staphylococcus epidermidis, or S. epidermidis, </I>which we consider to be an optimal therapeutic
candidate species for engineering of dermatologic therapies. The particular species demonstrates a number of well-described properties
in the skin. As of the date of this prospectus, we have identified among our microbial library over 60 distinct bacterial species that
we believe are capable of being engineered to create living organisms or engineered proteins with significant therapeutic effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a pioneer in genetically engineered bacteria for therapeutic use in dermatology. Our goal is to leverage our platforms and internal
microbial library bacterial strains to create new therapeutics that are either engineered living organisms or engineered proteins or
peptides to treat skin diseases. Our initial focus is on the development of our current product candidates, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ATR-12</B>,
                                            a genetically modified strain of <I>S. epidermidis</I> for treating the orphan disease, Netherton
                                            syndrome, a chronic and sometimes fatal disease of the skin estimated to affect approximately
                                            one in every 100,000, but its prevalence may be underestimated due to misdiagnosis
                                            caused by similarities to other skin diseases. We received Pediatric Rare Disease Designation
                                            for ATR-12 by the United States Food and Drug Administration, or FDA, in 2019. &zwnj;In
                                            December 2022, we submitted an investigational new drug application, or IND, for a Phase
                                            &zwnj;1b clinical trial of ATR-12 in Netherton syndrome patients&zwnj;, and on
                                            January 27, 2023 we received notification from the FDA that the &ldquo;study may proceed&rdquo;
                                            with respect to the proposed Phase 1b clinical trial. We expect to commence our Phase
                                            &zwnj;1b clinical trial in the first half of 2023 and report initial results in
                                            the first half of 2024.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ATR-04</B>,
                                            a genetically modified strain of <I>S. epidermidis</I> for treating the papulopustular rash
                                            experienced by cancer patients undergoing epidermal growth factor receptor inhibitor, or
                                            EGFRi, targeted therapy. We intend to submit an IND for a Phase 1b clinical trial
                                            in certain cancer patients undergoing EGFRi targeted therapy by the end of 2023. Subject
                                            to FDA approval of our IND, we expect to commence our Phase 1b clinical trial in the
                                            first-half of 2024 with initial results expected as early as late 2024.</FONT></P></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ATR-01</B>,
                                            an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a chronic,
                                            xerotic (abnormally dry), scaly skin disease with an estimated incidence and prevalence of
                                            1 in 250, which suggests a total patient population of 1.3 million in the United States.
                                            We are planning to complete lead optimization and IND-enabling studies in 2023 to support
                                            an IND filing in late 2024.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV STYLE="font: 10pt Times New Roman, Times, Serif; border: Black 1.5pt solid; padding-right: 0.1in; padding-left: 0.1in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
                                            separate strains of bacterial microbes being investigated and developed by us and
                                            Bayer Consumer Care AG, the consumer products division of Bayer AG, or Bayer, the international
                                            life science company. We entered into a Joint Development Agreement, or JDA, with Bayer in
                                            December 2019. Under the terms of the JDA, we are responsible for testing our library of
                                            bacterial strains and their natural products for key preclinical properties. After
                                            screening through hundreds of strains, we and Bayer have selected two particular strains
                                            to move forward. Bayer holds the exclusive option to license the patent rights to these strains.
                                            In December 2020, Bayer purchased $8 million of our Series B preferred stock.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="form424b4_016.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have established partnerships with teams from Carnegie Mellon University and the Fred Hutchinson Cancer Center, or Fred
Hutch, two of the premier academic centers in the United States. Our collaboration with the Carnegie Mellon based team also takes
advantage of the power of whole genome sequencing. This partnership is mining our proprietary library of bacterial strains for novel,
drug like peptides and proteins. The artificial intelligence/machine learning technology developed by this team predicts the molecules
made by microbes from their genetic sequences. The system then compares the predictions to the products actually made through tandem
mass spectroscopy and/or nuclear magnetic resonance imaging to refine future predictions. The predictions can be compared to publicly
available 2D and 3D protein databases to select drug like structures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hold an exclusive, worldwide license from Fred Hutch regarding the use of its patented SyngenicDNA Minicircle Plasmid, or SyMPL, technologies
for all fields of genetic engineering, including to discover, develop and commercialize engineered microbial therapies and microbial-derived
peptides and proteins for skin diseases. We are utilizing our licensed patent rights to build plasmids in order to make genetic transformations
that have never been previously achieved. To date, our team has successfully engineered our lead therapeutic candidates without the
SyMPL technology. However, we believe that SyMPL will open up the ability to make genetic transformations of an expanded universe of
microbial species, and we expect that some or all of our future product candidates will incorporate the SyMPL technology. Our collaboration
with Fred Hutch is led by Dr. Christopher Johnston, an expert in microbial engineering, and the innovator behind the SyMPL technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Bayer
Partnership</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, we entered into a Joint Development Agreement, or JDA, with Bayer pursuant to which we agreed to the joint development
of certain strains selected from our proprietary microbial library. We and Bayer have agreed to cooperate in the identification and <I>in
vitro</I> and <I>ex vivo</I> characterization of microbial strains for topical formulations, which we intend to develop as
potential over-the-counter cosmetic products. Bayer paid us a one-time payment upon execution of the JDA and has agreed to reimburse
us for our development costs. In October 2021, Bayer expanded the option agreement and paid us a second fee for additional characterization
work. We have granted Bayer an option to acquire an exclusive royalty bearing license for up to six strains subject to development activities
under the JDA, including an exclusive royalty bearing license to any related patent rights. Bayer has an option to acquire the exclusive
license rights for a period of six months following our delivery of the results of the JDA development activities to Bayer.
After screening through hundreds of strains, we and Bayer have selected two particular strains to move forward with in vitro and ex vivo
characterization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2020, Bayer&rsquo;s venture capital group, LEAPS by Bayer, purchased $8 million of our Series B preferred stock.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Strategy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
our three lead product candidates and collaboration with Bayer, our goal is to develop a broad portfolio of product candidates focused
on expanding the application of our platforms for precision dermatology. We believe that we have established a unique position in advancing
the development of biologics for precision dermatology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to create a broad portfolio of product candidates for precision dermatology through our development of genetically engineered
proteins selected from our proprietary microbial library of approximately 1,500 unique bacterial strains. Our strategy is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Build
                                            a sustainable precision dermatology company. </I></B>Our goal is to build a leading precision
                                            dermatology company with a sustainable pipeline of product candidates. To that end, we are
                                            focused on rapidly advancing our current pipeline of live biotherapeutic candidates while
                                            actively developing additional product candidates. Each of our current product candidates
                                            are proprietary and subject to pending patent applications. We expect that most, if not all,
                                            genetically engineered product candidates we develop will be eligible for patent protection.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Advance
                                            our lead product candidates, ATR-12 and ATR-04, through clinical trials.</I></B> In Netherton
                                            syndrome patients in 2022, we obtained pre-IND correspondence with the FDA for purposes of
                                            discussing our proposed regulatory pathway for ATR-12 and obtaining guidance from the FDA
                                            on the pre-clinical plan leading to the filing and acceptance of an IND for ATR-12. &zwnj;In
                                            December 2022, we filed an IND for a first-in-human trial of ATR-12 in Netherton syndrome
                                            patients. Our IND proposes a Phase 1b clinical study of ATR-12 in patients with Netherton
                                            syndrome. On January 27, 2023, we received notification from the FDA that the &ldquo;study
                                            may proceed&rdquo; with respect to the proposed Phase 1b clinical trial, and we expect to
                                            commence our Phase 1b clinical trial in the first half of 2023, with initial results
                                            expected in the first half of 2024. We also plan to conduct a Phase &zwnj;1b
                                            trial of our ATR-04 in certain cancer patients undergoing EGFRi therapy&zwnj;, and
                                            expect to file an IND for ATR-04 by the end of 2023.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Broaden
                                            our platform by selectively exploring strategic partnerships that maximize the potential
                                            of our precision dermatology programs.</I></B> We intend to maintain significant rights to
                                            all of our core technologies and product candidates. However, we will continue to evaluate
                                            partnering opportunities in which a strategic partner could help us to accelerate development
                                            of our technologies and product candidates, provide access to synergistic combinations, or
                                            provide expertise that could allow us to expand into the treatment of different types of
                                            skin diseases. We may also broaden the reach of our platform by selectively in-licensing
                                            technologies or product candidates. In addition, we will consider potentially out-licensing
                                            certain of our proprietary technologies for indications and industries that we are not ourselves
                                            pursuing. We believe our genetic engineering techniques and technologies have applicability
                                            outside of the field of medicine, including cosmetics and in the generation of clean fuels
                                            and bioremediation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; border: Black 1.5pt solid; padding-right: 0.1in; padding-left: 0.1in; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Leverage
                                            our academic partnerships. </I></B>We currently have partnerships with investigators at the
                                            Fred Hutchinson Cancer Center, Yale University, Jackson Laboratory for Genomic Medicine,
                                            and Carnegie Mellon University. We expect to leverage these partnerships and potentially
                                            expand them or form other academic partnerships to bolster our engineering platforms and
                                            expand our research and development pipeline.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Expand
                                            on our other potential product candidates. </I></B>Beyond our three lead product candidates,
                                            our goal is to develop a broad portfolio of product candidates focused on expanding the application
                                            of our platforms for precision dermatology. We have a proprietary platform for discovering
                                            and developing therapeutic products for precision dermatology. Our platform is built around
                                            a microbial library comprised of approximately 1,500 unique bacterial strains to allow screening
                                            for unique therapeutic characteristics and utilizes a microbial genetic technology that analyzes,
                                            predicts and engineers the proteins, peptides and molecules made by skin microbes. Our ability
                                            to genetically engineer intractable microbial species is uniquely leveraged by our exclusive
                                            license to the SyMPL technology.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, we own or exclusively license two issued U.S. patents, four pending U.S. patent applications, one pending
PCT application and 38 other foreign national-stage applications, including three European regional-phase applications that are important
to the development of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Leadership Team</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are led by Francisco D. Salva, our chief executive officer, and Travis Whitfill, our co-founder, who have more than 35 years of
combined experience in the management of biotechnology companies and healthcare investing. Mr. Salva was previously a co-founder of Acerta
Pharma, which was sold to AstraZeneca for approximately $6.3 billion in a staged acquisition beginning in 2016. He also worked
on the turnaround of Pharmacyclics, which subsequently sold to Abbvie for approximately $21 billion in 2015. Before that, Mr. Salva spent
almost a decade in life sciences venture capital. Mr. Whitfill served as associate research scientist and assistant professor adjunct
at Yale University with appointments in the Departments of Pediatrics and Emergency Medicine. He has led numerous grant-funded projects,
holds nearly a dozen patents and has co-authored over 50 publications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Competitive Strengths</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra
is a pioneer in genetically engineering bacteria for therapeutic use in dermatology clinical trials. We have built a proprietary platform
that includes a microbial library comprised of approximately 1,500 unique bacterial strains that are screened for therapeutic characteristics
as well as lead drug candidates. Furthermore, we have exclusively licensed a novel technology, which potentially enables the genetic
transformation of previously intractable bacterial microbes. The history of recombinant protein engineering in biotech has traditionally
been limited to less than 20 species. Our licensed technology opens up the potential to genetically engineer thousands of microbial species
to build proteins and peptides that have never been previously built. Our management team has significant experience in discovering,
developing, manufacturing and commercializing therapeutics. The members of our leadership team have specialized expertise developed at
companies including Pharmacyclics, Acerta Pharma, Botanix Pharmaceuticals, and Realm Therapeutics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; border: Black 1.5pt solid; padding-right: 0.1in; padding-left: 0.1in; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Market Opportunity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe there are significant market opportunities to capture in each of our addressable markets. The dermatology market itself has shown
considerable growth over the last decade and is predicted to continue to grow. According to Vision Research Reports, the dermatology
drug market surpassed $17 billion in 2021 and is expected to grow at a compound annual growth rate of 8.8% through 2030. Our first product
candidate to emerge from our platform focuses on the orphan indication of Netherton syndrome. Based on the Barbati and Sun Studies, we
believe that this product candidate represents a potential $250 million global sales opportunity by the mid-2030&rsquo;s. The
diseases we intend to target are well characterized, often by a monogenic genetic mutation. Additionally, the era of genomic sequencing
has ushered in unprecedented progress in genetic testing. The defined molecular pathophysiology of over 100 rare skin diseases has now
been defined.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Our Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated under the laws of the state of Delaware on January 2, 2014<I>. </I>Our principal executive offices are located at 21
Business Park Drive, Branford, Connecticut 06405, and our telephone number is (203) 646-6446. Our website address is www.azitrainc.com.
The information contained in, or accessible through, our website is not incorporated by reference into this prospectus, and you should
not consider any information contained in, or that can be accessed through, our website as part of this prospectus or in deciding whether
to purchase our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own U.S. and foreign registered trademarks, including our company name. All other trademarks or trade names referred to in this prospectus
are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus are referred to
without the symbols &reg; and &trade;, but such references should not be construed as any indication that their respective owners will
not assert, to the fullest extent under applicable law, their rights thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></DIV>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; border: Black 1.5pt solid; padding-right: 0.1in; padding-left: 0.1in; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Private
Placements of our Convertible Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have capitalized our operations through a series of private placements of our convertible preferred stock and convertible promissory
notes, all of which will convert into shares of our common stock upon the consummation of this offering, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            March 2017 placement of 205,385 shares of our Series A convertible preferred stock, at a
                                            price of $16.25 per share, which will convert into 1,458,234 shares of our common
                                            stock upon the consummation of this offering;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            February 2019 placement of 380,657 shares of our Series A-1 convertible preferred stock,
                                            at a price of $37.50 per share, which will convert into 2,958,120 shares of our common
                                            stock upon the consummation of this offering;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            September 2020 placement of 392,000 shares of our Series B convertible preferred stock, at
                                            a price of $43.45 per share, which will convert into 3,277,083 shares of our
                                            common stock upon the consummation of this offering;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            January 2021 placement of a $1 million unsecured convertible promissory note, the principal
                                            amount of which, along with all accrued and unpaid interest thereunder, converted into 23,432
                                            shares of our Series B convertible preferred stock in January 2023; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            September 2022 placement of $4.35 million of our unsecured convertible promissory notes,
                                            the principal amount of which, along with all accrued and unpaid interest thereunder, is
                                            convertible into shares of our common at the per share conversion price equal to
                                            the lower of (i) $30 million divided the number of our shares of common stock issued and outstanding, on a
                                            fully diluted basis, immediately prior to the close of this offering or (ii) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50% of the price per share in
this offering</FONT>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; border: Black 1.5pt solid; padding-right: 0.1in; padding-left: 0.1in; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise indicated, all information in this prospectus concerning our outstanding shares of common stock assumes the automatic conversion
of the above-described shares of convertible preferred stock and convertible notes into a total of approximately 9,542,519 shares
of our common stock upon the consummation of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Changes
to our Capitalization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 17, 2023, we amended and restated our certificate of incorporation to (i) increase our authorized common stock from 1,950,000
shares to 100,000,000 shares, (ii) change the par value of our capital stock from $0.01 to $0.0001, (iii) change our corporate name
from &ldquo;Azitra Inc&rdquo; to &ldquo;Azitra, Inc.&rdquo; and (iv) effect a 7.1-for-1 forward stock split of our outstanding
common stock, or the Stock Split.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Upon the
effectiveness of the registration statement of which this prospectus forms a part, we plan to further amend and restate our
certificate of incorporation to authorize 10,000,000 shares of &ldquo;blank check&rdquo; preferred stock. As a result of the Stock
Split, and after giving effect to the conversion of all outstanding shares of convertible preferred stock and convertible notes
discussed immediately above, we will have 10,586,510 shares of common stock issued and outstanding immediately prior to the
close of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except as otherwise indicated herein, all share and share price
information in this prospectus have been adjusted to give effect to the Stock Split. In addition, except for the financial statements
included elsewhere in this prospectus, and as otherwise indicated herein, all information in this prospectus concerning our outstanding
shares of common stock assumes the automatic conversion of the above-described shares of convertible preferred stock and convertible
notes upon the consummation of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Implications
of Being an Emerging Growth Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Jumpstart Our Business Startups Act, or the JOBS Act, was enacted in April 2012 with the intention of encouraging capital formation in
the United States and reducing the regulatory burden on newly public companies that qualify as &ldquo;emerging growth companies.&rdquo;
We are an emerging growth company within the meaning of the JOBS Act. As an emerging growth company, we may take advantage of certain
exemptions from various public reporting requirements, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            requirement that our internal control over financial reporting be attested to by our independent
                                            registered public accounting firm pursuant to Section 404 of the Sarbanes-Oxley Act of 2002;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
                                            requirements related to the disclosure of executive compensation in this prospectus and in
                                            our periodic reports and proxy statements;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            requirement that we hold a nonbinding advisory vote on executive compensation and any golden
                                            parachute payments; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            ability to delay compliance with new or revised financial accounting standards until private
                                            companies are required to comply with the new or revised financial accounting standard.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may take advantage of the exemptions under the JOBS Act discussed above until we are no longer an emerging growth company. We will remain
an emerging growth company until the earliest to occur of (1) the last day of the fiscal year in which we have $1.07 billion or more
in annual revenue; (2) the date we qualify as a &ldquo;large accelerated filer,&rdquo; with at least $700 million of equity securities
held by non-affiliates; (3) the date on which we have issued, in any three-year period, more than $1.0 billion in non-convertible debt
securities; or (4) the last day of the fiscal year ending after the fifth anniversary of our initial public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may choose to take advantage of some, but not all, of the available benefits under the JOBS Act. We are choosing to take advantage of
all of the other exemptions discussed above. Accordingly, the information contained herein and in our subsequent filing with the SEC
may be different than the information you receive from other public companies in which you hold stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
certain risks related to our status as an emerging growth company, see the disclosure elsewhere in this prospectus under &ldquo;<I>Risk
Factors&mdash;Risks Related to this Offering and Owning Our Common Stock - we are an &lsquo;emerging growth company&rsquo; under the
JOBS Act and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our
common stock less attractive to investors</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Implications
of Being a Smaller Reporting Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we are a &ldquo;smaller reporting company&rdquo; as defined in Rule 10(f)(1) of Regulation S-K. Smaller reporting companies may take
advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements.
We will remain a smaller reporting company until the last day of the fiscal year in which (1) the market value of our common stock held
by non-affiliates equals or exceeds $250 million as of the end of that year&rsquo;s second fiscal quarter, or (2) our annual revenues
equaled or exceeded $100 million during such completed fiscal year and the market value of our common stock held by non-affiliates equals
or exceeds $700 million as of the end of that year&rsquo;s second fiscal quarter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; border: Black 1.5pt solid; padding-right: 0.1in; padding-left: 0.1in; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
OFFERING</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
    Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock offered</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500,000
    shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock to be outstanding after this offering</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">12,086,510 shares (or 12,311,510 shares if
    the underwriters&rsquo; option to purchase additional shares is exercised in full) of common stock.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over-allotment
    option</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have granted the underwriters the option to purchase up to an additional 225,000 shares of our common stock at the initial
    public offering price, less the underwriting discount, within 45 days of the date of this prospectus, to cover over-allotments, if
    any.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
    of proceeds</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            estimate that we will receive net proceeds of approximately $6.5 million from our
                                            sale of common stock in this offering, or approximately $7.5 million if the underwriters
                                            exercise their over-allotment option in full. We intend to use the net proceeds from this offering, along with our existing
                                            cash and cash equivalents, for clinical trials and product development, research and development,
                                            clinical manufacturing as well as for working capital and other general corporate purposes.
                                            See the section titled &ldquo;<I>Use of Proceeds</I>&rdquo; in this prospectus for a more
                                            complete description of the intended use of processed from this offering.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Trading market and symbol</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Our
                                            common stock has been approved for listing on the NYSE American, under the symbol &ldquo;AZTR.&rdquo; </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    factors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
                                            in our common stock involves a high degree of risk. See the section titled &ldquo;<I>Risk
                                            Factors</I>&rdquo; beginning on page 11 and the other information in this prospectus for
                                            a discussion of the factors you should consider carefully before you decide to invest in
                                            our common stock.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lock-Up</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
                                            each of our directors, officers and any stockholder that owns 0.5% or more common
                                            stock have agreed, subject to certain exceptions, not to sell, offer, agree to sell, contract
                                            to sell, hypothecate, pledge, grant any option to purchase, make any short sale of, or otherwise
                                            dispose of or hedge, directly or indirectly, any shares of our capital stock or any securities
                                            convertible into or exercisable or exchangeable for shares of capital stock, for a period
                                            of six (6) months or twelve (12) months, as applicable, after the date of this
                                            prospectus, without the prior written consent of the representative. Following the expiration
                                            of the applicable lock-up period, all of the issued and outstanding shares of our common
                                            stock will be eligible for future sale, subject to the applicable volume, manner of sale,
                                            holding period, and other limitations of Rule 144. See the section of this prospectus entitled
                                            &ldquo;<I>Underwriting</I>&rdquo; for additional information.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; border: Black 1.5pt solid; padding-right: 0.1in; padding-left: 0.1in; margin-bottom: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of our common stock to be outstanding after this offering is based on 10,586,510 shares of our common stock outstanding
as of June 2, 2023 (after giving effect to the Stock Split and the conversion of our shares of convertible preferred stock and
convertible promissory notes described above), and excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,290,319
                                            </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
                                            of our common stock issuable upon exercise of outstanding options, with a weighted average
                                            exercise price of $1.33 per share, granted pursuant to our 2016 Stock Incentive Plan,
                                            or the 2016 Plan;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately
                                            275,210 shares of our common stock issuable upon exercise of outstanding warrants,
                                            with a weighted average exercise price of $4.23 per share</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">up
                                            to 225,000 shares issuable pursuant to the underwriters&#8217; over-allotment option;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60,000
                                            </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
                                            issuable upon exercise of a warrant to be issued to the underwriter as part of its compensation
                                            in connection with this offering (up to 69,000 shares if the over-allotment option
                                            is exercised in full) at an exercise price of $6.25 per share; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">157,989
                                            </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
                                            of our common stock reserved for future grants under our 2016 Plan and 2,000,000 shares
                                            of our common stock reserved for future grants under our 2023 Stock Incentive Plan, or the
                                            2023 Plan.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
we indicate otherwise or unless the context otherwise requires, all information in this prospectus assumes the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            automatic conversion of all outstanding shares of our convertible preferred stock and all
                                            of our convertible promissory notes upon the close of this offering;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
                                            exercise of outstanding warrants or options described above; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
                                            exercise of the underwriters&#8217; over-allotment option.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ds_002"></A>SUMMARY
RISK FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to numerous risks, including risks that may prevent us from achieving our business objectives or adversely affect
our business, results of operations, cash flows, and prospects, to consider before investing in our common stock. These risks are further
discussed in the section &ldquo;<I>Risk Factors</I>&rdquo; immediately following this prospectus summary<I>. </I>Some of those risks
include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    are an early-stage clinical biopharmaceutical company with limited operating history;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    have a history of significant operating losses and anticipate continued operating losses for the foreseeable future;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    expect we will need additional financing to execute our business plan and fund operations, which additional financing may not be
    available on reasonable terms or at all;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    clinical and commercial utility of our microbial library and genetic engineering platform is uncertain and may never be realized;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    product candidates are in early stages of development, and therefore they will require extensive additional preclinical and clinical
    testing;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ongoing COVID-19 pandemic could adversely impact our business, including our clinical trials, supply chain and business development
    activities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    will need to grow the size of our organization, and we may experience difficulties in managing this growth;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    currently have no sales and marketing organization;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    will be completely dependent for the foreseeable future on third parties to manufacture our product candidates for commercial sale;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    business model includes the potential out-licensing of strains from our proprietary microbial library or our product candidates to
    other pharmaceutical companies, however technology licensing in the pharmaceutical industry is a lengthy process and subject to several
    risks and factors outside of our control;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    business may suffer with the loss of key personnel;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization
    of our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    business operations could suffer in the event of information technology systems&rsquo; failures or security breaches;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    face significant competition from other biotechnology and pharmaceutical companies targeting medical dermatological indications;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    success is entirely dependent on our ability to obtain the marketing approval for our product candidates by the FDA and the regulatory
    authorities in foreign jurisdictions in which we intend to market our product candidates, of which there can be no assurance;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates or any future product
    candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">results
    of preclinical studies of our product candidates may not be predictive of the results of future preclinical studies or clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">even
    if we receive regulatory approval for any of our product candidates, we may not be able to successfully commercialize the product
    and the revenue that we generate from its sales, if any, may be limited;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">current
    and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product
    candidates and affect the prices we may obtain;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
    is difficult and costly to protect our intellectual property rights, and we cannot ensure the protection of these rights;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    product candidates may infringe the intellectual property rights of others, which could increase our costs and delay or prevent our
    development and commercialization efforts;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    active, liquid and orderly trading market for our shares may not develop;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">future
    capital raises may dilute your ownership and have other adverse effects on our operations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    market price of our shares may be subject to fluctuation and volatility;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our
    financial results or prevent fraud;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    ratified certain corporate actions pursuant to Section 204 of the Delaware General Corporate Law, or DGCL, however there can be no
    assurance that claims will not be made to challenge the validity of the ratification or the related corporate actions; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    charter documents and Delaware law may inhibit a takeover that stockholders consider favorable.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="ds_003"></A>Summary
Financial Data</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarize our financial data. You should read this summary financial data together with the section entitled &ldquo;<I>Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations</I>&rdquo; and our financial statements and related notes that
are included elsewhere in this prospectus. The financial information as of and for the fiscal years ended December 31, 2022 and 2021
is derived from the audited financial statements that are included elsewhere in this prospectus. The financial information for the
three months ended March 31, 2023 and 2022 are derived from our unaudited financial statements included elsewhere in this prospectus.
The unaudited financial statements were prepared on the same basis as the audited financial statements. Our management believes that
the unaudited financial statements reflect all adjustments necessary for the fair presentation of the financial condition and results
of operations for such periods. Our historical results are not necessarily indicative of the results that may be expected in the
future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Three Months
                                            Ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
                                            31</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Years
                                            Ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
                                            31,</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid">(in thousands, except share amounts)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(unaudited)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(unaudited)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%">Revenues</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">113</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">120</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">284</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">110</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2,457</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2,326</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(10,680</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(8,940</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss per share, basic
    and diluted</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(3.00</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2.86</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(12.74</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(11.20</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss &ndash; pro forma
    and pro forma as adjusted<SUP>(1)(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">$</P></TD><TD STYLE="vertical-align: bottom; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">(5,006</P></TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">(2,310</P></TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(14,014</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(8,940</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss per share, basic and
    diluted &ndash; pro forma<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">$</P></TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">(0.48</P></TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">(0.22</P></TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1.32</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.85</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss per share, basic and diluted &ndash; pro forma
    as adjusted<SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">(0.39</P></TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">(0.19</P></TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1.08</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.69</TD><TD STYLE="text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">(in thousands)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Actual</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pro
    Forma<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pro
    Forma as<BR> Adjusted<SUP>(2)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Balance Sheet Data:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 52%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1,833</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1,833</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">8,346</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Working capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">361</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">361</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6,874</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,655</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,655</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12,168</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible notes payable<SUP>(4)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6,400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Convertible preferred stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(34,819</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,093</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">46,024</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">51,368</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total stockholders&rsquo; equity (deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(38,679</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,550</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8,894</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0">The pro forma loss per share includes a $2.8 million loss upon conversion
of our convertible promissory notes, and the pro forma column reflects the (i) Stock Split, (ii) automatic conversion of all of our outstanding
shares of convertible preferred stock at the close of this offering into 7,693,436 shares of our common stock and reclassification into
common stock, and (iii) automatic conversion of all principal and accrued and unpaid interest under our outstanding convertible promissory
notes at the close of this offering into approximately 1,838,775 shares of our common stock and additional paid-in capital, .</P></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            pro forma as adjusted column reflects all adjustments included in the pro forma column and
                                            gives effect to the sale by us of 1,500,000 shares of common stock offered by this prospectus,
                                            at an initial public offering price of $5.00 per share, after deducting underwriting
                                            discounts and commissions and estimated offering costs payable by us.</FONT></TD></TR>
                                                                                                                                      <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
                                            the fair value of the convertible note as we have elected to account for the instrument at
                                            its fair value</FONT></P></TD></TR>
                                                                                                                                      </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="ps_002"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Any
investment in our common stock involves a high degree of risk. You should carefully consider the risks described below, which we believe
represent certain of the material risks to our business, together with the information contained elsewhere in this prospectus, before
you make a decision to invest in our common stock. Please note that the risks highlighted here are not the only ones that we may face.
For example, additional risks presently unknown to us or that we currently consider immaterial or unlikely to occur could also impair
our operations. If any of the following events occur or any additional risks presently unknown to us actually occur, our business, financial
condition and operating results may be materially adversely affected. In that event, the trading price of our common stock could decline
and you could lose all or part of your investment.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Relating to Our Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are an early-stage clinical biopharmaceutical company with limited operating history</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an early-stage clinical biopharmaceutical company, incorporated on January 2, 2014, and have limited operating history. We
have not commenced revenue-producing operations apart from limited grant and service revenue. To date, our operations have consisted
of the development of our proprietary microbial library, the identification, characterization, genetic engineering and testing of certain
bacterial species to provide therapeutic effect and the development of our initial product candidates. Our limited operating history
makes it difficult for potential investors to evaluate our technology or prospective operations. As an early-stage clinical biopharmaceutical
company, we are subject to all the risks inherent in the organization, financing, expenditures, complications and delays involved with
a new business. Accordingly, you should consider our prospects in light of the costs, uncertainties, delays and difficulties frequently
encountered by companies in the early stages of development, especially early-stage clinical-stage biopharmaceutical companies
such as ours. Potential investors should carefully consider the risks and uncertainties that a company with a limited operating history
will face. In particular, potential investors should consider that we may be unable to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
                                            implement or execute our business plan, or that our business plan is sound;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
                                            complete pre-clinical and clinical trials and obtain regulatory approval for the marketing
                                            of our product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
                                            demonstrate a favorable differentiation between our precision dermatological product candidates
                                            and the current products on the market;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
                                            contract for the manufacture of our clinical drug products and establish a commercial drug
                                            supply;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">secure
                                            market exclusivity or adequate intellectual property protection for our product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract
                                            and retain an experienced management and advisory team; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">raise
                                            sufficient funds in the capital markets to effectuate our business plan, including product
                                            and clinical development, regulatory approval and commercialization for our product candidates.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investors
should evaluate an investment in us in light of the uncertainties encountered by developing companies in a competitive environment. There
can be no assurance that our efforts will be successful or that we will ultimately be able to attain profitability. If we cannot successfully
execute any one of the foregoing, our business may not succeed and your investment will be adversely affected. You must be prepared to
lose all of your investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have a history of significant operating losses and anticipate continued operating losses for the foreseeable future</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal years ended December 31, 2022 and 2021, we incurred a net loss of $10.7 million and $8.9 million, respectively, and $2.5&nbsp;million
and $2.3&nbsp;million for the three months ended March 31, 2023 and 2022, respectively. As of March 31, 2023, we had
an accumulated deficit of $39.8 million. Following completion of this offering, we expect to continue to incur substantial expenses
without any meaningful revenues unless and until we are able to obtain regulatory approval and successfully commercialize at least one
of our product candidates. We also believe that, at a minimum, it will take us four to six years from the closing of the offering for
us to obtain regulatory approval of our first drug candidates, assuming we are able to get regulatory approval at all. Even if we are
able to commercialize our product candidates, there can be no assurance that we will generate significant revenues or ever achieve profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to have significant research, regulatory and development expenses as we advance our product candidates towards commercialization.
As a result, we expect to incur substantial losses for the foreseeable future, and these losses will be increasing. We are uncertain
when or if we will be able to achieve or sustain profitability. If we achieve profitability in the future, we may not be able to sustain
profitability in subsequent periods. Failure to become and remain profitable may impair our ability to sustain operations and adversely
affect our business and our ability to raise capital. If we are unable to generate positive cash flow within a reasonable period of time,
we may be unable to further pursue our business plan or continue operations, in which case you may lose your entire investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
report of our independent registered public accounting firm for the year ended December 31, 2022 and the three months ended March
31, 2023 states that due to our accumulated deficit, recurring and negative cash flow from operations there is substantial doubt
about our ability to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
expect we will need additional financing to execute our business plan and fund operations, which additional financing may not be available
on reasonable terms or at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2023, we had total assets of $5.7 million and working capital of $361 thousand. We believe
that net proceeds of this offering, along with our cash on hand as of the date of this prospectus, will be sufficient to cover our proposed
plan of operations over, at least, the next 12 months, including dosing in the proposed Phase 1b clinical trial for ATR-12 and the initial
enrollment in the proposed Phase 1b clinical trial for ATR-04. However, as of the date of this prospectus, we believe that we will need
additional capital beyond the next 12 months, and there can be no assurance we will not need additional capital sooner. In addition,
we believe that we will need additional capital to obtain marketing approval for ATR-12 and ATR-04, assuming such approval can be obtained
at all. We intend to seek additional funds through various financing sources, including the sale of our equity and debt securities, licensing
fees for our technology and joint ventures with industry partners. In addition, we will consider alternatives to our current business
plan that may enable to us to achieve revenue producing operations and meaningful commercial success with a smaller amount of capital.
However, there can be no guarantees that such funds will be available on commercially reasonable terms, if at all. If such financing
is not available on satisfactory terms, we may be unable to further pursue our business plan and we may be unable to continue operations,
in which case you may lose your entire investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
clinical and commercial utility of our microbial library and genetic engineering platform is uncertain and may never be realized. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can
be screened for unique therapeutic characteristics. The platform is augmented by artificial intelligence, machine learning and genetic
engineering technologies. To date, our focus is on the development of genetically engineered strains of <I>S. epidermidis, </I>which
we consider to be an optimal therapeutic candidate species for engineering of dermatologic therapies. However, we believe that the genetic
engineering of <I>S. epidermidis</I> is a novel and unproven mode of therapy. As of the date of this prospectus, we have tested and evaluated
our proprietary strains of <I>S. epidermidis</I> in pre-clinical studies and have not conducted any clinical trials designed to evaluate
safety, tolerability or efficacy. We currently intend to commence a Phase 1b clinical trial for our ATR-12 in
the first half of 2023 and a Phase 1b clinical trial for our ATR-04 product candidate in the first half of 2024. However, success
in early clinical trials does not ensure that large-scale clinical trials will be successful, nor does it predict final results. Even
after the completion of our proposed Phase 1b clinical trials, our initial product candidates will have only been tested
in a small number of patients. Results from these clinical trials may not necessarily be indicative of the safety and tolerability or
efficacy of our product candidates or our as we expand into larger clinical trials. Until such time, if ever, as we are able to provide
the FDA with substantial clinical evidence to support a claim of safety, efficacy, purity and potency sufficient to enable the FDA to
approve our proprietary product candidates for any indication, our proprietary microbial library and genetic engineering platform will
remain unproven.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
product candidates are in early stages of development, and therefore they will require extensive additional preclinical and clinical
testing. Success in preclinical studies or early-stage clinical trials may not be indicative of results in future clinical trials and
we cannot assure you that any ongoing, planned or future clinical trials will lead to results sufficient for the necessary regulatory
approvals. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
our product candidates are in early stages of development, they will require extensive preclinical and clinical testing. ATR-12 and ATR-04
are our only product candidates for which we have conducted meaningful pre-clinical studies. Following this offering we expect to commence
a Phase 1b clinical trial for ATR-12 in the first half of 2023 and file an IND for a Phase 1b clinical trial of ATR-04
by the end of 2023. Success in preclinical testing and early-stage clinical trials does not ensure that later clinical trials will generate
the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate. Preclinical studies
and Phase 1b clinical trials are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics and to understand
the side effects of product candidates at various doses and schedules. Phase 1b clinical trials also test how well a certain disease
responds to a new treatment. Success in preclinical studies and earlier clinical trials does not ensure that later efficacy trials will
be successful, nor does it predict final results. Our product candidates may fail to show the desired safety and efficacy in clinical
development despite positive results in preclinical studies or even if they successfully advance through earlier clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the design of a clinical trial can determine whether its results will support approval of a product, and flaws in the design
of a clinical trial may not become apparent until the clinical trial is well advanced. As an organization, we have limited experience
designing clinical trials and may be unable to design and execute a clinical trial to support regulatory approval. Many companies in
the pharmaceutical and biotechnology industries have suffered significant setbacks, including failure in late-stage clinical trials even
after achieving promising results in preclinical testing and earlier clinical trials. Data obtained from preclinical and clinical activities
are subject to varying interpretations, which may delay, limit or prevent regulatory approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
we cannot predict with any certainty if or when we might submit a Biologics License Application, or BLA, for regulatory approval
for any of our product candidates or whether any such BLA will be accepted for review by the FDA, or whether any BLA will be approved
upon review. Even if our clinical trials are completed as planned, we cannot be certain that their results will support our proposed
indications. Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful,
and we cannot be sure that the results of later clinical trials will replicate the results of prior clinical trials and preclinical testing.
The clinical trial process may fail to demonstrate that our product candidates are safe and effective for their proposed uses. This failure
could cause us to abandon a product candidate and may delay development of other product candidates. Any delay in, or termination of,
our clinical trials will delay and possibly preclude the filing of any BLAs with the FDA and, ultimately, our ability to commercialize
our product candidates and generate product revenues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
ongoing COVID-19 pandemic could adversely impact our business, including our clinical trials, supply chain and business development
activities. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the ongoing COVID-19 pandemic, governments have implemented significant measures, including closures of businesses, quarantines,
travel restrictions and other social distancing directives, intended to control the spread of the virus. While the disease and countermeasures
have abated to some degree in recent months, the impact of this pandemic will likely continue to be extensive in many aspects of society
and will likely continue to result in significant disruptions to the global economy, as well as businesses and capital markets around
the world. Many pharmaceutical companies have experienced delays and suspensions of their clinical trials due to the ongoing COVID-19
pandemic, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
                                            or difficulties in enrolling and maintaining patients in their clinical trials;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
                                            or difficulties in shipping and delivering in a timely manner supplies, samples or products
                                            required for their clinical trials due to the impact of the ongoing COVID-19 pandemic on
                                            government and commercial shipping organizations;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
                                            or difficulties in clinical site initiation, including difficulties completing any required
                                            contracts, successfully completing IRB review in a timely manner, or in recruiting clinical
                                            site investigators and clinical site staff;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruptions
                                            in supply chains that result in shortages of required raw materials, manufacturing devices,
                                            active pharmaceutical ingredients, and finished product for our preclinical research and
                                            clinical trials; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in local regulations as part of a response to the ongoing COVID-19 outbreak which may require
                                            us to change the ways in which our clinical trials are conducted, which may result in unexpected
                                            costs, or cause us to discontinue the clinical trials altogether.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
and other disruptions in our operations and the global economy could negatively impact our business, operating results and financial
condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will need to grow the size of our organization, and we may experience difficulties in managing this growth</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As our development
and commercialization plans and strategies develop, we will need to expand the size of our employee and consultant/contractor base. Future
growth would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain, motivate
and integrate additional employees. In addition, our management may have to divert a disproportionate amount of its attention away from
our day-to-day activities and devote a substantial amount of time to managing these growth activities. Our future financial performance
and our ability to commercialize our product candidates and any other future product candidates and our ability to compete effectively
will depend, in part, on our ability to effectively manage our future growth.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business
strategy. In addition, the loss of the services of our senior management would adversely impact our business prospects</I></B>. Our management
team has expertise in many different aspects of drug development and commercialization. However, our ability to compete in the highly
competitive pharmaceuticals industry depends in large part upon our ability to attract and retain highly qualified managerial, scientific
and medical personnel. We will need to hire additional personnel as we further develop our product candidates. Competition for skilled
personnel in our market is intense and competition for experienced scientists may limit our ability to hire and retain highly qualified
personnel on acceptable terms. Despite our efforts to retain valuable employees, members of our management, scientific and medical teams
may terminate their employment with us on short notice. The loss of the services of any of our executive officers or other key employees,
or our inability to hire targeted executives, could potentially harm our business, operating results or financial condition. In particular,
we believe that the loss of the services of our chief executive officer would have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
biopharmaceutical companies with which we compete for qualified personnel have greater financial and other resources, different risk
profiles, and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career
advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable
to continue to attract and retain high-quality personnel, the rate and success at which we can develop and commercialize product candidates
would be limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
currently have no sales and marketing organization. If we are unable to establish satisfactory sales and marketing capabilities or secure
a third-party sales and marketing relationship, we may not be able to successfully commercialize any of our product candidates</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At present, we have no sales or marketing personnel. Upon and subject to initial receipt of the requisite regulatory approvals for one
or more of our drug products, we plan to build focused capabilities in the United States to commercialize our development programs focused
on live biotherapeutic products and recombinant proteins for the treatment of skin diseases, where we believe the patient populations
and medical specialists for the indications we are targeting are sufficiently concentrated to allow us to effectively promote our products
with a targeted sales team. In other markets for which commercialization may be less capital efficient for us, we may selectively pursue
strategic collaborations with third parties in order to maximize the commercial potential of our product candidates. In some cases, we
may pursue the licensing of our microbial library or patent rights or enter into a joint development arrangement. If we are not successful
in recruiting sales and marketing personnel and building a sales and marketing infrastructure or entering into appropriate collaboration
arrangements with third parties, we will have difficulty successfully commercializing our product candidates, which would adversely affect
our business, operating results and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we enter into third-party marketing and distribution arrangements, we may have limited or no control over the sales, marketing and
distribution activities of these third parties. Our future revenues may depend heavily on the success of the efforts of these third parties.
In terms of establishing a sales and marketing infrastructure, we will have to compete with established and well-funded pharmaceutical
and biotechnology companies to recruit, hire, train and retain sales and marketing personnel. Factors that may inhibit our efforts to
build an internal sales organization or enter into collaboration arrangements with third parties include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            inability to recruit and retain adequate numbers of effective sales and marketing personnel;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            inability of sales personnel to obtain access to or persuade adequate numbers of physicians
                                            to prescribe any of our product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            lack of complementary products to be offered by sales personnel, which may put us at a competitive
                                            disadvantage relative to companies with more extensive product lines; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
                                            costs and expenses associated with creating an internal sales and marketing organization.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will be completely dependent for the foreseeable future on third parties to manufacture our product candidates for commercial sale,
and the commercialization of our product candidates could be halted, delayed or made less profitable if those third parties fail
to obtain manufacturing approval from the FDA or comparable foreign regulatory authorities, fail to provide us with sufficient quantities
of our product candidates or fail to do so at acceptable quality levels or prices</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not own or operate manufacturing facilities for the commercial production of our current product candidates. We currently rely
on third-party contract manufacturers for all of our required raw materials, manufacturing devices, and active pharmaceutical ingredients
for our preclinical research and clinical trials. Although we are able to manufacture finished product in our Groton Connecticut facility
for our clinical trials, we will rely on third parties for the manufacture of our finished product for commercial sale. We do not have
long-term agreements with any of these third parties. We also do not have any current contractual relationship for commercial supplies.
We intend to enter into agreements with third-party contract manufacturers and one or more backup manufacturers for future production.
We are analyzing the feasibility of building manufacturing capabilities for future development and commercial quantities of any products
that we develop. Such products will need to be manufactured in facilities, and by processes, that comply with the requirements of the
FDA and the regulatory agencies of other jurisdictions in which we are seeking approval. In the meantime, we will be obligated to rely
on contract manufacturers for our preclinical research and clinical trials and commercial production, if and when any of our product
candidates are approved for commercialization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
facilities used by us or any contract manufacturer to manufacture our raw materials, manufacturing devices, active pharmaceutical ingredients
and finished products must be approved by the FDA or comparable foreign regulatory authorities. Such approvals are subject to inspections
that will be conducted after we submit a BLA to the FDA or their equivalents to other relevant regulatory
authorities. Until such time, if ever, as we establish our own manufacturing facilities, we will not control the manufacturing process
of our product candidates, and will be completely dependent on our contract manufacturing partners for compliance with Current Good Manufacturing
Practices, or cGMPs, for manufacture of our raw materials, manufacturing devices, active pharmaceutical ingredients and finished products.
These cGMP regulations cover all aspects of the manufacturing, testing, quality control, storage, distribution and record keeping relating
to our product candidates. If our contract manufacturers do not successfully manufacture material that conforms to our specifications
and the strict regulatory requirements of the FDA or others, we will not be able to secure or maintain regulatory approval for product
made at their manufacturing facilities. If the FDA or a comparable foreign regulatory authority does not approve these facilities for
the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing
facilities, which could significantly delay our clinical trials and impact our ability to develop, manufacture, obtain regulatory approval
for or market our product candidates, if approved. Likewise, we could be negatively impacted if any of our contract manufacturers elect
to discontinue their business relationship with us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
contract manufacturers will be subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign agencies
for compliance with cGMPs and similar regulatory requirements. We will not have control over our contract manufacturers&rsquo; compliance
with these regulations and standards. Failure by any of our contract manufacturers to comply with applicable regulations could result
in sanctions being imposed on us, including fines, injunctions, civil penalties, failure to grant approval to market any of our product
candidates, delays, suspensions or withdrawals of approvals, inability to supply product, operating restrictions and criminal prosecutions,
any of which could significantly and adversely affect our business. In addition, we will not have control over the ability of our contract
manufacturers to maintain adequate quality control, quality assurance and qualified personnel. Failure by our contract manufacturers
to comply with or maintain any of these standards could adversely affect our ability to develop, manufacture, obtain regulatory approval
for or market any of our product candidates, if approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
for any reason, these third parties are unable or unwilling to perform we may not be able to locate alternative manufacturers or formulators
or enter into favorable agreements with them and we cannot be certain that any such third parties will have the manufacturing capacity
to meet future requirements. If these manufacturers or any alternate manufacturer of finished drug product experiences any significant
difficulties in its respective manufacturing processes for our required raw materials, manufacturing devices, active pharmaceutical ingredients
or finished product or should cease doing business with us for any reason, we could experience significant delays in our clinical trials
and significant interruptions in the supply of any of our product candidates or may not be able to create a supply of our product candidates
at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
manufacturing problem or the loss of a contract manufacturer could be disruptive to our operations and result in development and clinical
trial delays and lost sales. Additionally, we will rely on third parties to supply the raw materials needed to manufacture our product
candidates. Any such reliance on suppliers may involve several risks, including a potential inability to obtain critical materials and
reduced control over production costs, delivery schedules, reliability and quality. Any unanticipated disruption to the operation of
one of our contract manufacturers caused by problems with suppliers could delay our shipment of any of our product candidates, increase
our cost of goods sold and result in delays in clinical trials or lost sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
business model includes the potential out-licensing of strains from our proprietary microbial library or our product candidates to other
biopharmaceutical companies, however technology licensing in the biopharmaceutical industry is a lengthy process and subject to several
risks and factors outside of our control, and we cannot forecast our ability to successfully out-license our technology or the length
of time it takes to establish a new licensing relationship.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business model includes the potential out-licensing or joint development of strains from our proprietary microbial library or our product
candidates to other biopharmaceutical companies. Any such arrangement would typically begin with preliminary feasibility testing and
evaluation by our potential partner or licensee. Assuming the feasibility testing is successful, our ability to convert the successful
test into a commercial license or joint development agreement is dependent on a number of risks and factors, many of which are outside
our control, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            rate of adoption and incorporation of new technologies, by members of the pharmaceutical
                                            industry generally;</FONT></P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            potential licensee&#8217;s internal evaluation of the economic benefits of marketing a dermatological
                                            product that may be competitive with other products currently in development or commercial
                                            sale by our potential partner or licensee regardless of the perceived benefits or
                                            advantages of our technology or product;</FONT></P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            potential partner&#8217;s/licensee&#8217;s internal budgetary and product development issues,
                                            including their ability to commit the capital and human resources towards the development
                                            and commercialization of our technology or product; and</FONT></P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            potential partner&#8217;s/licensee&#8217;s willingness to accept our requirements for upfront
                                            fees and ongoing royalties.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we believe that in many cases our potential partners or licensee may engage with us in the early-stage feasibility testing
as part of their evaluation of multiple drug and drug delivery options and prior to making any decision or commitment to the development
of a new drug product. Consequently, even if our platform is successful in early feasibility studies, our potential partner/licensee
may decide, for reasons unrelated to the performance of our technology, not to enter into a license agreement with us. Therefore, we
are unable to predict the degree to which our proposed licensing model will be successful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization
of our product candidates</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will face a potential risk of product liability as a result of the clinical testing of our product candidates and will face an even greater
risk of such liability if we commercialize any of our product candidates. For example, we may be sued if any product we develop, including
any of our product candidates, or any materials that we use in our product candidates allegedly causes injury or is found to be otherwise
unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects
in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach
of warranties. In the U.S., claims could also be asserted against us under state consumer protection acts. If we cannot successfully
defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of
our product candidates. Even successful defense of these claims would require us to employ significant financial and management resources.
Regardless of the merits or eventual outcome, liability claims may result in:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
                                            demand for any of our product candidates or any future products that we may develop;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury
                                            to our reputation;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
                                            to obtain regulatory approval for our product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
                                            of participants in our clinical trials;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
                                            associated with our defense of the related litigation;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            diversion of our management&#8217;s time and our resources;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
                                            monetary awards to trial participants or patients;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
                                            recalls, withdrawals or labeling, marketing or promotional restrictions;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            inability to commercialize some or all of our product candidates; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            decline in the value of our stock.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, we carry product liability insurance that we consider adequate for our current level of clinical testing
and development. However, we will need additional product liability coverage at the time we commence commercial sale of our initial product.
Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product
liability claims could prevent or inhibit the commercialization of products we develop. Although we will endeavor to obtain and maintain
such insurance in coverage amounts we deem adequate, any claim that may be brought against us could result in a court judgment or settlement
in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage.
Our insurance policies would also have various exclusions, and we may be subject to a product liability claim for which we have no coverage.
As a result, we may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or
that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
business operations could suffer in the event of information technology systems&rsquo; failures or security breaches</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we believe that we have implemented adequate security measures within our internal information technology and networking systems, our
information technology systems may be subject to security breaches, damages from computer viruses, natural disasters, terrorism, and
telecommunication failures. Any system failure or security breach could cause interruptions in our operations in addition to the possibility
of losing proprietary information and trade secrets. To the extent that any disruption or security breach results in inappropriate disclosure
of our confidential information, our competitive position may be adversely affected and we may incur liability or additional costs to
remedy the damages caused by these disruptions or security breaches.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
face significant competition from other biotechnology and pharmaceutical companies targeting medical dermatological indications, and
our operating results will suffer if we fail to compete effectively.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
dermatological therapies market is highly competitive and led by significant technologic developments. We anticipate that, if we are
successful in obtaining regulatory approval of our candidates, we will face significant competition from other approved therapies or
drugs that will become available in our industry. Even if another branded, generic, or OTC product is less effective, it may be quickly
adopted by physicians and patients than our product based upon cost or convenience.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Product Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
success is entirely dependent on our ability to obtain the marketing approval for our product candidates by the FDA and the regulatory
authorities in foreign jurisdictions in which we intend to market our product candidates, of which there can be no assurance.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not permitted to market our product candidates as prescription pharmaceutical products in the United States until we receive approval
of a BLA from the FDA, or in any foreign countries until we receive the requisite approval from such countries. In the United States,
the FDA generally requires the completion of clinical trials of each biologic to establish its safety and efficacy and extensive pharmaceutical
development to ensure its quality before a BLA is approved. Of the large number of biologics in development, only a small percentage
result in the submission of a BLA to the FDA and even fewer are eventually approved for commercialization. As of the date of this prospectus,
we have not submitted a BLA to the FDA or comparable applications to other regulatory authorities for any of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends on our receipt of the regulatory approvals described above, and the issuance of such regulatory approvals is uncertain
and subject to a number of risks, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
                                            authorities may disagree with the number, design, size, conduct or implementation of our
                                            clinical trials or any of our collaborators&#8217; clinical trials;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
                                            authorities may disagree with our interpretation of data from preclinical studies or clinical
                                            trials or the use of results from studies that served as precursors to our current or future
                                            product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            results of toxicology studies may not support the filing of an Investigational New Drug Application,
                                            or IND, or a BLA for our product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            FDA or comparable foreign regulatory authorities or Institutional Review Boards, or IRBs,
                                            may disagree with the design or implementation of our clinical trials;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may not be able to provide acceptable evidence of our product candidates&#8217; safety and
                                            efficacy;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            results of our clinical trials may not be satisfactory or may not meet the level of statistical
                                            or clinical significance required by the FDA, European Medicines Agency, or EMA, or other
                                            regulatory agencies for us to receive marketing approval for any of our product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            dosing of our product candidates in a particular clinical trial may not be at an optimal
                                            level;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
                                            in our clinical trials may suffer adverse effects for reasons that may or may not be related
                                            to our product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            data collected from clinical trials may not be sufficient to support the submission of a
                                            BLA or other submission or to obtain regulatory approval in the United States or elsewhere;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            FDA may require development of a Risk Evaluation and Mitigation Strategy, or REMS, as a condition
                                            of approval;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes
                                            or facilities of third-party manufacturers with which we contract for clinical and commercial
                                            supplies; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            approval policies or regulations of the FDA or comparable foreign regulatory authorities
                                            may significantly change in a manner rendering our clinical data insufficient for approval
                                            of our product candidates.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of obtaining regulatory approvals is expensive, often takes many years, if approval is obtained at all, and can vary substantially
based upon, among other things, the type, complexity and novelty of the product candidates involved, the jurisdiction in which regulatory
approval is sought and the substantial discretion of the regulatory authorities. Changes in regulatory approval policies during the development
period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for a submitted product application
may cause delays in the approval or rejection of an application. Regulatory approval obtained in one jurisdiction does not necessarily
mean that a product candidate will receive regulatory approval in all jurisdictions in which we may seek approval, but the failure to
obtain approval in one jurisdiction may negatively impact our ability to seek approval in a different jurisdiction. Failure to obtain
regulatory approval for our product candidates for the foregoing, or any other reasons, will prevent us from commercializing our product
candidates, and our ability to generate revenue will be materially impaired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the FDA, EMA or other regulatory agencies may also approve a product candidate for fewer or more limited indications than we
request, may impose significant limitations related to use restrictions for certain age groups, warnings, precautions or contraindications
or may grant approval contingent on the performance of costly post-marketing clinical trials or risk mitigation requirements. The FDA,
EMA or other regulatory agencies may also not accept the labeling claims that we believe would be necessary or desirable for the successful
commercialization of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In
December 2022, the U.S. Congress enacted a new law, the Modernization of Cosmetics Regulation Act of 2022, or MOCRA. MOCRA will require
a cosmetic manufacturer or importer to: ensure that it has on hand substantiation of the safety of its products and ingredients; meet
increased registration, record-keeping and reporting requirements; include fragrance and allergen information on its labeling; and be
prepared to meet FDA&rsquo;s to be promulgated good manufacturing practices requirements. These additional requirements may impact budgets
and timelines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates or any future product
candidates, which would prevent or delay or limit the scope of regulatory approval and commercialization</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business model depends entirely on the successful development, regulatory approval and commercialization of our product candidates, which
may never occur. Our product candidates are in the early stages of development and as of the date of this prospectus we have not progressed
any of our product candidates beyond performance characterization, animal testing and limited in-human testing of ATR-04 as a consumer
health product. In December 2022, we submitted an IND for a Phase 1b clinical trial for our ATR-12, which is the means by which drug
companies obtain approval to initiate clinical trials in humans in the United States, and on January 27, 2023 we received notification
from the FDA that the &ldquo;study may proceed&rdquo; with respect to the proposed clinical trial. Other than ATR-12, we do not have
an active IND with the FDA, nor an application to any comparable foreign regulatory authority, for any other of
our product candidates. As of the date of this prospectus, we plan on submitting our IND for ATR-04 by the end of 2023; however, there
can be no assurance we will be able to submit the IND in such timeframe. We may not be successful in obtaining approval
from the FDA or comparable foreign regulatory authorities to start clinical trials for any of our product candidates. If we do not obtain
such approvals as presently planned, the time in which we expect to commence clinical programs for any product candidate will be extended
and such extension will increase our expenses, delay our potential receipt of any revenues and increase our need for additional capital.
Moreover, there is no guarantee that we will receive approval to commence human clinical trials or, if we do receive approval, that our
clinical trials will be successful or that we will continue clinical development in support of an approval from the FDA or comparable
foreign regulatory authorities for any indication. We note that most product candidates never reach the clinical development stage and
even those that do commence clinical development have only a small chance of successfully completing clinical development and gaining
regulatory approval. Success in early phases of pre-clinical and clinical trials does not ensure that later clinical trials will be successful,
and interim results of a clinical trial do not necessarily predict final results. A failure of one or more of our clinical trials can
occur at any stage of testing. We may experience numerous unforeseen events during, or as a result of, the clinical trial process that
could delay or prevent our ability to receive regulatory approval or commercialize our product candidates. Therefore, our business currently
depends entirely on the successful development, regulatory approval and commercialization of our product candidates, which may never
occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Results
of preclinical studies of our product candidates may not be predictive of the results of future preclinical studies or clinical trials.
</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
obtain the requisite regulatory approvals to market and sell any of our product candidates, we must demonstrate through extensive preclinical
studies and clinical trials that our product candidates are safe, pure, and potent in humans. Before an IND can be submitted to the FDA
and become effective, which is a prerequisite for conducting clinical trials on human subjects in the United States, a product candidate
must successfully progress through extensive preclinical studies, which include preclinical laboratory testing, animal studies, and formulation
studies in accordance with Good Laboratory Practices. Success in preclinical studies does not ensure that later preclinical studies or
clinical trials will be successful. A number of companies in the biotechnology and pharmaceutical industries have suffered significant
setbacks in clinical trials, even after positive results in earlier preclinical studies. These setbacks have been caused by, among other
things, preclinical findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including
previously unreported adverse events. The design of a clinical trial can determine whether its results will support approval of a product,
and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. Further, we or our investigators
may have little control over whether subjects comply with important aspects of clinical trial protocols In addition, preclinical and
clinical data are often susceptible to varying interpretations and analyses. Notwithstanding any potential promising results in earlier
studies, we cannot be certain that we will not face similar setbacks. In addition, the results of our preclinical animal studies, may
not be predictive of the results of outcomes in subsequent clinical trials on human subjects. Product candidates in clinical trials may
fail to show the desired pharmacological properties or safety and efficacy traits despite having progressed through preclinical studies.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to receive positive results in preclinical studies or clinical trials of our product candidates, the development timeline and
regulatory approval and commercialization prospects for our most advanced product candidates, and, correspondingly, our business and
financial prospects would be negatively impacted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Any
termination or suspension of, or delays in the commencement or completion of, any necessary studies of any of our product candidates
for any indications could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial
prospects</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
commencement and completion of clinical studies can be delayed for a number of reasons, including delays related to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            FDA or a comparable foreign regulatory authority failing to grant permission to proceed and
                                            placing the clinical study on hold;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subjects
                                            for clinical testing failing to enroll or remain enrolled in our trials at the rate we expect;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            facility manufacturing any of our product candidates being ordered by the FDA or other government
                                            or regulatory authorities to temporarily or permanently shut down due to violations of cGMP
                                            requirements or other applicable requirements, or cross-contaminations of product candidates
                                            in the manufacturing process;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            changes to our manufacturing process that may be necessary or desired;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subjects
                                            choosing an alternative treatment for the indications for which we are developing our product
                                            candidates, or participating in competing clinical studies;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subjects
                                            experiencing severe or unexpected drug-related adverse effects;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reports
                                            from clinical testing on similar technologies and products raising safety and/or efficacy
                                            concerns;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
                                            clinical investigators losing their license or permits necessary to perform our clinical
                                            trials, not performing our clinical trials on our anticipated schedule or employing methods
                                            consistent with the clinical trial protocol, cGMP requirements, or other third parties not
                                            performing data collection and analysis in a timely or accurate manner;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inspections
                                            of clinical study sites by the FDA, comparable foreign regulatory authorities, or IRBs finding
                                            regulatory violations that require us to undertake corrective action, result in suspension
                                            or termination of one or more sites or the imposition of a clinical hold on the entire study,
                                            or that prohibit us from using some or all of the data in support of our marketing applications;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
                                            contractors becoming debarred or suspended or otherwise penalized by the FDA or other government
                                            or regulatory authorities for violations of regulatory requirements, in which case we may
                                            need to find a substitute contractor, and we may not be able to use some or any of the data
                                            produced by such contractors in support of our marketing applications;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">one
                                            or more IRBs refusing to approve, suspending or terminating the study at an investigational
                                            site, precluding enrollment of additional subjects, or withdrawing its approval of the trial;
                                            reaching agreement on acceptable terms with prospective contract research organizations,
                                            or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation
                                            and may vary significantly among different CROs and trial sites;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">deviations
                                            of the clinical sites from trial protocols or dropping out of a trial;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adding
                                            new clinical trial sites;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            inability of the CRO to execute any clinical trials for any reason; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">government
                                            or regulatory delays or &#8220;clinical holds&#8221; requiring suspension or termination
                                            of a trial.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
development costs for any of our product candidates will increase if we have delays in testing or approval or if we need to perform more
or larger clinical studies than planned. Additionally, changes in regulatory requirements and policies may occur and we may need to amend
study protocols to reflect these changes. Amendments may require us to resubmit our study protocols to the FDA, comparable foreign regulatory
authorities, and IRBs for reexamination, which may impact the costs, timing or successful completion of that study. If we experience
delays in completion of, or if we, the FDA or other regulatory authorities, the IRB, or other reviewing entities, or any of our clinical
study sites suspend or terminate any of our clinical studies of any of our product candidates, its commercial prospects may be materially
harmed and our ability to generate product revenues will be delayed. Any delays in completing our clinical trials will increase our costs,
slow down our development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these
occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead
to, termination or suspension of, or a delay in the commencement or completion of, clinical studies may also ultimately lead to the denial
of regulatory approval of our product candidates. In addition, if one or more clinical studies are delayed, our competitors may be able
to bring competing products to market before we do, and the commercial viability of any of our affected product candidates could be significantly
reduced.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we receive regulatory approval for any of our product candidates, we may not be able to successfully commercialize the product and
the revenue that we generate from its sales, if any, may be limited.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
approved for marketing, the commercial success of our product candidates will depend upon each product&rsquo;s acceptance by the medical
community, including physicians, patients and health care payors. The degree of market acceptance for any of our product candidates will
depend on a number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">demonstration
                                            of clinical safety and efficacy;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">relative
                                            convenience, dosing burden and ease of administration;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            prevalence and severity of any adverse effects;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            willingness of physicians to prescribe our product candidates, and the target patient population
                                            to try new therapies;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">efficacy
                                            of our product candidates compared to competing products;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            introduction of any new products that may in the future become available targeting indications
                                            for which our product candidates may be approved;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">new
                                            procedures or therapies that may reduce the incidences of any of the indications in which
                                            our product candidates may show utility;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pricing
                                            and cost-effectiveness;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            inclusion or omission of our product candidates in applicable therapeutic and vaccine guidelines;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            effectiveness of our own or any future collaborators&#8217; sales and marketing strategies;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
                                            or warnings contained in approved labeling from regulatory authorities;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to obtain and maintain sufficient third-party coverage or reimbursement from government
                                            health care programs, including Medicare and Medicaid, private health insurers and other
                                            third-party payors or to receive the necessary pricing approvals from government bodies regulating
                                            the pricing and usage of therapeutics; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            willingness of patients to pay out-of-pocket in the absence of third-party coverage or reimbursement
                                            or government pricing approvals.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our product candidates are approved, but do not achieve an adequate level of acceptance by physicians, health care payors, and
patients, we may not generate sufficient revenue and we may not be able to achieve or sustain profitability. Our efforts to educate the
medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be
successful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, even if we obtain regulatory approvals, the timing or scope of any approvals may prohibit or reduce our ability to commercialize
our product candidates successfully. For example, if the approval process takes too long, we may miss market opportunities and give other
companies the ability to develop competing products or establish market dominance. Any regulatory approval we ultimately obtain may be
limited or subject to restrictions or post-approval commitments that render our product candidates not commercially viable. For example,
regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve
the price we intend to charge for any of our product candidates, may grant approval contingent on the performance of costly post-marketing
clinical trials, or may approve any of our product candidates with a label that does not include the labeling claims necessary or desirable
for the successful commercialization of that indication. Further, the FDA or comparable foreign regulatory authorities may place conditions
on approvals or require risk management plans or a Risk Evaluation and Mitigation Strategy, or REMS, to assure the safe use of the drug.
Moreover, product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following the initial
marketing of the product. Any of the foregoing scenarios could materially harm the commercial success of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we obtain marketing approval for any of our product candidates, we will be subject to ongoing obligations and continued regulatory
review, which may result in significant additional expense. Additionally, our product candidates could be subject to labeling and other
restrictions and withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if
we experience unanticipated problems with our product candidates. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain regulatory approval for any of our product candidates for an indication, the FDA or foreign equivalent may still impose
significant restrictions on their indicated uses or marketing or the conditions of approval, or impose ongoing requirements for potentially
costly and time-consuming post-approval studies, including Phase 4 clinical trials, and post-market surveillance to monitor safety and
efficacy. Our product candidates will also be subject to ongoing regulatory requirements governing the manufacturing, labeling, packaging,
storage, distribution, safety surveillance, advertising, promotion, recordkeeping and reporting of adverse events and other post-market
information. These requirements include registration with the FDA, as well as continued compliance with current Good Clinical Practices
regulations, or cGCPs, for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities
are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current cGMPs,
requirements relating to quality control, quality assurance and corresponding maintenance of records and documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has the authority to require a REMS as part of an BLA or after approval, which may impose further requirements or restrictions on
the distribution or use of an approved drug, such as limiting prescribing to certain physicians or medical centers that have undergone
specialized training, limiting treatment to patients who meet certain safe-use criteria or requiring patient testing, monitoring and/or
enrollment in a registry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to sales and marketing activities related to our product candidates, advertising and promotional materials must comply with FDA
rules in addition to other applicable federal, state and local laws in the United States and similar legal requirements in other countries.
In the United States, the distribution of product samples to physicians must comply with the requirements of the U.S. Prescription Drug
Marketing Act. Application holders must obtain FDA approval for product and manufacturing changes, depending on the nature of the change.
We may also be subject, directly or indirectly through our customers and partners, to various fraud and abuse laws, including, without
limitation, the U.S. Anti-Kickback Statute, U.S. False Claims Act, and similar state laws, which impact, among other things, our proposed
sales, marketing, and scientific/educational grant programs. If we participate in the U.S. Medicaid Drug Rebate Program, the Federal
Supply Schedule of the U.S. Department of Veterans Affairs, or other government drug programs, we will be subject to complex laws and
regulations regarding reporting and payment obligations. All of these activities are also potentially subject to U.S. federal and state
consumer protection and unfair competition laws. Similar requirements exist in many of these areas in other countries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if any of our product candidates are approved for a particular indication, our product labeling, advertising and promotion
would be subject to regulatory requirements and continuing regulatory review. The FDA strictly regulates the promotional claims that
may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected
in the product&rsquo;s approved labeling. If we receive marketing approval for our product candidates, physicians may nevertheless legally
prescribe our products to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such
off-label uses, we may become subject to significant liability and government fines. The FDA and other agencies actively enforce the
laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses
may be subject to significant sanctions. The federal government has levied large civil and criminal fines against companies for alleged
improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies
enter into consent decrees of permanent injunctions under which specified promotional conduct is changed or curtailed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or a regulatory agency discover previously unknown problems with a product candidate, such as adverse events of unanticipated severity
or frequency, problems with the facility where the product is manufactured, or we or our manufacturers fail to comply with applicable
regulatory requirements, we may be subject to the following administrative or judicial sanctions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
                                            on the marketing or manufacturing of the product, withdrawal of the product from the market,
                                            or voluntary or mandatory product recalls;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issuance
                                            of warning letters or untitled letters;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
                                            holds;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
                                            or the imposition of civil or criminal penalties or monetary fines;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
                                            or withdrawal of regulatory approval;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
                                            of any ongoing clinical trials;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
                                            to approve pending applications or supplements to approved applications filed by us, or suspension
                                            or revocation of product license approvals;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
                                            or imposition of restrictions on operations, including costly new manufacturing requirements;
                                            or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
                                            seizure or detention or refusal to permit the import or export of product.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue.
Adverse regulatory action, whether pre- or post-approval, can also potentially lead to product liability claims and increase our product
liability exposure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative
action, either in the United States or abroad, and compliance with such regulation may be expensive and consume substantial financial
and management resources. If we or any future marketing collaborators or contract manufacturers are slow or unable to adapt to changes
in existing requirements or the adoption of new requirements or policies or are not able to maintain regulatory compliance, it could
delay or prevent the promotion, marketing or sale of our products, which would adversely affect our business and results of operations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Obtaining
and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining
regulatory approval of our product candidates in other jurisdictions. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or
maintain regulatory approval in any other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may
have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product
candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of
the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative
review periods different from those in the United States, including additional preclinical studies or clinical trials, as clinical studies
conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the
United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some
cases, the price that we intend to charge for our products is also subject to approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and
costs for us and could delay or prevent the introduction of our product candidates in certain countries. If we fail to comply with the
regulatory requirements in international markets and/ or to receive applicable marketing approvals, our target market will be reduced
and our ability to realize the full market potential of our product candidates will be harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
though we may apply for orphan drug designation for a product candidate, we may not be able to obtain orphan drug marketing exclusivity.
</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that in some cases our products candidates may qualify for the FDA&rsquo;s orphan drug status. There is no guarantee that the
FDA will grant any future application for orphan drug designation for any of our product candidates, which would make us ineligible for
the additional exclusivity and other benefits of orphan drug designation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is generally
a disease or condition that affects fewer than 200,000 individuals in the United States and for which there is no reasonable expectation
that the cost of developing and making a drug available in the United States for this type of disease or condition will be recovered
from sales of the product. Orphan drug designation must be requested before submitting an BLA. After the FDA grants orphan drug designation,
the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan product designation does
not convey any advantage in or shorten the duration of regulatory review and approval process. In addition to the potential period of
exclusivity, orphan designation makes a company eligible for grant funding of up to $400,000 per year for four years to defray costs
of clinical trial expenses, tax credits for clinical research expenses and potential exemption from the FDA application user fee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such
designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other applications to market
the same drug for the same indication for seven years, except in limited circumstances, such as (i) the drug&rsquo;s orphan designation
is revoked; (ii) its marketing approval is withdrawn; (iii) the orphan exclusivity holder consents to the approval of another applicant&rsquo;s
product; (iv) the orphan exclusivity holder is unable to assure the availability of a sufficient quantity of drug; or (v) a showing of
clinical superiority to the product with orphan exclusivity by a competitor product. If a drug designated as an orphan product receives
marketing approval for an indication broader than what is designated, it may not be entitled to orphan drug exclusivity. There can be
no assurance that we will receive orphan drug designation for any of our product candidates in the indications for which we think they
might qualify, if we elect to seek such applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Current
and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates
and affect the prices we may obtain.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes
regarding the healthcare system that could prevent or delay marketing approval for our product candidates, restrict or regulate post-approval
activities and affect our ability to profitably sell our product candidates. Legislative and regulatory proposals have been made to expand
post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We do not know whether additional
legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact
of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress
of the FDA&rsquo;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product
labeling and post-marketing testing and other requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the Medicare Modernization Act, or MMA, changed the way Medicare covers and pays for pharmaceutical products. The
legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average
sales prices for drugs. In addition, this legislation authorized Medicare Part D prescription drug plans to use formularies where they
can limit the number of drugs that will be covered in any therapeutic class. As a result of this legislation and the expansion of federal
coverage of drug products, we expect that there will be additional pressure to contain and reduce costs. These cost reduction initiatives
and other provisions of this legislation could decrease the coverage and price that we receive for our product candidates and could seriously
harm our business. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage
policy and payment limitations in setting their own reimbursement rates, and any reduction in reimbursement that results from the MMA
may result in a similar reduction in payments from private payors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010 or,
collectively, the ACA, is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare
spending, enhance remedies against fraud and abuse, add new transparency requirements for healthcare and health insurance industries,
impose new taxes and fees on the health industry and impose additional health policy reforms. The ACA revised the definition of &ldquo;average
manufacturer price&rdquo; for reporting purposes, which could increase the amount of Medicaid drug rebates to states. Further, the law
imposed a significant annual fee on companies that manufacture or import branded prescription drug products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In 2011, the U.S.
Congress enacted the Budget Control Act of 2011, or the Budget Control Act, which included provisions intended to reduce the federal
deficit. The Budget Control Act resulted in the imposition of 2% reductions in Medicare payments to providers beginning in 2013 and,
due to subsequent legislative amendments to the statute, will remain in effect through 2027 absent additional congressional action. However,
pursuant to the CARES Act, and subsequent legislation, these reductions are suspended from May 1, 2020 through March 31, 2022 due to
the COVID-19 pandemic. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced
Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to
providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding, which
could have a material adverse effect on customers for our drugs, if approved, and accordingly, our financial operations. If government
spending is further reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA, to continue
to function at current levels, which may impact the ability of relevant agencies to timely review and approve research and development,
manufacturing and marketing activities, which may delay our ability to develop, market and sell any product candidates we may develop.
In addition, any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs
that may be implemented, or any significant taxes or fees that may be imposed on us, as part of any broader deficit reduction effort
or legislative replacement to the Budget Control Act, could have an adverse impact on our anticipated product revenues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products.
There have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among
other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce
the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. On September 24, 2020, the FDA
released a final rule providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November
20, 2020, the U.S. Department of Health and Human Services, or HHS, finalized a regulation removing safe harbor protection for price
reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless
the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale,
as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. On August 16, 2022,
Congress enacted the Inflation Reduction Act of 2022 which contains several provisions relating to prescription drug costs, including
requirements for federal government price negotiations, rebate requirements, and caps on out-of-pocket spending for Medicare Part D enrollees.
At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical
and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access
and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and
bulk purchasing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 20, 2020, the HHS Office of Inspector General finalized further modifications to the federal Anti-Kickback Statute. Under the
final rules, the HHS Office of Inspector General added safe harbor protections under the Anti-Kickback Statute for certain coordinated
care and value-based arrangements among clinicians, providers, and others, yet removed safe harbor protection for price reductions from
pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction
is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor
for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. This rule (with exceptions) became effective
January 19, 2021. We continue to evaluate what effect, if any, these rules will have on our business. CMS issued a final rule, effective
on July 9, 2019, that requires direct-to-consumer advertisements of prescription drugs and biological products, for which payment is
available through or under Medicare or Medicaid, to include in the advertisement the Wholesale Acquisition Cost, or list price, of that
drug or biological product if it is equal to or greater than $35 for a monthly supply or usual course of treatment. Prescription drugs
and biological products that are in violation of these requirements will be included on a public list. Any adopted health reform measure
could reduce the ultimate demand for our products, if approved, or put pressure on our product pricing. Individual states in the United
States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product
pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure
and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition,
regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products
and which suppliers will be included in their prescription drug and other healthcare programs. We expect that additional state and federal
healthcare reform measures will be adopted in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines,
is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different
priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however,
the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines
by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and
market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities
and affect our ability to commercialize any products for which we obtain marketing approval. Both in the United States and in the EU,
legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities
for pharmaceutical products. We do not know whether additional legislative changes will be enacted, or whether the regulations, guidance
or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any,
may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Third-party
coverage and reimbursement and health care cost containment initiatives and treatment guidelines may constrain our future revenues.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to successfully market our product candidates will depend in part on the level of reimbursement that government health administration
authorities, private health coverage insurers and other organizations provide for the cost of our product candidates and related treatments.
Countries in which any of our product candidates are sold through reimbursement schemes under national health insurance programs frequently
require that manufacturers and sellers of pharmaceutical products obtain governmental approval of initial prices and any subsequent price
increases. In certain countries, including the United States, government-funded and private medical care plans can exert significant
indirect pressure on prices. We may not be able to sell our product candidates profitably if adequate prices are not approved or coverage
and reimbursement is unavailable or limited in scope. Increasingly, third-party payors attempt to contain health care costs in ways that
are likely to impact our development of products including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failing
                                            to approve or challenging the prices charged for health care products;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">introducing
                                            reimportation schemes from lower priced jurisdictions;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limiting
                                            both coverage and the amount of reimbursement for new therapeutic products;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">denying
                                            or limiting coverage for products that are approved by the regulatory agencies but are considered
                                            to be experimental or investigational by third-party payors; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusing
                                            to provide coverage when an approved product is used in a way that has not received regulatory
                                            marketing approval.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
relationships with customers and payors are subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations,
which, if violated, could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual
damages, reputational harm and diminished profits and future earnings.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
providers, physicians and others will play a primary role in the recommendation and prescription of any products for which we obtain
marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse
and other healthcare laws and regulations, primarily in the United States, that may constrain the business or financial arrangements
and relationships through which we market, sell and distribute our products for which we obtain marketing approval. Restrictions under
applicable healthcare laws and regulations, include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal Anti-Kickback Statute prohibits, among other things, the knowing and willful offer,
                                            payment, solicitation or receipt of any form of remuneration in return for, or to induce,
                                            (i) the referral of a person, (ii) the furnishing or arranging for the furnishing of items
                                            or services reimbursable under the Medicare, Medicaid or other governmental programs, or
                                            (iii) the purchase, lease or order or arranging or recommending purchasing, leasing or ordering
                                            of any item or service reimbursable under the Medicare, Medicaid or other governmental programs.
                                            A person or entity does not need to have actual knowledge of the statute or specific intent
                                            to violate it in order to have committed a violation. In addition, the government may assert
                                            that a claim including items or services resulting from a violation of the federal Anti-Kickback
                                            Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal False Claims Act imposes civil penalties, and provides for civil whistleblower or
                                            qui tam actions, against individuals or entities for knowingly presenting, or causing to
                                            be presented, to the federal government, claims for payment that are false or fraudulent
                                            or making a false statement to avoid, decrease or conceal an obligation to pay money to the
                                            federal government;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA
                                            imposes criminal and civil liability for executing a scheme to defraud any health care benefit
                                            program or making false statements relating to health care matters. Similar to the federal
                                            Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute
                                            or specific intent to violate it in order to have committed a violation;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal false statements statute prohibits knowingly and willfully falsifying, concealing
                                            or covering up a material fact or making any materially false statement in connection with
                                            the delivery of or payment for health care benefits, items or services;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Physician Payments Sunshine Act, created under the ACA, and its implementing regulations,
                                            which requires specified manufacturers of drugs, devices, biologics and medical supplies
                                            for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance
                                            Program, with specific exceptions, to report annually to CMS information related to payments
                                            or other &#8220;transfers of value&#8221; made to physicians. All such reported information
                                            is publicly available;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous
                                            state and non-U.S. laws and regulations, such as certain state anti-kickback and false claims
                                            laws which may apply to items or services reimbursed by any third-party payor, including
                                            commercial insurers; state laws that require pharmaceutical companies to comply with the
                                            industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated
                                            by the federal government or otherwise restrict payments that may be made to healthcare providers
                                            and other potential referral sources; state laws that require drug manufacturers to report
                                            information related to payments and other transfers of value to physicians and other healthcare
                                            providers or marketing expenditures; and state laws governing the privacy and security of
                                            health information in certain circumstances, many of which differ from each other in significant
                                            ways and may not have the same effect, thus complicating compliance efforts; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulation
                                            by CMS and enforcement by the HHS Office of Inspector General or the U.S. Department of Justice.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our
future business activities could be subject to challenge under one or more of such laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts
to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve
substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current
or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations
are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant
civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare
and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom
we expect to do business with are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative
sanctions, including exclusions from government funded healthcare programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Relating to Our Intellectual Property Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>It
is difficult and costly to protect our intellectual property rights, and we cannot ensure the protection of these rights. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success will depend, in part, on our ability to prosecute and defend, if necessary, our patent rights against third-party
challenges and successfully enforcing these patent rights against third party competitors. The patent positions of pharmaceutical companies
can be highly uncertain and involve complex legal, scientific and factual questions for which important legal principles remain unresolved.
Changes in either the patent laws or in interpretations of patent laws may diminish the value of our intellectual property. Accordingly,
we cannot predict the breadth of claims that may be allowable or enforceable in any patent applications filed by us or our licensors
of patent rights. The patents and patent applications held by or licensed to us relating to our microbial platform and related technologies
may be challenged, invalidated or circumvented by third parties and might not protect us against competitors with similar products or
technologies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
degree of future protection afforded by the patent rights held by or licensed to us is uncertain, because legal means afford only limited
protection and may not adequately protect our rights, permit us to gain or keep our competitive advantage, or provide us with any competitive
advantage at all. We cannot be certain that any patent application owned by a third party will not have priority over patent applications
filed by us or in which we hold license rights or that we will not be involved in interference, opposition or invalidity proceedings
before United States or foreign patent offices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if we were to initiate legal proceedings against a third party to enforce a patent covering any of our product candidates, the defendant
could counterclaim that such patent is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims
alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include alleged failures to meet any of
several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for unenforceability assertions include
allegations that someone connected with prosecution of the patent withheld relevant information from the United States Patent and Trademark
Office, or the USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative
bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review
and equivalent proceedings in foreign jurisdictions, e.g., opposition proceedings. Such proceedings could result in revocation or amendment
of patents held by or licensed to us in such a way that they no longer cover our product candidates or competitive products. The outcome
following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot be certain
that there is no invalidating prior art, of which, we, any licensor of our patent rights or the patent examiner were unaware during prosecution.
If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all,
of the patent protection on any of our product candidates. Such a loss of patent protection would have a material adverse impact on our
business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on know-how and trade secrets to protect technology, especially in cases where we believe patent protection is not appropriate or
obtainable. However, know-how and trade secrets are difficult to protect. While we require employees, academic collaborators, consultants
and other contractors to enter into confidentiality agreements, we may not be able to adequately protect our trade secrets or other proprietary
or licensed information. Typically, research collaborators and scientific advisors have rights to publish data and information in which
we may have rights. Enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time
consuming, and the outcome is unpredictable. In addition, courts are sometimes less willing to protect trade secrets than patents. Moreover,
our competitors may independently develop equivalent knowledge, methods and know-how.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to obtain or maintain patent protection or trade secret protection for our product candidates or our technologies, third parties
could use our proprietary information, which could impair our ability to compete in the market and adversely affect our ability to generate
revenues and attain profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
product candidates may infringe the intellectual property rights of others, which could increase our costs and delay or prevent our development
and commercialization efforts.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends in part on avoiding infringement of the proprietary technologies of others. The pharmaceutical industry has been characterized
by frequent litigation regarding patent and other intellectual property rights. Identification of third-party patent rights that may
be relevant to our proprietary technology is difficult because patent searching is imperfect due to differences in terminology among
patents, incomplete databases and the difficulty in assessing the meaning of patent claims. Additionally, because patent applications
are maintained in secrecy until the application is published, we may be unaware of third-party patents that may be infringed by commercialization
of any of our product candidates or any future product candidate. There may be certain issued patents and patent applications claiming
subject matter that we may be required to license in order to research, develop or commercialize any of our product candidates, and we
do not know if such patents and patent applications would be available to license on commercially reasonable terms, or at all. Any claims
of patent infringement asserted by third parties would be time-consuming and may:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">result
                                            in costly litigation;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">divert
                                            the time and attention of our technical personnel and management;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prevent
                                            us from commercializing a product until the asserted patent expires or is held finally invalid
                                            or not infringed in a court of law;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
                                            us to cease or modify our use of the technology and/or develop non-infringing technology;
                                            or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
                                            us to enter into royalty or licensing agreements.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
parties may hold proprietary rights that could prevent any of our product candidates from being marketed. Any patent-related legal action
against us claiming damages and seeking to enjoin commercial activities relating to any of our product candidates or our processes could
subject us to potential liability for damages and require us to obtain a license to continue to manufacture or market any of our product
candidates or any future product candidates. We cannot predict whether we would prevail in any such actions or that any license required
under any of these patents would be made available on commercially acceptable terms, if at all. In addition, we cannot be sure that we
could redesign our product candidates or any future product candidates or processes to avoid infringement, if necessary. Accordingly,
an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from
developing and commercializing any of our product candidates or a future product candidate, which could harm our business, financial
condition and operating results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that there are other companies, including major biopharmaceutical companies, working in the areas competitive to our proposed
product candidates which either has resulted, or may result, in the filing of patent applications that may be deemed related to our activities.
If we were to challenge the validity of these or any issued United States patent in court, we would need to overcome a statutory presumption
of validity that attaches to every issued United States patent. This means that, in order to prevail, we would have to present clear
and convincing evidence as to the invalidity of the patent&rsquo;s claims. If we were to challenge the validity of these or any issued
United States patent in an administrative trial before the Patent Trial and Appeal Board in the USPTO, we would have to prove that the
claims are unpatentable by a preponderance of the evidence. There is no assurance that a jury and/or court would find in our favor on
questions of infringement, validity or enforceability. Even if we are successful, litigation could result in substantial costs and be
a distraction to management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used
or disclosed alleged confidential information or trade secrets of their former employers.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is commonplace in our industry, we will employ individuals who were previously employed at other biopharmaceutical companies, including
our competitors or potential competitors. Although no claims against us are currently pending, we may be subject in the future to claims
that our employees or prospective employees are subject to a continuing obligation to their former employers (such as non-competition
or non-solicitation obligations) or claims that our employees or we have inadvertently or otherwise used or disclosed trade secrets or
other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful
in defending against these claims, litigation could result in substantial costs and be a distraction to management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to this Offering and Owning Our Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>An
active, liquid and orderly trading market for our shares may not develop, which may inhibit the ability of our stockholders to sell shares
following this offering</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offering under this prospectus is an initial public offering of our common shares. Prior to this offering there has been no public market
for our shares. Upon completion of this offering, our common stock will commence trading on the NYSE American under the symbol
&ldquo;AZTR.&rdquo; However, an active, liquid or orderly trading market in our shares may not develop upon completion of this
offering, or if it does develop, it may not be sustained. The lack of an active market may impair your ability to sell your shares at
the time you wish to sell them or at a price that you consider reasonable. The lack of an active market may also reduce the fair market
value of your shares. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to
acquire other companies by using our shares as consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
failure to meet the continued listing requirements of the NYSE American could result in a delisting of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
after listing, we fail to satisfy the continued listing requirements of the NYSE American, such as the corporate governance requirements
or the minimum closing bid price requirement, the NYSE American may take steps to delist our common stock. Such a delisting would
likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when
you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing
requirements would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock,
prevent our common stock from dropping below the NYSE American&rsquo;s minimum bid price requirement or prevent future non-compliance
with the NYSE American&rsquo;s listing requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Future
capital raises may dilute your ownership and/or have other adverse effects on our operations</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we raise additional capital by issuing equity securities, our existing stockholders&rsquo; percentage ownership will be reduced and these
stockholders may experience substantial dilution. If we raise additional funds by issuing debt securities, these debt securities would
have rights senior to those of our common stock and the terms of the debt securities issued could impose significant restrictions on
our operations, including liens on our assets. If we raise additional funds through collaborations and licensing arrangements, we may
be required to relinquish some rights to our intellectual property or candidate products, or to grant licenses on terms that are not
favorable to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
market price of our shares may be subject to fluctuation and volatility. You could lose all or part of your investment</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial public offering price for the shares has been determined by negotiations between us and the representative of the underwriters
and may not be indicative of prices that will prevail in the trading market. The price of our shares may decline following this offering.
The stock market in general, and early-stage public companies in particular, has experienced extreme price and volume fluctuations that
have often been unrelated or disproportionate to the operating performance of such companies. These broad market factors may seriously
harm the market price of our common stock, regardless of our actual or expected operating performance and financial condition or prospects,
which may make it difficult for investors to assess the rapidly changing value of our common stock. In the past, following periods of
volatility in the market price of a company&rsquo;s securities, securities class action litigation has often been instituted. A class
action suit against us could result in significant liabilities and, regardless of the outcome, could result in substantial costs and
the diversion of our management&rsquo;s resources and attention The market price of our shares on the NYSE American may fluctuate as
a result of a number of factors, some of which are beyond our control, including, but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
                                            or anticipated variations in our and our competitors&#8217; results of operations and financial
                                            condition;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
                                            acceptance of our product candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in earnings estimates or recommendations by securities analysts, if our shares are covered
                                            by analysts;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">development
                                            of technological innovations or new competitive products by others;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
                                            of technological innovations or new products by us;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">publication
                                            of the results of preclinical or clinical trials for our product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
                                            by us to achieve a publicly announced milestone;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
                                            between our expenditures to develop and market new or enhanced products and the generation
                                            of sales from those products;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
                                            concerning intellectual property rights, including our involvement in litigation brought
                                            by or against us;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                            developments and the decisions of regulatory authorities as to the approval or rejection
                                            of new or modified products;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in the amounts that we spend to develop, acquire or license new products, technologies or
                                            businesses;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in our expenditures to promote our product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            sale or proposed sale, or the sale by our significant stockholders, of our shares or other
                                            securities in the future;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in key personnel;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">success
                                            or failure of our research and development projects or those of our competitors;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            trading volume of our shares; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
                                            economic and market conditions and other factors, including factors unrelated to our operating
                                            performance.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
factors and any corresponding price fluctuations may materially and adversely affect the market price of our shares and result in substantial
losses being incurred by our investors. In the past, following periods of market volatility, public company stockholders have often instituted
securities class action litigation. If we were involved in securities litigation, it could impose a substantial cost upon us and divert
the resources and attention of our management from our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are an &ldquo;emerging growth company&rdquo; under the JOBS Act and we cannot be certain if the reduced disclosure requirements
applicable to emerging growth companies will make our common stock less attractive to investors</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &ldquo;emerging growth company,&rdquo; as defined in the JOBS Act and we may take
advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not &ldquo;emerging
growth companies&rdquo; including, but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
                                            being required to comply with the auditor attestation requirements of Section 404 of the
                                            Sarbanes-Oxley Act;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
                                            disclosure obligations regarding executive compensation in our periodic reports and proxy
                                            statements;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemptions
                                            from the requirements of holding a nonbinding advisory vote on executive compensation and
                                            stockholder approval of any golden parachute payments; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">extended
                                            transition periods available for complying with new or revised accounting standards.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have chosen to take advantage of all of the benefits available under the JOBS Act, including the exemptions discussed above. We cannot
predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common
stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will remain an &ldquo;emerging growth company&rdquo; for up to five years, although we will lose that status sooner if our revenues exceed
$1.07 billion, if we issue more than $1 billion in non-convertible debt in a three-year period, or if the market value of our common
stock that is held by non-affiliates exceeds $700 million as of June 30 in any future year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
status as an &ldquo;emerging growth company&rdquo; under the JOBS Act may make it more difficult to raise capital as and when we need
it</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the exemptions from various reporting requirements provided to us as an &ldquo;emerging growth company,&rdquo; we may be less attractive
to investors and it may be difficult for us to raise additional capital as and when we need it. Investors may be unable to compare our
business with other companies in our industry if they believe that our reporting is not as transparent as other companies in our industry.
If we are unable to raise additional capital as and when we need it, our financial condition and results of operations may be materially
and adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have not paid dividends on our common stock in the past and have no immediate plans to pay such dividends</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to reinvest all of our earnings, to the extent we have earnings, to cover operating costs and otherwise become and remain competitive.
We do not plan to pay any cash dividends with respect to our common stock in the foreseeable future. We cannot assure you that
we would, at any time, generate sufficient surplus cash that would be available for distribution to the holders of our common stock as
a dividend. Therefore, you should not expect to receive cash dividends on the common stock we are offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
equity research analysts do not publish research or reports about our business or if they issue unfavorable commentary or downgrade our
shares, the price of our shares could decline</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our shares will rely in part on the research and reports that equity research analysts publish about us and our business,
if at all. We do not have control over these analysts and we do not have commitments from them to write research reports about us. The
price of our shares could decline if no research reports are published about us or our business, or if one or more equity research analysts
downgrades our shares or if those analysts issue other unfavorable commentary or cease publishing reports about us or our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Assuming
a market for our common stock develops, shares eligible for future sale may adversely affect the market for our common stock</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantially
all of our common shares outstanding prior to this offering, including the common shares issuable upon conversion of our convertible
preferred stock and convertible promissory notes, are subject to lock-up agreements whereby the holder has agreed not to sell, transfer
or pledge, or offering to do any of the same, directly or indirectly, any of our securities for a period of 180 days following the close
of this offering, except in the case of our officers and directors who have agreed not to sell for one year following the close of this
offering. Subject to the lock-up agreements, we have granted demand and piggyback registration rights to the holders of our convertible
preferred stock and convertible promissory notes pursuant to which they may request the registration for resale of up to 9,542,519
shares of common stock commencing 180 days following the close of this offering. Furthermore, commencing on the 90th day following
the close of this offering, our stockholders may be eligible to sell all or some of their shares of common stock by means of ordinary
brokerage transactions in the open market pursuant to Rule 144, promulgated under the Securities Act, subject to certain limitations
under Rule 144 and the lock-up agreements. In general, pursuant to Rule 144, non-affiliate stockholders may sell freely after six months
subject only to the current public information requirement (which disappears after one year).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
substantial sale of our common stock pursuant to Rule 144 or pursuant to any resale prospectus (including sales by investors of securities
acquired in connection with this offering) may have a material adverse effect on the market price of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>You
will experience immediate dilution in the book value per share of the common stock you purchase. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the price per share of our common stock being offered is substantially higher than the book value per share of our common stock, you
will experience substantial dilution in the net tangible book value of the common stock you purchase in this offering. Based on the initial
public offering price of $5.00 per share, if
you purchase shares of common stock in this offering, you will experience immediate and substantial dilution of $4.28 per share
in the net tangible book value of the common stock at March 31, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be at an increased risk of securities class action litigation. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
securities class action litigation has often been brought against a company following a decline in the market price of its securities.
This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant stock price volatility
in recent years. If we were to be sued, it could result in substantial costs and a diversion of management&rsquo;s attention and resources,
which could harm our business. <FONT STYLE="background-color: white">We maintain director and officer insurance that we regard as
reasonably adequate to protect us from potential claims; however, we are responsible for meeting certain deductibles under the policies
and, in any event, we cannot assure you that the insurance coverage will adequately protect us from claims made. Further, the costs of
insurance may increase and the availability of coverage may decrease. As a result, we may not be able to maintain our current levels
of insurance at a reasonable cost, or at all.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have broad discretion in how we use the proceeds of this offering and may not use these proceeds effectively, which could affect our
results of operations and cause our stock price to decline</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may invest or spend these proceeds in ways with which you do not agree and in ways that may not yield a return on your investment. Our
management will have considerable discretion in the application of the net proceeds of this offering, including for any purpose described
in the section of this prospectus entitled <I>&ldquo;Use of Proceeds&rdquo;.</I> However, our needs may change as our business and industry
evolve and, as a result, the proceeds we receive from this offering may be used in a manner substantially different from our current
expectations. We may use the net proceeds for purposes that do not yield a significant return or any return at all for our stockholders.
In addition, pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses
value. The failure by our management to apply these funds effectively could result in financial losses that could harm our business,
cause the price of our common stock to decline and delay the development of our product candidates. You will not have the opportunity
as part of your investment decision to assess whether the net proceeds are being used appropriately and, as a result, you will be relying
on our management&rsquo;s judgment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
ratified certain corporate actions pursuant to Section 204 of the DGCL, however there can be no assurance that claims will not be made
to challenge the validity of the ratification or the related corporate actions.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of our preparation for this offering, in February 2023, our Board and stockholders ratified certain actions pursuant
to Section 204 of the DGCL, which allows a Delaware corporation to ratify a defective corporate act with effectiveness that is retroactive
to the date the corporate act was originally taken. The Section 204 ratification, or the Ratification, was undertaken as a purely remedial
matter in respect of certain failures of authorization and thereby remove any uncertainty and ensure the validity of certain security
issuances, Board appointments and other corporate acts. To effect the Ratification, our Board identified and our Board and stockholders
then ratified: (i) the adoption of the corporation&rsquo;s bylaws; (ii) the fixing and changing the size and composition of the Board;
(iii) the issuance of certain shares, stock options, warrants, and convertible notes; and (iv) the issuance of shares pursuant to a dividend.
The Ratification also had the effect of removing uncertainty and ensuring the validity of actions whose validity has been called into
question as a result of the preceding uncertainty and consequent uncertainty in respect of the authority of the directors and stockholders
who authorized such actions (collectively with the acts ratified by the Ratification, the &ldquo;Corporate Acts&rdquo;) Thereafter, in
accordance with Section 204, we gave prompt written notice of the Ratification to all holders of putative and valid stock (as such terms
are used in Section 204) as of the date of the Corporate Acts and as of the date of the Ratification in accordance with Section 204.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Section 205 of the DGCL, any claim that any Corporate Act ratified under the Ratification is void or voidable due to a failure of authorization
(as defined in Section 204), or that the Delaware Court of Chancery should declare in its discretion that the ratification thereof in
accordance with Section 204 not be effective or be effective only on certain conditions, must be brought within 120 days from the Ratification
effective time, which in this case is June 2023. The Board and the holders of approximately % of our outstanding voting securities
(valid and putative) consented to the Ratification and the effectiveness of the Corporate Acts. We believe that it is unlikely that any
stockholder who did not consent to the Ratification will be able to show any injury sufficient to challenge the Ratification under Section
205 of the DGCL. While we believe that there is a low risk of challenge to the Ratification, and that it would be difficult for a challenger
to establish a legal or equitable basis to invalidate or limit the Ratification or the Corporate Acts, there is a possibility that a
court could uphold a challenge to the Ratification or to the Corporate Acts and, if it did, it could adversely affect the management
and governance of our corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
charter documents and Delaware law may inhibit a takeover that stockholders consider favorable. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of this offering, we intend to adopt an amended and restated certificate of incorporation and amended and restated bylaws.
Provisions of our amended and restated certificate of incorporation and amended and restated bylaws and applicable provisions of Delaware
law may delay or discourage transactions involving an actual or potential change in control or change in our management, including transactions
in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders might otherwise deem
to be in their best interests. The provisions in our amended and restated certificate of incorporation and amended and restated bylaws:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limit
                                            who may call stockholder meetings;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrict
                                            our stockholders from bringing matters before our annual meeting of stockholders or from
                                            making nominations for directors at our annual meeting of stockholders if the proper procedures
                                            are not followed;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">do
                                            not provide for stockholder action by written consent;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">do
                                            not provide for cumulative voting rights; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
                                            that all board vacancies may be filled by the affirmative vote of a majority of directors
                                            then in office, even if less than a quorum.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, once we become a publicly traded corporation, Section 203 of the DGCL may limit our ability to engage in any business
combination with a person who beneficially owns 15% or more of our outstanding voting stock unless certain conditions are satisfied.
This restriction lasts for a period of three years following the share acquisition. These provisions may have the effect of entrenching
our management team and may deprive you of the opportunity to sell your shares to potential acquirers at a premium over prevailing prices.
This potential inability to obtain a control premium could reduce the price of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
Risk Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
in accounting standards and subjective assumptions, estimates and judgments by management related to complex accounting matters may materially
impact reporting of our financial condition and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting
principles generally accepted in the United States and related accounting pronouncements, implementation guidelines, and interpretations
we apply to a wide range of matters that are relevant to our business, such as accounting for long-lived asset impairment and share-based
compensation, are complex and involve subjective assumptions, estimates and judgments by our management. Changes in these rules or their
interpretation or changes in underlying assumptions, estimates or judgments by our management could significantly change or add significant
volatility to our reported or expected financial performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>A
potential failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley
Act could have a material adverse effect on our business, financial condition, and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over
financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements in accordance with U.S. generally accepted accounting principles, or GAAP. Under standards
established by the Public Company Accounting Oversight Board, or PCAOB, a deficiency in internal control over financial reporting
exists when the design or operation of a control does not allow management or personnel, in the normal course of performing their
assigned functions, to prevent or detect misstatements on a timely basis. The PCAOB defines a material weakness as a deficiency, or
combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a
material misstatement of annual or interim financial statements will not be prevented, or detected and corrected, on a timely
basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be required, pursuant to Section 404 of the Sarbanes-Oxley Act, to furnish a report by management on, among other things, the effectiveness
of our internal control over financial reporting for our second annual report on Form 10-K filed with the SEC and in each year thereafter.
Our auditors will also need to attest to the effectiveness of our internal control over financial reporting at such time as we are an
accelerated filed or large accelerated filer and no longer an emerging growth company or smaller reporting company. If we are unable
to assert that our internal control over financial reporting is effective, or when required in the future, if our independent registered
public accounting firm is unable to express an unqualified opinion as to the effectiveness of our internal control over financial reporting,
investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could be
adversely affected, and we could become subject to litigation or investigations by the stock exchange on which our common stock are listed,
the SEC or other regulatory authorities, which could require additional financial and management resources and could have a material
adverse effect on our business, financial condition, and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
limited amount of public company experience of our management team could adversely impact our ability to comply with the reporting requirements
of U.S. securities laws, which could have a materially adverse effect on our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
officers have limited public company experience, which could impair our ability to comply with legal and regulatory requirements such
as those imposed by Sarbanes-Oxley Act. Such responsibilities include complying with federal securities laws and making required disclosures
on a timely basis. Any such deficiencies, weaknesses or lack of compliance could have a materially adverse effect on our ability to comply
with the reporting requirements of the Securities Exchange Act of 1934, or the Exchange Act, which is necessary to maintain our public
company status. If we were to fail to fulfill those obligations, our ability to continue as a U.S. public company would be in jeopardy
in which event you could lose your entire investment in our Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
identified material weaknesses in our internal control over financial reporting, and we may identify additional material weaknesses in
the future that may cause us to fail to meet our reporting obligations or result in material misstatements of our financial statements.
If we fail to remediate any material weaknesses or if we otherwise fail to establish and maintain effective control over financial reporting,
our ability to accurately and timely report our financial results could be adversely affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure
controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered
in their implementation, could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection
with Section 404 of the Sarbanes-Oxley Act, or the subsequent testing by our independent registered public accounting firm when required,
may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require
prospective or retrospective changes to our financial statements or identify other areas for further attention or improvement.
Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative
effect on the trading price of our common shares. There is also a risk that neither we nor our independent registered public accounting
firm (when applicable in the future) will be able to conclude within the prescribed timeframe that internal controls over financial reporting
is effective as required by Section 404. As a result, investors could lose confidence in our financial and other public reporting, which
would harm our business and the trading price of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the preparation of our financial statements for the years ended December&nbsp;31, 2022 and 2021, we and our independent
registered public accounting firm identified a material weakness as it relates to a lack of adequate segregation of accounting functions
and the appropriate accounting for certain warrants in 2021 that were issued in connection with our previously issued but no longer
outstanding debt instruments. We are in the process of implementing measures designed to improve our internal control over financial
reporting and remediate this material weakness. We intend to increase staffing within our accounting infrastructure sufficient to facilitate
proper segregation of accounting functions and to enable appropriate review of our internally prepared financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may identify future material weaknesses in our internal controls over financial reporting or fail to meet the demands that will be placed
upon us as a public company, including the requirements of the Sarbanes-Oxley, and we may be unable to accurately report our financial
results, or report them within the timeframes required by law or stock exchange regulations. We cannot assure that our existing material
weakness will be remediated or that additional material weaknesses will not exist or otherwise be discovered, any of which could adversely
affect our reputation, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will incur significant increased costs as a result of becoming a public company that reports to the SEC and our management will be required
to devote substantial time to meet compliance obligations</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company reporting to the SEC after this offering, we will incur significant legal, accounting and other expenses that we did
not incur as a private company. We will be subject to reporting requirements of the Exchange Act and the reporting and governance provisions
of the Sarbanes-Oxley Act and the Dodd-Frank Wall Street Reform and Protection Act, as well as rules subsequently implemented by the
SEC, that impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure
and financial controls and changes in corporate governance practices. There are significant corporate governance and reporting provisions
in these laws that will increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly
and may also place undue strain on our personnel, systems and resources. Our management and other personnel will need to devote a substantial
amount of time to these regulations. In addition, we expect these rules and regulations to make it more difficult and more expensive
for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur
substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain
qualified people to serve on our Board our Board committees or as executive officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by
geopolitical instability due to the ongoing military conflict between Russia and Ukraine.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
and global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the start of the
military conflict between Russia and Ukraine. In February 2022, Russia launched a full-scale military invasion of Ukraine. Although the
length and impact of the ongoing military conflict is highly unpredictable, the conflict in Ukraine could lead to market disruptions,
including significant volatility in commodity prices, credit and capital markets. Additionally, Russia&rsquo;s prior annexation of Crimea,
recent recognition of two separatist republics in the Donetsk and Luhansk regions of Ukraine and subsequent military interventions in
Ukraine have led to sanctions and other penalties being levied by the United States, European Union and other countries against Russia,
Belarus, the Crimea Region of Ukraine, the so-called Donetsk People&rsquo;s Republic, and the so-called Luhansk People&rsquo;s Republic,
including agreement to remove certain Russian financial institutions from the Society for Worldwide Interbank Financial Telecommunication
(SWIFT) payment system. Additional potential sanctions and penalties have also been proposed and/or threatened. Russian military actions
and the resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity
in capital markets, potentially making it more difficult for us to obtain additional funds. Any of the abovementioned factors could affect
our business, prospects, financial condition, and operating results. The extent and duration of the military action, sanctions and resulting
market disruptions are impossible to predict, but could be substantial. Any such disruptions may also magnify the impact of other risks
described in this prospectus.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="ps_003"></A>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus, including the sections entitled &ldquo;<I>Prospectus Summary</I>,&rdquo; &ldquo;<I>Risk Factors,</I>&rdquo; &ldquo;<I>Use
of Proceeds,</I>&rdquo; &ldquo;<I>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</I>,&rdquo;
and &ldquo;<I>Business</I>,&rdquo; contains forward-looking statements. The words &ldquo;believe,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo;
&ldquo;potentially,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;could,&rdquo;
&ldquo;would,&rdquo; &ldquo;project,&rdquo; &ldquo;plan,&rdquo; &ldquo;expect&rdquo; and similar expressions that convey uncertainty
of future events or outcomes are intended to identify forward-looking statements. These forward-looking statements include, but are not
limited to, statements concerning the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            future financial and operating results;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            intentions, expectations and beliefs regarding anticipated growth, market penetration and
                                            trends in our business;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            timing and success of our plan of commercialization;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to successfully develop and clinically test our product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to obtain FDA approval for any of our product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to comply with all U.S. and foreign regulations concerning the development, manufacture
                                            and sale of our product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            reliance on third parties to manufacture our product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            adequacy of the net proceeds of this offering;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            effects of market conditions on our stock price and operating results;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to maintain, protect and enhance our intellectual property;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            effects of increased competition in our market and our ability to compete effectively;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            plans to use the proceeds from this offering;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
                                            associated with initiating and defending intellectual property infringement and other claims;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            attraction and retention of qualified employees and key personnel;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">future
                                            acquisitions of or investments in complementary companies or technologies; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to comply with evolving legal standards and regulations, particularly concerning
                                            requirements for being a public company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in &ldquo;<I>Risk
Factors</I>&rdquo; and elsewhere in this prospectus. Moreover, we operate in a very competitive and rapidly changing environment, and
new risks emerge from time to time. It is not possible for us to predict all risks, nor can we assess the impact of all factors on our
business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained
in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and
circumstances discussed in this prospectus may not occur and actual results could differ materially and adversely from those anticipated
or implied in our forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected
in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events
and circumstances described in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes
responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any
forward-looking statements for any reason after the date of this prospectus to conform these statements to actual results or to changes
in our expectations, except as required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this prospectus and the documents that we reference in this prospectus and have filed with the SEC as exhibits to the registration
statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance and
events and circumstances may be materially different from what we expect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ds_004"></A>TRADEMARKS,
SERVICE MARKS AND TRADE NAMES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own or have rights to use a number of registered and common law trademarks, service marks and/or trade names in connection with our business
in the United States and/or in certain foreign jurisdictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solely
for convenience, the trademarks, service marks, logos and trade names referred to in this prospectus are without the &reg; and &trade;
symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable
law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names. This prospectus contains
additional trademarks, service marks and trade names of others, which are the property of their respective owners. All trademarks, service
marks and trade names appearing in this prospectus are, to our knowledge, the property of their respective owners. We do not intend our
use or display of other companies&rsquo; trademarks, service marks, copyrights or trade names to imply a relationship with, or endorsement
or sponsorship of us by, any other companies.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="ps_004"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We
estimate that the net proceeds from our issuance and sale of 1,500,000 shares of our common stock in this offering, at the initial
public offering price of $5.00 per share, will be approximately $6.5 million (or $7.5 million if the underwriters exercise in full their
option to purchase additional shares), and after deducting the estimated underwriting discounts and commissions and estimated offering
expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to use the net proceeds from this offering, along with our existing cash and cash equivalents, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately
                                            $3.0 million to fund clinical trials and product development, including $2.5 million
                                            for the ATR-12 Netherton syndrome program, which is expected to provide funding for dosing
                                            in the proposed Phase 1b clinical trial, and $0.2 million for the ATR-04 EGFR inhibitor
                                            associated rash program, which is expected to provide funding through the initial enrollment
                                            for the proposed Phase 1b clinical trial;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately
                                            $2.0 million for research and development, including approximately $1.0 million
                                            on ATR-12 biomarker development, $0.5 million on ATR-04 biomarker development and $0.5
                                            million on new product development;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately
                                            $0.5 million for clinical manufacturing; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            balance for other general corporate purposes, including in-licensing and partnering activities,
                                            laboratory facility improvements, general and administrative expenses and working capital.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
expected use of net proceeds from this offering represents our current intentions based upon our present plans and business condition.
As of the date of this prospectus, we cannot predict with complete certainty all of the particular uses for the net proceeds to be received
upon the completion of this offering or the actual amounts that we will spend on the uses set forth above. We believe opportunities may
exist from time to time to expand our current business through the acquisition or in-license of complementary product candidates. While
we have no current agreements or plans for any specific acquisitions or in-licenses at this time, we may use a portion of the
net proceeds for these purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amounts and timing of our actual expenditures will depend on numerous factors, including the progress of our clinical trials and other
development and commercialization efforts for our initial product candidates, as well as the amount of cash used in our operations. However,
we cannot estimate with certainty the amount of net proceeds to be used for the purposes described above. We may find it necessary or
advisable to use the net proceeds for other purposes, and we will have broad discretion in the application of the net proceeds. Pending
the uses described above, we plan to invest the net proceeds from this offering in short-and intermediate-term, interest-bearing obligations,
investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the government.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="ps_005"></A>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid any cash dividends on our common stock and we do not anticipate paying any cash dividends on our common
stock in the foreseeable future. Investors should not purchase our common stock with the expectation of receiving cash dividends.
The payment of dividends on our common stock, if any, in the future is within the discretion of our Board and will depend on our
earnings, capital requirements and financial condition and other relevant facts. We currently intend to retain all future earnings, if
any, to finance the development and growth of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="ps_006"></A>CAPITALIZATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth our cash and capitalization as of March 31, 2023:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
                                            an actual basis;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
                                            a pro forma basis to give effect to (i) a forward stock split, or the Stock Split, effected
                                            on May 17, 2023 at a ratio of 7.1-for-1, (ii) the automatic conversion of all outstanding convertible preferred
                                            stock into an aggregate of 7,693,436 shares of common stock upon the closing of this offering,
                                            and (iii) the automatic conversion of all convertible promissory notes into an aggregate
                                            of 1,838,775 shares of common stock, upon the closing of this offering; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
                                            a pro forma as adjusted basis to reflect, in addition, our sale of 1,500,000 shares
                                            of common stock in this offering at the initial public offering price of $5.00 per
                                            share,
                                            after deducting underwriting discounts and commissions and estimated offering expenses payable
                                            by us.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">All
other share and share price information in this prospectus have been adjusted to reflect the Stock Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read the information in this table together with our financial statements and related notes and &ldquo;<I>Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations</I>&rdquo; appearing elsewhere in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of March 31, 2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">(in thousands, except share amounts)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Actual</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Pro Forma</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Pro Forma As Adjusted</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 1.5pt solid; text-align: right">1,833</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 1.5pt solid; text-align: right">1,833</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 1.5pt solid; text-align: right">8,346</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Convertible notes payable</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,400</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Series A convertible preferred stock; $0.0001 par value, 205,385 shares authorized,
    issued and outstanding, actual; no shares issued and outstanding, pro forma and pro forma as adjusted</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,273</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Series A-1 convertible preferred stock; $0.0001 par value, 380,657 shares
    authorized, issued and outstanding, actual; no shares issued and outstanding, pro forma and pro forma as adjusted</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">14,101</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Series B convertible preferred stock; $0.0001 par value, 851,108 shares authorized,
    414,735 issued and outstanding, actual; no shares issued and outstanding, pro forma and pro forma as adjusted</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">17,446</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Common stock, $0.0001 par value, 1,950,000 shares authorized, 147,041 shares issued and outstanding,
    actual; 10,586,510 shares issued and outstanding, pro forma; 12,086,510 shares issued and outstanding, pro forma as
    adjusted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,093</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">46,024</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">51,368</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(39,772</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(42,475</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(42,475</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total stockholders&rsquo; equity (deficit)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(38,679</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,550</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,894</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total capitalization</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,541</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,550</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,894</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR STYLE="clear: both"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="ps_007"></A>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you invest in our common stock in this offering, your interest will be diluted to the extent of the difference between the amount per
share paid by purchasers of shares of common stock in this offering and the pro forma as adjusted net tangible book value per share of
common stock immediately after the completion of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">As
of March 31, 2023, our pro forma net tangible book value was approximately $3.4 million, or $0.32 per share of common stock. Our pro
forma net tangible book value per share represents the amount of our total tangible assets reduced by the amount of our total
liabilities and divided by the total number of shares of our common stock outstanding as of March 31, 2023, after giving effect to
(i) a forward stock split, or the Stock Split, effected on May 17, 2023 at a ratio of 7.1-for-1; and (ii) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
automatic conversion of all outstanding shares of our preferred stock and convertible notes as of March 31, 2023 into shares of
common stock upon the closing of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">After giving effect to our sale in this offering of 1,500,000 shares of
our common stock, at the initial public offering price of $5.00 per share, after deducting underwriting discounts and commissions and
estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of March 31, 2023 would have been approximately
$8.7 million, or $0.72 per share of our common stock. This represents an immediate increase in pro forma as adjusted net tangible book
value of $0.40 per share to our existing stockholders and an immediate dilution of $4.28 per share to investors purchasing shares in this
offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table illustrates this dilution:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 64%">Initial public offering price per share</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">5.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pro
    forma net tangible book value per share as of March 31, 2023, before giving effect to this offering</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.32</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; vertical-align: top; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Increase
    in pro forma net tangible book value per share attributable to new investors purchasing shares in this offering</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.40</FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pro
    forma as adjusted net tangible book value per share, after giving effect to this offering</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">0.72</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dilution
    per share to new investors purchasing shares in this offering</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">4.28</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The following table summarizes, on a pro forma as adjusted basis as described
above, the difference between existing stockholders (after giving effect to (i) the Stock Split and (ii) the automatic conversion of all
outstanding shares of our preferred stock and outstanding convertible notes into shares of common stock upon the closing of this offering)
and new investors with respect to the number of shares of common stock purchased from us, the total consideration paid to us and the initial
public offering price of $5.00 per share, before deducting underwriting discounts and commissions and estimated offering expenses:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="background-color: white">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="background-color: white"></FONT></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shares
    Purchased</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Consideration</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Average</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Price
    Per</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Percent</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Percent</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Share</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Existing
    stockholders</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">10,586,510</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">88</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">40,182,933</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">84</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">3.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">New
    public investors</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">1,500,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">12</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">7,500,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">16</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">5.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">12,086,510</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">100.0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">47,682,933</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">100.0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise indicated, the foregoing tables and calculations are based on the number of shares of our common stock outstanding as of
March 31, 2023, after giving effect to (i) the Stock Split; and (ii) the automatic conversion of all outstanding shares of our
preferred stock and convertible promissory notes into shares of common stock upon the closing of this offering, and excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,290,319
                                            </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
                                            of our common stock issuable upon exercise of outstanding options, with a weighted average
                                            exercise price of $1.33 per share, granted pursuant to our 2016 Stock Incentive Plan,
                                            or the 2016 Plan;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately
                                            275,210 shares of our common stock issuable upon exercise of outstanding warrants,
                                            with a weighted average exercise price of $4.23 per share</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">up
                                            to 225,000 shares issuable pursuant to the underwriters&#8217; over-allotment option;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60,000
                                            </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
                                            issuable upon exercise of a warrant to be issued to the underwriter as part of its compensation
                                            in connection with this offering (up to 69,000 shares if the over-allotment option
                                            is exercised) at an exercise price of $6.25 per share; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">157,989
                                            </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
                                            of our common stock reserved for future grants under our 2016 Plan and 2,000,000 shares
                                            of our common stock reserved for future grants under our 2023 Stock Incentive Plan, or the
                                            2023 Plan.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="ps_008"></A>MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION<BR>
AND RESULTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>You
should read the following discussion together with our financial statements and the related notes included elsewhere in this prospectus.
This discussion contains forward-looking statements that are based on our current expectations, estimates and projections about our business
and operations. Our actual results may differ materially from those currently anticipated and expressed in such forward-looking statements
as a result of a number of factors, including those which we discuss under &ldquo;Risk Factors&rdquo; and elsewhere in this prospectus.
See the section titled &ldquo;Cautionary Note Regarding Forward-Looking Statements.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were formed in January 2014 as a biopharmaceutical company focused on developing innovative therapies for precision dermatology using
engineered proteins and live biotherapeutic products. We have built a proprietary platform that includes a microbial library comprised
of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented
by an artificial intelligence and machine learning technology that analyzes, predicts and helps screen our library of strains for drug
like molecules. The platform also utilizes a licensed a genetic engineering technology, which can enable the transformation of previously
genetically intractable strains. We are an early-stage clinical biopharmaceutical company and have not commenced commercial
operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have capitalized our operations primarily through a series of private placements of our convertible preferred stock and convertible
promissory notes, all of which will convert into shares of our common stock upon the consummation of this offering, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            March 2017 placement of 205,385 shares of our Series A convertible preferred stock, at a
                                            price of $16.25 per share, which will convert into 1,458,234 shares of our common
                                            stock upon the consummation of this offering;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            February 2019 placement of 380,657 shares of our Series A-1 convertible preferred stock,
                                            at a price of $37.50 per share, which will convert into 2,958,120 shares of our common
                                            stock upon the consummation of this offering;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            September 2020 placement of 392,000 shares of our Series B convertible preferred stock, at
                                            a price of $43.45 per share, which will convert into 3,277,083 shares of our common
                                            stock upon the consummation of this offering;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            January 2021 placement of a $1 million unsecured convertible promissory note, the principal
                                            amount of which, along with all accrued and unpaid interest thereunder, converted into 23,432
                                            shares of our Series B convertible preferred stock in January 2023; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            September 2022 placement of $4.35 million of our unsecured convertible promissory notes,
                                            the principal amount of which, along with all accrued and unpaid interest thereunder, is
                                            convertible into shares of our common at the per share conversion price equal to
                                            the lower of (i) $30 million divided the number of our shares of common stock issued and
                                            outstanding, on a fully diluted basis, immediately prior to the close of this offering or
                                            (ii) 50% of the price per share in this offering.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise indicated, all information in this prospectus concerning our outstanding share of common stock (i) gives effect to
a forward stock split effected on May 17, 2023 at a ratio of 7.1-for-1, and (ii) assumes the automatic conversion
of the above-described shares of convertible preferred stock and convertible promissory notes, into a total of approximately
9,542,519 shares of our common stock upon the consummation of this offering.</FONT> Unless otherwise indicated, all other share
and share price information in this prospectus have been adjusted to reflect the forward stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results
of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an early-stage clinical biopharmaceutical company, formed in January 2014, and have limited operating history. We have
not commenced revenue-producing operations apart from limited service revenue derived through our JDA with Bayer. Under the terms of
the JDA, we are responsible for testing our library of microbial strains and their natural products for key preclinical properties
and Bayer reimburses us for our development costs. To date, our operations have consisted of the development of our proprietary microbial
library, the identification, characterization and testing of certain bacterial species from our microbial library that we believe are
capable of being engineered to provide significant therapeutic effect and the development of our initial product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Three Months Ended March 31, 2023 Compared to Three Months Ended March 31, 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three months ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">$ Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%; text-align: left; padding-bottom: 1.5pt">Service revenue - related party</TD><TD STYLE="width: 2%; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">113,300</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 1.5pt solid; text-align: right">120,000</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 1.5pt solid; text-align: right">(6,700</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; border-bottom: Black 1.5pt solid; text-align: right">(6</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total revenue</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">113,300</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,700</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6</TD><TD STYLE="text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">General and administrative</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">843,011</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">861,308</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,297</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2</TD><TD STYLE="text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Research and development</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">830,181</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,555,368</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(725,187</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(47</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,673,192</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,416,676</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(743,484</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(31</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss from operations</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(1,559,892</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,296,676</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">736,784</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(32</TD><TD STYLE="text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Interest income</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">285</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">520</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(235</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(45</TD><TD STYLE="text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Interest expense</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(89,832</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(17,637</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(72,195</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">409</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Other income</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,146</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,146</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Change in fair value of convertible note</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(800,000</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(800,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other expense</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(8,886</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(12,224</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,338</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(27</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Total other income (expense)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(897,287</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(29,341</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(867,946</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2958</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss before income taxes</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(2,457,179</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,326,017</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(131,162</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Income tax benefit (expense)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(2,457,179</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2,326,017</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(131,162</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Dividends on preferred stock</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(712,080</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(692,246</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(19,834</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss attributable to common shareholders</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(3,169,259</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,018,263</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(150,996</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Service
Revenue - Related Party</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
generated $113,300 of service revenue under the Bayer JDA during the first three months of fiscal 2023 compared to service revenue of
$120,000 under the JDA for the comparable period in fiscal 2022. The decrease of $6,700 in service revenue is attributable to a decreased
amount of reimbursable development costs in 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>General
and Administrative</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative costs during the first three months of fiscal 2023 decreased by $18,297 or 2%, to $843,011 from the prior year period.
The decrease was primarily related to a decrease of $158,000 in payroll and related costs attributable to the discontinuation of separation
benefits paid to our former chief operating officer and a $46,000 reduction in legal expenses, offset by an increase of $167,000 in accounting
and public relation fees, and $18,703 net increase of other overhead expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses include salaries and benefits of all research personnel, payments to contract research organizations, payments
to research consultants, and the purchase of lab supplies. These expenses are offset by income earned from government grant payments.
We generate grant revenue on contracts with various federal agencies and nonprofit research institutions for general research conducted
by us. These grant arrangements also do not meet the criteria for revenue recognition and amounts earned under these grant contracts
are recorded as a negative research and development expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the first three months of fiscal 2023, research and development expenses decreased by $725,187, or 47%, to $830,181 from the prior year
period. The decrease was primarily related to a decrease of $448,613 in research and development related costs attributable to our efforts
in moving our Netherton program forward and a net decrease in payroll and related costs of $281,000 attributable to a reduction in staff.
Research and development expenses for the first three months in fiscal 2023 and 2022 were offset by $0 and $4,426, respectively, of government
and nonprofit grant revenue received by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our research and development expenses to significantly increase in the future due <FONT STYLE="background-color: white">primarily
to our planned clinical trial activity and continued development of product candidates.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Income (Expense)</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
other income (expense) consists of refundable research and development credits, valuation of warrants, amortization of debt issuance
costs, change in fair value of the convertible note and interest expense on the placement of the $1 million unsecured promissory note
in January 2021. During the first three months of fiscal 2023, other income (expense) increased by $867,946, or 2,958%, compared to the
comparable period in fiscal 2021. The increase was primarily related to an increase of $800,000 attributable to the change in fair value
of the convertible note, an increase of $72,195 attributable to interest expense offset by a net decrease of $4,249 of other income and
expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year
Ended December 31, 2022 Compared to Year Ended December 31, 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">Years ended December 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">$ Change</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">% Change</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: left; padding-bottom: 1pt">Service revenue &ndash; related party</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 12%; border-bottom: Black 1pt solid; text-align: right">284,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; border-bottom: Black 1pt solid; text-align: right">110,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; border-bottom: Black 1pt solid; text-align: right">174,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; border-bottom: Black 1pt solid; text-align: right">158</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total revenue</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">284,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">110,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">174,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">158</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating expenses:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">General and administrative</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">3,639,666</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,951,352</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(311,686</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(8</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Research and development</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">6,097,938</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">5,380,102</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">717,836</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">13</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">Total operating expenses</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">9,737,604</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">9,331,454</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">406,150</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">5</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss from operations</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(9,453,604</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(9,221,454</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(232,150</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Other income (expense):</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Interest income</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">4,818</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8,759</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,941</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(45</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Interest expense</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(251,891</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(66,968</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(184,923</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">276</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Other income</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">65,849</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">112,141</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(46,292</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(41</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Employee retention credit</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">229,813</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">229,813</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Forgiveness of Payroll Protection Program loan</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">232,506</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(232,506</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Change in fair value of convertible note</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(1,250,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,250,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other expense</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">(25,351</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">(4,659</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">(20,692</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">444</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">Total other income (expense)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">(1,226,762</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">281,779</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">(1,508,541</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">734</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss before income taxes</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(10,680,366</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(8,939,675</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,740,691</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">Income tax benefit (expense)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(10,680,366</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(8,939,675</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,740,691</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Service
Revenue - Related Party</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
generated $284,000 of service revenue under the Bayer JDA during fiscal 2022 compared to service revenue of $110,000
under the JDA in fiscal 2021. The increase of $174,000 in service revenue is attributable to an increased
amount of reimbursable development costs in 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>General
and Administrative</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">General
and administrative costs during fiscal 2022 decreased by $311,686, or 8%, to $3,639,666 from the prior year period. The decrease
was primarily related to a decrease of $961,000 in payroll and related costs attributable to the discontinuation of separation benefits
paid to our former chief executive officer and chief operating officer and the reduction in recruiting expenses for our new
chief executive officer, offset by an increase of $607,000 in accounting and legal fees, and $43,000 net increase of other overhead expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses include salaries and benefits of all research personnel, payments to contract research organizations, payments
to research consultants, and the purchase of lab supplies. These expenses are offset by income earned from government grant payments.
We generate grant revenue on contracts with various federal agencies and nonprofit research institutions for general research conducted
by us. These grant arrangements also do not meet the criteria for revenue recognition and amounts earned under these grant contracts
are recorded as a negative research and development expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
fiscal 2022, research and development expenses increased by $717,836, or 13%, to $6,097,938 from the prior
year period. The increase was primarily related to an increase of $808,000 in research and development related costs
attributable to our efforts in moving our Netherton program forward offset by a net decrease in payroll and related costs of $85,738
attributable to a reduction in staff. Research and development expenses in fiscal 2022 and 2021 were offset by $4,426 and $202,509,
respectively, of government and nonprofit grant revenue received by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our research and development expenses to significantly increase in the future due <FONT STYLE="background-color: white">primarily
to our planned clinical trial activity and continued development of product candidates.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Income (Expense)</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
other income (expense) consists of refundable research and development credits, employee retention credit, forgiveness of the
payroll protection loan, valuation of warrants, amortization of debt issuance costs, change in fair value of the convertible note
and interest expense on the placement of the $1 million unsecured promissory note in January 2021. During fiscal 2022, other
income (expense) increased by $1,508,541, or 734%, compared to fiscal 2021. The increase was primarily related to
an increase of $1,250,000 attributable to the change in fair value of the convertible note, an increase of $229,813 attributable to
the employee retention credit, an increase of $184,923 attributable to interest expense offset by a net decrease of $156,195 of other
income and expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and Financial Condition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2023, we had total assets of $5.7 million and working capital of $361 thousand. As of March 31, 2023,
our liquidity included $1.8 million of cash and cash equivalents, which gives effect to our receipt of $4.35 million of proceeds
from our placement of unsecured convertible promissory notes in September 2022. As of the date of this prospectus, our projected working
capital needs consist of funds with which to further clinical trials and product development, research and development, clinical manufacturing
as well as for other general corporate purposes, including general and administrative expenses. See the section titled &ldquo;<I>Use
of Proceeds.</I>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Funding
Requirements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that net proceeds of this offering, along with our cash on hand as of the date of this prospectus, will be sufficient to cover
our proposed plan of operations over, at least, the 12 months following this offering, including dosing in the proposed Phase 1b
clinical trial for ATR-12 and the initial enrollment in the proposed Phase 1b clinical trial for ATR-04. However, as of the date
of this prospectus, we believe that we will need additional capital beyond the next 12 months, and there can be no assurance we will
not need additional capital sooner. In addition, we believe that we will need additional capital to obtain marketing approval for ATR-12
and ATR-04, assuming such approval can be obtained at all. We intend to seek additional funds through various financing sources, including
the sale of our equity and debt securities, licensing fees for our technology and joint ventures with industry partners. In addition,
we will consider alternatives to our current business plan that may enable us to achieve revenue producing operations and meaningful
commercial success with a smaller amount of capital. However, there can be no guarantees that such funds will be available on commercially
reasonable terms, if at all. If such financing is not available on satisfactory terms, we may be unable to further pursue our business
plan and we may be unable to continue operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be
diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common
stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting
our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends.
If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third
parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates,
or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings
or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future
commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market
ourselves.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
report of our independent registered public accounting firm for the three months ended March 31, 2023 states that due to
our accumulated deficit, recurring and negative cash flow from operations there is substantial doubt about our ability to continue as
a going concern. Our financial statements, in Note 1, include disclosure with respect to a substantial doubt about our ability to continue
as a going concern and the report of our independent auditor includes an explanatory paragraph with respect to that substantial doubt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contractual
Obligations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material
contractual obligations arising in the normal course of business primarily consist of operating leases. See Note 15 to our audited financial statements for future minimum payments under non-cancelable operating leases with initial or remaining terms in excess
of one year during over the next five years.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash
Flows</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows a summary of our cash flows for the periods indicated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Three
                                            Months Ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
                                            31,</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; text-align: left">Cash Used in Operating Activities</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(1,209,347</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(2,358,478</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash Used in Investing Activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(82,834</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(93,392</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash provided by Financing Activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(367,080</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,510</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net Decrease in Cash and Cash Equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,659,261</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2,450,360</TD><TD STYLE="text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Operating
Activities. </I>During the first three months of fiscal 2023, operating activities used $1.2 million of cash primarily driven by our
net loss of $2.5 million offset by non-cash items of $1.3 million. During the comparable period of fiscal 2022, operating activities
used $2.4 million of cash primarily driven by our net loss of $2.3 million and non-cash items of $0.1 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investing
Activities. </I>During the first three months of fiscal 2023, investing activities used $0.083 million of cash primarily driven by $0.069
million of trademark and patent costs and $0.014 million for the purchase of furniture and equipment. During the comparable period of
fiscal 2022, investing activities used $0.093 million of cash primarily driven by $0.063 million of trademark and patent costs and $0.030
million for the purchase of furniture and equipment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Financing
Activities. </I>During the first three months of fiscal 2023, financing activities used $0.367 million in cash driven by $0.367 million
of deferred offering costs. During the comparable period of fiscal 2022, financing activities provided $0.002 million in cash primarily
driven by the proceeds from the exercise of stock options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year
Ended December 31, 2022 Compared to Year Ended December 31, 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Years
                                            Ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
                                            31,</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    Used in Operating Activities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(8,349,469</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(8,067,359</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    Used in Investing Activities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(336,761</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(652,275</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    provided by Financing Activities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,134,624</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">992,862</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net Decrease in Cash and Cash Equivalents</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4,551,606</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(7,726,772</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Operating
Activities. </I>During the year ended December 31, 2022, operating activities used $8.3 million of cash primarily driven
by our net loss of $10.7 million offset by non-cash items of $2.4 million. During the year ended December 31, 2021,
operating activities used $8.1 million of cash primarily driven by our net loss of $8.9 million offset by non-cash
items of $0.8 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investing
Activities. </I>During the year ended December 31, 2022, investing activities used $0.336 million of cash primarily driven
by $0.308 million of trademark and patent costs and $0.028 million for the purchase of furniture and equipment. During
the year ended December 31, 2021, investing activities used $0.652 million of cash primarily driven by $0.206 million
of trademark and patent costs and $0.446 million for the purchase of furniture and equipment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Financing
Activities. </I>During the year ended December 31, 2022, financing activities provided $4.1 million in cash primarily driven by the issuance
of a $4.4 million convertible promissory note offset by $0.3 million of deferred offering costs. During the year ended December
31, 2021, financing activities provided $0.993 million in cash primarily driven by the issuance of a $1 million convertible promissory
note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Critical
Accounting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
management&rsquo;s discussion and analysis of our financial condition and results of operations is based on our financial statements,
which have been prepared in accordance with U.S. GAAP. The preparation of these
financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses
and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and
judgments, including those related to prepaid/accrued research and development expenses, share-based compensation and fair value of convertible
promissory notes. We base our estimates on historical experience, known trends and events, and various other factors that are believed
to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets
and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions
or conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
our significant accounting policies are described in more detail in Note 2 to our audited financial statements included elsewhere in
this prospectus, we believe the following accounting policies are the most critical to the judgments and estimates used in the preparation
of our financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Internal
Control Over Financial Reporting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Internal
control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements in accordance with U.S. GAAP. Under standards established by the Public Company Accounting
Oversight Board, or PCAOB, a deficiency in internal control over financial reporting exists when the design or operation of a control
does not allow management or personnel, in the normal course of performing their assigned functions, to prevent or detect misstatements
on a timely basis. The PCAOB defines a material weakness as a deficiency, or combination of deficiencies, in internal control over financial
reporting, such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not
be prevented, or detected and corrected, on a timely basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the preparation of our financial statements for the years ended December 31, 2022 and 2021, we and our independent registered
public accounting firm identified a material weakness as it relates to a lack of adequate segregation of accounting functions and the
appropriate accounting for certain warrants in 2021 that were issued in connection with our previously issued but no longer outstanding
debt instruments. We are in the process of implementing measures designed to improve our internal control over financial reporting and
remediate this material weakness. We intend to increase staffing within our accounting infrastructure sufficient to facilitate proper
segregation of accounting functions and to enable appropriate review of our internally prepared financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revenue
Recognition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 2 to our audited financial statements included elsewhere in this registration statement, under Accounting Standards
Codification, or ASC, 606, Revenue from Contracts with Customers, an entity recognizes revenue when its customer obtains control of promised
goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, we perform
the following five steps: (i) identification of the contract(s) with the customer, (ii) identification of the promised goods or services
in the contract and determination of whether the promised goods or services are performance obligations, (iii) measurement of the transaction
price, (iv) allocation of the transaction price to the performance obligations, and (v) recognition of revenue when (or as) we satisfy
each performance obligation. We only apply the five-step model to contracts when it is probable that the entity will collect consideration
it is entitled to in exchange for the goods or services it transfers to the customer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
optional goods or services are offered, we assess the options to determine whether the options grant the customer a material right. This
determination includes whether the option is priced at an amount that the customer would not have received without entering into the
contract. If we conclude the option conveys a material right, it is accounted for as a separate performance obligation. In identifying
performance obligations in a contract, we identify those promises that are distinct. Promised goods or services are considered distinct
when the customer can benefit from the goods or services on their own, or together with readily available resources, and the goods or
services are separately identifiable from other promises in the contract. If a promise is not distinct, it is combined with other promises
in the contract until the combined group of promises is capable of being distinct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate the transaction price based on the amount of consideration we expect to receive for transferring the promised goods or services
in the contract. The consideration may include both fixed consideration and variable consideration. At the inception of each arrangement
that includes variable consideration, we evaluate the amount of the potential payments and the likelihood that the payments will be received.
If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price.
For contracts that include sales-based royalties for licensed compounds, we recognize revenue at the date when the related sales occur.
Finally, we determine whether the contract contains a significant financing component by analyzing the promised consideration relative
to the standalone selling price of the promised goods and services and the timing of payment relative to the transfer of the promised
goods and services. At each reporting date, we reassess the transaction price and probability of achievement of the performance obligations
and the associated constraints on transaction price. If necessary, we adjust the transaction price, recording a cumulative catch-up based
on progress for the amount that was previously constrained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
is recognized when (or as) control of a performance obligation is transferred to the customer. When combined performance obligations
contain a promised license and related services or other promises, management judgment is required to determine the appropriate timing
of revenue recognition. In doing so, we must identify the predominant promise or promises in the contract to determine whether revenue
is recognized at a point in time or over time. If over time, we must determine the appropriate measure of progress. If a license is deemed
to be the predominant promise in a performance obligation, we must determine the nature of the license, whether functional or symbolic
intellectual property, to conclude whether point-in-time or over-time revenue recognition is most appropriate. The determination of functional
or symbolic intellectual property requires an assessment of whether the customer is able to exploit and benefit from the license in its
current condition, or if the utility of the license is dependent on or influenced by our ongoing activities or being associated with
us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
each reporting date, we calculate the measure of progress for the performance obligations transferred over time. The calculation
generally uses an input measure based on costs incurred to date relative to estimated total costs to complete the transfer of the
performance obligation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses consist primarily of costs incurred in connection with the development of our product candidates. We expense
research and development costs as incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
accrue an expense for preclinical studies and clinical trial activities performed by our vendors based upon estimates of the proportion
of work completed. We determine the estimates by reviewing contracts, vendor agreements and purchase orders, and through discussions
with our internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and
the agreed-upon fee to be paid for such services. However, actual costs and timing of clinical trials are highly uncertain, subject to
risks and may change depending upon a number of factors, including our clinical development plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
make estimates of our prepaid/accrued expenses as of each balance sheet date in our financial statements based upon facts
and circumstances known at that time. If the actual timing of the performance of services or the level of effort varies from the estimate,
we will adjust the accrual accordingly. Nonrefundable advance payments for goods and services, including fees for clinical trial expenses,
process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities,
are deferred and recognized as expense in the period that the related goods are consumed, or services are performed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share-Based
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
measure compensation expense for all share-based awards based on the estimated fair value of the share-based awards on the grant date.
We use the Black-Scholes option pricing model to value our share-based awards. We recognize compensation expense on a straight-line basis
over the requisite service period, which is generally the vesting period of the award. We have not issued awards for which vesting is
subject to market or performance conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Black-Scholes option-pricing model requires the use of subjective assumptions that include the expected stock price volatility and the
fair value of the underlying common stock on the date of grant. See Note 10 to our audited financial statements included elsewhere in
this prospectus for information concerning certain of the specific assumptions we used in applying the Black-Scholes option pricing model
to determine the estimated fair value of our awards granted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Estimating
the Fair Value of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to estimate the fair value of the common stock underlying our share-based awards when performing the fair value calculations
using the Black-Scholes option pricing model. Because our common stock is not currently publicly traded, the fair value of the common
stock underlying our stock options has been approved on each grant date by our Board, with input from management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
third-party valuations of our common stocks were performed using methodologies, approaches and assumptions consistent with the American
Institute of Certified Public Accountants, Audit and Accounting Practice Aid Series: Valuation of Privately Held Company Equity Securities
Issued as Compensation. In addition, our Board considered various objective and subjective factors to estimate the estimated fair value
of our common stock, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prices of our preferred stock sold to outside investors in arm&rsquo;s length transactions, and the rights, preferences and privileges
    of our preferred stock as compared to those of our common stock, including the liquidation preferences of our preferred stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    estimated value of each security both outstanding and anticipated;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    anticipated capital structure, which will directly impact the value of the currently outstanding securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    results of operations and financial position;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    status of our research and development efforts;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    composition of, and changes to, our management team and board of directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    lack of liquidity of our common stock as a private company;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    stage of development and business strategy and the material risks related to our business and industry;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">external
    market conditions affecting the life sciences and biotechnology industry sectors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
    and global economic conditions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    likelihood of achieving a liquidity event for the holders of our common stock, such as an initial public offering, or IPO, or a sale
    of our company, given prevailing market conditions; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    market value and volatility of comparable companies.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining the estimated fair value of our common stock, our Board considered the subjective factors discussed above in conjunction
with the most recent valuations of our common stock that were prepared by an independent third party. An independent valuation specialist
was utilized by our Board when determining the estimated fair value of common stock for the awards granted from October 2017 through
December 2021. Our Board, relying on these third-party valuations, approved valuations of our common stock of $3.39 per share
as of October 2017, $6.58 per share as of April 2019, $12.09 per share as of September 2020 and $11.05 per share as of December
2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Estimating
the Fair Value of Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
utilize a Black-Scholes method to value our outstanding warrants at each reporting period, with changes in fair value recognized in the
statement of operations. The estimated fair value of the warrant liabilities is determined using Level 3 inputs. Inherent in a Black-Scholes
model are assumptions related to expected share-price volatility, expected life, risk-free interest rate and dividend yield. We estimate
the volatility of our common stock based on market participant assumptions and matches the volatility used to value our stock options.
The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected
remaining life of the warrants. The expected life of our outstanding warrants is assumed to be equivalent to their remaining contractual
term. The dividend rate is based on the historical rate, which the Company anticipates to remain at zero.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Accounting Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 2 to our audited financial statements found elsewhere in this prospectus for a description of recent accounting pronouncements
applicable to our financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="ka_002"></A><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>BUSINESS</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered
proteins and topical live biotherapeutic products. We have built a
proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened
for unique therapeutic characteristics. The platform is augmented by an artificial intelligence and machine learning technology that
analyzes, predicts and helps screen our library of strains for drug like molecules. The platform also utilizes a licensed genetic engineering
technology, which can enable the transformation of previously genetically intractable strains. Our initial focus is on the development
of genetically engineered strains of <I>Staphylococcus epidermidis, or S. epidermidis, </I>which we consider to be an optimal therapeutic
candidate species for engineering of dermatologic therapies. The particular species demonstrates a number of well-described properties
in the skin. As of the date of this prospectus, we have identified, among our microbial library, over 60 distinct bacterial species that
we believe are capable of being engineered to create living organisms or engineered proteins with significant therapeutic effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a pioneer in genetically engineering bacteria for therapeutic use in dermatology. Our goal is to leverage our platforms and internal
microbial library bacterial strains to create new therapeutics that are either engineered living organisms or engineered proteins or
peptides to treat skin diseases. Our initial focus is on the development of our current product candidates, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ATR-12,
    </B>a genetically modified strain of <I>S. epidermidis</I> for treating the orphan disease, Netherton syndrome, a chronic and sometimes
    fatal disease of the skin estimated to affect approximately one in every 200,000, but its prevalence may be underestimated due to
    misdiagnosis caused by similarities to other skin diseases. We received Pediatric Rare Disease Designation for ATR-12 by the FDA
    in 2019. &zwnj;In December 2022, we submitted an investigational new drug application, or IND, for a Phase &zwnj;1b
    clinical trial of ATR-12 in Netherton syndrome&zwnj;, and on January 27, 2023 we received notification from the FDA that the &ldquo;study
    may proceed&rdquo; with respect to the proposed Phase 1b clinical trial. We expect to commence our Phase &zwnj;1b clinical
    trial in the first half of 2023 and report initial results in the first half of 2024.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ATR-04,
    </B>a genetically modified strain of <I>S. epidermidis</I> for treating the papulopustular rash experienced by cancer patients undergoing
    epidermal growth factor receptor inhibitor, or EGFRi, targeted therapy. We intend to submit an IND for a Phase 1b clinical
    trial in certain cancer patients undergoing EGFRi, targeted therapy by the end of 2023. Subject to FDA approval of our IND, we expect
    to commence our Phase 1b clinical trial by early 2024 with initial results expected in late 2024.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ATR-01,
    </B>an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic, scaly skin disease with
    an estimated incidence and prevalence of 1 in 250, which suggests a total patient population of 1.3 million in the United States.
    We are planning to complete lead optimization and IND-enabling studies in 2023 to support an IND filing in late 2024.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
    separate strains of microbes being investigated and developed by us and Bayer Consumer Care AG, the consumer products division
    of Bayer AG, the international life science company. We entered into a Joint Development Agreement, or JDA, with Bayer in December
    2019. Under the terms of the JDA, we are responsible for testing our library of microbial strains and their products for key
    preclinical properties which we intend to develop as potential over-the-counter cosmetic products. After screening through
    hundreds of strains, we and Bayer have selected two particular strains to move forward. Bayer holds the exclusive option to license
    the patent rights to these strains. In December 2020, Bayer purchased $8 million of our Series B preferred stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have established partnerships with teams from Carnegie Mellon University and the Fred Hutchinson Cancer Center, or Fred
Hutch, two of the premier academic centers in the United States. Our collaboration with the Carnegie Mellon based team takes advantage
of the power of whole genome sequencing. This partnership is mining our proprietary library of bacterial strains for novel, drug like
peptides and proteins. The artificial intelligence/machine learning technology developed by this team predicts the molecules made by
microbes from their genetic sequences. The system then compares the predictions to the products actually made through tandem mass spectroscopy
and/or nuclear magnetic resonance imaging to refine future predictions. The predictions can be compared to publicly available 2D and
3D protein databases to select drug like structures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hold an exclusive, worldwide license from Fred Hutch regarding the use of its patented SyMPL technologies for all fields of genetic
engineering, including to discover, develop and commercialize engineered microbial therapies and microbial-derived peptides and proteins
for skin diseases. We are utilizing our licensed patent rights to build plasmids that in order to make genetic transformations that have
never been previously achieved. Our collaboration with Fred Hutch is led by Dr. Christopher Johnston, an expert in microbial engineering,
and the innovator behind the SyMPL technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
our three lead product candidates and collaboration with Bayer, our goal is to develop a broad portfolio of product candidates focused
on expanding the application of our platforms for precision dermatology. We believe that we have established a unique position in advancing
the development of biologics for precision dermatology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="form424b4_016.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Business Strategies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to create a broad portfolio of product candidates for precision dermatology through our development of genetically engineered
proteins selected from our proprietary microbial library of approximately 1,500 unique bacterial strains. Our strategy is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Build
    a sustainable precision dermatology company. </I></B>Our goal is to build a leading precision dermatology company with a sustainable
    pipeline of product candidates. To that end, we are focused on rapidly advancing our current pipeline of live biotherapeutic candidates
    while actively developing additional product candidates. Each of our current product candidates are proprietary and subject to pending
    patent applications. We expect that most, if not all, genetically engineered product candidates we develop will be eligible for patent
    protection.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Advance
    our lead product candidates, ATR-12 and ATR-04, through clinical trials.</I></B> We are currently planning to begin two &zwnj;clinical
    trials in the next 12 months, including a Phase &zwnj;1b trial of our ATR-12 in Netherton syndrome patients and a Phase
    &zwnj;1b trial of our ATR-04 in certain cancer patients undergoing EGFRi therapy. We have successfully filed an IND for
    ATR-12 and expect to file an IND for ATR-04 by the end of 2023.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Broaden
    our platform by selectively exploring strategic partnerships that maximize the potential of our precision dermatology programs.</I></B>
    We intend to maintain significant rights to all of our core technologies and product candidates. However, we will continue to evaluate
    partnering opportunities in which a strategic partner could help us to accelerate development of our technologies and product candidates,
    provide access to synergistic combinations, or provide expertise that could allow us to expand into the treatment of different types
    of skin diseases. We may also broaden the reach of our platform by selectively in-licensing technologies or product candidates. In
    addition, we will consider potentially out-licensing certain of our proprietary technologies for indications and industries that
    we are not ourselves pursuing. We believe our genetic engineering techniques and technologies have applicability outside of the field
    of medicine, including cosmetics and in the generation of clean fuels and bioremediation.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Leverage
    our academic partnerships. </I></B>We currently have partnerships with investigators at the Fred Hutchinson Cancer Center, Yale University,
    Jackson Laboratory for Genomic Medicine, and Carnegie Mellon University. In January 2020, we entered into a clinical trial agreement
    with Yale University to evaluate the microbiome of approximately ten patients undergoing EGFR inhibitor therapy resulting in papulopustular
    rash. This is an observational trial meant to gain understanding of the microbial skin environment on these patients. Due to challenges
    with sample preservation, the commencement of patient enrollment was postponed and is planned to restart by late 2023. The estimated
    cost of the trial is expected to be less than $100,000, which will be paid by us. We have an ongoing scientific advisory board
    contract with Dr. Julia Oh of the Jackson Laboratories and have historically worked with Jackson Laboratories through sponsored research
    agreements for mouse experiments. We expect to leverage these partnerships and potentially expand them or form other academic partnerships
    to bolster our engineering platforms and expand our research and development pipeline.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><B><I>Management team</I></B>. We are led by Francisco
    D. Salva, our chief executive officer, and Travis Whitfill, our co-founder, who have more than 35 years of combined experience
    in the management of biotechnology companies and healthcare investing. Mr. Salva was previously a co-founder of Acerta Pharma, which
    was sold to AstraZeneca for approximately $6.3 billion in a staged acquisition beginning in 2016. He also worked on the turnaround
    of Pharmacyclics, which subsequently sold to Abbvie for approximately $21 billion in 2015. Before that, Mr. Salva spent almost a
    decade in life sciences venture capital. Mr. Whitfill served as associate research scientist and assistant professor adjunct at Yale
    University with appointments in the Departments of Pediatrics and Emergency Medicine. He has led numerous grant-funded projects,
    holds nearly a dozen patents and has co-authored over 50 publications. Our board of directors, or Board, is comprised of renowned
    group of senior executives, scientists and investors in the biotechnology industry<B><I>.</I></B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Microbial Library and Microbial Drug Delivery Platform</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commensal
microorganisms reside on either the surface of the body or in the mucosa without harming human health. They act on the host&rsquo;s immune
system to induce protective responses that prevent colonization and invasion by infectious pathogens, and thereby play a crucial role
in maintaining human health across a number of organ systems, particularly in the skin. Diverse communities of microorganisms populate
the skin, and a square centimeter can contain up to a billion microorganisms. These diverse communities of bacteria, fungi, mites and
viruses can provide protection against disease and form dynamic, yet distinct niches on the skin. Together, they make up the skin microbiome.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
genetically driven human diseases are systemically or partially related to the dysfunction of specific proteins that are missing or functionally
inert due to a mutation. Since approximately 1982, the biopharmaceutical industry has been genetically engineering recombinant proteins
in bacterial microorganisms for purposes providing therapies that mimic or support the body&rsquo;s normally functioning proteins and
peptides. For decades, the vast majority of genetic engineering has been limited to primary <I>E. coli</I> and a handful of other bacterial
species, many of which can become pathogenic, inducing infection. In contrast, we have chosen to focus on <I>S. epidermidis</I> because
of its beneficial effects as a commensal, naturally occurring microbe on the skin. Our goal is to leverage our platform and internal
microbial library of over 60 bacterial species to engineer and deliver commensal skin bacteria directly to the target through the stratum
corneum of the skin. At these deeper levels in the skin, engineered microbes can produce the missing or inert proteins and thereby resolve
the underlying disease cause.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>S.
epidermidis and Our Proprietary Microbial Library</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>S.
epidermidis</I> is a strong therapeutic candidate species due to a number of well-described properties in the skin. <I>S. epidermidis
</I>is a gram-positive bacterium that is ubiquitous in the human skin and mucosal flora. As one of the earliest colonizers of the skin,
<I>S. epidermidis</I> plays an important role in cutaneous immunity and maintaining microbial community homeostasis. <I>S. epidermidis
</I>is known to have a beneficial relationship with its host as a skin commensal. The species has shown inhibition of the pathogenic
strain, <I>Staphylococcus aureus, or S. aureus,</I> as well as the strain <I>Propionibacterium acnes</I>, or <I>P. acnes</I>. <I>S. epidermidis
</I>induces keratinocytes to produce antimicrobial peptides and produces non-inflammatory T cell accumulation of both CD4+ and CD8+ T
cells via immune cell signaling. The T cell responses induce re-epithelization of the skin after injury, accelerating repair and wound
closure. For these reasons, we believe <I>S. epidermidis</I> offers several advantages as a vector for topical delivery of therapeutic
proteins.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
their 2019 study, Stacy and Belkaid, world-leading experts in the skin microbiome, described <I>S. epidermidis</I> as &ldquo;a &lsquo;poster
child&rsquo; of the skin microbiota to illustrate the remarkable diversity of functions a microbe can exert on skin physiology and health.&rdquo;
We believe that <I>S. epidermidis</I> has enormous strain diversity that can be exploited for therapeutic purposes. In the 2020 Oh Study,
Julia Oh&rsquo;s lab reported that 1,482 unique strains of <I>S. epidermidis</I> were present on only five individuals. These strains
had not only significant genetic diversity but also large phenotypic diversity. We believe this large inter-strain variation among <I>S.
epidermidis </I>can be exploited. To that end, we collected samples from healthy volunteers to develop and characterize our own strain
library of <I>S. epidermidis</I> that includes over 900 unique <I>S. epidermidis</I> strains with potential for therapeutic use. We have
used this microbial library to screen against selected properties, including antimicrobial peptide secretion, <I>S. aureus</I> killing,
antibiotic sensitivity, and other therapeutically relevant characteristics. We have also collected other species in our library that
includes roughly 60 different skin commensal species that can also be screened for therapeutic purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
1. Representative Species in Azitra Microbial Library</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 23%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Staphylococcus
    epidermidis</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Helicobacter
    pylori</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Streptococcus
    pneumoniae</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vibrio
    cholerae</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Escherichia
    coli</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kelbsiella
    oxytoca</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enterobacter
    cloacae</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yersinia
    enterocolitica</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Staphylococcus
    aureus</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Klebsiella
    pneumoniae</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salmonella
    oslo</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Citrobacter
    freundii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bacillus
    subtilis</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kluyveromyes
    lactis</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deinococcus
    radiodurans</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enterobacter
    aerogenes</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corynebacteria</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kocuria
    rhizophila</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enterococcus
    faecalis</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enterobacter
    cloacae</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Saccharomyces
    cerevisiae</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Micrococcus
    leteus</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Morazella
    catarrhalis</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proteus
    mirabilis</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Candida
    albicans</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moraxella
    catarrhalis</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Streptococcus
    miltis group</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salmonella
    Senftenberg</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finegoldia
    magna</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Morganella
    morganii</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Streptococcus
    mitis/oralis</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Serratia
    marcescens</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gardnerella
    vaginalis</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mucor
    circinelloides</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Streptococcus
    pneumoniae</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shigella
    sonnei</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Haemophilus
    influenzae</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Staphylococcus
    haemolyticus</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Streptococcus
    pyogenes</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neisseria
    gonorrhoeae</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Haemophilus
    parainfluenzae</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Staphylococcus
    haemolyticus</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Streptomyces
    ambofaciens</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enterococcus
    faecium</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Haemophilus
    parainfluenzae</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Staphylococcus
    hominis</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thermoaerobacter
    marianensis</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salmonella
    typhimurium</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Haloarclula
    marismortui</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Staphylococcus
    lugdunensis</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thermus
    thermophilus</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acinetobacter
    baumannii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bacilus
    sterarothermophilus</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pseudomonas
    aeruginosa</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Predictive
Analysis of Our Microbial Library </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biopharmaceutical industry has seen success in identifying and isolating thousands of bacterial species. Yet only a relatively few such
species, believed to be less than 20, have been engineered to produce proteins or peptides with therapeutic potential. We have partnered
with Chemia Biosciences, Inc., a research and development group from Carnegie Mellon University. Through our collaboration with Chemia
Biosciences, we are able to use their proprietary genomic and peptidomic artificial intelligence and machine learning system, NRPMiner,
to develop and confirm natural product predictions of the proteins, peptides and small molecules that are generated by our proprietary
bacterial library. These predictions are confirmed via tandem mass spectroscopy or nuclear magnetic resonance. The information is then
fed back into the machine learning algorithm to refine the predictions. It can also be compared to existing 2D and 3D protein databases
to look for structural homology of our products to existing protein and peptide drugs. We believe our collaboration with the Carnegie
Mellon based team provides us with a scalable and modification tolerant way to accelerate therapeutic discoveries within our microbial
library.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
Delivery of our Microbially Produced Drugs </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
delivery of genetically engineered proteins to the subcutaneous target sites is hindered by the natural barrier and the defenses of the
stratum corneum. This is the skin&rsquo;s outermost layer which acts as a barrier that prevents unwanted materials from entering the
body. To address this challenge, we have developed a proprietary process capable of facilitating protein delivery in a manner that bypasses
the normally impenetrable stratum corneum. The strategy utilizes the ability of particular microbes to infiltrate into the deeper layers
of the skin. There, the genetically modified microbes act as miniature factories to produce a therapeutic protein or molecule where it
is needed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
protein delivery capability for treating skin conditions is based on engineering <I>S. epidermidis</I> and other microbes to secrete
proteins for drug delivery into the skin. We believe any number of proteins can be engineered and encoded by our bacteria to be produced
and delivered to the skin to treat a variety of skin conditions. We have also added key proprietary features in its platform to facilitate
protein delivery. A key feature of this system is that it bypasses the normally impenetrable skin barrier, a problem of topical protein
delivery. The skin barrier, composed of the stratum corneum, is sealed by enucleated keratinocytes and formed by numerous structural,
physical, and biochemical properties. Other transdermal delivery challenges arise due to susceptibility of protein to enzymatic digestion
by proteases and solubility and diffusion impediments due the hydrophobic surface and the layers of linked corneocytes comprising the
stratum corneum. We address this issue by leveraging the natural homing of <I>S. epidermidis</I> to layers below the stratum corneum.
In preclinical studies, we have shown that <I>S. epidermidis</I> homes to layers below the stratum corneum and delivers proteins into
the deeper epidermis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
expand upon our recombinant protein construction capabilities, we have acquired an exclusive license to proprietary technology that disguises
our genetically engineered DNA sequences to enable the production of proteins in previously intractable bacterial species. The technology
from the Fred Hutchinson Cancer Center or Fred Hutch, expands the universe of bacterial species that can be genetically
modified. It is based upon a restriction modification system-silent SyMPL toolset. The SyMPL technology platform makes human-made DNA
invisible to the bacteria&rsquo;s defenses. In theory, the method can be applied to any type of bacteria. Our current product candidates
do not incorporate the SyMPL technology platform, but we expect that some or all of our future product candidates will do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Virtually
all strains of naturally occurring bacteria have defense mechanisms called restriction modification systems. The four types of restriction
modification systems recognize and defend against insertion of foreign DNA used to code recombinant proteins. Functional genetic engineering
of S<I>. epidermidis </I>(as well as <I>S. aureus</I>) has previously been limited due to the presence of Type I and IV restriction systems
in virtually all strains of these bacterial species. These restriction systems recognize methylated cytosine bases in DNA from standard
clone expansion systems (such as <I>E. coli)</I> and hinder incorporation of foreign DNA in the microbe. <I>S. epidermidis</I> was once
believed to be an &ldquo;untransformable&rdquo; strain due to its genetic intractability. However, we have been able to overcome <I>S.
epidermidis&rsquo; </I>defenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
genetic engineering processes add specific modifications to disguise human made DNA to trick the bacterium into thinking the intruder
is a part of its own DNA. This approach often takes considerable time and resources to try to match the right disguise to each particular
recognition motif. In contrast, Fred Hutch&rsquo;s SyMPL technology platform is a systematic &ldquo;stealth-by-engineering&rdquo;
approach to overcome restriction modification defense systems. These restriction modification defense systems protect microbes from foreign
DNA and hinder the vast majority of genetic engineering approaches. The SyMPL technology platform is based on the ability to build minicircle
DNA plasmids which lack any of the target recognition motifs for the microbe&rsquo;s defense systems to identify. The technology uses
the genome and methylome from a target bacteria&rsquo;s genomic sequence to identify the restriction modification target motifs. They
are then eliminated from the nucleotide sequence of the genetic tool <I>in silico</I>. The resulting sequence is used to build the restriction
modification, SyMPL tools. These are propagated and then used for genetic transformations. Not only does the &ldquo;stealth by engineering&rdquo;
approach enable transformations in genetically intractable bacterial strains, but it has also been shown to drastically increase transformational
efficiency. Proof of principle experiments have shown improvements of over 10,000x in yields of genetically engineered colonies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2022, Fred Hutch granted us an exclusive worldwide, royalty bearing license to the patent rights, and a non-exclusive
worldwide, royalty bearing license to the related know-how, for the SyMPL technology platform in all fields of use. For more information
related to the intellectual property acquired pursuant to the Fred Hutch license agreement, see the section titled &ldquo;<I>Business-Licenses
and Intellectual Property Rights</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Product Candidates </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>ATR-12
for the treatment of Netherton syndrome </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATR-12
is our proprietary and patent-pending drug candidate that contains a novel strain of <I>S. epidermidis</I> which has been genetically
modified to express and secrete an active fragment of the full-length protein called the lympho-epithelial Kazal-type related inhibitor,
or LEKTI. It has also been engineered to be auxotrophic, meaning that it requires the D-alanine nutrient in its formulation to survive
and propagate. This provides an additional level of safety against potential systemic infection. ATR-12 is a topical application
intended to address the underlying cause of Netherton syndrome, by replacing deficient LEKTI with an active segment of human
recombinant LEKTI, or rhLEKTI-D6, to counter the dysregulated skin serine protease activity observed in Netherton syndrome patients.
The uncontrolled serine protease activity leads to a profound skin barrier defect and the release of pro-inflammatory and pro-allergic
mediators by keratinocytes and immune cells. As of the date of this prospectus, there is no known therapy for the cure or effective treatment
of Netherton syndrome. We believe ATR-12 has the potential to be the first therapy to effectively treat this disease of the
skin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Netherton
syndrome overview </I></FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Netherton
syndrome is a rare, autosomal recessive disease estimated to affect approximately one in every 200,000, but its prevalence may be underestimated
due to misdiagnosis. It is a chronic disease of the skin, characterized by severe inflammation, pruritus, scaling, red, and dehydrated
skin. Infants born with Netherton syndrome may suffer from a failure to thrive, and it has been reported that approximately one in ten
infants with Netherton syndrome die in their first year of life. Those that survive face a lifetime of skin disease challenges including
red, scaly skin, hair defects and an ongoing higher than normal risk for infection and allergy.</FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Netherton
syndrome is caused by mutations in the <I>SPINK5</I> gene, which codes for the serine protease inhibitor Lympho-epithelial Kazal-type
related inhibitor, or LEKTI. The function of LEKTI is to inhibit enzymes in the epidermis, such as kalikreins 5, 7 and 14, or KLK5,
KLK7 and KLK14, which facilitate the shedding of skin cells in a process known as desquamation. When LEKTI is absent or has reduced
activity, excess shedding results and the skin is sensitive, open, and appears red and scaly. This is accompanied by the detachment of
the stratum corneum, leading to severe barrier dysfunction, dehydration and potential exposure to environmental agents, such as chemicals.
Histopathology and immunofluorescence staining of skin from a Netherton syndrome patient compared to healthy volunteer reveal an absence
of LEKTI and abnormalities in the skin such hyperkeratosis, epidermal thickening, and reduction of the basophilic keratohyalin granules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b4_001.jpg" ALT="" STYLE="height: 306px; width: 670px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>Figure
2: Netherton syndrome pathophysiology and LETKI deficiency</B></P>

<P STYLE="font: 10pt/100% Times New Roman, Times, Serif; margin: 0 19.85pt 0 15pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Netherton
syndrome can range in severity from mild, such as red patchy areas of the skin, to life threatening. The degree of severity of the disease
correlates directly with the extent of loss of function of LEKTI on the skin. Netherton syndrome appears shortly after birth and is most
severe in the first year of an infant&rsquo;s life. Survival beyond the first year is common in most cases, but the implications of the
disease are a lifelong challenge.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, there is no known cure for Netherton syndrome and treatment options are limited. Dermatologic interventions
to treat the severe skin manifestations of Netherton syndrome include moisturizers, topical corticosteroids, and calcineurin inhibitors,
all of which are limited in that they do not provide sustained remediation. Given the severity of disease during neonatal stages, fluid/electrolyte
and diet support are needed in addition to treating infections that often arise in these patients. While immunoglobulin therapy to address
immunodeficiencies associated with Netherton syndrome has shown limited success, a sustained remediation of skin barrier defects, induced
by dysregulation of LEKTI, is currently unavailable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Our
solution &ndash; ATR-12 for the treatment of Netherton syndrome</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATR-12
is a topical ointment containing an <I>S. epidermidis</I> strain, SE351, that has been genetically modified to express LEKTI from the
chromosome. The SE351 strain has also been engineered to be auxotrophic for D-alanine, which means it cannot survive without the exogenous
D-alanine nutrient, provided in the formulation. ATR-12 is intended to address the underlying cause of Netherton syndrome by replacing
deficient/dysfunctional LEKTI with an active, recombinant, human fragment of the full-length protein, rhLEKTI-D6. The treatment consists
of applying ATR-12 to affected areas. rhLEKTI-D6 produced by SE351 will counter the dysregulated skin serine protease activity observed
in Netherton syndrome patients, to restore skin barrier function and reduce inflammation. We believe that among the important advantages
of this approach is the potential to deliver rhLEKTI-D6 over time into the lower layers of the stratum corneum and epidermis, the primary
sites of dysregulation in patients with Netherton syndrome.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
<I>S. epidermidis</I> strain selected to deliver rhLEKTI-D6 to the skin, SE351, was selected from our proprietary strain collection.
This strain is characterized by low virulence and is a non-biofilm forming host strain. To further enhance the safety of ATR-12, we have
engineered the microbe for D-alanine to be auxotrophic. The key advantage to engineering auxotrophy is the ability to control growth
and halt potential infection. Full length human LETKI, a 15-domain protein (145 kDa), is too large for reliable bacterial expression
and secretion. Given evidence that fragments of the full-length protein are sufficient to counter the dysregulated skin serine protease
activity observed in Netherton syndrome patients, we selected D6 for recombinant expression in <I>S. epidermidis</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2020, we received Rare Pediatric Disease Designation from the FDA for ATR-12. As a result, if we are able to obtain pre-market approval
for ATR-12 from the FDA, we will be eligible to receive a Priority Review Voucher upon approval, which can be used by us to obtain FDA
review of a New Drug Application for this or another drug candidate in an expedited period of six months. These vouchers are often
transferable and have been sold for over $100 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Preclinical
data for ATR-12 </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, we have conducted several <I>in vivo</I> and <I>ex vivo </I>experiments that collectively support
the potential efficacy of ATR-12 as a disease modifying therapy for patients with Netherton syndrome. The genetically engineered
strain of S. epidermidis used in the formulated ATR-12 drug product is called SE351. In 2021, we conducted <I>in vitro</I> studies
to assess the ability of exogenously applied SE351 to colonize sterile reconstructed human epidermis. SE351 successfully colonized
the reconstructed human epidermis and, furthermore, no <I>S. epidermidis </I>colonization occurred without D-alanine present,
confirming that D-alanine must be supplied for SE351 growth on skin. These data suggest that SE351 is capable of colonizing human
skin, and that colonization can be controlled with D-alanine supplementation.</FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
<I>in vitro </I>studies using tape stripped skin from healthy volunteers spiked with KLK5 to mimic Netherton syndrome showed that diluted
SE351 culture supernatant dose-dependently inhibited trypsin-like activity (KLK5 activity). Trypsin-like activity in the Netherton syndrome
surrogates returned to normal healthy levels when a solution containing &ge;0.5% of the SE351 culture supernatant was added.</FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b4_002.jpg" ALT="" STYLE="height: 212px; width: 670px">&nbsp;</FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
3: <I>In Vitro</I> Netherton Syndrome Model Using Human Skin Tape Strip Extracts Supplemented with Disease Level KLK5 Activity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, results from an <I>ex vivo</I> pig skin
model demonstrate that a single topical dose of ATR-12 at 3 dose levels led to secretion of active rhLEKTI-D6. Finally, data from an <I>ex
vivo</I> healthy human skin model demonstrate that a single topical dose of ATR-12 administered at the maximum intended dose of
10<SUP>9</SUP> CFU/g delivers enough active rhLEKTI-D6 into the lower layers of the stratum corneum to effectively inhibit the
protease, kallikrein 5 (&ldquo;KLK5&rdquo;), at levels typically observed in patients with Netherton syndrome.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
particular, data from an ex vivo healthy human skin model demonstrate that a single topical dose of ATR-12 administered at the maximum
intended dose of 10<SUP>9</SUP> Colony Forming Units per gram (CFU/g) delivers enough active rhLEKTI-D6 into the lower layers of the
stratum corneum to effectively inhibit KLK5 at levels typically observed in patients with Netherton syndrome. Amounts of LEKTI-activity
in layers extracted were from tape strips samples from ex vivo human skin treated with placebo and ATR-12. The collection proceeded right
after skin application (t = 0 hours, white bars) or after 8 hours incubation at 30&deg;C (t = 8 hours, black bars). Total LEKTI activity
levels were obtained by adding the pmol amounts through layers 1 to 30 of placebo (grey bars) or ATR-12 (black bars) samples. Data are
the average &plusmn; a standard deviation (SD) of 3 independent samples (N = 3). Statistical analysis in I was carried out using two-way
ANOVA, and ** represents p &lt;0.01.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b4_004.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
4: LETKI activity in Placebo and ATR-12-Treated Skin Samples Following 0- and 8-hour Incubation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, a single therapeutic dose of ATR-12 over 24-hour incubation yielded ~2-fold higher LEKTI activity compared to 8-hour incubation.
This indicates continuous production of functional rhLEKTI-D6 by ATR-12 over time.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b4_003.jpg" ALT="" STYLE="height: 212px; width: 670px">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
5: LETKI activity in Placebo and ATR-12-Treated Skin Samples Following 24-hour Incubation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
vitro stoichiometry work performed by Azitra indicates that KLK5 requires 2 molar equivalents on the LEKTI-D6 protein for inhibition
(as measured by IC50). Historical studies have indicated that Netherton syndrome patients to show up to ~6 fold the amount of KLK5
that the amounts found in normal skin. This equates to 60 pmol of KLK5 per given area. The studies shown above indicate that SE351
delivered 350 pmol of LEKTI-D6 at 8 hours and it delivered 700 pmol of LEKTI-D6 at 24 hours. This represents a 5-to-11 fold amount
above the predicted amount required for activity.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b4_006.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B>Figure
6: <I>In vitro</I> stoichiometry of LEKTI-D6 to inhibit KLK5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2022, we obtained pre-IND correspondence with the FDA for purposes of discussing our proposed regulatory pathway for ATR-12 and obtaining
guidance from the FDA on the pre-clinical plan leading to the filing and acceptance of an IND application for ATR-12. In December
2022, we filed an IND for a first-in-human trial of ATR-12 in Netherton syndrome patients. Our IND proposes a Phase 1b multi-center,
randomized, double-blind, single dose level, placebo-controlled clinical study of ATR-12 in patients with Netherton syndrome.
The primary endpoint is safety and secondary endpoints will include signals of efficacy and pharmacokinetics. Exploratory endpoints include
immune and inflammatory mechanism biomarkers. On January 27, 2023, we received notification from the FDA that the &ldquo;study may proceed&rdquo;
with respect to the proposed Phase 1b clinical trial, and we expect to commence our Phase 1b clinical trial in the first half of 2023,
with initial results expected in the first half of 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>ATR-04
for the Treatment of EGFRi-Associated Rash </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATR-04
is our proprietary and patent-pending drug candidate that contains a novel strain of <I>S. epidermidis</I>, SE484, which has been genetically
modified to be auxotrophic tor D-alanine. ATR-04 is a topical application intended to address the papulopustular rash experienced
by cancer patients undergoing epidermal growth factor receptor inhibitor, or EGFRi, targeted therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>EGFRi-Associated
Rash Overview</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Targeted
cancer therapies have produced significant treatment advances for patients diagnosed with a variety of tumor types, but they are also
associated with unique dermatologic toxicities that may hamper treatment efforts and cause significant physical and psychological discomfort
for patients. Prevention and management of these toxicities may allow patients to tolerate treatments better, remain on therapy longer
and thereby potentially receive maximum clinical benefit from the drug. One such class of targeted cancer therapy includes EGFR inhibitors.
EGFR is a protein on the surface of cells that helps them grow and divide. It is also a key factor in certain malignancies, and its activity
enhances tumor growth, invasion, and metastasis. While systemic exposure to EGFRi agents suppresses EGFR at the target cancer site, it
also suppresses EGFR throughout the body. In the skin, EGFR regulates multiple keratinocyte functions including proliferation, adhesion
and migration, survival, and differentiation. Consequently, inhibition of EGFR in the skin results in adverse skin reactions, which make
it difficult for patients to stay on these effective therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dermatologic
toxicities are amongst the most prevalent side effects seen with EGFRi-targeted therapies. The papulopustular rash is the earliest and
most common dermatologic adverse event of EGFRi treatment, often occurring in 50-80% of patients, depending on the drug, the cancer being
treated, and the treatment regimen. The appearance of the papulopustular rash is a dose-dependent skin drug reaction, which usually develops
in the first one to two weeks and peaks at three to four weeks on therapy. The intensity of the rash may start to decrease after two
weeks but can persists over the entire course of EGFRi treatment. The rash is characterized clinically as tender erythematous papules,
which after a few days evolve into pustules and then into crusts on the face, scalp, chest, and upper back. The rash is often accompanied
by severe xerosis and at times serious cutaneous bacterial infection, primarily <I>S. aureus</I>. While most skin rash episodes are considered
mild to moderate, some are severe. In many cases the rash leads to severe quality of life issues and can even lead to the interruption
or cessation of the EGFRi treatment<I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
current standard of care for rash treatment in patients undergoing EGFRi treatment varies depending on the rash severity. Typically,
skin moisturizers, topical steroids and doxycycline are administered prophylactically from the start of EGFRi therapy and are continued
throughout the entire treatment period. If the rash continues to advance, oral steroids and/or antibiotics are administered. However,
there are known systemic adverse events associated with these adjunctive therapies, and we believe that physicians and patients try to
limit their use. In addition, research indicates that oral antibiotics lead to a disruption in the gut microbiome, which in turn leads
to a decrease in the effectiveness of targeted therapies, including EGFRi. Given the high incidence rate of rash that continues with
these patients, as well as the concerns related to potential impacts of antibiotics on these therapies, we believe there is a clear unmet
medical need for additional safe and effective adjunctive therapies for addressing papulopustular skin rash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on studies conducted by Satoh and Lichtenberger, the cytokine, Interleukin-36 gamma, or IL-36&#947; and <I>S. aureus</I> are linked to
and play a significant role in the rashes experienced by patients treated with EGFRi&#8217;s. IL-36&#947;, is elevated in the skin of
patients undergoing EGFRi therapy. In 2020, Satoh used gene expression profiling to identify IL-36&#947; as a candidate driver of EGFRi/MEKi
skin toxicity. It is induced by EGFR inhibition and <I>Cutibacterium acnes</I> that synergistically induce IL-36&#947; in the skin and
subsequently IL-8 and NF-&kappa;B, which leads to cutaneous neutrophilia. IL-36&#947; could be a key therapeutic target in treating EGFRi-induced
rashes. In 2013, Lichtenberger noted high rates (70%) of bacterial infection in patients (n=107) on EGFRi and proposed a mechanism of
EGFR ablation leading to <I>S. aureus-</I>induced infection in mice. The study noted a majority of the patients were positive with <I>S.
aureus </I>(54%). Mechanistically, the authors noted that EGFRi therapy impairs host defense: impaired expression of antimicrobial peptides,
especially against <I>S. aureus</I>; and lowered expression of tight junctions. Also, the study revealed EGFR ablation leads to skin
barrier defects as well as impaired cutaneous immune response and cytokine expression.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Our
solution &ndash; ATR-04 for the treatment of EGFRi-associated rash</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATR-04
is our formulated, drug product candidate for the treatment of EGFRi associated rash. It includes a novel auxotrophic strain of <I>S.
epidermidis</I> strain that was selected from our microbial strain library, based on desired properties of IL-36&#947; reduction and
inhibition of <I>S. aureus</I> and its biofilms. The current lead strain is called SE484. We then genetically engineered SE484 to be
auxotrophic tor D-alanine and to create our drug product candidate, ATR-04.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SE484
was chosen from our microbial library based on key characteristics such as inhibition of IL-36&#947; as well as its effect against <I>S.
aureus</I>. Together, we expect these mechanisms of action to lead to significant reductions in rash severity among patients undergoing
EGFRi therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that ATR-04 has the potential to address current limitations to treatment of EGFRi-associated rash:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reduced
    antibiotic use. </B>From our surveys of clinicians and key opinion leaders, practitioners are reluctant to prescribe systemic antibiotics
    to patients undergoing EGFRi therapy. These patients can often be prescribed antibiotics for more than 12 months and suffer from
    antibiotic-related adverse events. We believe ATR-04 would reduce the need for antibiotics in these patients and lead to fewer adverse
    events due to EGFRi and antibiotic use.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Better
    EGFRi compliance. </B>Up to 20% of patients undergoing EGFRi therapy discontinue due to adverse events, primarily due to rashes.
    We believe we can reduce discontinuation rate in patients undergoing EGFRi therapy and thus increase compliance.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Higher
    </B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>quality of life. </B>Many patients on
    EGFRi therapy report a poor quality of life due to adverse events and papulopustular rashes. Current treatment options fail to adequately
    reduce these adverse events. We believe ATR-04 therapy in patients undergoing EGFRi therapy will have reduced rash severity and thus
    a higher quality of life.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Preclinical
data of ATR-04</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
screened over 100 strains based on safety (e.g., lack of antibiotic resistance) and biological activity (e.g., IL-36&#947; inhibition
and activity versus <I>S. aureus</I>) and designated SE484 as our lead candidate strain. After engineering this strain to be auxotrophic
for D-alanine, we nominated this candidate for use as the active microbe in the ATR-04 drug product formulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EGFRi
is a condition that is characterized by redness, itchiness, and irritation of the skin, and is induced by certain cancer treatments.
It was shown, by gene expression profiling (Satoh et al 2020), that skin biopsy samples from patients suffering from EGFRi had elevated
levels of cytokines IL-36&gamma; (IL-36 gamma) and IL-8 compared to skin from healthy donors. These are proinflammatory cytokines that
are signaling molecules of the immune system that increase the intensity of an immune response and can cause tissue damage. In addition
to elevated cytokine levels, EGFRi-treated patients have impaired skin barrier function. Infection with pathogenic strains of S. aureus
exacerbates the EGFRi-induced cutaneous disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
work was focused on identifying a Staphylococcus epidermidis strain, a skin commensal, that reduces IL-36&gamma; levels and thus reduces
the rash associated with EGFRi. We reasoned that many species of bacteria that live on human skin probably survive there because they
have evolved ways to reduce the human immune system&rsquo;s response to their presence, and we might be able to identify a resident human
skin commensal bacteria that survives thereby specifically reducing IL-36&gamma; activity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
identify such a Staphylococcus epidermidis strain, we developed an in vitro assay to measure the levels of IL-36&gamma; and IL-8 that
are produced by human skin cells that are grown in culture. The cell line we used is called HaCaT and is derived from human keratinocytes,
which are a cell type in the epidermidis. In order to simulate the inflammatory manifestation of EGFRi-related disease of the skin, HaCaT
cells are stimulated with an immunostimulant, Poly IC, which causes them to secrete elevated levels of IL-36&gamma; and IL-8. This assay
was used to identify and evaluate the ability of different S. epidermidis strains to lower IL-36&gamma; and IL-8 levels.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
screened over 100 strains based on safety (e.g., lack of antibiotic resistance) and biological activity (IL-36&gamma; inhibition and
activity against S. aureus) and designated SE484 as our lead candidate strain. After engineering this strain to be auxotrophic for D-alanine,
so that it will grow only if provided with D-alanine, we nominated this candidate for use as the active microbe in the ATR-04 drug product
formulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Figure
7 shows the results of the IL36g in vitro assay to evaluate the ability of strain SE484 to reduce or inhibit IL-36&gamma; levels
in HaCaT cells. The black bars show the effect of adding Poly IC to HaCaT cells to induce IL-36&gamma; levels approximately two-fold
over normal levels. In the presence of culture supernatant (CS) of SE484, the level of IL-36g is reduced to baseline levels, similar
to a chemical inhibitor of Poly IC (shown as Poly IC + inh). Panel A shows the results after 48 hours of exposure to the various treatments,
while Panel B shows the results after 72 hours.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b4_007.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
7. IL-36g induction by Poly IC is Reduced by CS of SE484</B>. Black bars are the levels of IL-36g when HaCaT cells are stimulated
with Poly IC. The presence of culture medium from SE484 prevents the stimulation and release of IL-36g by Poly IC (red arrow). An inhibitor
of Poly IC is used as control (blue arrow). Panel A shows suppression of IL-36g after 48-hour exposure of SE484 and Panel B, 72-hour
exposure. Data is representative of 2 independent experiments. CS= culture supernatant</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b4_008.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
8. IL-8 induction by Poly IC is Reduced by CS of SE484</B>. The presence of culture medium from SE484 prevents the stimulation
and release of IL-8 by Poly IC (red arrow). An inhibitor of Poly IC is used as control (blue arrow). Data is representative of 2 independent
experiments. CS= culture supernatant</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Figure
8 shows the inhibitory effect of SE484 culture supernatant on the induction of IL-8 by Poly IC. Similar to IL-36g, when Poly IC
are added to HaCaT cells, IL-8 are also secreted, several folds above background (as seen in &ldquo;untreated HaCaT and SE484 treated
HaCaT). However, in the presence of SE484, lower levels of IL-8 were detected, thus further demonstrating the efficacy of SE484 to inhibiting
the proinflammatory pathway involved in EGFRi-related rash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
results show that culture media of S. epidermidis strain SE484, which was isolated from a healthy human volunteer, can reduce the
level of IL-36g and IL-8 produced by HaCaT cells (Figure 7 and Figure 8, respectively) and thus help in the treatment
of EGFRi- related rash. In addition to its anti-IL-36g property, SE484 also has broad activity against different MRSA strain types
as well as methicillin sensitive S. aureus. The ability of SE484 to reduce IL-36g/IL- 8 levels as well as its activity against S.
aureus and the engineered D-alanine auxotrophy enabled us to nominate strain SE484 for use as the active microbe in the ATR-04 drug
product formulation to form the basis of a treatment and reduce the severity of EGFRi rash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also shown that SE484 leads to <I>in vitro</I> inhibition of known virulent strains USA300, which is resistant to methicillin,
and MSSA, which is sensitive to methicillin. The following data shows that ATR-04 reduces the ability of the pathogenic S. aureus
bacterial species to grow and instigate infections that are seen in patients with EGFRi rash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><IMG SRC="form424b4_009.jpg" ALT=""></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
9. Epidermin-expressing SE484 kills S. aureus with similar activity as mupirocin on in vitro agar plates.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="form424b4_01.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are proposing an initial study of SE484 in the ATR-04 formulation in patients. It is contemplated to be a Phase 1b multi-center, randomized,
double-blind, single- dose, placebo-controlled trial in patients with colorectal or head and neck cancer who are initiating EGFRi monoclonal
antibody therapies. The primary endpoint is safety and secondary endpoints will include efficacy and Quality of Life, or QoL We are planning
to submit an IND by the end of 2023. Subject to FDA approval of our IND, we expect to commence our Phase 1b clinical trial in
the first-half of 2024 with initial results expected in late 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>ATR-01
for the treatment of ichthyosis vulgaris</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATR-01
is our drug product candidate intended to treat ichthyosis vulgaris. The program is currently investigating a proprietary and patent-pending
novel engineering segment of human filaggrin protein. ATR-01 is being developed as a topical application intended to address ichthyosis
vulgaris, a chronic scaly skin disease with an estimated incidence and prevalence of 1 in 250, which gives a total patient population
of 1.3 million in the United States. Ichthyosis vulgaris is caused by loss-of-function mutations in the gene encoding filaggrin Using
synthetic biology tools for protein engineering, we attached a cell penetrating peptide to filaggrin, which helps facilitate deeper skin
delivery for filaggrin. This is designed to overcome the impenetrability of the skin barrier, which would otherwise limit topical protein
delivery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Ichthyosis
vulgaris overview </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ichthyosis
vulgaris, or IV, is a chronic, xerotic, scaly skin disease with an estimated incidence and prevalence of 1 in 250, which gives a total
patient population of 1.3 million in the United States. Clinical features of IV usually appear at around 2 months of age and include
generalized xerosis and fine, white to gray scales that are prominent on the abdomen, chest, and extensor surfaces of the extremities.
Although rare, some IV patients also experience hypohidrosis and heat intolerance. The pathogenesis of IV has long been identified as
a decrease in the size or number, or even a complete absence of, epidermal keratohyaline granules. In addition, patients with IV are
at increased risk for atopic dermatitis, asthma and allergies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ichthyosis
vulgaris is an autosomal semidominant disease caused by loss-of-function mutations in the gene encoding filaggrin. Filaggrin is an essential
structural protein that is derived from profilaggrin, which breaks down into individual filaggrin units in the stratum corneum. These
reinforce the skin barrier by binding to keratins and other intermediate filament proteins in the keratinocyte cytoskeleton. Many studies
have identified loss-of-function mutations in <I>FLG </I>in IV patients, and these mutations are associated with disorganized keratin
filaments, skin barrier defects and microfractures in the stratum corneum leading to enhanced percutaneous allergen sensitization. Moreover,
filaggrin and its breakdown products have significant additional functions in the skin including moisturizing the skin (via hygroscopic
amino acids or &ldquo;natural moisturizing factors&rdquo;), effecting production of antimicrobial molecules (particularly against <I>S.
aureus</I>) and maintaining both a beneficial lipid profile and pH in the skin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are few effective therapies for the treatment of IV. Current treatment options for IV include primarily topical water evaporation suppressants
(e.g., sodium chloride, urea, lactic acid, salicylic acid), and, to a lesser extent, moisturizers (e.g., glycerol, propylene glycol,).
Topical retinoids may also be prescribed in an effort to slow the body&rsquo;s production of skin cells. However, long-term retinoid
use is not ideal. Of particular concern is the teratogenic effect of all retinoids, which limits their use in women of child-bearing
potential. Chronic toxicities from long term therapy with retinoids may result in skeletal abnormalities. Furthermore, the chronic use
of retinoids in children may inhibit their growth. Notably, many patients with IV experience a significantly reduced quality of life,
due to self-consciousness and social embarrassment, and see a negative impact on domestic life, educational/professional lives and even
leisure/sports activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Our
solution &ndash; ATR-01 for the treatment of ichthyosis vulgaris</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is now known that IV is caused by loss-of-function mutations in the gene encoding filaggrin, leading to disorganized keratin filaments,
skin barrier defects and microfractures in the stratum corneum, and resulting in enhanced percutaneous allergen sensitization as well
as bacterial and viral skin infection. We are developing ATR-01 as a novel treatment modality for IV that directly addresses the disease
pathophysiology. ATR-01 consists of FLG5-6 functional unit of the human FLG protein with an attached cell penetrating peptide. The goal
is to supplement the skin with stable delivery of hFLG via topical application and deeper skin penetration with a cell penetrating peptide.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Preclinical
data for ATR-01 </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
FLG units (domains 9-10) were evaluated on human skin explants (from plastic surgery) <I>ex vivo</I>. The skin barrier of the explants
was compromised by repeated tape-stripping such that transepidermal water loss, or TEWL values were significantly increased compared
to normal skin. As shown in the example below, daily topical application of a human filaggrin unit with a cell penetrating peptide
for 5 days resulted in a dose -dependent (not shown) rapid improvement in TEWL, suggesting improved skin barrier. Thus,
topical delivery of a recombinant hFLG unit coupled with a cell penetrating peptide  can improve/accelerate the repair of
damaged human skin barrier.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b4_010.jpg" ALT="" STYLE="height: 284px; width: 630px">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Figure
10: Topical filaggrin application on tape stripped <I>ex vivo</I> human skin following human filaggrin application.</FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lastly,
we have shown that topical filaggrin can improve skin barrier defects in filaggrin-deficient mouse models. Recombinant mouse filaggrin,
or mFlg, was applied to the tail of flaky tail, or FT, mice (a mouse model that has a knockout in the <I>filaggrin</I> gene) once daily
for 2 weeks (50&micro;g total protein/tail sections or 15.2 &micro;g total protein/cm<SUP>2</SUP>). Daily treatment with mFlg significantly
improved transepidermal water loss in FT mice when treated (FT+FLG group) compared to vehicle (&ldquo;baseline&rdquo;
group). The third group on the X axis is a normal, control, wild type group (WT) that does not have the <I>filaggrin</I> gene knocked
out. Treatment of damaged mouse skin with recombinant mFlg combined to a cell penetrating peptide improved damaged mouse skin barrier
(Figure A below). Additionally, histological analysis of the epidermis of the mouse tail sections showed tendency for improved
stratum corneum thickness with mFlg treatment (Figure B below). In this graph, the Y axis represents thickening of the stratum
corneum, which starts to fractionate or scale after growing past a normal thickness. Treatment with mFlg improved the thickness in four
of six of the samples.</FONT></P>
<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="form424b4_017.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Potential Product Candidates</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
our three lead product candidates, our goal is to develop a broad portfolio of product candidates focused on expanding the application
of our platforms for precision dermatology. We have a proprietary platform for discovering and developing therapeutic products for precision
dermatology. Our platform is built around a microbial library comprised of approximately 1,500 unique bacterial strains to allow screening
for unique therapeutic characteristics and utilizes microbial genetic technology that analyzes, predicts and engineers the proteins,
peptides and molecules made by skin microbes. Our ability to genetically engineer intractable microbial species is uniquely leveraged
by our exclusive license to the SyMPL technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Bayer
Joint Development Agreement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, we entered into a Joint Development Agreement, or JDA, with Bayer pursuant to which we agreed to the joint development
of certain strains selected from our proprietary microbial library. We and Bayer have agreed to cooperate in the identification and in
vitro and ex vivo characterization of microbial strains for topical formulations. Bayer paid us a one-time $150,000 payment upon execution
of the JDA and has agreed to reimburse us for our development costs. In October 2021, Bayer expanded the option agreement and paid us
$375,000 for additional characterization work.&nbsp; We have granted Bayer an option to acquire an exclusive royalty bearing license
for up to six strains subject to development activities under the JDA, including an exclusive royalty bearing license to any related
patent rights. After screening through hundreds of strains, we and Bayer have selected two particular strains to move forward with in
vitro and ex vivo characterization which we intend to develop as potential over-the-counter cosmetic products. We expect to complete
the characterization work and deliver the data to Bayer in the third quarter of 2023, at which time Bayer will have 12 months to exercise
its option to license the strains and related patents. Upon the conclusion of the characterization studies and our delivery of the data
to Bayer, the JDA will end but for Bayer&rsquo;s option to license the strains and related patents. As of the date of this prospectus,
we have not negotiated a commercial license agreement with Bayer and we will not do so until such time, if ever, as Bayer exercises its
option to acquire an exclusive royalty bearing license.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2020, Bayer&rsquo;s venture capital group, LEAPS by Bayer, purchased $8 million of our Series B preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sales
and Marketing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
our stage of development, we have not yet established a commercial organization or distribution capabilities. We plan to build focused
capabilities in the United States to commercialize our development programs focused on live biotherapeutic products and recombinant proteins
for the treatment of skin diseases, where we believe the patient populations and medical specialists for the indications we are targeting
are sufficiently concentrated to allow us to effectively promote our products, if approved for commercial sale, with a targeted sales
team. In other markets for which commercialization may be less capital efficient for us, we may selectively pursue strategic collaborations
with third parties in order to maximize the commercial potential of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Manufacturing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not own or operate manufacturing facilities for the production of our current product candidates. We currently rely on third-party
contract manufacturers for all of our required raw materials, manufacturing devices and active pharmaceutical ingredients and for our
preclinical research and clinical trials. Although we are able to manufacture finished product in our Groton Connecticut facility for
our clinical trials, we will rely on third parties for the manufacture of our finished product for commercial sale. We do not have long-term
agreements with any of these third parties. We also do not have any current contractual relationship for the manufacture of Phase 3 clinical
trials or commercial supplies. We intend to enter into agreements with third-party contract manufacturers and one or more backup manufacturers
for future production. We are analyzing the feasibility of building manufacturing capabilities for future development and commercial
quantities of any products that we develop. Such products will need to be manufactured in facilities, and by processes, that comply with
the requirements of the FDA and the regulatory agencies of other jurisdictions in which we are seeking approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
bio-pharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary
drugs. While we believe that our knowledge, experience and scientific resources provide us with competitive advantages, we face potential
competition from many different sources, including other biopharmaceutical companies, academic institutions and governmental agencies
as well as public and private research institutions. Any drug candidates that we successfully develop and commercialize will compete
with existing treatments and new treatments that may become available in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Netherton
syndrome</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to Netherton syndrome, no drug has been approved by the FDA, specifically for Netherton syndrome, to date. Standard of care includes
cleansing of the skin with a gentle/soft non-detergent liquid cleansing oil, preferably with an acidic pH (5). Because Netherton syndrome
patient skin is most often dry, scaly and peeling, emollients and moisturizers are also often used. Keratolytics such as salicylic acid,
urea or alpha-hydroxy acids are often irritative and not well tolerated by Netherton syndrome patients. The skin of Netherton syndrome
patients is prone to frequent bacterial infections. Limited infections are treated with topical antibiotics for a short period of up
to 2 weeks. Oral antibiotics may also be used to treat the pathogenic <I>Staphylococcus aureus</I> and <I>Streptococcus</I> strains that
can drive more extreme infections. Bleach baths are also recommended two to three times a week for their antimicrobial effects. Topical
corticosteroids are often used to treat the inflammatory and hyperproliferation associated with non-infected Netherton syndrome lesions,
but due to their adverse effects, must be limited. These adverse events include aminoaciduria, Cushing syndrome, skin atrophy, adrenal
insufficiency, growth retardation, hypertension and weakness. Overuse of topical steroids can even aggravate the defective skin barrier
by inducing loss of the stratum corneum. Systemic retinoids have shown varying degrees of efficacy in Netherton syndrome, but also carry
bone toxicity and teratogenicity as adverse effects. Topical calcineurin inhibitors have been used to reduce erythema (redness) but patients
have shown a tachyphylaxis and reduced efficacy with prolonged treatment. These immunomodulators also carry risks of serious adverse
effects including increased risk of infections, swelling, burning sensations and tingling. Phototherapy (narrowband UVB (NB-UVB) and
psoralen-UVA (PUVA)) has also been investigated in Netherton syndrome patients but has been limited due to its potential to cause erythema
and increases in the risk of skin cancer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also aware that Sixera Pharma initiated a clinical trial in Europe with SXR-1096, a topical small molecule KLK inhibitor in December
2021 for Netherton syndrome. Krystal Biotech, MatriSys, Quoin and BridgeBio have reported they are developing Netherton syndrome programs
that are at a pre-clinical stage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize drugs that are safer, more effective,
have fewer or less severe side effects, are more convenient or are less expensive than ATR-12 or any other drug that we may develop.
Our competitors also may obtain FDA or other regulatory approval for their drugs more rapidly than we may obtain approval for our drug,
which could result in our competitors establishing a strong market position before we are able to enter the market. Many of the companies
against which we are competing, or against which we may compete in the future, have significantly greater financial resources and expertise
in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing
approved drugs than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources
being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors,
particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting
and retaining qualified scientific and management personnel and establishing clinical trial sites and subject registration for clinical
trials, as well as in acquiring technologies complementary to, or that may be necessary for, our programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EGFRi
Associated Rash</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, no drug has been specifically approved by the FDA for the treatment of EGFRi associated rash. The majority of patients (estimated
to be up to 90%) treated continuously with anti-EGFR therapies suffer from dermatological adverse events, especially papulopustular rash,
pruritus (itching), xerosis (dryness), and paronychia (nail infections). Papulopustular or acneiform rash is the most common adverse
event of EGFRis on the skin. This rash negatively impacts compliance with EGFRi treatment in many patients. Dose modification or discontinuation
treatment occurs in severe cases. Because evidence-based controlled trials are still very sparse, treatment of EGFRi skin toxicity primarily
relies on physician experience, and recommendations from expert consensus conferences. As a result, there are geographical variations
and even inconsistencies in the clinical treatment of EGFRi skin rash. Topical corticosteroids are avoided in Europe with respect to
acneiform rash, but are often used in the United States. Furthermore, topical treatment is frequently customized to the individual patient
and may change on a case-by-case basis. No topical treatment scheme is universally applicable for all patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are aware of the following Phase 2 programs developing investigational drug candidates for EGFRi associated rash. Lutris Pharma is developing
LUT014, a topical B-Raf inhibitor, in the US and Israel. Daewoong Pharmaceutical Co. Ltd. is developing DWP708 in Korea.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intellectual
Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Overview
</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
actively seek to protect our proprietary technology, inventions, improvements to inventions and other intellectual property that is commercially
important to the development of our business by a variety of means, such as seeking, maintaining and defending patent rights, whether
developed internally or licensed from third parties. We also may rely on trade secrets and know-how relating to our proprietary technology
platform, on continuing technological innovation and on future in-licensing opportunities to develop, strengthen and maintain the strength
of our position in the field of gene therapy that may be important for the development of our business. Additional regulatory protection
may also be afforded through data exclusivity, market exclusivity and patent-term extensions where available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, we own or exclusively license two issued U.S. patents, four pending U.S. patent applications, one pending
PCT application and 38 other foreign national-stage applications, including three European regional-phase applications that are important
to the development of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
policy is to file patent applications to protect proprietary technology, inventions and improvements to inventions and other intellectual
property that may be commercially important to the development of our business. We also intend to seek additional patent protection or
rely upon know-how or trade secret rights to protect other technologies that may be used to manufacture and develop our live biotherapeutic
products. As described below, we are a party to exclusive license agreements that grant us rights to use specific technologies in our
live biotherapeutic products and in the manufacturing and development of our products.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
Patent Portfolio</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
patent portfolio has broad coverage for therapeutic bacteria pharmaceutical compositions containing these therapeutic bacteria for treating
abnormal skin conditions and methods of making and using these recombinant bacteria. In our broadest filing, we have secured a US patent
that protects pharmaceutical compositions for treating abnormal skin conditions using a bacterial strain expressing a therapeutically
effective amount of a recombinant polypeptide. This patent expires in May 2035. Specifically, this issued patent covers a pharmaceutical
composition containing one or more of the following bacterial strains: Bifidobacterium, Brevibacterium, Propionibacterium, Lactococcus,
Streptococcus, Staphylococcus, Lactobacillus, Enterococcus, Pediococcus, Leuconostoc, or Oenococcus, wherein the bacterial strain has
been engineered to produce a therapeutical polypeptide for treating the abnormal skin conditions. We believe that this patent gives us
broad protection for using recombinant bacteria to treat skin diseases and disorders. through its expiration in May 2035.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
applications directed to our most advanced programs are summarized below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>ATR-12</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ATR-12 product candidate is subject to two issued US patents, four pending US patent applications, and 26 pending foreign applications.
These patents and patent applications represent four families of claims covering the pharmaceutical composition of <I>S. epidermidis
</I>expressing a recombinant therapeutic polypeptide, the auxotrophic strain of <I>S. epidermidis</I>, and the recombinant <I>S. epidermidis
</I>strain expressing a therapeutic LEKTI protein. One of the issued US patents covers a recombinant bacteria containing a therapeutic
polypeptide for treating abnormal skin conditions and expires in 2035. The second issued US patent covers an auxotrophic <I>S. epidermidis
</I>that will expire in 2039. If additional patents were to grant from the pending patent applications, they would expire between 2035
and 2039.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>ATR-04</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ATR-12 product candidate is subject to one issued US patent, two pending US patent applications, and 17 pending foreign applications.
These patents and patent applications represent two families of claims directed to auxotrophic strains of bacteria and their therapeutic
use for treating disease. We have one issued US patent that covers ATR-04. If additional patents were to grant, they would also expire
in 2039. Overall, these two families contain 1 issued US patent, 2 pending US applications, and 17 pending foreign applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Patent
Term and Term Extension</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
patents have terms for varying periods depending on the date of filing of the patent application or the date of patent issuance and the
legal term of patents in the countries in which they are obtained. Generally, utility patents issued for applications filed in the United
States are granted a term of 20 years from the earliest effective filing date of a non-provisional patent application. In addition, in
certain instances, the term of a U.S. patent can be extended to recapture a portion of the United States Patent and Trademark Office,
or the USPTO, delay in issuing the patent as well as a portion of the term effectively lost as a result of the FDA regulatory review
period. However, as to the FDA component, the restoration period cannot be longer than five years and the restoration period cannot extend
the patent term beyond 14 years from FDA approval. In addition, only one patent applicable to an approved drug is eligible for the extension,
and only those claims covering the approved drug, a method for using it, or a method of manufacturing may be extended. The duration of
foreign patents varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective
filing date. All taxes, annuities or maintenance fees for a patent, as required by the USPTO and various foreign jurisdictions, must
be timely paid in order for the patent to remain in force during this period of time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
actual protection afforded by a patent may vary on a product-by-product basis, from country to country, and can depend upon many factors,
including the type of patent, the scope of its coverage, the availability of regulatory-related extensions and the availability of legal
remedies in a particular country and the validity and enforceability of the patent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
patents and patent applications may be subject to procedural or legal challenges by others. We may be unable to obtain, maintain and
protect the intellectual property rights necessary to conduct our business, and we may be subject to claims that we infringe or otherwise
violate the intellectual property rights of others, which could materially harm our business. For more information, see the section titled
&ldquo;<I>Risk Factors&mdash;Risks Related to Our Intellectual Property</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Trade
Secrets and Know-How</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also rely on trade secrets, know-how, continuing technological innovation and confidential information to develop and maintain our
proprietary position and protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent
protection, including our proprietary processes for manufacturing our live biotherapeutic products. We seek to protect our proprietary
technology and processes, in part, by confidentiality agreements and invention assignment agreements with our employees, consultants,
scientific advisors, contractors and others who may have access to proprietary information, under which they are bound to assign to us
inventions made during the term of their employment or term of service. These agreements may be breached, and we may not have adequate
remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To
the extent that our contractors, commercial partners, collaborators, employees, and consultants use intellectual property owned by others
in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. For more information, see
the section titled &ldquo;<I>Risk Factors&mdash;Risks Related to Our Intellectual Property</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises
and physical and electronic security of our information technology systems.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exclusive
License Agreement with Fred Hutchison Cancer Center</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2022, we entered into an Exclusive License Agreement with the Fred Hutchinson Cancer Center, or Fred Hutch. Pursuant to
our agreement with Fred Hutch, we obtained an exclusive worldwide license under certain patents related to SyMPL technologies
developed and owned by Fred Hutch to develop, make, manufacture, have manufactured, distribute, have distributed, use, research,
improve, import, offer to sell and sell and otherwise commercialize products that are covered by such patents. Such exclusive license
is subject to certain rights retained by Fred Hutch and also the U.S. government. The patent rights licensed to us by Fred
Hutch consist of two families of patent applications directed to methods of bypassing restriction modification systems in order to
more easily introduce xenogeneic DNA. These patents applications and any patents that issue from these applications will allow us to
produce more modified microbes for the treatment of disease. Our current product candidates do not incorporate the SyMPL technology
platform, but we expect that some or all of our future product candidates will do so. If issued, these two families will expire in 2037 and 2040, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the license granted to us under the Fred Hutch license agreement, we paid Fred Hutch a nominal upfront
payment. In addition, we are required to pay Fred Hutch certain development and commercial milestone payments and running single
digit royalty on net sales of the licensed products. The Fred Hutch agreement also requires us to reimburse Fred Hutch
for the cost of the prosecution and maintenance of the licensed patents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Fred Hutch license agreement, we are required to use commercially reasonable efforts to bring a licensed product to market
through a vigorous and diligent program for exploitation of the licensed patent rights. The term of the Fred Hutch license agreement
will continue until the later of (i) the expiration of the licensed patents or (ii) ten years from the first sale of a licensed product.
We may terminate the Fred Hutch license agreement at will at any time upon prior written notice to Fred Hutch. Fred Hutch
has the right to terminate the Fred Hutch license agreement if we materially breach the agreement and fail to cure such breach
within a specified cure period or if we become bankrupt or insolvent. For more information related to the intellectual property acquired
pursuant to the Fred Hutch license agreement, see the section titled &ldquo;<I>Business-Licenses and Intellectual Property Rights</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also hold registered trademarks for our corporate name and design in the U.S. and in seven foreign countries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Government
Regulations </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
companies are subject to extensive regulation by foreign, federal, state and local agencies, such as the U.S. FDA, and various similar
agencies in most countries worldwide. The research, development, testing, manufacture, distribution, packaging, labeling, storage, recordkeeping,
marketing and sale of pharmaceutical products are subject to government regulation in the U.S. and various foreign countries. Additionally,
in the U.S., we must follow rules and regulations established by the FDA requiring the presentation of data indicating that our product
candidates are safe and effective and are manufactured in accordance with cGMP regulations. If we do not comply with applicable requirements,
we may be fined, the government may refuse to approve our marketing applications or allow us to manufacture or market our product candidates,
and we may be criminally prosecuted. We, our manufacturers and clinical research organizations may also be subject to regulations under
other foreign, federal, state and local laws, including, but not limited to, the U.S. Occupational Safety and Health Act, the Resource
Conservation and Recovery Act, the Clean Air Act and import, export and customs regulations as well as the laws and regulations of other
countries. The U.S. government has increased its enforcement activity regarding illegal marketing practices domestically and internationally.
As a result, pharmaceutical companies must ensure their compliance with the Foreign Corrupt Practices Act and federal healthcare fraud
and abuse laws, including the False Claims Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
regulatory requirements impact our operations and differ from one country to another, so that securing the applicable regulatory approvals
of one country does not imply the approval of another country. The approval procedures involve high costs and are manpower intensive,
usually extend over many years and require highly skilled and professional resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FDA
Market Approval Process</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S., our product candidates are regulated by the FDA as biologics under the Federal Food, Drug, and Cosmetic Act, or FDCA, the Public
Health Service Act, or PHSA, and regulations promulgated by the FDA. The failure to comply with the applicable requirements at any time
during the product development process, including preclinical testing, clinical testing, the approval process or post-approval process,
may subject an applicant to delays in the conduct of clinical trials, regulatory review and approval, and/or administrative or judicial
sanctions. These sanctions may include, but are not limited to, the FDA&rsquo;s refusal to allow an applicant to proceed with clinical
testing, refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, warning letters, adverse
publicity, customer notification, product recalls, product seizures, refusal to grant export or import approval, total or partial suspension
of production or distribution, consent decrees, injunctions, fines, and civil or criminal investigations and penalties brought by the
FDA or the U.S. Department of Justice, or other governmental entities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
steps usually required to be taken before a new biologic may be marketed in the U.S. generally include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of preclinical laboratory tests and animal studies performed in accordance with the FDA&rsquo;s current Good Laboratory Practices
    regulation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant
    changes are made;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
    by an independent Institutional Review Board, or IRB, or ethics committee at each treatment site before the trial is commenced;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well controlled human clinical trials to establish the safety, purity and potency of the proposed biologic product
    candidate for its proposed indication for use;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    of data supporting safety and efficacy as well as detailed information on the manufacture and composition of the product in clinical
    development and proposed labeling;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparation
    of and submission to the FDA of a BLA after completion of all pivotal clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA Advisory Committee review, if applicable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    determination by the FDA within 60 days of its receipt of a BLA to file the application for review;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced
    to assess compliance with cGMP standards and to assure that the facilities, methods and controls are adequate to preserve the biological
    product&rsquo;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with Good
    Clinical Practices, or GCP;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of any FDA audits of the non-clinical and clinical trial sites to assure compliance with CGP requirements and the integrity
    of clinical data in support of the BLA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment
    of user fees and securing FDA approval of the BLA for the proposed indication for use;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    review and approval of the BLA to permit commercial marketing of the product for particular indications for use in the United States;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
    with any post-approval requirements, including REMS and any post-approval studies required by the FDA.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Preclinical
Studies and Investigational New Drug Application</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
tests include laboratory evaluations of product chemistry, formulation and stability, as well as animal studies to evaluate the potential
for efficacy and toxicity in animals. The conduct of the preclinical tests and formulation of the compounds for testing must comply with
federal regulations and requirements. The results of the preclinical tests, together with manufacturing information and analytical data,
are submitted to the FDA as part of an IND application. Some preclinical tests may continue even after submission of the IND application.
The IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions
about the product or conduct of the proposed clinical trial, including concerns that human research volunteers will be exposed to unreasonable
health risks. In that case, the IND sponsor and the FDA must resolve any outstanding FDA concerns before the clinical trial can begin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, submission of the IND may result in the FDA not allowing the clinical trials to commence or allowing the clinical trial to
commence on the terms originally specified by the sponsor in the IND. If the FDA raises concerns or questions either during this initial
30-day period, or at any time during the IND process, it may choose to impose a partial or complete clinical hold. This order issued
by the FDA would delay either a proposed clinical trial or cause delay in initiation of a phase of an ongoing clinical trial, until all
outstanding concerns have been adequately addressed and the FDA has notified the company that investigations may proceed. This could
cause significant delays or difficulties in completing planned clinical trials in a timely manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Clinical
Trials</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials involve the administration of the investigational product candidate to healthy volunteers or patients with the disease to be treated
under the supervision of a qualified principal investigator in accordance with good clinical practice, or GCP, requirements. Clinical
studies are conducted under protocols detailing, among other things, the objectives of the study, what types of patients may enter the
study, schedules of tests and procedures, drugs, dosages, and length of study, as well as the parameters to be used in monitoring safety,
and the efficacy criteria to be evaluated. A protocol for each clinical study and any subsequent protocol amendments must be submitted
to the FDA as part of the IND process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
sponsor who wishes to conduct a clinical trial outside the U.S. may, but need not, obtain FDA authorization to conduct the clinical trial
under an IND. If a clinical trial outside the U.S. is not conducted under an IND, the sponsor may submit data from the clinical trial
to the FDA in support of a BLA so long as the clinical trial is conducted consistent with the spirit of GCP and in compliance with an
international guideline for the ethical conduct of clinical research known as the Declaration of Helsinki and/or the laws and regulations
of the country or countries in which the clinical trial is performed, whichever provides the greater protection to the participants in
the clinical trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
IRB, either centrally or individually, must also review each clinical trial at each institution at which the clinical trial will be conducted.
The IRB will consider, among other things, clinical trial design, patient informed consent, ethical factors, the safety of human subjects,
the possible liability of the institution, and, where appropriate, the protection of privacy of the human subjects. An IRB must operate
in compliance with the FDA regulations. The FDA, IRB, or the clinical trial sponsor, or the principal investigator may suspend or discontinue
a clinical trial at any time for various reasons, including a finding that the clinical trial is not being conducted in accordance with
FDA requirements or the subjects or patients are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive
GCP rules and the requirements for informed consent. Additionally, some clinical studies are overseen by an independent group of qualified
experts organized by the clinical study sponsor, known as a data safety monitoring board or committee. This group recommends whether
or not a trial may move forward at designated check points based on access to certain data from the study. The clinical study sponsor
may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive climate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials are usually conducted in three sequential phases, but the phases may overlap or be combined. Annual progress detailing the results
of the clinical trial phases must be submitted to the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Phase
    1</I> clinical trials are normally conducted in small groups of healthy volunteers to assess safety and tolerability of various
    dosing regimens and pharmacokinetics. For some products for orphan, severe or life-threatening diseases, especially if the
    product may be too toxic to administer to healthy humans, the initial clinical trials may be conducted in individuals having a specific
    disease for which use the tested product is indicated. These trials in patients are often referred to as Phase 1b trials. If they
    include a design to establish a particular dose, they are commonly referred to as Phase 1b/2a clinical trials. Nevertheless, additional
    Phase 2 (sometimes called Phase 2b) clinical trials are often necessary to refine the final dose chosen to take into a pivotal Phase
    3 clinical trial.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Phase
    2</I> clinical trials are generally conducted in a limited patient population to identify possible adverse effects and safety
    risks, evaluate the efficacy of the product candidate for specific targeted indications and determine does tolerance and optimal
    dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and
    more costly Phase 3 clinical trials.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Phase
    3</I> clinical trials proceed if the Phase 2 clinical trials demonstrate that a dose range of the product candidate
    is potentially effective and has an acceptable safety profile. Phase 3 clinical trials are undertaken to further evaluate,
    in a larger number of patients, dosage, provide substantial evidence of clinical efficacy and further test for safety in an expanded
    and diverse patient population at multiple, geographically dispersed clinical trial sites. A well-controlled, statistically robust
    Phase 3 trial may be designed to deliver the data that regulatory authorities will use to decide whether or not to approve,
    and, if approved, how to appropriately label a drug: such Phase 3 studies are referred to as &ldquo;pivotal.&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may order the temporary or permanent discontinuation of a clinical study at any time or impose other sanctions if it believes that
the clinical study is not being conducted in accordance with FDA requirements or that the participants are being exposed to an unacceptable
health risk. In some cases, the FDA may approve a BLA for a product candidate but require the sponsor to conduct additional clinical
trials to further assess the drug&rsquo;s safety and effectiveness after BLA approval. Such post-approval trials are typically referred
to as Phase 4 clinical trials. These studies are used to gain additional experience data from the treatment of patients in the
intended therapeutic indication and to document a clinical benefit in the case of drugs or biologics approved under accelerated approval
regulations. If the FDA approves a product while a company has ongoing clinical trials that were not necessary for approval, a company
may be able to use the data from these clinical trials to meet all or part of any Phase 4 clinical trial requirement or to request
a change in the product labeling. Failure to exhibit due diligence with regard to conducting Phase 4 clinical trials could result
in withdrawal of approval for products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Compliance
with cGMP Requirements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a product candidate moves through the clinical testing phases, manufacturing processes are further defined, refined, controlled and validated.
The level of control and validation required by the FDA increases as clinical studies progress. The FDA typically will not approve a
BLA application unless it determines that the manufacturing processes and facilities are in full compliance with cGMP requirements and
able to assure consistent production of the product within required specifications. The PHSA emphasizes the importance of manufacturing
control for products like biologics whose attributes cannot be precisely defined.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and the third-party manufacturers on which we rely for the manufacture of our product candidates and their respective components (including
the API) are subject to requirements that drugs be manufactured, packaged and labeled in conformity with cGMPs. To comply with cGMP requirements,
manufacturers must continue to spend time, money and effort to meet requirements relating to personnel, facilities, equipment, production
and process, labeling and packaging, quality control, recordkeeping and other requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturers
and others involved in the manufacture and distribution of products must also register their establishments with the FDA and certain
state regulatory bodies. Both U.S. and non-U.S. manufacturing establishments must register and provide additional information to the
FDA upon their initial participation in the manufacturing process. Any product manufactured by or imported from a facility that has not
registered, whether U.S. or non-U.S., is deemed misbranded under the FDCA. Establishments may be subject to periodic unannounced inspections
by government authorities to ensure compliance with cGMPs and other laws. Inspections must follow a &ldquo;risk-based schedule&rdquo;
that may result in certain establishments being inspected more frequently. Manufacturers may also have to provide, on request, electronic
or physical records regarding their establishments. Delaying, denying, limiting, or refusing inspection by the FDA may lead to a product
being deemed to be adulterated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BLA
Submission and Review</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
completion of all required testing in accordance with all applicable regulatory requirements, detailed information on the product candidate
is submitted to the FDA in the form of a BLA, requesting approval to market the product for one or more indications, together with payment
of a user fee, unless waived. A BLA includes all relevant data available from pertinent nonclinical and clinical studies, including negative
or ambiguous results as well as positive findings, together with detailed information on the chemistry, manufacture, controls and proposed
labeling, among other things. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish
the safety and efficacy of the product candidate for its intended use to the satisfaction of the FDA. The FDA also conducts a pre-approval
inspection of the manufacturer and laboratory prior to approval of the BLA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a BLA submission is accepted for filing, the FDA begins an in-depth review of the BLA. Under the Prescription Drug User Fee Act, or PDUFA,
the FDA&rsquo;s goal is to complete its initial review and respond to the applicant within ten months of submission, unless the application
relates to an unmet medical need, or is for a serious or life-threatening indication, in which case the goal may be within six months
of BLA submission. However, PDUFA goal dates are not legal mandates and the FDA response often occurs several months beyond the original
PDUFA goal date. Further, the review process and the target response date under PDUFA may be extended if the FDA requests or the BLA
sponsor otherwise provides additional information or clarification regarding information already provided in the BLA. The BLA review
process can, accordingly, be very lengthy. During its review of a BLA, the FDA may refer the application to an advisory committee for
review, evaluation and recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of
an advisory committee, but it typically follows such recommendations. Data from clinical studies are not always conclusive and the FDA
and/or any advisory committee it appoints may interpret data differently than the applicant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the FDA evaluates the BLA and inspects manufacturing facilities where the drug product and/or its API will be produced and tested, it
will either approve commercial marketing of the drug product with prescribing information for specific indications or issue a complete
response letter indicating that the application is not ready for approval and stating the conditions that must be met in order to secure
approval of the BLA. If the complete response letter requires additional data and the applicant subsequently submits that data, the FDA
nevertheless may ultimately decide that the BLA does not satisfy its criteria for approval. The FDA could also approve the BLA with a
Risk Evaluation and Mitigation Strategies, or REMS, plan to mitigate risks, which could include medication guides, physician communication
plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.
The FDA also may condition approval on, among other things, changes to proposed labeling, development of adequate controls and specifications,
or a commitment to conduct post-marketing testing. Such post-marketing testing may include Phase 4 clinical trials and surveillance
to further assess and monitor the product&rsquo;s safety and efficacy after approval. Regulatory approval of products for serious or
life-threatening indications may require that participants in clinical studies be followed for long periods to determine the overall
survival benefit of the drug.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA approves one of our product candidates, we will be required to comply with a number of post-approval regulatory requirements.
We would be required to report, among other things, certain adverse reactions and production problems to the FDA, provide updated safety
and efficacy information and comply with requirements concerning advertising and promotional labeling for any of our product candidates.
Also, quality control and manufacturing procedures must continue to conform to cGMPs after approval, and the FDA periodically inspects
manufacturing facilities to assess compliance with cGMPs, which imposes extensive procedural, substantive and record keeping requirements.
If we seek to make certain changes to an approved product, such as certain manufacturing changes, we may need FDA review and approval
before the change can be implemented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
physicians may use products for indications that have not been approved by the FDA, we may not label or promote the product for an indication
that has not been approved. Securing FDA approval for new indications is similar to the process for approval of the original indication
and requires, among other things, submitting data from adequate and well-controlled studies that demonstrate the product&rsquo;s safety
and efficacy in the new indication. Even if such studies are conducted, the FDA may not approve any change in a timely fashion, or at
all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may also require post-marketing testing, or Phase 4 testing, as well as risk minimization action plans and surveillance to
monitor the effects of an approved product or place conditions or an approval that could otherwise restrict the distribution or use of
the product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Fast
Track, Breakthrough Therapy and Priority Review Designations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA is authorized to designate certain products for expedited review if they are intended to address an unmet medical need in the treatment
of a serious or life-threatening disease or condition, or in the event of an emergency. These programs are fast track designation, breakthrough
therapy designation and priority review designation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specifically,
the FDA may designate a product for fast track review if it is intended, whether alone or in combination with one or more other products,
for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs
for such a disease or condition. For fast track products, sponsors may have greater interactions with the FDA and the FDA may initiate
review of sections of a fast track product&rsquo;s application before the application is complete. This rolling review may be available
if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast track product may be effective.
The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must
pay applicable user fees. However, the FDA&rsquo;s time period goal for reviewing a fast track application does not begin until the last
section of the application is submitted. In addition, the fast track designation may be withdrawn by the FDA if the FDA believes that
the designation is no longer supported by data emerging in the clinical trial process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second,
in 2012, Congress enacted the Food and Drug Administration Safety and Innovation Act, or FDASIA. This law established a new regulatory
scheme allowing for expedited review of products designated as &ldquo;breakthrough therapies.&rdquo; A product may be designated as a
breakthrough therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening
disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing
therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.
The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development
process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review
process; assigning a cross-disciplinary project lead for the review team; and taking other steps to design the clinical trials in an
efficient manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third,
the FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide
a significant improvement in safety or effectiveness. The FDA determines, on a case-by-case basis, whether the proposed product represents
a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased
effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented
enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new
subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and
to shorten the FDA&rsquo;s goal for taking action on a marketing application from ten months to six months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fourth,
the Secretary of Health and Human Services may authorize unapproved drugs and biologics to be marketed in the event an actual or potential
emergency has been designated by the U.S. government. After an emergency has been designated, the FDA may issue an Emergency Use Authorization,
or EUA, for the use of a specific product based on criteria established by the FDCA. An EUA is product specific and is subject to specific
conditions and restrictions. Once the emergency underlying the EUA ends, then the EUA terminates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Pediatric
Rare Disease Designation and Priority Review Vouchers</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the FDCA, as amended, the FDA incentivizes the development of drugs and biologics that meet the definition of a &ldquo;rare pediatric
disease,&rdquo; defined to mean a serious or life-threatening disease in which the serious of life-threatening manifestations primarily
affect individuals aged from birth to 18 years and the disease affects fewer than 200,000 individuals in the United States or affects
200,000 or more in the United States and for which there is no reasonable expectation that the cost of developing and making in the United
States a drug or biologic for such disease or condition will be received from sales in the United States of such drug or biologic. The
sponsor of a product candidate for a rare pediatric disease may be eligible for a voucher that can be used to obtain a priority review
for a subsequent human drug or biologic application after the date of approval of the rare pediatric disease drug product, referred to
as a priority review voucher, or PRV. A sponsor may request rare pediatric disease designation from the FDA prior to the submission of
its NDA or BLA. A rare pediatric disease designation does not guarantee that a sponsor will receive a PRV upon approval of its NDA or
BLA. Moreover, a sponsor who chooses not to submit a rare pediatric disease designation request may nonetheless receive a PRV upon approval
of their marketing application if they request such a voucher in their original. marketing application and meet all of the eligibility
criteria. If a PRV is received, it may be sold or transferred an unlimited number of times. Congress has extended the PRV program until
September 30, 2024, with the potential for PRVs to be granted until 2026.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Post-Approval
Regulation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
regulatory approval for marketing of a product or new indication for an existing product is obtained, the sponsor will be required to
comply with post-approval regulatory requirements, including any post-approval requirements that the FDA may have imposed as a condition
of approval. The sponsor will be required to report certain adverse reactions and production problems to the FDA, provide updated safety
and efficacy information and comply with requirements concerning advertising and promotional labeling requirements. Manufacturers and
certain of their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject
to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including
cGMP regulations, which impose certain procedural and documentation requirements upon drug manufacturers. Accordingly, the sponsor and
its third-party manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain
compliance with cGMP regulations and other regulatory requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
product may also be subject to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of
the product before it is released for distribution. If the product is subject to official release, the manufacturer must submit samples
of each lot, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the
manufacturer&rsquo;s tests performed on the lot, to the FDA. The FDA may in addition perform certain confirmatory tests on lots of some
products before releasing the lots for distribution. Finally, the FDA will conduct laboratory research related to the safety, purity,
potency, and effectiveness of pharmaceutical products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained
or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse
events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may
result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess
new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among
other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    warning letters or holds on post-approval clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    of the FDA to approve pending BLAs or supplements to approved BLAs, or suspension or revocation of product license approvals;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizure or detention, or refusal to permit the import or export of products; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
    or the imposition of civil or criminal penalties.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs and biologics
may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies
actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly
promoted off-label uses may be subject to significant liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Orphan
Drug Designation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition affecting fewer than
200,000 individuals in the United States, or in other limited cases. Orphan drug designation (ODD) provides for seven years of market
exclusivity, independent of patent protection, to the company with ODD that brings a particular product to market. In addition, companies
developing orphan drugs are eligible for certain incentives, including tax credits for qualified clinical testing. In addition, a BLA
for a product that has received orphan drug designation is not subject to a prescription drug user fee unless the application includes
an indication other than the rare disease or condition for which the drug was designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
gain exclusivity, if a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition
for which it has such designation, the product is entitled to the orphan drug exclusivity, which means that the FDA may not approve any
other applications to market the same active moiety for the same indication for seven years, except in limited circumstances, such as
another drug&rsquo;s showing of clinical superiority over the drug with orphan exclusivity. In addition, doctors may prescribe products
for off-label uses and undermine our exclusivity. Orphan drug exclusivity could block the approval of one of our product candidates for
seven years if a competitor obtains approval for the same active moiety for the same indication before we do, unless we are able to demonstrate
that our product is clinically superior.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
sponsor may request orphan drug designation of a previously unapproved product or new orphan indication for an already marketed product.
In addition, a sponsor of a product that is otherwise the same product as an already approved orphan drug may seek and obtain orphan
drug designation for the subsequent product for the same rare disease or condition if it can present a plausible hypothesis that its
product may be clinically superior to the first, approved product. More than one sponsor may receive orphan drug designation for the
same product for the same rare disease or condition, but each sponsor seeking orphan drug designation must file a complete request for
designation, and only the first sponsor that obtains approval for that drug for the orphan indication will obtain market exclusivity,
effectively preventing the FDA from approving products under development by competitors for the same drug and same indication, unless
the competitor is able to demonstrate that the product under development is clinically superior to the approved product or the approved
product is not available in sufficient quantities. To permit the FDA to end another manufacturer&rsquo;s orphan exclusivity period, the
FDA must determine that the manufacturer has demonstrated clinical superiority by showing the later drug is safer, more effective, or
otherwise makes a major contribution to patient care.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
period of exclusivity begins on the date that the marketing application is approved by the FDA and applies only to the indication for
which the product has been designated. The FDA may approve a second application for the same product for a different use or a subsequent
application for a different drug for the same indication. Orphan drug designation neither shortens the development time or regulatory
review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may plan to pursue orphan drug designation and exclusivity for some of our product candidates in the United States, European Union, and
other geographies of interest for specific products. We cannot guarantee that we will obtain orphan drug designation for any products
in any jurisdiction. Even if we are able to obtain orphan drug designation for a product, we cannot be sure that such product will be
approved, that we will be able to obtain orphan drug exclusivity upon approval, if ever, or that we will be able to maintain any exclusivity
that is granted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Biosimilars
and Exclusivity</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Patient Protection and Affordable Care Act, or ACA, which was signed into law on March 23, 2010, included a subtitle called the Biologics
Price Competition and Innovation Act of 2009 or BPCIA. The BPCIA established a regulatory scheme authorizing the FDA to approve biosimilars
and interchangeable biosimilars. The FDA has issued several draft guidance documents outlining an approach to review and approval of
biosimilars. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes
by which such products are manufactured, pose significant hurdles to implementation, which are still being worked out by the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the BPCIA, a manufacturer may submit an application for licensure of a biologic product that is &ldquo;biosimilar to&rdquo; or &ldquo;interchangeable
with&rdquo; a previously approved biological product or &ldquo;reference product.&rdquo; In order for the FDA to approve a biosimilar
product, it must find that there are no clinically meaningful differences between the reference product and proposed biosimilar product
in terms of safety, purity, and potency. For the FDA to approve a biosimilar product as interchangeable with a reference product, the
agency must find that the biosimilar product can be expected to produce the same clinical results as the reference product, and (for
products administered multiple times) that the biologic and the reference biologic may be switched after one has been previously administered
without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the BPCIA, an application for a biosimilar product may not be submitted to the FDA until 4 years following the date of approval of the
reference product. The FDA may not approve a biosimilar product until 12 years from the date on which the reference product was approved.
Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version
of that product if the FDA approves a full BLA for such product containing the sponsor&rsquo;s own preclinical data and data from adequate
and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The BPCIA also created certain exclusivity
periods for biosimilars approved as interchangeable products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulation
Outside the United States</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements
of other countries and jurisdictions regarding quality, safety and efficacy that govern, among other things, clinical trials, marketing
authorization, commercial sales and distribution of drug products. Whether or not it obtains FDA approval for a product, the company
would need to obtain the necessary approvals by the comparable non-U.S. regulatory authorities before it can commence clinical trials
or marketing of the product in those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions
and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other
countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country
or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country
or jurisdiction may negatively impact the regulatory process in others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Regulation
and Marketing Authorization in the European Union</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
European Medicines Agency, or EMA, is the scientific agency of the European Union, or EU, that coordinates the evaluation and monitoring
of new and approved medicinal products such as drugs and biologics. It is responsible for the scientific evaluation of applications for
EU marketing authorizations, as well as the development of technical guidance and the provision of scientific advice to sponsors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process regarding approval of medicinal products in the EU follows roughly the same lines as in the United States and likewise generally
involves satisfactorily completing each of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">preclinical
    laboratory tests, animal studies and formulation studies all performed in accordance with the applicable EU Good Laboratory Practice
    regulations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the relevant regulatory agencies in EU member states, or national authorities, of a clinical trial application, or CTA, for each
    clinical trial, which must be approved before human clinical trials may begin;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the relevant national authorities of a Marketing Authorisation Application, or MAA, which includes the data supporting safety
    and efficacy as well as detailed information on the manufacture and composition of the product in clinical development and proposed
    labeling;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an inspection by the relevant national authorities of the manufacturing facility or facilities, including those of
    third parties, at which the product is produced to assess compliance with cGMP;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    audits of the non-clinical and clinical trial sites that generated the data in support of the MAA; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    and approval by the relevant national authority of the MAA before any commercial marketing, sale or shipment of the product.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Preclinical
Studies</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate the potential efficacy
and toxicity in animals. The conduct of the preclinical tests and formulation of the compounds for testing must comply with the relevant
EU regulations and requirements. The results of the preclinical tests, together with relevant manufacturing information and analytical
data, are submitted as part of the CTA when seeking approval to start a clinical trial, and with the MAA when seeking marketing authorization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Clinical
Trial Approval</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Requirements
for the conduct of clinical trials in the EU including cGCP, are implemented in the currently Clinical Trials Directive 2001/20/EC and
the GCP Directive 2005/28/EC. Pursuant to Directive 2001/20/EC and Directive 2005/28/EC, as amended, a system for the approval of clinical
trials in the EU has been implemented through national legislation of the EU member states. Under this system, approval must be obtained
from the competent national authority in which a trial is planned to be conducted, or in multiple member states if the clinical trial
is to be conducted in a number of member states. To this end, a CTA is submitted, which must be supported by an investigational medicinal
product dossier, or IMPD, and further supporting information prescribed by Directive 2001/20/EC and Directive 2005/28/EC and other applicable
guidance documents. Furthermore, a clinical trial may only be started after a competent ethics committee has issued a favorable opinion
on the clinical trial application in that country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 31, 2022, the Clinical Trials Regulation (EU) No. 536/2014 replaced the current Clinical Trials Directive 2001/20/EC. To ensure
that the rules for clinical trials are identical throughout the EU, the Clinical Trials Regulation (EU) No. 536/2014 was passed as a
regulation which is directly applicable in all EU member states. The Clinical Trials Directive 2001/20/EC will, however, still apply
three years from the date of entry into application of the Clinical Trials Regulation to (i) clinical trials applications submitted before
the entry into application and (ii) clinical trials applications submitted within one year after the entry into application if the sponsor
opts for the old system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulation
(EU) No 536/2014 aims to simplify and streamline the approval of clinical trial in the EU. The main characteristics of the regulation
include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    streamlined application procedure via a single entry point, known as the Clinical Trials Information System;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    single set of documents to be prepared and submitted for the application as well as simplified reporting procedures which will spare
    sponsors from submitting broadly identical information separately to various and different national authorities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strictly
    defined deadlines for the assessment of clinical trial application; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    involvement of the ethics committees in the assessment procedure in accordance with the national law of the member state concerned
    but within the overall timelines defined by the Regulation (EU) No 536/2014.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Marketing
Authorization</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorization
to market a product in the member states of the EU proceeds under one of four procedures: a centralized procedure, a mutual recognition
procedure, a decentralized procedure or a national procedure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Centralized
Procedure</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
centralized procedure enables applicants to obtain a marketing authorization that is valid in all EU member states based on a single
application. Certain medicinal products, including products developed by means of biotechnological processes must undergo the centralized
authorization procedure for marketing authorization, which, if granted by the European Commission, based on the opinion of the EMA, is
automatically valid in all EU member states. Sponsors may elect to file an MAA through the centralized procedures for other classes of
products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
centralized procedure is mandatory for certain types of products such as, medicines derived from biotechnology processes such as genetic
engineering, advanced-therapy medicines such as gene-therapy or tissue engineered medicine, orphan medicines, and medicinal products
containing a new active substance indicated for the treatment of HIV, AIDS, cancer, diabetes, neurodegenerative disorders, autoimmune
and other immune dysfunctions, and viral diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
centralized authorization procedure is optional for other medicinal products if they contain a new active substance, if the applicant
shows that the medicinal product concerned constitutes a significant therapeutic, scientific or technical innovation, or that the granting
of authorization is in the public interest of the EU.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Administration
Procedure</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the centralized procedure, the EMA&rsquo;s Committee for Human Medicinal Products, or CHMP serves as the scientific committee that renders
opinions about the safety, efficacy and quality of medicinal products for human use on behalf of the EMA. The CHMP is composed of experts
nominated by each member state&rsquo;s national authority for medicinal products, with one of them appointed to act as Rapporteur for
the co-ordination of the evaluation with the possible assistance of a further member of the Committee acting as a Co-Rapporteur. After
approval, the Rapporteur(s) continue to monitor the product throughout its life cycle. The CHMP has 210 active days, to adopt an opinion
as to whether a marketing authorization should be granted. The process usually takes longer in case additional information is requested,
which triggers clock-stops in the procedural timelines. The process is complex and involves extensive consultation with the regulatory
authorities of member states and a number of experts. When an application is submitted for a marketing authorization in respect of a
drug which is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation,
the applicant may, pursuant to Article 14(9) Regulation (EC) No 726/2004, request an accelerated assessment procedure. If the CHMP accepts
such request, the time-limit of 210 days will be reduced to 150 days but it is possible that the CHMP can revert to the standard time-limit
for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment. Once the procedure
is completed, a European Public Assessment Report, or EPAR, is produced. If the opinion is negative, information is given as to the grounds
on which this conclusion was reached. After the adoption of the CHMP opinion, a decision on the MAA must be adopted by the European Commission,
after consulting the EU member states, which in total can take more than 60 days. After a drug has been authorized and launched, it is
a condition of maintaining the marketing authorization that all aspects relating to its quality, safety and efficacy must be kept under
review.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Conditional
Approval</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
specific circumstances, EU legislation (Article 14(7) Regulation (EC) No. 726/2004 and Regulation (EC) No. 507/2006 on Conditional Marketing
Authorizations for Medicinal Products for Human Use) enables applicants to obtain a conditional marketing authorization prior
to obtaining the comprehensive clinical data required for an application for a full marketing authorization. Such conditional approvals
may be granted for products (including medicines designated as orphan medicinal products), if&thinsp; (1) the risk-benefit balance of
the product is positive, (2) it is likely that the applicant will be in a position to provide the required comprehensive clinical trial
data, (3) the product fulfills unmet medical needs, and (4) the benefit to public health of the immediate availability on the market
of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional marketing
authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with
respect to the completion of ongoing or new studies, and with respect to the collection of pharmacovigilance data. Conditional marketing
authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an
assessment of the need for additional or modified conditions and/or specific obligations. The timelines for the centralized procedure
described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Marketing
Authorization Under Exceptional Circumstances</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
per Article 14(8) Regulation (EC) No 726/2004, products for which the applicant can demonstrate that comprehensive data (in line with
the requirements laid down in Annex I of Directive 2001/83/EC, as amended) cannot be provided (due to specific reasons foreseen in the
legislation) might be eligible for marketing authorization under exceptional circumstances. This type of authorization is reviewed annually
to reassess the risk-benefit balance. The fulfillment of any specific procedures/obligations imposed as part of the marketing authorization
under exceptional circumstances is aimed at the provision of information on the safe and effective use of the product and will normally
not lead to the completion of a full dossier/approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Pediatric
Studies</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to obtaining a marketing authorization in the EU, applicants have to demonstrate compliance with all measures included in an EMA-approved
Pediatric Investigation Plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted (1) a product-specific
waiver, (2) a class waiver, or (3) a deferral for one or more of the measures included in the PIP. The respective requirements for all
marketing authorization procedures are laid down in Regulation (EC) No 1901/2006, the so called Pediatric Regulation. This requirement
also applies when a company wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already
authorized. The Pediatric Committee of the EMA, or PDCO, may grant deferrals for some medicines, allowing a company to delay development
of the medicine in children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also
grant waivers when development of a medicine in children is not needed or is not appropriate, such as for diseases that only affect the
elderly population.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
a marketing authorization application can be filed, or an existing marketing authorization can be amended, the EMA determines that companies
actually comply with the agreed studies and measures listed in each relevant PIP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Period
of Authorization and Renewals</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
marketing authorization will be valid for five years in principle, and the marketing authorization may be renewed after five years on
the basis of a re-evaluation of the risk-benefit balance by the EMA or by a national authority. To this end, the marketing authorization
holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy,
including all variations introduced since the marketing authorization was granted, at least nine months before the marketing authorization
ceases to be valid. Once renewed, the marketing authorization will be valid for an unlimited period, unless the European Commission or
the national authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal.
Any authorization that is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the
market of the authorizing member state within three years after authorization will cease to be valid, the so-called &ldquo;sunset clause.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Orphan
Drug Designation and Exclusivity</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
European Commission can grant orphan medicinal product designation to products for which the sponsor can establish that it is intended
for the diagnosis, prevention, or treatment of&thinsp; (1) a life-threatening or chronically debilitating condition affecting not more
than five in 10,000 people in the EU, or (2) a life threatening, seriously debilitating or serious and chronic condition in the EU and
that without incentives it is unlikely that sales of the drug in the EU would generate a sufficient return to justify the necessary investment.
In addition, the sponsor must establish that there is no other satisfactory method approved in the EU of diagnosing, preventing or treating
the condition, or if such a method exists, the proposed orphan drug will be of significant benefit to patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orphan
drug designation provides a number of benefits, including fee reductions, regulatory assistance, and the possibility to apply for a centralized
EU marketing authorization (see &ldquo;&mdash;Government Regulation and Product Approval&mdash;Regulation Outside the United States&mdash;Centralized
Authorization Procedure&rdquo;), as well as 10 years of market exclusivity following a marketing authorization. During this market exclusivity
period, neither the EMA, nor the European Commission nor the Member States can accept an application or grant a marketing authorization
for a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and
which is intended for the same therapeutic indication. The market exclusivity period for the authorized therapeutic indication may be
reduced to six years if, at the end of the fifth year, it is established that the orphan drug designation criteria are no longer met,
including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. In addition,
a competing similar medicinal product may be authorized prior to the expiration of the market exclusivity period, including if it is
shown to be safer, more effective or otherwise clinically superior to the already approved orphan drug or if the holder of the marketing
authorization for the already approved orphan drug is unable to supply sufficient quantities of the product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the MAA of a medicinal product designated as an orphan drug includes the results of all studies conducted in compliance with an agreed
PIP, and a corresponding statement is subsequently included in the marketing authorization granted, the ten-year period of market exclusivity
will be extended to twelve years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Regulatory
Data Protection</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EU
legislation also provides for a system of regulatory data and market exclusivity. Upon receiving marketing authorization, new chemical
entities approved on the basis of complete independent data package benefit from eight years of data exclusivity and an additional two
years of market exclusivity. Data exclusivity prevents regulatory authorities in the EU from referencing the innovator&rsquo;s data to
assess a generic or biosimilar (abbreviated) application. During the additional two-year period of market exclusivity, a generic or biosimilar
marketing authorization can be submitted, and the innovator&rsquo;s data may be referenced, but no generic or biosimilar medicinal product
can be marketed until the expiration of the market exclusivity. The overall ten-year period will be extended to a maximum of eleven years
if, during the first eight years of those 10 years, the marketing authorization holder, or MAH, obtains an authorization for one or more
new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical
benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity and the innovator is able
to gain the period of data exclusivity, another company nevertheless could also market another version of the drug if such company obtained
marketing authorization based on an MAA with a complete independent data package of pharmaceutical test, pre-clinical tests and clinical
trials. However, products designated as orphan medicinal products enjoy, upon receiving marketing authorization, a period of 10 years
of orphan market exclusivity (see also &ldquo;Item 4.B&mdash;Government Regulation and Product Approval&mdash;Regulation and Marketing
Authorization in the European Union&mdash;Orphan Drug Designation and Exclusivity&rdquo;). Depending upon the timing and duration of
the EU marketing authorization process, products may be eligible for up to five years&rsquo; supplementary protection certificates, or
SPCs. Such SPCs extend the rights under the basic patent for the drug.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Regulatory
Requirements After a Marketing Authorization Has Been Obtained</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we obtain authorization for a medicinal product in the EU, we will be required to comply with a range of requirements applicable to the
manufacturing, marketing, promotion and sale of medicinal products:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Pharmacovigilance</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will, for example, have to comply with the EU&rsquo;s stringent pharmacovigilance or safety reporting rules, pursuant to which post-authorization
studies and additional monitoring obligations can be imposed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
requirements relate to, for example, the manufacturing of products and APIs in accordance with good manufacturing practice standards.
EU regulators may conduct inspections to verify our compliance with applicable requirements, and we will have to continue to expend time,
money and effort to remain compliant. Non-compliance with EU requirements regarding safety monitoring or pharmacovigilance, and with
requirements related to the development of products for the pediatric population, can also result in significant financial penalties
in the EU. Similarly, failure to comply with the EU&rsquo;s requirements regarding the protection of individual personal data can also
lead to significant penalties and sanctions. Individual EU member states may also impose various sanctions and penalties in case we do
not comply with locally applicable requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Manufacturing</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacturing of authorized drugs, for which a separate manufacturer&rsquo;s license is mandatory, must be conducted in compliance with
the EMA&rsquo;s cGMP requirements and comparable requirements of other national authorities, which mandate the methods, facilities and
controls used in manufacturing, processing and packing of drugs to assure their safety and identity. The EMA enforces its cGMP requirements
through mandatory registration of facilities and inspections of those facilities. The EMA may have a coordinating role for these inspections
while the responsibility for carrying them out rests with the member states competent authority under whose responsibility the manufacturer
falls. Failure to comply with these requirements could interrupt supply and result in delays, unanticipated costs and lost revenues,
and could subject the applicant to potential legal or regulatory action, including but not limited to warning letters, suspension of
manufacturing, seizure of product, injunctive action or possible civil and criminal penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Marketing
and Promotion</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
marketing and promotion of authorized drugs, including industry-sponsored continuing medical education and advertising directed toward
the prescribers of drugs and/or the general public, are strictly regulated in the EU. The applicable regulations aim to ensure that information
provided by holders of marketing authorizations regarding their products is truthful, balanced and accurately reflects the safety and
efficacy claims authorized by the EMA or by the national authority of the authorizing member state. Failure to comply with these requirements
can result in adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
U.S. Healthcare Laws and Compliance Requirements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
products distributed in the United States, we will also be subject to additional healthcare regulation and enforcement by the federal
government and the states in which we conduct our business. Applicable federal and state healthcare laws and regulations include the
following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal healthcare anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering,
    receiving, or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual
    for, or the purchase, order, or recommendation of, any good or service, for which payment may be made under federal healthcare programs
    such as Medicare, Medicaid, or other governmental programs. A person or entity does not need to have actual knowledge of the federal
    anti-kickback statute or specific intent to violate it to have committed a violation; in addition, items or services resulting from
    a violation of the federal anti-kickback statute may constitute a false or fraudulent claim for purposes of the False Claims Act;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Ethics in Patient Referrals Act, commonly referred to as the Stark Law, and its corresponding regulations, prohibit physicians from
    referring patients for designated health services (including outpatient drugs) reimbursed under the Medicare or Medicaid programs
    to entities with which the physicians or their immediate family members have a financial relationship or an ownership interest, subject
    to narrow regulatory exceptions, and prohibits those entities from submitting claims to Medicare or Medicaid for payment of items
    or services provided to a referred beneficiary;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal False Claims Act imposes criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals
    or entities for knowingly presenting, or causing to be presented, to the federal government claims for payment that are false or
    fraudulent or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health
    Insurance Portability and Accountability Act of 1996, imposes criminal and civil liability for executing a scheme to defraud any
    healthcare benefit program and also imposes obligations, including mandatory contractual terms, with respect to safeguarding the
    privacy, security and transmission of individually identifiable health information. This statute also prohibits knowingly and willfully
    falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of
    or payment for healthcare benefits, items, or services;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making
    any materially false statement in connection with the delivery of or payment for health care benefits, items or services;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Physician Payments Sunshine Act, created under the ACA, and its implementing regulations, which requires specified manufacturers
    of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&rsquo;s
    Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS,
    information related to payments or other &ldquo;transfers of value&rdquo; made to physicians. All such reported information is publicly
    available; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analogous
    state laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims
    involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, and some state
    laws require pharmaceutical companies to comply with the pharmaceutical industry&rsquo;s voluntary compliance guidelines and the
    relevant compliance guidance promulgated by the federal government.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our
future business activities could be subject to challenge under one or more of such laws. Efforts to ensure that our business arrangements
with third parties will comply with applicable laws and regulations will involve substantial costs. It is possible that governmental
authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving
applicable fraud and abuse or other health care laws and regulations. If our operations are found to be in violation of any of these
laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative
penalties, damages, fines, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or
restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found
to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions
from government funded health care programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Reimbursement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of our product candidates in the United States may depend, in part, on the extent to which the costs of the product candidates may be
covered by third-party payers, such as government health programs, commercial insurance and managed health care organizations. These
third-party payers are increasingly challenging the prices charged for medical products and services. Additionally, the containment of
health care costs has become a priority of federal and state governments, and the prices of drugs have been a focus in this effort. The
United States government, state legislatures and foreign governments have shown significant interest in implementing cost-containment
programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of
price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures,
could further limit our net revenue and results. If these third-party payers do not consider our product candidates to be cost-effective
compared to other available therapies, they may not cover our product candidates after approval as a benefit under their plans or, if
they do, the level of payment may not be sufficient to allow us to sell our product candidates on a profitable basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to secure coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic
studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain
FDA, EMA or other comparable regulatory approvals. Our product candidates may not be considered medically necessary or cost-effective.
A payer&rsquo;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved.
Third-party reimbursement may not be sufficient to enable us to maintain price levels high enough to realize an appropriate return on
our investment in product development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing
and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be marketed only after a
reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness
of a particular product candidate to currently available therapies. The conduct of such studies could be expensive and result in delays
in our commercializing efforts. The EU provides options for its member states to restrict the range of drug products for which their
national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU member states
may approve a specific price for a drug product or may instead adopt a system of direct or indirect controls on the profitability of
the company placing the drug product on the market. Other member states allow companies to fix their own prices for drug products but
monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become
very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries,
cross-border imports from low-priced markets exert competitive pressure that may reduce pricing within a country. There can be no assurance
that any country that has price controls or reimbursement limitations for drug products will allow favorable reimbursement and pricing
arrangements for any of our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party
payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased
and we expect will continue to increase the pressure on drug pricing. Coverage policies, third-party reimbursement rates and drug pricing
regulation may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which
we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Healthcare
Reform</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, there have been and continue to be a number of significant legislative initiatives to contain healthcare costs. The
ACA was enacted in the United States in March 2010 and contains provisions that may reduce the profitability of drug products, including,
for example, increased rebates for drugs subject to the Medicaid Drug Rebate Program, extension of Medicaid rebates to Medicaid managed
care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies&rsquo; share
of sales to federal health care programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other legislative changes have been proposed and adopted since the ACA was enacted. These changes included aggregate reductions
to Medicare payments to providers of 2% per fiscal year, effective April 1, 2013 and, due to subsequent legislative amendments to the
statute, will stay in effect through 2027, unless additional Congressional action is taken; however, pursuant to the CARES Act, and subsequent
legislation, these reductions are suspended from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic. In January 2013, the
American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers,
and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These
new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on
customers for our drugs, if approved, and, accordingly, our financial operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products.
There have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among
other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce
the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. The FDA released a final rule
on September 24, 2020, effective November 30, 2020, providing guidance for states to build and submit importation plans for drugs from
Canada. Further, on November 20, 2020, the U.S. Department of Health and Human Services, or HHS, finalized a regulation removing safe
harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy
benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected
at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers.
At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical
and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access
and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and
bulk purchasing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
a number of these, and other proposed measures may require authorization through additional legislation to become effective, Congress
has indicated that it will continue to seek new legislative measures to control drug costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CMS
issued a final rule, effective on July 9, 2019, that requires direct-to-consumer advertisements of prescription drugs and biological
products, for which payment is available through or under Medicare or Medicaid, to include in the advertisement the Wholesale Acquisition
Cost, or list price, of that drug or biological product if it is equal to or greater than $35 for a monthly supply or usual course of
treatment. Prescription drugs and biological products that are in violation of these requirements will be included on a public list.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
adopted health reform measure could reduce the ultimate demand for our products, if approved, or put pressure on our product pricing.
Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed
to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product
access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries
and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures
to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs.
We expect that additional state and federal healthcare reform measures will be adopted in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that additional state and federal healthcare reform measures, as well as legal changes by foreign governments, will be adopted
in the future, any of which could limit the amounts that governments will pay for healthcare products and services, which could result
in reduced demand for our product candidates or additional pricing pressures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, we have ten employees and full-time consultants, including our executive officers, providing management
and financial services, and general administrative responsibilities. We believe that we maintain a satisfactory working relationship
with our employees, and we have not experienced any significant labor disputes or any difficulty in recruiting staff for our operations.
None of our employees are represented by a labor union.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Human Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing
and new employees, advisors and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and
reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the
success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Legal
Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We
are not a party to any material legal proceedings. From time to time, we may be involved in legal proceedings or subject to claims incident
to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on us because of
defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be
obtained.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Facilities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
executive offices are located in approximately 12,030 square feet of leased office and laboratory space at 21 Business Park Drive, Branford,
Connecticut 06405. The lease expires in 2027, subject to our option to extend the lease for two additional five-year terms. We currently
pay $14,035 per month under the lease, which will increase to $14,385 in 2024, plus our pro rata share of certain
operating expenses of the property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also lease approximately 1,093 square feet of additional laboratory space, which is located at 93 Shennecossett Road, Groton, Connecticut.
The lease expires in April 2023, however, we have the option to extend the lease for two additional one-year terms. We pay $7,235 per
month under the lease plus our pro rata share of certain operating expenses of the property. The lease expires in April 2023 and we
are currently negotiating an extension of the lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also lease approximately 1,868 square feet of office and laboratory space, which is located at 500 Cartier Boulevard, Laval, Quebec,
Canada. We pay $6,583 per month under the lease.</FONT> The lease expired in April 2023 and we are currently negotiating an extension
of the lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our facilities are adequate to meet our current needs and that additional space can be obtained on commercially reasonable
terms as needed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><A NAME="ka_003"></A><B>MANAGEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive
Officers, Directors and Director Nominees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table <FONT STYLE="background-color: white">sets forth the names, ages and positions of (i) our current executive officers
and directors, (ii) our Chief Operating Officer upon the close of this offering  and (iii) our director nominees who will become
directors upon the close of this offering. </FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Age</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Position</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Francisco
    D. Salva</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Executive Officer and Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Norman
    Staskey</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Travis
    Whitfill</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Operating Officer and</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    McClary, MD</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Barbara
    Ryan</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director Nominee<SUP>(1)</SUP></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    Schroer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director Nominee<SUP>(1)</SUP></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><SUP>(1)</SUP> The director nominees are expected to transition on
to our board of directors upon the close of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Information about
our Executive Officers, Directors and Director Nominees</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B><I>Francisco
D. Salva </I></B>has served as our president and chief executive officer and a member of our Board since April 2021. Mr. Salva
has over 15 years of experience in senior leadership roles in the biotechnology and pharmaceutical industries. Mr. Salva served as president
and chief executive officer of Complexa, Inc., an inflammation and fibrosis focused biopharmaceutical company, from May 2018 to August
2020. From February 2011 to November 2016, Mr. Salva served as a co-founder and vice president of operations of Acerta Pharma B.V.,
Inc, a cancer and autoimmune focused biopharmaceutical company. Mr. Salva serves as a director of Vincerx Pharma, Inc. (Nasdaq: VINC).
Prior to his operating roles, Mr. Salva served in various senior positions in the venture capital and investment banking industries focusing
on healthcare, biotechnology and pharmaceuticals companies. Mr. Salva received a B.A. from Brown University and a MSc. In economics and
philosophy from the London School of Economics. We believe that Mr.&nbsp;Salva&rsquo;s experience as a senior executive, venture capitalist
and investment banker in the biotech and pharmaceutical industries qualifies him to serve on our Board.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Norman
Staskey</I></B> has served as our chief financial officer since October 2022. Since May 15, 2021, Mr. Staskey has also served as a senior
director of Danforth Advisors, a national consulting firm providing financial, accounting and reporting services to the life
science industry. From September 2014 to May 2021, Mr. Staskey was employed by EY (formally Ernst &amp; Young), most recently as
a managing director in EY&rsquo;s Financial Accounting and Advisory services practice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Travis
Whitfill</I></B> is a co-founder of Azitra and has served on our Board since inception. Mr. Whitfill has served in various roles
at Azitra, including chief scientific officer from January 2014 to September 2019 and director of advanced technology since September
2019, and will serve as Chief Operating Officer upon the completion of this offering. Mr. Whitfill has served as a partner at
Bios Equity Partners, LP, a biotechnology-focused venture capital firm, since October 2015 and a senior analyst at Bios Research since
September 2014. He has also served as an associate research scientist at Yale University from July 2016 to March 2022, with appointments
in the Departments of Pediatrics and Emergency Medicine. Mr. Whitfill has served on the board of directors of IN8Bio, Inc. (Nasdaq: INAB)
since March 2018, 410 Medical from September 2017 to July 2019 and SIRPant Immunotherapeutics since September 2021. Mr. Whitfill has
led numerous grant-funded projects, holds several patents and has co-authored over 50 publications. Mr. Whitfill received a B.S. from
Dallas Baptist University, an MPH from Yale University and an MPhil from University College London. We believe that Mr. Whitfill&rsquo;s
strong background in entrepreneurship and in the biotech and healthcare industries qualifies him to serve on our Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Andrew
McClary, MD</I></B> has served as a member of our Board since March 2019. Dr. McClary is the founding general partner at KdT Ventures
LP, a biotechnology focused venture firm founded in 2017. At KdT, Dr. McClary invests in companies leveraging the intersection of the
physical sciences and engineering, both computational and biochemical. In addition to leading KdT&rsquo;s investment in Azitra, Dr. McClary
has also led KdT&rsquo;s investments in PathAI, Dyno Therapeutics, Solugen, Terray Therapeutics, STRM Therapeutics, Elegen, and Checkerspot.
Prior to KdT, Dr. McClary served on faculty as a Pathologist at Stanford University and was an early employee at Included Health (formerly
known as Grand Rounds), where he was the physician lead for the Data Science and Analytics team. Dr. McClary received his M.D. from Tulane
University, where he has held prior academic appointments and was a HHMI/NIH Fellow, and his Sc.B. in Biochemistry and Molecular Biology
from Brown University. We believe that Dr. McClary&rsquo;s medical and scientific expertise as a physician-scientist coupled with his
experience working in the venture capital industry qualifies him to serve on our Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Barbara
Ryan</I></B> will become a member of our Board upon the closing of this offering. Ms. Ryan founded Barbara Ryan Advisors, a capital markets
and communications firm, in 2012 following a more than 30-year career on Wall Street as a sell-side research analyst covering the U.S.
pharmaceutical industry. Ms. Ryan has deep experience in equity and debt financings, M&amp;A, valuation, SEC reporting, financial
analysis and corporate strategy across a broad range of life sciences companies. Ms. Ryan worked on several of the industry&rsquo;s
largest M&amp;A transactions, including Shire&rsquo;s defense versus a hostile takeover attempt by Abbvie, Shire&rsquo;s takeover
of Baxalta, Allergan&rsquo;s defense against Valeant and Perrigo&rsquo;s defense versus Mylan Ms. Ryan served as an executive
team member and on the disclosure committee for Radius Health from January 2014 to December 2017. Previously, Ms. Ryan was a managing
director at Deutsche Bank/Alex Brown and head of the company&rsquo;s pharmaceutical research team for 19 years and
began her research career covering the pharmaceutical industry at Bear Stearns in 1982. Ms. Ryan currently serves as a director on the
board of MiNK Therapeutics, Inc. (Nasdaq: INKT), where she chairs the audit committee, INVO Bioscience, Inc, (Nasdaq: INVO),
Invidior, PLC (LON:INDV). and The Red Door Community (formerly Gilda&rsquo;s Club NYC), a non-profit organization. Ms. Ryan
is the founder of Fabulous Pharma Females, a non-profit whose mission is to advance women in the biopharma industry, is a member
of the editorial advisory board of Pharmaceutical Executive Magazine, a faculty member of the GLG Institute and a member of the
Prix Galien executive advisory board. We believe that Ms. Ryan is qualified to serve as a member of our Board because of her experience
and knowledge of corporate finance, mergers and acquisitions, corporate governance, as well as other operational, financial and accounting
matters gained as a past and present executive officer and/or director of other public and private companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>John
Schroer</I></B> will become a member of our Board upon the closing of this offering. Mr. Schroer has served as chief financial officer
of Alumis, Inc., a privately held biotechnology company developing precision immunology therapies, since March 2022. Mr. Schroer was
chief financial officer of Arsenal Biosciences, Inc., a privately held biotechnology company developing programmable cell therapy for
solid tumors, from February 2021 to February 2022. Mr. Schroer was chief financial officer of Translate Bio, Inc., a biotechnology company
developing mRNA therapeutics and vaccines acquired by Sanofi in September 2021 for $3.2 billion, from May 2018 to December 2020. Previously,
Mr. Schroer was Sector Head &ndash; Global Health Care for Allianz Global Investors, an international asset management firm, from
January 2014 to May 2018. Mr. Schroer received his B.S. and M.B.A from the University of Wisconsin &ndash; Madison. We believe that Mr.
Schroer&rsquo;s strong background holding leadership positions in the biotechnology industry and almost 30 years of investing in the
life sciences sector qualifies him to serve on our Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Family
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among any of our executive officers, directors or director nominees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Involvement
in Certain Legal Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the best of our knowledge, none of our executive officers, directors or director nominees were involved in any legal proceedings
described in Item 401(f) of Regulation S-K in the past ten years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Board
Composition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board may establish the authorized number of directors from time to time by resolution. Upon the completion of this offering,
our Board will consist of five members, three of whom will qualify as independent under the listing rules of the NYSE American.
Neither Mr. Salva nor Mr. Whitfill are considered to be independent due to their roles as executive officers of the Company. However, our Board has determined that Dr. McClary, Ms. Ryan and Mr. Schroer do not have a relationship
that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that he or she
is &ldquo;independent&rdquo; as that term is defined under the applicable rules and regulations of the SEC and the listing requirements
and rules of the NYSE American. In making this determination, our Board considered the current and prior relationships that each
of Dr. McClary, Ms. Ryan and Mr. Schroer has with our Company and all other facts and circumstances our Board deemed relevant in determining
their independence, including their beneficial ownership of our capital stock.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Role
of the Board in Risk Oversight</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
of the key functions of our Board is informed oversight of our risk management process. Our Board does not have a standing risk management
committee, but rather intends to administer this oversight function directly through the board of directors as a whole, as well as through
various standing committees of our Board that will address risks inherent in their respective areas of oversight. In particular, our
Board will be responsible for monitoring and assessing strategic risk exposure and our audit committee will have the responsibility to
consider and discuss our major financial risk exposures and the steps our management has taken to monitor and control these exposures,
including guidelines and policies to govern the process by which risk assessment and management is undertaken. The audit committee will
also monitor compliance with legal and regulatory requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Board
Committees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board has established an audit committee, compensation committee and nominating and corporate governance committee, each of which operates
pursuant to a committee charter. Our Board may establish other committees to facilitate the management of our business. The composition
and functions of each committee are described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Audit
Committee</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the close of this offering, our</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> audit committee
will consist of Dr. McClary, Ms. Ryan and Mr. Schroer, with Mr. Schroer serving as Chairperson. Our Board
has determined that each member meets the independence requirements of the Sarbanes-Oxley Act, Rule 10A-3 under the Exchange Act and
the applicable listing standards of the NYSE American. Each member of our audit committee can read and understand fundamental
financial statements in accordance with the SEC and NYSE American audit committee requirements. In arriving at this determination,
the Board has examined each audit committee member&rsquo;s scope of experience and the nature of their prior and/or current employment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board has determined that Mr. Schroer qualifies as an audit committee financial expert within the meaning of SEC regulations and
meets the financial sophistication requirements of the NYSE American listing rules. Both our independent registered public accounting
firm and management periodically meet privately with our audit committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
functions of this committee include, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">select
                                            a qualified firm to serve as the independent registered public accounting firm to audit our
                                            financial statements;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">discuss
    the scope and results of the audit with the independent registered public accounting firm, and review, with management and the independent
    registered public accounting firm, our interim and year-end operating results;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and approving the engagement of our independent auditors to perform audit services and any permissible non-audit services;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop
    procedures for employees to submit concerns anonymously about questionable accounting or audit matters;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    our policies on risk assessment and risk management;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    related-party transactions; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and evaluating on an annual basis the performance of the audit committee and the audit committee charter.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            believe that the composition and functioning of our audit committee complies with all applicable
                                            requirements of the Sarbanes-Oxley Act, and all applicable SEC and NYSE American rules
                                            and regulations. We intend to comply with future requirements to the extent they become applicable
                                            to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation
Committee</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the close of this offering, our</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> compensation committee
will consist of Ms. Ryan and Mr. Schroer, with Ms. Ryan serving as Chairperson. Each of the members is a
non-employee director, as defined in Rule 16b-3 promulgated under the Exchange Act. Our Board has determined that each member is &ldquo;independent&rdquo;
as defined under the applicable listing standards of the NYSE American, including the standards specific to members of a compensation
committee. The functions of this committee include, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing,
    modifying and approving (or if it deems appropriate, making recommendations to the full Board regarding) our overall compensation
    strategy and policies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing,
    modifying and approving (or if it deems appropriate, making recommendations to the full Board regarding) the compensation and other
    terms of employment of our executive officers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and approving (or if it deems it appropriate, making recommendations to the full Board regarding) the equity incentive plans, compensation
    plans and similar programs advisable for us, as well as modifying, amending or terminating existing plans and programs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">administering
    our equity incentive plans;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    policies with respect to equity compensation arrangements; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and evaluating on an annual basis the performance of the compensation committee and the compensation committee charter.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the composition and functioning of our compensation committee complies with all applicable requirements of the Sarbanes-Oxley
Act, and all applicable SEC and the NYSE American rules and regulations. We intend to comply with future requirements to the extent
they become applicable to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nominating
and Corporate Governance Committee</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the close of this offering, our</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> nominating and corporate
governance committee will consist of Dr. McClary and Ms. Ryan, with Dr. McClary serving as Chairperson. The composition
of our nominating and corporate governance committee meets the requirements for independence under the NYSE American listing standards
and SEC rules and regulations. Our nominating and corporate governance committee will, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify,
    evaluate and make recommendations to our board of directors regarding nominees for election to our board of directors and its committees;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluate
    the performance of our board of directors and of individual directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">consider
    and make recommendations to our board of directors regarding the composition of our board of directors and its committees;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    developments in corporate governance practices;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluate
    the adequacy of our corporate governance practices and reporting; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop
    and make recommendations to our board of directors regarding corporate governance guidelines and matters.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of our committees operates under a written charter that satisfies the applicable listing requirements and rules of the NYSE American.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Code
of Business Conduct and Ethics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to adopt a Code of Business Conduct and Ethics, or the Code of Conduct, applicable to all of our employees, executive officers
and directors. Once adopted, the Code of Conduct will be available on our website at www.azitrainc.com. The audit committee of our Board
of directors will be responsible for overseeing the Code of Conduct and must approve any waivers of the Code of Conduct for employees,
executive officers and directors. In addition, we intend to post on our website all disclosures that are required by law or the listing
standards of the applicable stock exchange concerning any amendments to, or waivers from, any provision of the Code of Conduct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Officer
Compensation </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the compensation awarded to or earned by our chief executive officer and our two other highest paid executive
officers for the years ended December 31, 2022 and 2021. In reviewing the table, please note that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Francisco
                                            D. Salva was appointed to serve as our president and chief executive officer in April
                                            2021;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeanne
                                            Bertonis served as our chief operating officer throughout 2021 and 2022 until
                                            April 2022; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Norman
                                            Staskey was appointed to serve as our chief financial officer in October 2022.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Salary
    ($)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Bonus
    ($)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Option
    Awards $ (1)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
    Other Compensation (2)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); width: 31%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Francisco
    D. Salva,</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); width: 6%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">403,846</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">202</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">404,048</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pres.
    and CEO</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: right">281,615</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: right">724,880</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">19,125</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,025,620</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Norman
    Staskey,</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">63,200</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">63,200</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">CFO</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Jeanne
    Bertonis,</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">87,610</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: right">169,523</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">257,133</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255); text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">COO</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">303,714</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">185</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">303,899</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; width: 30%"><DIV STYLE="border-top: Black 1.5pt solid; margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            dollar amounts in the Option Awards columns above reflect the values of options as of the
                                            grant date for the years ended December 31, 2022 and 2021, in accordance with
                                            ASC 718, <I>Compensation-Stock Compensation</I> (&ldquo;ASC 718&rdquo;) and, therefore, do
                                            not necessarily reflect actual benefits received by the individuals. Assumptions used in
                                            the calculation of these amounts are included in Note 11 to our audited financial
                                            statements.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            other compensation includes commuter benefits, vacation payouts, relocation reimbursements,
                                            401K match contributions, and life insurance premiums, plus a separation benefit payment
                                            to Ms. Bertonis and consulting fees paid for Mr. Staskey&rsquo;s services as chief financial
                                            officer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Narrative
Disclosure to Officer Compensation Table</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our current named executive officers are at-will employees and set forth below is a summary of the current terms of their compensatory
arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Francisco
D. Salva</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into an executive employment agreement dated April 22, 2021 with Mr. Salva, pursuant to which Mr. Salva serves as our president
and chief executive officer. We have agreed to pay Mr. Salva an annual base salary of $420,000 under the agreement. Mr. Salva is also
eligible to receive a bonus of up to 35% of his base salary based on performance parameters set by our Board. Mr. Salva&rsquo;s executive
employment agreement entitles him to participate in health insurance and other benefits, at our expense, made available to other executive
officers. In the event of Mr. Salva&rsquo;s termination by us without cause or his resignation for good reason, as such terms are defined
in the executive employment agreement, Mr. Salva will be entitled to the continuation of his base salary and health insurance coverage
for a period of 12 months and a prorated amount of his annual bonus for the year in which the termination occurred, subject to the achievement
of applicable performance targets. Mr. Salva&rsquo;s executive employment agreement is an &ldquo;at will&rdquo; agreement subject to
termination by either party at any time and for any reason, subject to certain notice requirements. The agreement contains customary
provisions relating to intellectual property assignment, confidentiality and indemnification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with our execution of the executive employment agreement, we granted to Mr. Salva an option to purchase up to 465,760
shares of our common stock at an exercise price of $1.56 per share under the 2016 Plan. The options vest and become exercisable
as follows. 80% of the options, or options to purchase 372,608 common shares, are subject to time-based vesting, with options
to purchase 93,152 shares (25%) vesting on the first anniversary of the grant and options to purchase 279,456 shares (75%)
vesting in equal monthly installments over the 36 months following the first anniversary. 20% of the options, or options to purchase
13,120 common shares, shall vest upon patient dosing in the first in-human clinical trial of ATR-12 or a substitute live biotherapeutic
product, as determined by our Board in its reasonable discretion. The options expire on the ten-year anniversary of the date of grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Norman
Staskey</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Staskey serves as our chief financial officer pursuant to a Consulting Agreement dated October 12, 2002 between us and Danforth Advisors,
LLC. Pursuant to the Consulting Agreement, Danforth Advisors provides to us certain strategic and financial advice and support services,
including Mr. Staskey&rsquo;s services as chief financial officer, at hourly rates between $135 and $575 per hour, depending on the level
of service and the seniority of the service provider. The Consulting Agreement is subject to termination by either party on 30 days written
notice and contains customary provisions relating to intellectual property assignment, confidentiality and indemnification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Jeanne
Bertonis</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
Bertonis served as our chief operating officer from September 2019 to April 2022 pursuant to an executive employment agreement dated
September 1, 2019. Ms. Bertonis was paid a base salary of $303,714 in 2022 and in 2021 and was eligible to receive a bonus
of up to 25% of her base salary based on performance parameters set by our Board. Ms. Bertonis&rsquo; executive employment agreement
entitled her to participate in health insurance and other benefits, at our expense, made available to other executive officers. Ms. Bertonis&rsquo;
employment ended in April 2022 and pursuant to the severance provisions of her agreement she received the continuation of her base salary
and health benefits for a period of six months from the date of separation. We paid Ms. Bertonis a total of $156,877 in severance
and $12,579 in vacation payout during 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Non-Employee
Director Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not paid any directors&rsquo; fees or other compensation to our directors for their services as directors. All of our directors
receive reimbursement for out-of-pocket expenses for attending board of directors meetings. We intend to commence the payment of our
non-executive directors, including the payment of cash and equity awards, or a combination of both, but we have not adopted any such
plans or policies as of this date. From time to time, we may also engage certain future outside members of the board of directors
to perform services on our behalf and we will compensate such persons for the services which they perform.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock
Incentive Plans</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted the Azitra, Inc. 2016 Stock Incentive Plan, or 2016 Plan, providing for the grant of non-qualified stock options
and incentive stock options to purchase shares of our common stock and for the grant of restricted and unrestricted share grants and
restricted stock units. We currently have reserved 157,989 shares of our common stock under the 2016 Plan. The purpose of the 2016 Plan
is to provide eligible participants with an opportunity to acquire an ownership interest in our company. All officers, directors, employees
and consultants to our company are eligible to participate under the 2016 Plan. The 2016 Plan provides that options may not be granted
at an exercise price less than the fair market value of our common shares on the date of grant. As of the date of this prospectus, we
have outstanding options granted under the 2016 Plan to purchase an aggregate of 1,290,319 shares of our common stock at an average exercise
price of $1.33 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2023, our Board and stockholders approved and adopted the Azitra, Inc. 2023 Stock Incentive Plan, or 2023 Plan, providing
for the grant of non-qualified stock options and incentive stock options to purchase shares of our common stock and for the grant of
restricted and unrestricted share grants and restricted stock units. We currently have reserved 2,000,000 shares of our common stock
under the 2023 Plan. The purpose of the 2023 Plan is to provide eligible participants with an opportunity to acquire an ownership interest
in our company. All officers, directors, employees and consultants to our company are eligible to participate under the 2023 Plan. The
2023 Plan provides that options may not be granted at an exercise price less than the fair market value of our common shares on the date
of grant. As of the date of this prospectus, we have not granted any awards under the 2023 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Related
Party Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as set forth below, since January 1, 2020, we have not been a party to any transaction in which the amount involved in the transaction
exceeded the lesser of $120,000 or one percent of the average of our total assets as of March 31, 2023 and 2022,
and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our voting securities
or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other
than compensation arrangements, which include equity and other compensation, termination, change in control and other arrangements, which
are described under &ldquo;<I>Executive Compensation</I>.&rdquo; We have adopted a policy that any transactions with directors, officers,
beneficial owners of five percent or more of our common stock, any immediate family members of the foregoing or entities of which any
of the foregoing are also officers or directors or in which they have a financial interest, will only be on terms consistent with industry
standards and approved by a majority of the disinterested directors of our Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2022, we issued unsecured convertible promissory notes in the aggregate principal amount of $4.35 million to five existing
stockholders, including notes in the aggregate principal amount of $4 million to three funds under common control, namely Bios Fund III,
LP, Bios Fund III QP, LP, and Bios Fund III NT, LP. The Bios entities beneficially own a collective 4,883,658 shares, or approximately
43.0%, of our outstanding common stock immediately prior to this offering. In connection the Bios entities investment in
our Company, we granted the Bios entities certain board appointment rights pursuant to which they appointed to our Board a Bios representative
who served on our Board from April 2016 to the date preceding the date of this prospectus. In addition, Travis Whitfill, our co-founder
and a member of our Board, is a partner of Bios Equity Partners, LP, the general partner of the aforementioned Bios entities,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, we entered into a Joint Development Agreement, or JDA, with Bayer pursuant to which we agreed to the joint development
of certain strains selected from our proprietary microbial library. Bayer paid us a one-time low six figure payment upon execution of
the JDA. Pursuant to the JDA, Bayer is responsible for reimbursing us for our development costs, and in 2023 Bayer has paid us
a six figure dollar amount for our development costs. We have granted Bayer an option to acquire an exclusive royalty bearing license
for up to six (6) strains subject to development activities under the JDA, including an exclusive royalty bearing license to any related
patent rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2020, Bayer&rsquo;s venture capital group, LEAPS by Bayer, purchased $8 million of our Series B preferred stock. In connection
with the investment, we granted Bayer certain board appointment rights pursuant to which they appointed to our Board a Bayer representative
who served on our Board from September 2020 to the date preceding the date of this prospectus.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnification
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the closing of this offering, <FONT>we expect to enter into indemnification agreements with each of
our directors and executive officers that may be broader than the specific indemnification provisions contained in the DGCL. These indemnification
agreements will require us, among other things, to indemnify our directors and executive officers against liabilities that may arise
by reason of their status or service. These indemnification agreements will also require us to advance all expenses incurred by the directors
and executive officers in investigating or defending any such action, suit, or proceeding. We believe that these agreements are necessary
to attract and retain qualified individuals to serve as directors and executive officers.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitation
of Liability of Directors and Indemnification of Directors and Officers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Delaware General Corporation Law provides that corporations may include a provision in their certificate of incorporation relieving directors
of monetary liability for breach of their fiduciary duty as directors, provided that such provision shall not eliminate or limit the
liability of a director (i) for any breach of the director&rsquo;s duty of loyalty to the corporation or its stockholders, (ii) for acts
or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) for unlawful payment of a
dividend or unlawful stock purchase or redemption, or (iv) for any transaction from which the director derived an improper personal benefit.
Our amended and restated certificate of incorporation provides that directors are not liable to us or our stockholders for monetary damages
for breach of their fiduciary duty as directors to the fullest extent permitted by Delaware law. In addition to the foregoing, our amended
and restated certificate of incorporation provides that we shall indemnify directors and officers to the fullest extent permitted by
law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above provisions in our amended and restated certificate of incorporation to be adopted upon the completion of this offering may have
the effect of reducing the likelihood of derivative litigation against directors and may discourage or deter stockholders or management
from bringing a lawsuit against directors for breach of their fiduciary duty, even though such an action, if successful, might otherwise
have benefited us and our stockholders. However, we believe that the foregoing provisions are necessary to attract and retain qualified
persons as directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to our directors, officers and controlling
persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC, such indemnification
is against public policy as expressed in the Securities Act and is, therefore, unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="ka_004"></A><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>PRINCIPAL
STOCKHOLDERS</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information regarding the beneficial ownership of our shares of common stock as of the date of this
prospectus by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    person who is known by us to be the beneficial owner of more than five percent (5%) of our issued and outstanding shares of common
    stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our executive officers, directors, and director nominees who will serve as such upon the completion of this offering;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    of the aforementioned directors, executive officers and director nominees as a group.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
beneficial ownership of each person was calculated based on 10,586,510 shares of common stock issued and outstanding prior to
the offering, including 1,043,991 shares issued and outstanding as of the date of this prospectus, and approximately 9,542,519
shares issuable upon the conversion of our convertible preferred stock and convertible promissory notes outstanding as of the date
of this prospectus. The SEC has defined &ldquo;beneficial ownership&rdquo; to mean more than ownership in the
usual sense. For example, a person has beneficial ownership of a share not only if he owns it, but also if he has the power (solely or
shared) to vote, sell or otherwise dispose of the share. Beneficial ownership also includes the number of shares that a person has the
right to acquire within 60 days of the date of this prospectus, pursuant to the exercise of options or warrants or the conversion of
notes, debentures or other indebtedness. Two or more persons might count as beneficial owners of the same share. Unless otherwise indicated,
the address for each reporting person is c/o Azitra, Inc., 21 Business Park Drive, Branford, Connecticut 06405.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">Name of Director, Executive Officer or Director Nominee</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Percentage Owned Prior to Offering<SUP>(1)</SUP></B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Percentage Owned After Offering<SUP>(2)</SUP></B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left"><FONT STYLE="font-size: 10pt">Francisco D. Salva <SUP>(1)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">186,304</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">1.7</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">1.5</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Norman Staskey</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Travis Whitfill <SUP>(2)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">412,652</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.8</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.4</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Andrew McClary <SUP>(3)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">291,049</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.7</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.4</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Barbara Ryan</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">John Schroer</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Directors, executive officers and director nominees, as a group (6 persons)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">890,005</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8.2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7.47</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">Name and Address of Five Percent Stockholders</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Percentage Owned Prior to Offering</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Percentage Owned After Offering</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left"><FONT STYLE="font-size: 10pt">Bios Equity Entities <SUP>(4)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">4,883,657</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">43.0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">40.4</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Bayer Health Care, LLC <SUP>(5)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,307,401</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11.0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.8</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Connecticut Innovations, Inc. <SUP>(6)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">689,054</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6.1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5.7</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Includes 186,304 common shares issuable upon exercise of presently
    exercisable options.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Includes 93,152 shares issuable upon exercise of presently exercisable
    options.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Includes 21,804 shares issuable upon exercise of presently exercisable
    warrants.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Consists of (i) 799,467 shares
    of common stock issuable to Bios Fund I, LP upon conversion of our convertible preferred stock following the close of this offering,
    (ii) 397,600 shares of common stock issuable to Bios Azitra Co-Invest I, LP upon conversion of our convertible preferred stock following
    the close of this offering and 39,760 shares of common stock issuable upon the exercise of warrants, (iii) 284,987 shares of common
    stock issuable to Bios Fund II, LP upon conversion of our convertible preferred stock following the close of this offering and 22,727
    shares of common stock issuable upon the exercise of warrants, (iv) 123,718 shares of common stock issuable to Bios Fund III, LP
    upon conversion of our convertible preferred stock and 77,953 shares of common stock issuable &nbsp;upon the conversion of the convertible
    promissory notes following the close of this offering, (v) 467,613 shares of common stock issuable to Bios Fund I QP, LP upon conversion
    of our convertible preferred stock following the close of this offering, (vi) 931,094 shares of common stock issuable to Bios Fund
    II QP, LP upon conversion of our convertible preferred following the close of this offering and 74,238 shares of common stock issuable
    upon the exercise of warrants, (vii) 808,058 shares of common stock issuable to Bios Fund III QP, LP upon conversion of our convertible
    preferred stock and 509,141 shares of common stock issuable upon the conversion of the convertible promissory notes following the
    close of this offering, (viii) 124,641 shares of common stock issuable to Bios Fund II NT, LP upon conversion of our convertible
    preferred stock following the close of this offering and 9,940 shares of common stock issuable upon the exercise of warrants, (ix)
    130,498 shares of common stock issuable to Bios Fund III NT, LP upon conversion of our convertible preferred stock and 82,223 shares
    of common stock issuable upon the conversion of the convertible promissory notes following the close of this offering. Bios Equity
    Partners, LP is the general partner of the following entities: Bios Fund I, LP and Bios Fund I QP, LP. Bios Equity Partners II, LP
    is the general partner of Bios Fund II, LP, QP, LP, Bios Fund II, LP and Bios Fund II NT, LP. Cavu Management, LP, an entity managed
    and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the
    general partners of Bios Equity I, LP and Bios Equity II, LP. Cavu Advisors LLC, an entity that is managed and controlled by Mr.
    Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher,
    is the general partner of Bios Capital Management, LP. The shares owned by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II
    QP, Bios Fund II NT and Bios Fund III NT (&ldquo;Bios Equity Entities&rdquo;) are aggregated for purposes of reporting share ownership
    information. Mr. Kreis and Mr. Fletcher share voting and investment control with respect to shares held by the Bios Equity Entities.
    Travis Whitfill, a director of the Company, is a partner at Bios Equity Partners, LP. but does not have voting or investment power
    over the shares described in this footnote 4. Gives no effect to any purchases of shares of common stock in this offering by any
    of the Bios Equity Entities. The address for Bios Equity Entities is 1751 River Run, Suite 400, Fort Worth, Texas 76107.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Consists of 1,307,401 shares of common stock issuable
    upon conversion of our convertible preferred stock following the close of this offering. The address for Bayer HealthCare, LLC is
    <FONT STYLE="background-color: white">610 Main Street Cambridge, Massachusetts 02139</FONT>.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Consists of (i) 605,907 shares of common stock issuable
    upon conversion of our convertible preferred stock following the close of this offering, (ii) 41,315 shares of common stock issuable
    upon the exercise of warrants and (iii) 41,832 shares of common stock upon the conversion of the convertible promissory notes
    following the close of this offering. The address for Connecticut Innovations, Inc. is 470 James Street, Suite 8 New Haven,
    CT 06513.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="ka_005"></A>DESCRIPTION
OF SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description summarizes the most important terms of our capital stock, as they are expected to be in effect upon the closing
of this offering. We intend to adopt an amended and restated certificate of incorporation and amended and restated bylaws in connection
with this offering, and this description summarizes the provisions that are expected to be included in such documents. Because it is
only a summary, it does not contain all the information that may be important to you. For a complete description of the matters set forth
in this &ldquo;Description of Securities,&rdquo; you should refer to our amended and restated certificate of incorporation and amended
and restated bylaws and investor rights agreement, which are or will be included as exhibits to the registration statement of which this
prospectus forms a part, and to the applicable provisions of Delaware law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately
following the closing of this offering, our authorized capital stock will consist of 100,000,000 shares of common stock, $0.0001
par value per share, and 10,000,000 shares of undesignated preferred stock, $0,0001 par value per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
giving effect to</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> forward stock split effected on
May 17, 2023 at a ratio of 7.1-for-1, and assuming the automatic conversion of all shares of our convertible preferred
stock and convertible promissory notes outstanding as of the date of this prospectus, which conversion will occur immediately upon the
closing of this offering, there are 10,586,510 shares of our common stock outstanding and no shares of our preferred stock outstanding
as of the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, we had 11 stockholders of record.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of common stock are entitled to one vote for each share of common stock. The holders of common stock are entitled to any dividends
that may be declared by the Board out of funds legally available for payment of dividends at such times and in such amounts as the Board
in its discretion. In the event of any liquidation, dissolution or winding up of the Company, holders of common stock are entitled to
receive the assets of the Company available for distribution to its stockholders ratably in proportion to the number of shares of common
stock held by the holders of common stock. The holders of shares of common stock have no preemptive, conversion, subscription rights
or cumulative voting rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, there are a total of 1,437,150 shares of convertible preferred stock authorized for issuance, including
205,385 shares of Series A convertible preferred stock, 380,657 shares of Series A-1 convertible preferred stock and 414,638 shares Series
B convertible preferred stock issued and outstanding. Immediately upon the completion of this offering, all outstanding shares of our
convertible preferred stock will convert into a total of 7,693,436 shares of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the completion of this offering plan to adopt an amended and restated certificate of incorporation pursuant to which we will authorized
to issue 10,000,000 shares of preferred stock. Our Board will be authorized, without further action by our stockholders, to provide
from time to time out of the unissued shares of preferred stock for one or more series of preferred stock, and with respect to each such
series, to fix the number of shares constituting such series and the designation of such series, the powers (including voting powers),
if any, of the shares of such series and the preferences and relative, participating, optional, special or other rights, if any, and
the qualifications, limitations, or restrictions, if any, of the shares of such series. The issuance of our preferred stock could adversely
affect the voting power of holders of our common stock and the likelihood that such holders will receive dividend payments and payments
upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring, or preventing a change of
control or other corporate action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the completion of this offering, we will have outstanding the following warrants to purchase shares of our common stock:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Warrants issued in connection
    with our April 2018 placement of unsecured convertible promissory notes to purchase up to an aggregate of 47,890 shares
    of our common stock, at a per share exercise price equal to $0.48. The warrants expire in April 2028.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Warrants issued in connection
    with our February 2019 placement of Series A-1 convertible preferred shares to purchase up to an aggregate of 215,854 shares
    of our common stock, at a per share exercise price equal to $5.28. The warrants expire in February 2029.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Warrants to be issued to
    ThinkEquity and its designees at the close of this offering to purchase shares of our common stock equal to 4% of the shares
    of common stock sold in this offering. This warrant is exercisable at $6.25 per share (125% of the price of the common
    stock sold in this offering), expiring five years from the date of this prospectus.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock
Incentive Plans</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted the Azitra, Inc. 2016 Stock Incentive Plan, or 2016 Plan, providing for the grant of non-qualified stock options
and incentive stock options to purchase shares of our common stock and for the grant of restricted and unrestricted share grants and
restricted stock units. We currently have reserved 157,989 shares of our common stock under the 2016 Plan. The purpose of the 2016 Plan
is to provide eligible participants with an opportunity to acquire an ownership interest in our company. All officers, directors, employees
and consultants to our company are eligible to participate under the 2016 Plan. The 2016 Plan provides that options may not be granted
at an exercise price less than the fair market value of our common shares on the date of grant. As of the date of this prospectus, we
have outstanding options granted under the 2016 Plan to purchase an aggregate of 1,290,319 shares of our common stock at an average exercise
price of $1.33 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2023, our Board and stockholders approved and adopted the Azitra, Inc. 2023 Stock Incentive Plan, or 2023 Plan, providing
for the grant of non-qualified stock options and incentive stock options to purchase shares of our common stock and for the grant of
restricted and unrestricted share grants and restricted stock units. We currently have reserved 2,000,000 shares of our common stock
under the 2023 Plan. The purpose of the 2023 Plan is to provide eligible participants with an opportunity to acquire an ownership interest
in our company. All officers, directors, employees and consultants to our company are eligible to participate under the 2023 Plan. The
2023 Plan provides that options may not be granted at an exercise price less than the fair market value of our common shares on the date
of grant. As of the date of this prospectus, we have not granted any awards under the 2023 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dividends</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not anticipate the payment of cash dividends on our common stock in the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
completion of this offering, certain holders of our common stock, or their permitted transferees, will be entitled to the registration
rights described below. The registration of shares of our common stock pursuant to the exercise of registration rights described below
would enable the holders to sell these shares without restriction under the Securities Act when the applicable registration statement
is declared effective. We will pay the registration expenses, other than the underwriting discounts and commissions, of the shares registered
pursuant to the registrations described below. The registration rights described below will expire upon the earlier of three years following
the completion of this offering, or when all investors, considered with their affiliates, can sell all of their shares in a three-month
period under Rule 144.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Convertible
Preferred Stock Registration Rights</I>. In connection with our convertible preferred stock financings, we entered into an investor rights
agreement, as amended, pursuant to which we have granted the purchasers of our convertible preferred stock certain demand and piggyback
respiration rights. Following the completion of this offering, those parties will beneficially hold approximately 9,542,519 shares
of our common stock, including 7,693,437 shares of our common stock issued upon conversion of our outstanding our convertible preferred
stock and unsecured convertible notes and 1,838,775 shares of our common stock issuable upon exercise of warrants issued to the
parties in connection with our 2018 placement of our unsecured convertible promissory notes and our 2019 placement of Series A-1 convertible
preferred shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the investor rights agreement, we will be required, upon the written request at any time more than 180 days after the completion of
this offering by the holders of at least 50% of the shares that are entitled to registration rights under the investor rights agreement,
to register, as soon as practicable, all or a portion of these shares for public resale. We are required to effect two demand registrations
pursuant to a registration statement on Form S-1, provided such requests for registration be for an aggregate offering price, net of
the underwriting discounts and commissions, equal or greater than $20.0 million. Subject to our eligibility to use a registration statement
on Form S-3, we are required to effect an unlimited number of demand registrations pursuant to Form S-3, provided such requests for registration
be for an aggregate offering price, net of the underwriting discounts and commissions, equal or greater than $1 million. Pursuant to
the investor rights agreement, we have also granted to the piggyback registration rights and demand registration rights. These demand
and piggyback registration rights terminate as to each investor when their shares subject to the registration rights agreement may be
sold by the investor pursuant to Rule 144 under the Securities Act without regard to both the volume limitations for sales as provided
in Rule 144.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Underwriter
Registration Rights.</I> In connection with this offering, we have agreed to issue to the representative of the underwriters or its designees
warrants, referred to as the Representative&rsquo;s Warrants, to purchase up to a total of 60,000 (or 69,000 if the over-allotment
option is exercised in full) shares of our common stock (4% of the aggregate number of shares of common stock sold in this offering).
The Representative&rsquo;s Warrants will provide for registration rights (including a one-time demand registration right and unlimited
piggyback rights) consistent with FINRA Rule 5110.05. The demand for registration may be made at any time beginning on the initial exercise
date of the Representative&rsquo;s Warrants and expiring on the fifth anniversary of the effective date of this registration statement
in accordance with FINRA Rule 5110(g)(8)(C). In addition to the one-time demand registration right, the Representative&rsquo;s Warrants
shall have unlimited piggyback rights, for a period of no more than two years from the initial exercise date of the Representative&rsquo;s
Warrants in accordance with FINRA Rule 5110(g)(8)(D).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover
Effects of Certain Provisions of Delaware Law and Our Charter Documents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of certain provisions of Delaware law and our amended and restated certificate of incorporation and amended and
restated bylaws to be adopted upon the completion of this offering. This summary does not purport to be complete and is qualified in
its entirety by reference to the corporate law of Delaware and our amended and restated certificate of incorporation and amended and
restated bylaws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware
Law</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to Section 203 of the Delaware General Corporation Law, an anti-takeover law<I>. </I>In general, Section 203 prohibits a
Delaware corporation from engaging in any business combination (as defined below) with any interested stockholder (as defined below)
for a period of three years following the date that the stockholder became an interested stockholder, unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prior
                                            to that date, the board of directors of the corporation approved either the business combination
                                            or the transaction that resulted in the stockholder becoming an interested stockholder;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
                                            consummation of the transaction that resulted in the stockholder becoming an interested stockholder,
                                            the interested stockholder owned at least 85% of the voting stock of the corporation outstanding
                                            at the time the transaction commenced, excluding for purposes of determining the number of
                                            shares of voting stock outstanding (but not the voting stock owned by the interested stockholder)
                                            those shares owned by persons who are directors and officers and by excluding employee stock
                                            plans in which employee participants do not have the right to determine whether shares held
                                            subject to the plan will be tendered in a tender or exchange offer; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
                                            or subsequent to that date, the business combination is approved by the board of directors
                                            of the corporation and authorized at an annual or special meeting of stockholders, and not
                                            by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting
                                            stock that is not owned by the interested stockholder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
203 defines &ldquo;business combination&rdquo; to include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            merger or consolidation involving the corporation and the interested stockholder;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation
                                            involving the interested stockholder;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
                                            to certain exceptions, any transaction that results in the issuance or transfer by the corporation
                                            of any stock of the corporation to the interested stockholder;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
                                            to limited exceptions, any transaction involving the corporation that has the effect of increasing
                                            the proportionate share of the stock of any class or series of the corporation beneficially
                                            owned by the interested stockholder; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            receipt by the interested stockholder of the benefit of any loans, advances, guarantees,
                                            pledges or other financial benefits provided by or through the corporation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting
stock of the corporation, or who beneficially owns 15% or more of the outstanding voting stock of the corporation at any time within
a three-year period immediately prior to the date of determining whether such person is an interested stockholder, and any entity or
person affiliated with or controlling or controlled by any of these entities or persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Charter Documents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
charter documents include provisions that could have the effect of discouraging others from making tender offers for our shares and may
have the effect of deterring hostile takeovers or delaying changes in our control or management. These provisions are intended to enhance
the likelihood of continued stability in the composition of our Board and its policies and to discourage certain types of transactions
that may involve an actual or threatened acquisition of us. These provisions are also designed to reduce our vulnerability to an unsolicited
acquisition proposal and to discourage certain tactics that may be used in proxy fights. However, such provisions may have the effect
of discouraging, delaying or preventing a change in control or an unsolicited acquisition proposal that a stockholder might consider
favorable, including a proposal that might result in the payment of a premium over the market price for the shares held by our stockholders.
Certain of these provisions are summarized in the following paragraphs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Effects
of authorized but unissued common stock and preferred stock. </I>One of the effects of the existence of authorized but unissued common
stock and preferred stock may be to enable our Board to make more difficult or to discourage an attempt to obtain control of our Company
by means of a merger, tender offer, proxy contest or otherwise, and thereby to protect the continuity of management<I>. </I>If, in the
due exercise of its fiduciary obligations, the Board were to determine that a takeover proposal was not in our best interest, such shares
could be issued by the Board without stockholder approval in one or more transactions that might prevent or render more difficult or
costly the completion of the takeover transaction by diluting the voting or other rights of the proposed acquirer or insurgent stockholder
group, by putting a substantial voting block in institutional or other hands that might undertake to support the position of the incumbent
Board, by effecting an acquisition that might complicate or preclude the takeover, or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cumulative
Voting. </I>Our amended and restated certificate of incorporation does not provide for cumulative voting in the election of directors,
which would allow holders of less than a majority of the stock to elect some directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Vacancies.
</I>Our amended and restated bylaws provide that all vacancies may be filled by the affirmative vote of a majority of directors then
in office, even if less than a quorum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Special
Meeting of Stockholders and Stockholder Action by Written Consent. </I>A special meeting of stockholders may only be called by our Board
or the chairperson of our Board. All stockholder actions must be effected at a duly called meeting of stockholders and not by written
consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advance
Notice Provisions. Our amended and restated bylaws provide advance notice procedures for stockholders seeking to bring business before
our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. Our amended
and restated bylaws will also specify certain requirements regarding the form and content of a stockholder&rsquo;s notice. These provisions
might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors
at our annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions may also discourage
or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&rsquo;s own slate of directors or otherwise
attempting to obtain control of our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Choice
of Forum. Our amended and restated certificate of incorporation and amended and restated bylaws will provide that the Court of Chancery
of the State of Delaware will be the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting
a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended
and restated certificate of incorporation or our bylaws; or any action asserting a claim against us that is governed by the internal
affairs doctrine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent and Registrar</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of this offering, the transfer agent and registrar for our shares of common stock will be VStock Transfer, LLC. The
transfer agent and registrar&rsquo;s address is 18 Lafayette Place, Woodmere, New York 11598.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>National
Securities Exchange Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have applied to have our shares of common stock listed on the NYSE American under the symbol &ldquo;AZTR.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="ah_001"></A>SHARES
ELIGIBLE FOR FUTURE SALE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering, there has been no public market for shares of our common stock<I>. </I>Future sales of substantial amounts of shares
of common stock, including shares issued upon the exercise of outstanding warrants and options, in the public market after this offering,
or the possibility of these sales occurring, could adversely affect the prevailing market price for our common stock or impair our ability
to raise equity capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the completion of this offering, a total of 12,086,510 shares of common stock will be outstanding, assuming the automatic conversion
of all outstanding convertible preferred stock and convertible promissory notes into shares of common stock in connection with the completion
of this offering. All 1,500,000 shares of common stock sold in this offering by us, plus any shares sold upon
exercise of the underwriter&rsquo;s over-allotment option, will be freely tradable in the public market without restriction or further
registration under the Securities Act, unless these shares are held by &ldquo;affiliates,&rdquo; as that term is defined in Rule 144
under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
remaining 10,586,510 shares of common stock will be &ldquo;restricted securities,&rdquo; as that term is defined in Rule 144 under
the Securities Act<I>. </I>These restricted securities are eligible for public sale only if they are registered under the Securities
Act or if they qualify for an exemption from registration under Rules 144 or 701 under the Securities Act, which are summarized below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the lock-up agreements described below and the provisions of Rules 144 and 701 under the Securities Act, these restricted securities
will be available for sale in the public market beginning more than 90 days after the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
144</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, under Rule 144 as currently in effect, once we have been subject to public company reporting requirements for at least 90 days,
a person who is not deemed to have been one of our affiliates for purposes of the Securities Act at any time during the 90 days preceding
a sale and who has beneficially owned the shares proposed to be sold for at least six months, including the holding period of any prior
owner other than our affiliates, is entitled to sell such shares without complying with the manner of sale, volume limitation, or notice
provisions of Rule 144, subject to compliance with the public information requirements of Rule 144<I>. </I>If such a person has beneficially
owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than our affiliates,
then such person is entitled to sell such shares without complying with any of the requirements of Rule&nbsp;144.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, under Rule 144, as currently in effect, our affiliates or persons selling shares on behalf of our affiliates are entitled to
sell upon expiration of the lock-up agreements described below, within any three-month period beginning 90 days after the date of this
prospectus, a number of shares that does not exceed the greater of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1%
                                            of the number of shares of common stock then outstanding; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            average weekly trading volume of the common stock during the four calendar weeks preceding
                                            the filing of a notice on Form 144 with respect to such sale.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
under Rule 144 by our affiliates or persons selling shares on behalf of our affiliates are also subject to certain manner of sale provisions
and notice requirements and to the availability of current public information about us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
701</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule
701 generally allows a stockholder who purchased shares of our common stock pursuant to a written compensatory plan or contract and who
is not deemed to have been one of our affiliates during the immediately preceding 90 days to sell these shares in reliance upon Rule
144, but without being required to comply with the public information, holding period, volume limitation, or notice provisions of Rule
144<I>. </I>Rule 701 also permits our affiliates to sell their Rule 701 shares under Rule 144 without complying with the holding period
requirements of Rule 144<I>. </I>However, all holders of Rule 701 shares are required to wait until 90 days after the date of this prospectus
before selling such shares pursuant to Rule 701.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-Up
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of our directors and officers have agreed, subject to certain exceptions, not to offer, pledge, sell, contract to sell, grant, lend,
or otherwise transfer or dispose of, directly or indirectly, or enter into any swap or other arrangement that transfers to another, in
whole or in part, any of the economic consequences of ownership of any shares of our capital stock or any securities convertible into
or exercisable or exchangeable for shares of our common stock, for a period of twelve (12) months after the date of this prospectus,
without the prior written consent of the representative. We, subject to certain exceptions, and all of our other stockholders of 0.5%
or more of the outstanding shares of common stock (or securities convertible into shares of common stock, including options and warrants),
have agreed, subject to certain exceptions, not offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose
of, directly or indirectly, or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares
of our common stock, for a period of six (6) months after the date of this prospectus, without the prior written consent of the representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity
Plans</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to file a registration statement on Form S-8 under the Securities Act to register all of the shares of common stock to be issued
or reserved for issuance under our 2016 Plan and 2023 Plans. Shares covered by this registration statement will be eligible
for sale in the public market, upon the expiration or release from the terms of the lock-up agreements and subject to vesting of such
shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="ah_002"></A>MATERIAL
U.S. FEDERAL INCOME TAX CONSEQUENCES FOR NON-U.S. HOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion is a summary of the material U.S. federal income tax consequences to Non-U.S. Holders (as defined below) of the
purchase, ownership, and disposition of our common stock issued pursuant to this offering but does not purport to be a complete analysis
of all potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state,
local, or non-U.S. tax laws are not discussed. This discussion is based on the U.S. Internal Revenue Code of 1986, as amended, or the
Code, Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the
U.S. Internal Revenue Service, or the IRS, in each case in effect as of the date hereof. These authorities may change or be subject to
differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely
affect a Non-U.S. Holder. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There
can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax consequences of the
purchase, ownership, and disposition of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
discussion is limited to Non-U.S. Holders that hold our common stock as a &ldquo;capital asset&rdquo; within the meaning of Section 1221
of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences relevant
to a Non-U.S. Holder&rsquo;s particular circumstances, including the impact of the Medicare contribution tax on net investment income
and the alternative minimum tax. In addition, it does not address consequences relevant to Non-U.S. Holders subject to special rules,
including, without limitation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
                                            expatriates and former citizens or long-term residents of the United States;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
                                            holding our common stock as part of a hedge, straddle, or other risk reduction strategy or
                                            as part of a conversion transaction or other integrated investment;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">banks,
                                            insurance companies, and other financial institutions;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">brokers,
                                            dealers, or traders in securities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;controlled
                                            foreign corporations,&rdquo; &ldquo;passive foreign investment companies,&rdquo; and corporations
                                            that accumulate earnings to avoid U.S. federal income tax;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">partnerships
                                            or other entities or arrangements treated as partnerships for U.S. federal income tax purposes
                                            (and investors therein);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax-exempt
                                            organizations or governmental organizations;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
                                            deemed to sell our common stock under the constructive sale provisions of the Code;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
                                            who hold or receive our common stock pursuant to the exercise of any employee stock option
                                            or otherwise as compensation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax-qualified
                                            retirement plans; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;qualified
                                            foreign pension funds&rdquo; as defined in Section 897(l)(2) of the Code and entities all
                                            of the interests of which are held by qualified foreign pension funds.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an entity treated as a partnership for U.S. federal income tax purposes holds our common stock, the tax treatment of a partner in the
partnership will depend on the status of the partner, the activities of the partnership, and certain determinations made at the partner
level. Accordingly, partnerships holding our common stock and the partners in such partnerships should consult their tax advisors regarding
the U.S. federal income tax consequences to them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS
DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE
APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP,
AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL, OR
NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Definition
of a Non-U.S. Holder</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this discussion, a &ldquo;Non-U.S. Holder&rdquo; is any beneficial owner of our common stock that is neither a &ldquo;U.S.
person&rdquo; nor an entity treated as a partnership for U.S. federal income tax purposes. A U.S. person is any person that, for U.S.
federal income tax purposes, is or is treated as any of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            individual who is a citizen or resident of the United States;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            corporation created or organized under the laws of the United States, any state thereof,
                                            or the District of Columbia;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            estate, the income of which is subject to U.S. federal income tax regardless of its source;
                                            or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            trust that (1) is subject to the primary supervision of a U.S. court and the control of one
                                            or more &ldquo;United States persons&rdquo; (within the meaning of Section 7701(a)(30) of
                                            the Code), or (2) has a valid election in effect to be treated as a United States person
                                            for U.S. federal income tax purposes.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Distributions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in the section entitled &ldquo;Dividend Policy,&rdquo; we do not anticipate declaring or paying dividends to holders of our
common stock in the foreseeable future. However, if we do make distributions of cash or property on our common stock, such distributions
will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits,
as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute
a return of capital and first be applied against and reduce a Non-U.S. Holder&rsquo;s adjusted tax basis in its common stock, but not
below zero. Any excess will be treated as capital gain and will be treated as described below under &ldquo;&mdash;Sale or Other Taxable
Disposition.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the discussion below on effectively connected income, dividends paid to a Non-U.S. Holder will be subject to U.S. federal withholding
tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty, provided
the Non-U.S. Holder furnishes a valid IRS Form W-8BEN or W-8BEN-E (or other applicable documentation) certifying qualification for the
lower treaty rate). A Non-U.S. Holder that does not timely furnish the required documentation, but that qualifies for a reduced treaty
rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. Non-U.S. Holders
should consult their tax advisors regarding their entitlement to benefits under any applicable income tax treaty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
dividends paid to a Non-U.S. Holder are effectively connected with the Non-U.S. Holder&rsquo;s conduct of a trade or business within
the United States (and, if required by an applicable income tax treaty, the Non-U.S. Holder maintains a permanent establishment in the
United States to which such dividends are attributable), the Non-U.S. Holder will be exempt from the U.S. federal withholding tax described
above. To claim the exemption, the Non-U.S. Holder must furnish to the applicable withholding agent a valid IRS Form W-8ECI, certifying
that the dividends are effectively connected with the Non-U.S. Holder&rsquo;s conduct of a trade or business within the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular rates. A Non-U.S.
Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable
income tax treaty) on such effectively connected dividends, as adjusted for certain items. Non-U.S. Holders should consult their tax
advisors regarding any applicable tax treaties that may provide for different rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sale
or Other Taxable Disposition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Non-U.S. Holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other taxable disposition of our
common stock unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            gain is effectively connected with the Non-U.S. Holder&rsquo;s conduct of a trade or business
                                            within the United States (and, if required by an applicable income tax treaty, the Non-U.S.
                                            Holder maintains a permanent establishment in the United States to which such gain is attributable);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Non-U.S. Holder is a nonresident alien individual present in the United States for 183 days
                                            or more during the taxable year of the disposition and certain other requirements are met;
                                            or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            common stock constitutes a U.S. real property interest, or USRPI, by reason of our status
                                            as a U.S. real property holding corporation, or USRPHC, for U.S. federal income tax purposes.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain
described in the first bullet point above generally will be subject to U.S. federal income tax on a net income basis at the regular rates.
A Non-U.S. Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by
an applicable income tax treaty) on such effectively connected gain, as adjusted for certain items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Non-U.S. Holder described in the second bullet point above will be subject to U.S. federal income tax at a rate of 30% (or such lower
rate specified by an applicable income tax treaty) on gain realized upon the sale or other taxable disposition of our common stock, which
may be offset by U.S. source capital losses of the Non-U.S. Holder (even though the individual is not considered a resident of the United
States), provided the Non-U.S. Holder has timely filed U.S. federal income tax returns with respect to such losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to the third bullet point above, we believe we currently are not, and do not anticipate becoming, a USRPHC. Because the determination
of whether we are a USRPHC depends, however, on the fair market value of our USRPIs relative to the fair market value of our USRPIs and
our other business assets, there can be no assurance we currently are not a USRPHC or will not become one in the future. Even if we are
or were to become a USRPHC, gain arising from the sale or other taxable disposition of our common stock by a Non-U.S. Holder will not
be subject to U.S. federal income tax if our common stock is &ldquo;regularly traded,&rdquo; as defined by applicable Treasury Regulations,
on an established securities market and such Non-U.S. Holder owned, actually and constructively, 5% or less of our common stock throughout
the shorter of the five-year period ending on the date of the sale or other taxable disposition or the Non-U.S. Holder&rsquo;s holding
period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-U.S.
Holders should consult their tax advisors regarding potentially applicable income tax treaties that may provide for different rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Information
Reporting and Backup Withholding</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
of dividends on our common stock will not be subject to backup withholding, provided the applicable withholding agent does not have actual
knowledge or reason to know the holder is a United States person and the holder either certifies its non-U.S. status, such as by furnishing
a valid IRS Form W-8BEN, W-8BEN-E, or W-8ECI, or otherwise establishes an exemption. However, information returns are required to be
filed with the IRS in connection with any distributions on our common stock paid to the Non-U.S. Holder, regardless of whether such distributions
constitute dividends or whether any tax was actually withheld. In addition, proceeds of the sale or other taxable disposition of our
common stock within the United States or conducted through certain U.S.-related brokers generally will not be subject to backup withholding
or information reporting if the applicable withholding agent receives the certification described above and does not have actual knowledge
or reason to know that such holder is a United States person or the holder otherwise establishes an exemption. Proceeds of a disposition
of our common stock conducted through a non-U.S. office of a non-U.S. broker generally will not be subject to backup withholding or information
reporting.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Copies
of information returns that are filed with the IRS may also be made available under the provisions of an applicable treaty or agreement
to the tax authorities of the country in which the Non-U.S. Holder resides or is established.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Backup
withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit
against a Non-U.S. Holder&rsquo;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional
Withholding Tax on Payments Made to Foreign Accounts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Withholding
taxes may be imposed under Sections 1471 to 1474 of the Code (such Sections commonly referred to as the Foreign Account Tax Compliance
Act, or FATCA) on certain types of payments made to non-U.S. financial institutions and certain other non-U.S. entities. Specifically,
a 30% withholding tax may be imposed on dividends on, or (subject to the proposed Treasury Regulations discussed below) gross proceeds
from the sale or other disposition of, our common stock paid to a &ldquo;foreign financial institution&rdquo; or a &ldquo;non-financial
foreign entity&rdquo; (each as defined in the Code), unless (1) the foreign financial institution undertakes certain diligence and reporting
obligations, (2) the non-financial foreign entity either certifies it does not have any &ldquo;substantial United States owners&rdquo;
(as defined in the Code) or furnishes identifying information regarding each substantial United States owner, or (3) the foreign financial
institution or non-financial foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial
institution and is subject to the diligence and reporting requirements in (1) above, it must enter into an agreement with the U.S. Department
of the Treasury requiring, among other things, that it undertake to identify accounts held by certain &ldquo;specified United States
persons&rdquo; or &ldquo;United States owned foreign entities&rdquo; (each as defined in the Code), annually report certain information
about such accounts, and withhold 30% on certain payments to non-compliant foreign financial institutions and certain other account holders.
Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA
may be subject to different rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of dividends on
our common stock. While withholding under FATCA would have applied also to payments of gross proceeds from the sale or other disposition
of stock on or after January 1, 2019, proposed Treasury Regulations eliminate FATCA withholding on payments of gross proceeds entirely.
Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospective
investors should consult their tax advisors regarding the potential application of withholding under FATCA to their investment in our
common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="ah_003"></A>UNDERWRITING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ThinkEquity
LLC is acting as representative of the underwriters of this offering. We have entered into an underwriting agreement dated June 15,
2023 with the representative. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to each underwriter
named below, and each underwriter named below has severally agreed to purchase, at the public offering price less the underwriting discounts
set forth on the cover page of this prospectus, the number of shares of common stock listed next to its name in the following table:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; border-collapse: collapse; width: 80%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Underwriter</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares</B></FONT></P> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left; width: 76%">ThinkEquity LLC</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; width: 20%">1,500,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">1,500,000</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters are committed to purchase all shares offered by us other than those covered by the over-allotment option described below,
if any are purchased. The obligations of the underwriters may be terminated upon the occurrence of certain events specified in the underwriting
agreement. Furthermore, pursuant to the underwriting agreement, the underwriters&rsquo; obligations are subject to customary conditions,
representations and warranties contained in the underwriting agreement, such as receipt by the underwriters of officers&rsquo; certificates
and legal opinions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters are offering the shares subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal
matters by their counsel, and other conditions. The underwriters reserve the right to withdraw, cancel or modify offers to the public
and to reject orders in whole or in part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters propose to offer the shares offered by us to the public at the public offering price set forth on the cover of the prospectus.
After the shares are released for sale to the public, the underwriters may change the offering price and other selling terms at various
times.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over-Allotment
Option</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted the underwriters an over-allotment option. This option, which is exercisable for up to 45 days after the date of this
prospectus, permits the representative to purchase a maximum of 225,000 additional shares of common stock (15% of the shares sold in
this offering) from us to cover over-allotments, if any. If the representative exercises all or part of this option, it will
purchase shares covered by the option at the initial public offering price per share that appears on the cover page of this
prospectus, less the underwriting discount. If this option is exercised in full, the total offering price to the public will be $8.6
million and the total net proceeds, before expenses, to us will be $8.0 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discount</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">The
underwriters propose initially to offer the shares of common stock to the public at the initial public offering price set forth on the
cover page of this prospectus and to dealers at that price less a concession not in excess of $0.30 per share of common stock. If all
of the shares of common stock offered by us are not sold at the initial public offering price, the underwriters may change the offering
price and other selling terms by means of a supplement to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the initial public offering price, underwriting discounts and proceeds, before expenses, to us. The information
assumes either no exercise or full exercise by the underwriters of their over-allotment option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.5in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per Share</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total Without</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over- Allotment</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total With</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over- Allotment</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: left">Initial public offering price</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><P STYLE="text-align: center; margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0">5.00</P><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 1%">$</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 18%">7,500,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 1%">$</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 18%">8,625,000</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Underwriting discount (7.5%)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="text-align: center; margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0">0.375</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">$</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="text-align: center; margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0">562,500</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">$</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="text-align: center; margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0">646,875</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Proceeds, before expense, to us</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="text-align: center; margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0">4.625</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">$</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="text-align: center; margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0">6,937,500</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">$</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="text-align: center; margin-top: 0; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0">7,978,125</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to pay a non-accountable expense allowance to the underwriters equal to 1.0% of the gross proceeds received in this offering
(excluding proceeds received from exercise of the underwriters&rsquo; over-allotment option).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have paid an expense deposit of $35,000 to the representative for out-of-pocket-accountable expenses, which will be returned to us to
the extent such out-of-pocket accountable expenses are not actually incurred in accordance with FINRA Rule 5110(f)(2)(C).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we have agreed to reimburse the representative for (i) fees and expenses of legal counsel to the underwriters in an amount
not to exceed $125,000; (ii) fees and expenses related to the use of Ipreo&rsquo;s book building, prospectus tracking and compliance
software for the offering in the amount of $29,500; (iii) up to $15,000 for background checks of our officers and directors; (iv) all
fees, expenses and disbursements relating to the registration, qualification or exemption of such shares under the securities laws of
such foreign jurisdictions as the representative may reasonably designate; (iv) all fees, expenses and disbursements relating to the
registration, qualification or exemption of such shares under the &ldquo;blue sky&rdquo; securities laws of such states, if applicable,
and other jurisdictions as the representative may reasonably designate; (v) $10,000 for data services and communications expenses; (vi)
$3,000 for the costs associated with bound volumes of the public offering materials as well as commemorative mementos and lucite tombstones;
(vii) up to $10,000 for actual accountable &ldquo;road show&rdquo; expenses; and (viii) up to $30,000 for market making and trading,
and clearing firm settlement expenses for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate that the total expenses of the offering payable by us, excluding the total underwriting discount and non-accountable expense
allowance, will be approximately $1,035,000, of which approximately $610,000 have been paid to date and approximately $425,00 remain to be paid as of the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Representative&rsquo;s
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to issue to the representative or its designees warrants to purchase up to a total of 60,000 (or 69,000 if
the over-allotment option is exercised in full) shares of our common stock (4% of the aggregate number of shares of common stock sold
in this offering), or the Representative&rsquo;s Warrants. The Representative&rsquo;s Warrants will be exercisable at a per share exercise
price equal to 125% of the public offering price per share of the shares of common stock sold in this offering. The Representative&rsquo;s
Warrants are exercisable at any time, from time to time, in whole or in part, during the four and one half year period commencing 180
days from the commencement of sales of the securities in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Representative&rsquo;s Warrants and the shares of common stock underlying the Representative&rsquo;s Warrants have been deemed compensation
by FINRA and are, therefore, subject to a 180-day lock-up pursuant to FINRA Rule 5110(g)(1). The representative or permitted assignees
under such rule may not sell, transfer, assign, pledge, or hypothecate the representative&rsquo;s Warrants or the securities underlying
the Representative&rsquo;s Warrants, nor will the representative engage in any hedging, short sale, derivative, put, or call transaction
that would result in the effective economic disposition of the Representative&rsquo;s Warrants or the underlying shares of common stock
for a period of 180&nbsp;days from the effective date of the registration statement. Additionally, the Representative&rsquo;s Warrants
may not be sold, transferred, assigned, pledged, or hypothecated for a 180-day period following the effective date of the registration
statement, except to any underwriter and selected dealer participating in the offering and their bona fide officers or partners. The
Representative&rsquo;s Warrants will provide for adjustment in the number and price of the Representative&rsquo;s Warrants and the shares
of common stock underlying the Representative&rsquo;s Warrants in the event of recapitalization, merger, stock split, or other structural
transaction, or a future financing undertaken by us. The Representative&rsquo;s Warrants will provide for registration rights (including
a one-time demand registration right and unlimited piggyback rights) consistent with FINRA Rule 5110.05. The demand for registration
may be made at any time beginning on the initial exercise date of the Representative&rsquo;s Warrants and expiring on the fifth anniversary
of the effective date of this registration statement in accordance with FINRA Rule 5110(g)(8)(C). In addition to the one-time demand
registration right, the Representative&rsquo;s Warrants shall have unlimited piggyback rights, for a period of no more than two years
from the initial exercise date of the Representative&rsquo;s Warrants in accordance with FINRA Rule 5110(g)(8)(D). The Representative&rsquo;s
Warrants will also provide for customary anti-dilution provisions (for stock dividends and splits and recapitalizations) consistent with
FINRA Rule 5110, and further, the number of shares underlying the Representative&rsquo;s Warrants shall be reduced if necessary to comply
with FINRA rules and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discretionary
Accounts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters do not intend to confirm sales of the securities offered hereby to any accounts over which they have discretionary authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-Up
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of our directors and officers have agreed, subject to certain exceptions, not to offer, pledge, sell, contract to sell, grant,
lend, or otherwise transfer or dispose of, directly or indirectly, or enter into any swap or other arrangement that transfers to another,
in whole or in part, any of the economic consequences of ownership of any shares of our capital stock or any securities convertible into
or exercisable or exchangeable for shares of our common stock, for a period of twelve (12) months after the date of this prospectus,
without the prior written consent of the representative. We, subject to certain exceptions, and all of our other stockholders of 0.5%
or more of the outstanding shares of common stock (or securities convertible into shares of common stock, including options and warrants),
have agreed, subject to certain exceptions, not offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose
of, directly or indirectly, or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares
of our common stock, for a period of six (6) months after the date of this prospectus, without the prior written consent of the
representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
agreed to file a customary universal shelf registration statement on Form S-3 within 30 days of the earlier of (i) the expiration of
the restricted period described above and (ii) the date of its initial eligibility to do so. Additionally, we agreed that for a period
of twelve (12) months after this offering we will not directly or indirectly in any &ldquo;at-the-market&rdquo;, continuous equity, equity
lines, or variable rate transaction, offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of shares of
our capital stock or any securities convertible into or exercisable or exchangeable for our shares of capital stock, without the prior
written consent of ThinkEquity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the expiration of the applicable lock-up period, all of the issued and outstanding shares of our common stock will be eligible for future
sale, subject to the applicable volume, manner of sale, holding period, and other limitations of Rule 144.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Right
of First Refusal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwriting Agreement will provide that for a period of fifteen (15) months from the closing of the offering, we will grant the representative
an irrevocable right of first refusal to act as sole investment banker, sole book-runner, sole financial advisor, sole underwriter and/or
sole placement agent, at the representative&rsquo;s sole discretion, for each and every future public and private equity and debt offering,
including all equity linked financings, during such fifteen (15) month period for us, or any successor to or any subsidiary of us, on
terms customary to the representative. The representative has the sole right to determine whether or not any other broker dealer shall
have the right to participate in any such offering and the economic terms of any such participation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent permitted by law, we have agreed to indemnify the underwriters and its affiliates, stockholders, directors, officers, employees,
members and controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to payments
that the underwriters may be required to make for these liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Electronic
Offer, Sale and Distribution of Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
prospectus in electronic format may be made available on the websites maintained by one or more underwriters or selling group members,
if any, participating in this offering and one or more of the underwriters participating in this offering may distribute prospectuses
electronically. The representative may agree to allocate a number of shares to underwriters and selling group members for sale to their
online brokerage account holders. Internet distributions will be allocated by the underwriters and selling group members that will make
internet distributions on the same basis as other allocations. Other than the prospectus in electronic format, the information on the
underwriters&rsquo; websites is not part of, nor incorporated by reference into, this prospectus or the registration statement of which
this prospectus forms a part, has not been approved or endorsed by us or any underwriter in its capacity as underwriter, and should not
be relied upon by investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stabilization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate-covering
transactions, penalty bids and purchases to cover positions created by short sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stabilizing
transactions permit bids to purchase securities so long as the stabilizing bids do not exceed a specified maximum and are engaged in
for the purpose of preventing or retarding a decline in the market price of the securities while the offering is in progress.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over-allotment
transactions involve sales by the underwriters of securities in excess of the number of securities that underwriters are obligated to
purchase. This creates a syndicate short position which may be either a covered short position or a naked short position. In a covered
short position, the number of securities over-allotted by the underwriters is not greater than the number of securities that they may
purchase in the over-allotment option. In a naked short position, the number of securities involved is greater than the number of securities
in the over-allotment option. The underwriters may close out any short position by exercising their over-allotment option and/or purchasing
securities in the open market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Syndicate
covering transactions involve purchases of securities in the open market after the distribution has been completed in order to cover
syndicate short positions. In determining the source of securities to close out the short position, the underwriters will consider, among
other things, the price of securities available for purchase in the open market as compared with the price at which they may purchase
securities through exercise of the over-allotment option. If the underwriters sell more securities than could be covered by exercise
of the over-allotment option and, therefore, have a naked short position, the position can be closed out only by buying securities in
the open market. A naked short position is more likely to be created if the underwriters are concerned that after pricing there could
be downward pressure on the price of the securities in the open market that could adversely affect investors who purchase in the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Penalty
bids permit the representative to reclaim a selling concession from a syndicate member when the securities originally sold by that syndicate
member are purchased in stabilizing or syndicate covering transactions to cover syndicate short positions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price
of our securities or preventing or retarding a decline in the market price of our securities. As a result, the price of our securities
in the open market may be higher than it would otherwise be in the absence of these transactions. Neither we nor the underwriters make
any representation or prediction as to the effect that the transactions described above may have on the price of our securities. These
transactions may be effected on the NYSE American, in the over-the-counter market or otherwise and, if commenced, may be discontinued
at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Passive
Market Making</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, underwriters and selling group members may engage in passive market making transactions in our common
stock on the NYSE American or on the OTCQB in accordance with Rule 103 of Regulation M under the Exchange Act, during a period
before the commencement of offers or sales of the securities and extending through the completion of the distribution. A passive market
maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids
are lowered below the passive market maker&rsquo;s bid, then that bid must then be lowered when specified purchase limits are exceeded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of the underwriters and their affiliates may provide in the future, various advisory, investment and commercial banking and other services
to us in the ordinary course of business, for which they may receive customary fees and commissions. However, we have not yet had, and
have no present arrangements with any of the underwriters for any further services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Offer
Restrictions Outside the United States</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered
by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be
offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with
the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result
in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are
advised to inform themselves about and to observe any restrictions relating to this offering and the distribution of this prospectus.
This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in
any jurisdiction in which such an offer or a solicitation is unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Australia</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus is not a disclosure document under Chapter 6D of the Australian Corporations Act, has not been lodged with the Australian
Securities and Investments Commission and does not purport to include the information required of a disclosure document under Chapter
6D of the Australian Corporations Act. Accordingly, (i) the offer of the securities under this prospectus is only made to persons to
whom it is lawful to offer the securities without disclosure under Chapter 6D of the Australian Corporations Act under one or more exemptions
set out in section 708 of the Australian Corporations Act, (ii) this prospectus is made available in Australia only to those persons
as set forth in clause (i) above, and (iii) the offeree must be sent a notice stating in substance that by accepting this offer, the
offeree represents that the offeree is such a person as set forth in clause (i) above, and, unless permitted under the Australian Corporations
Act, agrees not to sell or offer for sale within Australia any of the securities sold to the offeree within 12 months after its transfer
to the offeree under this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>China</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this document does not constitute a public offer of the securities, whether by way of sale or subscription, in the People&rsquo;s
Republic of China (excluding, for purposes of this paragraph, Hong Kong Special Administrative Region, Macau Special Administrative Region
and Taiwan). The securities may not be offered or sold directly or indirectly in the PRC to legal or natural persons other than directly
to &ldquo;qualified domestic institutional investors.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>European
Economic Area&mdash;Belgium, Germany, Luxembourg and Netherlands</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this document has been prepared on the basis that all offers of securities will be made pursuant to an exemption under
the Directive 2003/71/EC (&ldquo;Prospectus Directive&rdquo;), as implemented in Member States of the European Economic Area (each, a
&ldquo;Relevant Member State&rdquo;), from the requirement to produce a prospectus for offers of securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
offer to the public of securities has not been made, and may not be made, in a Relevant Member State except pursuant to one of the following
exemptions under the Prospectus Directive as implemented in that Relevant Member State:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            legal entities that are authorized or regulated to operate in the financial markets or, if
                                            not so authorized or regulated, whose corporate purpose is solely to invest in securities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            any legal entity that has two or more of (i) an average of at least 250 employees during
                                            its last fiscal year; (ii) a total balance sheet of more than &euro;43,000,000 (as shown
                                            on its last annual unconsolidated or consolidated financial statements) and (iii) an annual
                                            net turnover of more than &euro;50,000,000 (as shown on its last annual unconsolidated or
                                            consolidated financial statements);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            fewer than 100 natural or legal persons (other than qualified investors within the meaning
                                            of Article 2(1)(e) of the Prospectus Directive) subject to obtaining the prior consent of
                                            the Company or any underwriter for any such offer; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            any other circumstances falling within Article 3(2) of the Prospectus Directive, provided
                                            that no such offer of securities shall result in a requirement for the publication by the
                                            Company of a prospectus pursuant to Article 3 of the Prospectus Directive.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>France</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document is not being distributed in the context of a public offering of financial securities (offre au public de titres financiers)
in France within the meaning of Article L.411-1 of the French Monetary and Financial Code (Code mon&eacute;taire et financier) and Articles
211-1 et seq. of the General Regulation of the French Autorit&eacute; des march&eacute;s financiers (&ldquo;AMF&rdquo;). The securities
have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in France.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document and any other offering material relating to the securities have not been, and will not be, submitted to the AMF for approval
in France and, accordingly, may not be distributed or caused to distributed, directly or indirectly, to the public in France.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
offers, sales and distributions have been and shall only be made in France to (i) qualified investors (investisseurs qualifi&eacute;s)
acting for their own account, as defined in and in accordance with Articles L.411-2-II-2 and D.411-1 to D.411-3, D. 744-1, D.754-1 and
D.764-1 of the French Monetary and Financial Code and any implementing regulation and/or (ii) a restricted number of non-qualified investors
(cercle restreint d&rsquo;investisseurs) acting for their own account, as defined in and in accordance with Articles L.411-2-II-2 and
D.411-4, D.744-1, D.754-1 and D.764-1 of the French Monetary and Financial Code and any implementing regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Article 211-3 of the General Regulation of the AMF, investors in France are informed that the securities cannot be distributed (directly
or indirectly) to the public by the investors otherwise than in accordance with Articles L.411-1, L.411-2, L.412-1 and L.621-8 to L.621-8-3
of the French Monetary and Financial Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ireland</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this document does not constitute a prospectus under any Irish laws or regulations and this document has not been filed
with or approved by any Irish regulatory authority as the information has not been prepared in the context of a public offering of securities
in Ireland within the meaning of the Irish Prospectus (Directive 2003/71/EC) Regulations 2005 (the &ldquo;Prospectus Regulations&rdquo;).
The securities have not been offered or sold, and will not be offered, sold or delivered directly or indirectly in Ireland by way of
a public offering, except to (i) qualified investors as defined in Regulation 2(l) of the Prospectus Regulations and (ii) fewer than
100 natural or legal persons who are not qualified investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Israel</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities offered by this prospectus have not been approved or disapproved by the Israeli Securities Authority (the ISA), or ISA, nor
have such securities been registered for sale in Israel. The shares may not be offered or sold, directly or indirectly, to the public
in Israel, absent the publication of a prospectus. The ISA has not issued permits, approvals or licenses in connection with this offering
or publishing the prospectus; nor has it authenticated the details included herein, confirmed their reliability or completeness, or rendered
an opinion as to the quality of the securities being offered. Any resale in Israel, directly or indirectly, to the public of the securities
offered by this prospectus is subject to restrictions on transferability and must be effected only in compliance with the Israeli securities
laws and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Italy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offering of the securities in the Republic of Italy has not been authorized by the Italian Securities and Exchange Commission (Commissione
Nazionale per le Societa e la Borsa, or CONSOB), pursuant to the Italian securities legislation and, accordingly, no offering material
relating to the securities may be distributed in Italy and such securities may not be offered or sold in Italy in a public offer within
the meaning of Article 1.1(t) of Legislative Decree No. 58 of 24 February 1998 (&ldquo;Decree No. 58&rdquo;), other than:</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            Italian qualified investors (&ldquo;Qualified Investors&rdquo;), as defined in Article 100
                                            of Decree no. 58 by reference to Article 34-ter of CONSOB Regulation no. 11971 of 14 May
                                            1999, as amended (&ldquo;Regulation no. 1197l&rdquo;); and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            other circumstances that are exempt from the rules on public offer pursuant to Article 100
                                            of Decree No. 58 and Regulation no. 1197l.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
offer, sale or delivery of the securities or distribution of any offer document relating to the securities in Italy (excluding placements
where a Qualified Investor solicits an offer from the issuer) under the paragraphs above must be:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">made
                                            by investment firms, banks or financial intermediaries permitted to conduct such activities
                                            in Italy in accordance with Legislative Decree No. 385 of 1 September 1993, as amended, Decree
                                            No. 58, CONSOB Regulation No. 16190 of 29 October 2007, and any other applicable laws; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            compliance with all relevant Italian securities, tax and exchange controls and any other
                                            applicable laws.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
subsequent distribution of the securities in Italy must be made in compliance with the public offer and prospectus requirement rules
provided under Decree No. 58 and the Regulation No. 11971 as amended, unless an exception from those rules applies. Failure to comply
with such rules may result in the sale of such securities being declared null and void and in the liability of the entity transferring
the securities for any damages suffered by the investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Japan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities have not been and will not be registered under Article 4, paragraph 1 of the Financial Instruments and Exchange Law of Japan
(Law No. 25 of 1948), as amended (the &ldquo;FIEL&rdquo;) pursuant to an exemption from the registration requirements applicable to a
private placement of securities to Qualified Institutional Investors (as defined in and in accordance with Article 2, paragraph 3 of
the FIEL and the regulations promulgated thereunder). Accordingly, the securities may not be offered or sold, directly or indirectly,
in Japan or to, or for the benefit of, any resident of Japan other than Qualified Institutional Investors. Any Qualified Institutional
Investor who acquires securities may not resell them to any person in Japan that is not a Qualified Institutional Investor, and acquisition
by any such person of securities is conditional upon the execution of an agreement to that effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Portugal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document is not being distributed in the context of a public offer of financial securities (oferta p&uacute;blica de valores mobili&aacute;rios)
in Portugal, within the meaning of Article 109 of the Portuguese Securities Code (C&oacute;digo dos Valores Mobili&aacute;rios). The
securities have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in Portugal. This document
and any other offering material relating to the securities have not been, and will not be, submitted to the Portuguese Securities Market
Commission (Comiss&#259;o do Mercado de Valores Mobili&aacute;rios) for approval in Portugal and, accordingly, may not be distributed
or caused to distributed, directly or indirectly, to the public in Portugal, other than under circumstances that are deemed not to qualify
as a public offer under the Portuguese Securities Code. Such offers, sales and distributions of securities in Portugal are limited to
persons who are &ldquo;qualified investors&rdquo; (as defined in the Portuguese Securities Code). Only such investors may receive this
document and they may not distribute it or the information contained in it to any other person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sweden</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document has not been, and will not be, registered with or approved by Finansinspektionen (the Swedish Financial Supervisory Authority).
Accordingly, this document may not be made available, nor may the securities be offered for sale in Sweden, other than under circumstances
that are deemed not to require a prospectus under the Swedish Financial Instruments Trading Act (1991:980) (Sw. lag (1991:980) om handel
med finansiella instrument). Any offering of securities in Sweden is limited to persons who are &ldquo;qualified investors&rdquo; (as
defined in the Financial Instruments Trading Act). Only such investors may receive this document and they may not distribute it or the
information contained in it to any other person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Switzerland</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (&ldquo;SIX&rdquo;) or on any
other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards
for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses
under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland.
Neither this document nor any other offering material relating to the securities may be publicly distributed or otherwise made publicly
available in Switzerland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
this document nor any other offering material relating to the securities have been or will be filed with or approved by any Swiss regulatory
authority. In particular, this document will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial
Market Supervisory Authority (FINMA).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document is personal to the recipient only and not for general circulation in Switzerland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>United
Arab Emirates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
this document nor the securities have been approved, disapproved or passed on in any way by the Central Bank of the United Arab Emirates
or any other governmental authority in the United Arab Emirates, nor has the Company received authorization or licensing from the Central
Bank of the United Arab Emirates or any other governmental authority in the United Arab Emirates to market or sell the securities within
the United Arab Emirates. This document does not constitute and may not be used for the purpose of an offer or invitation. No services
relating to the securities, including the receipt of applications and/or the allotment or redemption of such shares, may be rendered
within the United Arab Emirates by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
offer or invitation to subscribe for securities is valid or permitted in the Dubai International Financial Centre.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>United
Kingdom</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
the information in this document nor any other document relating to the offer has been delivered for approval to the Financial Services
Authority in the United Kingdom and no prospectus (within the meaning of section 85 of the Financial Services and Markets Act 2000, as
amended (&ldquo;FSMA&rdquo;)) has been published or is intended to be published in respect of the securities. This document is issued
on a confidential basis to &ldquo;qualified investors&rdquo; (within the meaning of section 86(7) of FSMA) in the United Kingdom, and
the securities may not be offered or sold in the United Kingdom by means of this document, any accompanying letter or any other document,
except in circumstances which do not require the publication of a prospectus pursuant to section 86(1) FSMA. This document should not
be distributed, published or reproduced, in whole or in part, nor may its contents be disclosed by recipients to any other person in
the United Kingdom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
invitation or inducement to engage in investment activity (within the meaning of section 21 of FSMA) received in connection with the
issue or sale of the securities has only been communicated or caused to be communicated and will only be communicated or caused to be
communicated in the United Kingdom in circumstances in which section 21(1) of FSMA does not apply to the Company. In the United Kingdom,
this document is being distributed only to, and is directed at, persons (i) who have professional experience in matters relating to investments
falling within Article 19(5) (investment professionals) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005
(&ldquo;FPO&rdquo;), (ii) who fall within the categories of persons referred to in Article 49(2)(a) to (d) (high net worth companies,
unincorporated associations, etc.) of the FPO or (iii) to whom it may otherwise be lawfully communicated (together &ldquo;relevant persons&rdquo;).
The investments to which this document relates are available only to, and any invitation, offer or agreement to purchase will be engaged
in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Canada</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors,
as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted
clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale
of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements
of applicable securities laws. Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies
for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies
for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&rsquo;s
province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&rsquo;s
province or territory for particulars of these rights or consult with a legal advisor. Pursuant to section 3A.3 of National Instrument
33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI33-105 regarding
underwriter conflicts of interest in connection with this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="ah_004"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Greenberg
Traurig, LLP, Irvine, California, will pass upon the validity of the shares of common stock offered hereby<I>. </I>Venable LLP, New York,
New York has acted as counsel for the underwriters in connection with certain legal matters related to this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="ah_005"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements as of and for the fiscal years ended December 31, 2022 and 2021 included in this prospectus have been so
included in reliance on the report of Grassi &amp; Co., CPAs, P.C., an independent registered public accounting firm, given on the authority
of said firm as experts in auditing and accounting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="ah_006"></A>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of common stock offered
by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all the information set
forth in the registration statement, some of which is contained in exhibits to the registration statement as permitted by the rules and
regulations of the SEC. For further information with respect to us and our shares of common stock, we refer you to the registration statement,
including the exhibits filed as a part of the registration statement. Statements contained in this prospectus concerning the contents
of any contract or any other document is not necessarily complete. If a contract or document has been filed as an exhibit to the registration
statement, please see the copy of the contract or document that has been filed. Each statement is this prospectus relating to a contract
or document filed as an exhibit is qualified in all respects by the filed exhibit. You may read and copy the registration statement,
the related exhibits and other material we file with the SEC at the SEC&rsquo;s public reference room in Washington, D.C. at 100 F Street,
Room 1580, N.E., Washington, D.C. 20549. You can also request copies of those documents, upon payment of a duplicating fee, by writing
to the SEC. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference rooms. The SEC also
maintains an Internet website that contains reports, proxy statements and other information about issuers, like us, that file electronically
with the SEC. The address of that website is <U>www.sec.gov</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
completion of this offering, we will become subject to the information and reporting requirements of the Securities Exchange Act of 1934,
as amended, and, in accordance with this law, will be required to file periodic reports, proxy statements and other information with
the SEC. These periodic reports, proxy statements and other information will be available on the website of the SEC referred to above.
We also maintain a website at <U>www.azitrainc.com</U>. Our website and the information contained on, or that can be accessed through,
our website is not deemed to be incorporated by reference in, and is not considered part of, this prospectus. You should not rely on
any such information in making your decision whether to purchase our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not authorized anyone to give you any information or to make any representations about us or the transactions we discuss in this
prospectus other than those contained in this prospectus. If you are given any information or representations about these matters that
is not discussed in this prospectus, you must not rely on that information. This prospectus is not an offer to sell or a solicitation
of an offer to buy securities anywhere or to anyone where or to whom we are not permitted to offer or sell securities under applicable
law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>AZITRA,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="ah_015"></A>INDEX
TO FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ah_007">Report
    of Independent Registered Public Accounting Firm, Grassi &amp; Co., CPAs, P.C., Jericho, New York, PCAOB ID 606 for the years ended
    December 31, 2022 and 2021</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#VK_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    Sheets as of December 31, 2022 and December 31, 2021</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#VK_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
    of Operations for the years ended December 31, 2022 and 2021</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#VK_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
    of Changes in Stockholders&rsquo; Equity (Deficit) for the years ended December 31, 2022 and 2021</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#VK_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
    of Cash Flows for the years ended December 31, 2022 and 2021</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#VK_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Financial Statements</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6
    - F-32</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#noah_001">Balance
    Sheets as of March 31, 2023 (Unaudited) and December 31, 2022</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-33</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#noah_002">Statements
    of Operations for the three months ended March 31, 2023, And 2022 (Unaudited)</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-34</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#noah_003">Statements
    of Stockholders&rsquo; Equity for the three months ended March 31, 2023, And 2022 (Unaudited)</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">F-35</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#noah_004">Statements
    of Cash Flows for the three months ended March 31, 2023, And 2022 (Unaudited)</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">F-36</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#noah_005">Notes
    to Unaudited Financial Statement</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">F-37 - F-51</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="ah_007"></A>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and Stockholders of<BR>
Azitra, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Branford,
CT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Opinion
on the Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying balance sheets of Azitra, Inc. (the &ldquo;Company&rdquo;) as of December 31, 2022 and 2021, and
the related statements of operations, stockholders&rsquo; equity, and cash flows for the years then ended, and the related notes (collectively
referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial
position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended,
in conformity with accounting principles generally accepted in the United States of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Substantial
Doubt Regarding the Company&rsquo;s Ability to Continue as a Going Concern</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements have been prepared
assuming that Azitra, Inc., will continue as a going concern. As discussed in Note 1 to the financial statements, the Company&rsquo;s
significant operating losses raise substantial doubt about its ability to continue as a going concern. Management&rsquo;s evaluation
of the events and conditions, and management&rsquo;s plans regarding those matters, are also described in Note 1. The financial statements
do not include any adjustments that might result from the outcome of this uncertainty.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
for Opinion</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We conducted our audits in accordance with the standards
of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require
that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement,
whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control
over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting,
but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over financial reporting.
Accordingly, we express no such opinion.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><I>/s/
Grassi &amp; CO., CPAs, P.C.</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&rsquo;s auditor since 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jericho,
New York</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
20, 2023, except for Notes 9, 10, 11, 14, and 19, as to which the date is June 13, 2023.</FONT></P>

<!-- Field: Page; Sequence: 119; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="VK_001"></A>Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
Sheets</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">December 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current assets:</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 68%">Cash and cash equivalents</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">3,492,656</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">8,044,262</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Accounts receivable</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">182,820</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">160,867</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Tax credits receivable</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">69,666</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">173,311</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Income tax receivable</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">13,722</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Deferred offering costs</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>216,886</B></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">-</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Prepaid expenses</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">160,133</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">110,289</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total current assets</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">4,135,883</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8,488,729</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Property and equipment, net</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">846,958</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">946,681</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Other assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Other assets</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">47,507</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48,201</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Operating lease right-of-use asset</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,116,697</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Intangible assets, net</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">219,567</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">97,693</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Deferred patent costs</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">800,831</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">620,029</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Total other assets</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">2,184,602</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">765,923</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">7,167,443</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">10,201,333</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Liabilities, convertible preferred stock, and stockholders&rsquo; deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current liabilities:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Accounts payable</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">784,687</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">717,800</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Current operating lease liability</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">287,384</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Income tax payable</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,302</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Accrued expenses</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">993,961</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">475,485</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Contract liabilities</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">156,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">15,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total current liabilities</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">2,222,032</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,209,587</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Long-term operating lease liability</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">840,896</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">70,283</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">71,104</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Convertible notes payable, net</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">6,600,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">992,019</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total liabilities</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">9,733,211</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,272,710</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Convertible preferred stock:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Series A convertible preferred stock; $0.0001 par value; 205,385 shares authorized at December 31, 2022 and 2021; 205,385 shares issued and outstanding at December 31, 2022 and 2021; liquidation value of $3,337,506 as of December 31, 2022 and 2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">3,272,944</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,272,944</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Series A-1 convertible preferred stock; $0.0001 par value; 380,657 shares authorized at December 31, 2022 and 2021; 380,657 shares issued and outstanding at December 31, 2022 and 2021; liquidation value of $14,274,638 as of December 31, 2022 and 2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">14,100,533</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,100,533</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Series B convertible preferred stock; $0.0001 par value; 851,108 and 392,000 shares authorized at December 31, 2022 and 2021, respectively; 391,303 shares issued and outstanding at December 31, 2022 and 2021; liquidation value of $17,000,159 as of December 31, 2022 and 2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">16,321,065</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16,321,065</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Stockholders&rsquo; deficit:</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Common stock; $0.0001 par value;
    100,000,000 authorized at December 31, 2022 and 2021, respectively; 1,043,991 and 1,043,103 shares issued and
    outstanding at December 31, 2022 and 2021, respectively</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">104</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">104</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Additional paid-in capital</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,054,138</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">868,163</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(37,314,552</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(26,634,186</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Total stockholders&rsquo; deficit</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(36,260,310</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(25,765,919</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total liabilities, convertible preferred stock, and stockholders&rsquo; deficit</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">7,167,443</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">10,201,333</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>See
accompanying notes</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="VK_002"></A>Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
of Operations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Years ended December 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left; padding-bottom: 1.5pt">Service revenue - related party</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 12%; border-bottom: Black 1.5pt solid; text-align: right">284,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; border-bottom: Black 1.5pt solid; text-align: right">110,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total revenue</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">284,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">110,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating expenses:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">General and administrative</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">3,639,666</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,951,352</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Research and development</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">6,097,938</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">5,380,102</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Total operating expenses</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">9,737,604</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">9,331,454</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss from operations</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(9,453,604</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(9,221,454</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Other income (expense):</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Interest income</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">4,818</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8,759</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Interest expense</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(251,891</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(66,968</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Other income</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">65,849</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">112,141</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Employee retention credit</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">229,813</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Forgiveness of Payroll Protection Program loan</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">232,506</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Change in fair value of convertible note</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(1,250,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other expense</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(25,351</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(4,659</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Total other income (expense)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(1,226,762</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">281,779</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss before income taxes</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(10,680,366</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(8,939,675</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Income tax benefit (expense)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(10,680,366</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(8,939,675</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Dividends on preferred stock</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(2,768,984</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(2,768,984</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss attributable to common shareholders</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(13,449,350</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">(11,708,659</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss per share, basic and diluted</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(12.74</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(11.20</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Weighted average common stock outstanding, basic and diluted</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,055,457</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,045,766</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>See
accompanying notes </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="VK_003"></A>Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
of Convertible Preferred Stock and Stockholders&rsquo; Deficit</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the Years ended December 31, 2022 and 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Series
    A Convertible</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Series
    A-1 Convertible</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Series
    B Convertible</FONT></TD><TD STYLE="border-right: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Additional</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Preferred
    Stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Preferred
    Stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Preferred
    Stock</FONT></TD><TD STYLE="border-right: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Common
    Stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Paid-In</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Accumulated</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stockholders&rsquo;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount</FONT></TD><TD STYLE="border-right: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Capital</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Deficit</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Deficit</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-right: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance,
    December 31, 2020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">205,385</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,272,944</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">380,657</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">14,100,533</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">391,303</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">16,321,065</FONT></TD><TD STYLE="border-right: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,025,353</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">103</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">553,534</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(17,694,511</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(17,140,774</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock-based
    compensation</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="border-right: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">306,055</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">306,055</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Exercise
    of stock options</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="border-right: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">17,750</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">8,574</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">8,475</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net
    loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="border-right: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(8,939,675</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(8,939,675</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance,
    December 31, 2021</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">205,385</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,272,944</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">380,657</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">14,100,533</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">391,303</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">16,321,065</FONT></TD><TD STYLE="border-right: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,043,103</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">104</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">868,163</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(26,634,186</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(25,765,919</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock-based
    compensation</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="border-right: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">184,465</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">184,465</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Exercise
    of stock options</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="border-right: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">888</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,510</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,510</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net
    loss</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="border-right: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(10,680,366</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(10,680,366</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance,
    December 31, 2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">205,385</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,272,944</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">380,657</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">14,100,533</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">391,303</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">16,321,065</FONT></TD><TD STYLE="border-right: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,043,991</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">104</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,054,138</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(37,314,552</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(36,260,310</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>See
accompanying notes </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="VK_004"></A>Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
of Cash Flows</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Years Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">December 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash flows from operating activities:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 68%; text-align: left">Net loss</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">(10,680,366</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">(8,939,675</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to net cash and cash equivalents used by
    operating activities:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Depreciation and amortization</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">125,885</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">84,772</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Amortization of debt discount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">7,981</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,632</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Amortization of right-of-use assets</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">280,092</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Accrued interest on convertible notes</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">164,611</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">59,181</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Stock-based compensation</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">184,465</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">306,055</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Change in fair value of warrant liability</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(821</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(989</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Change in fair value of convertible notes</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,250,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Forgiveness of Payroll Protection Program loan</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(230,685</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Loss on disposal of property and equipment</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">7,923</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Changes in operating assets and liabilities:</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Accounts receivable</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(21,953</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(37,573</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Prepaid expenses</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(49,844</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">163,952</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Other assets</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">694</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(919</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Tax credits receivable</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">103,645</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">231,745</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Income tax receivable</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(15,024</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Accounts payable and accrued expenses</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">420,752</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">282,976</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Operating lease liability</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(268,509</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Income tax payable</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(8,831</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Contract liabilities</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">141,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">15,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net cash and cash equivalents used by operating activities</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(8,349,469</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(8,067,359</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash flows from investing activities:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Purchases of property and equipment</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(33,101</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(446,136</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Proceeds from sale of property and equipment</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">4,250</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Capitalization of deferred patent costs</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(180,802</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(196,267</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt">Capitalization of license</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(65,510</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Capitalization of patent and trademark costs</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(61,598</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(9,872</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Net cash and cash equivalents used by investing activities</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(336,761</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(652,275</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash flows from financing activities:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Proceeds from convertible notes, net of issuance costs</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">4,350,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">984,387</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Payment of deferred offering costs</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>(216,886</B></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><B>)</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Proceeds from exercise of stock options</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">1,510</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">8,475</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0pt; text-align: left">Net cash and cash equivalents provided by financing
    activities</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">4,134,624</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">992,862</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net decrease in cash and cash equivalents</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(4,551,606</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(7,726,772</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents at the beginning of the year</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">8,044,262</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">15,771,034</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents at the end of the year</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">3,492,656</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">8,044,262</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>See
accompanying notes</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="VK_006"></A>Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2022 and 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.
Organization and Nature of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> was founded on January 2, 2014. It is a synthetic
biology company focused on screening and genetically engineering microbes of the skin. The mission is to discover and develop novel therapeutics
to create a new paradigm for treating skin disease. The Company&rsquo;s discovery platform is screened for naturally occurring bacterial
cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic
proteins, peptides and small molecules for precision treatment of dermatology diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company maintains a location in Montreal, Canada for certain research activities. This location and operations completed there remained
consistent throughout 2021 and 2022. The Company also opened a manufacturing and laboratory space in Groton, Connecticut during 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Going
Concern Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements have been prepared on the going concern basis, which assumes that the Company will continue in operation for the
foreseeable future and which contemplates the realization of assets and liquidation of liabilities in the normal course of business.
However, management has identified the following conditions and events that created an uncertainty about the ability of the Company to
continue as a going concern. As of and for the year ended December 31, 2022, the Company has an accumulated deficit of $37.3 million,
a loss from operations of $9.5 million and used $8.6 million to fund operations. These factors among others raise substantial doubt about
the Company&rsquo;s ability to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
plans to continue to raise funds through equity and debt financing to fund operating and working capital needs, however, the Company
will require a significant amount of additional funds to complete the development of its product and to fund additional losses which
the Company expects to incur over the next few years. The Company is in an early clinical phase and therefore does not yet have
product revenue. In 2022, the Company issued convertible notes resulting in net cash proceeds of $4.4 million (see Note 7). There can
be no assurance that the Company will be successful in securing additional financing, if needed, to meet its operating needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
conditions and events create an uncertainty about the ability of the Company to continue as a going concern through February 20,
2024 (one year after the date that the financial statements are available to be issued). The financial statements do not include any
adjustments that might be necessary should the Company be unable to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">Azitra,
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Financial Statements (continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Summary of Significant Accounting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
of Accounting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of the Company are prepared in accordance with United States generally accepted accounting principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
of Estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the financial statement in conformity with accounting principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the balance sheet.
While management believes the estimates and assumptions used in the preparation of the financial statement are appropriate, actual results
could differ from those estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash
and Cash Equivalents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">For
purposes of the balance sheets and statements of cash flows, the Company considers all cash on hand, demand deposits and all highly liquid
investments with original maturities of three months or less to be cash equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accounts
Receivable</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company carries its accounts receivable at cost less an allowance for doubtful accounts. On a periodic basis, the Company evaluates its
accounts receivable and establishes an allowance for doubtful accounts based on a history of past write-offs, collections and current
conditions. There was no allowance for doubtful accounts at December 31, 2022 or 2021. Accounts receivable are written off when deemed
uncollectible. Recoveries of accounts receivable previously written off are recorded when received.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: justify"><B>Deferred offering costs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The Company capitalizes
deferred offering costs, which primarily consist of direct, incremental legal, professional, accounting, and other third-party fees relating
to the Company&rsquo;s initial public offering. The deferred offering costs&nbsp;will be offset against IPO proceeds upon the consummation
of an offering. Should the planned IPO prove to be unsuccessful, these deferred costs, as well as additional expenses to be incurred,
will be charged to operations.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Property
and Equipment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives, which range
from 3 to 10 years. Expenditures for maintenance and repairs, which do not extend the economic useful life of the related assets, are
charged to operations as incurred. Gains or losses on disposal of property and equipment are reflected in the statements of operations
in the period of disposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Financial Statements (continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Summary of Significant Accounting Policies (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Right
of Use Assets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued ASU No. 2016-02, Leases (&ldquo;Topic 842&rdquo;).
ASU 2016-02 requires lessees to present right-of-use (&ldquo;ROU&rdquo;) assets and lease liabilities on the balance sheet for all leases
with terms longer than 12 months. See Note 2 &ndash; Recently Adopted Accounting Pronouncements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
calculating the effect of ASU 2016-02, the Company elected the transition method thereby not restating comparable periods. The Company
elected to account for non-lease components as part of the lease component to which they relate. Lease accounting involves significant
judgments, including making estimates related to the lease term, lease payments, and discount rate. In accordance with the guidance,
the Company recognized ROU assets and lease liabilities for all leases with a term greater than 12 months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has operating leases for buildings. Currently, the Company has 3 operating leases with a ROU asset and lease liability totaling
$1,418,502 as of January 1, 2022. The basis, terms and conditions of the leases are determined by the individual agreements. The Company&rsquo;s
option to extend certain leases ranges from 36 &ndash; 52 months. All options to extend have been included in the calculation of the
ROU asset and lease liability. The leases do not contain residual value guarantees, restrictions, or covenants that could incur additional
financial obligations to the Company. There are no subleases, sale-leaseback, or related party transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2022, the Company had operating right-of-use assets with a net value of $1,116,697 and current and long-term operating lease
liabilities of $287,384 and $840,896, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intangible
Assets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of trademarks and patents. All costs directly related to the filing and prosecution of patent and trademark applications
are capitalized. Patents are amortized over their respective remaining useful lives upon formal approval. Trademarks have an indefinite
life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for other indefinite life intangible assets in accordance ASC Topic 350, <I>Goodwill and Other Intangible Assets</I>
(ASC 350). ASC 350 requires that intangible assets that have indefinite lives are required to be tested at least annually for impairment
or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Intangible assets that have
finite lives will continue to be amortized over their useful lives. No impairment losses relating to intangible assets were recorded
in 2022 or 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Financial Statements (continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Summary of Significant Accounting Policies (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Deferred
Patent Costs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
patent costs represent legal and filing expenses incurred related to the submission of patent applications for patents pending approval.
These deferred costs will begin to be amortized over their estimated useful lives upon the formal approval of the patent. If the patent
is not approved, the costs associated with the patent will be expensed in the year the patent was rejected. No impairment losses relating
to deferred patent costs were recorded in the years ended December 31, 2022 and 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Impairment
of Long-Lived Assets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC Topic 360-10, <I>Accounting for the Impairment or Disposal of Long-Lived Assets </I>(ASC 360-10), the Company&rsquo;s
policy is to review its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount
of an asset may not be recoverable. In connection with this review, the Company also reevaluates the periods of depreciation for these
assets. The Company recognizes an impairment loss when the sum of the undiscounted expected future cash flows from the use and eventual
disposition of the asset is less than its carrying amount. If an asset is considered to be impaired, the impairment to be recognized
is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is determined using the
present value of the net future operating cash flows generated by the asset.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Convertible
Debt and Warrant Accounting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Warrants</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&rsquo;s
specific terms and applicable authoritative guidance in ASC 480, <I>Distinguishing Liabilities from Equity </I>(&ldquo;ASC 480&rdquo;)
and ASC 815, <I>Derivatives and Hedging</I> (&ldquo;ASC 815&rdquo;). The assessment considers whether the warrants are freestanding financial
instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements
for equity classification under ASC 815, including whether the warrants are indexed to the Company&rsquo;s own common stock, among other
conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant
issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Financial Statements (continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Summary of Significant Accounting Policies (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Convertible
Debt and Warrant Accounting (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Warrants
(continued)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
issued warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional
paid-in capital at the time of issuance. For issued warrants that do not meet all the criteria for equity classification, the warrants
are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the
estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations under Other Income/loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Convertible
Debt</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
the Company issues debt with a conversion feature, it first assesses whether the conversion feature meets the requirements to be accounted
for as stock settled debt. If it does not meet those requirements then it is assessed on whether the conversion feature should be bifurcated
and treated as a derivative liability, as follows: a) one or more underlyings, typically the price of our common stock; b) one or more
notional amounts or payment provisions or both, generally the number of shares upon conversion; c) no initial net investment, which typically
excludes the amount borrowed; and d) net settlement provisions, which in the case of convertible debt generally means the stock received
upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not
have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer&rsquo;s
own equity. The scope exception applies if the contract is both a) indexed to its own stock; and b) classified in stockholders&rsquo;
equity in its statement of financial position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.7pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Convertible
Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Convertible Preferred stockholders have liquidation rights in the event of a deemed liquidation event that, in certain situations,
are not solely within the control of the Company and would require the redemption of the then-outstanding Convertible Preferred Stock,
the Company classifies the Convertible Preferred Stock in mezzanine equity on the balance sheet. Due to the fact that the occurrence
of a deemed liquidation event is not currently probable, the carrying value of the Convertible Preferred Stock is not being accreted
to its redemption value. Subsequent adjustments to the carrying value of the Convertible Preferred Stock would be made only when a deemed
liquidation event becomes probable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Financial Statements (continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Summary of Significant Accounting Policies (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revenue</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the five steps to recognize revenue from contracts with customers under ASC <I>606,</I> Revenue from Contracts with Customers
(&ldquo;ASC <I>606&rdquo;</I>), which are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
    <I>1:</I> Identify the contract(s) with a customer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Step 2: Identify the performance obligations in the contract</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
    <I>3:</I> Determine the transaction price</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
    <I>4:</I> Allocate the transaction price to the performance obligations in the contract</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Step 5: Recognize revenue when (or as) a performance obligation is satisfied</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates service revenue through a joint development agreement with a research partner. The Company recognizes revenue related
to the research and development aspects of the agreement over time using the input method as work is performed on the contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also generates grant revenue, which represents monies received on contracts with various federal agencies and nonprofit research
institutions for general research conducted by the Company to further their product development and are therefore considered contributions
to the Company. The contracts are generally for periods of one year or more and can be cancelled by either party. The Company concluded
that the grant arrangements do not meet the criteria to be treated as a collaborative arrangement under FASB ASC Topic 808 as the Company
is the only active participant in the arrangement. The grant arrangements also do not meet the criteria for revenue recognition under
Topic 606, as the U.S. Government would not meet the definition of a customer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
earned under these grant contracts are recorded as a negative research &amp; development expense when eligible expenses are incurred
and the right to payment is realizable or realized and earn The Company believes this policy is consistent with Topic 606, to ensure
that recognition reflects the transfer of promised goods or services to customers in an amount that reflects the consideration that the
Company expects to be entitled to in exchange for those goods or services, even though there is no exchange as defined in Topic 606.
Additionally, the Company has determined that the recognition of amounts received as costs are incurred and amounts become realizable
is analogous to the concept of transfer of control of a service over time under Topic 606.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Financial Statements (continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Summary of Significant Accounting Policies (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revenue
(continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receipts
of grant awards in advance, which are payable back to the funding agency if not used in accordance with conditions in the grants related
to allowable costs or receipt of funding from research partners related to service revenue arrangements before work is performed on the
contract are classified as contract liabilities in the accompanying balance sheets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for research and development costs in accordance with Accounting Standards Codification (ASC) subtopic 730-10, <I>Research
and Development</I>. Accordingly, internal research and development costs are expensed as incurred. Research and development costs consist
of costs related to labor, materials and supplies. Research and development costs incurred were $5,920,538 and $5,380,102 during the
years ended 2022 and 2021, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2022 and 2021, the Company has a state tax credit receivable of $32,459 and $71,396, respectively, for pending refunds related
to the selling of research and development tax credits back to the State of Connecticut. At December 31, 2022 and 2021, the Company has
$28,925 and $89,855, respectively for pending refunds related to Canadian Scientific Research and Experimental Development credits. At
December 31, 2022 and 2021, the Company has also recorded $8,282 and $12,060, respectively, related to refunds of Canadian Goods and
Services Tax (GST) and Quebec Sales Tax (QST). Receipts of refunds are recorded in other income on the statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock-Based
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based compensation in accordance with ASC 718, <I>Compensation-Stock Compensation </I>(ASC 718). ASC 718 requires
employee stock options and rights to purchase shares under stock participation plans to be accounted for at fair value. ASC 718 requires
that compensation costs related to share-based payment transactions be recognized as operating expenses in the financial statements.
Under this method, compensation costs for all awards granted or modified are measured at estimated fair value at date of grant and are
included as compensation expense over the vesting period during which an employee provides service in exchange for the award. For awards
with a performance condition that affects vesting, the Company recognizes compensation expense when it is determined probable that the
performance condition will be achieved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Financial Statements (continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Summary of Significant Accounting Policies (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock-Based
Compensation (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses a Black-Scholes option pricing model to determine fair value of its stock options. The Black-Scholes model includes various
assumptions, including the value of the underlying common stock, the expected life of stock options, the expected volatility and the
expected risk-free interest rate. These assumptions reflect the Company&rsquo;s best estimates, but they involve inherent uncertainties
based on market conditions generally outside of the control of the Company. As a result, if other assumptions had been used, stock-based
compensation cost could have been materially impacted. Furthermore, if the Company uses different assumptions for future grants, stock-based
compensation cost could be materially impacted in future periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for equity instruments issued to non-employees in accordance with the provisions of ASC 718 as updated by Accounting
Standards Update (ASU) No. 2018-07, <I>Improvements to Nonemployee Share-Based Payment Accounting</I>, which expands the scope of ASC
718 to include share based payment transactions to non-employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following assumptions are used in valuing options issued using the Black-Scholes option pricing model:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Expected
Volatility</I>. The expected volatility of the Company&rsquo;s shares is estimated based on the Company&rsquo;s external valuation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Expected
Term</I>. The expected term of options is estimated using the simplified method which is based on the vesting period and contractual
term for each grant, or for each vesting-tranche for awards with graded vesting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Underlying
Common Stock Value. </I>The underlying common stock value of the Company&rsquo;s shares is estimated by a third party valuation expert.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Risk-free
Interest Rate</I>. The Company bases the risk-free interest rate on the implied yield available on a U.S. Treasury note with terms equal
to the expected term of the underlying grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividend
Yield</I>. The Black-Scholes valuation model calls for a single expected dividend yield as an input. The Company has not paid dividends
on Common stock in the past nor does it expect to pay dividends on Common stock in the near future. As such, the Company uses a dividend
yield percentage of zero.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 131; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Financial Statements (continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Summary of Significant Accounting Policies (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Income
Taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses the liability method of accounting for income taxes, as set forth in ASC 740, <I>Accounting for Income Taxes</I>. Under
this method, deferred tax assets and liabilities are recognized for the expected future tax consequence of temporary differences between
the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently
enacted tax rates (see Note 13).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has evaluated the effect of ASC guidance related to uncertain income tax positions and concluded that the Company has no significant
financial statement exposure to uncertain income tax positions at December 31, 2022 and 2021. The Company&rsquo;s income tax returns
have not been examined by tax authorities through December 31, 2022. The Company is not currently under audit by any tax jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
Value Measurements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company carries certain liabilities at fair value on a recurring basis. A fair value hierarchy that consists of three levels is used
to prioritize the inputs to fair value valuation techniques:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 &ndash; Inputs are based upon observable or quoted prices for identical instruments traded in active markets.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 &ndash; Inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments
    in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the
    market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 &ndash; Inputs are generally unobservable and typically reflect management&rsquo;s estimates of assumptions that market participants
    would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option
    pricing models, discounted cash flow models, and similar techniques.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of
unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 132; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Financial Statements (continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Summary of Significant Accounting Policies (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recently
Adopted Accounting Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;) 2016-02,
Leases (Topic 842). This ASU requires a lessee to recognize a right-of-use asset and a lease liability under most operating leases in
its balance sheet. The ASU is effective for annual and interim periods beginning after December 15, 2021. The Company adopted ASU 2016-02
on January 1, 2022. See Note 15 &ndash; Operating Leases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, the FASB issued ASU No. 2019-12, <I>Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</I>. This standard
simplifies the accounting for income taxes through the removal of various exceptions previously provided, as well as providing additional
reporting requirements for income taxes. The ASU is effective for the Company on January 1, 2022. The Company has adopted this standard
effective January 1, 2022, which did not have a material impact to the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU No. 2020-06, <I>Debt &ndash; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging &ndash; Contracts in Entity&rsquo;s Own Equity (Subtopic 815-40)</I>, which simplifies the accounting for certain financial
instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&rsquo;s own
equity. This standard will be effective for the Company on January 1, 2024, with early adoption permitted (but no earlier than fiscal
years beginning after December 15, 2020). The Company has adopted this standard effective January 1, 2021, which did not have a material
impact to the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any other recently issued, but not yet effective, accounting standards could have a material effect on the accompanying
financial statements. As new accounting pronouncements are issued, the Company will adopt those that are applicable under the circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
Instruments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s financial instruments are primarily comprised of accounts receivable, accounts payable, accrued liabilities, and long-term
debt. For accounts receivable, accounts payable and accrued liabilities, the carrying amount approximates fair value due to the short
term maturities of such instruments. The estimated fair value of the Company&rsquo;s long-term debt approximates carrying value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Financial Statements (continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
Employee Retention Credit</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CARES Act provides an employee retention credit (&ldquo;CARES Employee Retention credit&rdquo;), which is a refundable tax credit against
certain employment taxes of up to $5,000 per employee for eligible employers. The tax credit is equal to 50% of qualified wages paid
to employees during a quarter, capped at $10,000 of qualified wages per employee through December 31, 2020. Additional relief provisions
were passed by the United States government, which extend and slightly expand the qualified wage caps on these credits through September
30, 2021. Based on these additional provisions, the tax credit is now equal to 70% of qualified wages paid to employees during a quarter,
and the limit on qualified wages per employee has been increased to $10,000 of qualified wages per quarter. In April 2022, the Company
determined it qualified for the tax credit under the CARES Act and recorded a receivable for $229,813 and recognized the amounts as other
income on the statement of operations. The Company received full payment for the amount in September 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.
Property and Equipment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consisted of the following at December 31, 2022 and 2021:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify">Lab equipment</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">1,034,579</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">1,016,737</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Computer equipment</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">30,825</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,825</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Furniture and fixtures</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">24,316</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">24,316</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Leasehold improvements</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">28,855</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">28,855</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt">Building equipment</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">14,932</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">14,932</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,133,507</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,115,665</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt">Less: accumulated depreciation</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(286,549</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(168,984</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Net property and equipment</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">846,958</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">946,681</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense was $120,651 and $81,866 for the years ended December 31, 2022 and 2021, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 134; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Financial Statements (continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
Intangible Assets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consisted of the following at December 31:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Estimated</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Useful Life</B></FONT></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Gross Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Accumulated Amortization</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Net Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: justify">Trademarks</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: justify">Indefinite</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">53,999</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">53,999</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Patents</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">17 years</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">108,198</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">8,140</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">100,058</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt">License agreement</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt">17 years</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">65,510</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">65,510</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Intangible assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">227,707</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">8,140</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">219,567</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021<B>:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Estimated</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Useful Life</B></FONT></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Gross Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Accumulated Amortization</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Net Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: justify">Trademarks</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: justify">Indefinite</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">50,955</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">50,955</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt">Patents</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">17 years</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">49,644</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">2,906</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">46,738</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Intangible assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">100,599</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">2,906</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">97,693</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2022 and 2021, amortization expense related to intangible assets was $5,234 and $2,906, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
amortization expense is as follows for the years ending December 31:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 40%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 72%; text-align: justify">2023</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24%; text-align: right">2,920</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">2024</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,920</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">2025</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,920</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">2026</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,920</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">2027</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,920</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">85,456</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">100,058</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 135; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Financial Statements (continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.
Accrued Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses consisted of the following at December 31, 2022 and 2021:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify">Employee payroll and bonuses</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">371,010</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">138,671</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Vacation</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">27,082</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">43,473</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Research and development projects</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">316,389</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">149,711</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Interest</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">223,792</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">59,181</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Professional fees</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">24,502</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">58,892</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt">Other</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">31,186</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">25,557</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">993,961</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">475,485</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accrues expenses related to development activities performed by third parties based on an evaluation of services received and
efforts expended pursuant to the terms of the contractual arrangements. Payments under some of these contracts depend on research and
non-clinical trial milestones. There may be instances in which payments made to the Company&rsquo;s vendors will exceed the level of
services provided and result in a prepayment of expense. In accruing service fees, the Company estimates the period over which services
will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level
of effort varies from the estimate, the Company will adjust the accrual or prepaid expense accordingly. The Company has not experienced
any material differences between accrued costs and actual costs incurred since its inception.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 136; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Financial Statements (continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.
Convertible Debt</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2022, the Company entered into a Convertible Note Purchase Agreement (the Agreement) to issue up to $4,500,000 convertible
promissory notes. On the same day, the Company entered into convertible promissory notes (2022 Convertible Notes) with three investors
totaling $4,350,000. The 2022 Convertible Notes mature on January 13, 2023 or the occurrence of an Event of Default (as defined) and
bear interest at a rate of 8% per annum which shall accrue but is not due and payable until conversion or full repayment of outstanding
principal. The principal and interest outstanding under the 2022 Convertible Notes is automatically converted a) upon the closing of
a Qualified Financing resulting in gross proceeds to the Company of at least $20 million into securities issued in connection with the
Qualified Financing, at a discount of 30% per share; b) upon the closing of a Change of Control event into shares of capital stock of
the Company or Series B preferred stock; and c) upon the closing of a Public Company Event, into shares of capital stock being issued
to investors equal to two-times (2x) the amount of the outstanding principal and accrued interest then outstanding divided by the public
offering price per share. The principal and interest outstanding under the 2022 Convertible Notes is convertible, at the option of the
holders, at the maturity date into a new class of Company&rsquo;s Preferred Stock (Series C Preferred) equal to the quotient of the outstanding
principal amount plus interest divided by the Capped Price, which is defined as the price per share equal to the Valuation Cap of $30
million divided by the Company Capitalization, as defined in the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for the 2022 Convertible Notes under ASC 815. Under 815-15-25, the election can be at the inception of a financial instrument
to account for the instrument under the fair value option under ASC 825. The Company has made such election for the 2022 Convertible
Notes. Using the fair value option, the convertible promissory note is to be recorded at its initial fair value on the date of issuance,
and each balance sheet date thereafter. The Company evaluates the change based on the conversion price at the current market value. When
recognized, changes in the estimated fair value of the notes are recognized as a non-cash gain or loss in Other Income (Expense) on the
statements of operations. The Company recognized a change in fair value of the 2022 Convertible Notes of $1,250,000 for the year ended
December 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
January 5, 2021, the Company entered into a Note Purchase Agreement to issue up to $2,000,000 of convertible promissory notes. On the
same date, the Company entered into a convertible promissory note (2021 Convertible Note) with one investor for $1,000,000. The 2021
Convertible Note bears interest at a rate of 6% per annum and is due and payable in full on January 5, 2023. The 2021 Convertible Note
automatically converts upon a qualified equity financing, as defined in the note agreement to the number of shares equal to all principal
and accrued interest divided by the conversion price of $48.00, which is subject to adjustment as defined in the note agreement. The
2021 Convertible Note is also optionally convertible as defined in the note agreement for certain non-qualified financing, a change in
control, or upon the maturity date of the 2021 Convertible Note. The Company incurred issuance costs of $15,613 related to the 2021 Convertible
Note, which has been recorded as a debt discount and were amortized over the term of the 2021 Convertible Note. The issuance costs were
fully amortized at December 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 137; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Financial Statements (continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.
Convertible Debt (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated the terms and conditions of the Note Purchase Agreement related to the 2021 Convertible Note in order to assess the
accounting considerations under ASC 480 &ndash; Distinguishing Liabilities from Equity, and ASC 815 &ndash; Derivatives and Hedging.
The Company determined the Convertible Note does not meet any of the criteria to be accounted pursuant to an ASC 480 liability. The Company
also assessed the embedded features pursuant to the guidance in ASC 815 and determined the embedded features do not meet any of the criteria
for bifurcation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
notes payable consisted of the following at December 31:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify">2021 Convertible Note</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">1,000,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">1,000,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt">2022 Convertible Notes</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">5,600,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">6,600,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,000,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt">Debt issuance costs</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(7,981</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">6,600,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">992,019</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was $7,981 and $7,632 amortized related to the debt issuance costs during the years ended December 31, 2022 and 2021, respectively. Interest
accrued on the convertible notes was $223,792 and $59,181 at December 31, 2022 and 2021, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.
Payroll Protection Program Loan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 10, 2020 the Company received a loan in the amount of $230,685 under the Payroll Protection Program (PPP Loan). The loan accrued
interest at a rate of 1% and had an original maturity date of two years which could be extended to five years by mutual agreement of
the Company and the lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the requirements of the CARES Act, as amended by the PPP Flexibility Act and Consolidated Appropriations Act, 2021, proceeds could only
be used for the Company&rsquo;s eligible payroll costs (with salary capped at $100,000 on an annualized basis for each employee), or
other eligible costs related to rent, mortgage interest utilities, covered operations expenditures, covered property damage, covered
supplier costs, and covered worker protection expenditures, in each case paid during the 24-week period following disbursement. The PPP
Loan could be fully forgiven if (i) proceeds are used to pay eligible payroll costs or other eligible costs and (ii) full-time employee
headcount and salaries are either maintained during the 24-week period following disbursement or restored by December 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company received notification of full forgiveness of the PPP Loan on January 25, 2021 and has recorded the amount in other income on
the statement of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 138; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Financial Statements (continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.
Stockholders&rsquo; Equity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2022 and 2021, respectively, per the Company&rsquo;s amended and restated Certificate of Incorporation, the Company was
authorized to issue 100,000,000 shares of $0.0001 par value common stock. Refer to Note 19, Subsequent Events for more
information related to the Forward-Stock Split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had 1,043,991 and 1,043,103 shares of common stock issued and outstanding as of December 31, 2022 and 2021, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&rsquo;s stockholders and the
holders of the Common Stock are entitled to elect one director of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently has 8,504,678 shares of common stock reserved for future issuance for the potential conversion of the outstanding
Preferred Stock and the exercise of stock options and warrants outstanding at December 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2022 and 2021, respectively, per the Company&rsquo;s amended and restated Certificate of Incorporation, the Company has
authorized 1,437,150 and 978,042 shares of $0.0001 par value preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A, Series A-1, and Series B Preferred Stock have the following rights, preferences and privileges:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Conversion</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preferred stock is convertible, at the option of the holder, into common shares based upon a predefined formula. A holder of preferred
stock may convert such shares into common shares at any time. For purpose of conversion, the initial conversion price is $2.2887
per share (original issue price) for Series A Preferred Stock, $5.2817 per share (original issue price) for Series A-1 Preferred
Stock, and $6.1190 per share (original issue price) for Series B Preferred Stock, and is subject to adjustment as described in
the Certificate of Incorporation. Preferred stock will automatically convert into common shares upon the earlier of (a) an initial public
offering with gross proceeds in excess of $100,000,000 or (b) the date and time, or the occurrence of an event, specified by vote or
written consent of the required preferred stock shareholders, all outstanding Series A, Series A-1, and Series B Preferred Stock shall
automatically convert into common shares, at the then effective conversion rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 139; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Financial Statements (continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.
Stockholders&rsquo; Equity (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of the Series A, Series A-1, and Series B Preferred Stock are entitled to vote on any matter presented to the stockholders of
the Corporation for their action or consideration at any meeting of stockholders of the Corporation (or by written consent of stockholders
in lieu of meeting), each holder of outstanding shares of preferred stock shall be entitled to cast the number of votes equal to the
number of whole shares of Common Stock into which the shares of preferred stock held by such holder are convertible as of the record
date for determining stockholders entitled to vote on such matter. The holders of the Series A and Series A-1 Preferred Stock are each
entitled to elect one director of the Corporation. The holders of the Series B Stock are entitled to elect two members of the Board.
Each class of preferred stock can remove from office such directors and to fill any vacancy caused by the resignation, death or removal
of such directors under certain circumstances as described in the Certificate of Incorporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividends</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series A Preferred Stock are entitled to receive dividends at a rate of 8% per annum of the Series A original issue price
of $2.2887 per share on each outstanding share of Series A Preferred Stock (subject to appropriate adjustment in the event of
any stock dividend, stock split, combination or other similar recapitalization with respect to the Series A Preferred Stock). Dividends
accumulate from the original date of issuance of the Series A Preferred Stock, are cumulative and are payable upon declaration of the
Board of Directors or liquidation of the Company. At December 31, 2022, cumulative dividends on Series A Preferred Stock were $1,541,575.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series A-1 Stock are entitled to receive dividends at a rate of 8% per annum of the Series A-1 original issue price of $5.2817
per share on each outstanding share of Series A-1 (subject to appropriate adjustment in the event of any stock dividend, stock
split, combination or other similar recapitalization with respect to the Series A-1 Preferred Stock). Dividends are cumulative and
are payable upon declaration of the Board of Directors or liquidation of the Company. At December 31, 2022, cumulative dividends on
Series A-1 Preferred Stock were $4,332,153.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series B Stock are entitled to receive dividends at a rate of 8% per annum of the Series B original issue price of $6.1190
per share on each outstanding share of Series B (subject to appropriate adjustment in the event of any stock dividend, stock split,
combination or other similar recapitalization with respect to the Series B Preferred Stock). Dividends are cumulative and are payable
upon declaration of the Board of Directors or liquidation of the Company. At December 31, 2022, cumulative dividends on Series B Preferred
Stock were $3,135,585.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 140; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Financial Statements (continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.
Stockholders&rsquo; Equity (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Liquidation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of any liquidation, dissolution or winding up of the Company, the holders of the preferred stock are entitled to receive, prior
to and in preference to the holders of the common shares, an amount equal to the Series A, Series A-1, or Series B Preferred Stock original
issue price, plus declared and/or accrued but unpaid dividends. In the event of any such liquidation event, after the payment of all
preferential amounts required to be paid to the holders of shares of preferred stock, the remaining assets of the Corporation available
for distribution to its stockholders shall be distributed among the holders of the shares of preferred stock and Common Stock, pro rata
based on the number of shares held by each such holder, treating for this purpose all such securities as if they had been converted into
Common Stock pursuant to the terms of the Certificate of Incorporation immediately prior to such liquidation event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued warrants to purchase 47,889 shares of common stock in 2018 in conjunction with convertible debt financing that
have a redemption provision providing the holder the right to have the Company redeem all or any portion of the warrant (or shares it
has converted into) at a purchase price equal to the fair market value of the shares as determined by the board of directors or an independent
appraiser. As a result of this redemption provision, the warrants have been classified as a liability in the financial statements based
on ASC 480 &ndash; Distinguishing Liabilities from Equity. These warrants have an exercise price of $0.48 per share a term of
10 years. The warrants are marked to market each reporting period. The fair value is $70,283 and $71,104 at December 31, 2022 and 2021,
respectively. At December 31, 2022, the Company estimated the fair value of the warrants using the Black-Scholes option pricing model
with the following assumptions: Underlying common stock value of $1.70; Expected term of 5 years; Expected Volatility of 86.0%;
Risk Free Interest Rate of 3.01%; and Dividend Yield of 0%. At December 31, 2021, the Company estimated the fair value of the warrants
using the Black-Scholes option pricing model with the following assumptions: Underlying common stock value of $1.70; Expected
term of 6 years; Expected Volatility of 86.0%; Risk Free Interest Rate of 1.35%; and Dividend Yield of 0%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also issued warrants in 2016 and 2019 which did not meet the criteria under ASC 480 to be classified as a liability, and instead
meet equity classification criteria.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 141; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Financial Statements (continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.
Warrants (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about warrants outstanding at December 31, 2022:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="9" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Warrants Outstanding</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="9" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Warrants Exercisable</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year Granted</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise Price</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Number of Warrants at 12/31/2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Remaining Contractual Life</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Warrants at 12/31/2022</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Remaining Contractual Life</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: center">2016</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">0.01</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">11,467</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7 years</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">0.01</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">11,467</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7 years</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">0.01</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.48</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">47,889</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3 years</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.48</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">47,889</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3 years</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.48</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center">2019</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">5.28</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">215,854</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1 years</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">5.28</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">215,854</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1 years</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">5.28</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">275,210</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">4.23</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">275,210</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">4.23</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.
Stock Options</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2016, the Company established the Azitra, Inc. 2016 Stock Incentive Plan (the Plan) which provides for the granting of stock options
and restricted shares to the Company&rsquo;s employees, officers, directors, advisors and consultants. There are 1,490,595 shares
available for granting under the Plan at December 31, 2022 and 2021. Options vest over varying time frames.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022 and 2021, the Company granted 0 and 495,580, respectively, stock options to acquire shares of
common stock. The options vest over varying time frames between two and four years, have a life of ten years and an exercise price of
$1.70. During the years ended December 31, 2022 and 2021, the Company recognized stock compensation expense of $184,465 and $306,055,
respectively, relating to the issuance of service-based stock options. At December 31, 2022, there was $427,784 of unamortized compensation
expense that will be amortized over the remaining vesting period. At December 31, 2022, there were 93,152 performance-based options
outstanding with a fair value of $109,551. During the year ended December 31, 2022, the Company did not recognize any compensation expense
for performance-based options. The Company determined the options qualified as plain vanilla under the provisions of SAB 107 and the
simplified method was used to estimate the expected option life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
determine the estimated fair value of the options granted during 2021, the Company used the Black-Scholes option pricing model with the
following assumptions: Underlying common stock value of $1.70; Expected term of 7 years; Expected Volatility of 86.0%; Risk Free
Interest Rate of 0.66% - 1.26%; and Dividend Yield of 0%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 142; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Financial Statements (continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.
Stock Options (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about options outstanding and exercisable at December 31, 2022:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="9" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Options Outstanding</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="9" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Options Exercisable</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise Price</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Number of Options at 12/31/2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Remaining Contractual Life</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Options at 12/31/2022</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Remaining Contractual Life</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right">0.48</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">246,136</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.0 years</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">0.48</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">246,136</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.0 years</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0.48</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.93</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">231,680</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.0 years</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.93</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">231,680</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.0 years</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.93</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">1.70</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">812,502</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3 years</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">1.70</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">411,707</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.0 years</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">1.70</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,290,318</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">889,523</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
stock option activity for the years ended December 31, 2022 and 2021 is summarized as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">959,827</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">1.11</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">495,580</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.70</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(17,750</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.48</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(55,749</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">1.03</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2021</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,381,908</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">1.34</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(888</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">1.70</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(90,702</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">5.91.41</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">1,290,318</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">1.33</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are 157,989 shares available for future grant under the Plan at December 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 143; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Financial Statements (continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.
Fair Value Measurements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarize the fair values and levels within the fair value hierarchy in which the fair value measurements fall for assets
and liabilities measured on a recurring basis as of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif">December 31, 2022</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">Description</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Level 1</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Level 2</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Level 3</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Liabilities:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 44%; text-align: left">Common stock warrants</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">70,283</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">70,283</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">2022 Convertible Notes</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">5,600,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">5,600,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">5,670,283</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">5,670,283</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif">December 31, 2021</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">Description</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Level 1</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Level 2</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Level 3</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%">Liabilities:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Common stock warrants</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">71,104</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">71,104</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the changes in Level 3 instruments measured on a recurring basis for the years ended December 31, 2022 and 2021:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 82%">Balance at January 1, 2021</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">72,093</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in fair value of warrants</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(989</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">71,104</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Change in fair value of warrants</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(821</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Issuance of 2022 Convertible Notes</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">4,350,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Change in fair value of 2022 Convertible Notes</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">1,250,000</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">5,670,283</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fluctuation
in the fair value of the Company&rsquo;s Common stock is the primary driver for the change in the Common Stock Warrant liability valuation
during each year. As the fair value of the Common stock increases the value to the holder of the instrument generally increases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fluctuations
in the various inputs, including the enterprise value, time to liquidity, volatility, and discount rate are the primary drivers for the
changes in valuation of the 2022 Convertible Notes each reporting period. As the fair value of the enterprise value, estimated time to
liquidity, volatility, and discount rate increase, the value to the holder of the 2022 Convertible Notes generally increases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 144; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Financial Statements (continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.
Income Taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes are provided on temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes
and those for income tax reporting purposes. Deferred income tax assets / (liabilities) as of December 31, 2022 and 2021 are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax assets:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 68%; text-align: left">Net operating loss carryforwards</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">7,870,665</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">6,994,967</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Tax credits</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,729,421</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,216,246</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Depreciation and amortization</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,189,975</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Accrued expenses</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">81,876</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48,288</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt">Other</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">28,057</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">25,240</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total deferred tax assets</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">10,899,994</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8,284,741</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred tax liabilities:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Depreciation and amortization</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(234,616</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total deferred tax liabilities</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(234,616</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Valuation allowance</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(10,899,994</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(8,050,125</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net deferred tax (liability) asset</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has federal net operating loss carryforwards of approximately $29,192,000 and $25,954,000 for the tax years ending December 31,
2022 and 2021, respectively, of which $1,285,000 will expire in tax years 2036 through 2037 and approximately $27,907,000 which does
not expire. The Company has state net operating loss carryforwards of approximately $29,374,000 and $25,947,000 for the tax years ending
December 31, 2022 and 2021, respectively, which will expire in tax years 2036 through 2042.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has federal research tax credits of approximately $1,235,000 and $859,000 for the tax years ending December 31, 2022 and 2021,
respectively, which expire in tax years 2039 through 2042. The Company has state research tax credits of approximately $350,000 and $249,000
for the tax years ending December 31, 2022 and 2021, respectively, of which $60,000 will expire in tax year 2036, $100,000 will
expire in tax year 2037 and the remainder can be carried forward indefinitely. The Company has Canadian research tax credits of approximately
$218,000 and $138,000 for the tax years ending December 31, 2022 and 2021, respectively, which expire in tax years 2039 through 2042.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 145; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Financial Statements (continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.
Income Taxes (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. Internal Revenue Code Section 382 imposes an annual limit on the ability of a corporation that undergoes a greater than 50% ownership
change to use its net operating loss carry forwards to reduce its tax liability. If in the future the Company undergoes an ownership
change exceeding the 50% limitation threshold imposed by Section 382, the Company&rsquo;s net operating loss carryforwards may be significantly
limited as to the amount of use in a particular year. In addition, all or a portion of the Company&rsquo;s net operating loss carryforwards
incurred before 2018, may expire unutilized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
realization of deferred tax assets is dependent upon the Company&rsquo;s ability to generate future taxable income during the periods
in which the temporary differences become deductible. Based on the Company&rsquo;s recent earnings history and projected future U.S.
earnings, management believes that it is more likely than not that its federal and state deferred tax assets will not be fully realized
in the foreseeable future. As a result of this assessment, management believes that a full valuation allowance against its net federal
and state deferred tax assets is required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the provisions of ASC 740-10 to account for uncertain tax positions. ASC 740-10 addresses the determination of whether
tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the
Company may recognize the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be
sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has determined that it
has no significant uncertain tax positions requiring recognition and measurement under ASC 740-10.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to U.S. federal income tax, Connecticut state income tax and Canada branch tax. The Company has not been audited by
the IRS, state, or foreign tax authorities in connection with income taxes. The Company&rsquo;s tax years remain open to examination
for all federal and state tax matters until its net operating loss carryforwards are utilized and the applicable statute of limitations
have expired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will recognize interest and penalties related to unrecognized tax benefits, if applicable, as a component of income tax expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 146; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Financial Statements (continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14.
Net Loss Per Share</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss per share were calculated as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
numerator for basic and diluted net loss per share is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">For the Year Ended December 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Net loss</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">10,680,366</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">8,939,675</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Dividends on preferred stock</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">2,768,984</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">2,768,984</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss attributable to common shareholders</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">13,449,350</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11,708,659</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
denominator is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">For the Year Ended December 31,</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Weighted average common stock outstanding, basic and diluted</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">1,043,990</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">1,034,299</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">$0.01 warrants</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">11,467</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">11,467</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Total</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,055,457</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,045,766</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share, basic and diluted is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">For the Year Ended December 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Net loss per share, basic and diluted</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">(12.74</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">(11.20</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 147; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Financial Statements (continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14.
Net Loss Per Share (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following potential common stock equivalents, presented based on amounts outstanding at each period end, were excluded from the calculation
of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">December 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left">Options to purchase shares of common stock</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">1,290,318</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">1,381,908</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Warrants outstanding</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">263,743</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">263,743</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,554,061</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,645,651</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.
Commitments and Contingencies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Legal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to legal proceedings or claims which arise in the ordinary course of its business. Although occasional adverse decisions
or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on
its financial position, results of operations or liquidity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License
Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
January 26, 2022, the Company entered into an Exclusive License Agreement (the Agreement) with an unrelated third party. Under the Agreement,
the Company is granted an exclusive license for certain patents and a non-exclusive license for certain know-how. The Agreement continues
until the later of the expiration of the last to expire licensed patent or ten years after the first commercial sale of the first licensed
therapeutic or non-therapeutic product. The Company may terminate the Agreement at any time by providing at least 30 days written notice
to the third party. The Agreement is also terminated upon breach of a material obligation under the agreement or bankruptcy. Upon any
termination of the agreement, neither party is relieved of obligations incurred prior to the termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company capitalized payments made under this license agreement in the amount of $65,510. These
capitalized costs will be amortized over the life of the licensed patents, once issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Operating
Leases</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases office and lab space in Branford, CT; Groton, CT; and Laval, Quebec. The Company&rsquo;s leases expire at various dates
through May 31, 2027. Most leases are for a fixed term and for a fixed amount. The Company is not a party to any leases that have step
rent provisions, escalation clauses, capital improvement funding or payment increases based on any index or rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 148; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Financial Statements (continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.
Commitments and Contingencies (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Operating
Leases (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2020, the Company entered into a new lease agreement for the Company&rsquo;s primary office and laboratory space in Branford, CT. The
Branford lease requires monthly payments of $13,033 for the first year of the lease, which increases approximately 2% in each of the
following years. The Branford lease also requires the Company to pay a pro-rata share of common area maintenance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
May 2021, the Company entered into a new lease for office and laboratory space in Groton, CT. The Groton lease required monthly payments
of $4,234, which was increased to $6,824 in September 2021 upon leasing additional space. The Groton lease is initially for a one-year
term, with up to three additional years renewal available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum payments under non-cancelable operating leases with initial or remaining terms in excess of one year during each of the next
five years follow:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: justify">2023</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">329,937</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">2024</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">335,988</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">2025</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">277,209</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">2026</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">204,159</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify">2027</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">76,324</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total future undiscounted lease payments</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,223,617</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: interest</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(95,337</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Present value of lease liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">1,128,280</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent
expense for all operating leases was $338,864 for the year ended December 31, 2022. The weighted average lease term for all operating
leases is 3.8 years. The weighted average discount rate for all operating leases is 4.25%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16.
Retirement Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
January 1, 2019, the Company sponsors a 401(k) plan that covers substantially all employees. In order to be eligible to participate,
an employee must complete two consecutive months of service and work a minimum of two hundred and fifty hours or work 1,000 hours in
their first year of service. Employees may make pre-tax deferrals upon meeting the Plan eligibility requirements. Effective January 1,
2020, the Plan was transitioned to a safe harbor plan in which highly compensated employees are not eligible for matching contributions
and non-highly compensated employees earn 100% match on first 3% contributed and 50% on the next 2% contributed. Total employer matching
contributions were $23,466 and $31,548 for the years ended December 31, 2022 and 2021, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 149; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Financial Statements (continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17.
Concentration of Credit Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to credit risk consist principally of cash and accounts receivable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2022 and 2021, all grant revenue was from one grantor and three grantors, respectively, and all service
revenue was from one customer for both years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cash balance identified in the balance sheet is held in an account with a financial institution and insured by the Federal Deposit Insurance
Corporation (FDIC) up to $250,000. At times, cash maintained on deposit may be in excess of FDIC limits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
early March 2020, there was a global outbreak of COVID-19 that has resulted in significant changes in the global economy. While the Company
has not experienced any disruptions to its business operations to date, these changes, including a potential economic downturn, and any
potential resulting direct or indirect negative impact to the Company cannot be determined, however they could have a prospective material
impact to the Company&rsquo;s business, cash flows and liquidity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18.
Related Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company earned service revenue from an entity who was also an investor in the Company&rsquo;s Series B Preferred Stock financing (see
Note 9). Total related party revenue was $284,000 and $110,000 for the years ended December 31, 2022 and 2021, respectively and accounts
receivable due from the related party was $175,000 and $125,000 at December 31, 2022 and 2021, respectively. Contract liabilities from
the related party were $156,000 and $15,000 at December 31, 2022 and 2021, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2022 the Company entered into a convertible
promissory note totaling $4,350,000 of which $4,000,000 was attributable to an entity who was also an investor in the Company&rsquo;s
Series A, A-1, and B Preferred Stock financing. (See Note 7)</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>19.
Subsequent Events</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated events occurring between December 31, 2022 and June 13, 2023, the date the financial statements were available
to be issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, the Company elected to convert the 2021 Convertible Note (see Note 7), including interest accrued but not yet paid of $120,058
at a conversion price of $48.00 into 23,335 shares of its Series B Preferred Stock in accordance with the terms outlined in the Note
Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2023, the 2022 Convertible Notes were amended to extend the maturity date to March 31, 2023 and to change the conversion price
upon a Qualified Financing or Change in Control event to $30 million divided by the number of shares of the Company&rsquo;s common stock
issued and outstanding, on a fully diluted basis, immediately prior to the close of the Qualified Financing or Change in Control event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2023, the Company&rsquo;s Board of Directors and stockholders approved the 2023 Stock Incentive Plan (&ldquo;2023 Plan&rdquo;);
however, no grants shall be made until the date which the proposed forward stock split and increase in the authorized shares of common
stock becomes effective which is expected to occur upon the effectiveness of our registration statement of which this prospectus forms
a part. The 2023 Plan allows the Committee to grant up to&nbsp;2,000,000&nbsp;shares of Common Stock in the form of incentive and
non-statutory stock options, restricted stock awards, restricted stock units, and other stock-based awards to employees, directors, and
non-employees.&nbsp; As of March 20, 2023, there were no awards issued under the 2023 Plan.</FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 17, 2023, the Board of Directors approved a forward stock split at a ratio of 7.1-for-1&nbsp;upon </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
effectiveness of the registration statement of which this prospectus forms a part. The Board of Directors also approved an increase in the authorized shares of the Company&rsquo;s Common Stock to 100,000,000 along with
a change in the Common Stock par value to $0.0001. All references to common stock, options to purchase common stock, share data, per share data and related information contained in the
consolidated financial statements and related footnotes have been retrospectively adjusted, where applicable, to reflect the effect of
the stock split, change in par value of our Common Stock, and the adjustment of the preferred stock conversion ratios, where applicable.
Accordingly, an adjustment was made between common stock and additional paid-in-capital in the consolidated balance sheets to reflect
the new values after the stock split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 150; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="noah_001"></A>Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
Sheets</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unaudited</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">March 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current assets:</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; width: 60%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">1,833,395</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">3,492,656</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">97,389</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">182,820</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Tax credits receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72,356</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69,666</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Income tax receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,722</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,722</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Deferred offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">583,966</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">216,886</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Prepaid expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">43,636</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">160,133</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,644,464</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,135,883</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">830,798</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">846,958</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,535</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,507</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Operating lease right-of-use asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,045,454</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,116,697</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Intangible assets, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">223,208</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">219,567</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Deferred patent costs</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">864,035</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">800,831</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Total other assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,180,232</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,184,602</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,655,494</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,167,443</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Liabilities, convertible preferred stock, and stockholders&rsquo; deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">982,870</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">784,687</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Current operating lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">292,036</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">287,384</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">965,461</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">993,961</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Contract liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">42,700</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">156,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,283,067</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,222,032</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Long-term operating lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">767,159</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">840,896</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,662</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,283</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Convertible notes payable, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,400,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,600,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,514,888</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,733,211</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Convertible preferred stock:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Series A convertible preferred stock; $0.0001 par value; 205,385 shares authorized at March 31,
    2023 and December 31, 2022; 205,385 shares issued and outstanding at March 31, 2023 and December 31, 2022; liquidation value of $3,337,506
    at March 31, 2023 and December 31, 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,272,944</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,272,944</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">Series A-1 convertible preferred stock; $0.0001 par value; 380,657 shares authorized at March 31,
    2023 and December 31, 2022; 380,657 shares issued and outstanding at March 31, 2023 and December 31, 2022; liquidation value of $14,274,638
    as of March 31, 2023 and December 31, 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,100,533</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,100,533</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Series B convertible preferred stock; $0.0001 par value; 851,108 shares authorized at March 31,
    2023 and December 31, 2022; 414,735 and 391,303 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively;
    liquidation value of $18,018,162 and $17,000,159 as of March 31, 2023 and December 31, 2022, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,445,824</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,321,065</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stockholders&rsquo; deficit:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">Common stock; $0.0001 par value; 100,000,000 shares authorized at March 31, 2023 and
    December 31, 2022; 1,043,991 shares issued and outstanding at March 31, 2023 and December 31, 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">104</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">104</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,092,932</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,052,138</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(39,771,731</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(37,314,552</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Total stockholders&rsquo; deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(38,678,695</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(36,260,310</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total liabilities, convertible preferred stock, and stockholders&rsquo; deficit</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,655,494</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,167,443</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
accompanying notes are an integral part of these condensed financial statements.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 151; Options: NewSection; Value: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="noah_002"></A>Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
of Operations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unaudited</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three months ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left">Service revenue - related party</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">113,300</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">120,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">113,300</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">843,011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">861,308</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">830,181</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,555,368</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,673,192</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,416,676</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,559,892</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,296,676</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">285</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">520</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(89,832</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(17,637</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,146</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Change in fair value of convertible note</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(800,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Other expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,886</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,224</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total other income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(897,287</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(29,341</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss before income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,457,179</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,326,017</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Income tax benefit (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2,457,179</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2,326,017</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dividends on preferred stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(712,080</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(692,246</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss attributable to common shareholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(3,169,259</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(3,018,263</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss per share, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(3.00</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2.86</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Weighted average common stock outstanding,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,055,457</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,055,223</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 152; Value: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="noah_003"></A>Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
of Convertible Preferred Stock and Stockholders&rsquo; Deficit</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the Three Months Ended March 31, 2023 and 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unaudited</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Series
                                            A</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Convertible
                                            Preferred Stock</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Series
                                            A-1 Convertible</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Preferred
                                            Stock</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Series
                                            B</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Convertible</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Preferred
                                            Stock</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>Additional
    Paid-In</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>Accumulated
    </B></FONT></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Total Stockholders&rsquo;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 34%">Balance, December 31, 2021</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; text-align: right">205,385</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 3%; text-align: right">3,272,944</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; text-align: right">380,657</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 3%; text-align: right">14,100,533</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; text-align: right">391,303</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 3%; text-align: right">16,321,065</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; text-align: right">1,043,103</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 3%; text-align: right">104</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 3%; text-align: right">868,163</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 3%; text-align: right">(26,634,186</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 3%; text-align: right">(25,765,919</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,983</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,983</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Exercise of stock options</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">888</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,510</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,510</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,326,017</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,326,017</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Balance, March 31, 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">205,385</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,272,944</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">380,657</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,100,533</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">391,303</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,321,065</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,043,991</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">104</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">926,656</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(28,960,203</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(28,033,443</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Balance, December 31, 2022</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">205,385</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">3,272,944</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">380,657</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">14,100,533</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">391,303</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">16,321,065</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,043,991</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">104</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,054,138</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(37,314,552</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(36,260,310</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Issuance of Series B Convertible Preferred Stock</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">23,432</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,124,759</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,124,759</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stock-based compensation</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">38,794</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">38,794</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(2,457,179</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(2,457,179</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Balance, March 31, 2023</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">205,385</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">3,272,944</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">380,657</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">14,100,533</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">414,735</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">17,445,824</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,043,991</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">104</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">1,092,932</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(39,771,731</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(38,678,695</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 153; Value: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="noah_004"></A>Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
of Cash Flows</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unaudited</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from operating activities:</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 60%; text-align: left">Net loss</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 16%; font-weight: bold; text-align: right">(2,457,179</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">(2,326,017</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Adjustments to reconcile net loss</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">to net cash used by operating activities:</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Depreciation and amortization</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">32,149</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,539</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Amortization of debt discount</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,968</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Amortization of right-of-use assets</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">71,243</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">66,679</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued interest on convertible notes</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">89,832</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,669</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stock-based compensation</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">38,794</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,983</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Change in fair value of warrant liability</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(5,621</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(356</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Change in fair value of convertible notes</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">800,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss on disposal of property and equipment</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,923</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Changes in operating assets and liabilities:</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounts receivable</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">85,431</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,200</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Prepaid expenses</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">116,497</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,509</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other assets</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(28</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(167</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Tax credits receivable</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(2,690</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(231</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounts payable and accrued expenses</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">204,610</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(224,992</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating lease liability</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(69,085</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(61,785</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Contract liabilities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(113,300</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net cash used by operating activities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(1,209,347</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,358,478</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from investing activities:</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Purchases of property and equipment</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(14,392</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(29,731</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Proceeds from sale of property and equipment</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,250</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Capitalization of deferred patent costs</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(63,204</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(67,326</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Capitalization of licenses</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(3,858</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Capitalization of patent and trademark costs</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(1,380</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(585</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net cash used by investing activities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(82,834</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(93,392</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from financing activities:</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Payment of deferred offering costs</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(367,080</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Proceeds from exercise of stock options</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,510</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net cash provided by financing activities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(367,080</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,510</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net change in cash and cash equivalents</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(1,659,261</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,450,360</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash and cash equivalents at the beginning of the year</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">3,492,656</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,044,262</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash and cash equivalents at the end of the year</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">1,833,395</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,593,902</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Supplemental disclosure of cash flow information:</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Non-cash transactions:</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Obtaining a right-of-use asset in exchange for lease liability</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,418,502</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Conversion of note to Series B Convertible Preferred Stock</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,124,759</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: center; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The accompanying
notes are an integral part of these condensed financial statements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 154; Value: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="noah_005"></A>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #080D06"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.
Organization and Nature of Operations </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #080D06"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> was founded on January 2, 2014. It is a synthetic
biology company focused on screening and genetically engineering microbes of the skin. The mission is to discover and develop novel therapeutics
to create a new paradigm for treating skin disease. The Company&rsquo;s discovery platform is screened for naturally occurring bacterial
cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic
proteins, peptides and small molecules for precision treatment of dermatology diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company maintains a location in Montreal, Canada for certain research activities. This location and operations completed there remained
consistent throughout 2022 and into 2023. The Company also opened a manufacturing and laboratory space in Groton, Connecticut during
2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Going
Concern Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed financial statements have been prepared on the going concern basis, which assumes that the Company will continue
in operation for the foreseeable future and which contemplates the realization of assets and liquidation of liabilities in the normal
course of business. However, management has identified the following conditions and events that created an uncertainty about the ability
of the Company to continue as a going concern. As of and for the three months ended March 31, 2023, the Company has an accumulated deficit
of $39.8 million, a loss from operations of $1.6 million and used $1.2 million to fund operations. These factors among others raise substantial
doubt about the Company&rsquo;s ability to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
plans to continue to raise funds through equity and debt financing to fund operating and working capital needs, however, the Company
will require a significant amount of additional funds to complete the development of its product and to fund additional losses which
the Company expects to incur over the next few years. The Company is still in their pre-clinical phase and therefore does not yet have
product revenue. There can be no assurance that the Company will be successful in securing additional financing, if needed, to meet its
operating needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
conditions and events create an uncertainty about the ability of the Company to continue as a going concern for twelve months from the
date that the financial statements are available to be issued. The financial statements do not include any adjustments that might be
necessary should the Company be unable to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #080D06"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Summary of Significant Accounting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #4D544F"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
of Accounting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of the Company are prepared in accordance with United States generally accepted accounting principles (&ldquo;U.S.
GAAP&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #080D06"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Unaudited
Interim Financial Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited interim financial statements and related notes have been prepared in accordance with U.S. GAAP for interim financial information,
within the rules and regulations of the United States Securities and Exchange Commission (the &ldquo;SEC&rdquo;). Certain information
and disclosures normally included in the annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted
pursuant to such rules and regulations. The unaudited interim financial statements have been prepared on a basis consistent with the
audited financial statements and in the opinion of management, reflect all adjustments, consisting of only normal recurring adjustments,
necessary for the fair presentation of the results for the interim periods presented and of the financial condition as of the date of
the interim balance sheet. The financial data and the other information disclosed in these notes to the interim financial statements
related to the three-month periods are unaudited. Unaudited interim results are not necessarily indicative of the results for the full
fiscal year. These unaudited interim financial statements should be read in conjunction with the financial statements of the Company
for the year ended December 31, 2022 and notes thereto that are included in the Company&rsquo;s Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 155; Value: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
of Estimates </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the financial statement in conformity with accounting principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the balance sheet.
While management believes the estimates and assumptions used in the preparation of the financial statement are appropriate, actual results
could differ from those estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash
and Cash Equivalents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of the balance sheets and statements of cash flows, the Company considers all cash on hand, demand deposits and all highly liquid
investments with original maturities of three months or less to be cash equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050A03"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Property
and Equipment </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050A03"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #050A03">Property
and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives, which range
from 3 to 10 years. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenditures for maintenance
and repairs, which do not extend the economic useful life of the related assets, are charged to operations as incurred. Gains or losses
on disposal of property and equipment are reflected in the statements of operations in the period of disposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accounts
Receivable</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company carries its accounts receivable at cost less an allowance for doubtful accounts. On a periodic basis, the Company evaluates its
accounts receivable and establishes an allowance for doubtful accounts based on a history of past write-offs, collections and current
conditions. There was no allowance for doubtful accounts at March 31, 2023 and December 31, 2022. Accounts receivable are written off
when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Deferred
Offering Costs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company capitalizes deferred offering costs, which primarily consist of direct, incremental legal, professional, accounting, and other
third-party fees relating to the Company&rsquo;s initial public offering. The deferred offering costs will be offset against IPO proceeds
upon the consummation of an offering. Should the planned IPO prove to be unsuccessful, these deferred costs, as well as additional expenses
to be incurred, will be charged to operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Right
of Use Assets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued ASU No. 2016-02, Leases (&ldquo;Topic 842&rdquo;).
ASU 2016-02 requires lessees to present right-of-use (&ldquo;ROU&rdquo;) assets and lease liabilities on the balance sheet for all leases
with terms longer than 12 months. See Note 2 &ndash; Recently Adopted Accounting Pronouncements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
calculating the effect of ASU 2016-02, the Company elected the transition method thereby not restating comparable periods. The Company
elected to account for non-lease components as part of the lease component to which they relate. Lease accounting involves significant
judgments, including making estimates related to the lease term, lease payments, and discount rate. In accordance with the guidance,
the Company recognized ROU assets and lease liabilities for all leases with a term greater than 12 months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has operating leases for buildings. Currently, the Company has 3 operating leases with a ROU asset and lease liability totaling
$1,418,502 as of January 1, 2022. The basis, terms and conditions of the leases are determined by the individual agreements. The Company&rsquo;s
option to extend certain leases ranges from 36 &ndash; 52 months. All options to extend have been included in the calculation of the
ROU asset and lease liability. The leases do not contain residual value guarantees, restrictions, or covenants that could incur additional
financial obligations to the Company. There are no subleases, sale-leaseback, or related party transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2023, the Company had operating right-of-use assets with a net value of $1,045,454 and current and long-term operating lease
liabilities of $292,036 and $767,159, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 156; Value: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intangible
Assets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of trademarks and patents. All costs directly related to the filing and prosecution of patent and trademark applications
are capitalized. Patents are amortized over their respective remaining useful lives upon formal approval. Trademarks have an indefinite
life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for other indefinite life intangible assets in accordance ASC Topic 350, <I>Goodwill and Other Intangible Assets</I>
(ASC 350). ASC 350 requires that intangible assets that have indefinite lives are required to be tested at least annually for impairment
or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Intangible assets that have
finite lives will continue to be amortized over their useful lives. No impairment losses relating to intangible assets were recorded
during the three months ended March 31, 2023 or 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Deferred
Patent Costs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
patent costs represent legal and filing expenses incurred related to the submission of patent applications for patents pending approval.
These deferred costs will begin to be amortized over their estimated useful lives upon the formal approval of the patent. If the patent
is not approved, the costs associated with the patent will be expensed in the year the patent was rejected. No impairment losses relating
to deferred patent costs were recorded in the three months ended March 31, 2023 or 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Impairment
of Long-Lived Assets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC Topic 360-10, <I>Accounting for the Impairment or Disposal of Long-Lived Assets </I>(ASC 360-10), the Company&rsquo;s
policy is to review its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount
of an asset may not be recoverable. In connection with this review, the Company also reevaluates the periods of depreciation for these
assets. The Company recognizes an impairment loss when the sum of the undiscounted expected future cash flows from the use and eventual
disposition of the asset is less than its carrying amount. If an asset is considered to be impaired, the impairment to be recognized
is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset, which is determined using the
present value of the net future operating cash flows generated by the asset.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Convertible
Debt and Warrant Accounting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Warrants</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&rsquo;s
specific terms and applicable authoritative guidance in ASC 480, <I>Distinguishing Liabilities from Equity </I>(&ldquo;ASC 480&rdquo;)
and ASC 815, <I>Derivatives and Hedging</I> (&ldquo;ASC 815&rdquo;). The assessment considers whether the warrants are freestanding financial
instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements
for equity classification under ASC 815, including whether the warrants are indexed to the Company&rsquo;s own common stock, among other
conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant
issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
issued warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional
paid-in capital at the time of issuance. For issued warrants that do not meet all the criteria for equity classification, the warrants
are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the
estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations under Other Income/loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Convertible
debt</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
the Company issues debt with a conversion feature, it first assesses whether the debt should be accounted for in accordance with ASC
480 &ndash; Distinguishing Liabilities from Equity. If the debt does not meet the criteria of an ASC 480 liability, the note&rsquo;s
conversion features require bifurcation in accordance with ASC 815 &ndash; Derivatives and Hedging. If the Company determines the embedded
conversion feature requires bifurcation in accordance with ASC 815, the Company also considers if it can elect the fair value option.
If the fair value option is elected, the Company records the note at its initial fair value with any subsequent changes in fair value
recorded in earnings. As noted in Note 7, the Company has elected the fair value option for the 2022 Convertible Notes and will record
the notes at their initial fair values with any subsequent changes in fair value recorded in earnings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 157; Value: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Convertible
Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Convertible Preferred stockholders have liquidation rights in the event of a deemed liquidation event that, in certain situations,
are not solely within the control of the Company and would require the redemption of the then-outstanding Convertible Preferred Stock,
the Company classifies the Convertible Preferred Stock in mezzanine equity on the balance sheet. Due to the fact that the occurrence
of a deemed liquidation event is not currently probable, the carrying value of the Convertible Preferred Stock is not being accreted
to its redemption value. Subsequent adjustments to the carrying value of the Convertible Preferred Stock would be made only when a deemed
liquidation event becomes probable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #080D06"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revenue
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the <I>five</I> steps to recognize revenue from contracts with customers under ASC <I>606,</I> Revenue from Contracts
with Customers (&ldquo;ASC <I>606&rdquo;</I>), which are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Step
    <I>1:</I> Identify the contract(s) with a customer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Step
    <I>2:</I> Identify the performance obligations in the contract</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
    <I>3:</I> Determine the transaction price</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step
    <I>4:</I> Allocate the transaction price to the performance obligations in the contract</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Step
    <I>5:</I> Recognize revenue when (or as) a performance obligation is satisfied</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates service revenue through a joint development agreement with a research partner. The Company recognizes revenue related
to the research and development aspects of the agreement over time using the input method as work is performed on the contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also generates grant revenue, which represents monies received on contracts with various federal agencies and nonprofit research
institutions for general research conducted by the Company to further their product development and are therefore considered contributions
to the Company. The contracts are generally for periods of one year or more and can be cancelled by either party. The Company concluded
that the grant arrangements do not meet the criteria to be treated as a collaborative arrangement under FASB ASC Topic 808 as the Company
is the only active participant in the arrangement. The grant arrangements also do not meet the criteria for revenue recognition under
Topic 606, as the U.S. Government would not meet the definition of a customer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
earned under these grant contracts are recorded as a negative research and development expense when eligible expenses are incurred and
the right to payment is realizable or realized and earn The Company believes this policy is consistent with Topic 606, to ensure that
recognition reflects the transfer of promised goods or services to customers in an amount that reflects the consideration that the Company
expects to be entitled to in exchange for those goods or services, even though there is no exchange as defined in Topic 606. Additionally,
the Company has determined that the recognition of amounts received as costs are incurred and amounts become realizable is analogous
to the concept of transfer of control of a service over time under Topic 606.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receipts
of grant awards in advance, which are payable back to the funding agency if not used in accordance with conditions in the grants related
to allowable costs or receipt of funding from research partners related to service revenue arrangements before work is performed on the
contract, are classified as contract liabilities in the accompanying balance sheets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 158; Value: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for research and development costs in accordance with Accounting Standards Codification (ASC) subtopic 730-10, <I>Research
and Development</I>. Accordingly, internal research and development costs are expensed as incurred. Research and development costs consist
of costs related to labor, materials and supplies. Research and development costs incurred were $<FONT STYLE="font-weight: normal; text-transform: none">830,181
</FONT>and $<FONT STYLE="font-weight: normal; text-transform: none">1,555,368</FONT> during the three month period ended March 31, 2023
and <FONT STYLE="font-weight: normal; text-transform: none">2022</FONT>, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2023 and December 31, <FONT STYLE="font-weight: normal; text-transform: none">2022</FONT>, the Company has a state tax credit
receivable of $32,459 for pending refunds related to the selling of research and development tax credits back to the State of Connecticut.
At March 31, 2023 and December 31, <FONT STYLE="font-weight: normal; text-transform: none">2022</FONT>, the Company has $<FONT STYLE="font-weight: normal; text-transform: none">29,009
</FONT>and $<FONT STYLE="font-weight: normal; text-transform: none">28,925</FONT>, respectively for pending refunds related to Canadian
Scientific Research and Experimental Development (SRED) credits. At March 31, 2023 and December 31, <FONT STYLE="font-weight: normal; text-transform: none">2022</FONT>,
the Company has also recorded $<FONT STYLE="font-weight: normal; text-transform: none">10,888</FONT> and $<FONT STYLE="font-weight: normal; text-transform: none">8,282</FONT>,
respectively, related to refunds of Canadian Goods and Services Tax (GST) and Quebec Sales Tax (QST). Receipts of refunds are recorded
in other income on the statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock-Based
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based compensation in accordance with ASC 718, <I>Compensation-Stock Compensation </I>(ASC 718). ASC 718 requires
employee stock options and rights to purchase shares under stock participation plans to be accounted for at fair value. ASC 718 requires
that compensation costs related to share-based payment transactions be recognized as operating expenses in the financial statements.
Under this method, compensation costs for all awards granted or modified are measured at estimated fair value at date of grant and are
included as compensation expense over the vesting period during which an employee provides service in exchange for the award. For awards
with a performance condition that affects vesting, the Company recognizes compensation expense when it is determined probable that the
performance condition will be achieved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses a Black-Scholes option pricing model to determine fair value of its stock options. The Black-Scholes model includes various
assumptions, including the value of the underlying common stock, the expected life of stock options, the expected volatility and the
expected risk-free interest rate. These assumptions reflect the Company&rsquo;s best estimates, but they involve inherent uncertainties
based on market conditions generally outside of the control of the Company. As a result, if other assumptions had been used, stock-based
compensation cost could have been materially impacted. Furthermore, if the Company uses different assumptions for future grants, stock-based
compensation cost could be materially impacted in future periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for equity instruments issued to non-employees in accordance with the provisions of ASC 718 as updated by Accounting
Standards Update (ASU) No. 2018-07, <I>Improvements to Nonemployee Share-Based Payment Accounting</I>, which expands the scope of ASC
718 to include share based payment transactions to non-employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following assumptions are used in valuing options issued using the Black-Scholes option pricing model:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Expected
Volatility</I>. The expected volatility of the Company&rsquo;s shares is estimated based on the Company&rsquo;s external valuation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Expected
Term</I>. The expected term of options is estimated using the simplified method which is based on the vesting period and contractual
term for each grant, or for each vesting-tranche for awards with graded vesting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Underlying
Common Stock Value. </I>The underlying common stock value of the Company&rsquo;s shares is estimated by a third party valuation expert.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Risk-free
Interest Rate</I>. The Company bases the risk-free interest rate on the implied yield available on a U.S. Treasury note with terms equal
to the expected term of the underlying grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividend
Yield</I>. The Black-Scholes valuation model calls for a single expected dividend yield as an input. The Company has not paid dividends
on Common stock in the past nor does it expect to pay dividends on Common stock in the near future. As such, the Company uses a dividend
yield percentage of zero</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 159; Value: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; color: #070C05"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #070C05"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Income
Taxes </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses the liability method of accounting for income taxes, as set forth in ASC 740, <I>Accounting for Income Taxes</I>. Under
this method, deferred tax assets and liabilities are recognized for the expected future tax consequence of temporary differences between
the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently
enacted tax rates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has evaluated the effect of ASC guidance related to uncertain income tax positions and concluded that the Company has no significant
financial statement exposure to uncertain income tax positions at March 31, 2023 and December 31, <FONT STYLE="font-weight: normal; text-transform: none">2022</FONT>.
The Company&rsquo;s income tax returns have not been examined by tax authorities through December 31, <FONT STYLE="font-weight: normal; text-transform: none">2022</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #040A02"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
Value Measurements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company carries certain liabilities at fair value on a recurring basis. A fair value hierarchy that consists of three levels is used
to prioritize the inputs to fair value valuation techniques:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 &ndash; Inputs are based upon observable or quoted prices for identical instruments traded in active markets.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 &ndash; Inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments
    in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the
    market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 &ndash; Inputs are generally unobservable and typically reflect management&rsquo;s estimates of assumptions that market participants
    would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option
    pricing models, discounted cash flow models, and similar techniques. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of
unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Accounting Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;) 2016-02,
Leases (Topic 842). This ASU requires a lessee to recognize a right-of-use asset and a lease liability under most operating leases in
its balance sheet. The ASU is effective for annual and interim periods beginning after December 15, 2021. The Company adopted ASU 2016-02
on January 1, 2022. See Note 13 &ndash; Operating Leases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, the FASB issued ASU No. 2019-12, <I>Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</I>. This standard
simplifies the accounting for income taxes through the removal of various exceptions previously provided, as well as providing additional
reporting requirements for income taxes. The ASU is effective for the Company on January 1, 2022. The Company has adopted this standard
effective January 1, 2022, which did not have a material impact to the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU No. 2020-06, <I>Debt &ndash; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging &ndash; Contracts in Entity&rsquo;s Own Equity (Subtopic 815-40)</I>, which simplifies the accounting for certain financial
instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&rsquo;s own
equity. This standard will be effective for the Company on January 1, 2024, with early adoption permitted (but no earlier than fiscal
years beginning after December 15, 2020). The Company has adopted this standard effective January 1, 2021, which did not have a material
impact to the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
does not believe that any other recently issued, but not yet effective, accounting standards could have a material effect on the accompanying
financial statements. As new accounting pronouncements are issued, the Company will adopt those that are applicable under the circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 160; Value: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
Instruments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s financial instruments are primarily comprised of accounts receivable, accounts payable, accrued liabilities, and long-term
debt. For accounts receivable, accounts payable and accrued liabilities, the carrying amount approximates fair value due to the short
term maturities of such instruments. The estimated fair value of the Company&rsquo;s long-term debt approximates carrying value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
Employee Retention Credit </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CARES Act provides an employee retention credit (&ldquo;CARES Employee Retention credit&rdquo;), which is a refundable tax credit against
certain employment taxes of up to $5,000 per employee for eligible employers. The tax credit is equal to 50% of qualified wages paid
to employees during a quarter, capped at $10,000 of qualified wages per employee through December 31, 2020. Additional relief provisions
were passed by the United States government, which extend and slightly expand the qualified wage caps on these credits through September
30, 2021. Based on these additional provisions, the tax credit is now equal to 70% of qualified wages paid to employees during a quarter,
and the limit on qualified wages per employee has been increased to $10,000 of qualified wages per quarter. In April 2022, the Company
determined it qualified for the tax credit under the CARES Act and recorded a receivable for $229,813 and recognized the amounts as other
income on the statement of operations. The Company received full payment for the amount in September 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.
Property and Equipment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consisted of the following at March 31, 2023 and December 31, <FONT STYLE="font-weight: normal; text-transform: none">2022</FONT>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; text-transform: none; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-transform: none; text-align: center; border-bottom: Black 1.5pt solid">March 31,
    2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-transform: none">&nbsp;</TD><TD STYLE="font-weight: bold; text-transform: none; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-transform: none; text-align: center; border-bottom: Black 1.5pt solid">December
    31, 2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-transform: none">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: justify">Lab equipment</TD><TD STYLE="width: 2%; font-weight: bold; text-transform: none">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-transform: none; text-align: left">$</TD><TD STYLE="width: 20%; font-weight: bold; text-transform: none; text-align: right">1,049,152</TD><TD STYLE="width: 1%; font-weight: bold; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-weight: normal; text-transform: none">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-transform: none; text-align: left">$</TD><TD STYLE="width: 20%; font-weight: normal; text-transform: none; text-align: right">1,034,579</TD><TD STYLE="width: 1%; font-weight: normal; text-transform: none; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Computer equipment</TD><TD STYLE="font-weight: bold; text-transform: none">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-transform: none; text-align: right">30,825</TD><TD STYLE="font-weight: bold; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-transform: none">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-transform: none; text-align: right">30,825</TD><TD STYLE="font-weight: normal; text-transform: none; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Furniture and fixtures</TD><TD STYLE="font-weight: bold; text-transform: none">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-transform: none; text-align: right">24,316</TD><TD STYLE="font-weight: bold; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-transform: none">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-transform: none; text-align: right">24,316</TD><TD STYLE="font-weight: normal; text-transform: none; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Leasehold improvements</TD><TD STYLE="font-weight: bold; text-transform: none">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-transform: none; text-align: right">28,855</TD><TD STYLE="font-weight: bold; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-transform: none">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-transform: none; text-align: right">28,855</TD><TD STYLE="font-weight: normal; text-transform: none; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Building equipment</TD><TD STYLE="font-weight: bold; text-transform: none; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-transform: none; text-align: right">14,932</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-transform: none; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-transform: none; text-align: right">14,932</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; text-transform: none; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,148,080</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,133,507</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Less: accumulated depreciation</TD><TD STYLE="font-weight: bold; text-transform: none; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-transform: none; text-align: right">(317,282</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-transform: none; text-align: left">)</TD><TD STYLE="font-weight: normal; text-transform: none; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-transform: none; text-align: right">(286,549</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; text-transform: none; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Net property and equipment</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">830,798</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">846,958</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense was $</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">30,552
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">29,809
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the three months ended March
31, 2023 and </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">2022</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
Intangible Assets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consisted of the following at:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">March
31, 2023</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Estimated</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Useful
                                            Life</B></FONT></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Gross Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Amortization</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 38%; text-align: justify">Trademarks</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">Indefinite</TD><TD STYLE="width: 2%; font-weight: bold; text-transform: none">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-transform: none; text-align: left">$</TD><TD STYLE="width: 12%; font-weight: bold; text-transform: none; text-align: right">54,776</TD><TD STYLE="width: 1%; font-weight: bold; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 12%; font-weight: bold; text-align: right">-</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-weight: bold; text-transform: none">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-transform: none; text-align: left">$</TD><TD STYLE="width: 12%; font-weight: bold; text-transform: none; text-align: right">54,776</TD><TD STYLE="width: 1%; font-weight: bold; text-transform: none; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Patents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">17 years</TD><TD STYLE="font-weight: bold; text-transform: none">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-transform: none; text-align: right">108,801</TD><TD STYLE="font-weight: bold; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-transform: none">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-transform: none; text-align: right">9,737</TD><TD STYLE="font-weight: bold; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">99,064</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">License agreement</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">17 years</TD><TD STYLE="font-weight: bold; text-transform: none; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-transform: none; text-align: right">69,368</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-transform: none; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-transform: none; text-align: right">69,368</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-transform: none; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Intangible Assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">232,945</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">9,737</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">223,208</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">December
31, 2022</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Estimated</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Useful
                                            Life</B></FONT></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Gross Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated Amortization</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Net Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 38%; text-align: justify">Trademarks</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">Indefinite</TD><TD STYLE="width: 2%; font-weight: normal; text-transform: none">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-transform: none; text-align: left">$</TD><TD STYLE="width: 12%; font-weight: normal; text-transform: none; text-align: right">53,999</TD><TD STYLE="width: 1%; font-weight: normal; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-weight: normal; text-transform: none">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-transform: none; text-align: left">$</TD><TD STYLE="width: 12%; font-weight: normal; text-transform: none; text-align: right">53,999</TD><TD STYLE="width: 1%; font-weight: normal; text-transform: none; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Patents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">17 years</TD><TD STYLE="font-weight: normal; text-transform: none">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-transform: none; text-align: right">108,198</TD><TD STYLE="font-weight: normal; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-transform: none">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-transform: none; text-align: right">8,140</TD><TD STYLE="font-weight: normal; text-transform: none; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,058</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">License agreement</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">17 years</TD><TD STYLE="font-weight: normal; text-transform: none; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-transform: none; text-align: right">65,510</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-transform: none; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: normal; text-transform: none; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; text-transform: none; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">65,510</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Intangible Assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">227,707</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,140</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">219,567</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2023 and <FONT STYLE="font-weight: normal; text-transform: none">2022</FONT>, amortization expense related
to intangible assets was $<FONT STYLE="font-weight: normal; text-transform: none">1,597</FONT> and $<FONT STYLE="font-weight: normal; text-transform: none">730</FONT>,
respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 161; Value: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; color: #050B04">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.
Accrued Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses consisted of the following at</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; text-transform: none; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-transform: none; text-align: center; border-bottom: Black 1.5pt solid">March 31,
    2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-transform: none">&nbsp;</TD><TD STYLE="font-weight: bold; text-transform: none; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-transform: none; text-align: center; border-bottom: Black 1.5pt solid">December
    31, 2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-transform: none">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: justify">Employee payroll and bonuses</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 20%; font-weight: bold; text-align: right">425,528</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">371,010</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Vacation</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">43,353</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,082</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Research and development <BR>projects</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">292,529</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">316,389</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Interest</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">188,865</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">223,792</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Professional fees</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">13,082</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,502</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Other</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,104</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">31,186</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">965,461</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">993,961</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accrues expenses related to development activities performed by third parties based on an evaluation of services received and
efforts expended pursuant to the terms of the contractual arrangements. Payments under some of these contracts depend on research and
non-clinical trial milestones. There may be instances in which payments made to the Company&rsquo;s vendors will exceed the level of
services provided and result in a prepayment of expense. In accruing service fees, the Company estimates the period over which services
will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level
of effort varies from the estimate, the Company will adjust the accrual or prepaid expense accordingly. The Company has not experienced
any material differences between accrued costs and actual costs incurred since its inception.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7<FONT STYLE="color: #050B04">.
Convertible Debt</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2022, the Company entered into a Convertible Note Purchase Agreement (the Agreement) to issue up to $4,500,000 convertible
promissory notes. On the same day, the Company entered into convertible promissory notes (2022 Convertible Notes) with three investors
totaling $4,350,000. The 2022 Convertible Notes mature on January 13, 2023 or the occurrence of an Event of Default (as defined) and
bear interest at a rate of 8% per annum which shall accrue but is not due and payable until conversion or full repayment of outstanding
principal. The principal and interest outstanding under the 2022 Convertible Notes is automatically converted a) upon the closing of
a Qualified Financing resulting in gross proceeds to the Company of at least $20 million into securities issued in connection with the
Qualified Financing, at a discount of 30% per share; b) upon the closing of a Change of Control event into shares of capital stock of
the Company or Series B preferred stock; and c) upon the closing of a Public Company Event, into shares of capital stock being issued
to investors equal to two-times (2x) the amount of the outstanding principal and accrued interest then outstanding divided by the public
offering price per share. The principal and interest outstanding under the 2022 Convertible Notes is convertible, at the option of the
holders, at the maturity date into a new class of Company&rsquo;s Preferred Stock (Series C Preferred) equal to the quotient of the outstanding
principal amount plus interest divided by the Capped Price, which is defined as the price per share equal to the Valuation Cap of $30
million divided by the Company Capitalization, as defined in the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2023, the 2022 Convertible Notes were amended to extend the maturity date to March 31, 2023 and to change the conversion price
upon a Qualified Financing or Change in Control event to $30 million divided by the number of shares of the Company&rsquo;s common stock
issued and outstanding, on a fully diluted basis, immediately prior to the close of the Qualified Financing or Change in Control event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for the 2022 Convertible Notes under ASC 815. Under 815-15-25, the election can be at the inception of a financial instrument
to account for the instrument under the fair value option under ASC 825. The Company has made such election for the 2022 Convertible
Notes. Using the fair value option, the convertible promissory note is to be recorded at its initial fair value on the date of issuance,
and each balance sheet date thereafter. The Company evaluates the change based on the conversion price at the current market value. When
recognized, changes in the estimated fair value of the notes are recognized as a non-cash gain or loss in Other Income (Expense) on the
statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 162; Value: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
January 5, 2021, the Company entered into a Note Purchase Agreement to issue up to $2,000,000 of convertible promissory notes. On the
same date, the Company entered into a convertible promissory note (2021 Convertible Note) with one investor for $1,000,000. The 2021
Convertible Note bears interest at a rate of 6% per annum and is due and payable in full on January 5, 2023. The 2021 Convertible Note
automatically converts upon a qualified equity financing, as defined in the note agreement to the number of shares equal to all principal
and accrued interest divided by the conversion price of $48.00, which is subject to adjustment as defined in the note agreement. The
2021 Convertible Note is also optionally convertible as defined in the note agreement for certain non-qualified financing, a change in
control, or upon the maturity date of the 2021 Convertible Note. The Company incurred issuance costs of $<FONT STYLE="font-weight: normal; text-transform: none">15,613
related to the 2021 Convertible Note, which has been recorded as a debt discount and will be amortized over the term of the 2021 Convertible
Note.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, the Company elected to convert the 2021 Convertible Note, including interest accrued but not yet paid of $124,759 at a
conversion price of $48.00 into 23,432 shares of its Series B Preferred Stock in accordance with the terms outlined in the Note Purchase
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated the terms and conditions of the Note Purchase Agreement related to the 2021 Convertible Note in order to assess the
accounting considerations under ASC 480 &ndash; Distinguishing Liabilities from Equity, and ASC 815 &ndash; Derivatives and Hedging.
The Company determined the Convertible Note does not meet any of the criteria to be accounted pursuant to an ASC 480 liability. The Company
also assessed the embedded features pursuant to the guidance in ASC 815 and determined the embedded features do not meet any of the criteria
for bifurcation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
notes payable consisted of the following at</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; text-transform: none; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-transform: none; text-align: center; border-bottom: Black 1.5pt solid">March 31,
    2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-transform: none">&nbsp;</TD><TD STYLE="font-weight: bold; text-transform: none; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-transform: none; text-align: center; border-bottom: Black 1.5pt solid">December
    31, 2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-transform: none">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: justify">2021 Convertible Note</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 20%; font-weight: bold; text-align: right">-</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">1,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">2022 Convertible Notes</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">6,400,000</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,600,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">6,400,000</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,600,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">There
was $0 and $1,968 amortized related to the debt issuance costs during the three months ended March 31, 2023 and 2022, respectively. Interest
accrued on the convertible notes was $188,865 and $223,792 at March 31, 2023 and December 31, 2022, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.
Stockholders&rsquo; Equity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2023 and December 31, 2022, per the Company&rsquo;s amended and restated Certificate of Incorporation, the Company was authorized
to issue 100,000,000 shares of $0.0001 par value common stock. Refer to Note 17, Subsequent Events for more information
related to the Forward-Stock Split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had 1,043,991 shares of common stock issued and outstanding as of March 31, 2023 and December 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&rsquo;s stockholders and the
holders of the Common Stock are entitled to elect one director of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently has 8,671,045 shares of common stock reserved for future issuance for the potential conversion of the outstanding
Preferred Stock and the exercise of stock options and warrants outstanding at March 31, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 163; Value: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2023 and December 31, 2022, per the Company&rsquo;s amended and restated Certificate of Incorporation, the Company has authorized
1,437,150 shares of $0.0001 par value preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, the Company issued 23,432 shares of its Series B Preferred Stock related to conversion of the 2021 Convertible Note at
a conversion price of $48.00 per share (see Note 7).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A, Series A-1, and Series B Preferred Stock have the following rights, preferences and privileges:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Conversion
</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preferred stock is convertible, at the option of the holder, into common shares based upon a predefined formula. A holder of preferred
stock may convert such shares into common shares at any time. For purpose of conversion, the initial conversion price is $2.2887
per share (original issue price) for Series A Preferred Stock, $5.2817 per share (original issue price) for Series A-1 Preferred
Stock, and $6.1190 per share (original issue price) for Series B Preferred Stock, and is subject to adjustment as described in
the Certificate of Incorporation. Preferred stock will automatically convert into common shares upon the earlier of (a) an initial public
offering with gross proceeds in excess of $100,000,000 or (b) the date and time, or the occurrence of an event, specified by vote or
written consent of the required preferred stock shareholders, all outstanding Series A, Series A-1, and Series B Preferred Stock shall
automatically convert into common shares, at the then effective conversion rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of the Series A, Series A-1, and Series B Preferred Stock are entitled to vote on any matter presented to the stockholders of
the Corporation for their action or consideration at any meeting of stockholders of the Corporation (or by written consent of stockholders
in lieu of meeting), each holder of outstanding shares of preferred stock shall be entitled to cast the number of votes equal to the
number of whole shares of Common Stock into which the shares of preferred stock held by such holder are convertible as of the record
date for determining stockholders entitled to vote on such matter. The holders of the Series A and Series A-1 Preferred Stock are each
entitled to elect one director of the Corporation. The holders of the Series B Stock are entitled to elect two members of the Board.
Each class of preferred stock can remove from office such directors and to fill any vacancy caused by the resignation, death or removal
of such directors under certain circumstances as described in the Certificate of Incorporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividends</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series A Preferred Stock are entitled to receive dividends at a rate of 8% per annum of the Series A original issue price
of $2.2887 per share on each outstanding share of Series A Preferred Stock (subject to appropriate adjustment in the event of
any stock dividend, stock split, combination or other similar recapitalization with respect to the Series A Preferred Stock). Dividends
accumulate from the original date of issuance of the Series A Preferred Stock, are cumulative and are payable upon declaration of the
Board of Directors or liquidation of the Company. At March 31, 2023, cumulative dividends on Series A Preferred Stock were $1,608,325.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series A-1 Stock are entitled to receive dividends at a rate of 8% per annum of the Series A-1 original issue price of $5.2817
per share on each outstanding share of Series A-1 (subject to appropriate adjustment in the event of any stock dividend, stock split,
combination or other similar recapitalization with respect to the Series A-1 Preferred Stock). Dividends are cumulative and are payable
upon declaration of the Board of Directors or liquidation of the Company. At March 31, 2023, cumulative dividends on Series A-1 Preferred
Stock were $4,617,646.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series B Stock are entitled to receive dividends at a rate of 8% per annum of the Series B original issue price of $6.1190
per share on each outstanding share of Series B (subject to appropriate adjustment in the event of any stock dividend, stock split,
combination or other similar recapitalization with respect to the Series B Preferred Stock). Dividends are cumulative and are payable
upon declaration of the Board of Directors or liquidation of the Company. At March 31, 2023, cumulative dividends on Series B Preferred
Stock were $3,608,757.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 164; Value: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Liquidation
</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of any liquidation, dissolution or winding up of the Company, the holders of the preferred stock are entitled to receive, prior
to and in preference to the holders of the common shares, an amount equal to the Series A, Series A-1, or Series B Preferred Stock original
issue price, plus declared and/or accrued but unpaid dividends. In the event of any such liquidation event, after the payment of all
preferential amounts required to be paid to the holders of shares of preferred stock, the remaining assets of the Corporation available
for distribution to its stockholders shall be distributed among the holders of the shares of preferred stock and Common Stock, pro rata
based on the number of shares held by each such holder, treating for this purpose all such securities as if they had been converted into
Common Stock pursuant to the terms of the Certificate of Incorporation immediately prior to such liquidation event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #050B04">The
Company issued warrants to purchase 47,889 shares of common stock in 2018 in conjunction with convertible debt financing that
have a redemption provision providing the holder the right to have the Company redeem all or any portion of the warrant (or shares it
has converted into) at a purchase price equal to the fair market value of the shares as determined by the board of directors or an independent
appraiser. As a result of this redemption provision, the warrants have been classified as a liability in the financial statements based
on ASC 480 &ndash; Distinguishing Liabilities from Equity. These warrants have an exercise price of $0.48 per share a term of
10 years. The warrants are marked to market each reporting period. The fair value is $64,662 and $70,283 at March 31, 2023 and December
31, 2022, respectively. At March 31, 2023, the Company estimated the fair value of the warrants </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">using
the Black-Scholes option pricing model with the following assumptions: Underlying common stock value of $78.38; Expected term
of 5.04 years; Expected Volatility of 95.0%; Risk Free Interest Rate of 3.01%; and Dividend Yield of 0%. <FONT STYLE="color: #050B04">At
December 31, 2022, the Company estimated the fair value of the warrants </FONT>using the Black-Scholes option pricing model with the
following assumptions: Underlying common stock value of $1.70; Expected term of 5 years; Expected Volatility of 86.0%; Risk Free
Interest Rate of 3.01%; and Dividend Yield of 0%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also issued warrants in 2016 and 2019 which did not meet the criteria under ASC 480 to be classified as a liability, and instead
meet equity classification criteria.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about warrants outstanding at March 31, 2023:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="8" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrants Outstanding</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="8" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrants Exercisable</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year
                                            Granted</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
                                            Price</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Warrants at 3/31/2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Contractual Life</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
                                            of Warrants at 3/31/2023</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Contractual Life</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 14%; text-align: center">2016</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.01</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">11,467</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">3.5 years</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.01</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">11,467</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">3.5 years</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.01</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.48</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,889</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5.0 years</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.48</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,889</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5.0 years</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.48</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">5.28</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">215,854</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">2.9 years</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5.28</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">215,854</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">2.9 years</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5.28</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">275,210</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">4.23</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">275,210</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">4.23</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.
Stock Options</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2023, the Company&rsquo;s Board of Directors and stockholders approved the 2023 Stock Incentive Plan (&ldquo;2023 Plan&rdquo;);
however, no grants shall be made until the date which the proposed forward stock split and increase in the authorized shares of common
stock becomes effective which is expected to occur upon the effectiveness of our registration statement of which this prospectus forms
a part. The 2023 Plan allows the Committee to grant up to 2,000,000 shares of Common Stock in the form of incentive and non-statutory
stock options, restricted stock awards, restricted stock units, and other stock-based awards to employees, directors, and non-employees.
As of March 31, 2023, there were no awards issued under the 2023 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 165; Value: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2016, the Company established the Azitra, Inc. 2016 Stock Incentive Plan (the Plan) which provides for the granting of stock options
and restricted shares to the Company&rsquo;s employees, officers, directors, advisors and consultants. There were 1,490,595 shares
available for granting under the Plan at December 31, 2022. Options vest over varying time frames.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2023 and 2022, the Company did not grant any stock options to acquire shares of common stock. During
the three months ended March 31, 2023 and 2022, the Company recognized stock compensation expense of $38,974 and $56,983, respectively,
relating to the issuance of service-based stock options. At March 31, 2023, there was $388,990 of unamortized compensation expense that
will be amortized over the remaining vesting period. At March 31, 2023 and 2022, there were 13,120 performance-based options outstanding
with a fair value of $109,551. During the three months ended March 31, 2023 and 2022, the Company did not recognize any compensation
expense for performance-based options. The Company determined the options qualified as plain vanilla under the provisions of SAB 107
and the simplified method was used to estimate the expected option life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.
Stock Options (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about options outstanding and exercisable at March 31, 2023:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="8" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options Outstanding</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="8" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options Exercisable</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
                                            Price</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Options at 3/31/2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Contractual Life</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
                                            of Options at 3/31/2023</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Contractual Life</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">0.48</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">246,136</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 13%; text-align: center">2.8 years</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">0.48</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">246,136</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">2.8 years</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.48</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.93</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">231,680</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2.8 years</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.93</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">231,680</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2.8 years</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.93</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">1.70</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">812,502</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">8.0 years</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">1.70</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">411,707</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">7.8 years</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">1.70</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,290,318</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">889,523</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no stock options granted, exercised, or forfeited during the three months ended March 31, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are 157,989 shares available for future grant under the Plan at March 31, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.
Fair Value Measurements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarize the fair values and levels within the fair value hierarchy in which the fair value measurements fall for assets
and liabilities measured on a recurring basis as of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>March
                                            31, 2023</I></B></FONT></P>
                                                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
    1</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
    2</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
    3</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Liabilities:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 36%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    stock warrants</FONT></TD><TD STYLE="width: 2%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">64,662</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">64,662</FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022
    Convertible Notes</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,400,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,400,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,464,662</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,464,662</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>December
                                            31, 2022</I></B></FONT></P>
                                                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
    1</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
    2</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
    3</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Liabilities:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 36%; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common stock
    warrants</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">70,283</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">70,283</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022
    Convertible Notes</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,600,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,600,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,670,283</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,670,283</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 166; Value: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the changes in Level 3 instruments measured on a recurring basis for the period ended March 31, 2023:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%">Balance at December 31, 2022</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">5,670,283</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Change in fair value of warrants</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(5,621</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Change in fair value of 2022 Convertible Notes</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">800,000</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Balance at March 31, 2023</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">6,464,662</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fluctuation
in the fair value of the Company&rsquo;s Common stock is the primary driver for the change in the Common Stock Warrant liability valuation
during each year. As the fair value of the Common stock increases the value to the holder of the instrument generally increases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fluctuations
in the various inputs, including the enterprise value, time to liquidity, volatility, and discount rate are the primary drivers for the
changes in valuation of the 2022 Convertible Notes each reporting period. As the fair value of the enterprise value, estimated time to
liquidity, volatility, and discount rate increase, the value to the holder of the 2022 Convertible Notes generally increases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.
Net Loss Per Share </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss per share were calculated as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
numerator for basic and diluted net loss per share is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Three Months Ended March
    31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left">Net loss</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 16%; font-weight: bold; text-align: right">2,457,179</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">2,326,017</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Dividends on preferred stock</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">712,080</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">692,246</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss attributable to common shareholders</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">3,169,259</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,018,263</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
denominator is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Three Months Ended March
    31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left">Weighted average common stock outstanding, basic and <BR>diluted</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">1,043,990</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">1,043,756</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">$0.01 warrants</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">11,467</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">11,467</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Total</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,055,457</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,055,223</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share, basic and diluted is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
                                            the Three Months Ended March 31,</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left">Net loss per share, basic and diluted</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 16%; font-weight: bold; text-align: right">(3.00</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">(2.86</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following potential common stock equivalents, presented based on amounts outstanding at each period end, were excluded from the calculation
of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left">Options to purchase shares of common stock</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; font-weight: bold; text-align: right">1,290,318</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">1,378,359</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Warrants outstanding</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">263,743</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">263,743</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,554,061</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,642,102</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 167; Value: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.
Commitments and Contingencies </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #1F2722"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Legal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to legal proceedings or claims which arise in the ordinary course of its business. Although occasional adverse decisions
or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on
its financial position, results of operations or liquidity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License
Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
January 26, 2022, the Company entered into an Exclusive License Agreement (the Agreement) with an unrelated third party. Under the Agreement,
the Company is granted an exclusive license for certain patents and a non-exclusive license for certain know-how. The Agreement continues
until the later of the expiration of the last to expire licensed patent or ten years after the first commercial sale of the first licensed
therapeutic or non-therapeutic product. The Company may terminate the Agreement at any time by providing at least 30 days written notice
to the third party. The Agreement is also terminated upon breach of a material obligation under the agreement or bankruptcy. Upon any
termination of the agreement, neither party is relieved of obligations incurred prior to the termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended March 31, 2023, the Company capitalized payments made under this license agreement in the amount of $3,858. These
capitalized costs will be amortized over the life of the licensed patents, once issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #1F2722"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Operating
Leases </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases office and lab space in Branford, CT; Groton, CT; and Laval, Quebec. The Company&rsquo;s leases expire at various dates
through May 31, 2027. Most leases are for a fixed term and for a fixed amount. The Company is not a party to any leases that have step
rent provisions, escalation clauses, capital improvement funding or payment increases based on any index or rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2020, the Company entered into a new lease agreement for the Company&rsquo;s primary office and laboratory space in Branford, CT. The
Branford lease requires monthly payments of $13,033 for the first year of the lease, which increases approximately 2% in each of the
following years. The Branford lease also requires the Company to pay a pro-rata share of common area maintenance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
May 2021, the Company entered into a new lease for office and laboratory space in Groton, CT. The Groton lease required monthly payments
of $4,234, which was increased to $6,824 in September 2021 upon leasing additional space. The Groton lease is initially for a one-year
term, with up to three additional years renewal available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum payments under non-cancelable operating leases with initial or remaining terms in excess of one year during each of the next
five years follow:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">2023</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 26%; text-align: right">331,801</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2024</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">337,984</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2025</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">257,540</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2026</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">184,541</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">2027</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">30,983</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total future undiscounted lease payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,142,849</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Less: interest</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(83,654</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Present value of lease liabilities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,059,195</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent
expense for all operating leases was $27,156 for the three months ended March 31, 2023. The weighted average lease term for all operating
leases is 3.6 years. The weighted average discount rate for all operating leases is 4.25%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 168; Value: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14.
Retirement Plan </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #050B04">Effective
January 1, 2019, the Company sponsors a 401(k) plan that covers substantially all employees. In order to be eligible to participate,
an employee must complete two consecutive months of service and work a minimum of two hundred and fifty hours or work 1,000 hours in
their first year of service. Employees may make pre-tax deferrals upon meeting the Plan eligibility requirements. Effective January 1,
2020, the Plan was transitioned to a </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">safe harbor
plan in which highly compensated employees are not eligible for matching contributions and non-highly compensated employees earn 100%
match on first 3% contributed and 50% on the next 2% contributed. Total employer matching contributions were $2,191 and $8,743 for the
three months ended March 31, 2023 and 2022, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.
Concentration of Credit Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B03"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to credit risk consist principally of cash and accounts receivable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three month periods ended March 31, 2023 and 2022, all service revenue was from one customer. For the three month period ended March
31, 2022, all grant revenue was from one grantor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cash balance identified in the balance sheet is held in an account with a financial institution and insured by the Federal Deposit Insurance
Corporation (FDIC) up to $250,000. At times, cash maintained on deposit may be in excess of FDIC limits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B03"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
early March 2020, there was a global outbreak of COVID-19 that has resulted in significant changes in the global economy. While the Company
has not experienced any disruptions to its business operations to date, these changes, including a potential economic downturn, and any
potential resulting direct or indirect negative impact to the Company cannot be determined, however they could have a prospective material
impact to the Company&rsquo;s business, cash flows and liquidity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16.
Related Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
related party revenue was $113,300 and $120,000 for the three months ended March 31, 2023 and 2022, respectively and accounts receivable
due from the related party was $0 and $175,000 at March 31, 2023 and December 31, 2022, respectively. Contract liabilities from the related
party was $42,700 and $156,000 at March 31, 2023 and December 31, 2022, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2022 the Company entered into a convertible promissory note totaling $4,350,000 of which $4,000,000 was attributable to an
entity who was also an investor in the Company&rsquo;s Series A, A-1, and B Preferred Stock financing. (See Note 7)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17.
Subsequent Events </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated events subsequent to the balance sheet date through June 13, 2023, the date these condensed financial statements
were available to be issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
April and June 2023, the 2022 Convertible Notes were further amended to extend the maturity date to June 30, 2023 and allow
for the sale of additional notes of $500,000 for a total aggregate principal of $4,850,000.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 17, 2023, the Board of Directors approved a forward stock split at a ratio of 7.1-for-1 upon the effectiveness of the
registration statement of which this prospectus forms a part. The Board of Directors also approved an increase in the authorized
shares of the Company&rsquo;s Common Stock to 100,000,000 along with a change in the Common Stock par value to $0.0001. All
references to common stock, options to purchase common stock, share data, per share data and related information contained in the
consolidated financial statements and related footnotes have been retrospectively adjusted, where applicable, to reflect the effect
of the stock split, change in par value of our Common Stock, and the adjustment of the preferred stock conversion ratios, where
applicable. Accordingly, an adjustment was made between common stock and additional paid-in-capital in the consolidated balance
sheets to reflect the new values after the stock split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #050B04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 169; Value: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>1,500,000</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>
Shares of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="logo_002.jpg" ALT="" STYLE="height: 84px; width: 370px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Azitra,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B> </B></FONT><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>ThinkEquity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">June
15, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
and including July 10, 2023 (the 25th day after the date of this offering), all dealers effecting transactions in these securities,
whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer&rsquo;s obligation
to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 170; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>form424b4_001.jpg
<TEXT>
begin 644 form424b4_001.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '=!!4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEJD7AJ,7-^EPDL9N)C HG!$YCBW[(RX8[B@!.34L/[0OP_N&VIKSD^^GW/\
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M\,?\\]6_\'E]_P#'J/\ A3?AC_GGJW_@\OO_ (]7;44>TGW#V%+^1?<CB?\
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MO/RCD8]ZYIXU4Y<K;VO_ %J>_@^%ZV.H^VIJ*7/R:I_%[O51:2]Y:R:/6O\
MA3?AC_GGJW_@\OO_ (]1_P *;\,?\\]6_P#!Y??_ !ZN#\-_%KQ!\:M6N;?X
M?W^FVFB:3&(M0URXB\\3WC1AA%#'D?(N<LYZ]!ZUF:!XN^)\VN>/8KWQ'HTU
MKX1=5E2/3"K76;43\'?\OWL=^E+Z]>SC=I]?Z9K_ *JU(\\*TJ<)P2;B[\R4
MFDKVBTFW*.E[JZO;4]/_ .%-^&/^>>K?^#R^_P#CU'_"F_#'_//5O_!Y??\
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M%=&I^R^SH?R_D3_\)NO_ $,/_D\?_BJ3_A.$_P"AB_\ )X__ !50_P!F6?\
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M/\*SSKK?] /4#_VR7_&F-KI[^']0/_;%?\:"O8_W5_Y*7_[5N._B>8_5H_\
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MCD?],/;1[/[G_D=K17%?\)%XU_Z%"W_\&B?_ !-'_"1>-?\ H4+?_P &B?\
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MA!1DG=>3.UHKBO\ A(O&O_0H6_\ X-$_^)H_X2+QK_T*%O\ ^#1/_B:GD?\
M3-/;1[/[G_D=K7+?%+PE/X\^''B7PY:SQVUSJEA-:1S2@E$9U(!('..:I_\
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M92,@CV(K"6Y_/G&63K+<?[6DOW=75>OVE^OS):***D^!"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBO+O!_A>#XAZ/)KNM7NHSW-Q>7
M2+%'=O%%"D<\D2JBJ0 ,("?4DU25U=F4IN+48J[?]?J>HT5Q/_"H= _OZE_X
M,)O_ (JC_A4.@?W]2_\ !A-_\53M'N3S5?Y5]_\ P#MJXFX^($UKK45B]I$
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M7]-?P _Y(/\ #?\ [%K3?_26.@#O:*** "BBB@ HHHH **** "BBB@ HHHH
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M?[RG-0K^Z4(XVD<>QI6D!X4;V]!4W*LBZK!@"#D5'+'N&:+>,PPHA.2!4C'
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M#XFKDKXMO.F<>7'_ /$TFD_M,?$K6M%L[U/%5W;O/$LFWRXSC(SC[M'*SG?
M^/32]K#[Y?\ R)^@] ..:_/S_AHKXI+U\47C?[J1_P#Q-+_PT=\4/^AFOO\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X?X+_ /)/[;_K]O\
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MJ:$1\.G<CL]UY)%-YS(L#")%"Y'H3]?>K.JV\T:^8D@E*'G(YZ\ 5G>"%/\
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MF+ZT>8OK2T#4=41S/($3DT;FF;:@R:G9A8Q;5YF;O3W#8R[&7['KFM11\O\
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MST'88K[I^QMY?F?9_DQG=Y?&/7I0MFTFS;;[M^=N(\YQUQQ4?VT_^??X_P#
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MPN[9N*<;O3ZT?93N=?(^9,EEV<C'7-']FK^?\/\ @FW_ !&N:_YE_P#Y4_\
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MDD]J\EUS4VU;4YK@_=)VH/11TKRLPQ3PU-*#]YGK99S0Q$:\=X.Z]>A\Q?\
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MVBF&%5D0RNIR&R1M'!X]:3[5I]KXDO-7:^29,O) D(R^\_=X/''6N;_LZ?\
MNC\Z/[.G_NC\ZV>(QCY6Z.L;6T>\59''[&DKI3WOVZG7Q:O8PW5U>6VH*@FV
MRBU?Y-TA4AMY';OM[DUQ#?>/U[=*L?V=/_='YT?V=/\ W1^=<V*>+Q2BI4FK
M7>B>[W-J,:5&]I7O;MT*S6XO%:!D#K*"A5AD$'KFO'I_V3_,FD>/Q L4;,2L
M8M\[03P,Y[5[KI]DT+,\@PW05?KZ7(WB,OIRE%\KET]#IIYMB<%)K"SLGOL_
MS/G!OV1)#,S_ /"2K\V/^7;_ .O2_P##(LG_ $,J_P#@-_\ 7KZ.HKZ7^T\7
M_/\ @O\ (Z?]9<T_Y^_A'_(^<8_V1'29G/B9>5QQ;?KUK[%^$?VJT\#Z=IE_
M??VC?:?&+=[DKM,BC[I(^F!^%<16SX4U;^R=6C9CB&7]W)_0_G73ALSK>UBJ
MTKQ?H>#G&88O-J"AB)<W+JM%^B/4J***^M/@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *X?X+_ /)/[;_K]O\ _P!+9Z[BN'^"_P#R3^V_Z_;_ /\
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MRB:&^C;R]C< ,/XES5J-I[>^\ECN"IB0=B!TQ[UG36.H:EJL5Y:S%4CZ1@
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ME*_IK^ '_)!_AO\ ]BUIO_I+'00=[1110 4444 %%%% !1110 4444 %%%%
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M .DL=?S*5_37\ /^2#_#?_L6M-_])8Z!'>T444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% #9$$D;(PRK#!KR+6-.?2M2GMF_A;*GU4]#7K]<EX^TG[
M1:1WL:Y>'Y7QW4]_P/\ .O&S3#^UH\ZWC^74]+ UO9U.5[,X&BBD9@JEB< #
M)KXT^C%HK(;7CDXA!';YJ3^WF_YX#_OJM.20'&W'A;QL_P"T)::['K4:^ %T
M-X9-/\E#(;OS1A=^-VT\/P?X,=Z]*K'_ +>;_G@/^^J/[>;_ )X#_OJJDI2M
MIL2DE<V**Q_[>;_G@/\ OJK]C?"]C+8VLIP5J'%K5E%FBD=A&I9CA0,FLG^W
MCVA&/]ZDHN6P&O0.OK6/_;S?\\!_WU1_;S?\\!_WU5<D@.+^''A/QIHWQ.^(
MFJ>(]:74- OI[9=#MDBC4K"L9RTA4 EESLYX(YZUZ96/_;S?\\!_WU1_;S?\
M\!_WU524I.[1,4HJQL45C_V\W_/ ?]]5>L+X7T;';M93@KFH<6M646J*1F"*
M68X &362=>.3B$$=OFI*+EL!HWUJ+ZRN+9I)(1-&T?F1,5=,C&Y2.A'4?2N$
M^ _PUU#X3_#6P\.ZMKESXCU.*:>:?4;J5I&D+RLR@%N0 I''J6]:ZG^WF_YX
M#_OJC^WF_P"> _[ZK2T^5QZ$V5[FQ16/_;S?\\!_WU3EU[+ -" N>3NJ>278
MHUJ*0$, 1R#534-1%CM 7>S<XSCBH2;T0%?Q5IEYK7AG5;#3[^32]0N;62*V
MOHOO02E2$<#O@X..]<[\$_">M^!_A3X:T3Q)J;:OKUI9JEY='&WS.NQ< #:H
MPHQV7-;W]O-_SP'_ 'U1_;S?\\!_WU6MI\O+8FROS&Q16/\ V\W_ #P'_?5'
M]O-_SP'_ 'U4\DBC8KS/XN?#WQ)XT\3?#^]T'7YM'LM)U7S]6AC8#S[7;R%R
M.'R ,CLQKM/[>;_G@/\ OJC^WF_YX#_OJJBIP=TB9)25F;+'<Q.,4E8_]O-_
MSP'_ 'U5FQU07DA1DV-C(YSFHY6M2B_7+?%+0=:\4?#OQ#I?AO4SH_B"YLY$
ML+W@K'-M.W<"""IZ$$=#74UG7FL"WG,:QA]O4YQS1&][H3U5F4/A[H=_X9\!
M^'=)U6]DU+4[.PAANKN0@M)*$&X\=@<@>P%=!UXR1GC(ZBL?^WF_YX#_ +ZH
M_MYO^> _[ZJG&3=[ K)6.,^!?@#Q/\/]%UZW\4^(9?$-U=ZQ<W%G))@"&T+_
M +I3@<N1DL>Y/M7I=8_]O-_SP'_?5']O-_SP'_?5.2G-N30HI15D;%%8_P#;
MS?\ / ?]]5/9ZN+J81L@3/0YS4<DD4:-%%4+[519S>6J;SC)YQBI2;T0'%?&
MWX-V/QJT#2=-O+R>P_L_5+>_\RW8J98T<&2%L'[KKD'W /:O1,!<!1A1P![5
MC_V\W_/ ?]]4?V\W_/ ?]]5JU-I1>R)LDVS8KS7QQX!\4:]\7O 7B#2O$<VG
M>&]+2Z75]-4+_I.X Q[21D$GAL8X0>M=E_;S?\\!_P!]4?V\W_/ ?]]414XN
MZ022DK,V**Q_[>;_ )X#_OJI;;6A-,L;QA W&[-1R2*-.N-^,GAG7O&'PP\1
MZ1X7U0Z-XAN;1EL;O *B4<A6!!&UN5.1T;/:NRK/O-6%K,8U02$=3G'X40OS
M)KH*235F0^$=+O-#\*Z/I^HW\FJZA:VD45S?2@!IY H#.0.!DYX%:U8_]O-_
MSP'_ 'U1_;S?\\!_WU3<)-WL&AL45C_V\W_/ ?\ ?5']O-_SP'_?5')(9L45
ME1Z[ND56B"J3@MNZ5JU+BX[@%:WA?2SJNKQ(1^ZC/F.?8?\ UZR:])\$Z3_9
MVEB9UQ-<?.>.0O8?Y]:[\#A_K%9)[+5G)BJOL:3:W9T5%%%?='RH4444 %%%
M% !1110 4444 %%%% !1110 5Y=X+\7:=\/]'ET'73<V-]:WET^6M)2DJ23R
M2JZ,%(8;7 XZ$$5ZC15)JUF92@VU*+LU_7Z'&?\ "X/"O_/_ "_^ DW_ ,31
M_P +@\*_\_\ +_X"3?\ Q-=G13O'M_7W"Y:O\R^[_@GG$FN6_CSQUX4GT:.Y
MN+329KBYNKI[=XXE#6[Q*H9@,L6D!P.P-<')#+%XDO764B)[B4NW)&<MZ^U?
M0=?/+>(/$%GJVIK/I.AS+]IF$!77(%(7<0-P)R#['I2D[Z'K9=4^K>T<M6RS
M!;+IEA:7%I*WFM-M<J<>9746VG*;J:^7S()I-IDC/W6X_P \UQE_K=_>Z=';
MG1]*22-O,1U\06XPWKUIMCXN\56]NX>QT5I23M7^WH&4CMD$U)VU:\:L;WU.
MM.W4)IH0'S*0[?+@)&#R#ZFJ-UKC+?.T<0:WA7;N'\([8]ZP8O%7B 0%I-(T
M629EVLH\0P!.O;G/)JC<:KK]Q=2;M+T,6LB<JNOP;MV1TYZ4B8587M)G6K"#
M=W%WMD"1E2B*_P#K..3^OZ5IK>;;F!8P6782S,>U<1'X@U^.:<+IVBQPO]S9
MKT&0??)I9/$6OO<*5TG01;J!A?[=@SG^+G/>A:#=2FWJSL;&>-3J%RS-G:2\
M/<8'&/K4&CROJ%C]HD@P[\^7(,XS[=ZY2T\2>(8YYYIM-T5S(<+$NO6X15[#
MKR:FL?%'B""UD+Z3HIN2"%V^((-@_6CJ3*I3LTGN=0+K[1>$QD2HI # ?-QU
M7VJUIH-M9;G78S2D!/Z5RT7BS6(5WIHNC>:><_V_;X)]>M0P^*]?1D,FDZ*3
MN);&OP>O;GTIDRK1:L=PS$2 /\BX^_Z'TK*U*(1V;L6";BR'/ '!P:PIO%FL
MR0F(:1HX4'(_XJ"WX_6L?Q!KGB74=/NDM;+18;F0*$:37[<HI' .,T&=.4>9
M7,3X@V37VBIJ3*!/:QA9%]1D<@>M>=>:?LC*^W##)QU.>N/I7H/D>+'T&>UD
MM/#YO+@8DF&NP[/K@FN77P%XF144P: V,!F.NPY]\<U#1]-AL=0IJTI'2>#[
M[QAI6N*-'T>PU*U$*[)YKEE/(Y! '!KV?PS?^*+R\8:UI&GZ?:%-RO:W+2N6
M[#!'3'>O.?!>H:[X5C:(Z;HSQGGY-?@!SW[UUJ?$35T4 :)I6!_U,%O_ (U4
M=-SY?'58UJKE'8T_'7_(8\#_ /8>B_\ 06K^?7]HS_DO'C__ +#5U_Z,-?OA
M_:>K^-?$WAB%K'3+&&QU)+R61-7AG<JJD;513DDYK\ROBY_P3.^(WC'XI>+-
M<M?$O@Z"VU#4Y[F..?6$6159R0&'8\]*IZGFGY_T5]I?\.J?B;_T-7@G_P '
M4='_  ZI^)O_ $-7@G_P=1T@/BVBOM+_ (=4_$W_ *&KP3_X.HZ/^'57Q-_Z
M&KP3_P"#J.@#XMHK[2_X=5?$W_H:O!/_ (.HZ/\ AU3\3?\ H:O!/_@ZCH ^
M+:*^TO\ AU3\3?\ H:O!/_@ZCIR_\$I_B>RLR^*/!3!>I&M)@?6@#XKHK[2_
MX=5?$W_H:O!)_P"XU'3E_P""5?Q,5LGQ5X)_\'4= TCXUL[5KF147JQP*["S
ML8M%MBTLZM,1PHZU]5+_ ,$N_B/$J^7XD\%;AW_MJ.E;_@F#\3" 3XG\$LWJ
MVM1UR5(RJ:=#Z+!UJ&%U;3D?(^I7>Y=\AR<<5R]S)YDA-?:]Q_P2Y^*-TWS^
M*O!(7L/[:CJLW_!*OXFG_F:O!/\ X.HZTIT_9HXL=BOK,M-CY'\)VN@WFJ>7
MXAO;JPL-A/G6<(E?=V&">E=A_8?PJ/\ S,^O#_N')_\ %5]#_P##JKXF_P#0
MU>"?_!W'2_\ #JKXF?\ 0U^"?_!U'6YY1\?>(H-+MM7GCT:YGO-.!_=37,81
MVX[J.E?TL_ #_D@_PW_[%K3?_26.OQF;_@E7\354G_A*O!)P/^@W'7[5_"?0
M9_"OPL\&Z)=212W6FZ-9V<LD#;HV>.!$8J>X)4X/I0(ZNBBB@ HHHH ****
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MH9#A5L)=EO&4W+D [I3D!?E(QNR>AJG3CTBOO)4Y=7^![HR[6(SG!QFDKA?
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M3+,/[&CS/>6O^1\WC:WM*G*MD%%%%>N><%%%% !1110 4444 %%%% !1110
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M=_"L>Z)1E%.".K"J]KF7=EV27(8,O.0/[PJ]+?)-(J1PNGS['8\4D,:+,X8
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M*RO6M21QLD7U7-9?8TZ>QGB]9(2OZ:_@!_R0?X;_ /8M:;_Z2QU_,I7]-?P
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M:_@!_P D'^&__8M:;_Z2QU_,I7]-?P _Y(/\-_\ L6M-_P#26.M3@.]HHHH
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M4,'[//A"UU"74(([^'47<2K>QWCB:)P7.Y6SD$^8^3_M?2M^>F_M,Q4)KHC
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M\X\ZHHHH **** "BBB@ HHHH *[&];01X3T7[ \QUEEE&I1R9,8.[]V4_P"
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M8.19H",$^A8Y.*3-(:MHYA6_=FF(M'1:16I%]DR;H.*DB)C^;%0CJ*LLP:,
M5FSKIZW?8EVO(H<#CIBJ5P3YG(K6T^=1A&Z=:IZTJ^?N7H:F+]ZQU8BG^X]H
MF9[5_35\ /\ D@_PW_[%K3?_ $ECK^92OZ:_@!_R0?X;_P#8M:;_ .DL==!X
M9WM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 0WELMY;R0N.&&/H?6N'FA,,C1L/F4X-=]7/>([';(MPHX;AOKVKS,=
M2YH\ZZ';AJG*^5]3G]HJ.XD$$3.>W2K6WVK'U2X\R;RU/RIU^M>*HGI%)CN8
MD\DTE+16HQ**6B@!**6B@!**6B@!**6B@!**6J&O:Q#X=T/4-5N5D>WL;=[B
M18EW.54$D =SQ3*C&4Y*,=6R]17D^D?'6YU#0[[5Y?"\D=A%ILFI07%K?QW$
M;A!GRY&4?NG(/0YYR*Z>Y^)VFKI=M<6SV]Q=LUFMQ:M<!/LYN "JL^""PS]W
MJ?:K=.2Z'I5,LQ=*7+*&M[:-/7U3:Z_H=C17-6/Q+\+:IKL>C6FN6MQJ<C.J
M6Z,=S,F=R],9&#QUKGO&WQ:NO"_C0>'++0H]3N/[._M)IIM12U0)N*E1N4Y/
M'K24)-VL9T\!BJM3V2@U*U]?=T[ZV/1J*X;3?C)X;F\*:-KFI77]BIJD+3Q6
MUR"T@56*LQ"@_*"/O=.16C=_%+PG8W@M9M>LUN&02",/N.TIOW<?P[1G/2CD
MEV)E@<7&3C[*5U?HWMH_N9U%%<=8_%30M4U@VUEJ%E<:?':RW$U^+D!8_+*A
MA@CE<,#N!P*L6_Q4\)76FR:@FO6@LXYE@>61BFUV&5!! (R <'H>U')+L*6"
MQ4=Z;^Y]=O3T.IHKB/'7Q1M_"?@>P\2:=9'7X+^[M[2UBCE\GS#,Y56W,#@9
M'<5%X?\ BLEQJ6KZ7XFTJ3PCJFEP+=S17EPDL1A)QO61>#SQCZ4^25KFD<OQ
M4J3K*&B;6ZOI9/W;\VC:OIU.\HKSCQ5\=O#NA^'K?4].F76Y+B[6RBMHG,1\
MPD9WEAE  0>1SVKI;#XA>'M0UI-&CU6V.KE<M:J^<-MR4#8P6 [9S[4N225[
M$RP&+A#VDJ;2UZ=M]-TE?=Z'145Q&H?&CPC9Z?J]S#K$%Z^FQ/-+! 26<+P=
MG&&YXR,@'K73>&_$%IXIT.SU6Q??:W48=<C!'J#[@\4G&25VC.IA,11A[2I!
MQ5[:JVMK_D:-%+14G()12T4 )12T4 )12T4 )12T4 "L58,.".16Y#()HE<=
MZPZO:3/MD,1Z-T^M3)7 T=HJ:SM3>7,<*_Q'GZ=Z-OM70>'+'RXVN&'+?*OT
MJZ%'VLU$QJ5.2+9L11K#&L:#"J,"GT45]/MH>*%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7#_!?_DG]M_U^W__ *6SUW%</\&.
M/A_;?]?M_P#^EL]6O@?R_4PE_%CZ/\T=Q1114&YP_C;_ )'[X=_]?]W_ .D4
M]9.L6LB7EQ&DC-%(S$MD<')_E6MXV_Y'[X=_]?\ =_\ I%/6#K"1RS7Y43,T
M,K#;%G.2<\>]7+:/]=6;X&352IZK\D<KJFCRE9)F99)"NUI.< #O]:YJ&1Y%
MC18/,A8["Y]O4'J*]"MYPUJTA=)7;CD??/=2#_.L/5O#ZR3K=1%XG"XCA0?*
MK'OBH/IZ59?#(YKY)+D@*I7&U5QSD&K$5O'(S2;%5RN.ORC';/>G-%B60-YL
M=Q$N&)48 ]1QQFHD5S(L:X,3(6)S^M!U\U]$688U\Q7$JA@,*67G/UI+BSN9
M'=O,W$ %2#@,1U'U]Z2';"H1QOC? 61?\:L23&-@%D9U<_>7G8*6I&S)([K4
M+6WC6W9U)/W&DR /6I&U[65A >9NG+[LD'_"H;B3RVWA2%7D'.-P]/:I(MV_
MD+@C/!I$<L7NAEY<2W&Q)#YCL,JV>01Z^U1-+/-*QCW,<?,V[ !]1[U-N#S*
M^QL8YX&13&DCC4I%N [\\T7#E789OEF'S9BDQELU'(K*W()YZT]758]H9B??
MFJ]Q(67.XG'Z4C2*?0KQR".^@1B/*.0[>G/!K2LI'T^[256XCZGN<&LF$;[J
M,$9;< WY]*Z/5M)-K(C 8 <YS],U:?4Z=.51EU/7=-N!=V,$ZG(D0-^E7*Y#
MX?ZQ]JTXVC@B2$9 _P!DFNN%7L?#XBFZ55Q9Q?Q$_P"0IX%_[#T/_H+5_/9^
MT;_R7KQ__P!AJZ_]&&OZ$_B)_P A3P-_V'H?_06K^>S]HW_DO7C_ /[#5U_Z
M,-0<YYU1110 4444 %%%% !1110 "NO\:7%C<7V^PTE]&@6WA3[/(,,2$ +G
M_>//XUR'2NY^((UF2^MKC77ADNKJPMYHVAQ@Q%,1YQWP.:B1TT;79Q<?W&^E
M1K4B_*IJ*FC.6B1(6S4J2X4"JP-3J!MI-&E.3OH6HV(&_'%%XIECW <"GVJB
M1=I''7-7VM=]LVT<5SN7*SV(TG4IM+8YROZ:_@!_R0?X;_\ 8M:;_P"DL=?S
M+2KM<\5_33\ /^2#_#?_ +%K3?\ TECKK/GVK.QWM%%% @HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H;NW6ZMWB;HPX^M
M344FE)68T[.Z.)DC:*1D8<J<&N>U"V-M<,/X6^8&NZUZSVR+.HX;AOK7/:G9
M_:K8[1\Z\K_A7SU2FZ<G$]>G-229SM%%%8G0%%%% !1110 4444 %%%% !5+
M6[.YU#1[VULKPZ?=S0LD-T(UD\IB.&VMPV/0U=HH*C)Q:DNAX-#\ ];NKJ\N
MIY-!T:XDTNXL&.BQ21I?22* ))TP% !^;"@\FKVG_ ;4M#T)M!L=4MWT;^T+
M#5$6XW-+'-$09UW8Y5B,KGD5[716_MIGORS['25G)6TTMV=U]WY.VVAY1H_P
M=O=,;PXS7=H7TS7+O59656RZ3;\(#CJ-PSGCBG>/_A3J7B;XAIXDM8-!U& :
M6-/^QZY"TJJV\MYB@ \\X_.O5:*GVDKW.=9MBE5]M?6S6W23N_Q/![CX"^)(
M_#NFZ/#K=K=VD>G7%I*DDDMNL3R,6#1[,LR+T",0*U-%^!M]INB>*[22\LI+
MG6-(M]-BF5&_=F./:23C.TGGBO9**KVTS>6>8V<7%R6KOLM^;F_-'DGBWX'R
M^)H;:WBO;>QMH?#S:/B-"#YF]&#8'\/R8/?FLA?@'J%\L4]ZVFPW8O;.:39<
M7-R)88220S3,>3V   ]37N5%)5II6N33SO'4X*$9Z+_A_P"KG$_%[P1?^/O"
MMOIVE7%K9WEOJ=KJ$;W2L8OW+[]I"\\\5R.N_!?7O'"^(M1\2:Q8_P!N:A;0
MVMJNG1.EM D<@DP<G<=S#GT[5[)12C4E%61SX?-,3A*<:=%I6=T[*^Z;U[/E
M1XWI_P %-0")<SMI]K?MK%EJ$WDW%S<;X[?. 9)226.3C@ # YJ'3?@)=6OB
M21I[BUN-)_M&XU&.X:YN?M$;2AN%B#"(,-Q^?G([5[513]M,Z/[;QOO>_OI^
M%O71:'D&D?"CQ)#X6/AR]NM$&GV>D3Z797%O;$W$F\$*\C$?(!W"YR>:]#\$
MZ?J>D^$],L=8^R'4+:$0R&Q+&(A>%(W 'H!GCK6Y14RFY;G'B<?6Q47&I;5W
MT5M>OWWU"BBBLSS0HHHH **** "BBB@ HHHH *MZ;;FXN0?X4^8U4KH]-L_L
MMJH(^=OF:FE<F3LBU;6[75PD:CEC7811K#&J*,*HP*R]!L]BM.PY/"_2M>O9
MPM/DCS/=GE5Y\TK+H%%%%=QS!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5QDWPW:&ZN9-)\2ZUH,%Q*T[V=BT#0B1N691+$Y7)Y
M(! R2<<UV=%4I-;$2A&>YQ7_  K_ %;_ *'_ ,2?]\6/_P C4?\ "O\ 5O\
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M_P#ASQ\ /3Q3_P"#9?\ XU1_PYX^ 'IXI_\ !LO_ ,:H _#BBOW'_P"'/'P
M]/%/_@V7_P"-4?\ #GCX >GBG_P;+_\ &J /PXHK]Q_^'/'P ]/%/_@V7_XU
M1_PYX^ 'IXI_\&R__&J /PXHK]Q_^'/'P ]/%/\ X-E_^-4?\.>/@!Z>*?\
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MT'_/04>RAV#GEW*_]DQ_WVH_LF/^^U6/MT'_ #T%'VZ#_GH*/90[!SR[E?\
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M/MT'_/04?;H/^>@H GHJ#[=!_P ]!1]N@_YZ"@">BH/MT'_/04?;H/\ GH*
M)Z*@^W0?\]!1]N@_YZ"@">BH/MT'_/04?;H/^>@H GHJ#[=!_P ]!1]N@_YZ
M"@">BH/MT'_/04?;H/\ GH* )Z*@^W0?\]!1]N@_YZ"@">BH/MT'_/04?;H/
M^>@H GHJ#[=!_P ]!1]N@_YZ"@">BH/MT'_/04?;H/\ GH* )Z*@^W0?\]!1
M]N@_YZ"@">BH/MT'_/04?;H/^>@H GHJ#[=!_P ]!1]N@_YZ"@">BH/MT'_/
M04?;H/\ GH* )Z*@^W0?\]!1]N@_YZ"@">BH/MT'_/05)',DW*,&H ?1110
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M%>&K[[%J_C#0-*O/.^S?9[W4X(9!+@'RRK,"&PRG'7##UKG&_:&\%1?&2_\
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MHAO+^Q?>D'&\8"U]6ZQ^R_)JG@/XT>&_^$@6-OB)>B\%P(,BR_T>&';C^/\
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M;ZG>F4".SDB($B2'^$KD9^HKF]<_:2^%GAK4ET[5?'VAZ??M*L/V>XN@KJ[
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFJMSRJY#%MW2N5^#<.J?#;6O@1X@\4?"[Q7J6G>'_!-YHM\\6A2W,NE7GVH
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M]G7Q=X@USQG?P6/Q5TGXQ?#Z33Q/'JJFWCU+3KO=CRI8X0,HZ\@LH(QBNO\
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M;'-;GC3]J[POX4U)K'3]#\2^,)[;3(=9U$>'M/$PTVTE7>DD^]TPQ7+;%RV
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M),01+<.B*NV/!VYRV3VK.^,U]XUTG]M7P)?^!]&T[Q!J$/@B^%SINI79M!-
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M+FWTCS#:QRRN798S(2[ 9QN/4@G KTBB@ HHHH **** "BBB@ HHHH ****
M%3[R_6MZL*-2TB@=2:W: %HHHH **** "BBB@#-U7[T?TJC5_55.8SVZ50H
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>form424b4_002.jpg
<TEXT>
begin 644 form424b4_002.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %+!!4# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML CG(YSGCW[7/V\O!7PS_9]^&'Q*\>P7]FGC.QAE2#2K;S_+G,(>1>6&%!)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#XG_X*^_\F<WO_8<L?_0GKZ _9+_Y->^$
MO_8K:;_Z31U\_P#_  5]_P"3.;W_ +#EC_Z$]?0'[)?_ ":]\)?^Q6TW_P!)
MHZ /6**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XG_X*^_\
MF<WO_8<L?_0GKZ _9+_Y->^$O_8K:;_Z31U\_P#_  5]_P"3.;W_ +#EC_Z$
M]?0'[)?_ ":]\)?^Q6TW_P!)HZ /6**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX17Z]USNA_#OPMX9\1:QK^D>'=+TS7-88-J6I6EI'%<7A!)!E=1N?&3U)ZT
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MI%FGEVUC8PK##"N<[410 HY/ H TJ*** "BBB@ HHHH **** "BBB@ HHHH
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MI* "BBB@ HHHH ^)_P#@K[_R9S>_]ARQ_P#0GKZ _9+_ .37OA+_ -BMIO\
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M-:O<M;R0PS.A+7,++EHF8G!'4G%?K[X3U#^U?"VCWOVK[=]ILX9OM6S9YVY
M=^WMG.<=LUX_XI_8<^!OC'1= TC4OA[IK:9H5U-=Z?:V[RPI$TTGF2KA'&Z-
MGY*'*^@ KW&"".UACAAC6*&-0B1H,*J@8  [ "@#\P/VVOVL/A+\7/BMX \*
MW'Q3\1:/X$TJ]U&U\5VWAJ&XMKE+E558'8F/$D8=)%.W<1NR <Y'L?[!"? !
M?B!XD/PB^)'B[QKK']EK]LM?$4T[Q10>:OSH)(4&[=M'!/!J;Q%\*_B)X0US
M4+OPO\:_AOXPA:>20:+\0-#LU>(EB3&;JW(D/IEEXKUG]G'Q'\0-0UZ]L_%_
MPH\+>%K7[(9(?%7@_58+JRO7#@&((%$B=2PW9'RGO0!] T444 %%%% !1110
M!\3_ /!7W_DSF]_[#EC_ .A/7T!^R7_R:]\)?^Q6TW_TFCKY_P#^"OO_ "9S
M>_\ 8<L?_0GKZ _9+_Y->^$O_8K:;_Z31T >L4444 %%%% !1110 4444 %?
MFC^Q]_RE2_:&_P"N%]_Z5V]?I=7YH_L??\I4OVAO^N%]_P"E=O0!^EU%%% !
M1110 4444 %%%% !7R'_ ,%6_P#DR'QI_P!?6G?^EL-?7E?(?_!5O_DR'QI_
MU]:=_P"EL- ''_"G_DE?@O\ [ EC_P"DZ5U-<M\*?^25^"_^P)8_^DZ5U-?S
M77_BS]7^9_0-#^%#T7Y!1116!N%%%% !1110 4Z/_6+]13:='_K%^HH \T_X
M)0_\CI^TK_V-B_\ HR[K]#*_//\ X)0_\CI^TK_V-B_^C+NOT,K^D\/_  8>
MB_(_GZO_ !9^K_,****Z# **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *R_%-SJ-GX9U>XTB!;K5HK.:2S@;I),$)C4_5L#\:U*X?XM?$KPS\/
M/#<PU_QEHW@NYU&&:#3KW6+V.V7SMG!7>1NVDJ2!F@#\:[/]H;5K7_A(+O\
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MPPR@$9!*LP."*H?\+K^'G_0^>&?_  <6_P#\70!VE%<8/C5\/6.!X\\,D_\
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M **** /B[]M#X$ZY"WB[XN3_ +0OC#X=^%]-T])I-#T8.85,:! L>)D!>5\
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M^"K?_)D/C3_KZT[_ -+8: ./^%/_ "2OP7_V!+'_ -)TKJ:Y;X4_\DK\%_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3?\ TFCKY_\ ^"OO_)G-[_V'+'_T)Z^@/V2_^37OA+_V*VF_^DT= 'K%%%%
M!1110 4444 %%%% !7YH_L??\I4OVAO^N%]_Z5V]?I=7YH_L??\ *5+]H;_K
MA??^E=O0!^EU%%% !1110 4444 %%%% !7R'_P %6_\ DR'QI_U]:=_Z6PU]
M>5\A_P#!5O\ Y,A\:?\ 7UIW_I;#0!Q_PI_Y)7X+_P"P)8_^DZ5U-<M\*?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%% !1110 4Z/_6+]13:='_K%^HH \T_X)0_\CI^TK_V-B_\ HR[K]#*_//\
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M_P#DR'QI_P!?6G?^EL-?7E?(?_!5O_DR'QI_U]:=_P"EL- ''_"G_DE?@O\
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M\1?]@RZ_]$O6S6-XU_Y$KQ%_V#+K_P!$O6=3X)>ATX;^/#U7YGT'_P $F?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP9J '_HJOPD_X;,^.^<_\+>\9Y_[#4__ ,51_P -F?'?.?\ A;WC/_P=3_\
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M%^HIM.C_ -8OU% 'FG_!*'_D=/VE?^QL7_T9=U^AE?GG_P $H?\ D=/VE?\
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M#_[$X?\ H=]7;@?]ZI?XE^9X6??\BG%?]>Y_^DLDHHHK]6/Y)"BBB@ HHHH
M**** "O#_P!JK_D%> O^QFM__037N%>'_M5?\@KP%_V,UO\ ^@FO+S3_ '.I
MZ?J?5<+?\CK#?XOT9^W=%9\>FW":_/?F_E:UDMHX%L2!Y:.KNQD!]6#*I]D%
M)8:;<6>JZI=2ZA-<P7;QM#:N!LM@J!2%_P!X@L?<U^8']4FC169H>EW.E_;_
M +3J,VH_:+N2XC\X >0C8Q$O^RN./K3-'T>ZTW0?L%QJD]_=8D_TZ4 2?,S%
M>/\ 9! '^Z* -:OY[?AU\-?#?C?4O&MYK>G&]N8M>N(DD\Z1,+N)Q\K#/)K]
M^6T.\;P?_9 U>X74/L(M?[6VCSO,V;?.QTW9^;ZU^%OP/_UGCK_L8KBNW!Q4
MJJ4E<\3.*DZ6$<H-IW6WJ7/^% ^ _P#H!?\ DU-_\51_PH'P'_T O_)J;_XJ
MO0:*]WV-+^5?<? _7<5_S]E][//O^% ^ _\ H!?^34W_ ,51_P *!\!_] +_
M ,FIO_BJ]!HH]C2_E7W!]=Q7_/V7WL\^_P"% ^ _^@%_Y-3?_%4?\*!\!_\
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M\3_\%??^3.;W_L.6/_H3U] ?LE_\FO?"7_L5M-_])HZ^?_\ @K[_ ,F<WO\
MV'+'_P!">OH#]DO_ )->^$O_ &*VF_\ I-'0!ZQ1110 4444 ?S??MH?\G:?
M%S_L9K[_ -'-7C%>S_MH?\G:?%S_ +&:^_\ 1S5XQ0 4444 %%%% !1110 4
M444 ?:O_  2%_P"3R-/_ .P+?_\ H*U^Z=?A9_P2%_Y/(T__ + M_P#^@K7[
MIT %%%% !7R'_P %6_\ DR'QI_U]:=_Z6PU]>5\A_P#!5O\ Y,A\:?\ 7UIW
M_I;#0!Q_PI_Y)7X+_P"P)8_^DZ5U-<M\*?\ DE?@O_L"6/\ Z3I74U_-=?\
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M?5<+?\CK#?XOT9^W=%%%?F!_5(4444 %?@I\#_\ 6>.O^QBN*_>NOP4^!_\
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M9J7N='M],FDO(%& 2\(7>H&Y>2/XAZU_4#7YH_LTPRK_ ,%>OC=(4<1MI=X
MQ4X/[RQ[T ?F;_PS3\7O^B5>-O\ PG;S_P"-T?\ #-/Q>_Z)5XV_\)V\_P#C
M=?TP44 ?S/\ _#-/Q>_Z)5XV_P#"=O/_ (W1_P ,T_%[_HE7C;_PG;S_ .-U
M_3!10!_/]^RO;?&W]EGXL0>.M-^"/BW7;J*SGLQ:7>A7T:8D !;*Q9R,5]G?
M\/*/VD?^C7=9_P#!;J7_ ,9K],Z* /S,_P"'E'[2/_1KNL_^"W4O_C-'_#RC
M]I'_ *-=UG_P6ZE_\9K],Z* /S,_X>4?M(_]&NZS_P""W4O_ (S7EO[3/[5W
M[07[3'P<UCX?:E^SCXAT6UU*2WD:]M=)U"21/*F2485HL')3'XU^PM% 'XU^
M%_VD_COX9\,Z/HR?LX>)9TTZRALUF;2]0!<1QJ@8CR>"=N:T_P#AJ[X]?]&U
M^(__  6ZC_\ &:_8&BOG9</97)N3HZOS?^9[L<\S&*255V7DO\C\?O\ AJ[X
M]?\ 1M?B/_P6ZC_\9H_X:N^/7_1M?B/_ ,%NH_\ QFOV!HI?ZNY7_P ^?QE_
MF/\ MW,O^?K^Y?Y'X]7'[6WQUM8))Y_V;_$$,,:EWDDT_4%55 R228> !WK&
M\(_MU?%3X@6,U[X7^!E]XDLX9/)EN-(BO+J-), [&:.(@-@@X/."*_7SXCY_
MX5YXHQU_LNZQC_KBU?"G_!%**2']GKQLLB-&?^$I<@,"/^72WH_U=RO_ )\_
MC+_,/[=S+_GZ_N7^1X7_ ,-7?'K_ *-K\1_^"W4?_C-'_#5WQZ_Z-K\1_P#@
MMU'_ .,U^P-%'^KN5_\ /G\9?YA_;N9?\_7]R_R/Q^_X:N^/7_1M?B/_ ,%N
MH_\ QFE7]K#X]*P/_#-7B/@Y_P"0;J/_ ,9K]@**7^KN5_\ /G\9?YA_;N8_
M\_7]R_R/Q7_9G^/7Q[_9GUCXAZAIG[/7B366\8ZH-3FCNM(U",6S!I6V*5B^
M8?O3R?2O=?\ AY1^TC_T:[K/_@MU+_XS7Z9T5]%&*BE%;(\.4G)N3W9^9G_#
MRC]I'_HUW6?_  6ZE_\ &:/^'E'[2/\ T:[K/_@MU+_XS7Z9T51)^9G_  \H
M_:1_Z-=UG_P6ZE_\9KP?]J;X[?'O]J4^"#JG[/?B70_^$7U(ZE%]DT?4)//)
MV?(VZ+@?)U'K7[5T4TW%IHB<54BX2V9^)[_&KXYN[-_PSOXF&3G_ )!6H?\
MQFD_X71\<_\ HW?Q-_X*M0_^,U^V-%>W_;F8?\_?P7^1\-_J+P[_ - J_P#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN?A_^S;XA^*&O?!_3/'OPX\10>%Y_&_C#4M;L-0MIH5M[>:.&2V$[H1M1Y$
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% &=%X<TF#7I]<CTRSCUF>!;:745@47$D2G*QM)C<5!Y )Q6
MC110 4444 %%%% !1110 4444 %%%% !1110 4444 9V@^'=*\+6'V'1M,L]
M)LO,>7[/8P+#'O=BSMM4 9)))/<FM&BB@ HHHH **** "BBB@ HHHH ****
M"BBB@ JCKFA:;XFTFYTO5]/M=4TVY79/9WD*RPRKD'#(P((R!U':KU% #(84
MMXDBB18XT4*J*,!0.  .PI]%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
(% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>form424b4_004.jpg
<TEXT>
begin 644 form424b4_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #( G # 2(  A$! Q$!_\0
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M>7[_ *?_ %Z?LO\ IW5^Y?\ SP'I_)2_\ 7^13^R)_SR7_Q__&C[(G_/)?\
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M3_GDO_C_ /C1]D3_ )Y+_P"/_P"-7/+]_P!/_KT>7[_I_P#7H]E_T[J_<O\
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M^F:G\1?A[X>\37NFPSSN]Q>0Z;-?MI]O>S37)N+2UMV2\NHPDI^E_+]_T_\
MKU#I+I3K/_MU+\/[1?YBT_EHOS]G;]"G]D3_ )Y+_P"/_P"-'V1/^>2_^/\
M^-7/+]_T_P#KT>7[_I_]>CV7_3NK]R_^> :?R4O_  !?Y%/[(G_/)?\ Q_\
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MI_)2_P# %_D4_LB?\\E_\?\ \:/LB?\ /)?_ !__ !JYY?O^G_UZ/+]_T_\
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M^:E5YNG[J$UHI-7;S6#2YG9JS35GNM2RWY:*]:=_T/LO]JOXY?M=?L8?L?\
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MEE@GBE>S0 4444 %-92<%3M8$<XS\NY6=<'CYU7;GJN<CD4ZB@#Y3\>?LD>
M/B#^T'HG[06L7NHC5/\ AG3XL?LN_$+PC$98_#?Q1^%GQ1\4>"/&45MXE^S7
M=K?0:OX'UWPKKP\(:E93K]@TGXF?$+36@9M9@N[/S?4_^"=OP!TSP%XW\/\
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MUIWA[4+'X?\ B7X*>&;&VTO1O .C?!WX-@'PSXU_X+3?"_X;_M[_ !R/P$\
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MIE<LVW?O>-HG,DT7G+L) 1@ZRJ5)+QLC#:A#*(W#^6XD*N0$*A07WJ ?B/\
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MT[&8IO+;@#\S?V:_@!\:?$/@+]LGQ!XGUCXN_L9>)_VMOVGH?C?X,TKPM>?
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MTJ\OM.CN+.*_M7F2YA\BB^&W_!4IE#C]L?\ 8"#,JJQ_X=J_M$ D*20!Y?\
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M?L,_"K1?!WPTTZZ^,_[7WC_6?"GA?X!6K>.-4_;@_:ST:7X@7WP$\ V/P_\
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M*O\ "H&3T'4_Q$DD#I3Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.]VD).[(A*!<@9555?N[LE=Q=P" TCD;J )J*;N'HW_?#_\ Q-&X>C?]\/\
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M.OQ?%-O%,7AE_ UZYM?%RI+X2N+74EU-]+F=+%9+B*V0M)>,7FLX(I/Y]O\
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MNLP!X64*T:2J721 [1R%5EADAG$;2P0M-$DR).D8CE!&"O\ D*_\'13O;_\
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M\!?_ $&U? W_ !%$_P#!=C_H^ _^(S_LB_\ S@*/^(HG_@NQ_P!'P'_Q&?\
M9%_^<!0!]\_\/*?^#QO_ *)S^WU_XJ>\!?\ T&U'_#RG_@\;_P"B<_M]?^*G
MO 7_ -!M7P-_Q%$_\%V/^CX#_P"(S_LB_P#S@*E3_@Z%_P""Z[)+(_[<@BCB
M4,6?]F7]DDAG9@J0JR?L^LJRN-S)YK11E8WS(&"JP!]Z?\/*?^#QO_HG/[?7
M_BI[P%_]!M1_P\J_X/&<A3\//V]E)#-M;_@E#\/PY5<;G6+_ (8W\V1$++YK
M1HXB#*7 W*&^!Y/^#HC_ (+JQG'_  W(CD,R-L_9J_9"<*Z'# 2)\ VBD7/*
M/%(ZNA5LC.!]1?L._P#!Q[_P6R^-7[9W[)/PA\7_ +5UG\1_"_Q/_:;^!'P]
M\3?#S4_@O^R[\/\ 2_''AKQI\3/#GAO7O"^H^.?#/P!D\2^$;36M.U*73Y_$
MFBVM[=:%;W,VKBRO/L*VLX!ZT_\ P4E_X/&@Q$?P[_;ZD"EE+?\ #IKP,O(8
M[<*/V-&<!HS')\ZH1O*8)0FOTN_X(]_MO?\ !RW\6_\ @HM^SO\ #_\ ;V\#
M?M;V'[*NMM\69OB9<?%?_@G_ .%?@!\/Q/HGP*^)^O> X]?^+6F_LP>";[PM
M]J^).F>#K*P\G7+<:G>W4.FN'%R(I?Z\X_B9^W:HY_9+_9Z:0HADC7]M#Q:X
MA8@L$Q-^R0D6&#;U:#*[2L1 $*,Q)\2OV[9"F?V2OV?U".'VK^V?XF4/@$8<
M#]DOG;N+QG@QS+%*,E-K 'U!97_BMQ(\6A>&'(Q$9SXNU>02"-Y6")>/X.F^
MU+$\D@<"7%K.T]J%(B$T][[=XP_Z ?A;_P *_5/_ )B:^44^)7[=JL[-^R3^
MS\Q?'*_MG^*$;"L^T,W_  R:VX!"O "KYQGF 'GE$D_X6;^W5_T:1\ O_$U/
M%'_T)= 'TYJ-UXUDM9_(T+P>;A8)/LR77C+6%M))W*1^7=^5X,1C;"![B4X$
MA\Z&!51"WVB#-^#[_$>7X7?#R;XQVWANS^+]SX%\&W/Q6L_!KW<W@^S^),GA
MG2T\=6OA:YO'DEN- @\51ZLNDR.WG?V?]F-R'N&DFF^-?BI\:/\ @H=X<^&_
MC[6_!O['?P&U3QAH_@CQ=K'A32K?]L'Q%KEWJ7B32M!OKO1;2#0Y_P!F'04U
MGS=12W5].&LZ8USE(DO()&C<??>@274VD:=-?6L=CJ$MC9R:C81E@EE?R6T4
MMU;K&99A$$DD/[L.YYW/)(S%R ;%%%% !1110 4444 >'?M!^/\ 3?AQ\/;G
M6]8\!^-?B%I.J7D?A35M)\$:!:Z_/8Z7XAMKNVN]8\4QW.J:0NF> K!HH7\6
M:R;S[/IUD8Y]1C72Q>W-O_+-_P $,_'NHVG[96L:#X<\$_\ !3_]GSX ?$[X
M&:]XS^ _[.?QI_9%^*/[//["NGZ?H_BJS\1ZOXE^&>N_'S]NW]MG7KOQCK6C
M_$306TG0_@8_PB^%>J6D+ZO=^%A91^&++3/Z:_VRO@CX7_:+_9L^*WP>\:^-
MOBS\./"GC#PU)#KOC?X'>,_$'@'XG>';#2+ZQ\0O>^'/$GAC.JA7DT>.UUC0
MW@OM&\4:'/J7ASQ%I]QH>IW\D'\_/_!(?0_V&_"'QH_9 7X6?&C]L']H+XG_
M !*_8+\4?$;X7ZI\=_VR?!?[0WA[X(^%3JGP6TKXI> M0^#7@GXF>)K;X*_$
M/6K35OAOK5C9^&_#>M>%8K%-=\+?\)5'<>#_ .S[( _2C_@MSX<^%FM_\$Y/
MB[:_''7?A5I_P7T;Q7\'?%?Q5T[XT_&'XJ_ 7X7^-_ G@;XL^#O$6N?#SQ!X
M\^!'P\^*/Q=75_'-GHT7A7PQX?\ AKX%UOQ/KWC*^T2TT#2Q>1 )XO\ \$ M
M._8LM_V5_B3XH_86^%GP!^%WPD\7_&6Y?5='_9__ &H/VLOVH;*X\9Z5X*\)
M6UY+\0;W]KKX#_ ?XG?#'QK'H4^@D^"F\(R:7)X<E\/Z[%?/+JLE>E_\%HOB
M9X>\'_LP)I'B?XV?$_\ 9%MK;QY\,/BYH7[8?@W]COQ)^VGX/^!GB7X#?%#P
MA\3=*'COP)X)M;^X\(QW]UH%@VG^)?%<&G>&&ADUBU.KZE%;ZAHUU^?O_!%3
MQA\3/C!^T7\4?C;X4_X*L_$[_@H?\$_BAI^IZU\3];?_ ())']C7X2Z]\6M!
M\+^ _AGX1U*W_:.\2:;X:O\ 6=<\'^%_"=MHEI\-?AM:/I =K[6=8L=!O+Z.
M?7@#^I>*:.8;HV#J0&5T(=&!++Q(N8V8,C!E1V*84OMW*#+7,:CXH\/Z'<Z=
M8ZEK6DVVJ:]/=6>A6%WJ5I!?ZS=:?;S3W%AI5HQ&HZM<6ODSF>UTZUU*_@!:
M66$)NV6X_$6D7%WJ%C:ZEIEQ>:08VU:WCU*S:;2X)'E47&HP1RRW%C$XM;]8
M7O(8$FGL9XE<*/- !MGJOU_H:_/SX9_\I2OVQ_\ LP'_ ()I_P#K0G_!5FON
M;2O$.FZYIEKK&CWNG:KIUX=UG>:;J=G?6=W$UT+19+6]MY'LYRLADAE$<[*M
M[#):1/,0)3\,?"]EE_X*A_MA7,;!HIOV _\ @FQY)PV9(D_:&_X*L".X5E#0
MF*X5@\(25I0GS310AH_, /T$[GZ#^;4M)W/T'\VI: "BBB@ HHHH **** "B
MBB@ HHHH :W\/^\/ZU_D&?\ !TC_ ,ITOVW?^N7[-7_K(_P'K_7S;^'_ 'A_
M6O\ (,_X.D?^4Z7[;O\ UR_9J_\ 61_@/0!_/Y7]_'_!C)_K?^"H/^[^Q5_[
M]K7\ ]?W\?\ !C)_K?\ @J#_ +O[%7_OVM '^@!6=J7^I/\ N2?R6M&L[4O]
M2?\ <D_DM<V+_P!WG_BP_P#ZF8 3^&I_UZJ_^FYE*0R+#&R $*C.P;S"OR .
M&D\LB1455;$D2O-'.8'C1\-&_P#-%_P2T^-GQ(\>?&[X5VO@GPWX&O(+3]G;
M5M*^._Q%M_C7\9S<?M<ZSK>K?LK_ !,;]KSQ1<?$']BKX;:?XZ^)/AOX(_&#
MX;>/_#UWI?BR*SU;3/VG+CP0_BC3=%\(>&2_[0?MV_M0:E^QU^S7K'QYTGP-
M<_$:]T3XC?L\^"!X3M+N:VNK^S^-'[1WPC^"FIW=A'!9:A)J.J:%IOQ#N_$E
MAHZV\#:P^C2:9_:VBK=MJ=OYE^S/^S_^SIX"^*F@^+/A?^SS\9/A)XB^'_P5
MU7X/^$=2\?0^(K'P9X8^$US=_#B6Y\ Z%I5QXRU;2(Y)=,^%GP7\-0S7>F:E
M?:;X'^$?@[P[HUUIUK97;7%4M*$=-\52:?N[*GFJ:WYMVGM9^32O:_\ <%/\
MXG"?\%4?@KX\^+&@_L:Z]X&F^,VL/\+O^"C/[!7CGQ!\//APM_=>#]7\-Z1^
MU[\$M5\3_$#XM:/X>T.X\3^(/!WP@\'Z-XE\3I;ZGK-I\+?#$VKW_P 1O&.F
M:GK'@CP+XG\"^:_"GX7?M*_"#]O_ /X*A?$_X8^#/%'Q>U3XJ_"#]@&]^%EU
M^T[\2?&?PG^"-_>:3XZ_;5D\>_##X7_%GPA\ _BOH_A#PG\'/"?BWPSJ<'@K
MP7\+/$-\=6U[3==^)ES'X_\ B=XR\<7WK_\ P4]C^,^G>&/V0/$'PB^*7Q,\
M :=I7_!0S]A+2_B'X8^%\4L-]\3_ (>>,?VK_@UX<\9:%XY\2V5K=>)-&^$M
MEX+U?QG=>.=%TJZTBR\1P#2K'Q/K/_"%P:]X7\3?-?[#WQ;^.$7QM_;$7QM\
M(_CM\1_B&OCKXWB72)/V@_%&M+;^%O!W[9'QV\%?!W0]3^!OQ<T+X3_!+]EZ
MXU3]GB7X<>-_@_\ \*X\<WL_QW^!$6A>-?& U+7#H_BWQCN2=?\ \%$/A/\
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M3:%<:OK?ZNPP"$@C8"R0HRQ1^3#NAC9-Z1;GV%EPG+,1#'#$681 GX$^&?\
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M\+X?%UW\6KSP7;>%O$NHOXY\*^'?!_C*V^+VN_"70-?YCX1?M'?'#1/V[O\
M@HE\-_C5X@G\9?![X2_"?]A?QK\#/AC\'?A1XC\0ZYX+TWXV>*/VL=!UZ1[;
M1++7/B#XZ\5:S#\,_!7B3Q3?1:9IOA_P/8VZZ/I.@6^F>']0\9^(^B_X*5^)
M;_P6G[/GB33/"'[,?C_6]2^*7A[P-X ^''QI^#NH_&;XM_%;XE>,?'/PZBT_
MX?\ [/UA;^,?"-E\.K^;X=Z9\3_%7Q)^,=_:^,[7X3>$O"D/Q%U;PE?^$O"W
MBN2'SK]D_P#;F\+>//BI^U%XG^,?B_X&?#+2/"_B3Q_X)MH8/A!\8/A7XDM/
M#_[/O[67QS_9DCN]<_:9^(EW9?#C]IRPFU_P[H]W<6GPSTC2V^"GC_Q]JW@C
M59O$EIXZ\/>(+_L$:/[:W[2?BZ#Q+\!O _P"^,_Q3^%_QW\>?%C4_AS\-/@9
M<_"'1=%G^.&L^%-8^&7B#XD_$3QOJOQD\!ZKKS_LF_!/X1GQ9K?Q7\??#-M'
M?Q3+XJTCPC\-?BA?_&4_#OPW-9_9:_:%^(?A[XN_M*>'/C3\:;+]H?PQHWA;
MXG_M!>!O$'P!U:'XTZ9X7^%,'[0_QL\)Z5\&K'X._![X Z-\1K3XE_#71/"N
ME?";0-,T;Q3\:/&GQQ\9_#WXE1:1X;\*>*/"-UX:URU^W+\1_#UYI?PW^+G@
M'P]^RK\;/"?P;^/?@SX<?%ZS^(/PD_X7-XE\%7'C/X[_  '\-^.;K0_%-CXC
M\-:9\"8/AG\-M:\8?$SXL_$K7Y?%4'@*[\+>!=?O? ?B9=/;3+S&_8Z_:CUJ
M[\?_ +1/B/XVVW[/7PQ\"7'@KQS^T7<^-O"/@ZZ^$\_A;P%\._VD?VE?@MK-
MU\??&7B/XA>(]*\=ZIX<^'WPD^'OB3Q#\5KFR\(Z59W$_CZ5(%\-OH:Z. ?A
M/^VK_P %Q/'_ .S-_P %ROV<O"/[/7PLU?6?A/\ ME_"3]@KX*?'BS_:*_9$
M_;#^%_QTL-&\(_M;_M::7<R_L_?"KXA:1\$_B!K>O:EX6^.OB*P\,:HGPW^(
MGA3Q/X\AM/#NF6U[K_A_QAH(_JE^!O[6O@_XX?&'XI?"#0/ 'QI\(ZM\+_AY
M\(_B'JNI?%OX5^/OA0FI:?\ %SQ%\9M T?2]"TCXD:!X;U[5Y-&G^#FM76KZ
MWIUEJ'AASKFF:;INO7FJ:?KNDZ#_ "M?MC?\%<_^">?@[_@N7^S<UK\%OV,_
M^"@6@_'+X8_L!_#'P5^UC9_&'X(_$C3_ -ASQIX3_:W_ &KCXD\=>'O%MEX
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M!KOS36'A[Q(]D ?,/AK_ (*M?LF^,M,FUGPEX<_;>\3Z3;:[XI\+W6I^'?\
M@EW_ ,%-M;TZU\3^!O$^L>"?&WANXO\ 3/V0[FSCU[P=XR\/Z]X1\5Z1YYO?
M#WBC1-8T#58;75--N[:+?_X>8?LY?]$[_;Z_\52_\%1?_H/*XW]EOXT?LW_
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MXB"R0E1-:32R+&E\&DCFCEBF$D,3P3P6=Q#%;B6TA:&$I(L"><57]&_VZ/\
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M=7\0Z]+IT<FMZS=W6J7-L9;E43YW^,7[ _PM^.OCOXR_$3Q7XP^(]AKWQE\
M?LE>#)I?#VK:%!9>!M2_8K^/GQ!_:2^ _C_P39W_ (<O]/N/&.@?%?Q[<>(M
M6MO'FG^-O!VKG0]%TF^\*S>'KKQ-HGB#X3O/^"OVF^#OBUJ6D^*?A_XDU/X%
M?#KPK_P5B\?_ !F^*2Z-X,T'Q%X'TW_@FS\?= ^$VMZ5X:\"V7Q&U_5/&.GK
M:ZS;6-IK=@T7B+Q4;_PMJTO@;0["[\8GP1]#7W_!4WPOHOC30_@YJ_[+O[26
MD_M%^(_BS\)OA19? "_N/V=9_&*-\;_@'\?/V@/AQ\1K[Q?X;^/_ (B^$"^
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M^&-.\5V_AOQ&WAO4M6M-731KJ>UMWB^PJBEB\P##%& .'7(<?,C%=P92(WV
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M7[+4]$U'Q9+I6LZC9W-SX>T,V'VIYGM^O_UJ/,]OU_\ K4>U7\E7_P $U?\
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M#_QK?^ ]?E\6_#_QYX%M;K6--TO1]7GU/PG>>-O#7AZT\?>"IK37+ :?\0O
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M7_@+_P P^UI_SU7_ ,?_ ,*/M:?\]5_\?_PHHH_LR7_03_Y;4_\ YJ#ZR_\
MGW2_\!?^8?:T_P">J_\ C_\ A1]K3_GJO_C_ /A111_9DO\ H)_\MJ?_ ,U!
M]9?_ #[I?^ O_,/M:?\ /5?_ !__  H^UI_SU7_Q_P#PHHH_LR7_ $$_^6U/
M_P":@^LO_GW2_P# 7_F'VM/^>J_^/_X4?:T_YZK_ ./_ .%%%']F2_Z"?_+:
MG_\ -0?67_S[I?\ @+_S#[6G_/5?_'_\*/M:?\]5_P#'_P#"BBC^S)?]!/\
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M@^LO_GW2_P# 7_F'VM/^>J_^/_X4?:T_YZK_ ./_ .%%%']F2_Z"?_+:G_\
M-0?67_S[I?\ @+_S#[6G_/5?_'_\*/M:?\]5_P#'_P#"BBC^S)?]!/\ Y;4_
M_FH/K+_Y]TO_  %_YA]K3_GJO_C_ /A4,\D%PHCE>.2(D>9%(ADCD4$,%>.1
M60X=48-MW*5^4KDFBBC^S9?]!/\ Y;4__FH/K+_Y]4O_  %_YB!XA@K+$-DO
MF1?++B,%&1E(#@,,23;!PB>8,1DIEHML (=9SYL:LL,DDU]*R!E*%6+7&]T8
M"-I$WJ)9HH[AR9HX7B**?]FR_P"@E?\ A+3_ /FKKU[W=]V'UA_\^J7_ ("_
M\QBQ0*0?/C.R?[1$Q@C$D4S),DDZRB(,;J5)Y(99WW&2U)A="\D\TT4%K! H
M NLM@J9%0QRB(OO6%)47SHHX@TD4.R0/Y<LLMP]Q?2RWKE%']G3_ .@K?3_=
MH=K?]!?8/K#_ .?5+_P%_P#R188)((S+=%Y(WE82!2C%)58&$[4_U4;%'B&=
M^^VM9)I)IHFDDM"YC4L1*HW8) #\D<;CQDL1@$GJ H[<E%+^S9?]!/R^K4[=
M]OK5@^L/_GU2_P# 7_F.^UI_SU7_ ,?_ ,*/M:?\]5_\?_PHHH_LR7_03_Y;
M4_\ YJ#ZR_\ GW2_\!?^8?:T_P">J_\ C_\ A1]K3_GJO_C_ /A111_9DO\
MH)_\MJ?_ ,U!]9?_ #[I?^ O_,/M:?\ /5?_ !__  JAJ%[;K QDF0%4=T!9
MUY4 %GRIQ$FX&1R-B#!<@'-%%:4LFI5ZD*6(J^UHRG3<Z?L(PYG3JT*L/>CB
E)-<M2G3GHG?D2>C9G7Q4XT:TH0IQDJ4[246VKQ:>[[-KYG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>form424b4_003.jpg
<TEXT>
begin 644 form424b4_003.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $H Z@# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN ,4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%92Q60OX99$C4L=@"H2Q##=BN8^-'PA\=W7[4%UKG@/P3XKT7Q1J.N:1=?\
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M6%=H8<[B2< 5ZW^P%\>_'/C;5OB;\+/B;J$>M^,OA]J?V0ZPD80WEN6=%9@
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M>Q!]*^4/^"//QP\3^*U\9?#W7=2NM5TW0;.UGTKSW&VSAR4,*+CI\P/)_AH
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M?^3E/%?_ &*^E_\ I5?5ZA7E^B_\G*>*_P#L5]+_ /2J^KU"@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *Y3XJ_#?2?C!\.?$7@K7?.&DZY9O9W#6[
M!9%5A]Y200&!P1D$<5U=>4_'?]G^#X[0Z/'-XU\7^#O[-:1@WA3538F?>%&)
M< [@-O'ID^M '@_AWX0Z3\%_VVO EJWB#Q'X@DU_2-6U&TMKRXC6TLKM8+6*
M[N"H7<[SA%8KD*&+'GC'TY\7_A;I?QJ^'.M>"M;N]0LM(U>(0W4FESB"=HPP
M8H'(. V,$8Y!([UXS\%?V/\ PCX!^*%GX[L_B1XO\>:UH]O/81+X@UU=1CME
MF #KC;E2=HXR.GM7IG[2C>'8_@7XQ?Q;XFU'PAX:6R+7^KZ3-Y5U%$&&5C;!
M.Y_N8 R=^!R: ,CX8_LO^'OA;\-=?\"6?B+Q5K7A[5[(Z?Y.MZI]I-E;F)HC
M';?(!$-K'@#J :ZWPE\&_"/A#PCX9\.PZ/:ZE:^'=.ATNPN-3@CN+A((T"*#
M(5ZD#G&,Y-?F'>:AJ4?[/^G-X5UBWT7X>^.?B5I\,?AO4/$TTT6C:4\)$<>H
M7,<K2VZW$D8DD0."!P""37T]^RY^T5?:!\(O"^AZ5\,/&7BJTAN=2LGU;1;D
MZKI\+6]Q*F([F9Q(T3;?W8.["E1N.,T >L?%K]B[P-\6_$WAO7)-2\0^$;SP
MZDBZ6GA.]33HK9W.7E55C.)&X!8<X4>E1ZE^Q/X%UOQEIWB#5-7\6:H+>6RN
MKG2;S6Y)+#4;JT0)!=7,)'SRC )(*AB,E3S7SE^V=XST;XO?"!O$.IKK7PU^
M(NEZ5>7^E>$_%VL2:3(D$3J9;Z".%PLUT NV)&?G<<K7FNJ?$.X\0_&B'Q?#
MXAUI/'UOXR\':9X>TZ^OI(KF71[FRC:X5K4-M=9=TC2-M.&SR* /T^\:$KX/
MUTCJ+"?_ -%M7R;_ ,$P/@KX1^&WP+LO$VB:FVI:]XNLK6_U5)I8I&M7 <"-
M=HW*O)X8GD5Z9\9M9^/EO<>)H?"GAGP+>^$Q:2""ZU35+J*\9/*^<LBQE00=
MV.>@%?$?_!&<&'XF_$Z+3OFT=M%TUYVC^9!=9;@MUSS+Q]: /U;HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@?C'\
M'=*^-&AZ/I^I7EYITND:Q:ZW8WE@X62*X@?<O4$%2"RD'LQKP+]E7X>Z/\(?
MVF/BQX*L]3US6I]+T?2VM+C5+A&AL]/D>XDALXD502(RSC<Q)Q@8'?T3XX?L
MLV7QA\4#Q'=_$SQ[X.6&T6!K3PWKILK3:I9O,9-I&[YN6] /2D_9Q_9C\+_!
M77/$/BG1/&?B+QQJ'B"""UN=2U_55U!BD);8JR!0>-Y'4T ='^T-^SEX;_:8
M\*Z?X>\4ZCK5CIME>KJ"IHUX+<R2J"$+DJVX+N) ]<'M5.^_9@\.ZU\+=+\"
M:WK_ (H\0Z=I^JP:Q%J&K:G]HOFFAF$L:M*4Y0, -N.G&:Y#]O#5O .@_!NU
MU'XC:KK$6AV^IQ/#H.BWQM)-?N=K^59.ZD-Y9.68AEP$W$\5\"?$)O%/AGP[
M\.?#OB/Q9I6OZ'HO@?5_$L,,GBRYAMENDO';[);7D#YGO((=D48<LH.>", @
M'ZVZAX!\,ZM>7-W?>'-)O;JY4)//<6,4CRJ,8#,5RP^4=?0>E>,M^Q/X/A^,
MUQ\3-.\3^,M#UZXEMVEM=*U9;>S>&$H8[4Q+'_J/D \O.""?6JMI^U-K5CI-
MNME\%OB/KMI%HEGJ,-_;VL4RW?FQPGRE=G4O*OFG=D#F-Z^=/BOXN\.W'[2G
MPM\>Z1K>K:=XFN?%>F6'B7P[>:Q*-9TKSX=L.GII^X1?9WW;YF&YAC*GDB@#
MZJ\'?L@^!_!?Q0A\<PWGB'4[VSGN[K2M,U;59+FPTF:Z_P"/A[6)ON%QQR3@
M'C%8_P#P4$C6;]C[XBQ,YB22WM4:13@J#=P D'M@5\K_ ++?B*[E_:4^'>JP
MZ]>WOC;Q/J?C*W\<:?)J4DPCAM9P+(26Y8K"$PH3"KD'O7>?MSW_ ,?I?V:?
MB1'XFTGX?0^##"@N)M-O+QKX6_VF/:55U";_ +N<G'6@#Z6_9A^"/@WX$_"O
M3O#W@O49-;TA))IHM2N)X[B1C*^YU$B #;N'0=Q7KM?$/_!)^7Q(W[.VEQ7J
M(OA5;3.EM'T:8WEY]HW''WLB/@$C&WN37V]0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6!XZ\?>'
MOACX7O/$?BK5[;0M#L]OGWUVVV./<P5<GW8@?C6_6?KWA_2_%.ES:9K.FVFK
M:=-CS;2^@6:)\'(W(P(." ?PH _,*Q_:3OOBUXL\;ZGJO[8MG\,K>WUVZM-+
MT33]*BEMS8(V()DF8#S ZX/KD'-?IEX(F%QX+T"5=7_X2!9-/MV&K;0OVW,:
MGS\#@;_O8']ZOS&E%[X^\>?$"!OB)\$_A''H?B&\TBW\-:IX9T^6=((GVQRE
MW W;UYR"><].@_3CP-";?P3X?B:\M=19-/MU-Y8QK';SXC4>9&J\*C=0!P 1
MB@#<HKP7XA_MV? ;X6Z])HOB'XDZ5!JD3[);>S66\,3?W7,".$/L2"*[WX5_
M'CX>_&ZSFN? OB_2O$R0\S1V4X,L6>F^,X=?Q H [VOCK_@H+\5/%W@/4/AA
MHWAKQ#K^DV6MWEZ-1L_!5K'=:_<K%;[XS;QNI!B5O]8>, BOL6O'/CQ^S7IW
MQMUKPMXB@\3:YX)\7^&C<#3=>T"5%GCCG39-&RNK*RLH';(H ^-K7X\?%OXP
M^#_A%X=L_B8= U:Y\ :KXOU3Q!H,$3O>W-M(\<$$FY<+M* 2JH&6WCTKG]8_
M:P^+WQ8\(ZEXOT7QM<>#I/ GP]TSQ1/86=G$8-8OY9,3>>'!/E%48!5P 2#7
MU%K7_!/#P1-X%\&^'O#WB;Q-X1NO#5A>Z6NLZ7=1_:[VUO&9KN.<NA5O,=V;
M( VECCBG^._^"=_@#Q<=(@T[6_$7A32;?0[7PUJ>FZ1=(L>L:=;NKQ17!9"=
MV5Y=2"0: .S\6?M7:5X!T'P?>ZKX/\9ZS/X@TB#5!_PC&@3:C%!O124=D^ZV
M3T/.*\T_8S\>6OQ,_:(_:0\2V6FZMI%M>WVB;+/7+)[.\CV6&P^9"WS+DJ2,
M]00>]?6]A8P:78VUG:Q+!:V\:PQ1*.$10 H'L !7S;^ST2?VN_VH<_\ /]H'
M_IM% 'TU1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%4]9O7TW1
M[Z[C57>W@DE56Z$JI(!_*OQX;_@MG\4U8C_A!?!_7TNO_CU 'ZAZ+_R<IXK_
M .Q7TO\ ]*KZO4*_$RU_X+!?$FU\=:CXJ7P5X4-[?:?;Z<\1%SY82&29U8?O
M<Y)F8'GL/>NY\$_\%F/B=XH\9Z!HT_@GPE%!J&H6]I))&+K<JR2*A(S+UP:
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M\3/"#R.P5577;4EB3@ #S.N:]#H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#YH_;^\(Z_X]^"-GI'AW0=0\7R+K^GW&I>
M'--O!:OJ-BCL9H9)-P*HP Y'.0O%>'_LEVOC;X0_'+Q%'HO[//BCP/\ #SQ3
M)I]M'IJZQ#<6>E.@99[R0,Y.6W#A.R]SBO2/V_/V<T^('A"/Q'X7\#?\)CXP
MN-5TN#4M/6]%N=1TZWDD=K<L[A4SO/S*-_/>KO[$?P[T[P'J_BL6G[/]S\$I
MKB"WWR7/B)-3-^ SX4*&)3;R<D#.[VH ^DO&'P^\+?$*T@M?%/AK2/$MK;N9
M(8=8L(KM(V(P659%(!QQD5D3? WX<3Z+INCR> /"[Z1ILYNK+3SH]OY%K,3E
MI(X]FU&)Y) !-=O10 BJ%4 # '  KG+KX:^$K[QA;^++CPOHT_BFW3RH=;DL
M(FO(UQC:LQ7>!C(X/<UNSWUM:W%O!-<1137#%88Y'"M(0,D*#U('/%3T <_I
M/P]\+:#XFU+Q%IOAO2=/\0:D M[JMK8Q1W5T!VDE50S]!U)Z"O&_V_HUE_9%
M^($;J'1XK165AD$&\@!!_"O>(]:T^:]:S2^MGO%)!MUF4R#'7Y<YKP?]OZ18
MOV1?B [L$18K1F9C@ "\@))]J /:O!OA71?!?ANRTCP_I-EHFE0IF*RT^!88
M4W?,V$4 #))/U-;5>4VO[4WP96UA!^+/@D$( ?\ BH;3T_ZZ5+_PU/\ !C_H
MK/@C_P *&T_^.4 >HT5Y=_PU/\&/^BL^"/\ PH;3_P".4?\ #4_P8_Z*SX(_
M\*&T_P#CE 'J-%>7?\-3_!C_ **SX(_\*&T_^.4?\-3_  8_Z*SX(_\ "AM/
M_CE 'J-%>7?\-3_!C_HK/@C_ ,*&T_\ CE'_  U/\&/^BL^"/_"AM/\ XY0!
MZC17EW_#4_P8_P"BL^"/_"AM/_CE'_#4_P &/^BL^"/_  H;3_XY0!ZC17EW
M_#4_P8_Z*SX(_P#"AM/_ (Y1_P -3_!C_HK/@C_PH;3_ ..4 >HT5Y]H'[0W
MPL\5ZQ:Z3HOQ(\)ZOJMV_EV]C8ZW;333-C.U$5R6. > .U>@T %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5R7Q4O_ !GIO@>_N/A_I>F:SXJ5
MH_LMGJ\[06S@R*)-SKR,)N(]P*ZVB@#\]O'O[.?Q.UOQKKVH0?LQ?!76(;J]
MFF34-0N7^T7(9R?,DY^^V<GW)K[@TS1+C_A5]IH]SI-C:77]CK:2Z3;.1:QO
MY 4P(PY$8/R@CG KX>\7?\%#/B%:^/\ QG)HNA^$X/!VAQZ[#9VNK7S1W]U/
MI;0><9CN B$BRMY:;26(Q]?NWP'XJC\=>!_#WB2*VDLXM8TZWU!+>;[\0EC6
M0(WN-V/PH _/?5OB5\3?V4=)TW3=2^&'P!^'%I< K:03:JT,DX'!;C+O[NV?
M<U]5?LY^!K'Q9I.B_%'Q-X(\$Z/\0)HYTAU;P8ZRP36DA&TB9?\ 6AE ^]G'
M;%>-_M+_  G\9Z'^TG=_$G3O@OIGQXT'6/#\.C1Z;?7,*2Z/-&TA+*LP*^7(
M'!) SD'E>_LW[$OPA\0?!/X!:=X?\306^GZK-?7FHMI%G-YL&F)/,TBVL;9.
M0@.."1DGD]: />:**S?$'B32/">ER:EKFJ66C:=&0'N]0N$@B7/3+N0!^= &
ME16%JOCSPUH.EV>IZEXBTK3]-O2JVMY=7L44,Y894([, V1TP>:DU;QGX?\
M#]YI]IJFN:;IMUJ+;+."[NXXGN6](U8@N?IF@#9KYE_9Y_Y.[_:A_P"O[0/_
M $VBOIJOF7]GG_D[O]J'_K^T#_TVB@#Z:HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** ,OQ5_R+&L?]><W_H!K^6R3_6-]:_J3\5?\BQK'_7G-_Z
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M9*\X)SQFOV"\0?!_P)XLT'3-#UKP9H.K:-I95K#3[S3898+4J,#RD92J8''
M%2^(_A3X+\8:AI%]KOA+1-8O='(.G7%]I\4SV>,8\IF4E,8'3'04 >6:]HOQ
MYUSPGX'G\#^*_"_A]_[#MO[7A\2:7-=S279C4LP*.N!U!!YS7GO[&=GXLT_]
MH;]I"W\<ZEINL>*4O=#^V7NCVS6]K)_H&4V1L21A-H.2<D$U]?U\R_L\_P#)
MW?[4/_7]H'_IM% 'TU1110 4444 %%%% !1110 4444 %%%% !1110 4444
M9?BK_D6-8_Z\YO\ T U_+9)_K&^M?U)^*O\ D6-8_P"O.;_T U_+9)_K&^M
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M*]OENKIB\S+/<23 .Q)+, ^"W?&:[*BB@ HHHH **** "BBB@ HHHH ****
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MFR-P"=P8;CS\H':OK[_A16G?]#9XW_\ "HO/_BZ]*HH \U_X45IW_0V>-_\
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MZ>'_  CHGA2ULKR07>DO(]Y,]U%!FS*OTCAE28I)]XHP4]2!]S5X/\(?V/\
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MR>%_VSM-U#5-4T#Q_J'CC7O$1M;WP]KU]+=:$(MS>5=6C,(1&%^0?NP0QZG
MKK?V[+O]H)_V9/B8GB33_AW'X.^SJ)I--N+XWXA^T1["H<;-_P!W.>.M '.0
M_P#!,W]DMXD9O']\"5!/_%4V7I_USI__  [+_9*_Z*!??^%39?\ QNOQMHH
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M=L[(4+12(&0E2,C@C@\BB'P_IL,,<8L;8A%"Y,*]ACTJ^JA%"J J@8  P!0
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ML_\ X2#2^?\ B96?_?\ 3_&K-K?6U\K-;7$5PJG!,3A@#^% $]%%% !1110
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M7%WXSNKRUM;B/3;X1V[6]J]PQ<&3)#*A48[D5W/]B_M7?]#-\*?_  5ZA_\
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MW'.(9!U1]A.UO8\UKT ?.7]B_M7?]#-\*?\ P5ZA_P#'*/[%_:N_Z&;X4_\
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MHGQ:T==6_P"%H^)O#?B(R&/[!_PC^FR6GE ;O,\S>[;LY3&.F#ZT >G4444
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M[%.EZ[HG[*'PNL?$D5Q!K$.B0B6&[!$L:<F-6!Y!$908/(QBO;*** "OD/\
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M.\CNL^:CB%1M?/.X# .>X->HT44 %%%% !1110 4444 %%%% !1110 4444
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M\5Z=XL_8]^&[:?=-=-I^G+I]T7C=2D\?WU^8#=C(Y&0>QH ^C**** "BBB@
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M- 'A\G[4WQ2T[_A ;7PI'>>($UCXI:KH%\VMW\'FRI!+A+.-Q$!'$5W,&P6
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MJZU2>?[,(VT"\14DP3M=C'A.AZXH ^EZ*Y;X8_$K1/B[X)T_Q7X<DN9='O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
&4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>form424b4_006.jpg
<TEXT>
begin 644 form424b4_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #2 1<# 2(  A$! Q$!_\0
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M>7[_ *?_ %Z?LO\ IW5^Y?\ SP'I_)2_\ 7^13^R)_SR7_Q__&C[(G_/)?\
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MGP_XJ>_MKZ\T_3CX<N9/[6':2?(GA_\ X+)?LZ^)?#-_K^F?##X_2ZAKEO\
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M%] D7L7_  5H^*G_  5+_9R\ ?"6\^'WQ@TGQ3HOB74M<;QKXL_9X_9T\2^
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M;\/:/!9Z-H6@:'HNGV&DZ/I&E6-I8Z=IUG;6=M$EO##''^D5 !1110 4444
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M<MH?X(_J5DN%@CC9MH C9V9V**B1@98L%8G,C11[5!<^9N56VD5^$'_!<O\
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M<9VRN(DA$P& %\Q85)0$A<#KG<WXO?\ !#'X0ZQ\)/V4_%MGK?\ P3M\/?\
M!."_\1_%>_UQ/A[X?^(6L^-(/B_IT/A;PSI-E\;)O"OBG7O$GC7X,/KZV$OA
MN#X3^.=;U/Q9X>M_"T>H:C?7<&L6<I_:?B,$LQ*DEB6.=N2,* %^[UQDY' Y
MSQUDCZ8_\/U/_H#T;R21L8<<%BFTGL,JS, ?7;^9P"C'.!CD$Y(Y&=CY /!.
M._ ZCOD  ^ O^":7_)N_Q(_[/]_X*O\ _KT[]LNOT!K\_O\ @FE_R;O\2/\
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M9W^+]C;_  K\<:K\3O@O\:[+P+X\LY/#7B::?XA? OQ?\.;6UB\(:K937_\
M:GB;2=(\6_$<7DNE)<7>A0>#]3AU*:R-C%G]06T.U*V86&P0V,D[VA&G0YL_
MM$$UO(U@=P-G+)%*8II(R1- ]Q"T>R9?*^./VI=%L_#/C']DCXA0P6</_"*?
MM&'1M5N4M8K5'LOB_P" OB%X%8/Y)5%NM8\?>(O!5Q<.T<@U+4X8/.59Y89[
M;S,XH8?$X*E2Q&&I5:>"Q>"J8=U81G&_UBE3DU%IM6C4MJHNZ34ENOO/#3'Y
ME@\^S+"Y?CLPRVMQ;P%QQP%C(9;BZF$K2PN></YIBZ$O;4J]"+A',,KH.K"5
M22G"<DX2NXOZ)T#XI?#;71X4;0?'W@35H_'J:Y%X#31O%_AS4$\;1^&(YFUV
M3P2-/OIO^$G&C00-_:PTH7 TN*VNI=0:UCMR69X9^,?PNUUO"4&B?$;P'K?_
M  G]OKUUX"DTGQOX3U-/&]GX5FDC\3W_ (/6QUFXF\36?AZXDCM-=ET:&].C
MW'RZFEHK1-)UVGZ/;12V[M;62RZ<\BV$L5K"DEM%.TT-RL)6-?(^T/$R3*A(
ME6.-Y2Q6-8]"WTFP$UO)!:6]LUA#+%9/%!"LEI#=/,+F.T9440K<R1037*LD
MD=TT4?VF.5XH)(?9G-7:AR^RE2IJGR[>ZHVY=+I*-[72T\]#\[HRA.$8TJ4L
M,JLJ.82I3DIRC*I0E[:AS1;C:%6I%*SY7RRY;K;EM,^+GPUUN;PA%H?CSP3K
MA^(-IKFH> UT?QAX<U&7QIIOA8V__"4:KX1AM=2D?Q5IGAX7VFKJ]YX:_M9=
M,FU"V@U)+*1U#,T7XP_#'Q(W@Q?#WC_P/KQ^(NBZYXE^'PT7QGX7U5O'?AKP
MW-I-KKGB/P4EAJT[>*]"TN[\0^'+34=3T'[?;:9<>(=%AU5["74[%+CK(?#U
MA;BR$$-M;#3+;[+I8M;.W@&F0&,1-#8JJLL=N%2-EMY%EA:5 ]RER(K5+:2S
MT#2]/ATRWL;#3K2+1K=[32DM["VB72;62V6WDMM(4*180.(XLQ+YB&)/(=6C
M$0BR.@Y#1OB_\,O$@\'/X;\?>"/$4?Q%\'ZE\0/ATVA^,O#&J?\ "P? VDOX
M;2^\9>!VL]5EB\5^$8/^$S\'-/XHT*6_T&Q'BK0$U34+"76-+CO5T/XO_##Q
M/+X/B\-_$/P)K_\ PL3P7J/Q%^'KZ/XQ\.ZBOCOP%I,WA.#4?'/@X6>H3/XI
M\$6DGC[P,MQXP\.KJOA^UD\7^&[>\O[:YU[18=1ZRT\/:=91VD=O!!"+"%X=
M/,%M!&=-68 W'V [&: 7$@\RY+M-)>EF349;U/+6-UIX?TJP:S>SL+"UDT^&
M:VT]K:QMK<:?:736S7=C8+#&GV33[E[6&2:SB(BDGCBN)!)/#%(@!R&E?&#X
M8Z\G@QM!^('@;63\1? =_P#%#P"NF>,_"][_ ,)K\.M+C\*R:AXZ\)/:ZM,G
MB?P79+X[\#_:_%WAYM4\.6J^,O"<MSJ<,'B70Y=073OB_P#"_6;;PW=Z'\0_
M NN6_C/P+=_%+P;)HOB_0-47QA\,;'_A'/M?Q$\*/97T\7B'P3;'QEX.-WXK
MTN2Y\/64?BWPU+>ZI;KKFE_:^NA\/Z3;QV20V-FG]FV)TS3REE9Q?8]-D2!)
M["U2""&*VL[@6T#36<"1V<A@MT>W:&V@B1$\.Z-'&D46F:?"D&G/H]L(K&U0
M6^D2/'))I<0$0"Z?(\41FL@!:W AA6YAF$?S '':5\9?A1KMOH=WH?Q*^'VL
MVOBCP//\3O#%SI/C?PQJ5MXE^&UM;Z/>S_$'0;BRU2>'5/!$.G^(O#=]-XMM
M7?P[#;^)/#TDNIHFL632RV7Q?^%>HV]G>6/Q)^']]9:GX%;XGZ5>V'C7PS>6
MFJ?#:(VBW/C^PGAU-DNO!-JU_8?:/%L1;PZB7]BQU/=<!%[--&TZ(6XAL[.!
M;2T:QM%AL[=%M;1G@=K:W3RS'#;![6UD2V1!"LMM#(RNR"H+;P[HUF+<6NFZ
M?;&STR#1+1[>RMXY;;18&CD31X9BKRII?F1)C3P_V-8TCC6 %-Y .43XO?"R
M2*":/XD> &BNO C_ !1M9/\ A-/#7EW/PVB2"6;Q_ _]ID2^"X8KJUDF\6)N
M\.QK<P%M4 E4EY^+?PO"&4?$;P%Y2^!!\47D/C/PT$3X:\Y\?EAJC#_A"AC_
M )&PX\.'G_B:9&*ZN/0=*B2&-;"Q$=OICZ);Q?8K;RK?1W$"2:9#&8R([*6.
MUM5EM ?LDAMXB;<!0HF_L?3=@C%C:",6":68UM+95;38PP33V41 &P =E^Q$
M&UVDJ(0"P8 XAOC#\+(XKJYE^(_@%+.R\!Q_%*\O1XU\,M:V?PUG6:2T\>W<
MIU1?)\'7<5K>RV_BG#^')([&Y8:K\@#%Q\8/A?:)JDMW\1/ -I#HG@6P^)^M
M3W?C7PU;P:-\.-5&J?V7X^U:>34A#8>"]2&B:R]CXJFD_L*YBTC4Y$O\V<B5
MV4F@Z/*DT;Z;8D7&F'1IP+2#;+I)22,:9(A1DDT]$ED$5C(KVD9DD*P_.X)-
MH>ESFX\VPLG6\T]=(O%>T@;[5I4;7+Q:;/)L$TMA&UW<A+&21[%8[FY1;9?/
M=J ,?3?'W@O6-:7PWI?BOPUJ7B%O#>B>,_["T_7-.O\ 5E\(>)9]7M_#GBA[
M*SFFF&@>()M UR#0M8VG3=9N-$UN'3+NZ;2;XP]:&!)'< '&>=K9P2.HR0>O
MH??&?#I5E!.;R.WMTOC;)9->QVUO%<FRBFGN(K;S(XUQ$D]Q//L4"/SIYI%1
M#)A;Z)M)Y!^5%!(_>$)G =\G?RQ(X&"6ZEB: 'U')V_'^E25')V_'^E9U=H?
M]?:/_IV(U^C*L_5O\_Q&BB?JW^?XC17RN:_[S#_KQ3_]+Q Y;0_P1_4@BF6&
M-&99& B=\1Q22DB)0Y V(P#, 0BL5+MA$#,<5\<_M8?$[POX1TBW@^)O[/\
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M ? O_!-+_DW?XD?]G^_\%7__ %Z=^V77Z U^?W_!-+_DW?XD?]G^_P#!5_\
M]>G?MEU^@- !1110 4444 %%%% !7QU^WI'';?LP?$/Q<T>^7X2_\(U\=[<@
M$NDWP&\7^'_B^IC4?,Y;_A#/+,8!,JN8MK[]C?8M>>?$_P +Z?XV\'>(O!FK
M11S:3XN\.ZYX7U.*:$7$,FGZ[:+I]XDT#%5FADMII8I(F91(CLA=<YK#$T98
MBC.E%V;Y9)WM;V<E4;OK;E4>;9OW=$W8]?A_,Z62Y_D6;8BWU7+\YRK$8QN$
MJJ6!6886ECFZ4?>JKZGB<2G2C=U%-PLU*2.GTRZCN[&"Z1U99;>WG5E^8,T@
MWLX<'#!V9B  /[VYMX T[>19"Y P0<''3 DE4?J&/XX[5\J?L9>*M8\9_LS_
M  4U'Q#EO$Z?#CPSH?BV=IC/(WC+PCIUOX7\6+.2D82Y&OZ9J"74')M+F.:W
M=YG1GKZFL[<P&7+[]Q&/EVXS)-+_ 'FS_K@O;A<]\#6A*$L/&4FDVU[%)\UX
MM7MS+3W8MJ[M?E:2.?.\MKY)Q!Q%DE:'+B,DSW,LFK1:4;++LSS/#2E&SE%Q
MG1CE]:/)*<7'%1492]G-J]1115' %%%% !1110 4444 %%%% !1110 4444
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M^_\ !5__ ->G?MEU^@-?G]_P32_Y-W^)'_9_O_!5_P#]>G?MEU^@- !1110
M4444 %%%% !6?? /Y<>2K.DJ@@9R',4.S/4'S)8Y,CM&PP<Y&A67J,QA:VQ$
M)%+%G8-AXU66W7>%VG<@9U:0EE"[5ZYR-:*;J12WUMJEJHMK?3=+3=O1:M!:
M]GSQA&#56I*;48JE1O6J)MM)7C3CK=;6WDD_C']K*)_!P^!7QXBBDN(/@S\8
M?#[^)&MH7:[F^'WQ0TNY^#WBV25E5TBT30)_%6B?$#7S=2);6VE>#[G4))(W
ML8YX_L/0;IKF*8M&J$;6+H2R2EI[M=Z,RH[*4C1LO'&26)VC) _GW_X+C?\
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M3KB>Y@$NHW,'VP6MK 7NW,3W-O&QMC0!\#Z-_P %7/V2O$6I>+=&\/\ A_\
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M^'_@&W\/:1;^"[B_A-[$FI^'=$:WDTB75A,FHP&^LS?WUO>0Z@TT]K/"MO\
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M/^C*%FD@2;Z0_&S\_/$G_!5G]DSP=IUOK'B[P]^VYX6TF[U_PIX4M=4\1_\
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M6Y\OS?D?]K7PO\/?VHOV/_VHO@D/C'X+\#>&?CI\#OC)^SU>?%U+[0O$^A^
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M_P"_BT?:!Z+_ -_%H]O2_GC_ .!0_P#EH<K\O_ H_P"98HJO]H'HO_?Q:/M
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M4>SI_P#/NG_X+I__ " !]HN/^>\W_?U__BJ/M%Q_SWF_[^O_ /%444>SI_\
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MW]?_ .*H^T7'_/>;_OZ__P 5111[.G_S[I_^"Z?_ ,@ ?:+C_GO-_P!_7_\
MBJ/M%Q_SWF_[^O\ _%444>SI_P#/NG_X+I__ " !]HN/^>\W_?U__BJ/M%Q_
MSWF_[^O_ /%444>SI_\ /NG_ ."Z?_R !]HN/^>\W_?U_P#XJC[1<?\ />;_
M +^O_P#%444>SI_\^Z?_ (+I_P#R !]HN/\ GO-_W]?_ .*J:*65R=\DC89
M-SLV 6Y')/!P,^N.:**BI1I2@U*E2DGNI4J4D]>J=-I_-,QKMJFVFT^:&J;3
M^./5-/\ $2-F;5#"S,84M+ATB))C5Q/:*&5"=JL%9AN !PS#."<E%%<E;"81
M.DEA<*E]7HJRPN&2M%3C%66'2M&*48K:,4HQ2BE%>5C9S]LO?E_!HOXI;NFF
,W\6[>K>[>K;>I__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>form424b4_007.jpg
<TEXT>
begin 644 form424b4_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $I AD# 2(  A$! Q$!_\0
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MT]E_T[J_<O\ YX!I_)2_\ 7^13^R)_SR7_Q__&C[(G_/)?\ Q_\ QJYY?O\
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MT[J_<O\ YX!I_)2_\ 7^13^R)_SR7_Q__&C[(G_/)?\ Q_\ QJYY?O\ I_\
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M3_GDO_C_ /C1]D3_ )Y+_P"/_P"-7/+]_P!/_KT>7[_I_P#7H]E_T[J_<O\
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M3O!<WBV]\$^+--'Q0\/:EKNI?$ZYL=?T'2]"S_\ @G;\1/B/;_LY?";]JO\
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MPCH\\=UHWA77/["TXZOX;TBYMO\ B7W&FZ%J'VG2K:?3";&5;0R1D2M,!VM
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MO5M[VWFEM#(&0.ICDC*2K+&9C*5\L1*Y:0(UL8Q-'<P-&S7 FW+- RDR7**
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MJ->)F'_(PC_V+L-_ZE8HY,7_  <+_@E_[::D/3_@/_LIJRG0_7^@JM#T_P"
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M)QCP[^T3\KJ?^&R_VGP1(EV)/D^)%]&/,DNXD^T-M0 3V\EU:LH5(KJ0HZH
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M3M4C'B3]H+6-&D\N.9XKV,V7@RYG5I(YM-1XQ%!I5RMU^Z&GJZPN')),SD9
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MGX'\1+:R3ZCH,4OAF[MO'WB'PYKB^'8XV\007NKWFF+>0R2:==2Q2B&/^?\
M_:5_:^_X*.:#\8_B-\"(?C1\2_#?C_P_\2_C_;_!;QC\)O&?[!\/P<UWXP^+
M_B-8:U^RG\.OC!>?%3Q3=^,/#WP4\)? N+3)O&O@/4O!VC?$K7O%(^)-QC7Y
MK;P1;I^^?_!0KXF?$GX+?\$Z/VE_BGHOC"S\!?%CP'^SUK7B&/Q9X.?3;32_
M#?BZ'P\;2>^\.7WCB>:P\/Z/]JEFM='\0W9FET%7.NSV^H3V,UG* <3^R'_P
M4*\$?MJ_M3?M#>#/@AXCT/XA?L[?"WX-_ G7M ^(6E^#O'6@SZO\4?'OB?XW
M6?CKPC>:CXITK0K;4[?P[X2\)> M2M--M[1[B"Z\3WU[.S02V*1\YJ__  25
M^'?BR#]I67QG\<?BIXVU[]ISXP6_Q?\ %GB[QUX._9_\9>,?#TL?@_Q!\/[+
MX?>'M7\1_!_5!8?#WPCX \47W@_X;: D377P_P!/M;6_T;5I=6U3Q9?>)OG;
M_@B[\7]=^*:_'676OCUKGQJETRQ\ M!_;'_!1GX!_M[WV@R7P\6M?WD2_"+X
M5_#;4?AE!'<*;?9K\%Y#JZNECI>EBXTG4;JY_6ZY_:H_9OTB'QD]_P#&_P"$
MNGP_#[Q6_@SQL;KQUX=T]/"OBVXDU,V_AW7GO;VWMM*U>YN=(UNS,-[<P(VI
M:1JMFLGVNQO+>U /C;X[?LP? [X4?$+]@SQ7X.^'N@0>-_#G[2?PG^&]E\0-
M3@GU/QW=>%/#/[/'QE\&Z3::QXJEN4U?6KF#0M/L[9KW5+BZN9?*(F>2/RHX
M?U)C VNPZN=YR%SDQH "552VU0J[GW.0 "V  /BO]K:\MKCQ)^Q9/'*DMN?V
MQ_!ES#+;/%<BYC3X,?'6XA> I($DBF,9C,HDPF'D5944;_M5,!77DE,*V5(&
M1$GW20 PP1\RY .5^\I  /\ '>_X.6O^4W_[>7_8V?"/_P!9U^#]?A;7[I?\
M'+7_ "F__;R_[&SX1_\ K.OP?K\+: '+T/\ G^%J_P!@O_@V,_Y0?_L2?]>G
MQY_]::^,U?X^B]#_ )_A:O\ 8+_X-C/^4'_[$G_7I\>?_6FOC-0!^]=5+B5H
MRS>6K*B(Y8N0=N9/,P@1B2BA60!LR,^T%-N6MU\V?M<_&U/V;_V<OCA\=Y;:
MQO$^$GPH\:>/8+/47:*TO=3\/Z1<WVD64MQ''<2VZW=_%%9B1;6:,&Z#S/$D
M6)=*&!Q6:8O Y5@:-3$8[-<=@\LP-&E*C"K4QF.Q%+#X6%*>)E#"TZDJ]2G&
M-7%5*>&I*4JU6I"-%26=6M3P]&MB:TG&AAJ53$5Y*,I.-"C"52J^6*<I6A%^
M[%2E+:,9-I/PS_@H9^VMHO[%?P+N/&-KHEQXW^,OQ UNQ^%_[/'PDTEI+KQ'
M\4?C!XDD6U\*:'IEA:0W=W)I>G7$\>L^++N"TF:QT.SN51)[N6QMKOB_^":/
M[%>L?LN_##Q3X[^,NIV_C3]L#]H?Q,WQ1_:=^)K@7-SJOC75K:VG7P5I%RUW
M>K#X*\ PRRZ%X7L;6;["J)/J-NGDWD<2?F)_P2T^(!_X*M_M1>.O^"B7QOT6
M^TF\^!-MI?PU_9B^ LNFZ]J'A#X0V7B'1()_''Q8MO%VHZ9I'A;QEX]\2:M=
MZQHUKK7AMKFXT'0;:&W>,ZE!97<7],.FQ,(7+;E#2(R(?NHAMK?:D88)(L:X
M*JDL<;J00(TC"*/U[CNA/PRRFMX0858>/%$Z^%SSQ0SW"55B(5,=67M,GX$R
MC$TY.AB>'>'J4EFF88VA.LLUXNQ6(JJI6RS+\#*?RV33AQ-B%Q)4YEE]!UL-
MD]"<9PC7I5+4JN+E0J*-2G.+I-056G&2BVXKWN9R8,?+$$;V8D?(D:<[<AW;
M:J(BAV!^>0O((U#%5IZEK-IH]E?ZIJ+20V&FVLMW>S1VUW=&*&V5Y;AHH+:W
MDN[H1I$Y46UM*TH4B-6?Y*TYEW!8\C$@>,A@60[XI22Z!EWCY,%21P3@@@&O
MX)?V@OC'^U[\1/VS?^"@VGV/[=W[:'PQ\/\ PP_;+^*GPG^'7@[X6_&^?P-X
M!\/^%M \,>!=>TC3HM%LM!N)5EM;_P 4:D'G6\1I; V5JV&MFGF_&XQ2ISBE
MR.C3E&C%._M93C:^FD7%W;YFDVV];GU]E4E34IJG&,FY:-IQC2KM1M%-^_45
M&"LK)R4G:,9-?USZW_P42_9!M)]-M-0^).LZ=/K^H/X=T2&]^$WQCM[G5=:^
MSZIJ,NF:0C?#XG4-173]#U;4&M;;>XTO3[W4-PMK.8UK?LRP_LJZQK_Q;\=?
ML\^&]&C\3>*/&5]XM^(WB23P!XL\(>(M:\2^)C?W=O+J^H^+_#.D:GJ]G=3:
M?JMTBV%Q/#8$;OLX;4?G_A6UJQ_X*+:[=^$;W4?^"FW[5,T_A/Q&_B2PEOOC
M_P".[VY@NTTC6]"M[O2Y+=4CT35/L&MWVGW5V!??:-(N]3T[[+$-1%S;^G>%
M-5_;I3S6\:?\%,OV]+Y8EB^SR>#_ -I;Q#I\#)%8LEU'?R:QH6ISS2W%RB31
M?919M8VW[A)[AYFDBBOA\/B%EU;$4:=>KAY6E&4(MT7)K]]&<KV<'&[]F^:2
MDXJZNCHP699C@(9M#"8O&X/"YE@LMP.,P.$Q56A',\+EE.>:T\-BHTJM*C6H
M3SG$U:<*.)YJ5.K36)Y7'DK+_0JT^83),1$RHLHC0L(0)%6*++J(I'VGS3(&
M66.WE6177R!&$>33C& W)/S'&>PP./Z]>]?EG_P14^*'Q*^.?_!*_P#8M^+/
MQ=\<^(OB'\2?''PH76?%?C?Q9J%QK'B/Q#J'_"2^(;,7NK:G=2-<7MT;:UMX
M'GE;<RPK\HZ#]3U&!UR>,G&,G !/XXS6CYE5K+F<Z<IJ5.3O[L4DN2TM;+II
MT:=U8XX-2A"4*/U6,N9RPK<9NE*[U4X7@^9ZMQ>JDKI--):***904444 %%%
M% !1110 4444 %5Y/]8/^N;?^@O5BJ\G^L'_ %S;_P!!>LJNR]9?^F<0/I+_
M  2_(JS_ .K/_7-O_0'JC5Z?_5G_ *YM_P"@/5&O$S#_ )&$?^Q=AO\ U*Q1
MR8O^#A?\$O\ VTU(>G_ ?_935E.A^O\ 056AZ?\  ?\ V4U93H?K_05Z6&^#
M#?X(?^H&'.V7Q/\ PP_)%*\CC9UD959U0HH78LSEG5XXHY7*!)'E16M]\B1B
M= 05F\F>#^2GPO\ L4?'OX6?M5_LX?M(>.?%\U_^WI\<OVDM>O=+^%VI? ;]
MC9-)M_!G@OXHZJO[5GQ*\8_&;2OA5;_&7Q#\ [;X!IX#3X&Q:;XXTWXL>%/B
M1XNT*#6/$WBK2O$UMJFA_P!;-PI,O+[5$#. BEYR8G#DQQ$2I,R.86C)@+PN
M"L8E^U,(OP9^,_\ P41\5?%'6/!GP\^"?["'[?'@7XVV7QJ^%O@_PE\</&'[
M-GPIL_ W@OP9JGQQ^'.D?&'5$\9W_P 2O$5WX=^'7BGX8:9X@TO4]0M]#2]U
M71H-/M8X8M7L(;C3NX@\\_X+4?$/PM\)/B5^S'XW^,/C_P >_#[PEI5G\1+7
MX3:G^S7\9K_X:_M+7OBK6-+T>;XKP#2_$OP&^*7@'QGX&M?">E:1<IH.K^-_
MA_J.KWTLS7=EXR@T^W?PIZS\'?VV?@7\:O\ @EKXR\;?LB^,_P!M3]IK4/A;
MX3L[ >%]/MY/#G[<6M>,-<U>'Q3X/\+Z_=:3\/FM-(_X22+4].BN/&>D^"-:
MT+4/A:E_K^@GQ9<:?=KJ//?\%I_'<_A#Q-^QM;?#SQS>?!W]H;7[WX\0_"'X
MS:E^V1X&_8[^&?ASP;9:#\.XOBUX:\=^,?B-X$^,7AOQW?>.[6_\%7_P_P#"
M,?PTU;5[>^\(W?B&V\2>'3IEQ8:SZO\ \$:8?V0O%/[/UE\:_P!FOQCK&O:[
MX]\#_"GPK\5?"WBSX]>&?VA/%/@"Y^%]YXXL-'T[Q%XOT!9+C4CXK\8:S\2_
MBAIOC3Q#8Z/J7C(^+DUNQTCP9HLMCX+\/ 'F?[-5W_P48T[XD16^L:_XN^+/
MC/3OV4;9[>^^*UMK_@+]D;QIXU'PI^#=[\.]5M]9/A75_&VA>)-8^-TOQ<T3
MQI=)X=7X@+X:T_2/$-YX$MM%O-%6^^X?^"9]U\4;SX*?%:X^-NC> ?#WQ=D_
M:R_:</Q%T/X5^(?$GBOX;:9XG/Q1U<WMOX*\1^,-!\*^)]7T-D\F>.YUGPQH
M%VMU-=6XT\00PW-S]\-&]Q:2QB5A*ZRK.OG W-O)/;%)6)MQ>11RH?-,,4JW
MD49*I"_E+' OR1^Q. - _:- V #]LW]IX$*(U<N/B)=^;).D3LB37$N^Y91'
M 669)&A#.9) #6_X*!?\F'?MK_\ 9I'[27_JF/&U?X8LGWA_N1_^BUK_ '.O
M^"@7_)AW[:__ &:1^TE_ZICQM7^&+)]X?[D?_HM: &5)'_%_NO\ ^BI*CJ2/
M^+_=?_T5)0!_KH?\&JO_ "A _91_[&;]HK_UHKXH5^]_Q&94\!^-F=2ZCP?X
MG!0-M#+_ &)?R."<-]X1!,X^4,Q&>E?@A_P:J_\ *$#]E'_L9OVBO_6BOBA7
M[X?$9-_@+QJN<;O"/B1<XSCS-%OX<XR.GF[L=]N,C.0GT]5^H'\=7P'W0_ K
MX(JK,"_P;^%@N/+EN8X;AXO ?A^!'>V%P8.(88D(9')V9+8(4>K+/.K9,\VW
M"#RT?R8V"SPRM&Z0B-7A>.)XMA&\&9W,K ".O*?@8<_ SX(-_>^#7PL?'IYG
M@707Q[XW8SWQG SBO4:[8INDTN\?S 42W"PM$+B8+]F$7E^;/+:@Q"*Y9A87
M4MS89;[%*B,ULTZ&Z9C.ZPQQ']#/^#?GCX%_MUH"Q1/^"HW[5R1[R&98QHOP
MF*(2JHGR [5$<<2!0 $&"3^>)^Z_^Y+_ .DEY7Z'?\&_/_)#?V[?^TH_[5W_
M *8_A+652+4;M=5V _>:0]!U&Z+\_.09_4?E7^>]X'!7PXP78I_X2CXALKX<
M2*Q^(WBWJZR+N08!"8'.XY^; _T(9!RONT9_[YFC/ZYK_/<\$/\ \4VC8^]X
ME^(9QGICXD^+UQTY^[GMUQVK #K75Y!^]E>1B@5F?$A+*28MIE$K)%'NEQ"&
MVYE=@02V78WJD<BQOAK<YV; KI. DT*1,B1S"$10EV$F5B7C&%"*=PSC'.*<
MOWA_O0_^CEH _97_ (-TG,FN_P#!4!R78G]JWX2#=(P>0X_94^$8RSA4W'CK
MM'&!VK^EN2,R,J[RN"70J 2&1\,'#AT=75@N-BN@#%) S*R?S0?\&YO_ "&O
M^"G_ /V=;\)?_65?A'7],?\ RT7_ '9?_0XZ /\ *V^#?R>$->*';$OQD_:)
M6*':A2"/_AH'XG,(HAL"I$I9BL:*J@EB ,FO4O-;CIR,_=C]2/[GM7EGP<.?
M"&O)T_XO)^T0<_\ =P'Q-&,?AZUZ@PQ@>@_J: $D<L"K%BABN2\8\L(Y,7V2
M,E?*/,<EZMQGG=Y C^7?YB?U.?\ !MJ%D^&W[;6X?-)\?/AXLC*%7<#\ /A\
M'PH3"^8ZR2-UYDP.5W-_+$5W G./W,HZ?]/.G^]?U/\ _!MH-OPW_;7&<_\
M%_?AZ?\ S 7@*@#^EY P!#-O.]R"1CY6<NJXY^XK! >X7/&<!](.K?7^@I:
M"BBB@ JC=(SN0%RK1X<+Q,2HE,;0M(R1HT+$DE")B9%;?$(D$MZJLZL6& 0#
MY W9CR5^T+YT867>I62/B0+&DA7:L<CR%/* /YO/VJ?^"4?@+PIX*U;P9X%^
M#/AOXN^.OVN_VE/C-X.^(7[6OB/X6?#O4?B5^QM^S'^TWXB\2?'7XJ^--0U+
M6K,0>,]>\ >+M-?PU\-?BWXAOXO'?P\7Q'H%QH>N6VG^"(O#&M?H-_P4:\+?
M#+X=?L*^,_B?XIU/XOZ[H'[+?PQO/&^@P^!_V@O%?P:O_&=MHGA&/PS##XV\
M>:<UQX6UJQU'252XU/4/'&@:]X3MKN277+_1U26<W'XS?ME_\%!/VM_'UK^U
M/^RW?_%+]F?PQ\,_B!9?&WX$W=S<?\$N/^"SGB#QQH/A'QG#X@\!1WT_C'P+
M\.-3^&NN>*+/2KT76D^(_#%KJOAN6\LXW2ZV7*3O^Y'Q_/Q6^$__  30\;']
MGSPP/BO\7_!O[*UE8?#;PC-\,[[QD?&'B33?A_I6CV%JWPFUF3PYJ6N?;8IK
MJ]D\'^(YM-U.\EEBTS6YH56>V4 _(G_@G9^W=X]^'G[6Z?LC_%3X:7KV_P 3
M]2^'N@:5XKTK]I;]CW]H*Z^'NK^)?AO\5?BIX5L-:U3]G[X$?!O5_&6D>-="
M^&/BK1KB_P!2U#QWKOAZ72]'U:6Q\-6GCBWU34OICQ__ ,$LOV@OBMXD_:%^
M)WC_ .*WP0U#XK>/_BE+-\*KN/PGXME^'?@']G2Y^%G[07P>T#X0ZEX(;4='
MCDU_P&?VA/'?Q:/Q#L[R?6_'GQ:U"_U?53I-L=-L]'\$_P""3>N:[\,OCGX@
M^!_B?]B[]IW3/AW/-HGBCX!_'CXJ?\$S?A)^R==>"OB!XH\/?$.^_:!/B[Q-
M\%;#0_!6G>'=4T_2OAQX8\">+)]'_P"$OURZ\0WG@_7M?N[2U;66_I726.)-
M[%HGC$K,ET5A2UC!\L(\D4,5JW AMHWDEDC(CE:WN;HP2-( ?EM\7?V>[+X6
M>.OV"=<L/B?\8]7G\-?M'?"+X<+X4U3X@>(H?ABT7A?]FOXP>"AK5M\-H;[^
MQ[#4-9BL$UW4B+BZ2_U2\N;Z9Y)+R1J_5R%56(A%"KC<%4*JKN16( 55XRQY
M;<Q.26.>/C#]K=6'BG]BF(G#G]LWP6V2+EXPT7P9^.TP0.(YBH;R1&&D95!<
M.^S>BO\ 9\1S&_! !9 6 !81J(RVW)*@LK8#8; R0,XH _QX/^#EK_E-_P#M
MY?\ 8V?"/_UG7X/U^%M?NE_P<M?\IO\ ]O+_ +&SX1_^LZ_!^OPMH <O0_Y_
MA:O]@O\ X-C/^4'_ .Q)_P!>GQY_]::^,U?X^B]#_G^%J_V"_P#@V,_Y0?\
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M(-RTXD=R9"RS,ZJ)'D=(A&AD8*, &O\ \% O^3#OVU_^S2/VDO\ U3'C:O\
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M1 )TC5%Y,B1B,R\?.C+N-BB@"A+:QE4B8XC4,8XPPCA@C2"6WR8=K1SHD4R
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M.,7 9FN'ECN%C$MHHE3R[1[:#9&T12OM6, 0HHY"Q* 1T("#!'7C\3]: /\
M'>_X.6O^4W_[>7_8V?"/_P!9U^#]?A;7[I?\'+7_ "F__;R_[&SX1_\ K.OP
M?K\+: '+T/\ G^%J_P!@O_@V,_Y0?_L2?]>GQY_]::^,U?X^B]#_ )_A:O\
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MZ_\ 52/%_M7(!UBC:,9SSFESM(/7+Q#_ ,BJ:9YGM^O_ -:E!WX'3$D1]?\
MEJGTH _97_@W.&-:_P""GWO^U9\)3^?[*OPDK^F+_EHO^[+_ .AQU_,[_P &
MYQSK7_!3[V_:L^$H_+]E7X25_3%_RT7_ '9?_0XZ /\ *V^#O_(FZ]_V67]H
MC_UH#XF5Z<>B_3^IKRWX/OM\'Z\N,_\ %Y/VB#G/_5P/Q,&.E>I'HOT_J: '
M#[I_ZY3?^E.GU_4[_P &VO\ R3C]M?\ [+Y\/?\ U0?@*OY8A]T_]<IO_2G3
MZ_J=_P"#;7_DG'[:_P#V7SX>_P#J@_ 5 ']+XZM]?Z"EI!U;Z_T%+0 4444
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M'.0 ?Q-,=VTXQ\BC_P =%)01@D?W69/KY;M'GVSMSCMG&3C)* /U4_X(A_\
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M %HKXH5^]GQ*_P"1 \;_ /8G^*/_ %']4K\$_P#@U5_Y0@?LH_\ 8S?M%?\
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M-_\ MY?]C9\(_P#UG7X/U^%M #EZ'_/\+5_L%_\ !L9_R@__ &)/^O3X\_\
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M_@OF-W_!-3XF+G&[XK?LT+GKC/[0WPV;..,_ZO&,]\YXP;G_  ;[_P#*&?\
MX)_?]D2'_J8^*:J?\%\3C_@FM\23Z_%G]F@?E^T%\.C0!_$R!OW-G&79L=?]
M8QEQVZ;]N>^,X&<!WE^_Z?\ UZ:K;0.,Y"G_ ,<4?TJ13N&<8YQ0!^J/_!$1
M,?\ !3KX1G/3X'_M%=O]KX4>]?W3D\K[/C_QQC_6OX6O^"(Q_P"-G7PC7'7X
M'?M$G/\ P+X4_P"%?W2D<K[OG_QQA_2D^GJOU _FF_;/_P"3I/C+_P!C#I7_
M *B7AVOF*OIW]L__ ).D^,O_ &,.E?\ J)>':^8J[Z6L/N\NJ >GWE_W)O\
MT.VK^D7]AO\ Y-4^#_\ V!]9_P#4KUZOYND^\O\ N3?^AVU?TB_L-_\ )JGP
M?_[ ^L_^I7KU175H+;XEU3Z/L!]84445R %5Y/\ 6#_KFW_H+U8JO)_K!_US
M;_T%ZRJ[+UE_Z9Q ^DO\$OR*L_\ JS_US;_T!ZHU>G_U9_ZYM_Z ]4:\3,/^
M1A'_ +%V&_\ 4K%')B_X.%_P2_\ ;34AZ?\  ?\ V4U93H?K_056AZ?\!_\
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M&&"0/.+60/\ -ON?VT_V8+4VZ3?%/[/-=O-#91WOP]^+-E]MNXX?-CL+,3^
M5EN[^9=]PMG:PS3_ -GV>J7X1DL'CDLI^V9^S0$>5?B5=/!&2QN1\,OC+]GG
M DE:S:S;_A7)EG6\2%/FDA@\F21HR)/+#2?WD>,+7]E_]J?X[^'/!-UXZLO$
M7QF_X)_?&?PK\9-8\$>%?%;6.O?#CX@>,/@QXNT?P1+\0M B"W=WX?\ $WPM
M^+VMZOI-O-;MI=_<36DYOUN=.BM;S["@S<(TRB6W:3!<NB>:6 ADC4X=PHMO
MWEM-"R*?.$^-IR\H!_%I_P $3/\ @IU^PQ^R[J?[>]Q\=_CLGPZ3XN_M$?#K
MQG\.H]:^%_QK>X\2>%-&_9^^'W@V^UR"+3_AM>I;VJ:_X>UBQ1)Y4N#+83&2
M&.%H)I_W4'_!>_\ X)+%(IC^U[H:@VXG=9/A9\>(B$G6"1%C:3X5I')(6FMU
M,;/&RK,LC;0-I_7Y8 .?D)625T^5R%$SEY00TC;F;<PW#:J[CM0+\M(ULC/O
M*Q8VA OED_*Q43(<N4*21Q6Z!1&-AB+9;<%0 _R9/AS\:?ACX?\ #^M:;K&N
M:]974WQ/^-NLPAOAI\5+B*ZTKQ)\:?'_ (AT/4+6:R\$W2/:ZCHNIZ?>1B?[
M-=1-.\,]K$T6Y^VN?VC_ (,6RQM/XLU* 2M)#;?:OAY\4[,W]VEI=WBZ;IJW
M7@>*2^U6:.U=H;&) TD0EE63]RZ'_5AED2TCDDF<E45I9IR8H$ W;8_,9I8(
M@VT+'O)"@1AI&C4KGRWX@^"/"'Q&UCX=0^(Y;O\ M?X;>/-*^*OA>RL=5^R7
M*Z]HVGZ]X5MM2N]+4'4-6\/P_P#"47D5TDL=I82_N[S[4@@A6Y /\OE_VAOA
M) KO_;OB"4+%=3P^5\-OB@YF:VV'RN/!GR>9%(LN_P"<+]W:W6OZ"?\ @AQ_
MP5"_84_97\#_ +4FE?'KX\0?#F^\=?&/P-K7A2SUOX9_&I[W5]#TOX0>!_";
M:M%#IWPUOX%MYM4T[480ANS-'+931O'Y96X/]I]LB.J%56-X/W#1KAEC*A=X
M!,<;$2)L*2;4,L/DR[%#;:F\@!5&5)CWF(N@(1B3M.T%00@( Z-@$[@3F@#\
M@A_P7P_X)+ X/[7FB'<TH0)\*_CU*[F'S P2&/X5/,2JPL[GRP@4KY;RD,%_
M2_X)?&WX6_M&_"[PA\:?@MXNM/'7PQ\>:?)JGA/Q396>JZ=!JUC#=W%C+*-.
MURPTO6+%X[NTN(7MM2TZSNE,>YH0CHS>F-;@DLNQ')1LJC+N:,EE\PI(CR(K
ML[+&7";G<L'+&I(8O)39O>3+.Y=]NYF=B[$A%1!EB3A$10/X<Y8@$M%%% !1
M110 4444 %?)G[7O[5FG?LG>"O"OB>?P#XB^)6L>,_%.L>&]!\+>';_3=(GG
M3PI\,OB'\9/&&H7&KZOC3;3^R?A[\+O%MYIMG<,DFO:\ND:#;RVS:C)?6?UG
M7A/Q_P#V:_@Y^T_X2M? WQK\)CQ=X8LM2;5;:QCU?7/#MW!=7&CZSX;U-8-<
M\+ZGHNOV]MK7A;Q'XA\,:Q9P:I'::EH6N:G8W<$JW 9 #X#_ &JOVSOV9+W6
M/V*;O5?C3\./">I6O[17PD^*7B/POXK\9>'M"\6>#O!WB?X"_$O7].U+Q7X?
MO]0AU#1$^Q>,?#9E2^BAE4:E'(L;1[#+]:K^WM^Q2JM%_P -8_LZF=2\1A'Q
M@\$^8TT:J-L49U42S1A0SRRQQ,L6TC#X8K]3:5H6EZ'I%AH.D6D.FZ-I>G6>
MD:;IUG&([2QTG3K2*PL-.M8F\Q8;6TLH8H(HH]JJ%9E"ES5R2UWER)"I=6^7
MRXBBR/$\;2K\HF#MO!;$PR%VC;N<L ?X]O\ P<(6ES\9O^"Q'[:GQ+^$=I??
M$OX>>*/$WPNG\.^-? ]E/XF\,ZU'I_P&^%>CW[Z;K.C+>V%VEKJNG7UE(T4Y
M/F6S%E7(%?C$_P +_B% ]M#=^!O&=M<7T\EOI]O)X9U-9KZ:&SN;Z:"TBECB
MFN+I+:VEN5MK>*662TM[^Y4;+"8'_>NWFWD$17*299&RRQ1[00L"H0^T"*,/
M\A,8VS/(+8- DORM\:O@7\//VD/B3^SOXGU3QO>V7B3]COXW1_';2]"\)ZKX
M<O%;QCJ?P@^)/PNTW2?'EK=:?J&KV&D7/AOXK:WK5A96IT:^UB:QLI1<V\<4
M<T8!_B"R?"#XHP([R?#OQTJ8G9)3X0U]('6UCD^TL))+%&"I,/L\;^68YYA)
M'&Y>,H?]4C_@W8_:H_9M^"__  1U_8^^&OQ>^.?PN^&'Q"\.6OQK7Q!X(\>^
M,=(\(^*M$;4OVB?BUJ]@FIZ'K\^G7]L]SIM_9WD1,+PO%.FR9F$BI_2M;6\+
M"XVH0KR+YBN$WDM#;/AV1_/9P -S7I:Z\TNP(MS"E6(K9(P_$;-)+)*[F)0S
M,YX+X.&94"IN &0H^4=* /YO?^"YO[5_[-/Q2_8W^'OA[X9_'7X5_$'7++]M
M3]BSQ1>Z1X.\;^'_ !!J5MX=\)?M ^#]?\2:L]KI]_*1::1I%E/>W;NR".!&
M<D#&[\]KC]H3X'"XN%_X6OX&?R]LFZ#7K::*3S+5KR7R;@8MG2!S]E=GFC<S
M)-F-%1?,_M--NN]I$VQ2,BHTL<:"4JC[T3<X==GS2AE*,3YF59&4$U7*QN;=
M_NND>YU5(XHFG9H J)(2A$KD@(OVE_,D_?\ EH8/,:DXNZW_ ,_F@/XMH?VA
M_@+="5K3XQ_#F[2"YN;.9[7Q1IMZD-Y93R6M[9S2:?->10WEC=Q36=]:2R)<
M6EY!/!+&-BN]#X)_'KX*:9_P5'_X)M>-]0^*G@>Q\&^$;?\ ;:7Q7XNOM=M;
M#POX8E\1?L^Z;HWAR/7]>OC;Z=I8UO49KBULWN)ES-;%2NV0.G]A_P )?AKH
M_P )M$\5:)H=]JVJV_B3XH_%#XG7\VIF*2Y@UKXK^/-=\?ZW9VPCCMU_LS3]
M4\0W-G8JK7#0P0>0S1- ]K;^HE/.$FX)\PCC<%7*.HR[KNWH)8V25D'RA5??
MO$F"@;J2DK-.WKV^; ^11^W_ /L/S-&\?[77[-C8:Y*(GQK^'DDK-:I<I,'B
MCU]WB7*GR\@S2$KM@PP-?P]>,?BI\.9_VP/^"CVOQ^,]!?0?&7[>OQ9\6^$=
M86[<:?XD\-7_ (*^%]E::YHUS+#%#J6E7%YIVH6L.HV+W-E-/9W,<4[O#(J?
MZ'_V5"7WL[K(A1T=Y)(W5VD:1&BE>2$HP?8 (PP0;-Y3:J-;?$1^[,BD[I&7
MS2VYN,11 R\&3YF#/#'&C[@SE9,2!_GBW'QA^%%N]LES\1_!MG+?7D.GV,5_
MK^G:>U]J%S%<26>G6#7\]LE[J-W]EG:"QMFENGMK:]N5B9+4K):A^+'PR=HF
M@\<Z#,)K62:V<S7%M!,\^G&XMXEEO;:VW_:&86T$]LES;37*RPI,TD$J+_;1
M\?O@C\*/VMO%/P1:]^(SQ:Q^QC^U5X,^/@TWP%KGAJ]N[3XF>#?A_P".=*TO
MP+X]2^L]5FTR#4O"WQ,77[[1HQHVK6ML-/U66^BM/L<MQ]B6T8D69F2/+W)<
MNI\Q95B9'M)@V5D)$8C)\W)#@K"SVBV[N ?S[_\ !#/]KK]EWX6_\$EOV'/
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MMU#%J.E70FTS6+%W6XT[5[2^L)D+VWF2?ZB<S+#%-+))%;[8DEGNI'2&!!D
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M^7 *]'612<$@.CHR@X0E1C< ,GIA/)S]_P N0+MV;XRY0_\ +4[I)'8[Q@
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MI?V+/!L6M>-?A_\ %OX5>)--^)/BK]GZ_P#C#XW_ &D/'=EXGU7XB_"SQ!X
M_8@T#X >#O&<>M_&_P"%6J^$M?OOBYKOC'Q)X+\*?"FSOM MO%-[?W9US0-/
M_97]H'X73_'?X2>,/A1#\2O'WPEM_'NG6OAW6/&_PIU:+1_'VF>&[_4[23Q!
M;^%=?-E>S>'M6\3>&H=2\-6?B*UMTU#P\=?.L:23KUAI%Q9_EC\ O^"=?Q'\
M&?#SQ_\ \$\_BMK/BO6_V'?A_)9>)_V3/CU\&?B]XN^ G[0-AX.U?Q-XAD\4
M?LT?'&Y^$]YX;U#QD_A:!Y;6X^(L&K"P^+_A'Q#:1>/O#3^,K/7I+8 _-?\
MX)(_LF?''QS\>?@_^T]HGB/6+_X"^ O#TLO@W]K;PMXQN?AQ\/\ ]L?]FR;X
M3:E\,?V?_P!G&+]B;PE;:7\/O@X/A%J4_B;Q=^T9K/Q&\)ZMXWA^-.EW5Y\.
M/%EWI7CF/4/#_P#7-;2&6/S=I42,S(K)*CB/.U&=)5C='D4"5D,<>POL(8J9
M'X?X>_#/P'\+?!'A#X<?#CPSI/@[X?\ @+PYH7A'P;X1T&U6PT;P_P"&O#EA
M_9VAZ/96\6QWL[&R*(D-Z]T#*@N7#7C2W,O<P1-#&$:1Y2,9=RS,< +U9F;)
MQN;+$%RQ4*I"* 356N+G[/EF0M$BAY7#QIY,8)\R=_.:)#! @+S&.1YD7;M@
M?>N9))#&,A=_'"A@KNQ/RHF_:C$@.3F1<;5&,-E?SK_:6_X*&_"SX8_#_P#:
M9N/@EJ7A?]H[X^_LN^%]"\4>+_V=O /B2[U'QK>'7O%UIX;LO"L#>'_"WC&:
MT\;>(#]MT#P[8_V-?V=EXQNK#1O&%SX<TJ\DURW .?\ VQO^"D7P'^ GA;XR
MZ)HNNZ#XV^,/PH\:_"#X1>,_A]KNI>*O!'A?X;^*/VCDM[7X3^,_CMXZC\+:
MC#\*O@'J,=_))X@^.=W;W?P]TGRY=$N-9;Q,L5C8?D?_ ,$Y?V$?B)XB^.UU
M\2?$W@CXN_L_:O\ L_>/K > OB#XI^(EUXO^/7P:M]#TCPAX6^(O_!/[4_$&
MM:=K/@C]K/\ X)Y?$3X>ZKI7Q3_9M^-5O>6?BKP]!J5U#JJ2_$;1=5U/2/T?
M\,_L\?#[_@J!\*_V7OVTOB)X$O\ ]GCXV?V%XP\,^+_"$.F6WB2[U_\ 9]\6
M^(O$'A?XK_L8_M&^'/B'X/TBS^('@GQ?X?LX-/\ '.@>(/#'F> _B3IS^*?A
M3K.FW%E#KNM?JMX(^'_A;X;>#O!WP]\#:9#X=\$^ /#6A>$?!WA^V::Y@T#0
M/#.E6^AZ+86EU?37-].MKI%NMG)/J5S?W=R0MQ-<-<&>2X .O@W>6-Y&["Y
M8,$)125RJJ#@GJ %.<HJ(5C26HXXQ$NQ0H4$D*JA%7)R0JC. 3ECDD[F/(&
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M[4%O"85<-)YK/*\A<QQ1,=Q&U"(E166! MO"S R_9XH4FDGE5YY)Z "BBB@
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M95 9R[9)+$ <L2V% Z(N=J EF"@!F8@L0!$0(& Q@LS]#G+G<Q)R<DL6.0
M"% ^7)2658E9C@!5+?,=BDYPHWL-@+,0OS,,9R>*;+,(B05=OW4LPV(\AVPA
M=XV1J\C,2Z!$B221R2%C)'/Q[^V#^UQIG['O@KPQ\4?&?PX\:>)OAA=>(SH'
MQ(\?>%I-#&A_!+1[[0M5FTOXB_$@ZQJ%I>Z9\,5\6PZ'X9\8^-H=+N-)^&-C
MJ<OCOXA-HG@;2-6UFT *W[3W[9?@3]F;Q/\ "_P7XR\/^+1KOQR/BCPA\(O$
MYLX=)^%.N?&&QL[.X\(_!#Q%\6;N6Y\+_#CXA_%S4)CI'PQD\>6>D^'=8O\
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MXR_%:.[\+_L_6/B_1+J[G2SMO&OQ*N=+T338[^R%OK.;F,WEO96M]>67\_\
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M3FUO2/#6L>'_ !5XX\9>(+#2%T?X=> -'UW16UW5KVXNY]4MUM+.RUKXKO\
M]CWP[^U5_P %0/#?[3-C^TV+7XL?L--^SYX?^/'[/^C_  D\6:+\*/&'C2_^
M'WCOQ0GC#5!KGCRT77/&NFZ'\6=+NOA!XI%C?-\*$;Q5I.M0>.)O$TNG^'0#
M\KOA?^QA^T9J7Q3T#_@G?\6H/ ?Q0\'>+/'/AW5?VX_AM\-?@/\ M%7O@?0]
M"M?@[J^IV/[:UU_P46^/U[:^+'_:SUGXI6?A"_\ A?X0^",%OIWA>:TU'P[J
MUI;Z-9VL@_J,_9!_8^^%_P"R'\-]5\&>!=2\:>./%7B[7Y?%OQ>^-_Q:\1R?
M$#XT?';XB3:=;Z9?^/\ XK>.]0WW/B/7$LK>VT'3;."'3=%\+:%I5AX4\.Z7
MI^@Z5:6]?5,5A'%&8K9HX8X8Y;>UA6)?)LT*JL44 C,,T,$0QB"*X0(H2.W>
MWACBBCG4_9A(K;G+.TOG,D2>:TTDFR$+ N^22")8XMQA+/$L;-)+)YA  I>.
MW,OW2S,)7(P&W2D11>;MW2-O9!#$ZQN1'&L>,19,$CB9XPBR"1XV,+& QR0-
MEHFGQ=)%GRPY/E[O,"[9!!*D@*I<2EY(E&\289/*'GC_ %KQ(;I%\A6F^R%H
M\NK)%")W:62)Q%N_GJN_VQ?'_P"TO^RQ^V-\?/CS\6?"'P$_8_D^(GCW]DW0
M/AM\%_"/CBZ_;(^&'CCPS^T_H/[-DT/Q7^(9\33V=CX@^*$]M?0ZQX#\&_#A
M=>\+^"_&>@ZSHGC#7=0T^]MY #T#P=^VU^T[\*/VYDN/^"A'@C5OV7OV7?VD
M=*L/A1^Q#I]GXE^'_C+X::-\1].UW7I]5L?VMO'OA^SUF3PA^T!\5M#T_P +
M:I\)8-$\<W_PGB\+7GB7P-=ZAJOQ L-2DB^I/"'_  20_9.\&_&>P^+/A^7X
MQ6/@_1_C#J?[1&@?LNS_ !:\3WG[*/AGX^ZO+JE]>_&#P_\ !6>>70],\7#6
MM9O_ !-86EM>2>$-&\3W<^NZ-X;L]1CL;FQ^;?\ @DS^PG\?O@7\&?B-X&_:
METGP_HGPD\5^*],\6^!OV/?$6O>&OV@O _P5^(&FZM%XMU_Q3\*O'MW:(VC?
M"OQ!X\GFU_X8_!_6K#Q%J7P[T30O"&HW/C&X\5:EXKAF_<^"(1)L7A,Y2, !
M(4VJJQ1@?=C0#A<D*2P0)&$C0 2&!(0P0 ;Y'E?:J1AI)&W.Y"*I9B>2\A>1
MNLDCM\U0W%X+:6*-H]RRM$N\2(OEF63RE,@D**%+%2C;\28>%<W;V=M>6))=
MC*NTL65F'./NO$I49&"Q$F5!(W%<9&21^:O[3?[6E]XL\=_$[]AC]EK6OB/I
M?[7-[\-XD'QF\+_ _4?BY\'?V4/$WC[P_K>J_"SQ5\=]4GO--\/Z*VN6VF3W
M^C^'IHO$-[=PSV&HW_A^^T59K:_ .+_;D_X*K_#+]C3XQ_#;X(ZAHGA/6/&&
MO>$8_B_\1=0^(7Q@\._!;PM\./@M_P + T?X;+KFF7NMZ'XD\0?%CXIZ]XGU
M>/3_  /\$/AKX7UOQ9XJN+:4O>:/97>DZAJ7QK^VA^RM\+O^"SO@;X(_M3?L
M>?$'X<>.]"U"XN/AOKWC7X@:I\6OA]K?P^\&^#]9\8W<_B'X1VVDZ1HWQ)^$
MOQV^%GQHNO#?CKQ9HTMEX)\0^,M1^%W@7P'XQU72='TBYLYO'/\ @G#\"_%G
MQ\^'OQO_ &;_ (ZZ5X:_9B_:F_8\\8^"[#X1W(^'WA[]HS]H;X-^(_&=U+XQ
M\<_MH>&OVH?CYX8\2Z/\7Y?VU?%T_B36]2U[P'X;\/Z;X1TG3[[P=:7-C?V,
M\5C^_O[+7[,O@?\ 95^$T'PN\"ZIXJ\0M>>*/&'C[QUX\\=ZC%J_C[XH?%+Q
MYXBOO$_CSXD^.=7LK;38+[Q#XH\07MQ/-%86ECI%CI$.EZ%H]A8:+IEE90@&
MG^SY^SWX$_9Z\#2^$_!R1WVNZWJMOXK^*?Q#OM'\-Z7XV^-'Q3ET'0=#\0_&
M7XLMX4T3PUH?B#XL>-]/\/Z)?^+O$W]@V5SJFIP17<\3JD4:^^1(T:X9S(Q.
M2Y55+<  D(%7<P 9RJJK2%F5$4A%(XQ&I4,S98MEB6//4;F)8@'IN9B!A0=J
M@"2@ HHHH **** "J\G^L'_7-O\ T%ZL57D_U@_ZYM_Z"]95=EZR_P#3.('T
ME_@E^15G_P!6?^N;?^@/5&KT_P#JS_US;_T!ZHUXF8?\C"/_ &+L-_ZE8HY,
M7_!PO^"7_MIJ0]/^ _\ LIJRG0_7^@JM#T_X#_[*:LIT/U_H*]+#?!AO\$/_
M % PYVR^)_X8?DA]%%%=Q!!-/Y)51&\KNLA2-"BLYC7<45I6CBWMD*BM(N6.
MYML*32Q? W[0O_!2?]D[X ^+O'WP@USXH^&_$?[1O@?X+^./C=8_L\>'KN:^
M^(OB[1O!G@'Q)\3K3PQH\:6<NF6_CKQ7X2\(ZOK/A7P=?W$7BK6-*M+G7]%T
M;5-*LFGG^^I(0[A][)P X7!WA=^U2'#*%!D<MM57?Y59S$&C?\/V_P"":?BK
MX3?\%&?A_P#'CX=7>H_$?]DKQM\6/BW^T_\ $OX(>)O& @C^!?[;?BSX;#P'
M9?M3>$$O=/U3Q+\4(O'/A&TOO 9^'7B7Q/9>'OA+K.L:CXT^&UQH6DQZ9X)T
MX _+WX!?LX^%_P#@I)^TQ\7=>\4_"C]FC7/A5XZT[P5\8/V@K+X1_'+Q]X\\
M .?VJ?ACXC/A7X_?LH_'O3O#7@_XB? 3]I_1Q\-M'^%'[8OP(AN=+\!_&CP)
M=?#3QI?6VG0K<:1XL_I0_8:^ _CO]FO]DKX&? +XF>.H?B3XO^$G@BT\"7?B
MY'N;R#4-*\/WMW:>%+,7^HPVNKZG-X;\*QZ/X<EU;4D@O=3N],N-3EAC-Q'&
MGM/PZ^$OPZ^%>E:GH_PP\"^"?AOI6K:WK&O:G8^!/"'AWPG!J6OWUPZS:[JD
M/A_3M-L]6U:=0_VO4-5M+W4;W;:R7M[<WEO->7?I4,0A01AF8+@!G9Y)& 55
M!EED>1Y9..9&;)&!@8Y '(I1<%MW)QP0%7HB@$L?E0*&)/S-N?"[MH?110!^
M:7_!3+]MO7_V+OAQ\.+KPOIO@S1?$7QI\?GX9Z'\;_C:NN6O[,7P$U1?#^L>
M(H?&/QWUGPP\GB."UU*WTJZTSX?>&=*ATQO'WC5++PC)XL\-W&H6-S-^3/\
MPHG]O;]OCQ5^SS^UCXL^& \$2?%OP+^S3XD\/^((/CCX[\&^%_V0=%\&?$+6
M'_:G\)7?[-FM:6NG_M"_#/\ ;E^!NHV][X?\,>.](FUV&#Q3'X)^*4OAE_"F
MBZNO])'Q?^#_ ,./CU\-_&?PB^+OA#0O'_PU^(7AO5/"?C/P7XGL$U+0?$6A
M:M&B7-CJ%H[(ZE)(H+NSOK*:SU;3+^VM=0TC4=/O[>*Y7)^#'P7T+X'?"OX<
M_"3P[XB\:>*-$^&/AC3/!^@Z]\0_$$OB_P 9WNBZ2D4%BNN^)[J&#4-4U"&T
M@@MGU21TOK];:VEUB;5)XVDD .#^$G[(?[/GP5C^&*?#7X8:+X3;X,?#_6OA
M/\,EBU#Q'KJ>!?AUXEUG1O$_B/PGX1D\2ZSJCZ3I>K:UX?\ #J7$JQF]71_#
MVDZ#;3PZ1I^G06OTU&A12"[.2[OEB3C>[/M&22$7=M123M4!1@  )$GEJ0=I
M9F+.RAEW,>YW/(W"@* 7(5555"HJJ)* (Y'*<X&P8WL2W .?N*J.78$#*D*,
M'.XX(KYV^,G[57[.OP#FUE/C3\9OAW\,Y?#O@ZU\>:]9^+?&&BZ3J.D>!=3\
M56G@FR\7WFC2ZE]O;P_?^*;V#0[?6GT[^S;.]AO5N[V$QB*7QW]LC_@H5^SU
M^Q.NDQ_%0_$;Q7K][X>U_P ;:QX+^#'P]\1_%3QIX*^#OA9H3X^^.WCK0?"]
MK<W'A+X0> =UNGB#QGJS6]NUU<&PT>'5+^WNK6'\)_BIXP^/O[=G[<^B_#K1
M_$G@7X3?$_X>_%OX\:'\%-:\/_LZ>,E^+W[+WPH\+^ /^$E^&O[1?B7XP:SX
MBMOA1^TO^R1^V'X2O=&\'?'/X WB:+INOP_$KP1H^@ZC8_%/X1/KWA\ ^_\
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M^$8T*\T;0M=GLI]/L/#GZDQPNL85IG+]688YP ,#S3,P&T!>7+-@.[-*SR,
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M8XPD4<82%,L4B_=[PK/(P=W^<@@!Z)L4+DG'J7/ X ^=W/"@9^;ELM@%C3Z
M"BBB@ HHHH **** "J\G^L'_ %S;_P!!>K%5Y/\ 6#_KFW_H+UE5V7K+_P!,
MX@?27^"7Y%6?_5G_ *YM_P"@/5&KT_\ JS_US;_T!ZHUXF8?\C"/_8NPW_J5
MBCDQ?\'"_P""7_MIJ0]/^ _^RFK*=#]?Z"JT/3_@/_LIJRG0_7^@KTL-\&&_
MP0_]0,.=LOB?^&'Y(?1117<0%0R0B1E8LPVJZE06 *N.<%&0AMRHP8DX"D*%
M+;A-10!'%'Y:E<C&XE552B(@ 5$1-S!0J*N[!"L^]PJ!MBR444 %%%% !111
M0 4444 ?D[_P4M_X)I>'/VTK'P_\1OA_J.F?#W]I?P3;^'-$T[Q1J4_BB#X?
M_'+X1Z/\0-%^('B+]EO]IW0_"&J:)=_$_P#9Z\<:CI<\DW@K6M0:ST;Q1JB^
M)M)C\X:MINN?J#I&DK;V%@K6NF:?/%IFF6,L&BV\"Z7&EA%;O;6NFEH(YO[-
MTV3[3#I*S1Q-;I--+%!"9$5-F>#SN0^UE",G^L"^;'()(VE$4L3S(CJ"(3(J
M,&D5]P?Y9(H_+14!!"JH& ?X55?XF=CDC.7=VYP6.,T -@A\E63>T@+E@7+%
M@" ,$EB">,LRA=[$R2!IGDEDD+$,H"Y')9B<!0!]""2>V1@9)/JR239D*C2,
M IVK@'YV*IRVU<$AMQW94#.T@BL37-<M=(TN\U2XDM4LK*WNKF6YN[ZTL--"
M6<8D(N]4NI$T_3XI9?\ 1?.O9XE28@LAA$LL0!D>-_'/A'P!X<U?QEXY\6:#
MX'\(^'](O]1U[Q?XFU.ST?PUX=L8UR=5UG6]4EM=,TNRMQ$P:ZOYH;42RPVT
MDR37-I%=?R=_MB_&'X@_MP_M_?"GX5>$O!7@'3M<\&CQ]-^R;\1/!7B;0_C/
MX?UOX<_$_2M2T^XUO]L/X,Z)KUPGQG_8._;!^''@/5A<_$#X;VEQX@_9S@\1
M>"/%%]JU]K/C:YT+1?2?BC^TY\4/^"L7CWPY\!((?BM^RW\(?$K:E\-X] L_
MAMX/\=?';]F3_@H3\"_'7A+X[?#GQ!^U?\+_ !+I]U)-^SCXL\"^'-&O_A'K
M5CJ.F^ ?'LGB34)O&6O>"?%$_P ,[G3/V[_89_8D\/?LF_"G1/#NIZAX:\6_
M$:UN-9%YXOT#P9#X:TKPQX>U/Q!!X@@^$_PTL=;U+Q=XET/X1>'[^W^UZ'IF
MN>*=>UO5-6U'7/'&HZJGB+Q3J3H '["/["/PK_8H^%FG>&O >ER:?XRU;PI\
M/]&\=:@?%OCWQ[HFFKX)TDMH/PX^%ES\3]?\3ZYX2^!7@6^UKQ+;_#KP+:Z@
M_P#9.G:Q<WMWJ$WBB]UG5;S[SBC$08#'S2.Y(W?Q,2H)=G;Y$VH!N"JJA8TC
MC5(T(HS&@4E"Q)=_+C$49D?YI62,%BHDE+RD/)*^^1MTC=:DH **** "BBB@
M HHHH **** "BBB@ HHHH *IW%F+B:&5I9%2$,1&A9"9/X'$B,K* &=9 ,NZ
M'R5DCMI;V"\N44 <!X4^%WP_\"ZGXUUKP=X-\*>&=7^(_B*/Q;X]U/0O#FC:
M->^,?$T6E:7H":[XGFTFSL3KFKIH.AZ)HRZIJ(GU%M/TC3K:XN[B*T@2/N1F
M+Y<[WD9F7<2-[<DKP&"*B!0O7@ <MR9J8ZEL8;:<KSC) # N <@@NN5)!XZX
M.,4 5+F^6W;:R*"S0Q(\LT44;7%T[Q6T9)+2A9)D\H.(F9Y)(TMH[ES(L?\
M.?\ \%&?VW_$NO?&7P_X2_92\=?M#76L^!?&'Q%_9;^*/PRTCP[X@^''P"_:
M6\9^(/!ECXV\5? WX0_M;:19*WPB_;B\">%])?7?@9XDU'4X/AM?^,'OOA9X
MIN[76]5OCHWFG_!P!\%_VAM1NO#WQ@\0R2_$G]B^/X>7'PMU*+2-;^*/@RX_
M8"^,/CGQOH]F?^"A_BCP]\%;E_B)^T/H'PJ\!/?6VB^"-*N-)D\#^+=/TK71
M9ZAI7B/Q!?:-^GWPW_X)@?L^6GQ6\-?M$+\0?C=XLNI?&GA#X^:I\/[SXFZT
MO[/7CW]I+P[X%T_PAIO[3]Y\(HC'I]A\2-2LK>+6M673;S2]"UCQ7:Z=XIUG
M1-5\1:/IFO  ^0_^"<GP._:-^#7[8/C_ ,97/BSXZ?%[]EG]LG]EGX4?'CQ)
MXH_:5^$OAKX4_&;X0_&[X<0:-\-?"/@'XG:=X=CTW3?%/QJ\7_#"[MA\9M2U
M3P%X;\67.I?"GP)=7^J:W+9W]_JO[_)$?WK!Y(S,X=@%@!!"(GW@C,Q*H!ND
M=W&-J;(UC1%6%E=")/W:1E0F)"=P"B-PS3,@V9GW QDR!X06'V=2\D<?E[QE
M2&?<"$VL<H@8RMN(DD9U9BX6,!"B;/DWL *B! 5& H/R@ @@8&=Q+$LQ;<Q;
MC((!!(+-\Z?M::)\?_$7[.WQAT7]E7Q=X0\#?M'ZIX!UNS^#GBKQ[IUWJOA3
M0O%\T:Q07NHV>GSP7&]X)I(K"_O8]5T70]9&DZ_K&A:WIVEW>CZE]'55GMVE
MDC<2;1$&94*L1YX*F"8,DD;KY8\V.6-6"W,,[Q390*  ?R:_\$T_V4;?]K_0
M?VM?"'Q:^)W[4OP!\<?!O]H;X':YX7^%GB[]H?Q-\3/VP_V2?VL_AUX/\2V?
MQ(_:?'Q2^(?A_4_"]HG[4D?CC6-(TSPMX1\-:_\ !CQS\)X#>Z?H/AF;QCKW
MASP[_1]^R]^S!X#_ &5?A9%\,? >K>*_$4E[XH\<>/?'OQ#\>:AI^M_$?XI?
M%'XE^(K_ ,8?$;XH>.M>T[2M$TV\\9>,?%6I76JZHNAZ+HOA;3E\K0_#_AO1
M]%TW3;"R]XM/#6BV&H:MJ]EI6E6FL:ZNGQZSK-KI6GVVKZK#H\5Q%HD6IZA!
M;QS:BNAI<S1:.+WSTL('>*% TDDC;$$7DQ["58DEF*H(T+MR[*F6(,C[I7+.
M[-*[N6.[  'HA3?EBVYV?I@*#C"J.PP,L?XG+N<%L"K=2.IPB,[*8&  :--L
MCR+*9)W*P^4D:,\P5C+"BAUBGEDMH)9)[@0?\LWD 4N^P%F5 KG>L84R3G>L
M<7E6RS7&^:("$[US_/5_P4Q_X*Q:S\+9/#OAW]F?6OA2O@N7XK?$7]F[XN_M
M!?&'PUXNUW]GWPE\;M!TOP%?I\%]?\>>#/$GA2X\$V][X>\6^)KWQG\2-.U3
M6I?#VJ^#6\ >'/#?B+XDW;:)I8!XK_P4O_X*5_$V_C^.?P8^!/Q,^ GAK]FB
M_P!!\/> [;]M[P?\6M0CTSX,?M,:1XM_MK5?V3/VA]=\!_VQJ7P"TKX\^$O"
MVL?#WPQ^T3;7^E:7X6\1>,8;73/$-EXYM[;3M)^BO^":_P#P3JAU+2?!/[1'
M[9WP'T>Z^,'@'5-'U?\ 9P\1_$CXBZG\6?CAX4\(7FGVWBX:=\1/B-IGQ#\7
M>'O'GAWPI\2_$?C0_LY:#X@G\27_ ,)/A.?#-A<:G<>*=0U=='J?\$T?^";7
MA[PK\0],_;3OH;SP/X$\<?"FTT?X#_L^S>#-?^''COPI\&?%&F>!]1\&_![]
MJS2=9\4>)[+XK:A^SX?"-C8?!R+5;"RU;P?>ZEXJ\9>,-5\9^/?&&J:II/[_
M ,$!B4+D,5$:%G#N75(TR0TDLDN6D+NSRR32,[,SN['<0!T487>-\C%9Y)&W
M84;I,2[%"*B>6@<*I"!FP6F:2=I9I'22^6P7&2Y.UF(6-<*SD._S,#MCD8'9
MMX"DJ2"9@,?YY/UJ)X@S!A@-\H)(R&4;QM(R/X9) IS@,V2K ;: /R?_ &ZO
M^"@_P^^%&L^-?V;=)\5^,OA?XWG^&"W_ ,1?VL+2S^&UE\&_V(K#XI)KWA3X
M3?%7XO>)?B_XZ^'GAS5;J;QA8Q:CI?PW\*S>+/%NMO8:?9W?AN>PUW3A?_@!
M^R'X&^)_QJT'7?\ @GS\0?A#=?%C_A.=0^%WB;5S\(=<\6^"?V2OB)\*;?QC
MX7^+_C'_ (+"^)OVX])&H_$[XW_'3]I?XA:'>Z'\-?A'X<\2Z??^"=6LS\,O
M&GAW1/"OA[Q5K7A_^BO]M;_@FC\-?VH/%&@?'#P)HOP%\ ?M;>&/^$?TG0_V
MB/BY^SEH'[2MQIOA'03J[V^FQ?#KQ7XP\)>$;SQ)ITNL74WA+QKK"ZIJO@N6
MXU!M#@B75+Q'^E/V0_V3OA_^QG^S?\)_V:OAC?:W>^%/A5I&IV=KJVO7*3:M
MK^K^*->U+Q=XX\1ZG;Z>NGZ/9:CXF\7:]X@UV.UT+3M*TCP__:C:3H6GV>B1
M'3I@#KO@7^SM\$OV<?"=WX#_ &??AEX$^#_@&XU^^\23^#/A_H5KH7AA]?U>
M#0QJ&MIHVF&UTF#4KVTTJS#W=O:"2Y<1:E>-/>S7@G]SBC\M=I9G8XW.Q)9]
MJJBLV21N*(N\J%5GW.$7<0&P0B!"@.X&260G&/FFE>5R1D_,SNSN1A2[-L2.
M/9$DU !1110 4444 %%%% !1110 57D_U@_ZYM_Z"]6*KR?ZP?\ 7-O_ $%Z
MRJ[+UE_Z9Q ^DO\ !+\BK/\ ZL_]<V_] >J-7I_]6?\ KFW_ * ]4:\3,/\
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MI*E@O(3=L4A%15FH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH K7-K'=!4F"O#\V^)D#"3=&\15BV<1LDLBRJ@5ID;RI':!I897P1&%-I
MD,K83?*Z1)+*R11Q&27R8XHFD?R]S%(HT4$)'&D:(HFHH **** "BBB@ KS;
MXL?%SX=_ WP#XK^*?Q7\6:)X&^'?@;2&U[Q?XO\ $%Z++1_#ND+*+<:AJMQY
M<AMK5[J2&W27:P+/(Y 2"1J])K\V_P!O;PM^UMI5YX+^-_[,D&F?'GP_X,\.
M^*?"'QV_8)\;GPAI_@[]IOX1>+[C3(O%USX-\1Z_;1+HGQL\)Z;$\GA"U\67
M6I_#7Q;HMQKW@SQ!H]I?:_I^L0@'YK?\%8_VJ/#W[2;_ !*_8S^&_A_XNZOX
M6^#_ ,//A%^TK\<OC]^S/\4[SP5^TY\'? /BW7A?^ /CY^R1\.;;0Y[[]J;P
M3X5TNQU&^^+UU\/=<ET[_A%=7N/"F@W-_P"/Y].M+'ZQ_P""9G['_P 5_AGJ
M?Q.^//QD/PX\(:E\<-&T.R\8_#7X!ZKXAN/V;OVAM9T72_"UOX:_;1U;X5_$
M3PK8ZQ\(?CS\4_!NGPZ)X\\(^&-7N=#OM/BT[5?'LWB_XDI=ZWI?FW_!,_\
M82M+*-/C-\5O@!XG^"/A/X3?&WX@>+_^";WP<^*_B1=1^/\ ^QW\%OB5\.M"
M\*?$#X7>(]?\*>(M3@L?!WC/QW+X_P#&O@[X#ZUXF^(O@SX8^$O$'@_2YKK7
M=7\/Z#_PAO[M06\49DVI'O\ -+N_EG>TC0Q99G9B7(4*B8"I% D5M$B1P(*
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M1YI_N_JW_P 17=S/_GW5_P#!4_\ ,5O./_@4?_DB:BH?-/\ =_5O_B*/-/\
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M'S3_ '?U;_XBCS3_ '?U;_XBCF?_ #[J_P#@J?\ F%O./_@4?_DB:BH?-/\
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M_P! \?\ P)_Y&AE/^>7ZC_&C*?\ /+]1_C6?11S_ -ZK_P"!Q_\ E(?6*?\
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M (''_P"4A]8I_P#0/'_P)_Y&AE/^>7ZC_&C*?\\OU'^-9]%'/_>J_P#@<?\
MY2'UBG_T#Q_\"?\ D:&4_P">7ZC_ !HRG_/+]1_C6?11S_WJO_@<?_E(?6*?
M_0/'_P "?^1H93_GE^H_QHRG_/+]1_C6?11S_P!ZK_X''_Y2'UBG_P! \?\
MP)_Y&AE/^>7ZC_&C*?\ /+]1_C6?11S_ -ZK_P"!Q_\ E(?6*?\ T#Q_\"?^
M1H93_GE^H_QHRG_/+]1_C6?11S_WJO\ X''_ .4A]8I_] \?_ G_ )&AE/\
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:+37<Y,7BH3I81O#4]*3LG*3M>STTT_IG_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>form424b4_008.jpg
<TEXT>
begin 644 form424b4_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $Z 50# 2(  A$! Q$!_\0
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MT]E_T[J_<O\ YX!I_)2_\ 7^13^R)_SR7_Q__&C[(G_/)?\ Q_\ QJYY?O\
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MT[J_<O\ YX!I_)2_\ 7^13^R)_SR7_Q__&C[(G_/)?\ Q_\ QJYY?O\ I_\
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ME1R"1 XQM))4@AE="<QNK#AED0JX() W;2<@T /HHHH **** "BBB@ HHHH
M*8\@CVEL!20I=F50&9E2->2"6D=E1 .K'&<E07U6FA61B"S+YJ"-C$7BE*!9
MLJ+B%XYD_P!9NC*.K12#>AW,30!&;MO,"+$CC?%&[+<19MWE28@7(;:J@S1Q
M6R+;O<S-).C&%(E+U8AF68,R@@*P7Y@5;F-'^:-@LD1&_:4E2.3C<4"LI/\
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MC?LJ>+?V;OCAXZOO O\ P3]\1_$4_'_Q#\:O"WB;PE9^'/%?Q"M/V>+2^_:
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MHH **** "JT\S(VQ=H;RGE#.RA=J*RNW=@L+M"93M^[*-F]@R59J)X@S%]S
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MG^(O&G@KPK9ZE;:18WVL6&GRZK=VLVL&SLA="R@]9_X(&^$--^'W_!-_POX
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MYQ@XS\T8_P"^Y%7/X=??VK^:O]AB1S\0?^"H$1+O W_!6;]JL2VLD]TMC/\
M\4E\$ #<VMO/;K/M^RY"R/@[P&#*F& /T%TQ2NJP6I -P+V&)XQ$I:1;&_\
M];,DUM"MP;1;A[NWM'>:)I#(+>>WF\V6O@W_ ()L13-^Q?\ "Z>99Y"/$7QI
M$EW<3^;;O%'\>OB=&MQ_:%Y<71E:2WC6Y:T6:2:UW&U6,QQ1RR=?XE_9W^.V
ML^*=4\1:)^WG^T3X)TN_UL:WI'@W0?!OP!O_  ]X8CCN'D@TG2)=;^$^I:N=
M-BWW ,-[J5U,[SM*\Q("GQ?X9_L$?$[X/>"-%^'GP[_X* _M.:!X8\/G7IM*
M@7X??LNW=]:77B;4M<U[6;F+4KWX%SWD377B#Q#J6HA()(DBBDCM8PLBO=R
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M/V_O?\%:?VJ(\>FWP;\&$SGOG;G';.,]Z /ODJ0L?SMRI/!Q_&X]\].OX=J
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MUCAM-/T[3[&"&WMK2S@@MHE0F.)-S"NP_9Z_X*E?!75O@CXB\<?MG^.?V?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %1OU/\ NC_T(5)4;]3_ +H_]"%9UOX-;_KU/_VTJ.[]'^AEW/\ K?\
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MH?!H5_2G+T_X'!_Z.6OYK?V&!GX@_P#!4!L_=_X*U?M5G'K_ ,4C\&N/;]:
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M&XQIRECL=B<;5KU8WFW5C;$8W,\P<JB2DL3&GS.HG$T****1H%%%% !1110
M4444 %%%% !1110 5&_4_P"Z/_0A4E1OU/\ NC_T(5G6_@UO^O4__;2H[OT?
MZ&7<_P"M_P" C^M%%S_K?^ C^M%>17_C5O\ K[4_]*9Y-;^+4_QR_,N0]/\
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M9=S_ *W_ ("/ZT47/^M_X"/ZT5Y%?^-6_P"OM3_TIGDUOXM3_'+\RY#T_P"
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MHY'CD /E 'H?V>O^"<G_  5-_9>^"'PM_9X^$?\ P5=^"%E\,/@WX+T+X?>
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M):PZA%8_Z2ULUW/JW22O&2;]&O7[* ^"OB;^Q?XT^#WP(^)?B/P'_P %%O\
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MN3]CGX ^([OQO\+?@]:-<VU[^S]\0?C.+R^FUOPRGACQ;H6L-K$VBS_T\?\
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M\<WVHVUMXZG\+V*OJ_B#2]%N-.@:YTOP_:W^OSO=E='LKZ:WND7Z$^"7Q?\
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M(:!#J%TDJV=E%J6N7MC975[>!+H6NF>?#J-R;*YDL;:[6)VC *'QY^/?P?\
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MQB,R;3Q)(TFT+&JJ6"A@NQ%+;V#2NTADD:21_G";$22@ HHHH *C?J?]T?\
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M0R2E'5%0NS*S@;E7<J8#A,YS("R85_+0[O\ 6#!%351O _6.$3,+>8[6  E
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M#:#X;T>+4I[[3+C4[T V?V:_V6O@M^RMX%USX<? 7PW/X'^'.N?$/QC\2H_
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MOA;>77@74?$G@OPG;V/B+Q#\-OA;X9^"_@W6_%NJM_;'C7Q/X<^%GA&&#0?
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M6#FHOZCAU\49..^B:=F]%W/7>K;7\M/?3=:;VW)Z*A\U_P#GDWZ__$T>:_\
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MR;]?_B:.?^Y5_P#!<O\ Y(+>:_\  H__ "1-4;]3_NC_ -"%-\U_^>3?K_\
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MG_X'_P#;&GN3^XWYC_XJC<G]QOS'_P 569@>@_(48'H/R%']H8K_ * LL_\
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*;2N]-;=%;H?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>form424b4_009.jpg
<TEXT>
begin 644 form424b4_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #K CP# 2(  A$! Q$!_\0
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ME^_Z?_7H]E_T[J_<O_G@&G\E+_P!?Y%/[(G_ #R7_P ?_P :/LB?\\E_\?\
M\:N>7[_I_P#7H\OW_3_Z]'LO^G=7[E_\\ T_DI?^ +_(I_9$_P">2_\ C_\
MC1]D3_GDO_C_ /C5SR_?]/\ Z]'E^_Z?_7H]E_T[J_<O_G@&G\E+_P  7^13
M^R)_SR7_ ,?_ ,:/LB?\\E_\?_QJYY?O^G_UZ/+]_P!/_KT>R_Z=U?N7_P \
M T_DI?\ @"_R*?V1/^>2_P#C_P#C1]D3_GDO_C_^-7/+]_T_^O1Y?O\ I_\
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MBQ,7>:2)$7EG!**Y[+_IW5^Y?_/ -/Y*7_@"_P AOV1/^>2_^/\ ^-'V1/\
MGDO_ (__ (U1;7=(33TU:34;*'29(K6=-5GN88=+:&]:V2T9=1D86+_:7N8X
M[<Q7$D<LS)"LGF2**JW7BG0+#4K#1;[5]-M-:U:*YN-)T2>^MH=<U.WLPSW<
MUAHMQ)#JEZMM$%>9+.TN)E.]5C951Y3V7_3NK]R_^> :?R4O_ %_D;'V1/\
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M ]YX=MK6&TB\/3^%[RRN-(DT(1PI_H$MM)PD40F$$,42\/\ #7]EO]G/X.>
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M4%%1M^W;M$V=\D221JY6!P<IYCO)QMC$+,F)1MN*RNH93D'D'_$=0?8X(Z$
MU^>B^/?VBOA]^W%\-O@OXH\:?#+Q/\$?C-\*OCKXQ\*:7I7PXU#PO\0/ 6I?
M"R?X/65DFI>+D\>ZMHWC2'4_^$TU.7,/@;PF=/#O;QF[A\A+7]"(LX8G!W.6
M#;0N]7 920 .44B+)R6\O<3DX !+1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,9
M\$C:QVJ&)QPV=_RIUWN"G*<8#*<\@'C?'/@SPG\1?"_BCP%XYT#3?%/@_P <
M^'M6\(>+/#&IV4=]IGB7PUK6GW>GZOHFM*\>#8W5AJ-U$8?.A*B>1XY':0H/
MCC]M3]M>_P#V3_&G[)7@O3O@KXT^([?M._M,?"K]GV\\>Z?]DL? 'PBMOB;X
MEM_#4/B/Q=K#F[O9-7N+JYC7PSX9M]-AA\1?9M42?Q!H[V4*WGP7:_\ !7_Q
M_P"+X?C)-X _9T\.7>FZ9X9\;_$?X$W>N>.]8EN_B'\+O@M^UE/^R;\8;[Q?
MX;M_!-G=>'?$UGXILK[Q=X*\/:5J?B.VUK0[RT&I:]I,INA;@'U%X;_X(E_\
M$F?"FN:?XET'_@G[^S+I^LZ/J5OJ>FWLWPXT_41!>6TJW$5REMJDEY;-)%,7
M\EIK<JC%BL)7:S?J#I]C;Z;:16=K'#%#"B11)!;6UK&D,,:06L2P6D4-NB6U
MI%!:Q+'$B+#!$BJJJJC\_/!G[=W@WPWXC_:3M?VJO$_P@_9U\._"7]HV7X*?
M#WQ1XK^(>G>']!^)6CM\+/!'Q T[78M1\8_\(_#)X@F77M4BU'1]);4[?2X;
M.VL5O;Z:UGO)_P!!-/OK;4K*UU&RN+:[L;ZVMKRQO+*YAO+*\L[JWBN+>ZL[
MJ!FAN;6>.0/!<1L8YHBLL9,;HQ +E%%% !1110 4444 %%%% !1110 4444
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M^N_8_P#WRA'3G.< $E%(#G\\=_Z@4M !1110 5$_4?3^IJ6HGZCZ?U-<6/\
M]W?^.G^<BX?%\F00]/\ @/\ [*:LIT/U_H*K0]/^ _\ LIJRG0_7^@I8;X,-
M_@A_Z@8<)?$_\,/R0^J<X#2Q!L*J8*O))(D;2R-B%%575)V$D0+1R E=T;1D
M,:N55N69$D8,ZJL$W^K3?)O*,ZO$.0TD:QOMC*G>77D8PW<04?(BAF>5(U1Y
M5$]SN=$\QK8;?-FG@7S[DQ*(X,7;2XB972-C#)$\TC1'(>:,(LBLY>0,829I
M4CEC=F?RI#>_(B2L4V1&&- 8GC'\]/Q,_P""B7[9FA_&3]MSX(:QH?PH^%VN
M^"OVH?\ @GI^S_\  ?5M)MIOB1#\/_ /[8WBOQ5HVH_%SXA7+W'A(:QXGN_"
MNBOK>D^%"='TOPUK%[;Z3?:_J$4_VF-_PX_:J_X*/_'#X!^%_C7\.[8ZI9>*
M?@O9:;J-OX!^%/AF[M;;XO> _P!JW7/A/\0_&OA:Q\07EYJU]'\2OA_HT?B2
M3PAJ48M_#EE+JOB/P\9(H8KK40#]&OBH0_\ P4<_8P*$A9?V>?VR=Q>&6&?:
M=6_9M=2T<JQ-;W F>>5V$*%TE13&FS<_Z$)DER<<L",#! \M."<G<<YYP.,#
M'&3^/>B?%G5/'?\ P46_9'\*>)? GQ.\.^/_ (>_LM_M13_$/4-=^%OC7PO\
M/=6\3ZQ>_LT?VW'\/?&FM:7#H7BNRBUIKIHY+;4,O;RQ2Q[(WBMH_P!@XSD,
M05*EAM9&W!E"* <X !)!X4L!Q\Q.0 "2BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHIC.5)^7(VYSGDG)XQ@^F<_AZ9.V^K25DWJ_39=V]%U:$VDFV[
M))M_+\WV2U?1#Z*@\X#[X5">@+]3_P!\C'ITZT"8\[D"\\8?=D>O"XYYXSVZ
M\TI-0MS/E3O9O2.G][X5Y:Z]!*5U%J-2TE>/[N:NEUU2M\_E<GHJ#SU]#^(8
M?KMI1+D<!2>>"Q';/=<4E.#=E.F_2<7^I3O'>$^_P2?Y)DU%1"1B<% /HX/]
M!^=/5BP.0!@D<'=D<<YP/RHYX\RBG=M-WC[T;+O.-X)^3DF^B)C)25U=:VM)
M.$O_  &24K>=K#J***HH**** "BBB@ HHHH **** "LW4;"#4(IK>XBMKFWN
M;=[:YLKJ&*:VO()5DBEANXIDECN8#%-*B031/;[Y&>6*?"HNE32,G^'&.A7)
M_/(X]L4 ?@;K_P#P0^L=7^&GPW^&EM^T;K6F6>E:3\>_AO\ %W5K;X;Z)/J'
MQ(^"WQU_:DT;]J>;POX>^U^))8OAKXN\(>)M$@\+:+XVLD\26CZ!=:I_Q25L
MUU:6^G?KIJG[+?[/NN:NGB+5/A%X O?$*:OK6O\ ]OR^'K5]:&N>)/#^G>%=
M?UB/523J,&IZCX<TRSTAKV.[^U6\%I8SV\T=W8V\Z=I\0_BS\./A*WA$_$7Q
MGX:\$P^/?&6A?#OPA-XDU*+3AXE\=>*)I+;P[X4TA9"QN-3U2>*2.)#L16:)
M07,A5?#]<_;P_9!\-S_%BRO_ (_?#5;_ .!NO>%/#'Q9TBTUPZCK7@?Q!XV\
M367@[POI&L:-I=K?:FU_K_BF_M?#FC1V-K>)?:_+_9!E@N8Y=@!\^_M[?L;_
M +-NN?L8?M53ZE\+M(EO-*^$/QH^*=O?6VJ>)]+OKGQUH7P=\8:?H6J:OJ&C
MZ]IVIZY8:+92&TTOP[K%]?>'[&U1(;73H2"Y^U/V;B6_9[^!DK'+S_![X83.
M<!>7\#:#@84*@VJ%0;$12%!V[BQ/S7^TS\=?A=\6_P!C[]N[2/AYXKLO$FJ>
M /@1^T+X,\5V<4&H::^F^)+;X6>.(FL(FUNRTQ-4B^T:=?V+:AI!U#3EU+3]
M3TU;M[S2=3AM/I7]F\ ?L\_ @*2R#X,_"X1LRF-V0>!M! 9XFYB<X.4W/M&/
MF.> #VFBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BD)!0;"X9@
MK *&V@@X9LNH"@YR<.?13R1+7YO_ +8?_!1SP#^R%\3/"_PO\3_"OXE>/]5\
M3>!3X]AO?!TWA"#2;+3U\2S>&XK2Y.O^(=(O9;][BVN;F1([=[1+=;8)++--
M,MMY.>9]DG#.5XK.^(LVR_(\HP482Q699IBJ>#P=#VM6%&E&=:HI+GJU:D*=
M*G&,IU)MJ,?=DX^WP[PUQ#Q=G."X>X6R3,^(<\S"52.#RK*,)4QN-K^QI5*]
M:<:-.4.6E1HTIU*U:<X4Z4>3GDG4@I>T?&+XF_M#?##PWXW\;Z;X*^"^M>%O
M#3)-IT6I_$'QK8:Q>VT]YI]C ES!I/PQUFUL&,EX\C@7%ZZ-&RG*21LOKG@J
M\^-LVKW ^(WA_P"%>F:']G(M)O!GBKQ;KNKRW"RS!1/8ZUX'\.V\,#Q")V=;
M^=D9F41G:7?\,OV@_P#@LW\+O%GP:\>>'U_9X^-T!U/3[*/S&OOACYD45MX@
MT4QLL8\8X*,Y<K'(VY<,1(0PV^NR_P#!<3X2A]K?L\_&L2))']K5=5^&RHB2
M[EC8L/'$(9MR&-I&C(PJD] @^%I>-GA!7CS4/$O@NJN;'14:>>X9SD\M@YXS
MEA*G2<E2@G*+C)JLFO8>U<DG^EOZ.OCSSU(+P@\093I?V?[2-/AO&57!9G)0
MP<FJ56H^2<G^]G9PPJO+%2H13:_<B(Y7&<E3AAN5BAP#L8J!R 02",C(Y(P:
MDKY%_9 _:[\*_MA_#S5_B+X-\(^+/"-AH?B[4_!>KZ3XSET#^T[76],TG0M:
MD%J?#NHZQ97.F36'B'3F@NIKN&[:X^UQR6BPQ6\]Q];HS,&W*%PQ PVX,, [
MLX&.21CGIG/-?HN!Q^#S/!8',LOQ-+&8#,\%ALQP.+P\E4H8C!8RE&MAJ\*D
M;I1JTY*48RY9K52C&2:7Y+F.79AD^9YIDN;X#&97FV2YCB\IS3+LPPU;!XO!
MYA@:OL<5AZE&O&$I.E4]WVE/GHS34J=2<6I-]%%%=9QA43]1]/ZFI:B?J/I_
M4UQ8_P#W=_XZ?YR+A\7R9!#T_P" _P#LIJRG0_7^@JM#T_X#_P"RFK*=#]?Z
M"EAO@PW^"'_J!APE\3_PP_)#ZCD1FP58+@Y.5+' !*A,.@5A*(W)8.K*AC*@
MN'1LDPC)W8"A=Q<DA8U =F>9BNV.,!  Y8Y).554+5SGC+Q1%X+\*^)_%UQI
M.LZ[;^%] U?7[C1?#-G_ &KXEU6'1M.N-2?3M TAI+5=3UB\CMY8;"P^UVYN
M9S#&LJ^;E.X@\A\;_LM_L\?$-?BQ#XX^#O@/Q7!\=;#PG9?&.#7O#<&JM\1+
M+X?374_@F+Q UQ'*;YO"4VH74_A_;LFTZZEAGLI86@VR^D^"/ ?A#X<^$_#G
M@'P'X>TGP?X*\'Z58:)X0\,>&M.LM(TGPMH]E;26UEIECI%O##I=A:06;K9V
M\$5BKE3(\SS7$CSU^&-[_P %Q[J7X$_#/XTV7[*_BG2[SQ3;?M3_ !)^(OPZ
M\:?$&Q\,>+?AM\!/V//B/HO@+XF:Y) ?#%T-6^*>L'Q+I&J:%\-Y+?2=.Q'K
M.EWOCEKC2X)+OZ%LO^"BGQ,O?AA^T5XA_P"%8_#K2_&7PF\;>&X/!VGZ]\1]
M.TKPSXV^'NN6UAXFUC4M%U2_\FX\7>-_"'@>ZAO+WPUH5JUQ=^(+W1_"_P#H
M,TLNJ7 ![Q\5[>!_^"C?[%D/E(H@^ '[8TL"N$E>QD75_P!G#"6\;&6WMB8G
MC0"*/*P)$$8#:1^A<2A0P&>6!QEBH^1  JLQ"*% &Q J;LL%#,V?R='QT^%W
MQE_X*(_L9)X!\;Z!XA\3:/\ LM?M3:WXS\%QZKIL?CCP!_PD\W[,VI:98_$+
MPI%?WNI^#]6E^T_9Y]'OQ+>V-POERHT+0W$OZPPMO4MTR1D?-D$(@((94=2#
MD8=$;&"5&<4 2T444 %%%12R&, A0<M&O+%1\\@0XPKDE0<@8 8E5+*"65-J
M*<GHHIM]=%Y*[?R5Q-I;DM%9LVIQ6\$\\L4S&WBDE>VM4-[>/Y4*3/%#:6HE
MN)IR6,:0QQL[L%V@B2/=\Z:C^U;X%TNZT6RO?!7QM@O?$EY>Z=H%K)\%/B6)
M-6U&QMKF[DL[1D\-21-(]M974T<C2+"R1[A(0W$RFH1C*4:EIQ<HN-*K*Z23
M;?+"36CNDTF^E[.RE*,8\TG:-TKZ]79=._W=3Z=HKA/!/CVS\<V%S?VF@^+M
M ^RW\UA)8^,/"NN^$]2+11K-'=1V6O6%A+-8W$,D+0W<'FQ-*TUON\VVE [6
M"9+B,2QLK(P5D='61'5T61'1TRCJR.K*R%E8$$,13<DG3BU).K%S@G"2O&*4
MG>Z]UV::4^5M;)C34E=:KO\ Y7W)J***H84444 %%%% !5:<["9.>$ &/4DX
M/H.O?T]0*LU5F!+')RK*B;<="S/\V?; XP,^M',H-2:O&Z4O*+:3?=VNM%KK
MIU$U%RIJ4>:/M8-J]MN9W?=*S;77LS.ED2,(\RL[2#*JIZ+N.3@ DGN1@ Y'
ML*;-J=CI]K)=7]U!IUK#@W-S=W<=K:6S,50":XN?)10\I$<3' D(& ,@#+\6
MS2V/A;Q%J5M*\-WIOAW6;RVFCV"6.6TL9[E6C,B2QJY:)=K-$X1OFVOC;7\/
M%W\<?VF?B3\/;.T\1?M)_%K7IO$&G:5J.K:=XG\47FI^$KR_EM;>XGN'\*6,
MNBV;*T[M) LUQ/+"V \T\:1QQ_D'BMXS<.>$,,HK<2T<SQ&"SC%U\+AI993I
M5L6\1AHPK8B"A72H0H8>C4A4JRJ-2G&<5052:J07[GX'_1^XT\?\3Q1A^%<T
MR?#3X=HX+$RPF:SQ&'H2PV-J5:5"JJU"/.ZDJE*48T^CNZG+'E;_ +C7\6>&
MHED>7Q)I$0BR)1-J]C$8GVK(JR%YEC0-$R2*TDJJRNA&=RDW[34K3488KJTF
MMKV&4?)-;7MK=Q]> )K:66)P25 \II,%^>AK_/\ %T3XTVNNZEXD/QED^U:E
MHMIH;VLOA^S$#V]I<75PDT[VM[;3W&3=M$@\V*XC2*,-=RJJJGU'\/OCS^TM
MX7UGX1:7;?M*_&H6MG\0_AGI#:)9^-I8_!\ND77Q%\*)>Z0- DLIITTRYM3=
MVK6<FK7&U;V9C-(I,1_+</\ 3$\+<VS7*<IRG*^*L5B,VQV"RRE3QN&R[#X=
M8C,,3A\'0]I*G[Z;Q&*HTHM/V:G.4JDH4XNHOVO,/V?WC+D>2YOG699MPG1H
M91@<=F=9X#'8ROB'A,NP>,Q^*<(5W[*48X7!8BI.+_>25.,:49U)QA+^V^"2
M*4'8P*YPC;T=6  R0R$C@[E(."65CTP39B  8 [OF/X<#@^^,5G0;A'%*S%I
M&P9"2Q#,-J$J&9_+4[0?+!*@ECR6)-^'[K'U<G]%K^JZ2IP2A1A[*+BJE6C)
MWE2G)R@ES)N+M4IU(/DE*/NW7NN+?\.4G*;52HU-V;P]6*Y8UJ,N6\^3>+:E
M!VFHR5]M&34445L;!1110 4444 %%%% !1110 4UG"GG&,<=22<] ,?KG\.]
M12W"1,$.UI& 98A)$DK("1(X65XP4C&&<JQ.,_+G ;Y;M?VE7O/VS]<_9'B\
M'3!M%_9I\,?M##QV=8B:RNU\2?$_QC\.4\+?V0M@)H)+<>%/[7&K)J-T)A=M
M8G3(3;->2@'SG_P4._8VO?VH/%/[%7Q"\%^%_".H_$C]F7]M#]G?XQ-XJ\2Z
MI)INK^$_A%X;\>6VK?%J#P<R)*%\1>)]'TZRTVUMW2*/54MY;6:\LE@61OBK
M]F#_ ()7_$S0_BQ\3-%^/<?A8? W2?AQ^TS\(O!WB'P3XJEN/%GQ>L?V@?VV
M]8_:YT[7_$&EWND2Q^")/AY;W.D^"AI=]<^-9[[5[.]U.SU/2[6WBT^7]^+B
M3_61[YT\R*?!9F"JH5(WY10(I"UQ;O;QRS0RR$.(_* D>3)?Q+X>AO;"PGU[
M1K>_UF>:/1;8:I8+<ZRNGRSO-:Z;$7$VI2VXBNOM4%E#+-;>5+#<;<)<7 !^
M5/[6_P"PYX,^'O[''[:VH_!WXJ_&/X/7/BKX9?'3XD^+'\#ZUX2FB\06-G\.
M/B)JL/PX9O%/@[Q+<V'P^AUCQ%XBU.WLM/N;;6X;O7-46+6Q8/86EC^C'[-[
M%_V>O@5(0JB3X._#*1(T#;(HW\$Z&T42EV=V\N,JC.S$R.&DVQAQ&GDO[9/B
M+1M6_8K_ &RTTC4M/U2?3/V;/VA[#4[?3KE+J32]3MOA-XMEFTO4X;1KIM+O
MX %BN;.[\NXBN=\9A\[]V?6OV< J_L]? A4<2*OP:^%RK( 0KJ/ V@A77/56
M7#<$@$E<D@T >T4444 %%%% !4;/M;;M8@+N8A9#@'( 7:C*[$CE P95PQ&"
MN?F7]I;]HF^^ %KX &D?#R;XB:U\0O%%YX8TS3%\5Z7X1A@DL?"^O^)IKF2_
MO[+5'E(31%MC EBJ*+P7!N<P&WE_.'XM_P#!1;XI:%XEM;%-'T+X6LVCPW!T
M*_U_PUXXFN)IY;J.WU9+\Z'9%('G5K!;%=FV339+C>OVK:GL8'(,WS+#2QF!
MP-7$8>$XPE4A*G=2DVDN24E4>J=VHM+JU=&,J]*$U3E.TVG)*TMEN[I6_&Y^
MVWFXP" ';.%W@9Q_UT"/TP3A#@=,U(CAP2,<'!PRL,X!."I/KCG!]@",_P _
M'P3_ ."G/QL\70_#V^UZ'P]KFJ:Y907NL^#K=]'\/3W-Q>01SI8+KXT">RM!
M!%)%$+N2W61V5G:UA0IN_3O]G_\ :JU_XO\ Q(U[X8^)?A%=_#O5-&\$0>.H
M+]O'6B>,M/O["YU]= CLXIM#T>PAMIO/$T[+/*;I(D#26RQS0R,8K(,YP5">
M)Q6 KT*%-)SJ5%%1C=V775MNR2NWT6A<:D)OEC)-V;MKLMS[.HI@?...I(^F
M#CTY_#Z4X'.?8D?E7BJ<7RV?QIN.CU25WZ:=RQ:***H HHHH **** "OYB/^
M"S>X?M??"\H44G]F]0Y= VY/^%K:Q\O5<=3]2<<=:_IWK^8/_@M!+Y7[7GPO
M;C_DV^,<]/F^+&L+V],YZU_//TJ)3AX&\9.G4E3ES9*E*#J1>N=8%-7I-3L^
MJORNWO+1']5?0J3E])'P_@HQDZO]NTU&=.%1-RR/&?9J1E%.T9-3:7+9VDF]
M?QJ^*1+?#WQ6I?\ =K80!8HPH= ?$.C$@N58G=G*CH.3@9(/<SK"))OM%O\
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M-WXATSP5I]])X?TAK:*X:/5=7>SLYIX&M;>2:X)C3Z4AZ?\  ?\ V4U\??\
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M_@+Z=G_(I\/?^Q_Q)_ZJL"?Z>?LR/^1UXJ?]B+AC_P!6...LJ72O^1S^&?\
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M_P Y'S&8_P"\P_Z]O]"3/R$_W=Q^NX ?AC'XUZO^R0-O[5?B9<YQ^S=;C/\
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MTOSY[=;IK74=/\R6"*SN&$4&IV5G<RQB"^MV>9(3"DK^1YC2*^U@=E7\P?\
MP6@/_&8'PG&/N_LZJWUS\4]9&/;&WK[]*_IYC?>"2I4AB,%7'! 93\Z(22C*
M6V@JC[X]S,C&OYAO^"SXS^V!\*3G_FW-!^7Q3ULU_/7TJO\ DPG'W_7C(_\
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MFG]J'1/ 'PT\50>$O^$8^%.C>%+G]FK2;2S\)WNC>'-+\2W<UWI-K9VE]?\
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M*"/)N/\ 6.)96F7>IRP\DT?QS\6--^*GQ2\:+^SK\9I=!\4^$? .B::D.O\
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M!_\ R,,?/[-:%65-_P RC"-W;=6\[>1.8?[M_P!Q:7YR/*?V]O\ D*_LS?\
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MVXB1?FUP"OR,&(@D95A$9B> -8O&T220O#)9S2)8BW5K1M.N//TJT:UEDO\
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MU&QN].2SO?$GAG]R\C>&)(##/3@921C\WL#D\#&!_>X_#2RC:7Q;\;%<%O\
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M!!Y,#6^/L\MO:RQ26T/\[W_!9\X_; ^%(Q_S;FA_/XIZV*_GKZ57_)A./O\
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ME@MX_P"*/YGR9\,_^28_"_\ [)A\-_\ U"- KM:XKX9_\DQ^%_\ V3#X;_\
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MIO9K)?2V.A?\))J<2:CXU.AV>GOXSU2"SU+7)+BXLH"H!^<GQI_:M^%'@/\
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MKZYN+J]M+"WC2RLY[]LW=_);621"UL[N6YFFN8A8Q0BYNUCLV>YB_ 3XI?M
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M _\ LIJRG0_7^@I8;X,-_@A_Z@8<)?$_\,/R0^BBBNX@**** "BBB@ HHHH
M**** "BBB@"M/ \K(R3-'Y8+H 9@OGJ&$32+%/")H 'D\ZVDW+,?)97B>$,W
MX\_"S_@CY\)OAK^U]XN_:6\0_$[XD_%;PU*_B'5_A;\,OB9K]WXTM_AOK7Q
MU:XUKQMI46K>)9=;U+7_  B-:N-2OO"7AR232] T>QU^YT?6M&\3R:!X9UK1
M_P!CZ:RD]'91C&%V_GDJ2#]"* *EK:+:Q-%#(X.^>1R[/*#-<,9B5,\DLRP0
MF016MMY_E6MK'#:0!+>")5G!\M]F!B0EDQNQNP6D4\$+T+J<_,68;05W-(H9
M<[B#DY!"E3MP -Y+-N;CEAM!&!M&.6O'O!&YAS&>#T,;[U('3E@ W]Y1@]J
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<J/I_4U+43]1]/ZFN+'_[N_\ '3_.1</B^3/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form424b4_01.jpg
<TEXT>
begin 644 form424b4_01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $8 D # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1*PC.^,8P5*@C.,YXKTKPQ+<S>&--DO(+B"X:W3S([E]\BG'\1P,G\,UK44
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<7\2[?Q)>
M>'/LWAV)W+-NN/)F\N4J,$*A]SU]A[T =I17FVB:?XK/BS6I6-S9-*DN)[DF
M:WR9%,(1=P!VQ[@<8]ZZ7P;J>I:E9ZG'JLT,US9:C+:>;#%Y:NJ;<';DX//K
M0!TE%%% !1110 4444 %%%% !1110 5R5AI^LZ7I_B+4X[**XUR]NI)((GE
M5D7Y(5+=@%&<>YKK:* .2\$Z?J=FE[-K.GRQZE<LLEQ>2W"2&=L8PH7[B+T"
M^A]<USS> =0.FV4=O!;VEZ;C4&N+I&&\+,LH0DCEN63CMCVKTZB@#RJ3PAK=
MS T]OH5IIKVME;0+:QW"8NY(IDDSE>  %(!;GYN<5?MO"VJ:GXE34]6TBWCM
MWU8WC022I+M06HB4GL3N'3M7HU% 'GGA?PQJVD^+#<G3XK:P'VC>9)(Y>7?<
M/)8 2 $\E7X':O0Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH-
M>0ZAI&OS1:\MO;:]!:R74,D:%_,=F7?N 'F9,9.PE@1P0,<4 =IXO_Y"OA7_
M +"Z_P#HJ2NJKSG4K?78]2\&/J-Q:I;_ &R%39I&2\4GD/G]X6.X Y[?C7HU
M $+W,"$HT\:,.Q< BN3U>75+%+5X?%6[SKN*%@;>'Y59L$].U?.'QE=U^*^M
M@.P&Z/H?^F25P?F2'^-OSH ^Y]/\VU>0W>NK>JP&T.D:;?\ OG&:U(Y$E7=&
MZNOJIR*^!?-D_P">C?G7U7\ "6^&*$DD_;)NOX4 >HT444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5RG@?KXE_[#MS_ "2NKKE/ _7Q+_V';G^24 =717EGQ.^+,O@/6K?2TT:.
M]2XMO-+M<&,C+%<<*?3K7DQ^+]H;]9QX8D$(B*&#^V+C#,2"&S[ $?C0!]64
M5Y!\-_C'+XQ\20Z!_8<=G$+=F60732$!0,#E1GZYKU^@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBO*;_XA:O:RZI;)?:4_E7,:PW:H3''&RRL0WS<G,6SD@Y)XZ4 =9XO_ .0I
MX5_["Z_^BI*ZJO.M3UG4-4U/P8UQH\MO;S7D,XN3*I4LT#DH%SN&"2.1VKT6
M@#X\^,__ "5C6_\ >C_]%)7!UWGQG_Y*QK?^]'_Z*2N#H *^K?V?_P#DF*?]
M?DW]*^4J^K?V?_\ DF*?]?DW]* /4J*** "BBB@ HHHH **** "BBN:\4ZQ<
MPF#1M).=6O\ *QGJ((_XI3].WO4RDHJ[-:-*5::A'_AEU;\D=+14-K$\%I#%
M),TSH@5I'ZN0.I^M351F]] HHHH$%%%% !1110 4444 %%%% !1110 4444
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M4J2J3<YN[84444R HHHH **** "BBB@ HHHH **** "BBB@ HHHH *#THHH
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MX^>M>P?&3_D06_Z_K7_T:M>/GK0 5H^&?^1Z\-_]?W_LC5G5H^&?^1Z\-_\
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MP[-T;37_ +:(1=?VW<^:("2F["?=SSCZUV5<IX'Z^)?^P[<_R2@#P_\ :/\
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M+_DG?B'_ *\)O_037!0_\>\7_7-?Y"F@'UE^(?\ D"R?]=8?_1JUJ5E^(?\
MD"R?]=8?_1JTP/<Z\G^*/_(YZ%_UXW/_ *%'7K%>3_%'_D<M"_Z\;G_T*.I
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M@H?^/>+_ *YK_(5WOQ"_Y)WXA_Z\)O\ T$UP4/\ Q[Q?]<U_D*: ?67XA_Y
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M ,CWJG_8-C_]&-0!UGQ&_P"0/I?_ &%[3_T.IC]X_6H?B-_R!]+_ .PO:?\
MH=3'[Q^M '/^-_\ D2-8_P"O<_S%>CP_ZB/_ '1_*O./&_\ R)&L?]>Y_F*]
M'A_U$?\ NC^5 'S/??\ (P:[_P!A6Z_]&&HZDOO^1@UW_L*W7_HPU'0!Z7\%
MO]7XC_Z_(O\ T4M=5XX_X\[/_KH?Y5ROP6_U?B/_ *_(O_12UU7CC_CSL_\
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M#7?^PK=?^C#4= 'I?P6_U?B/_K\B_P#12UU7CC_CSL_^NA_E7*_!;_5^(_\
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MQZ"@:1XNU'3-\/AI/+N8<HQU&/HR\'&/>J ]'\$?\B)H/_7A#_Z *\J\1_\
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M\/\ J(_]T?RKS'7K+QAK&@WNFIX46)KF/8)&U.(A>1SC%=*FN>+415_X0K.
M!_R%(O\ "@#Q"^_Y&#7?^PK=?^C#4==%<> ?&LVHZA=#08 +J[EN0OV^/Y0[
M%L'Z9JA8>$O%FI/>+;:+$QM+AK:;-Z@PX ) ]>&% '<?!;_5^(_^OR+_ -%+
M75>./^/.S_ZZ'^5<EX'TOQCX034Q+X72Y-[,DHV:C&NS"!<'(]JUM=E\7ZS#
M#&OA 1>6Q;)U.(YX^E &#5W1_P#D-67_ %V7^=9%]%XGTZ:RAN?#2J][/]GA
M U",Y?:6P>..%-:EEIOC"TOH+@^%D81.'VC4H^<?A5 >I3?ZB3_=/\J^9&^^
MW^\:]R?7/%KHR_\ "%8R"/\ D*1?X5Y:?A_XV+$_V%!R<_\ '_'4@<]7N'PS
M_P"1)MO^NLO_ *&:\BTKPGXKUG3TOK+18F@=F52UZ@.58J>/J#7I'A9O%_AW
M0HM.?PBL[([MO74X@#DD],4 >B45DZ-J&KWIF_M31/[,VX\O_2DF\SKG[O3'
M'YUK4 %%%% !1110 4444 %%%% !1149GB$PA,J"4C<$W#<1ZX]* ,OQ'K\6
M@Z7-<!//N%3=';J3N89 +8 )VC()(!P*\PMK/6O$GBY[_3WN8+H%'>>0>4]D
M6 X^89D@*AMJX4Y)+#H:[S5= CMO$-OKMAJ1MM6FE6!A<N7CN(N,PA?X<8+
MKT.<Y!-;VFZ1I^CPO%I]I';I(YD<(/O,>I)[F@"[1110 5R7B?Q99V\,^EVC
MRS:D\HM?+AE\EXG92RG>PVJ2!\I/!;BK&I^))735;;2+=WNK-=BW$VU;<SG;
MB(DL.?F'Y^M);^'EURUTW4/$=C$NKPH5G6+[C D_(>H= <$9[@'@T 4? MEK
M*QOJ&H7UW(DX.Z.Y'^M.?ED"'F%L95D'RY&17:444 %0W=U#8V<]W<,5A@C:
M21@"<*!DG ]A4>I:A;Z5IMQ?W;[+>W0R2,!G %>7W/BJ]U?Q+YELLEY92Q&
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M3/*A"[)3"HW.A^;"9 8<D\8K2\#>"QIL5OJE]&T-Q\\T5B%"QVKOPS*.3EE
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MDS7=PQG3_1RA,)B&9"0Q )7(.WJ>U &CJ6M:)::M9:?J$T0O)&#VZO&6VDY
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MO\,AQA0W#'([5-X+\,/%:6.IZFD\-W$9)(K/S#Y,+/D,Z1D90L"?D)(7<<4
M:?@_2I+#3S.(Y;*"[59AI;D,EHY^\$/4*>#MZ#VZ5TE%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 UW6*-I'8*B@EF/0 5G:/KEKK=L+BWCN(XF)\
MHW$?EF91@[T!Y*G(YK(\1:I?Q'S;$I=:6K&VOUMX_-GMVR/F"_Q#!PRXR <B
ME\.^$X]-FMKN:>\;[+')#96L\JNMI&Q&0K  L"%7&XG XH OVHL]3U]]033\
M/:(UM'?-E3)D_.BC^)00.3QG./6MJBL7Q)J,]GIY@L+S3[;4;CY(&O9-JJ20
M-V.K8R..Y(H H>*_%8TJTN;?3"MQJ4*K)-&BF1K>(GYI-@^\0.=F03]*YWPB
M)_%^MV^NWT[BYTR-$#VSJUM=!E8@L!P) &&0"=I/!YJ.U\(?\)(R3SBYL-1@
MF4:F+@NSF9 N)82"$!8*/G /!QP<UZ3;6MO90""U@B@B!)"1(%4$G)X'N: )
MJ*#7GNH:Q-XFLKJPEU%=*6;4A86C6FYKN*1&.2XR N0N1U !&<YH R_&][K%
MUK+Z9?6SQ6S7$?\ 9C6\R)*'RH$T8Y:1E+'<I 4 =<\UVWA/0[W1=.\N_N89
M)B%016ZE8HE7/W<_,222Q+$Y)K5L+(6EC:02$2RV\2Q^:1R<  GG)Y^M6Z "
MN+\:>+!IDW]B0O/;7-U;,XNXDWM"#D I& 3(01R!C YS6MJ/B%8[R]TRSBF:
MZ@MS))<;5$,#%24#LQ R>N/SQ5?3M*O]=\-QP>+X8OMAD8R)9RLB;<\ ,IR5
M(Z@]>XH YKPCINHZ[H8TS5+5H]((WL\4Q6.<'E5B(.YXV4EG9SDEL8X->E*H
M50J@  8 %-AACMX4AA18XHU"HBC 4#@ "E=MB,V,X&<>M $&H7AL+":Z%O/<
M-&N5A@3<[GL /\BN1M)+GQC8V&JVMU%INOZ9-(DMN\9<0EN'AD0D'IM^8$=,
MC@UBWFKZAXPT&ULX=11=4O9'EAM+*1H3 L>-T<SY+*RY.#@ L ,8KO\ 1],:
MQMHY+QXKC4WB2.ZNUC"-,5SC..N,F@!FA:*ND6*)+*+F\.XRW3( SEF+$>H4
M$\#/ Q6K17">*];O]3L=0M=$C=4LIUBFEDF6%+M@1NMHWSN5B2!G'/(SS0!L
M+XNTS4+VZTFROHX+\;XK>2< )+(,@[ 3E]I'./2N<\+>#[R^O+G4/%5LLT@E
M*HEQ&A,^WH\BC*DKT5AAMI(/ %:6C^%+#4CINO31^5<,$NIX$M%MQ)<#.'<$
M;\KD\;L<9KM* $    & .@JE>:QI]A=VUI=721W%TQ6&,\E\=>G0>YXJ'6=;
MMM)2&*1R;NZ)2VB6-I"S>I"@G:,C)["O/K'0[[Q>E]'JXCAURQ98)A<L[I(K
M$L3L0JK19_U8R>AW<T 6=3T'Q'JOC+4])DOS)H\H2\07:%T4' "Q%<-&Z,K$
M'=W''6N[T?1;'0[(6UE!''G!D=8U5I6QRS8 !)J72=/72=(L]/6:29;:%8A)
M*<L^T8R3ZU<H **** "BBB@ HHHH **** "BBB@ /2O-[7PUJ]]XMU*VUV\O
MO**">VN[>1O+D82;HV4'*Q/&!MVX.[))S7I%&* *6DZ7;Z-IT=E;;RB%B6<Y
M9F9BS$GU))/XU=HHH **** .6T7P9;:'K=]<0,DFGW,02*VE!;[-EBSHA/ C
M8G=MQU]JZ@ *    . !2T4 %5K_4;/2K*2\O[F*VMHQEY96VJ/QJS6#XK\-_
M\)'IBQ17<EG?6[^;:7*<^5)@C)7H002/QXYH Y+Q'K]SK>OP:;H<TJNC;!Y5
M]L%RK1B7.T?,JX'RRC(#<$$$UU7A#1;W0-/NK"YN#/;K<O):LY&\1MAB&P .
M&+=!TJ]HFE0Z9I5C!]EMXIK>V2#]T,A0!]T,>2,^M:= !112."48*VUB.#C.
M* ,KQ%JR:/I,DWGI%<."EOOB>7=)@D#8GS$<$G'8$UQVAZ[KVJ^(=/U*6!7T
MR\#V<T,8?]T=OF(_/RNG4"08R' (R*- \(7\VJ:K;^(Y;V1T>.2"[AGD596R
MW[Y6S^[?#;"BX  '7->@6=G;Z?90V=K$(K>% D:#HH'2@!;6UM[&UCMK6&.&
M",;4CC7:JCT [5-110 5Q'C;Q*UL(K+1]16+489UDG*(TODH 3\\:@LRL=JG
M'3<#2>/O$RVNDW>GZ?+!-=8"7*K.4D@5N 1MR022 #C"\$TSP9X/DM+A-<U)
MYC?NH*!W(8_)MW2KR/-QP<'!ZXS0!KZ#HUO*YUV;3FL+W488WO;(LK1F53D.
M1C[X]?SYKI*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@".XN(;6WD
MN+B5(H8U+/(YPJ@=237G_BSQC97UG;0:-?RDR*LZ7MK. %!?RP-A.91N.&4<
M@<]<5V>NZ+;>(-(FTZ[+B.3!#H<,C*<JP]P0#SQ6=X:\-+IFDV\.J0VEW?PS
MR3?:_+RSNS9,O(^5FX)QQZ<4 4/"'A[5M%U.[N+N=VM[V"-Y899_.:.X7*G:
M^ 64J%Y;G@>E=C165KOB"U\/P13WD4[12OY8>-055L?*&)("[CP">,D9(H -
M7U-8;:ZM+.XB&J&']S'C<5=\K&S*.0N[N>*Y#1-.77[O38=3TW5I#IJ&X>ZU
M*1UDBNRR_*AX5A@'D< ?6K&FRV_C:]N))5GTW6='NML<@B,<OD-R%=6ZJPRI
M'(RN1VKM[>WBM+:.W@0)%$H1%'8#H* ):AN;JWLX#/=3QPQ @%Y&"J"3@<GW
M(IFHW]OI>G7-_=,5M[>-I9"JEB% R>!R:\\U7Q3JOBC1Y8M*TB80;VAN$\F.
M[$FZ,/$" VW8V[#$'*\?6@#:U:ZL_%EW/I.EZCY.I64?GPS)('BDY*/'(H/S
M+_"RG!&X$5KZ1H,%O*FHWEE9#52@7S(HAF)=H'EJ^,L!@@$\XK.T+P3;:;<:
M9J,CO]NM(W3/!;8Z@>4SXRZIC@GG@>E=90 5F:S<3BW^R:=>6UOJLZLUJ+A=
MRN4P6!'7&."1R,YK*USQKHUA'=VD=S#<WL12-[<3>6%WL%RS]%4%AD_PYKDM
M"\/:IK$=GK-O?3J]K>(]J\UV9 R*QCD1Q@J^%#!9%QO!&>E &Q:>'CXGDGN]
M2AU/3WN$,.H0^<JB<JQ_=,H7#( <+(""5.#7>*H10J@  8 ':EJKJ&HV>E63
MWE_<1V]M'C?+(<*N3@9/;DB@":258\+E?,;.Q2V-QQG KRW4+[7/&5YJ.EQ6
M4T=I^[@N;.Y=5>TN,'#87F2 \$GUP5Z$4:_K<_C;5UTK2+:59-.GD=&6X6*4
MR*,+(IP2NTD$J>&5Q]*])T^SDA@AEO?(FU+R5CGN8X@AD(_7&<G'O0!1\->'
MH]!TR**1DN+W8%FNB@WOZ*6QN8#H"V3@<UMT5PGB+Q7%?76K^&[1Y8)TM''G
MHY217*;@Z^D:CK(3C) &>: $\4^.1!%+%X?N$FU&RNT6>W>%F\Y-Q5E3 R2&
MPI*YVGK5_3_#EAK30:[=V%[I]Q<,EQ<Z:\Q$9F0_*SIT+# Y[X!YK'\(^#[N
M[N+?7_$"1QWX=)D^S%/WX"G8\I _UF&.[:=K<=:]%H *IZK>2Z?I-W>06SW4
ML,32) GWI"!G J#6-6_LZ'RK:-+G495)MK3S K2D8R?H,Y)KS:W_ .$E\0^)
MK]/(FCAF\F+4;5Y=HA0\,F20=A4,RLF&RQ#4 ;FEW\OC>9;B*9](UO2F.R>%
M/,BFADXX5P"5)3H0""M=AHNE1Z+I%OI\4LDPB!S+(<LY)+$G\2>.U3VNGV=B
M9#:VL4)D(,A1 "Y P,GOQ5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** $9E12S$!1R23TKB?%_B^6
MRNH],TF0/.Q:.Y*1EGCRN?W7\+2J/F\LG)'2MKQ1:ZE<Z<!I\,%W&,BZL)P
M+N(C#(&_A;N#TSP?6LKP;X7:RA>^U&WECN7?$<,\@D81*?W1EQD-*HR XYQ@
M$G% $?A#PDEM)!KUZ)TU.2/]XAE)1VQM\W:PW*S+@E3T)/?FNVHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P?&&LWFA:!)?65OYA5
M@)9=AD%O&?O2E!RX4<X'-<I:^&M3\7MI>NZI-:&*XAC:6,!B0@+95 &V[95(
MW*V<>^./2" 1@C(J*UM+>QMDMK2"."",82.-0JKWX H AL]*L;"3S+6W6-_*
M2'=DD[$!"KD]AD_G5RBB@!" P((R#V-9FB:!8^'HKB#3E:*VFF:809^2)F^\
M$'8$\X]2:U** "BBB@#D]+\$V^E>)+N\B,<VFW$#JEI."WV=G?=($SQL<\D'
MN!CCBNJCC2&-8XD5$4855& !Z 4ZJNH:E9Z5:&ZO[A+> ,J&1^%!8X&3VY/6
M@"Q)(D4;22.J(H)9F. !ZDUY=KVN7GC:Z&G^'2[)#*4E@GCC,-PH;#.X8_,@
M. 5X(W CG%-\07.I^,M9GT^RMI_L$3/:3VSSE%E88;,@ S$?XHW^96Q@]17H
M&C:)!I<7FM' ^HRHHNKM(5C:=A_$V* &Z#X?L]!M/+MU+2L!OD=B[8 X0,>=
MHZ $\"M>BB@#.U[2VUK0[O3DNGM3<)L\Y!DKSZ=P>A'H37%Z!X"DFN6D\00L
M\%L52SA9T' )+ B, >23M(C.[!7)KT6B@!  HP!@#L*JZI<W-II5W<V=L;JY
MBB9XH <&1@.%_&K=% 'CEK_;?B/Q4MQ;H8M32)&NTN#LA9%<A&V*S/&R,<^4
MQ&_&3C%>JZ5I<.E6GE1K&97.^>98U0S2'J[!1C)J>"SMK5I6M[>*%IFWR&-
MI=O4XZGWJ>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KGO$>AWV
MH21W>F742SK&T,MI>9>UN8FZJZCH>X8<]CD&NAHH Q_#6A+H.C6MH[K/<Q0K
M%)<;<,P!)5<GG:N< $\"MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
6*** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form424b4_005.jpg
<TEXT>
begin 644 form424b4_005.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M^5Z!BT""@ H * %Q0 M !0 4 +0 4@"F 8H * "@ H 6@ H * "@!: "D 4P
M#% "T#"@ H 6@04 % !0 N* "D 4 %, H 6@84 % @H 7% PH * "@08H 6@
M H * "D M, H * "D N* "F 4 % !0 N*!A0 4 % "XH *0!0 4 %,!<4@#%
M "T %, H !2$+3 6D,* "@ H * %Q0 4 % "4 % !0 M !0 4P"@ H ,4 %
M"T@"F 4 % !0 M !B@!:0!0 4 % !0 4 % !0 N*8!0 4@"@ S0 4P"@ Q0
MM( H 6@ H 2F 4 % !2 * #% !0 4 % "T % !0 4 % !0 F: "@!* "@!:
M$H 6@ H 2@ H 6@ H * $H * "@ H * "@ H * %H *  4 +0 4 % !0 F:
M"@ H * $H * "F 4@"@ H 2@!: $H * "@ H * "@ H * "@ H ,4 % !B@
MH * "@ H * "@ H * "@ H * #% !B@!,4 % !0 4 % "4 &: "F 4@"@ H
M* "@ H 2@ H * "@ H * #% "4 % !0 M "4 % !0 8H * "@!* "F 4@#%,
M!,4 %( I@% !0 4 &* #%(!* "F 4 % !B@!*0!0 4P"D 8H 2F 4 % !0 8
MH 2@ H$% PH * "@!*0!0 4""F 8H 2@84 % !0 8H 2@04#"@ H$%( H 2F
M 4 % !0 4 )0 4#$H * "@ H$% "4 +0 E !0 4 % "8H *!A0 4 &*!"4 %
M !0 8H 2@ H * $H *!A0 4""@ H * $Q0 E !0 4 % "T % "T % !B@!:
M"@ I %, H&% @H 6@ H * %Q0 M !0 4 &* "@84 % A: "@ H 7% !0 4@"
MF 4 +0 4 % PH ,4"%H *!A0 4"%H *0!3 * %Q2 *8!0 4 % "B@ H * "@
M8M !0 4 % !B@!:0!0 4 % "XH * %H * "@ H 7%, H 6D(*!A0 M !B@!:
M "@!*8"4@%H 2F M !0 4 % !B@!:0!0 4 %, H ,4 +2 *8!0 M( H #3 *
M "@ I +0 4P$I +3 2D M !0 8H * %I@% !0 4@"@ Q3 7%( Q3 *0!0 4
M(: "@ I@%(!: "@ H * #% !B@!* "@ H * "@ H * "@!* "@!: "@ H *
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M0 4#$Q0(2@84 % !0(* $H 6@!* "@ H * "@!* "@ H * "@!* "@ H 2@
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M% "4 %( I@% !0 4@$Q0 8I@% !2 2F 4 % !BD 4 )0 4 %, H 2D M "4
M% !0 8H 2@ H * "@ Q0 E !3 * "@ H 2@ H * #%( IB#%(84 )0 4 % !
MBF E !0 4 &*!"4 % PH *!!0 E !0 4 % !0 4 )0 4 )0,* "@ Q0(* $H
M * "@ H *!A0 8H 2@04 % PH$)0 4 % "4 % !0 4 )0,* "@ H$)2 6F V
M@!<4 +0 4 % "T %( H *8!0,* "@!<4""@ H 6@ H 6@ H * "@84 % "XH
M$% !0 4 +0 4 %( I@+0 4 % !B@!<4#"@ H *!"XH * "@ H ,4 +0 4 %
M!0 M !0 4#"@ H$+0,* "@04#%Q0 4 % !2 7%, I +0 4 % !B@!: "@ H
M*8!0 N* "@ H 6@ H *!!BD,6@ H 2@ I@&* "D M, I % !0 4 ** "@ H
M* "@ H 6@ H * "@ H * "@!<4 &* "@!: $H * "@ H * %Q0 4 +0 4 %
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MA0 M @H * "@!<4 +0 4 % !0 4#"@04 +0 4#"@04 +0 4@"F M !0 4 %
M"XH&% !0 4 &*!"T@"@ I@% "XH * "@ H * %H&% !0(* %Q0,* "@ H 7%
M !0 4@"F M !2 6@ H * "@!: "@ H * #% "XH * "@ H * "@!: #- !FF
M 9H * %H * "@ I %, Q2 * %H * "@ H ,4 +B@!* %I@!I )0 M  * #%,
M!:0!0 4 % "T )0 M !0 8H *8!2 * "F 4@%H * %H * "@ H * "@ H *
M"@!* #% !B@!: "@ H ,T % !0 4 % !0 E !0 4 % !0 8H ,4 &* "@ H
M6@!* "@ H * "@!: "@ H * "@ H #0 E !0 4 )0 M !0 4 )0 9H * "@
MH * "@ Q0 E !B@ Q0 8H ,4 &* #% !0 4 % !0 4 % !0 4 % !0 4 % !
M0 8H ,4 &* $H * "@ H * "@ H * "@ H 3% !B@ H * "@ H * "@ H ,4
M % !0 4 )0 4 % !0 4 % !0 4 % !0 F*8!BD 4 % !0 4 %,!*0!BF 4@"
MF E !2 ,4P$I % !0 4P#%( H * "@ H 3% !B@!*8!0 4 % !B@!* "@ H
M* #% !2 2@ H$+0 E,84@"@ H 3%,!* "@ H ,4 )0 4 % !0 E @H * "@
MH 2@!: $H * $H&% !0 8H$% !0 4 &* $H&% !0 4"$H&% !0 E @H * "@
M!* "@ H 2@ H&% !0(* "@!<4 % !0 4 % !0,* %H$% !0 4 +B@!: "@ H
M * "@84 +B@ H * "@!<4""@ H *0"TP"@ H 6@ H *!A0 4 +0(*0!0 4P%
MQ0 4@"F 4 % "T % PH * %Q0 4 % !0 N* "@ H * %H ,4 +2 * "@ Q0
M4 +0 4 % "XH * "@ H * "@!<4 %,!* "D M, Q0 4@%H 2@ H 6@ H 6@
MH * "@ H * %H *  T % !0 8I@&*0!0 M !0 "@ I@%( H 6@ H * "F 4
M% !2 6@ Q0 4 % !0 4 +0 E "T &* "@!: "@!* "@ H * "@!* "@ H 6@
M!* %H * #% !B@ H * "@ H * "@ H ,T )0 M "4 % "T )0 M "4 +0 4
M% !0 4 % "4 &* "@ H ,4 % "4 % !0 4 % !F@ H * "@ H * "@ H * $
MH * %H * "@ H * "@!* #% !0 4 % !0 4 % !0 4 % !0 4 % "4 % !0
M4 % !0 4 % !0 4 )0 8H * "@ H 6@!* %H 2@!* "@ H * "@ I@%( H *
M "@ I@%( H *8"8H * "@ H 2D 4 % !3 2@ H * "D 4 % "4 +0 F* "@
MH * "@!,4 &*8"4 %( I@% !B@!* "@ H * "@!*!!0,,TA!3&% "4@"@ H
M2@ I@%( I@&* $H * "@ H$)0 4 % !0 4 % !0 E !0,2@!: "@0E !0 4
M%(!*8!0 4 % "4 % PH 3% @H * "@!* "@ H * $H&% !0(6@ H * "@ H
M6@84"#% !0 4 % "T +2 * "F 4#"@ H 7% !0(*!BT % A: "@ H * %I )
M0 M, H&% !0 N* "@04 % PQ2$+3 * "D 4 +3 *!A0 4 &* %H * "@ H 6
MD 4P"D 4P%Q0 M( H * "@!: "@ H *8"XI % !0 4 % !0 4P%H *  T )0
M N*0!0 4 % !0 4P#% "T@"F 4 % "T %( I@+2 *8"4@%H ,4 % !0 4 %
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M % PH 2@04 % !0 E !0 4 % "4 +0 4 % "XH * "@ H&% "T"$H 7% "T
M% "4 +0 4#"@ H$+0 4#"@0M "T % !0 8H 6D E "T %, H *!A0 M !0 4
M +B@ H$%( H * %Q0 4P"@ H * %H&% !0 4 +B@ I % !0 N* "@!: "@ H
M * %H * "@ Q0 M !0 4 +0 8H * "F 4 % !0 8H 6D 4 )0 4 &*8"XH *
M0!3 * "@ Q0 M( H *8!0 M( H * "@ H * "@!<4 &* "@ H 6@ H 2@!:
M#% !B@!: $H * %H 2@ H ,4 *!0 4 +0 4 )0 4 % !0 N* "@ H * "@ H
M * "@ H * "@ H * "@ H * #% !0 4 % !0 M !0 E "T % !0 E !0 4 +
M0 4 )0 4 % !0 4 % !0 4 % "4 +0 E "T )0 4 % !0 4 % !0 4 % !0
M4 % !0 4 )0 M !0 E "T % !B@!,4 &* "@ H * "@ H 2@!: "@ H * $Q
M0 8H * "@ H * "@ H *8!0 4@"@ H 2@ H * "@ H * "@ Q0 E !0 4 %
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M !0 4 % !0 4 +0 4 % !0 4 % !0 4 % !0 4 &* #% "T % !0 4 )0 4
M% !0 4 % !0 M !B@ Q0 8H ,4 &* "@ Q0 8H * "@ Q0 4 % !0 4 % !0
M E !0 4 % !0 4 % !B@ Q0 8H ,4 )B@ H "* "@ H * "@ H 2@!: "@ H
M * "@ H * "@ H 2@!: #% "8H ,4 % !0 4 % !0 4 % !0 4 %  10 E !
M0 4 % !0 4 % !0 4 )B@ H * "@ H ,T % !B@!* "@ S0 4 % !0 8H 2@
M H * "@!: #% "8H ,4 % !0 4 % !BF F*0!0 4 % !B@!,4 % !0 4 &*
M$Q0 4 % !0 4 )B@ H * "@!* #%,!* "D 4 % !B@!*8!0 4@#%,!* "@ H
M * $H$%(84""@!*8PI % !0(2F,* "@ H 3% @H&% @H * $H * %H 3% !0
M,2@ H *!!0 4@$I@% !0 4 )0 4#"@ H 2@04 % "4 % !0 4 +0 4 % !B@
M!:!A0 4 +0(* "@ Q0 M !0 E Q<4""@ H * %H * "@!: "D M, H ,4 %
M"T % !B@84 % "T""D M PI@%(0M !0 E,!:0!BF 4 % PH ,4 +2 * "@ H
M 4"@04P"@ I#%I@% A:0PH * "F M !2 * "@!: "@ H !0 N*8!0 8H * "
M@ Q0 4 +2 2@ I@% !B@!<4@"@ H * "@ Q0 M !0 4 % !0 N* "@ H * "
MF 4@%Q0 8H 6@ H * "@ H * #% !B@ H 6F 4@"@ H 2@ H * "@ H * "@
M!<T % !0 4 % !0 4 +0 4 % "4 % !0 4 +0 E !0 M !B@ Q0 4 % !B@
MH 6@ H * "@ H * $H 6@!* "@ H * "@ H * "@!* "@ H * "@!: $H *
M"@ H * "@ H * "@!* "@ H * "@!: $H * %H 2@!<4 )B@!<4 )B@ Q0 4
M % !0 4 % !0 4 % !0 8H 3% !0 4 % !0 4 % !0 4 '6@ H 3% !B@ H
M*8!0 4 %( H ,4 )0 4 % !0 4 % !B@!,4 % !0 M !0 8H 3% !B@ H *
M"@ H * $Q0 8H * "F 4@#% !0 4 % !0 E "8H * "@ H * $Q0 4 % !0
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M "@ H * "@!<4 % !0 4 % "XH ,4 % !0 M "4 % "XH * %H * "@ H *
M%Q0 8H * "@ H * $H 6@ H * "@ H * $H * "@ H 7% "T % !0 E "T %
M "4 % !0 4 +0 8H * "@ H * "@ H * "@ H ,T % !0 M !0 4 % !B@ H
M 2@ Q0 M !B@!,4 &* %H * $Q0 4 &* "@!: $H ,4 &* #% !B@ Q0 F*
M#% !0 4 !H 2@ H * "@ H * "@!: "@!* %H * "@ H * "@ H 2@ H * "
M@ H * "@ H * "@ H * $H ,4 % !0 4 % !0 4 % !0 E !B@ H *8!2 *
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M )0 4 % "4 +B@ Q0 4 +0 4 % !0 4 % !B@ Q0 8H * "@ H * "@ H *
M"@ H * "@ H * #% !0 M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % "4 +0 4 % "4 % !0 4 % !0 4 % !0 4 )0 M "4 % !0 4 &* %Q0
ME !B@ Q0 8H * "@ H *  T )0 M !0 4 &* #% "8H ,4 % !0 4 % !0 4
M % !0 F* #% !B@ H * "@ H * "@!,4 % !0 4 +0 4 )0 8H * "@ H *
M"@ H ,4 % "4 % !0 4 % !0 E !0 4 % !0 E "T )0 4 &* "@!* "@ H
M2@ H * $I@%( H 3%, H * "@ H * $H * "@ H 2D 4P"D 4 )0 4 % !0
MF*8!0 4 % "8H$% Q* %H 2@ I %, I &*8"4 % !0 4 )0(* "@ H * "@
MH&)0(*!B4 % !0(* $H * "@ H * $H *!A0(2@84""@ Q0,6@04 % !0 M
M!0 4 +0 4@"F 4 % Q: "@ Q0(6@ H * %H * "D 8I@+2 * "@!: "F 4 %
M "T#"@ H * %I""@!*8"T % !0,6@08H *!BT )0 M !BD 4 % !3$+2&%,
MH * "@!: "D 4 % "XH * "@ I@+BD M, H * "@!:0"T % !3 * #% !BD
ME !3 *0!0 N* "@ H * "@ H 7% !0 4 % !0 4P"D M !0 4 % "XH * "@
M H * %H *8!BD 8H ,4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 M !B@ H
M * "@ H * "@ H * "@ S0 4 % !B@ Q0 4 +0 4 !H * "@ H * "@ H *
M"@ H * "@ H * #% !0 8H * "@ H ,4 % !B@ H *  T % !0 8H 2@ Q0
M4 % !0 4 )0 4 % !0 4 +0 4 % !0 4 !H * "@ H * "@ H 3% !0 4 %
M!0 E "T % !0 4 % "4 &* #% !0 4 % !0 4 % !0 4 % "8H * "@ H *8
M!2 * #% !0 E !0 M !0 E !BF 4@"@ H * "@ H * $H * "@ H * #% "4
M % !0 4 % "4 +0 E !0 4P$I %,!*0!0 4 )B@ H * "@ H 2@ I@%( H *
M $Q3 * "@ H * $I % !0 4 )0 4 % !0 F*8@H&%( I@)B@ H *!"4#"D(*
M "@ H&&*8"4 % !0 8H 2@04 % !0 4#"@0E !0,2@ H *!"4#"@04 % !0
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M H * "@ H * $Q0 4 % !0 4 % !0 8H 2@ H * "@!* "@ H * "@ Q0 E
M!0 4 % "4 &* $H * "@ H ,4 )0 4 % !0 E !0 4 %,!*0!3 * "@ H 3%
M !2 *8!2 ,4 )0 4 %,!,4@"F 4 % "8H *!!0,* #%(0E PH *8!2 2F 4
M% !0 E @H * "@ H * "@8E "4 % !0 E !0(* "@ H * $H * "@84 % @Q
M0 M !0 4 +0 4 % !0 4#"@ H 7% A: "@ H * %I %, H 6D 4 % !3 6@
MH *0"XI@% !0 4#%H *0!0 4""F 4 % Q<4 % !0 4 +B@!:0!0 4 % !3 *
M "@ H ,4 +2 * "@ H 7% !0 4 % "B@!: "@ H * "@!: "@ H 44 +0 E
M!0 E "XH * "@ H * "@!: "@!: $H ,T % "T % !0 4 % !B@!: "@ H *
M "@!<4 % !0 4 % !0 4 % !0 4 +0 4 )0 4 % !0 4 +B@ Q0 4 % !0 4
M % !B@ H 6@ H * "@ H 2@!: $H 6@ H * "@ Q0 4 % !B@!: "@ H * "
M@ H * "@ H * $H 6@ H * "@ H * "@ H * "@ H * #% !0 8H ,4 )0 4
M % !0 4 % !0 4 % "4 % !0 M "4 % !0 4 % "T )0 M !0 E !B@ H ,4
M % "4 +0 4 % !0 4 % "4 % !0 8H * "@ H * "@ H * "@ H 3% !0 4
M% !0 4 %  10 4 % !0 4 % !0 8H 2@ H * "@ H * #% "8H * "@ H *
M$Q0 4 % !0 4 )B@ H * "@ H 0B@ H 2@ H * "@ Q0 E !0 4 % "4 % !
M0 4 % "8H * "F 4@$Q3 * "@!* "@ I % !0 &@!* "@ H *8"8H * "@ H
M 3% !0(*0PIB$H&%( H * #%,!* "@04#"@0E !0 4 % !0 4 )B@8E !0 4
M % @H 2@ Q0 4 % !0 E PH *!"T % !0 M( H * "F 4#"@!: #% A: "@
MH * "D M, H 6@ I %, H 6@ H * %H *!A0(,4#%H * "D N* "F(2@ H&+
M0 4 %(!<4 % "T )0(6@84P"@ H * #% "T@"@ H * "@!: "@ H 6@ H *
M"@!: "@!: "@ H 7% !0 4 % !0 8H * "@ H * %H ,4 % !0 4 % !B@ H
M 6@ H * "@!10 4 % !0 4 +B@ Q0 N* "@ - "4 % !0 M !0 4 % "4 %
M"T &* #% !0 4 % !0 4 % !0 8H 6@ H * "@!* %H * "@ H ,4 &* #%
M!B@ H 6@!* "@!: "@ H * "@ H * #% !B@ H * %- "4 +0 4 % !0 4 %
M !0 4 % !0 4 % !0 E "T )0 4 % !0 4 % !0 4 &* $H * #% !0 8H *
M #% !B@ H ,4 )0 M !0 E  : "@ H * "@ H * "@ Q0 8H * "@ H * "@
M H * "@ H 2@ H * "@ H * "@ H * "@ Q0 E !0 M !0 4 % !B@!* "@
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M* %I % !0 4 &* %H * "F(,4ABTP"D 4P"@!12 6@!!0 M !B@!<4 % !0
M4 +B@ H * $H * %Q0 4 % !0 4 % "XH * "@ H * #% "XH * "@ H * %
MH * %% !0 M !0 E !B@ H * "@ H * "@ Q0 8H * "@ H * "@ H ,4 &*
M "@ H 6@ H 2@!: "@ H * %H * "@ H * "@ H * "@!* "@!: "@!<4 &*
M $H 6@ H * "@ H * $H 6@ H * "@ H *  4 % !0 4 % !0 4 % !0 4 )
M0 N* $H * "@ H * "@ H * $H * #% !0 &@ H * "@ H * "@ H * "@ H
M * "@!* "@ H * %H 2@!: $H * "@ Q0 4 % !0 4 % !0 4 % !0 4 % !
M0 E !0 4 % !0 8H * $H 6@ H * "@ Q0 E !0 4 % !0 4 )B@ Q0 4 %
M!0 E !0 E !0 4 % !0 E !0 4 % !0 E !0 4 % !0 E !3 *0"4P%- "8I
M )0 4P%I )3 *0!0 4 )0 4 % !0 4 )0 E, H * %H 2D 4 % !0 F*8!0
M4 % "8H * "@ H ,4"$I#%H 2@08IC#% !0(*!B8H 2@ H * $H$% !0 8H
M*!A0 E !0 E !0 4""D 4 % "4P"@ H * #% "T@"F 4 % PH * %Q0(6@84
M % @H 6@ I % !3 *!A0(6@!: "@ H ,4 +0 4 % "T#"@ H ,4 +2 * "@0
M4P%H&)0 M "T %( H *8!0 4 % !0 M !2 * "@ Q0 N* $S3 6D 4 %,!:
M"@ H ,4 +0 4@"F M( H 6@ H * %% !0 4P"@!*0"XH * "@ H * %H * "
M@ H * "@ Q0 M !0 4 % !0 N* "@ H 6@ H 6@ H * $H * "@ H * #% !
M0 M "4 % !0 4 % !B@ H * "@ H * "@!: "@ Q0 4 % !0 M !0 4 % !0
M 4 &,T &* "@!: "@ H * "@ H * "@ H * "@ H ,4 % !B@!<4 &* #% !
M0 8H * "@ Q0 4 % !0 4 % !0 4 % !0 4 )0 4 % !0 8H * #% "4 &*
M#% !0 8H * "@!#0 4 % !0 4 % !0 4 % "T )0 4 % !0 8H 3% !0 4 %
M "T )0 M !0 4 )0 8H ,4 % !0 4 % !0 4 % !0 AH * "@ H 6@!* "@
MQ0 E !0 M "4 +0 4 )0 4 % !0 E !0 4 % "4 % !0 4 &* $- !0 4 %
M!0 E !0 4 % "4 !% "4 +0 E !0 8H *8"4@%H * $Q0 E, I % !0 4 %
M"4 % !0 4 % !0 F*8!0 4 )0 4 %( H * #% "4P"@ H * $H * "@ H$%
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M0 E "T % !0 9H ,T % !0 8H * %H * $H * "@ H 7% !0 4 % !0 4 %
M!0 8H ,4 % !0 4 +0 E  * %Q0 8H 7% "8H 7% !0 4 % !B@ Q0 4 % !
M0 4 % !0 4 % "XH * "@ H * "@ H !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % "4 % !0 4 % !0 4 % !0 4 % !0 E !0 4 % !0 4 % !0
M E "XH 3% !0 4 % !0 4 % !0 4 % !B@ Q0 8H * $H 6@ H * "@ H *
M"@!* "@ H 2@!: "@ H * "@!* "@ H * "@ H ,4 )0 4 % !0 4 % "8H
M#0 4 % !0 4 )0 4 )0 4 % !B@ H 2@!: "@!* "@!*8!2 * "@ H * $H
M6@ H 3% !0 E "T )0 8H 2@ H *8!2 2@!: "@!* "@ H * $H *8"4 +0
M4 &*0"4 % !0 8H 2F 4 %( Q3 2@ H 6D 8H 2F 4 %(!*8"4 % !0 E !0
M(*!A0(*0!3 * $H *!A0 F* "@ H$)0 4 % !2 3%,!: "D 4P"@84 +0 4"
M"@ H 6@ H * "@!10 4 +0 4 % PH * %Q0 M !0 4 +B@ H * "@!:0!0 4
M +0(* "@ IC#% "T %( H *8!0(*!A0 M( H * "@ Q0(6@84""@ Q3&% !2
M * %H * %H * "@ Q0 M !0 4 %,!: %H *0!0  4 +0 4 % !B@ H * "@
MH * %Q0 4 +0 E !0 4 +B@ H 6@ H * "@ Q0 M !0 E !0 4 &* "@ H *
M "@ H * %H * "@ H * "@ H * #% !0 M "4 % !0 M !0 4 % "T % !0
M4 % !0 4 % !0 4 &* #% "T &* "@ H * "@ H * "@ H * #% !0 8H ,4
M +B@ H * "@ Q0 8H ,4 &* #% "4 +0 4 % !0 4 % "4 %  10 4 &* $Q
M0 4 +0 E !B@ Q0 $4 % !0 E !0 4 % !0 4 % "4 +0 4 % !0 4 % !0
M8H 2@ H * "@ H ,4 % !0 4 &* #% !0 E "T % "4 % !0 4 % !0 4 %
M!0 4 % "4 % !0 E !0 4 % !B@!* "@ H * "@ H ,4 )0 4 % !0 4 )0
M4 % !0 4 &* $H * "@ H ,4 % "4P"@ I % !0 E !0 4 % !0 E !0 4 &
M* $H * "@ Q0 4 % !0 F* "@ H * $Q3 * "@ H *0"4 % !0 4 )3 *0!0
M 4 % !0 4 )0(*!B4 % @Q0,2@ I@% "4 % !0 4""D 4 )0 4P"@ H&)B@0
ME PH * "@04 % !2 *8!0,* %H *!!0 4 +B@ H * "@!: "@ H 7% !0,*
M"@!<4 +0 4 % "T % !0 N* "D 4 % !3 7- @H * %H&%( H * "F 4 % !
MB@!:0!3 * %Q2 * "@04 &*!BT %,!* %H ,4@"@ H * %H *8"T@"@ H 44
M % !0 4 +0 4 +0 4 % !B@ H * %H 2@!<4 % !0 4 % !0 N* "@!: $H
M6@ H * "@!<T !- "4 % !0 4 % !0 4 % "T % !0 4 % !0 4 &* #% "T
M % "4 % "T )0 N* #% "XH ,4 % !0 4 % "T &* #% !B@ Q0 4 !H * "
M@ H * "@ H * "@ H 6@!,4 &* %H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H 2@ H ,4 % !0 4 % !0 4 % !0 E !0 4
M% !0 4 )0 8H ,4 &* "@ H * "@ H * "@ H ,4 &* "@!* "@ H 6@!* "
M@ H * "@ H 2@ H * "@ H * "@ H * $H * %H * $H ,4 % "4 % !0 4
M% !B@!* "@ H * "@ H 2@ H * "@ H * $H * "@ H 3% !0 4 % !0 F*
M"F 4@"@ H * "@ H 2@ H * $H * "@ H * $H 6@!*8!2 * "@!* "@ I@%
M !2 2F 4 % !0 E( H *8!2 ,4 )3 * "@ H *0"4Q!0,*0"4 % !3 2@ H
M* "@!* "@ H *!!2 * $I@% PH 2@04#$H * "@04@"F 4#"@!: %H$% "4
M+0 4@"F 4 +0 4#"@!<4 % !0 M !0 M !0 8H 6@ H * %Q0 4@"@04P"@
MH&% "T % "T@"@ I@% !2 * %H * "@ Q0 M !0 4 % "T %, I % !B@!:
M"@ H 2@!<4 % !0 4P%I %,!: "D 4 +0 4 % !0 M !3 6D E "T &* %H
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M4 % !3 *0"4 % !0 8H 2@ I@% !B@!*0!0 M "8H * "@ H 3% !3 * "@
MH 2D 4 %, I &*8"4 % !0 4@"@0E,88I % !0 E, H 2@ H ,4 )0 4 % !
M0(* "D E, H&% @H&)0 E !0 4""@84 +0 M @H&% @H *0!3 6@ H&% !0
MM !0 4 +B@!:0!3 * #%(!: "F 4@%I@&:!"4 ** "@84 %( H 7- !3 *0"
MT % !0 8H 6@ H * "@ H * "@!<4 +0 4 % !0 4 &: "@ H 6@ H * "@
MQ0 M !0 4 % !0 M !0 4 +0 M !0 4 % "T % !0 M !0 8H 6@ H * #%
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M !0 8H * "@ H * "@ H * #% "XH ,4 &* "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@!* %H * /IK]G;P)::Y:J\Z*S%'ZJC=)6'\2GM3$
M>O?\*>T[_GBG_?N/_P"(H /^%/:=_P \4_[]Q_\ Q% !_P *>T[_ )XI_P!^
MX_\ XB@#@?C3\-[+2;%I(HU5L/R$0=(V/91Z4 ?(E(84 % !0 F* "@ Q0 8
MH 2@ H ,4 !% !B@ H * "@!* "@ H 6@ H 2@ H * "@ H * "@ H !0 4
M%  : "@!* "@ H * "@ H * "@ Q0 F* "@ H ,T % !0 4 )B@!: $H * "
M@ H * #% "8H * "@ H #0 4 )0 4 % !0 E !0 4 % !0 4 )B@ H * "@
MH ,4 )0 4 % !0 4 % "4 &: "@ H 2@ H * "@!* "@ H * $H * "@ I@%
M(!*8!2 * "@ H * "@!,4P$H * %H 2@ I % !0 4 )3 * "@ Q2 * "@!#0
M E,04@"@8$4P$H * "@!* "@04#"@04@"@!*8!0 4 % Q* $H * "@!: %H
M*!!0 4 +2 2F M !0,* %Q0 4 % !0 H% "T@"F 4"%I % !0 4 %,84 % "
MT@"@ H * "@ H * %H 6@ H * "@!: "@!* %H * "@!<4 % !F@ S0 4 +0
M 4 % !0 8H 6@ H * "@!<4 % !F@!* %H * "@ H 6@ H ,T +0 4 ** #-
M "T % !0 M !0 M !0 4 % "XH * "@ H 2@!<4 % !0 4 % !0 8H 6@!*
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M?\,EVO\ STF_.+_XB@!/^&2[7_GI-^<7_P 10 R;]DZUC4MYDW )ZQ?_ !%
M'SAXQT1=#NGMU)(7;R<9Y4-VX[TAF+0 4 % !0 E "T % !0 E !B@ Q0 8H
M !0 4 % !0 E "T % "4 % !B@ H #0 4 % "4 % !F@ H 6@!* "@ H * "
M@ H * $Q0 4 % !0 4 % !0 E !0 4 % !0 4 % "8H * "@ H 2@ H ,4 %
M !0 4 )0 4 % !0 4 )0 4 % !0 4 % !B@!* "@ H * "@!* "F 4@"F E(
M H * "F 4@$H * "@ Q0 E !0 4 % "4 % !0 4 % !0 E !0 4P$H 6@ H
M*0"4 % !3 * "@ I &* $H$)3 *!A0 E( H *8"4 % !0 E @H * #% "4@"
M@ I@% !0,* $- !0(*!A0(* %H * %I % !3 *!A0 HH * "@!: "@!:0!3
M*0@I@% !0 M !0,*0!0 4 +0 4 % !0 4 % "T % "T % !0 4 % !0 M !0
M 4 *!0 $T )0 4 +B@!: "@ H * %H * "@ H * %S0 4 !H 2@!: "@84""
M@!:!A0 E @H 6@!: #- !0 M "T +0 4 % "T &* %H * "@ H ,4 +B@ H
M* $H * #% "XH * "@ H ,4  % "XH 2@ H * "@ H ]:^"/A#[7(;F0?+AU
M_A(_A[=:\7'5K+E7E^IZ^#I7?-ZGO).:^</?*][?I8KOD.%SC."?Y548N6B)
M<N75F/\ \)]9?\]#_P!\O_\ $UT?5Y=OQ1C[>/?\&'_"?67_ #T/_?+_ /Q-
M'U>7;\4'MX]_P8?\)]9?\]#_ -\O_P#$T?5Y=OQ0>WCW_!A_PGME_P ]#_WR
M_P#\31]7EV_%![>/?\&'_">V7_/0_P#?+_\ Q-'U>7;\4'MX]_P8?\)[9?\
M/0_]\O\ _$TOJ\NWXH/;Q[_@P_X3VR_YZ'_OE_\ XFCZO+M^*#V\>_X,/^$]
MLO\ GH?^^7_^)I_5Y=OQ0>WCW_!CHO'-G*<"0Y_W7_\ B:3H273\4'MH]_S-
MQ6W#(KG.@CNK1;M=C=#_ )[TT^5W):OH?*WCCPXVA7!0C 8%AR.A9AV^E?8T
M*GM(W_K8^4K4^25CGJZCF#% !B@!: "@ H 2@ H 6@!* %Q0 4 &* #% !0
M4 % !0 4 % !0 4 % !0 4 % !B@ Q0 N* "@ H * "@ H * #K0 4 % !0
M4 % !0 4 % !F@ H !0 9H * "@#ZY_99_X\U_W)/_1S4Q'NE !0 4 >9_M
M?\@YOI)_Z+>@#X=-(84 >D? 3_D(?]L__:D= 'W-3$% !0!#>_<;_=;^5 'P
M'\5O^0C-](__ $6M(9R.* #% !0 4 %  10 &@ H 2@ H * %H * $Q0 8H
M,4 % !0 4 )0 4 +0 4 % "4 % !0 8H 2@ H 44 % !0 F* "@ H * "@ H
M * $H * "@ H * "@ H 2@ H * "@ H * "@!,4 !H * "@!* "@ H * $H
M6@!* "@ H * "@ H 2@ H * "@ H * $H * "@ H ,4 )0 4 % !0 E !0 4
M % "4 % !0 4 )B@ H * "@ H 2@ I@% !2 * "@ H 3%, H !0 4@"F E !
M0 4 %( H ,T )BF E(04 %,84@$H * #%,!* "@ H 2@ H * "@0E !0 4 %
M !0 4 )0 4 % !0 M !0 4@%I@% PH$** "@ H 6@ H *0"T#"@04 %, H 6
M@ I#"@ H * "@ H 7% !0 4 % "T % !0 M !0 4 % "XH * "@ H 44 &:
M$H 7% "T % !0 4 % !0 9H ,T +0 4 % !0 4 +0 4 % Q* %H$% !0 4 %
M "T#"@ H * %H 6@09H 7-  * %H 7- !0 M !0 4 +0 4 % !0 4 &* "@
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M #% "4 +0 E "T )B@ H * "@ H * $H * "@ H 2@ H * "@!* "@ I@%(
MH 2@ H * #% "4 % !0 4 % "4 % !3 *0!0 4 )0 4 %, H * "@ H * $H
M * $H *!!2 2@84P"@!*0@H #3 2@84 % !B@!* "@ H$% "4 % !0 4#"D
ME,04 +0 4 % "T % PH 6@ H * %H$%( H * %I@% PH$%(!:!A0 4 % !0
M4 % "T % "T % !0 4 % "T % !0 4 +B@ H * "@ H * "@!<4 &: "@!*
M%H 6@ H * #% !TH 6@ H 2@8M @H&% !0 4"%H * "@ H 6@84 % !0 4 *
M*0!0 4 % "TP%S0 4"%% "B@!: %H * "@!: $H 6@ H * "@ H ,4 % !0
M4 % !0 N* "@ H * "@#UGX(>$/M3FYD'RX=1]TC^'MUKQ<=6LN5>1Z^#I7?
M,_,]X)S7SA[YGZ[K*Z/%YKG W =">OTK6G#G=C.<^17/DO5]3;4G\Q^N .Y_
MG7VD(\JL?(2ES.Y3K0@2@ H * "@ H 7% !B@ H [OX3^*_[&N%5CA#O)^\>
M=N.@^E>=BZ7/&_73\SOPM7DE;IK^1])H^\!AW -?*'TPRYM5NUV-T/XTT[:B
M:OH?+'COPX="N"A& P+#IW9AV^E?8X>I[2-_ZV/E:]/DD<[74<H8H ,4 &:
M$H 6@!* "@ H * "@!<4 &* #% !0 4 % !0 4 % !0 4 % !0 4 % !0 8H
M 7% !B@ H 2@ H 7% !B@ Q0 4 &*  T % !0 4 % !0 E "T % !0 4  ;%
M "[S0 F\T +N- ";B: $H * /1_@*/\ B8?]L_\ VI'0!]S4Q!0 4 0WOW&_
MW6_E0!\!_%4?\3&;Z1_^BUI#.2H * "@ H * $H 6@ H #0 E !0 M !0 E
M!B@ H * "@ H * "@!* %H 3% !B@ Q0 8H * $H * "@ H ,4 % !0 4 %
M"4 % !0 4 )0 4 % "T % "4 &* #% !0 4 % "4 % !0 E !0 4 % "8H *
M "@ H * "@!* %H 2@ H * "@ H 2@ H * "@ H 2@!: $H * "@ H 3%  :
M "@ H * $H * "F 4@$H * "@ H 3% !0 4 % !0 E, H *0!B@ H * "@!*
M8!0 "D M "&F E !0 4 )0 4 %(!*8!0 4 % "4""@ H 2D,*8!2 *8"4 %
M!0 4"$H *0!0 4 )3 6@ H *!BT""@84 **!!0,* %Q0(*0!0 4P%H&% !0
M4@%H 2@ H 6@ H * %Q0 4 % "T % !0 4 % "XH * "@ H 6@ H * "@ H
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M Q0 E !0 4 % !B@ H 2@ H * "@ H 2@ H * "@ H * "@ H 0T % !0 4
M)B@ H 2@!: $Q0 4P"D 4P"D E !0 4 &* $H * "@ H * "@ H * $H * "
M@ I@%( H * $Q3 2@!: $H * $H * $Q0 4 % !0 E( IB"D 8H&)3 *0!0
ME, H * "@0E !0 4 % !0 4 +0,* "@0M !0 4#%H$%( H !3 6@84@"@ H
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MQQ'&/X2>RT 7_ 'P;L-1LHY7C0L2^28XR>'8=2M '0_\**T[_GE'_P!^HO\
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M % !0 4 % !0 4 )0 4 % "4 % !0 4 &* $H * "@ H * $H * "@ H ,4
M% "4 % !0 8H * "@!* "@ H * "@ H 2@ H * "@!* "F 4 % !2 2@ H *
M #% "4 % !0 4 % !0 4 )B@ H *8!2 * "@ H 3% "4P"D 4P$H * "@ I
M)3$% !0,2D(* "@ H&)3 *0!0 E, H * "@0E !0 4#"@!: "@ H 6@04@"@
M I@+0 4 % "TAA0 4 % !0 4 +0 4 % !0 M !F@ H * %H * "@ % "YH 3
M- !0 N* "@ H * %S0 E !0 M !0 9H 2@!: "@ S0 4 % "YH ,T % PH *
M "@09H * %H&% !0 4 % "YH ,T % "T %( I@+2 *8"T % "T@"@!<4 +0
M8H 6@ Q0 H% "T +0 8H ,4P%Q0  4"%H * $H * %Q0 4 % !0 4 % !0 4
M &: "@"YI>E/J3;(QDXSV'&0.Y'K43FHJ[+C%R=D?5WAG0ET2'RE'\1/0#K]
M*^+JU/:.Y];3AR*QJ@9K$V/$_C=XO\QOLL9X^1N-P/\ %]!7T&!H_:?F>'C*
MOV5Y'CIKW3Q1* "@ H * "@ H * "@ H * "@!\4IC.1P:35QIV/IOX8>*1K
MEMR?F5MN.>R*>_UKY+%4O9R_KNSZC#5>>/\ 78[&N [3B_B#\/%\4893M8*
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M'?@'%I2)<W:[I"L;[76-P#M.0#SW-,1[?;6B6H"HH4  8  ''3I0!+0 4 %
M!0 4 % !0 4 % ',>-? -OXGA:.1%W%7 ;:I8%@.02.O% 'QE\4?AO+X,N"K
M ^4SN(V)7D+CLI..OH*0SB* /J/]D?[EQ_NQ?^A24P/HB@04 % !0 4 % !0
M 4 % !0 4 % &!X\_P"/&X_Z]YO_ $!J /S\U+_6-^'\J0SZO_9:_P"/-?\
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M0 4 % !B@!* "@ H * "@ H ,4 )0 4 % "T )0 4 &* $- !0 4 % !0 E
M!0 4 % !0 8H 2@ H * "@ Q0 E !0 4 % !B@!* "@ H * "@ H * $H .M
M !B@ H 2@ H * "@!* %H 2@ H * "@ Q0 E !3 * "D E !0 4 !H 2@ H
M* "F 4@"@ H * $H * "@ H * $I@%(!* "@ H ,4 )3 *0!3 2@ H * $H$
M%( H ,4 )0,* "@ Q3 2@ H * $H *!"T#"@ H 6@04@"F 4 % Q:! *!BT@
M"@ H * "@ H 6@ S0 F: %H * "@ H 6@!: $H * %H * "@ H * "@ S0 M
M !0 4 % !0 4#"@04 % !0,* "@04 % "YH&% @S0,,T % @H 6@84 % @S0
M,6@ H * "D 8H 6F M !2 7% !B@!: "@!13 7%(!<4 +B@ H ,4 +B@!<4
M+0 N* "F N* "@ H *!!0 4 +B@ H 2@ H * %H * "@ H * $H 7% '9_"G
M6(M*NF>?&TPLHR"PSN0]@?0UP8N#G%)=_P!&=V%FHRN^WZH^F\[NE?(GU J4
M ?+7Q&TJ73[DB7/W5P203T^IK['#34HZ'RF(BXRU.4KL.0,4 +B@!* "@ H
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M H * "@ H * "@ H * ,#QY_QXW'_7O-_P"@-0!^?NI#]X?P_E2&?5W[+?\
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M Q0 E !0 4 % "8H 7% "4 % !0 4 &* $H * "@ H * $H * "@ H * $H
M* "@ H * $H * %H 2@ H 2@ H * "@ H * "@!* "@ H * $H * "@ I@%(
M!* "@ H ,4 )0 4 % !0 4 % !0 E !0 4 !H 2F 4 % "4@"@ H ,4 )3 *
M0!0 E, H * "@!*0@H *8"4AA0 4 &*8A*!A0 4 % !0 4 +0(*0!3 * "@8
M4 ** %I % "4 +0 4 % !0 4 % "XH * "@ H 7% !F@ S0 4 +0 4 )0 M
M!0 F: "@!10 N: $S0 4 +0 F: "@ H ,T % PH$+0,,T"#- !F@ H ,T##-
M !0 M "T % "4 +0 M !F@ % !0 N*0!0 M, Q2 7% "T % "XH ,4 *!3 4
M4@%I@+BD N* %H * "F N*!"XH&% "T )0 4 +B@08H *  T )0 4 +B@ H
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M %H 2@ H ,4 &* $H * "@ H * "@ Q0 E !0 4 % !0 E !0 4 % !0 8H
M2@ H * "@ Q0 E !0 4 % !B@!* "@ H * "@!* "@ H * "@!* "@ H ,4
M)0 N* $H * "@ H * "@!* "@ H * $H *8!2 *8"4@"@ H * $H * "@ H
M* "@ H 3% !3 * #%(!* "@ H * $H * "@!*8!0 4@$-, H$% PH$)2 *8!
M0 E PI % !0 E, H * "@0M !0 4 % !0,* % I +0 E !0 M !0 4 % !0
M4 ** "@ H * %S0 E !0 M !F@ S0 9H * #- !0 4 % Q:!!0 4 % "9H ,
MT +0 9H 3- !0,* #- !F@!: "@ H * "@!<T % "T +0 4 %( I@&* %Q0
MM "T@#% "@4 *!0 N* "@ H 7% !B@!: %% #@* %I@% !0 4 +0 4 +0 4
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M7"_OH_\ K@G_ *,>@9\VT@"@!* "@ H * "@ % !0 &@ H * "@!* "@ Q0
M4 )B@ H *  T % !0 E !0 4 % !B@!* "@ H * "@!* "@ H * "@ Q0 F*
M "@ H * "@!* "@ H * #% "4 % !0 4 )0 4 % !0 4 %  * $H * "@ H
M* $H * "@ H 3% !0 4 % !0 E !0 4 !% "4 % !0 4 % !0 4 )3 * "D
M4 )0 4 &* $H * "@!*8!0 4@"@!*8!0 4 )2$% !3 *0"4#"@ H 2F 4 +0
M(*0!3 * "@84 %(!: "@ H 6@ H * "@ H * "@ H * %H * "@ H * "@ H
M * %H 2@ H * "@ H * %H ,T )0 4 +0,2@04 % "T#$- !0 HH 6@ H *
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M88)!^_SR/I7IX.ESROTU_(\[%5>56ZZ?F?.#N7.3U-?4GS@E A,T#%S0 9H
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M@#ZW_9;_ ./-?]R3_P!'-3$>Y4 % !0!YI\?O^0<WTD_]%O0!\04AB4 >C_
M7_D(?]L__:D= 'W)3$% !0!#>?<;_=/\J /@;XJ#_B8R_P#;/_T6M(9R= !B
M@#T/X&#_ $\_]<F_]#2@#[HIB"@ H * ,3Q=XGC\.0^=*0!N"\YZD$]@?2@#
MX+\7>+9O$LQFF9CD+P69@,#'>D,PJ "@!* '(Y3D4 ;X^(-^.ES-_P!_9/\
MXJ@!?^%A:A_S\S_]_9/_ (J@!/\ A86H?\_,_P#W]D_^*H /^%A:A_S\S_\
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M0 E !0 4 )BF 4@"@ H 2F 4 % "4" T % !0 E(84 % !0(*8!0 4 % PI
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MT /0>U &W0 4 % !0!\Q_M;_ .MC_P"N"?\ HQZ!GS;2 ,4 )0 4 % !0 4
M% !B@ H * $H * "@ H * "@!* "@ H * "@!* "@ H * "@!,4 % !0 4 %
M "8H * "@ H * $H * "@ H * $H ,4 % !0 4 % "4 % !0 4 )0 4 % !0
M E !0 M "4 &* "@ H * $H * "@ H 0T !H * "@!* "@!: "@ H 0T % !
MB@!* $H * "@ H * "@!* "@ H 2@ I@% !0 E( H * #% "4 % !0 AI@%
M!2 0TP"@04 % "4AA0 4""F 4#"@ I % "T % !0 4 % !0 M !0 4 % !0
M4 % !0 9H * "@ H * "@ S0 4 % !0 4 &: "@ H *!BT % !0 4 &* %H
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M^?\ D'U67;\A#\*;_P#YY-^:_P#Q5'UN'?\ /_(/JTNP?\*IO_\ GDWYK_\
M%4?6X=_S_P @^JR[!_PJF_\ ^>3?FO\ \51];AW_ #_R#ZK+M^0?\*IO_P#G
MDWYK_P#%4?6X=_S_ ,@^JR["?\*HO_\ GDWYK_\ %4?6X=_S_P @^K2[$D/P
MEOG.#$P]_E_^*I/%P[_G_D-8678^A_"NA+H< B4#L3P!SM /3Z5\S5GSRN?0
MTX<BL:]8&QYU\9?%O]E0&%#AV",,$@XW>WTKT\'2YY7Z:_D>;BJO*K==#YR=
MBYR>IKZA*Q\Z-Q3 3% "T % "T )0 4 )0 4 )0 M 'J?P2\7&RF%LY^5V[D
M]D/;IVKQ\;2YES=O\SU,)5L^7O\ Y'T$#N&1T-?-GT!G^(-(75X'A8 [@.P/
M0@]_I6M.?)),RG'F5CY1\4:0VDW$D;# $CXZ= Q Z?2OL*4^>*?DCY6I'EDU
MYLRMU;F0NZ@!=] A1)0!)'F0@#DFF(]&\%_ Z_\ $H#^6R1G:=WRG@C(.-X-
M 'M_A3]EZWLU5KA][84D-&A&<<CDFF(])T?X5Z?IH %O"V,<F&//'_ : -V'
MPW:P?<AB7Z1H/Y"@"Y'9I']U5'T % $H&* "@ H * "@ H * (;W[C?0T ?!
M_P 7_P#D*77_ %V;^E(9QE "T % "JA<@#J30![[\ O@LU^RWUVN$!C= RJP
M;#G/4G'W?3O0!]36ULMLH1 %4=   !^ IB)* "@ H KW]\MC&TKG"JK,3[ 9
M- 'R7\=?C*^MRM:VKD1*2-RLZ[@R $$<<<FD,\3)S0 @H ,T % 'UO\ LM_\
M>:_[DG_HYJ8CW*@ H * /-/C]_R#F^DG_HMZ /B"D,,4 >C_  %'_$P_[9_^
MU(Z /N.F(* "@"&\^XW^Z?Y4 ? _Q4'_ !,9?^V?_HM:0SDZ "@#T+X&?\?Y
M_P"N3?\ H:4 ?=%,04 % ",<4 ?$_P"T3K'V_4F .0(X_7K@^OL:0SRV@ H
M* $Q0 8H * .A\,^ +SQ(VVVB9NO(QVZ]2* /<_"'[*F[YKN1E//!1".@Q_$
M: /5M%^!^GZ9UBB<\\M#'G^1IB.K@\(6=O\ =MX1](D'\EH O1:;%%]U%'T4
M#^E %A4"]* %H * "@ H * "@ H ^8_VM_\ 6Q_]<$_]&/0,^;<T@"@ H ,4
M &* $H * "@ H * "@ H 2@ % !0 4 % !0 E !0 4 % !0 4 )B@ H * "@
M H 3% !0 4 % !0 8H 2@ H ,T % !B@!* "@ H * "@!* "@ H #0 E !0
M4 % "8H * "@ H * $H 6@!* #% "4 +0 4 % "4 % !0 4 )0 4 % !0 4
M% !0 E !F@!* "@ - "4 % !B@ H * "@!* "@ H #0 E, H * $I % !0 4
M )0 4 % "&F 4 %( I@)0 4 % A*0Q*8A:!A2 * "@!: "@ H * "@ % "T
M% "4 +0 4 % !0 4 )0 HH * "@ H * "@ H * "@ H *!AB@ H * %Q0 M
M!0 4 &* #% "XH 2@ Q0 M !0 4 % !0 4 ** %H * "D HH 6@ I@% !BD
MM !3 =2 * %Q3 7% !0 ZD 8H 6@ H 44 *!0 M !0 4 % "T %, I %, H
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M>_C<;IVL;)SM4NKLK.N0R 8/0'J?6D,^?)',ARQR?4\F@!M !0 4 % 'UO\
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M?_7!/_1CTAGS=B@!* "@ H * "@ Q0 8H * "@!,T % !0 4 &* $H * "@
MH * "@!* "@ H * "@!* "@ H * "@!,4 % !0 4 % "4 % !0 E "T !H 2
M@ H 2@ H "* #% !0 4 % "4 % !0 4 )0 4 % !0 4 % !0 4 )0 E !0 4
M % !0 4 % "4 % "T % "&@!* "@ H 2@ H * #% "4 % !0 4 % !0 E !0
M 4 '6@!* "F 4 )2 * "@ H 2@ H * $Q0 4P"@ H 3% @Q0,*!"4#"D E "
M@4 +0 4 )0 M !0  4 +0 4 )0 M !0 AH 6@ H * #% !0 4 % PH *!!0
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MTI\^)0 M 'M'[-GP\_M^Z^TRIF.%TX9593N5_7Z"A"9]E6]NMNH10 J@  #
M '   Z51))0 4 !.* /.?B!\;K/PGE=ZM(-PV'<#E2 1PI]:!GAGB;]J>YO2
M5@C"#YN1(X/L>-N*0'#:A\9]2O<_Z1,N<\":7_XJ@##N?'%]<_?N9S]99#_-
MJ ,RXU&6Y_UCLWU8G^9H ]"^ 0_XF47_ %VB_FU 'V^*8@H * (;[[C?[IH
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M!30[CS0!^A/@3_CU3Z+_ .@K3$=!0 4 % 'S'^UO_K8_^N"?^C'I#/FZ@ H
M*!B4""@ H * "@ H * #% !0 E !0 4 % !0 F* #% !0 4 !H * $Q0 4 %
M !0 4 (10 4 &* "@ H 2@ H * "@ H ,4 )0 4 % !0 4 )0 4 % "4 % !
M0 4 % !B@!* "@ H * "@!* "@ H * "@ H 2@!* "@ H * "@ H * $H *
M"@ H 0T % !0 4 )0 4 % !B@!* "@ H * $H 6@!* "@ H * $I@% !0 E
M!2 * "@!* "@ H ,4 )3 * "@!*0@H 2@8E "XH 6@!*  4 +0 4  % "T %
M !0 4 % "4 +0 4 % "XH 2@84"#% Q: $H ,4"%Q0 4#$H 7% !B@ Q0 4
M*!0 M !0 8H 7%( Q3 2@!<4 % !0 8H ,4 +0 E "T % "T % !B@!: "@
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MR2JO(J\DC&\XZ]*^NP]/DBO1?D?+UZG/+[_S.6KL.4* "D!]N?LX:$-.L0X
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M-(97H 2@!: "@ H * /K;]EO_CS7_<D_]'-3 ]RH$% !0!YK\?O^0<WTD_\
M1;4 ?$%(84 >C? ;_D(?]L__ &I'0!]QTQ!0 4 0WGW&_P!T_P J /@CXI_\
MA&;_ +9_^BUI#.3H 6@#T+X&_P#'^?\ KDW_ *&E 'W-3$% !0 V7H?H: /@
M/XH?\?S_ .ZG_H(I#.3H * "@ H ]Q_9;T);N\,K $!)%Y /9#W^M 'US3$%
M !0!!>WBVB[F.!F@#X3^)WQ&G\53Y+N$"A=N]F7(+'.#QGFD,X?% "4 % !0
M!/9Q&5PH]_Y4 ?H;X2M_(MT'^RO_ *"*8C8H * "@#YD_:W_ -;'_P!<$_\
M1CT#/FVD 4 % PH$% !0 E "T )0 4 % !0 4 &* $H * "@ H * #% "4 %
M !0 4 % "8H *  T % "4 +0 E !0 AH 6@!,4 % !0 E "T )0 4 % !0 4
M )0 4 % !0 8H 2@ H *  T )0 4 % !0 &@!* "@ H ,4 % "4 % !B@ H
M2@ H * "@ H * $Q0 4 % "4 !H * "@!* "@ H #0 E !0 4 !H 2@!: $H
M * "@ H 3% !3 2@ I % !3 *0 10 E !0 4 )3 * "@!*!#:0Q: "@!: $H
M 6@ H  * %H * "@ H * "@ H&% @H 6@ H *!AB@ H * #% "T""@ H *!A
M0 4 &* %Q0 4 % "XH * "@ H 7%( Q0 &F 4 %( H *8!B@!: #% "T@#%,
M H 6D 4 +BF 4 +0 8H 7% "T@"@!10 M !0 M !0 4 +0 4 +B@ I@+2 *
M"@ H 44 %, I % "XH 6F E "T@"F 8I &* #% "T % "4 % "XH *8"T@"@
M!*8!BD 8I@% !2 2@ Q0 N* "@ H * "@!* $H * $- "4#$S0 M !B@!I%
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M E !0 4 % !0 4 )0 M "4 +0 @% !0 4 (: "@ H * "@!,4 % !0 4 &*
M$H * "@ H 2@ H * #% "4 +0 E !0 8H 2@ H * "@ H 2@ H * "@ H 2@
M H * "@!* "@ H 2@ H * "@!*8!2 * "@ H * $Q0 E !3 * "D 4 % "4P
M"D 4 % "4P"@ I -H * %H ,4 &* #% "XH * "@ H 6@!*!A0(6@ H&&*!!
MB@ H * %Q0 4#$H$+0 4#"@ Q0 N* #% !0(,4#%Q2 *8!B@ Q0 N* #% !B
M@!<4 % !0 F* %H * #% "XH 3% "T % "XH *0!0 N* "@!:8!0 N* %H *
M0!0 4 +0 M !3 *0"XI@% "T@"@!U !0 4 % !0 N* "@ H * %% "T % !3
M * "D M !0 4 % !B@ I@%(!: "@ H ,4 % !0 4 )3 ,4@%H 2@ H * "@
MH * $)H 2@!* "@8E !B@!0* "@!#0!):736C!T)!&<$'!Z8J6KJPT[:GU7X
M$\2+KUL)!U&%/)/(52>OUKX^O3]G*W];GU5&ISQN=$#BN4Z3Q[XY^$?,7[7&
MOW513A1W<]_QKW,#6^R_/\CQ\92^U_6YX85KZ \,,4 +0 4 -- "$4 % !0
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M5 @H * /-?C]_P @YOI)_P"BVH ^(:0PH ]%^!+;-0_[9_\ M2.@#[CIB"@
MH ",T >(?&SX'GQ0YN;<XD+)D*@)PJ$==P[XH&>!7OP1U2V./L\A_ #_ -FI
M ,M_@KJDIQ]GD_(?_%4 =)\-O",_AG4VBN%*L(<X( /+(1W- 'V73$% !0 V
M7H?H: /@3XG_ /'\_P#NI_Z"*0SDQ0,* "@ H$?1/[)]Z!(T7?,I_P#'8Z /
MJ"F(* "@"IJFG+J";&Z9!Y&: /@7Q[X+E\+3F*52 0&!(QU)QT)]*0SF: "@
M H LV&FR:@VR%2[<\ 9/% 'U[\!/A)_PC,0N+@?OB[$;D 8!HT&,Y)QG-,1[
M+0 4 % !0!\R_M;#]['_ -<$_P#1CTAGS;0 4##% @H * $(H * "@ Q0 4
M% !0 E !B@ H 2@ H 7% !0 F* "@ H #0 E !B@ H 2@!: "@!,4 % "4 +
M0 4 )B@!* "@ H * "@ Q0 E "B@ H 3% !0 4 % !0 E !0 4 % "4 % !0
M 4 &* $H * "@ H 2@ H * #% "4 % !0 8H 2@ H * "@!* "@ H 2@!: "
M@!* "@ H * $H * "@!,4 % !0 4 )0 4 % !0 4 % "4 )0 4 % !0 4P"@
M!* "D 4 % "4P"D E !0  4 +0 4 +0 4 )0 4 +0 4 &*!A0(* "@!<4 %
MPH *!"T )0 8H&+0(* "@ H&% !0 N*0!3 * %H * %H *0!BF M !2 2F(6
M@8AH *  4 .%( H *8!0 4 +0 4 &* %I %, H 6D 4 +3 *0"T )0 M !3
M44@%H 7% !0 N* "@!: "@ H ,4 +0 4 %  !0 N* %H 6@ H ,4 &*8!2 *
M #% !0 M !0 4 )B@!0* %H 2@ H * "@ Q0 4 % !0 E !0 4 (: #- !0
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MZ4 ?(MY'Y7B?ZW\?_H2T@/KJV^Z/I3 DH * "@ H :\8?J,T ,^RI_='Y"@
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MSVX$(QU/_304#.>/[*USG_6M_P!^A_\ ':0&SH_[)K$YFG;O_P LAZ?]=#3
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M"@ Q0 M( H * %Q3 *0"T % "XH 7% !0 HH 44 +B@ H * "@!<4 &* "@
MQ0 N* %Q0 M !0 4  %,!: "D 4 )BF M(!#0 4 +0 4P%Q2 !0 4 % "4 %
M !0 4P"D E, H 6D E !0 E !0 4 +B@ H&)0(2@8M A#0,!0 8H 2@ H 6@
M":SNVM&#H2",\@X/3%2U=6*3MJ?4_@3Q(NO6P<'D84C.>0JD^GK7Q]>G[.5O
MZW/J:-3GC<Z('%<ITGG/Q)^&/_"1.)(CM(0#A ?XB3W'K7J8;$^S5G^9YN(P
M_M'=?D<+_P *&G_OG_OW_P#9UZ'UY=OQ_P" </U-_P!+_@A_PH6?^^W_ '[_
M /LZ/KR[?C_P ^IO^E_P0_X4+/\ WV_[]_\ V='UY=OQ_P" 'U-_TO\ @A_P
MH6?^^W_?O_[.CZ\NWX_\ /J;_I?\$/\ A0T_]\_]^_\ [.CZ\NWX_P# #ZF_
MZ7_!$/P%G_OM_P!^_P#[.CZ\NWX_\ /J;_I?\$3_ (4)/_?;_OW_ /9T?7EV
M_'_@!]3?]+_@A_PH2?\ OM_W[_\ LZ/KR[?C_P  /J;_ *7_  38\*_!%[&=
M))F+*I.08QC[I']X]ZQJXWFBTOS_ . ;4\):5W^1[/!$(55!T50!^ Q7A-WU
M/92L,O;Q;)#*YP%QG/UQ3BN9V$W97/E7XA^)&UNY<DDJK.J\DC&\XZU]?AZ?
M)%?+\CY>O4YY??\ F<O74<HM PH$)F@ S0!UOPS\</X1NXYP3L#@N-Q4$ $<
MX!]?2F!]V^"_%D7B:WCGB8$F.-F ).TLN<'(%40;U !0 4 % !0 4 % !0!S
M?B;Q];>'V2.5U#N6"@G!)&,CH?6@#;TR^%_&LJ]&4$?C0!9H *  C- 'RGXI
MLS;^)8FQ]Z_7_P!"2D4?4]K]T?2F22T % !0 4 % !0 4 % !0 4 % !0 4
M?-G[67W(O^NW_M.D,Z']ES_CS7_<D_\ 1S4Q'N5 !0 4 >:_'W_D'-])/_1;
M4 ?$5(84 2VTYMV#J2"""".#P<T ?:_P4^(L?B>U568>< Y92Q9@-^!U ]13
M$>ET % !0 4 %  : / /%_\ R'Y/^N$?_LE SW^@04 % #9>A^AH ^!?B?\
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M !0 4 !H * $H 6@!"* $H * "@!*8!0 4 %( H ,4  % !0 4 % !0 4 %
M!0 4 % "T % !0 4 +0 4 +0 4 )0,*!"B@88H !0 4 % !0 4 % !0 N* "
M@ I +3 * "@!: #% !0 4 % "XH *0@H&%,!: $H * "D M "TP"@!0* "@
MH !2 =BF 8I &* #% #@* "@ H * % H =0 4 % !B@!: %H * "@!<4 %,!
M: "@ H 6D 4P"D 4P#% "XI )3 *0!B@!<4 +0 E !0 4 % !3 2D 4 % !0
M 8H * #- "&@ H 3% "XH  * %H&(: &T *!0 8H$!H&-S0 9H * #- !F@
MH ],^#'B[^SIQ;N?D8NW)./N>F/:O)QE'F7-Z?F>GA*O*[?UL?0@.X ^HS7S
M)]" .* %W&@ W&@ W&@ W&@ W&@ W&@ W&@ W&@ W9H 3K0!YI\:O%HTV VZ
M'YG4'@X/#C/;VKU<'2YI<W;_ "/-Q=3E5N_^9\Z2.7))ZDU],?/#:8A:0!0
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M+P+^T=::P MR5A;!/S.3_%@#.P=CFF(]0L?%5K??ZJ56^A_"@#228/T- #Z
M"@!K2!>IH ^?_%]RG]OR'(QY$?\ [)2&>\?VI%_>%,0?VI%_>% !_:D7]X4
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M &@ H 3% !0 4 )0 M "8H * "@!* "@ H ,4 % !0 E !0 4 )0 4 % !0
M4 % !0 E !0 4 % !B@!*  4 % !0 E !0 4 % "4 % !0 4 (10 4 % !0
ME !0 4 )0 4 % !0 E !0 4 % !0 4 (10 4 % "4 % !0 4 % "4 % !0 4
M )0 4 % "4 +0 E !B@!* "@ H 2F IH 2D 4 % !0 4 % !0 4 % !0 4 +
M0 4 % PH$+0 4 % "B@ H 2@84 % !0 M !0 4 % !0 4 % "T % "4 +0 M
M !0 4 ** %S0 E !0 M !0 4 % !0 4 +0 8I +0 4 %,!<4@"F M !0 HI
M*!0 N* #% !B@!<4 % "XH ,4 &* %H 7% !B@ H ,4 +0 M !0 4 % !0 Z
M@ H * "@ H *8!0 9H * %I % !0 M "4 &* #- !0 8H * $Q0 4 +0 8H
M2@!#0 4 % !0 4 % !0 $4#$Q0 HH 0F@!": $H * $H * "@ H FM+IK5@Z
M$@C/(X/3%2U=6&G;4]U\)_&R&2,)< *PXR7)X"C_ &?6OG:V":=UK\O^">[2
MQ::L]/F=%_PMRR_YZ)_WU_\ 6KF^J2[/[CI^LQ[K[P_X6Y9?\]$_[Z_^M1]4
MEV?W!]9CW7WA_P +=LO^>D?_ 'U_]:CZI+L_N#ZS'NOO$_X6[9?\](_^^O\
MZU'U279_<'UF/="_\+=LO^>D?_?7_P!:CZI+L_N#ZS'NOO#_ (6[9?\ /2/_
M +Z_^M1]4EV?W!]9CW7WB?\ "W;+_GI'_P!]?_6H^J2[/[@^LQ[H/^%NV7_/
M2/\ [Z_^M1]4EV?W!]9CW0?\+>LO^>D?_?7_ -:CZI+L_N#ZS'N@_P"%O67_
M #TC_P"^O_K4?5)=G]P?68]U]Y3U/XUVEHI*%7;L Q]?4*:N.#D^Z^7_  2)
M8N*/!_&/BI_$4QE?.,MM!8L "Q/M7T-&DJ:L>'5J.H[F#70<X4P%I )3&(:0
M"4 +0 8H$6;'4Y; YA=D/JK%3^A% '>^'_CIJ.D *9I7  &#*W88]Z86.ZTO
M]K.X@&)("W3DS'_XV:+BL;"?M?D#FV_\C'_XU3N%BE?_ +74KCY+?!_Z['_X
MW1<+'):Q^TE?WV=ADCSGI*W?\!2N%C@]:^(%]K!)FN)6!SP9&(YZ]Z!G/NY<
MY)R3WI % S<TWQS?:8NR&YF10  HD8  = !G H$6_P#A9VI_\_<__?QO\: %
M_P"%G:G_ ,_<_P#W\;_&@ _X6=J?_/W/_P!_&_QH @N?']_=%6DN96*G*DNQ
MP?;GVH G7XFZFO NYO\ OXW^- "CXG:G_P _<_\ W\;_ !H </B=J?\ S]S?
M]_&_QI@.'Q.U/_G[F_[^-_C0*Q(/B;J1_P"7J;_OXW^-,0__ (67J7_/U-_W
M\;_&@ 'Q+U+_ )^IO^_C?XT '_"R]2_Y^IO^_C?XT +_ ,+*U+_GZF_[^-_C
M0 ?\+*U+_GZF_P"_C?XT '_"RM2_Y^IO^_C?XT '_"RM2_Y^IO\ OXW^- !_
MPLK4O^?J;_OXW^- !_PLK4O^?J;_ +^-_C0!F:OXEN=8Q]IE>3!R-S%N>G>@
M"72_%UWI*[;>:2,>BL5'7/;WH O?\+*U+_GZF_[^-_C0 ?\ "RM2_P"?J;_O
MXW^- !_PLK4O^?J;_OXW^- %;4/'%]J*[)KB5UYX9V(Y&.Y]* ,.@84 &* #
M% #D<Q\J2#[4 :]AXTO; YBN)5^DC?7UH$=#:_&C4H/^7B8_]M6H O)\>=17
M_EM+_P!_6_PH 1_CQJ+?\MI?^_K?X4 5)_C5J4O_ "\3#_MJU ',W/BRZN93
M.TTAD( W%B6P.V?PH OGXE:E_P _4W_?QO\ &@ _X65J7_/U-_W\;_&@ _X6
M5J7_ #]3?]_&_P : #_A96I?\_4W_?QO\: .?NKM[IM\C%F/<G)H AH * "@
M H 3% !B@!R2&,Y!(/MQ0,ZK0?BA?Z-]R>7'/'F,.OY^E CO=)_:>NK/_6(T
MG7K,P_\ 9#0!T<'[6K#K;?\ D8__ !N@ G_:U8CBV_\ (Q_^-T <UJ7[3MW=
M_<1D^DK?_$B@#B=<^+6HZKPUQ,!QP)6_^M0!R=S>/<G,C%CZDDG]: (: -#2
MM?N-(.ZWE>,\_=8KU&#T/I0!JGXE:E_S]S?]_&_QH 3_ (67J7_/W-_W\;_&
M@ _X67J7_/W-_P!_&_QH 9+\1=1F&UKF8CT+L1_.@#GW<N22<DGDT -H * $
MH #0 4 % !0 4 &* $Q0 4 % !0 4 % "4 % !0 E !0 4 &* $H 6@!* %H
M 2@ Q0 4 % "4 &* "@ H * "@!* #% "4 % !0 $4 !H * $H * "@ H *
M$- !0 4 % !0 E !0 4 % !B@!* "@ H * $H * "@ H 3% !0 4 )0 4 %
M : $Q0 4 % !0 E !0 4 % "4 % !0 E !0 8H * "@ H 2@ H * "@!* "@
M I@%(!* "@ Q0 E !0 &F E !0 4@"@ H * "@ H * "@ H * %H * "@84"
M%H 2@!:!A0 4 +0(2@84 % "T )F@!: "@ H * %H * $H * %I +3 ,4 %
M!0 M !0 M( I@% !2 * "F N* %Q2 ,4P%Q2 ,4P#% !0 N* %Q2 ,4 *!0
MN* %Q0 4 +B@  H 7% !B@ Q0 N* %Q0 4 +0 E "@4 % !0 4 +B@ Q0 4
M+0 4P"D 4 % !0 4 % "B@ H * "@ H * $S0 4 +3 *0!0 E PS0 HH$&*
M%Q0 TB@8E !0(* "@89H ,T"#- Q": $S0 F: $H 6@ Q0 E !F@!* #- !0
M A- ";J #- "9H 3-(!<TP#- Q*!!2 * #- !0 AH 2@ S3 6@ H 0TAB4"%
MH&+0(*!A0 4 -S0 N: %H * "@!: "@ H * "@ H 7- "B@0H- "@T .#4 2
M*],0\&F(44 +0 M  : #% !0 4##% @H * "@ H&% @H #0,* "@ H$% PH
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M@ H 2@!: $H * "@!* "@ H * $H * "@ H 2@ H ,4 )0 4 !%,!* "@ H
M*0!0 4 % !0 4 % !0 4 % "T +0 4 % !0 4 % PH *!!0 4#"@ H 6@ H
M* %H * "@ H * "@!10 M "&@ H 6@ H * %H 6@!*0!3 4"@!<4 +2 *8"X
MH * "D 8H 7% "T &* % H =3 ,4@"@!0* %H * "@ Q0 M "T % !0 N* "
M@ H * #% "@4 % !0 H% "TP$I )B@ H 4"@ H * %H ,4 % "4 &: $H ,4
M +B@ S0 9H 0F@!*  "@8X4""@ )H 0T#$H * "@ H 0T -S0 N: $W4 )F@
M!: $H 7- "9H 2@ H * "@!": &YH 0&D M "4P"D 4P#- !F@!* #-  #0
M9I !H 2@ IC%I"%H&)0 E  * %H 44 )0 AH 2@!:  4 +0 HH * "@ S0 4
M % "T % "B@!: %H$% Q0:!#U;%,1*K9IB' T ** "@!:  T %  : "@ Q0
M8H * #% PQ0("*!AB@0F*!AB@ Q0 4 % !0 "@ % @H 6@ H&(:!!0,6@!*
M$H ,4 % !0(0T % !0 4#"@ H$% PH *!!B@8E !0(* "@84 % A,4 !H *
M"@84""@ Q0 F* "@ H * "@ H 2@ - !0 4 )0 4 &* $H 6@!* %H 0B@ Q
M0 4  H * "@!* "@ H * $H * "@ H 2@ Q0 4 % !0 AH * "@ H 3% !0
M4 % !0 A% !0 4 % !0 E !0 4 % "4 % !0 $4 )0 M "4 % "4 % !0 4
M% "4 % !0 4 )B@ H * $H ,4 % !0 E !0 4 % "4 % !0 F* "@ H * $-
M !0 4 )0 4 % !0 E !0 8H 2F 4 %( H * "@ H * "@ H * %H&% !0 M
M@H 2@84"%H * "@84 % !B@!: "@ H$% PH * %H 6D E, Q0 M "T % !B@
M H *0!0 M,!: $I *!3 <!0 4@"F M "T % "XI &* #% "T *!0 M "T %
M!B@!: "@!<4 +B@ Q0 4 +0 8H 6@ H * "@  H 6@ I@% !BD HI@!H 2D
MN* "@ I@+2 * $H * "@ H 3% !B@!: $H 0T )F@!: "@8F: %S0(* "@!#
M0 E Q<T &: "@!IH ;0 4 )0 "@!:  T )0 4 )0 9H 3- !F@!#0 VD H%
M"T &:!B9H$(33 ,T % "9H 2D 4 ** %H&% "4P 4A"T % Q,4 % "B@!<T
M-- "4 % "T +0 "@!: "@ - "4 % "T % "B@!10 M "9H 7- "B@0M "@T
M2*],1(#FF(6@!10 M !0 4 % PH * "@04#%H$)0 4#"@04#"@ H$% !0,*!
M!F@ Q0 4##% "4""@84""@ H&% "4 % !0(*!A0(0B@88H *!!0,* "@04 %
M PH 3% @Q0 4 % !0,2@08H&+B@0E  : $H 6@ H 2@ H #0 4 % !0 AH ,
M4 % "8H * "@ Q0 4 )0 4 +0 E !B@ Q0 4 &* $H #0 E "T &* "@!#0
M4 % !0 F* $H 6@!* "@ H * "@ Q0 E !0 4 )B@ Q0 8H * "@!* "@ H
M* #% "4 % !0 E !0 4 &* $H * "@ H * "@!* $H 7% "8H * "@ H 3%
M!0 4 !H 2@ H * $H * "@ Q0 E !0 4 )0 4 % "8I@%( H 2@ H * $-,
MH 3-(!: "@ H * "@!* "@!: "@ H 6@!: $H * %H 2@!:!A0 4 % "T %
M!0 4 % !2 6F M( H 3%,!: "@!:0!3 * %I &*8!2 44P#%  !0 ZD M !B
MF N* #% !2 7% "T +B@ Q0 N* #% "T &* %Q0 4 % #@* %H * "F 8H 6
M@ I % "TP"D E !0 N:8!0 4@"@ I@%( % "YH #3 2@!: %S0 A-(!,T %
M"T % !0 4 (: $H *!B4"#- !0 4 **  T -- #<T#%S0 9H 3=0 A:@!":
M$H 6@ H 7- #2U #=U !F@ S0 N: $S0 9H *!B4A!0,#3 0F@09H&)0 4 +
M2$)0 E !0 4 &: %S0 4#"@!0:!!F@84 )0 9H ,T )F@!* %H 6@!: "@ S
M0 9H * "@ H 6@ H * %% "T )0 M "B@!: %S0 H- AZO3$2!J8#P:!"T %
M "T % !0,,4 % !B@ Q0 8H$&*!B4 &* %H$)0 4#"@04 % Q:!"4 % !0 &
M@ H 2@88H * $Q0 4 % !0 4""@84""@ Q0,3% @Q0,* "@04 % PH$% "4
M% !0 4#"@ H ,4"$Q0 4 !H * "@8E @H * "@ H * "@!,4 % "4 +0 E !
MB@ Q0 4 % !0 4#$H$% !0 4 '6@!,4 % !0 4 % "4 % !0 =: $- !0 4
M% "4  H *  T )B@ H * "@ Q0 @H * "@!,4 % !0 4 % "4 % !0 E !0
M4 !H 2@ H * "@!* "@ Q0 4 % !0 E !0 4 )0 4 % "4 % !0 4 (: "@
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MH 2@89H ,T &:!!F@!"<T#$Q0 F: $S0 F: #- "9H 7- !F@ S0 A- #2:
M$S0 M !0 M #: "@!:0!0 4 (:8#: #- Q: "D 9H 3- @H ,4 % Q* #- "
MYH ,T &:!!F@84 )F@ S0 4 % !0 9H * %S0 N: #- !F@ H *  4 +0 F:
M %H 7- !F@ S0 H- "YH ,T +F@!<T +F@!P:@1(LE,1*&S3$.H 3- "T#"@
M H 6@ H * $Q0 4 % !0 4 % !0 4 % !B@ Q0 8H * $H *!!0,,T""@ H
M2@ H ,4#$QB@ Q0(* "@ H * "@84 )0 8H$&* "@84 % @Q0 4 )0,*!!0
M4#"@04##% A,4 &* "@ H&% @H 3% !0 4 % "8H *!AB@08H #0 4 % "8H
M * "@ H * #% !B@!* "@ H * $Q0 4 % !0 E !0 4 % !0 E !B@ H * $
MZ4 % !0 4 )0 4 % !0 G2@ H * "@ Q0 E !0 $4 % "4 % "8H * "@ /-
M "4 % !0 4 )0 4 % !0 4 )0 4 % !0 4 )0 4 % "4 % !0 4 )0 4 &*
M$H * "@!* "@ H * "@!* $H * "@!M !F@ H 7- !0,2@0M !0,2@!: #-
M!0(6@ S0 4#"@!:!"4# 4 +0 4 % "T )F@ H 6@ H * '4 **0"4P%H * "
M@!<4 +0 M(!* %Q3 7%(!<4 &* % H <!0 8H ,4 +0 N* %H 4"@ Q0 4 %
M "XH *8!0 M( H 6@ H !3 6@!#0 4 %( S0 M !FF 9I % !F@ S0 4 +3
M,T )FD 4 % "YI@)FD 4 % !0 F: #- "YH&)0 9H$+F@ )H&-S0(,T +F@!
MI- PS0 9H 0F@!,T *#0 A- !F@!,T --  : $H ,T &: %S0 9H :30 A-
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M0 8H * "@ H$% !F@!,T % !0 4 )0 M "$4 % "4 +0 4 % "8H * "@ H
M2@ Q0 4 % !0 4 % "4 % !0 4 )0 4 % !B@!* "@ H ,4 )0 8H * "@ H
M 2@ % !0 4 )0 4 % !0 E !0 4 % "4 % !0 E "T )0 $4 )0 4 % !0 E
M !0 4 % !0 E !0 8H * $H 2@!: $H * "@ H 0B@ H * "@!* "@ H 2@
MH * $H * "@ H 2@ H * $H ;0 E "T % !0 M "4 % !0,* "@0HH&% @H
M6@84 % !0 M( I@% !0 4 % "T@"F 4 +0 4 .H ,4 % "B@!0* %H ,4 &*
M %Q2 7%,!<4@#% "XH 7% "B@!0* #% !B@!: '"@ H * "@ H 6F E(!<4
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M #-  #0 N: %S0 N: %S0 N: #- "YH 7- #U:@1*LE,1*&S3$+0 4 +0,*
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M 4 !H * "@!,4 % !0 4 )0 4 % "4 % !0 4 )0 4 % "4 % !0 E !0 4
M)0 4 % "4 ,H 6D E,84"%H * "@!:!A0 E "T""@ H * %H *!A0 4"%H *
M!BT )0 4 +0 4 +0 8H *0"TP' 4@"@ I@*!2 44 +B@!<4 +B@ Q0 H%,!0
M*0"XI@% "T &* '4@ T )B@!: %I@%( H * "@ H 6F 4 %( H 6@!* "@!:
M8"T@$H 2@ % "T % "4 ** %H 2@!* $H * %!H 7-,!,T %(!10 [- "&@!
MA- P% #A0(,T (30 F: $S0,,T (: &T &* %S0 ;J!!NH&)F@!,T &: #-
M#<T &: #-  : $H 6@!* $)H 3- "9H !0 X4@"F,::!"4 %( S3 *0 *8"T
MA@: $I@% "4@$H * %Q0 4 )F@ H  : %S0 4 )0 N: #- !0 4 )F@ S0 4
M +0 M "4 &: $S0 N: "@ S0 M !F@ S0 4 +F@ H 6@!: "@!<4 %( H 44
MP'4@"@!:8"T **0"@TQ$BO3$3*V:!#Z8!0,6@!,4 % !0 4 !H !0 &@ H !
M0 =: "@ ZT &:  B@ H ,4 )B@ - "4  H * "@ - !0 4 )0 M "4""@84
M H$% !0 4 &* $Q0,* "@ H$% "4 +B@!,4#"@04 % !0,*!!0 F* "@ H 2
M@ H *!A0(*  T % !B@!.E !0 4 % !0 8H * $H *  T &* $H&% @H&% !
M0(2@!: $H * $H * "@ H * "@ H 3% "4 % "T )B@ H 2@ H ,4 (: "@
MH * "@!* "@ H 2@ H ,4 )0 4 % "4 % !0 4 % "4 % !0 E !0 4 )0 4
M % !0 4 % "4 % !0 E !0 4 )0 4 %  : $H * "@!* "@ H 2@!: $H CS
M0 4#"@ H * "@!: "@04#%H$% !0 8H&% @H 6@84 % "T""@8M "4 &* %H
M 6D 4P%H 7%(!<4 % "XH ,4P%Q0 X"D H% "XH ,4 +B@!0* %Q0 M !B@
MQ0 4P#-(!: "@ H * %H *  T % !0 4 % !0 N: $S0 9H ,T &: %S0 4
M% !0  TP%H * %% !0 E( Q3 :: $I **  T )F@89H 4&@0N:!B$T -S0 9
MH 4&@0N: $)H 3- Q,T +0 AH 3- !F@!I- ";J %!H ,T &: $S0 A- "4
M% "YH 3- "YH 7- "$T -S0 E !0 4@#- !F@!* "@ H *!B9H$&:!BYI@&:
M0"4"%S3&)2 * "@ S0 $T -)H !0 4 % !F@ H ,T +F@ S0 E !F@ H 44
M% !F@ H 2@ H 6@ H * %H * "@ H 6@!<T % "B@!:0!F@ S0 9H =F@ H
M4&@!<TP%S2 ,T  -,!P- AZOB@"9),TQ$H-,0M !0,* "@ H$&*!A0 E !B@
M H ,4 % !0 4 % !F@ H 2@!: $H ,4 % !B@!* "@ H * "@ H * "@!* #
M% !0 4 % @H !0 8H 3% PH *!!0 4#"@!* #% !0(* $H 6@!* "@84""@
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M- #LT +F@!": &DT  - "[J $+4 -+4 &: $S0 4 *#0 4 )F@!": $S0 4
M!H 3- !F@ W4 *&H ,T -H * #- !F@ S2&% !0 9H 0F@!,TP#-( S0 F:
M#- "YH ,T &: $S0 N: #- "$T )0 HH * $S0 4 % !0 4 &: "@ S0 4 *
M* #- !F@ S0 9H 3- !0 M "T % !F@ H 6@ H ,T .% "BD N:8!2 2F 4
M+2 6@ S3 6@!<T &:0"T +0 H-,!ZMB@1*LE,5B57IB'9H * %H&% !0 4 )
M0 4 % "T % !0 E !0 8H "* $H * "@ H *  4 % !0 8H ,4 )B@ Q0 4
M)0 M !B@!* %H 2@ H$% !0 4 &* #% "$4#"@ H *!!0,* $H * "@!*!"T
M#"@!*!!0,,4 %  : $Q0(,4 % !0 4 &* $Q0 4 % !0 4 !% "4 +0 4 )0
M 4 (: "@ ZT % "4 % !0 &@!* "@ H * $H 6@ H 3% !0 4 % "8H 2@!:
M $H ,4 )0 4 &* $H * "@ Q0 E !0 4 % "4 %  10 E !0 4 % "4 % !0
M E !0 4 % "4 % !0 E !0 4 % !0 AH * "@!* "@ H 0T % !0 4 )0 4
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MFF22 TP%H&&* "@04# B@ Q0 8H ,4 %  : $H * "@ H * "@ H 3% !B@
MH * "@ H ,8H * "@ H ,4 )0 4 % !0 4 &* $Q0 4""@ H * "@ H 2@88
MH * "@!* %H 2@ - !0 @H$% Q: $H$% !0,*!!0,,4"#% "4 % !0 &@88H
M$)0 4 % !0 4 % !0 4 )B@ H 2@ H ,4 )0 M "4 &* $H * "@ H 2@!:
M"@ - "4 % "4 % "4 % !0 &@!* "@ H 2@ H *  B@!* "@ ZT )0 4 % !
M0 E !0 4 )0 4 % !0 E !0 4 )0 4 % !0 E !0 &@ H * $- !0 4 )0 4
M % "&@ H * "@!* "@ H AH * "@ H * "@!:!A0 4 ** "@ H 6@!: $Q0
M8H 44 .Q0 M( H 6@  H <!0 N* #% #@* %Q0 8H 4"@!:  4 ** %H 2F
M"@!U "4@"@!: #- !0 8H * "@ S0 M !0 AH 2@!10 N: "@!10 4 (30 F
M: "@ H ,T *#0 N: $)H :30 "@!V: $S0 9H * #- !0 4#"@0E !F@8AH
M3- "YH ,T )F@ S0 9H 3- "9H 0&@!P- "YH 0F@!M "T % "&@!M "T )F
M@ - !0 9H 0F@!N: "@!: #- !F@ S0 E !2 *!AFF 9H #0 E(0HH 7- "9
MH&)F@!": "@04 (:!A0 [- "4 (30 F: %H * $H * "@!U "&@!* %S0 9H
M ,T !- "9H 6@ H 3% !0 M !0 E !F@ H <* %H *0!0 &F,*!"B@!: "@
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M* "@ H 2@ H ,T &: #- "4#%H ,T (: $S0 NZ@ H 44 &: $)H ,T )F@
MS0 A- !0 F: #- !F@ - #<T )F@!10 N: #-  30 W- "AJ #-  : $H *
M"@!* $S0 9H 2@ H * #- !FD 9H 2@ I@%( - "4P"@!<T )2&&:!!NH&)F
M@09H *!BT )0(3- PH 7- !0 E "4 ** "@!* "@!<T &: $H 6@ H 0T )F
M@ H 7- "@T +F@!": "@ S0 9H * $H ,T *#0 N: %S0 4 %(!:8"T &: "
M@!,T +FD 9I@*#2 44 % !0 HI@+0 4 +FD M !0 N: %S0 4 +F@!: %H <
M#BF!*CT$DRMFF(?3&% !0 4""@84  H * "@ H * "@ H * $(H ,4 % !0
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M01D$$+@@CD$=:!&9J^AW&C.([J*2%RH8+(C1L1D@'# '&01GV- REF@ H *
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M E !0 4 )0 4 % $% !0 M Q10 4 &* %Q0 8H 7% "@4 &* %Q0 H%(!P%
M"@4 *!0 NV@!<4 *!0 H% "T )3 6D M !0 4P"@ S0 4 &:0"YH *8"T )0
M 4@"@ H * "@ H 2@#Z;_8M_Y?\ _MU_]KTQ,^FJ8@H * .>\;^ +/QK ;>]
MC##:P1\#S8R<'<C$$J<J">S8PP9<B@#X7^)OP[G^']XUG.0PVAXW7H\9)"MC
M)*G*D%3T(."RX8R4<IF@ H ,T &: $S0 HH ,T &: $W4 )NH 7- "$T#$H
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MSA0JX 8D?+.:DH*  T )3 *0!0 4 ?HW\*_^018?]>-K_P"B4JS,^7?VR_\
MD+P_]>,?_HZ>I92/!J104 +0 4 --  * %H * "@ H * "@ H * "@!: #-
M!0 9H 2@ H ,T % "T +0 M !0 4 %( H ,TP"@!:0!0 HI@+2 ,T &: %S0
M N: %!H 7- !F@!: "@!: %H * %S0 N: %!H 4&@"16Q3$3)+3$2ALT"%!I
M@??WPT_Y!=E_UY6W_HI*8CYO_:V_Y"D/_7E'_P"C9J0SQ*@84 % 'W[\-/\
MD%V7_7E;?^BEIDGS=^UM_P A2'_KRC_]&S4AGB= PQ0 8H 2@ H * "@ H *
M #I0 4 % !B@!,4 % !0(* "@ H&% "4 % !0 =* "D 4P B@!,4 ?4OPP_9
M;BT_R[K5F\R4;6^SC'E*>?E<\^9_"2!M7(*GS$/((\>_:$MDM-;N8XU"HJVZ
MJJ@!0!;Q   <  < #I0!YW0,_26F2?$?[1O_ "';O_MA_P"B(J0SS7&: #%
MPH *!!0 E !TH&% @H&?0OPB_9C3688K_4W(CD572!" 60[60NX)P&7.57#
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M F* "@ H * $H ,4 %  10 E !0 E !0 4 % "$4 % !0 =: $Q0 4 % !0
ME !0 4 )0 4 !H 3% !0 4 )0 4 % !0 E !0 4 )0 4 % "4 %  : $H *
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M?LH:SHL)F017&W)*0NS28 ))"NB;NF-JY<D@!3V+"N>/W5J]H[12J4=&*LK
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M2@#T+P7\!=6\6JLL4/EPOTEF/EIC:&# <R,I! 5E5E)/7 ) !U__  R#JO\
MSVM?^^YO_C- 'FGB_P"&NH>#L&_MWB5L8?Y7CR=V%WH63=\I.W.[ SC'- ',
MT )0!L>%?"-UXLF%K8QF64J6P"  !U)9B%4=!DD9) ') (!ZK:_LC:M,BLTE
MLA*@E6DD+*2,E3MB9<CH<$CT)'- 'GGCKX7:AX(?;>PE4W865?FA;EL8<< D
M*2%;:^.2HH U]+_9_P!:U6*.XAM=T<J*Z-YL RK ,IP9 1D'H0#ZT <]XF\
M7GA>X2SO8Q%-(JLH:2+;AF* EPY11E3DL1C&3@<T =7_ ,,V:]_SZ?\ D:W_
M /CM 'GFJ:;)I<LEO,-LD3LCKD'#*2K#()!P1U!(]* *M '<^&O@CJ_B:W2[
MM+?S(9-VUO,A7.UBIX:12/F!'(_2@#'\9?#^\\%ND=_&(W=2RKYD3M@'&2(W
M8@9X!.,D'&<' !SM !0 8H 2@ H * $H * "@ H 2@ H * #% "4 % !0 E
M!0 4 )0 4 % "4 % !0 E !0 4 % "4 % !0 E !0 4 )0 4 !H 2@ H * $
MH AQ0,7% "XH 7% "@4 +BD 8H 4"@!V* #% #@* #% "XH 4"@!<4P%H$%
MPI &:8!0(*!A2 *8"T +0 4 % !F@ H 2D 4 %,!<T )FD 4 % !F@!<T )0
M 4 (30!]-_L5_P#,0_[=?_:],3/3_P!I7_D 7?\ VP_]*(J8'PMFI&;'AKP?
M>>)W\NR@DF(9 =BDJI8D+N;[J X/+$# ))P#3 ^VO@-\/)/ FF+;S_Z^1VEE
M7<&568*H4$ =$5=W+#=NPQ7%,1P'[9.LI#8VMH0=\ER9 >-N(T*L#SG.95QQ
MC .2.,H$<!^QX?\ B;3?]>,G_HV&@&?6FO:.FMV\MI(2$FBDC8K@, ZE21D$
M9P>,@C/:F(JZAKUCX62..>6"V3;MC5WCA7" #"ABHPH(&!P!CVH \4_:Z\6H
M--MK>%R1<R^8&1@8GCC7."0?F!:1&7@J=N[((&4-%K]F'X/IH=NNK7: W,R[
MH3D-Y<+*-I  PKN"<G)(0A?E)=2 STWQW\4M/\#)NO9@KE<K$OS3-PV,(.0"
M5(#-M3=P6%,1Q7AW]JK1]9E$+F6WW8P\R*(\D@ %D=]O7.YL* "2P[H=CT3Q
MKX*MO&=LUG>+NC;D$<.C#.'4X.&&?<$$JP*D@L1\ ^._"4GA"]FL)3EHG(#<
M#<I 9'P"V-R$-C)(S@\@U)1VG[/?PF3X@WC?:<_9;=5:4*0"Y8_)%G(8!L,2
MR@G"D94LK!@?:FIZG;>%;8S3%(+:!!VVHJC"JH"CZ*JJ,DX5020*9)Y/_P -
M<Z/YOE;;C9OV^;Y:^7C./,QYGF;<<XV;L?PYXI#L>NZ%KL&O0)=6KB2&1=R.
MO0CIWY!!X(."""" 013$?%G[1WPN7P1?^9!_Q[76^2,850C!OWD0"X^5=RE?
ME "L%&2I)12*O[-'_(?M/^V__I/+2!GW75$GYH:5ITFJS1V\(W22NJ(N0,LQ
M"J,D@#)/4D#UJ2C]$O!/@FV\&6RV=FNV->23R[L<9=S@98X]@  J@* !1)Q/
MCC]I/2?",YM7:2:5&99!"JL$(Q\K,[(I/."%+%2"&VD8I#L'@?\ :3TGQ=.+
M5&DAE=E6,3*JAR<_*K(SJ#Q@!BI8D!=Q.*86.V\;>";;QI;-9WB[HVY!'#HP
MSM=#@X89]P02K J2""/ST\3^')O#5S+97 Q+"[(W! ..C#< 2K##*<#*D'O4
MEGT7^Q3_ ,Q#_MT_]KTT2ST_]I?_ ) %W_VP_P#2B*F"/A+-24?5'[,OP+CC
MCCUN_7=(WS6T3 @( ?EF8,!ECC='U4*0X)8KL9+/>_%GC"T\)0&ZOI1%$&"Y
M()))Z*%4%F/4X ) !)X!(8CRK3/VN]&O)!&ZW$*G.9'C4H, GD1R2/ST&%/)
MYP,D*X['L?[G5X?X)894]GC=&'XJRE3[@@^E,1\6?M"?!8?#Z=9[7)LYV;8"
M&)B8<^66/!!',9)W$!@<E"S(I'$?"T_\3:P_Z_K7_P!')2&?HI5$'G6K:GI'
MP=CFNICLDNYYI6XWSS.2TFT  ?*N[:N=J+N&Y@SEF0S!\-_M7:-K4PA<RV^[
M #S(JQY)  +([[>N=S80 $EAW+A8]CIB/@+X[> $\#:I+;0*5MV5)(0S!SL8
M<C/7 <.HW?-A023G<9*1YZ:!@* %H ^V_P!F?X71^%;!+U]CW-W&DF\ Y6)U
M5DB!/_?38 RQ .X(K4R6=WX_^)5CX#A$U_)MW;A&@!:1RHR0JC\!N.$!*AF&
M13$<'X;_ &KM&UJ80N9;?=C#S(JQY)  +([[>N=S80 $EAW5QV/5=*T&#23*
MT"!#-*99-O :0JJL^.@)"C.,9.6.6))8CQ;]LG_D$P_]?T?_ *)GI,:/E#P=
MX3G\77<5C:@&65B!N.U0 "S,3Z!02< D@8 )P"BC]"?!'@BU\%6J65DFV->2
M3R[L<;G<X&6./8  *H"@ 40<'XO_ &H-&\.2"(.]RW\1MPLB+PI'SLZ(V<_P
M%L$$-@C%(=CH_AO\8]/^(0(LW(E5=SPR#9*J[BN[ )5ATR49@NY0V"0*8'GW
M[3GP:AUZUDU>W7;=P1[I,8 EC7[Q;)'S(@)#<DJNS#?)M0(^.*11^B_PL_Y!
M-A_UXVO_ *)2J(-2/PW"EVU_C,S01PY('RHCN^%.-PW,_P W.#M3C(Y (M&\
M:6.N.8K2Y@F<*6*QRQR,%! +85B<9(&>F2/6@#YN_9R\2?\ "3>)K^]!<K-!
M<.F\Y<(;B'RU/+8VIA0 2 !@< 4BF?3>OZ,FN6\UI*2$FBDC8K@,%=2I(R",
MX/&01GL:9)Y5KGQYT+X8[=+@5V$&4,=NH98R,$AF=T#,23N(+-O#>9ANJ'8]
M!\!?$"T\=V_VNQ8L@;:P92K*^U6*'/!(##)4LN>C&F(-9^'UGK-Y!J,\8>>V
M5A&2!C)*E6/&6*$$QY.%+,P&[! !Y[XD_:PT;19C"AEN-N07A16CR"00&=TW
M=,[ERA!!#'LKCL>K:#KT&OP)=6KB2&1=R.O0CIWY!!R"#@J000""*8CYC_;+
M\$+;R6^JQ)CS,PS,-@!91NB)& Q8J'!8Y 5%'&!F64CYMM+5[QUBB4N[L%55
M!9F8G 4 <DD\ #DFD4?H-\(OA?!\/;-;>-1Y[JK7$@.XO)CG!(4[%)(08&!R
M1N9B;(,#QS^TOI/A"<VKM)/*C,L@A56",,?*S.R*3S@A2Q4@AMI&*06-7X9_
M'/3OB([0VAD29%9C'(FUM@* OE2Z8RX&-V[.?EQS0%C4^*O@)/'>GS6+8#LN
MZ)CCY95Y1L[6(!/RL5&[8S =:8'Q-\"_$]OX7UBVO+Q_+AC\[<VUFQNAD0<(
M&8_,P' _2I*9]T>#/'5GXTA:XT^3S8ED*%MKIA@%8C#JIZ,.<8YJB \9^.K/
MP7"MQJ$GE1-($#;7?+$,P&$5CT4\XQQ]* /G+]ICXPZ7XTTZ*WT^?S95NT<K
MY<J841RJ3ET4=6'&<\TBDCA_V=_@F/B%.UQ=9%G R[P P,K'GRPPX  P9"#N
M *@8+AU0VS[9_<Z1#_!%#%'[)&B(/P5551[  >E40>-:G^U_HUG(8XUN)E&,
M2)&H0Y / DDC?CH<J.1QD8)5QV/5O"7C&T\70"ZL)1+$6*Y ((8=5*L RGH<
M$ D$$<$$L1X#^T]\"(Y(Y-;L%VR+\US$JDAP3\TRA0<,,[I.BE07)#!MZ929
M\IU)1^C?PK_Y!%A_UXVO_HE*LS/EW]LS_D+P_P#7C'_Z.GJ64CQGPMX;F\37
M45E;C,LTBHO#$#/5CM#$*HRS'!PH)[4BC[^^%GPLM?AU:BWMQND;!FF(P\C#
MN>N%&3L3)"@GDL69K(,KXC?'[3/ ,GV>X9Y)_E+11*'=0P)!8LRH.@^7=OPR
MG;M.:5PL'PY^/VF>/I/L]NSQS_,5BE4([!0"2I5F0]3\N[?A6.W:,T!8U?BG
M\++7XBVIM[@;9%R89@,O&Q[CIE3@;TR P Y#!65@? 7BCPW-X9NI;*Y&)89&
M1N& ..C#<%)5AAE.!E2#WJ"CU']F+X61^-;YKBYV-;VFQGB8$^8SA_+&.!M!
M4LV<@X"E2K'#0,^V;N[2S1I96"(BEF9B%55 R6)/  '))X JB#Q75/VP-&LY
M#'&MQ,HQB1(U"'(!X$DD;\=#E1R.,C!*N.QV^C0Z5\09;;7+-A));M*B2KE6
MP4=&BD5@&P-^]0P!!(93M<[F!W% CX'_ &<O%I\-ZU;G)V3M]G<*%)(E("#Y
MN@$NQB00< XS]TR6S[I\0:,FN6TUI*2$FBDC8K@,%=2I(R",X/&01GL:H@_-
M35=,DTF:2VG&V6*1T=<@X92589!(."#R"1Z5!H>U_L@^$CJFJM>D'9:1,005
M \R4&-5(/)!3S#QC!49/8M$L^HOBUXM/A'2KJ]0D.D1$94*Q$CD1QMAN" [*
M3G/ /!Z&A'YT5!8M !F@ H _4.K,SB-9ATOX?RW.N7C".2X:)'E;+-@(B+%&
MJ@M@[-[!022"S':@VH9P^F?M?Z->2".1;B%3G,CQJ4& 3R(Y)'YZ#"GD\X&2
M"X6/9?W.KP_P2PRQ^SQNCC\5964^X(/I3$?$/[27PM7P-?\ F0#_ $:ZWR1C
M"*$8-^\B 7'RKN4K\J@*P49*DF66CSGPOX<F\3745E;C,LTBHO#$#/5CM#$*
MHRS'!PH)[4AGWY\+/A9:_#JU%O;_ #2-@S3$8>1AW/7"C)VIDA03R6+,UD&7
M\1OC[IG@*3[/<,\D_P I:*)0[J&!(+%F5!T'R[M^&4[=IS2N%@^'/Q]TSQ[)
M]GMV>.?YBL4JA'8* 25*LR'J?EW;\*QV[1FBX6-3XI?"VU^(EJ;>X^61<F&8
M#+QL>XZ94X&Y<@, .0P5E /@7Q1X;F\,W4ME<#$L,C(W! ..C#<%)5AAE.!E
M2#WJ2S]"?ASXL'B[3[>^!!,L2E]H95$@^650&YP'# <G(&02.39F?*O[7?A,
MZ7JBWH!V7<2DDE2/,B C90!R $\L\YR6.#V$LM&-^RYX;_MG6XG(1DMXY)F#
MC/0;$*C!&X2.K#.,8R#D#*0,^YJL@^0OVR?#?V._M[U0@6> H<##EXF^9FXY
M^21%!R3A<< #,LI'$?LZ>$SXDUJW&#L@;[0Y4J"!$04/S=09=BD 9P3C'4"&
MS[JU74X]*ADN)CMBBC9W;!.%4%F. "3@#H 3Z51!\&>!/"<_Q;U=@P"B65[B
MY*G8$C:0&0INWG.7VH,-R1N^4,1!9]TZ9IEKX5M1#"$@MH(SWVHJC+,Q+'ZL
MS,<DY9B22:L@\P\1_M6Z-HTQA0RW&W(+PHICR"00&=TW=,[ERA!!#'LKCL=Y
MX!^)-EX\A,UC)NV[?,0@K(A89 93^(W#*$A@K'!I@>$?M4_!N&VC;7+-=C;U
M%R@P$.\X$W)&&+D*P .XL'(!#LTL:9\Q"I*/T[K0S,>VT:WT)[F])"F9EDFD
M;:H CB6, M@8150M\Q(!9SD XH JR?$*Q:WGNX)X[A+:)I)1#)'*P"JS8^5L
M D*=N2 2.O6@#X[^!?PS?XEZ@TEV2]O$WF7+%R)'+[BJYY8EV!+'@[0WS!BN
M81;/MBYNK?P_!ND:."WC55!)6*)!PJKSA5'0 <#H!5D'D6I_M<:/9R&-%N)5
M&,2)&H0Y / DDC?CH<J.1QD8)5QV/4_"GC"U\6P"ZL91+$6*Y (((Z@JP#*>
MAP0"001P02Q'RM^TU\'HO",B:A9+LMYW*O&,!(Y,;AM&<[6 8[0,(5(! 95$
MM%IGC6@Z0^MW$5I&0'FECC4MD*"[!03@$XR>< \=JD9^@O@#P1#X*LX[*W P
MJC>P&TR/@!Y#DL<L1T).T84?*H%:&9SWQ"^.^F^!9/(N&>2?Y2T42AG4,"06
M+%4'0?+NW893MVG-*X[$7@?XV:5\1"UI&2)'5QY$Z*"Z;1NQ@NC @G*YW8#$
MKM&:+A8[[3--CTN)+>$;8XT5$7).%4!5&223@#J23ZTQ'RG^UM_R%(?^O*/_
M -&S4AGB6:!BT % 'W[\-/\ D%V7_7E;?^BEIDEG6?L>@F35;G;&RPA'F;.1
M&K%@@Z]6;HHR[;1R0H !YO\ \-5Z3YOE;9]N_;YOEKY>,XWXW[]N.?N[L?PY
MXH&>K:)K<.N0I<VSB2*1<JPZ$?S!!X(."""" 010(^:OVI?AK'I<BZM;A469
MQ'*@!!,I#OYOI\P4ANGS -\Q=B$,N_LB>*"'N=.8D@J)T&%V@@B.3)^]DYCP
M.1\IZ'J >D?M%^%SK^D2E02]NRSJ 5 PF0^=W4"-G; ()(&,]"Q'Q7BD4?6'
M[)WA<Z?82WK@@W,H"\J5*194, .0=[2 Y_N@@ <D$'[6/B@Z?8162D@W,I+<
M*5*188J2>0=[(1C^Z02!P0#Y/H&% !0![]^RM\/(M5DEU.YCW"!T6 D@IYF-
MSMMZ[E!0J3P"Q(RP!4$?1OBCQ9:^%83<WL@BB#!<G)))Z !068]3@ X )/ )
M#$>4_P##6VE_\\;K_OB+_P"/4#/5O"_BRU\50BYLI!+$6*Y&001U!# ,IZ'!
M R"".""01\]_M1?"V.QVZO:)M#OMN0N<;F^[+@+A<G(<D@%BG!9F)0SG_P!E
M7Q2=-U)K,D[+J)@  I&^,&16)/( 3S!QU+#([@ ^D?BCX7/BG3;FS4$N\1*
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M"45@<?+\@X#$ED,D_9V^+&F^$+"2WOI_+D:Z=POERO\ *8XE!RB,.JGC.>*
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M)3"IEGQG+PJICR"00"[INZ9RN5(((8]@#N/ OQ$L_&\1FLI-VW;O0@K(A(R
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M >A:#HZ:);Q6L9)2&*.-2V"Q"*%!. !G YP!]* /D_\ :_\ ^0K#_P!>4?\
MZ-FI#/I/X5>*CXKTRVO&)+O$ Y(5270F.1L+P 74D8QP1P.@8CYG_:R\*'3-
M36\ .RZB4Y)4C?&!&R@#D )Y9YZEC@]@AGC6F:9)JDJ6\(W22.J(N0,LQ"J,
MD@#)/4D#UH _1K0='31+>*UC)*0Q1QJ6P6(10H)P ,X'. /I3$?$?[0OBL^(
MM9N#D[(&\A 0H($9(?[O4&3>P).<$9QT"&>;XH !0 4 !H 2@ H * $Q0 4
M% !0 E !0 4 !H 2@ H * $H * "@!* "@ H 2@ H * $H * "@!* "@ H 0
MT % !0 4 )0 4 !H 2@ H ,4 18H&+B@!<4@% H =B@ Q0 H% "XH 7% "@4
MP%Q0 4 &* %I %, H * "@ H 6D 4 %,!12 ,TP#-(!,TP%S2 ,T ** $- "
M&@ H ,T )F@ %,!:0"9H 7- !0 A- "4P/IW]BK_ )B'_;I_[7H$SZ<IB"@
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MR8)9=N=N[8A;;G!QG&,X./0U1!^=.IZG)JDLEQ,=TDKL[M@#+,2S'   R3T
M ]*@T':5J<FERQW$)VR1.KHV <,I#*<$$'!'0@CUH _13POK7]NVD%WMV>=!
M%+MSNV[T#;<X&<9QG SZ"K,SY:_:X?&JP_\ 7E'_ .C9J0SQ4'- "T#"@#[]
M^&G_ ""[+_KRMO\ T4M,D\%_:[\1.]Q;6 R$6(S'YCM8NQ1<KC&5"-@\_?(&
M.<H9\^T#/H?]D;Q5(LMQII&8RGGJ>!M8%(W[9.X,O4X&S@?,30(]H^,>D)JN
MD7D;D@"W>3C .8OWJCD'C<@!]LX(/-,1\<_"_P 4#POJ5M>,0$24!R0S (X,
M<C87DD(Q(QGD#@]"BC[SN;9+I&CD4,C*596 *D$8((/!!'!!ZTR3\\-<T=M&
MN);60@O#*\;%<E248J2,@'&1QD#Z4BC[X\$>'_\ A';&WLR%#10QJVP84N%&
M]AP,Y;+$D DG)Y-,D^1OVB_% U[5Y0A!2W58%(# Y3)?.[J1(SKD8! &,]2A
MGF5 PH ,T ?3/[(OBJ,Q7&FD8D#^>IY.Y2$C?M@;2J]3D[^!\I- CVWQCX.M
MO%]LUI=KN1N01PR,.CJ><,,_0C((*D@L1XGX@_9"B?+6-TRX0X290^7YQETV
M;5/ ^XQ')YZ4AG-V_@+Q1\,(W6P;?"VUW\C9.-V=O$<J;]V,;BB8*XR2%^4
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MXA^*AX3T^XOB0#%$Q3<&92Y^6-2%YP7*@],9R2!R&(_.^D,* $-  : "@ H
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M %_6O_HY*DL_1:J(/SG^*G_(6O\ _K^NO_1SU)9RU 'Z,_"O_D$V'_7C:_\
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MY$;\@8&.<9&1C1\I5)1ZW^RMI<EYKT$D8RL,<[R'(&%,31@\GGYY%&!D\YZ
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M+=HKW\18!V6V8+D;BJF8,P'4@%E!/0%AGJ*2&SV']HK3)-2T&\CB&YA&CD9
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M)GH_Q>^([_#VS%\EN;@>:J. Q0(&#?.6"/@;@%Y &6 SG ((\6_X;8_ZA_\
MY,__ &BE<=@_X;8_ZA__ ),__:*+A8/^&V/^H?\ ^3/_ -HHN%CYAI%'Z>U9
MF?"7[3'_ "'[O_MW_P#2>*H9:/,!2&?=/[,5TD^@VRHP)1IU< @E3YTC;3CH
M=K X/."#T(JT0RU\:?C"_P -$@D%J;A)6=2V\QJA4*54GRW&6!8@<'"G&><
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MDX'-,1Z)I&N6^LH9+66.9 VTM&ZR*#@$C*DC."#CW% 'FW[0OPWA\2V$EX%
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MD E !0 E !0 4 % !0 E !0 8H 2@ H * "@!* "@ (H 2@ H 3% !0 4 %
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MR P Y#!65B/D?4_V5]>LY#'' DRC&)$FB"'(!X$C1OQT.5'(XR,$S8JY]"_
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MPK$?,FX 9*ME3P#D$$ \59F7]5U./2H9+B8[8HHV=VP3A5!9C@ DX Z $^E
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MDC4@K&L94B1E.<KGC(P1SG("&>0>._ %SX(ECM[S;YDD*2[5.[:&++M8X W
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M 6@ H 6@0AH&% "T@$S0 "F M !0 4 +0 A- "4 **0"YI@)0 "D N: $S0
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MS_\ MI^+0$M=+4@DL;B08;<  8XB#]W!S)D<G*CH/O)E(^5ZDH* #- !0 4
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MPHN%CQ_X\_$JW^(-]'=VBR(BVRQD2!5;(>1B?E9QC#COG.>*3&CS@&D,<&H
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M1U!C(YI#/G&ZNGNG:21BSLQ9F8EF))R22>22>23UH BH ]+^%GQYO? 6(?\
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MIB/SZ\2^()?$5S+>3G,DKEFY) ST4;B2% PJC)PH [4BC,H * "D 4 %, H
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M0?M?^-&@C@TN)L>9F:91N!*@[8@3D*5+!R5.3N13Q@90SY>H 3% !0 9H *
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M 4@"F E "B@!: $H *!A0 4""@8E( % !3 *0!0 4 % !F@ H 2F 4 %( H
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M* #% @H * "@8F* "@ H * $H .E !0 4""@!* "@ H .M "=*!A0(* %(H
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MQ0 4 % !0 E !F@ S0 4 )0 M !0 4 )F@!:!A0(*!B4""@ I %, I % !3
M*0!0 4 )3 7- PI &: $H * "@04#"@ H * "@ IB"D 4 % PH * "@ H *
M"@ H 0T % !0(6@ H&% !0 4 % @H&% "&@!: $Q0 "@!: "@ H *!!0,7%
M"4 % !0 HH * #- !0 4 % !0 M "T % !0 M !0 4 % "T +0 &@!* %H *
M "@ S0 M "T %( I@% !0 M(!:8!0 4 ** %S2 6@ S0 M,!<T@#- #@: '
MT 2 T")4?%,"='S3)),T#%S0 4P"@!: "@!*0"]:8"=*  B@ H !0 4@"@ I
M@%(!,4P"@ I % !0 4 % !0 E, H *0!3 ,4@$I@% !0 8H *0"$4  I@%(
MI@&* $Q0 4 '2@ H #0 F* #% !0 9H 2@04 % PH$)0 4#"@04##&: $H *
M #% !0("*!A0(* $H "* #I0 E P- @H 2@ H * $-  : "@!,4 % !0 $4
M% "4 % !B@!* "@ H * "@ H 3% !0 E !B@!* "@ H 0T % !0 E !0 4 %
M "4 %  10 E !0 A% !0 4 )0 4 % !0 E !0 4 )0 4 % "4 % !0 E !0
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M04##- !F@ H ,T &: %S0 4 )3 6D(*!A0 4 % "B@ H * "@ H ,T % !0
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M "@ H 2@ H ,4 )B@ H *  T )0 4 !H 2@ H ,T &:!AF@0M PS0 E "YH
M3- "T &: $S0 9H ,T % !0 4@#- "9I@&: $I +0 ;J #=3 * #-( S0 4
M% #<T ** #- "YH * #% "4 )F@ H&&: %H 0T )F@ S0(0F@ S0  T#%S0
ME !F@!,T &: #- !F@ S0 E !F@ S0 9H #0 AH ,T &: #- !0 E "T % "
M4 % !0 9H 2@ H 7- "9H * %% !0 4 % !0,2@04 &: $H 6@ I )FF 4 %
M !F@ H *!A0(* "@ H&% !0 4@$S0 9H$+0 4 )0 M "4 +0 4#"@0E,84 +
M2$)B@ Q0,6@0F: "@84 +0(2@ H 6@84"$H !0,6@0E !0,* "@ H * "@ H
M *!!0 4#"@ % @H 6@84 % !0 4 % "YH * "@ - "4 +0 4 +0 4 +F@ H
M* "@ H #0 4 +0 4 % "T +0 E !0 4@%I@+0 E !0 M "@T +0 M !0 4 +
M0 4 &:0"TP%% !2 =0 M "@T +NH 56H E1\4Q%A)<TQ$P.: '9H 6@!: "@
M!,4 &* "@ H * "@ H * #% "8H * "@ H 6@!.M !B@!,4 % !0 =* "@!"
M*8"T@"@!#3 ,4 )B@!: $- !F@ H * $H *  4 % "8H * $H 6@!*  T %
M!0 E !0 4""@ %  :!B4 % !0 4 % "4"#%  10 4 % !0 F* $S0 4 !H *
M $H 6@!* $H * "@!,4 % !0,,4"$H * "@ H 2@ H * "@ H 2@ - "4 %
M"4 % !0 E !0 4 (: #- !0 E !0 4 )B@ H * "@!* "@!#0 4 % "8H *
M"@ H 2@ H * $H * "@!* "@8E "T"#- PH * $H !0 Z@!I- "9H 7- !0
M4 &:0!FF M(!#0 F: %H 2F 4@#% !3 3-( H 7- !F@!#0 4 &: %S0 N:
M&DT (30 9Q0 9H ,T +0 A- "9H&% !0(3% "T#$- "9H * "@!*!"T#"@!*
M #- !0 4 % !F@ H 0T % !0 4 &: #- "4 &: "@ H ,T )F@ H * #% !0
M N: "@ S0 9H 3- !0 4 % !0 9H * "@ H * "@ I &:8Q*!!2 6@ I@&:
M"@84 )2 *8!2$% !0 4 %, I % PIB"@84A!0 M PH 0T % "4 +0 4""@84
M % !0(*!A0 4""@84 % !0 4 % !0 4""@84""@ H *!@*!"T#"@ H * "@
MH * #- "YH * $Q0 M !0 4 % "YH * %H * "@ H * %% !0 4 +F@ H *
M"@ I %,!: "@ H * %S0 H- "YH 6D 4P"D 4 +3 ,T@%S0 M "B@!<T &:8
M!F@!0: 'JU("57IB)TDIB)P<T .H 6@ H * %H * $Q0 4 % !0 4 %  * #
M%,!,4@"@ % !B@ H * "F 8H 2D 4 % !0 &@!*8"T )2 *8"8H * "@ H *
M #% "4 % !2 * $I@)0 4 % !B@ H .E !0(3% PH$% PH$&* "@8E !0 8H
M *!!0 4 )0,,4 % @H 3% "4 % !0 4 % "8H * "@!* %H 3% "4 +0 F*
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M S0 F: "@ H * "@ H * $S0 9H 6@ H * $S0 4 +0 E !0 M !0 4 )F@
MS0 4 )0 N: $H * %H *!A0 4""D M "4 %,84 % !2 *8@I )0 4 +0,*!"
M4 +0 9H 6@!*!A0 4 % !0 4 )0(* "@8M !0 4 % !0 E @H * %H&% !0
M4""@ H * "@!: "@84 % @H *!A0 4"$H 6@!: "@ % !0 "@84 % "T +0
M4 )0 M "4 +F@!: "@ H * %H * "@ H * "@ S0 4 % #A0 N: #- "YH ,
MT@"@ H 7-, S0 HH =FD 9H 6@!,T ** '*: ) : )%:F!-'+BF23H^: 'T
M.I@)2 6@ H *8!2 *8!BD F*  T  H * "@!: $H ,4 % "4 '2F M(!*  B
MF E "XI )0 4P"D 4 )0 4 &*8"4 !H * "@ H 3% !0 4A!3&%(!*8!0 "@
M!* "@!* %H ,4 !% @H *!B4" B@8E "YH 2@ Q0 4"$H *!AB@04 % "8H
M* "@ Q0 E !0 E !0 &@ H * $H * $H * "@!* "@ - !0 E !0 E !0 4
M)0 4 % "4 %  : $H * "@!* "@ H 2@ H * $- !0 4 )0 4 % "&@ H *
M$H * "@!* "@ H * $H * (Z!BT %  * #- "4 +B@ H 3- !0 4 % !F@!*
M "@ H ,T +F@!<T@#- "9H ,T &:8#32 ,T % "T (: $S0 N: %H 2@!I-,
M I +0 9H ,T )F@ H !0 N:  T -)H&&: "@04 &:!BYH$&: $S0,* "@!*
M$H * $S0 9H 7- !0 4 % !F@ H 2@ S0 9H * %H 2@ H * $H ,T )0 4
M+F@ H 2@ H 7- !0 4 % !0 9H 2@ H 6@ H 2@ H *0"TP"@8E(04 +0,*
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M !% !0 4 % !0 8H 2@ H * "@ H 2@ H 2@ H * "@ H 2F &@ H * $Q0
M&@ H .E !0 8H ;2 6@04QB&D 4P"@ I )B@ -, Q0 8H ,4 % @H * $H *
M!B4 % !0 8H 2@0M "8H * "@ ZT#$H$% !0 F* #% !0 4 )0 4 % "&@ H
M 2@ H 3% !0 4 !H 2@ H * $H * "@!* #- "4 % !0 F* "@ H * $H *
M"@!#0 4 % "4 % "4 % !0 4 )B@ H * $H * "@!* "@ H 0B@ H CH&% !
M0 9H ,T ** %H :: $H 6@!* %I (:8!F@ H 3-( I@%( S3 ,T &: %S2 *
M $- "4 ** %H 0T -Q3 44@#- !F@!#0 "@ S0 9H 2@ H =0,0T )F@09H
M2@!:!A0 E !0 4 )F@ S0 9H$&:!AF@ H ,4 )B@ H 6@!.E !0 9H ,T %
M!F@ H 2@ % !F@ S0 E !0 M "4 % !0 4 % !0 4 % "T %( I@% "4 &:
M"@ S0 4 % !2 * "@ H * #- PH$% PH$)3&+0(*0!0 E,!:!A0(*!A0(6D
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MB@ H * "@ H *0!3 ,4 )B@04#"@!* "@ H *!" 4#"@04 % "4#"@ H$(:
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M@ H *  F@!* "@ H 3- !0 M "4 % "4 % "T % "4 % !0 4 % !0 4 )0
MM( H 6F 9H * $- "4 % !0 M !0 4 %( H * "@!*8PH$% "YH 2@8M @I
M% "4P"@84 +B@04@#-, I % "4QBT""@8E !0 4 +0(*0!0 4#%H 2@04 %
M!0 4 % !F@ H *!A0 4""@8M !0 4 % !0 4 % !F@!:!"9H 6@ H * "@ H
M&&*!!0,7% !0 9H * "@ H * %H 2@ H * "@ H 4&@!<T +0 4 +F@!* #-
M !0 "@!: "@ H * %% "XH * "@ % "T % !2 * %S0 N: #- !0 4 &: %!
MH =F@!0:8#P: '!J0$BO3$6HYZ8B=6S0(=0,44P#- "T@ 4 )B@ Q0 8H ,4
M %, I )3 6D E !0 4 )0 M !0 F* $I@&:0!0 4 )B@ H * "@ H 3%, H
M.E !0 4 &* $H ,4 % !B@!* %H * $Q0 &D 4 %, ZT (: "@ H ,4 )0 4
M % A*!A0(* "@88H 2@04 % "8H&% @H #0 E PH$!H 2@ H * $H 3- !0
MM #: "@ H * $H * $H * "@ H 2@ H 0T % !0 4 )0 4 % "4 % !0 E !
M0 E !B@ H ,4 )0 4 % "$4 % !0 E !0 4 )B@ H * $H * "@""@84 % !
M0 4 )F@!<T % "4 +0 E(!<TP"@!#0 F: %!H 7-(!* %H * $H * "@ S0
MW-  * %H ,T )0 M  : $H  U #LT -)H 2@ H&&:!!F@ S0 &@8E !F@!<T
M )0(2@84 .S0 E "4 % !0 E "T &: #- !F@ S0 4 % !0 F: $H * %S0
M4 % "4 % !0 4 % "4 ** "@ I &:8"4 +0 9H *0!0 9I@)0 4 % !0 4 +
M2 * "F 4@"@ H * "@ -,!* "@ H&% "T""@!*!A0 HH$%(!*8!2 *8PH *
M"@!:!"4#"D 4P%I""@ I@&:0!0 4P 4AA0 4""@ -,!*!BBD M !0 E !0 M
M !0(*!A0 4 % !0 4 +0 4 )F@0N:!A0(* "@84 % !F@04 % !0,* %H *
M"@ H * "@ H * %H * %H ,T &: %S0 E !0 M !0 4 +0 4 ** %S0 A- !
M0 M !2 * "@!: "F 4 +FD 4 &: "@!: %S0 H- #@: ' T /!I@2*] B>*;
M% BRDF:8#P: %H 44 % !0 &@ H *8"4@"@!*8!2 6@ H 0B@ Q0 4 &: "@
M!* #% "4  H * "@ Q0 8I@)BD 4 % !BF F* %H * $Q0 4 )0 M "8H ,4
M % !0(*!AB@!* "D 4P$Q0 &@ H ,4 )B@ H$&* #% "4 % PH #S0 E !0
M4" B@!* "@84 (:!!0,2@0&@ H 2@ H * $H #0 AH * "@ H 2@ H * $H
M* $H ,4 % "4 % !0 4 )0 4 !H 2@ H * $H * "@!* "@ H 2@ H * $-
M!0 4 (10 4 % "4 % !0 E !0!7H&*#0 4 % "4 % !0 4 % !2 * %I@% "
M4 &* "@ I  H 6@!II@%( H ,T (: $H 44 +0 E "4 .H 0T )0 9H * "@
M - "4#$H$.!H&% "4 % "4 %  : $H ,T .H 2@ H 2@ H * %H 2@ H * "
M@ H *  T )0 4 % !0 4 % !F@!* %H * $- !0 M "4 % !0 4 % !0 M !
M0 E !0 4 % !0 9H 7- "4 % !0 4 +0,*!!0 E PH$% !0,* "@ H * "@
MH 6@0E(84P"@!:0@H 2@84P"@!<4"$H * "@84 %(04QA0 4 +0(*!A0(*!A
MBD 4""@ H * %H&% !0(#0,2@!: "@ H * "@ S0 4 % @H * %H *!A0(*
M"@ H * "@8M !0 4 +0 E !0 4 +0 E "YH ,T % A:!A0 4 +0 4 % !0 4
M !H 44 +F@!": "@!0: #- !2 6@ % "YH * "@ H * "@!<T  - "@T .%
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M "4 % !0 4 % !0 4 &: #-( H * "@ I@%( H * "F 4@"@ H *8!0 4 %
M!2 * "@ I@% !0,*0!0(* "F,* "D 4P%H *!!0 E PH 6@ H$% "4 % PH
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M#"@ H 3- !F@ S0 9H *0!0 4P%S0 F:0!FF 9H ,T &: #-( S0 4 % !0
M4 )3 *0!0 4 % !0 F: %H * $H * "@ H 0T#$H$+F@89H 2@04#%S0 9H
M,T )0 4 % !0 4 &: $H * "@ H * "@!: "@!* $H 6@ H * "@ H * $H
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MYZ8BRC9H$.Z4 % QU  * $H #0 8H ,4 )0 4 &*8!BD E, H * "@ - "4
M&*  4@%H 2F 4 &*0""F 4 %( Q3 2@ - "T &* &XH * %H 3% !0 4 )0
M4 % !0 4 % "4 )0 M "4 % !0 4 )0 4 )0 8H$)0,* "@!,4 % @H 2@84
M""@!,T !% !0,2@0&@!*  T &* $Q0 4 % "&@8E A: $H * "@ (H 2@ H
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M % !F@ H * "@ H 6@84 % "4""@!*!BT"%H&% !F@09H 2@ H 4"@8M !0
M4 % !0 4 &* $H 6@!<T %  * %H * $H 6@ H #0 E "T % "T )0 4 +0
MM !0 E !0 4 +0 4 % !F@ S0 4 +0 N: #- !0 M !2 * %H 6@ S0 9H ,
MT .S0 H- #@: '9H <&H >KTP+$4^*9);CFW4")0<T +0,* #&: "@!* %ZT
M &* $Q0 4P#% !0 E  : "@ H 2@!:0"4 %, H * "D 4P$- !2 * "@!* "
M@ ZTP#% !B@!* "@ H 3% !0 4 % "8H * "@ H * $H * "@!,4 % !0 E
M"&@0M "4 )B@ H *!B4 % @H #0 E !0 4 (10 E !0 &@!* "@ H 2@ H&%
M A* "@84"$H * #%  : $H * "@!#0 4 &* $H * #% "4 % !B@!* "@ H
M2@ H * $H * "@!* $H * "@ H 0T % !0 E !0!3H&% !0 9H * "@ H 0T
M % !F@ H  *0"T )3 * "@ H ,T@#- !0 9H 2F "D M !3 *0!F@ S0 F:
M$H * "@!<T#$H$% !0,*!"XH&)0(*  T#"@!* "@ H * "@ H * %S0 E "T
M (:  4 % !F@ H #0 E !0 N: $H * "@ H ,T % !0 4 % !0 4@#- !0 4
M % !0 E, H * "@ H ,T % !0 4 % !0 4 %  * "@ H *0!3 * "@ H * %
MI % !0 4 % !0 4 % "4P%I % !0 4 % !0 E !0 M !3 *0!0,* "@04 %
M!0,* "@ H 44""@ H&)3 6@04@"@ H * "@ H 6@8E !0(* %H&)0(* "F M
M(84"%H&% !0 4 +0 E !0 4 &*!"XH&&* "@!: "@!* %% "T % "&@ Q0 4
M % "T )0 4 +0 4 &: "@ H * %H * "@ H 2@!: %% "XH 2@ H 44 +2 *
M %I@%( I@&:0!F@!0: %S0 H-,!P:@!P:@!P- $BM0!+'+B@1;CFS3)+ ;-
M#J!A0(,4QABD @I@% !2 ,4 &* "@!* #% "$4 &* #%, I &*8 : #% "8H
M * "@!:0"8H ,4P$Q0 4 &* $Q0 M !0 F* "@!*0!0 $4P$H * #- "&@ H
M * "@ H 2@ H$&:!B4 % "4 &,T &*!"4 % "4#"@ H$% "4 % !0,2@0E "
MT##% A* $H * $H * "@!* "@ H 3% !0 4#$H$% !0 8H 2@ H #0 4 % "
M&@ H 2@ (H * "@!#0 E !0 &@!* "@!,4 % !0 E !0 4 (: "@ H 2@ H
M* $H IT#"@ H 3- !0 9I +FF 4 &*0"8I@% "T@"@ I@)0 4 &*0!0 4 )0
M 4 &* %H * $H ,T (30 4 )0 4 +0 4 % !0 4#"@ S0(,T !- "4 +0,2@
M H * #- !0 4 % "9H$% PS0 M !0 E !0 4 % !0 4 % !0 4 )0 M !0 4
M % "9H 7- "9H * "@ % "T@"@!,TP"@ H * "@ H * "@ H * "@84""@ H
M * "@8M A* "@ H * "@ Q0 M( H 2F 9H * %I )3&% A:0"4QA0 4""@ S
M0 9H * %I % !3 *0!0 4#"@ H *8@I % PH * %Q0(* "@ - "4QBTA : $
MIC%H 2@!:0@H 6@84 % !0 4 % "4""@!10 4 % "T % !0,* "@ H * %H$
M+0,2@ H 6@ H * $H 6@!: "@ H ,4 % !0 4 % !0 M "4 % "T % !0 4
M% !0 4 % "T +0 E "T@"@ I@% "YI &: #-, H !0 M !F@!:0"@TP' T .
M!H <#2 >K4P)4DQ0(N0SYIDEE6S0 ZF,6@ H * $Q0 4@"@!* "@ Q0 4 )0
M 4 !H -M  :8"4 +B@ Q2 0B@  I@%( H ,9H 2F 4 % !0 F* "@!* "@ Q
M0 E( H !3 3% !0 4 % "4 !H #0 F* "@ H * $- "4 &: "@ H$)0,*!!B
M@8AH #0 &@!*!"4 % !B@ H *!B4"$(H *  T &,4 )0 4 &* $H * $H *
M"@ H 2@!<4 )0 4 % "4 % !0 F* "@!*  T % "4 &* $H * "@!* "@!,4
M % !0 F* "@ H 2@ H * $H * "@"CF@8M "&@ H 2@ H 6@!: #- "4 % "
M4 &: %H * "@ H * "D E !0 4 &: #- "9H * "@!: $H 2@!: "@ S0 4
M)F@ H * $!H 6@ H * "@ H *!B4 % !F@!: $H * "@ H * "@ H * "@ H
M * "@!* "@ H 6@!* "@ H * "@ H * "@ H * "@ H * "@ H 2@!: "@ H
M *!A0 4""@ H * "D 4P"@ H * "@ H 6D 4 )FF 4 % !0 4 % !0 4 +2
M* $IC"@04 % !0 4 % "T %( H&% !0 4 % !0(*8"T )0 4 +2 * "@!:!B
M4""@ H 2@8M !0(6F,*0!3 *0!0 4 % !0(*8"4@%H&% !0 M @Q0 4#"@ H
M * "@!: "@ H * "@!: "@ H * "@ % "T +2 2F 4 % !0 4 % !0 4 +0
M4 % !0 4 % !0 4 ** "@ H * "@ S0 M !0 4 % !2 ,TP%I % !FF H- #
MLT ** ' T .!H <&H E1\4"+<,],1<1\TQ#Z0PI@% !0 4@#% "8H * "F 4
M (10 E "T % !0 8I % "4 '2@!:8"&@ I )0 M,!,4 )0 4@"@!,4 % !BF
M 4 (12 *8"4 % !0 8H 2@ H 3% !0 @H 6@!* "@ H #0 E !0 E  : "@
MH 2@!* "@08H 0B@ H *!A0(2@8E @H 2@ H * $- "T )0 8H 2@!<4 (:
M"@!* #% !0 4 !% "4 % "8H * "@!#0 4 % "4 )0 4 &* $H #0 8H 2@
MH 2@ H * $H *  T )0 4 &* $H * *- PS0 4@"F E "T %( I@)0 9H ,T
M % !2 *8!F@!,T@%S3 6@!,T@"F 8I % !3 2D 4 )0 4 &: "@ H * "@ H
M * "@ H *!AB@ H$)0 4#%S0 4""@84 &* $H * "@ H * "@ H * $H 6@
MH 2@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * $H * %H *
M "@ H * "D 4 %, I %, H * "@ H * "@84""D 4 %,84""@ H * "@ H *
M "D 4P"@ H * "@ H *  4@%H * "@84 % !0(* "@ I@% !0 M( H * "@
MH * "@ H ,4 % Q: $H 6@ H * "@ H * "@04 % PH$+B@84 % !0 "@!:
M$- !0 4 % !0 M "T )0 M !0 4 %  * %% "T@$-, H 6@!* "@ H * "@
MH * "@!: "@!* %H * "@ H 6@ H 2@ H 6@!: "D 4 % !3 ,T +2 *8!2
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M0 4 % !0 4""@ H * "@ H * "@ H * %I )3 *0"T % !0 4 % PH * "@
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M@ H * $Q0 4 % @H&)B@ H #0 E !0 4""@!N*!AB@ H ,4 )0 8H *!"=*
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M?)6:0Q: "@8AH$% PH$% !0,,T % !0!U7P^^&=]X^F,%A'NV[3([$+'&&.
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M/_"J=(_Y\+3_ ,!X?_B*HD^(/CYX$/@S5YX0 (I6,T(4*BB.1B0H52=H5@R
M<9"Y"@$5)1YYB@9]L_LZ?#[3M6T*UGN;.WEE;S]SO#$[G$\H&6923@  >P I
MDL])_P"%4Z1_SX6G_@/#_P#$4Q!_PJG2/^?"T_\  >'_ .(H /\ A5.D?\^%
MI_X#P_\ Q% '-_$OX::79Z7>RQ65JCI97+*RP1*RL(F(8$+D$'D$<@TAGR3^
MSII4.K:[:P7,:2Q-Y^Y'570X@E(RK @X(!'N :13/MK_ (53I'_/A:?^ \/_
M ,15$!_PJG2/^?"T_P# >'_XB@ _X53I'_/A:?\ @/#_ /$4 <MXH_9FT/7]
M[?9_(D?;\\#&/;C'W4YA&0,'Y.<D_>.ZD.Y\;?%+X:S_  [O6LK@AQM#QR+T
M>,DA6QDE3E2"IZ$'!9<,44<A2 6@ H 2F,W_  -X'NO&UTEE9)ND;DD\(BC&
MYW.#A1GD\DDA5!8@$$??&E?!K2-.AC@^Q6\GEQHF^2"%I&V@#<S;!ECC+'N<
MFJ)/@SXEVB6>J7L42A$2]N555 5542L H X  X ' %24<W2&>S_ ?]G>3X@Y
MN[PO#8C<%9<"25AD83<& 53]YR""1L4$[BC$V?5>B_ [1-'0QQ6,# L6S*@G
M;. .&FWL!QT!QG)QDG-$W*GB?]G_ $3Q"FQ[2.(A7"O ! RE@!N_=[58C *[
MPP![8)!07/D'XX?!N3X9W2H&\RVFWF!R1OPN-R.!CYEW#) VL"",'<JHI'FU
M Q:0!0!]#?LZ?LZ1^+8QJ>IC=:MO$408J9""49V*$,JJP( !#,PR<( )'8EL
M^K]#\*6>@;OL=O#!OQN\J-(]V,XSL SC)QGID^M427[NT2\1HI5#HZE65@&5
ME(P5(/!!'!!X(H \8^)W[+&G>)D>6P46EUM.W9\MNS84 /& 0HPN,QA2"Q=@
MYX*L.Y\3W=H]F[12J4=&*LK JRL#@J0>00>"#R#4ED5 @H&+0 4 % "T % !
M0 4 % !0 4 &* "@!: "@ H * "@ H * %H * "@ H * %H * "@ I % !0
M4P%%( I@)0 4 +0 4 % !0 4 )0 M !0 M "4 &* "@!<4@$Q3 * "@!: "@
M I +0 M !0 4 % !0 E, H ,T +F@!<T % "AJ 'J: 'AJ 'AJ )8Y=M B]!
M<@TR2TKYH =0,* #%, H ,4 %( I@&* "@!!0 4 +0 4 )B@ - "4 !H 2@
MH 2D &@ Q3 2@ I %,!"* "@ I % "&@ I@% "4 % "4@"F 4 )0 4 %  10
M E !0 4 (: "@ - "4 % "4 +0 E @H * $(H&% !0 E !0(04# B@0E !0
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ME5'RJ3R?UH [35?V=-=TF&2YGM=L44;N[>=;G"J"S' E). #P 3Z"@+GF](
MH * "@#[)_8U\(G3=.FOW!!NI0%Y4J8X=RA@!R#YC2 Y/(4$ #EJ1+/<H=:2
M:YDM #OCBAE8\;=LK2JH'.<YA;/ &",$\X8CY]_;1\&_:[6WU.-?FAD,4A"9
M.R3E&9QT577: >-TO!!.&3&CY%I%&_I?Q!U'28Q!;7EQ%$N=J)-*B#)).%5@
M!DDD^Y)H M?\+6U?_G_N_P#P(F_^+H _2*J(/@+XE_$O5+/5+V**]ND1+VY5
M56>5551*P"@!\  < #@"I+.6N_B7JEXC12WMTZ.I5E:>5E92,%2"^""."#P1
M0!UW[,'_ ",-G_V\?^D\M"$S[4^)=V]GI=[+$Q1TLKEE92596$3$,".00>01
MR#5$GP%_PM;5_P#G_N__  (F_P#BZDL/^%K:O_S_ -W_ .!$W_Q= 'UK^S#\
M7KOQ_!<17^'EMVC_ 'H 4NLGF$ JH"@KL(R, @C(R"S,EF+^VII<<FG6UR1^
M]2[V*V3PLD;LXQG!R8TY(R,<$9.1@CX[I%"TAB4 >I_ ;X)_\+/FE\R;RH+?
MRC)@;I&WEL*N?E7Y4;YCG:=OR,"<,39]D^"?A[IWPUMG6U41)M#32NWS-L7E
MW=N  ,M@;44EB%7)JB#KJ /S?^*W_(7O_P#K_NO_ $<]26<K2&?HY\+Y+&UL
MHK'3[B"X%M%&CM"T9&[!R[*C-M+L&8Y)).XY)R:LS/E7X^_'+4+[5)K:SN)K
M>"VD>%5C=H69E.V1V*-\V74[,G 0#Y58OF2DCT/]D[XOWOB*672[UC,$B::.
M9V+2@!T5HV)R7&7RI)RN"O*E0C0,[G]JK2X[S09Y)!EH9('C.2,,95C)X//R
M2,,'(YSC(! Q(^$JDH,4#"@#]/\ 2M+CTF&.V@&V**-$1<DX50%49)). !R2
M3ZFK,SX3_:&\<:AK>J7-K>.ZPP3LL4'S)&%4L(Y-A/+,C;MYR2&^4A-H$EHX
M'PUXINO#$PN;*5X91CYD.,@$-M8=&4E1E6!4XY!I ?=G@+XZ:=K]C!<W-U;P
M3O&/-B>6*-E<$J^%:0L%+ E,G)0J3R:HFQ\M_M1S6=YK!N;&=)UF@B>1DD21
M ZYBV@IT^2-2023DD]" $QHX'P7X$O/&LS6VGQ^;*L9<KN1,*"JDY=E'5AQG
M//3K0,W_ !/\"-8\+6[WEY;>7!'MW-YL+8W,$'"2,Q^9@.!^E '!4@.I\#_#
M#4/'/F?V=#YOE;-_SQIC?NV_ZQUSG:>F<8Y[4P+?C/X.ZIX*A6YU"#RHFD"!
MO,B?+$,P&$=CT4\XQQUZ4@,OP9X$O/&LS6VGQ^;*L9<KN1,*"JDY=E'5AQG/
M/3K0!O>)_@3K'A>W>\O+;RX(]NYO-A;&Y@@X21F/S,!P/TIA<T/ /[.NK>-$
M\Z*,0PE<K).6C5\A2-H"L[ ALA@NP@'YLC%%@N7_ !A^RYK/AN,3+&ERO\0M
MRTCKRH'R,B.V<_P!L $M@#-%@N>;^&_"UUXGF%M91/-*<?*@S@$A=S'HJ@L,
MLQ"C/)%(#V*T_8WUB=%=I+5"5!*-)(64D9*G;$RY'0[21GH2.:=A7/,OB!\,
M[[P#,(+^/;NW&-P0T<@4X)5A^!VG#@%2RC(I#.6H&>I?\,Q>(/\ GS_\C6W_
M ,=IV%<Y?1?A?J6MW4EC;6[R3PR,DH&W8C+N!#29\M>48 EL,1A232 ],N_V
M.-8@1G62U<A20BR2!F(&0HW1*N3T&X@9ZD#FG85SQ[Q)X6NO#,QMKV)X91GY
M7&,@$KN4]&7*G#*2IQP32*/2/"'[+FL^)(S,8TME_A%P6C=N6!^14=UQC^,+
MD$%<@YIV%<B\=?LSZMX/@-TZQSQ(K-(869BBC'S,KJC$<Y)4,% );:!FBP7/
M**0R6TM'O'6*)2[NP554%F9B<!0!R23P .2: /7/#/[*>M:VGF.D=L"J,HG<
MAF# G[L:R,I'&X.%()QC(.'85S5N_P!CG6($9UDM7(4D(LD@9B!D*-T2KD]!
MN(&>I YHL%SR[QK\.;_P0Z1ZC"8C(I9#E75@#@X9&9<CC(SD @D8(RAG-T >
MCZ5^SMKFK0QW,%KNBEC1T;SH!E6 93@R@C((X(!]:+"N5M&^!NK:K?2:8D&)
MX?+,Q+IY<8<*5+.I93\K;MJ[G(#84E2 6"YU&M_LEZWIVWRDAN-V<^5*%VXQ
MC/G"+KGC;GH<XXR[!<P=5_9WUS289+B>UVQ11N[MYT!PJ@LQP)23@ \ $^E*
MP7/.*!FIX8\,7'BBX2SLT\R:3=M7<JYVJ7/+E5'RJ3R?UH Z[7O@#K/A^![J
MZMQ'#&NYW:>WP!T[2Y))P !DL2  20*+"N>>TABBF AH *  4@%H #3 *0!0
M 4 )3 6@ H * "D HI@&* "D 4P#% !B@ Q0 4 %(!:8!F@!:0!0 4 (:8!2
M 2@!:  4 +0 4  I@/!H 4&@!P- #P:0$B28IB+L%S3$7$DS0(E% Q!0 HH
M* "@ I@%( Q3  * #%(!*8!2 *8"&D E, H * $Q0 4@$H *8!2 2F 4@ TP
M"@!* "@ H 2@ H * $H #0 E !0 4 &* $H * "@!,4 % !0 4 )0 8H *0"
M4P"@ Q0 A% !0(*!A0 E !0 E !0(2@ Q0 8H * "@!* "@84 )0(*!A0(3%
M !0 4 )0 4 )0,3% @S0 4 )0 4 )0 4 % !0 F* "@!* $H * "@!,T %
M: $H * $H * "@!* "@!* "@ H SZ!AF@!* "@ H * "D 4 % !3 2@ H *
M"@ H *0'ZDU1)YO\+/BJOBBYOM.F.+FSN[A1DH-\7G2*A51@_( $;@_P,6+.
M0 #AOVMOA:-<M/[7@4FXME"R %CN@RQ/R@'E&;=GY0$WEB<+A#1YE^Q?_P A
M>;_KPD_]'04 SWS]I_\ Y%Z\_P"W?_THBIB/@RUM7O'6*)2[NP554%F9B<!0
M!R23P .2:11^AGP@^%D'P[LEMXU'GNJM<2 [B\F.<$A3L4DA!@8')&YF)9)Y
MQXZ_;"LM"G-O8PF[",RO)Y@BB)&/N$+(7&<@G"CC*EE(-(=CO?A+\;K+XE(P
M@S%<1JIDA<C< 0,LA'WT#';NP"#C<J[ERQ'B?[7/PBCT_;K5G'M#R;;H+G;N
M;[DV N%R<J[$@%RG!9F)0T;_ .S!\:+/[/9^']DWVG_2/GVIY/WI9^N_=]WC
M[OWN.G- ,^@?$&M)H5M-=R@E(8I)6"X+%44L0,D#.!QD@9[BF(^7_C'^TYIW
MC72Y]/MHKA99?*VETB"#;*CG)65CT4XX/./K2&6OV'_^8C_VZ?\ M>@&?0WC
M3[#:PK>:EL$5I()U9\E4=0R*P ^\WSD(,$[RNT;PM,1X'JG[;L,<A%M8N\7&
MUGF6)SP,Y58Y .<@?,<C!XS@*X['OG@;QS:^-K5+VR?=&W!!X=&&-R.,G##/
M(Y!!#*2I!+$?)?[7?@!/#^HI?0X"7BLS*,#$J;1(V H #!E;.69G+DXR*12(
M?V6OA%'XRNGO+V/?:VV,*V=DDIY53\I5U51N=<CDQA@R,00#ZK^)7Q3LOAW
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M#_D7K/\ [>/_ $HEIDLT/BGXVT[X;!M6N$#7DD0@B4'][(JL7" G.Q S[I&
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M1@<A2"0."V"/CJH*%% "4P%Q2 *!A0 4"#% !0,*!!0 4P#- !2 * '4 +0
M8H 2@ H #0 E !3 *0"T %, I &*8 : "@ I % !B@!: "@ H * %H 7- "@
MT /!I@.!I 2*V* +,$^VF38T(I=U,1,#0 4QABD M, Q2 0BF 4@"F 4@"F
ME !0 E  : $H * "@!* "@!"* "@ H 2@ H #0 4 (10 4 % !0 F,4 %( H
M *8"8Q0 8H 2@ H *0!0 F*8"$4 % !0 $4 )0 4@#%,0E PH * #% "4 +0
M F* $H * #% "4""@ H 2@!30 E PH 2@ - @H 0T !H 0T % "4 % "4 +0
M E "4 % "&@ H * $H * "@!#0 4 )0 4 )0 $4 )0 4 (: "@ H 2@ H *
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M<8RHC;#9)PY QSE,$?-5(H^I?V'O^8C_ -NG_M>FB6=3^VA_R"(?^O\ C_\
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M$$CFI+/N3]F_Q</$NB6QR-\"_9W"A@ 8@ @^;J3%L8D$C).,?=#)9\L_M/\
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MX R,"-2>"3D'<[BL>S^&/VK=$UQ_+=Y+8ED53.@"L6)'WHVD50.-Q<J #G.
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MF,* %Q2 * $Q3 *0"&F 4 )0 9H 2D 4P T -H 6D E, (H 2@ ZT % !BD
MAI@% !B@ H 2@ H *0"$4P"@ H * $H ,4 )2 *8!2 *8"8H *0!3 2@!: $
MH * "@!* "@!*  B@!* "@ Q0 4 &*!"$4 % PH * $H$&* $H * $H&% "&
M@04 % "4 % !0 E !0 E "4 % !B@ Q0 E !B@!* "@ - "4 % "8H 2@ H
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M'ITIE,:AG/E6B*H)P,L\:KD\X&<D D# . "'Q[XX\8:9#/;ZGYRP&,I,WV>
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MP3;3VMA:QW>3<+;0K*6;>WF"-0^6R=QW9R<G)YR:H@^&_P!I:[2Z\07C1L&
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M &*8PH 6D 8H 2@!*8!0 F*0!FF E "4 *10 E !0 E !0 8H 3&* #K0 4
M% !0 8H 2@  H ,4 )0 4 % !0 E !2 3%,!* %H .M "4 % !2 0TP"@ H
M* $H * "@ (H 3% !0 A% @Q0,*  T )0 4 (: "@ H ,4"$H * $Q0 4 &*
M $Q0 F* %H 2@!* "@ H 2@ H * $H * $Q0 4 )0 8H 2@ H 0T % !0 F*
M $H * $H * #% "4 % !0 E !0 E !0 4 9E PH * "@ - !2 * "@!*8!0
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M(PS,L:*,*@)_$M@ %RS!1G%26?9_[,'_ "+UG_V\?^E$M-$L\"_;0_Y"\/\
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MQC_]'3TF-'EOPJ_Y"]A_U_6O_HY*11^CU69GY<5!H?J/5F9^<7Q5_P"0O?\
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M0 A% "4 ** '4""@!,T +0 AH * #% PH$+0,6@ (H 0T % "B@0&@!* #-
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M "4 % !0 E !0!F4#$H 44 &: "@!*0!0 4 %,!*0!0 4 % !0 4 +0!U/\
MPM;5_P#G_N__  (F_P#BZ8'-W=V]X[2RL7=V+,S$LS,3DL2>22>23R32 BH
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M,VO^%KZO_P _]W_X$3?_ != CEJ!G26GQ+U2S18HKVZ1$4*JK/*JJH& H ?
M '  X H Q=4U:;5I#/<R/+*V-SNS.YP !EF))P  /8 4 5: "@#?\->/]0\,
M8%E<S0J) ^Q'81EACEDSL;.T A@00,$$<4 =I_PT_P"(?^?S_P @VW_QJ@5C
MSS6O$%SKKB6[FDF<*%#2.TC!020N6).,DG'3)/K0,H4@-[2_B#J.DQB"VO+B
M*)<[42:5$&22<*K #)))]SF@"AK7B&YUUQ+=S23.%"AI7:1@H)(4%B3C))QT
MR3ZTP*EI=O9NLL3%'1@RLI*LK Y# CD$'D$<@T#.E_X6MJ__ #_W?_@1-_\
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MXFF-Q>RO-*<_,YS@$EMJCHJY8X50%&> *!E^T^)6J6:+%%>W2(BA559Y555
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M8N)(&H ?FF M Q#0  T )F@ I )3 * "@ - "$4 )0 M !0 F* "D @I@+0
ME !2 *8!0 F* "@ Q0 E !0 E !0 8H * "@ H 3% !0 8H "* $H * #% "
M4 % !0 A% !0 4 % "4 % !B@0E !0,,4"$H *!A0(2@ H #0,2@04#$H$)0
M,#0(* $H * #% "4 % !C- #:  T !H 2@ H 0T )0 4 )0 4 % "4 )0 &@
M H 2@ - "4 %  : $H * "@!* "@!* ,R@8E( I@&: $S0 4 +0 E !0 M "
M4@"@ H 6@ H * "@ H * $H * %H 2@!* "@!: %H * $H * $H * "@84 +
M0 E !0(* "@ H * "@ H * "@ H *!A0(* "@8M !0 E !0 4 +0 4 )0 4
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M0 4 % "T % !0 9H ,T *#0 [=0(4-0!(CXH M076*8K&C%/OIDEC- !3&%
M"4@#%, S0 8S0 E !0 4 &* $H * "D F*8!0 4 %  10 &@!* % H 2@!*
M%H 3% !B@!,4 % !B@!* "@ H ,4 % "4 % ""@!2* $H * $H *  B@ (H
M2@ (H$% PH 3% !0(2@88H * "@0AH&% A*!@10(2@ H 0B@88H$% "4 )0
M4##% "8H$% "&@!* "@!"* $H * $- !0 &@!* "@!#0 4 % "4 % "4 !H
M* $H 2@ H * "@ H 3% &50,,T )0 4 %( H *8!2 * %I@)2 * %H *8"4@
M%H * $H 6@!#0 E "T )0 4 +0 E !0 N: "@!* "@ H * "@ H * "@ H *
M "@ H&% !0(*!A0(* "@ H #0 "@ H&% !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % @H&% !0 4""@84 % !0 4 % "T % !0 4 % "T@$H *8PH *0!3
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M !0 O6D F*8 * #% "&@ H * "@!"* $H * #% !0 4 % "8H * "@ Q0 E
M!0 8H 0T % !0 E !0(*!B4 %  : $Q0 4 )0(* #% !0 A% PH * $Q0(2@
M!: $H 2@ H 0T#$H * "@!*!!0 AH 2@ - "4 % !0 E "4 !% "4 % "&@
MH * $Q0 4 )0 4 )0 &@ H * $(H * "@#(S0,* "D 4P"D 4P"@ H *0!0
M4P"D M "4 % !0 4 % !0 4P$I % !0 M, H * $I % !0 4 % !0 4 % !0
M 4 % !0 4 % !0,* "@ H$% !0 4 % !0 4 &: "@ H&% !0 4 % !0 4 %
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M*  4 ** "@ H * "@ H 7% !B@ Q0  4 % !0 E !B@ H 2@ % "@4 ** '
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M * "@ H * "@ H 2@!: "@ H * "@!: $H * %H 3- !0 4 % !0(*!A0 M
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M6@0F*8 !0 [%( (I@-(H ,4 % #J $-(!*8"B@ (H 3% !0 HH 7% !0 AH
M2@ H 44 +2 * "F 4 )0 E "XH ,4 )B@ H 44 :T'A&\G4.EO,RL 01$Y!!
MY!!"\BN=UX+1RC]Z-U1D];/[F2?\(7??\^T__?J3_P")I>WA_-'_ ,"7^8>P
MG_++[F'_  A=]_S[3_\ ?J3_ .)H]O#^:/WK_,/83_EE]S%_X0R^_P"?:?\
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M*/K$/YH_^!+_ ##V$_Y9?<P_X16[_P">$O\ W[?_  H^L0_FC_X$O\P]A/\
MEE]S ^%;O_GA+_W[?_"CZQ#^:/\ X$O\P]A/^67W,3_A%;O_ )X2_P#?M_\
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M\_Y]YO\ OV_^%'UB'\T?_ E_F'L)_P LON8G_")WG_/O-_W[?_"CZQ#^:/\
MX$O\P]A/^67W,/\ A$[S_GWF_P"_;_X4?6(?S1_\"7^8>PG_ "R^YA_PB=Y_
MS[S?]^W_ ,*/K$/YH_\ @2_S#V$_Y9?<P_X1.\_Y]YO^_;_X4?6(?S1_\"7^
M8>PG_++[F)_PB5Y_S[S?]^W_ ,*/K$/YH_\ @2_S#V$_Y9?<P_X1.\_Y]YO^
M_;_X4?6(?S1_\"7^8>PG_++[F'_")WG_ #[S?]^W_P */K$/YH_^!+_,/83_
M )9?<Q/^$2O/^?>;_OV_^%'UB'\T?_ E_F'L)_RR^YA_PB=Y_P ^\W_?M_\
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M % !0 E "T % "T )0 4 % !0 M !0 4 % !0 4@"F 8H * "@ H * "@ H
M* "@ H * "@ H *0"T % "8I@% Q:0@H * "@84 % "T )0(*!BT""@84 %
M!3 *0A*8PH 44@#% !B@  H 7% !0 4 % !0 4 &* %H * $H 44 .- #: "
M@ H * % H&.VT )BD E,08H !0 M !B@ H 510 I6D,,4 +B@!"* $Q0 H%
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0!D>,?^/*Y_P"O>;_T!JZ</_$C_BC^:.>O_#E_A?Y'
MRS7WQ\.% !0 E !0 8H QZ!A0 4@"@ I@% !0 4@"@!* %% !0 4 )0 4 %
M"T % !0 E !0 M,!*0!0 4 % !0 4 % !0 4 )0 4 +0 4 % !0 4 % "4P"
MD M Q*!!0 4 % !0 4 % !0 4 % !0 M Q* "@!: $- @H&+2 *8!0 E @H&
M+0 4 % !0 4 % !0 4 +0 E !0 4 % "T % !0 4 &* %I % "4P#% !0 4
M%( I@% !0 4 % !0 4 % !0 4 +2 * "@ I@)0,6D(* %H * $H *8PH 6D(
M* #- PH$% !0 M Q*!!0 Z@84 )0 4 +0 E "@4 +B@ Q0 [;0 TB@!* "@
MH 4"@!30 W% "T &*  "@!X% PH *0!C- ";: %VT &* '!: ';: % I#'[:
M &LM $9XH$*%S3 7;2&*%H >(LT +Y-  +<T .%L30 OV,T /2R)H&2?8#2
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!D>,?^/*Y_Z]
MYO\ T!JZ</\ Q(_XH_FCGK_PY?X7^1\M5]\?#B4 %  : $H * ,>@8M(!*8!
M2 * #-, I %, I % "4P%I )3 *0!0 4 % "T )0 4 % !0 4 % !0!^F7C/
MPC!XPM);"Z!,4J@-M.U@00RL#ZA@",@@D8((R#1)^<_C/PC/X/NY;"Z $L3
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M!0!U7PH_Y"]A_P!?]K_Z.2@#U/\ ;1_Y"\/_ %X1_P#HZ>FP1X%2&% "T %
M * "@ H 6@ H * "@ H * "@ H ZGX7^.?\ A!=0AU'R_-\KS/DW;,[XWC^]
MM;&-V>ASC'O0 ?%#QS_PG6H3:CY?E>;Y?R;M^-D:1_>VKG.W/08SCWH Y:@
M% "T@$I@ H 6D 4P$H * %H 2@ H * "@ H * %I % !0 4 % !0,* %H$%
MQ*8!2$% Q:!!0 E,!:!GO?[&'_(7F_Z\)/\ T=!0B6>7?%;_ )"]_P#]?]U_
MZ.>@9RU(88H 4"@ H * #% "XH 7% "8H 6@ H * #- !UH ,4 &VD 8I@;?
M@G1$UR^MK24D)-<PQL5P&"O(JDC((S@\9!&>QH ]!_:4\#6O@J]MK*R3;&MC
M&23R[L99MSN<#+''L  %4!0 &Q(\DVTB@(H ;0(510!(12&-(I@ %(!PH <%
MI .\K- QWV<T .%N: 'K:DT /%D32 D6P- R0:?F@!1I>: )ETP>E $BZ6/2
M@#Z0_8\MA!]OQW^R_P#M:KB1(^=!8@=J@LD%D/2@!WV,>E "BT'I3$.^RB@8
MBVX% A_E"@!3$* %50* '!10(7;3 0)2 1DH&(JT / IB$- Q<4"&E:0P6F(
M?0!V/PK^(G_"!73W7E>=NA:/;O\ +QED;.=K?W<8QWZTT)G/^(M7_MFYFNMN
MWSII)-N<XWL6QG SC.,X&?2D!FFD,7.*8"'FD @.*!@.:8@84 *HH 4T )B@
M H ^A2,^"O\ /_/[5=">IY[\(OBQ_P *]\_]QYWG>5_RT\O;LW_[#YSO]L8]
MZ2T&]3STH*D8W8*!B^6* N-, -%@&?9A2 /LHI@1M;"D,:;,4 +]C H 1K4>
ME %>2RSVH 8=/H B.G9H :VFT@('L2*8#?LQ% B)XB*8$94T .2@0KB@9&5H
M ;0 8H$+MH  *!BB@ - A,T %, S0!]7>"_^/&V_Z]H?_1:U\)7_ (DO\3_-
MGVM#X(_X5^1LUS&X4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!D>,?\ CRN?^O>;
M_P! :NG#_P 2/^*/YHYZ_P##E_A?Y'RU7WQ\.% "4 % "&@ H R*!AFD E,
MH * $I %,!: "@ H 2D 4 %,"UI>ERZK*L$"EY'.%4=3_0 #DD\ 9)( K.<U
M!.3T2+C%S=EJV=MJ/P.U&RA$VU'.,F-&S(O!)X( )&,84L2?N@]:\Z.84Y.V
MJ\VM/Z]3T)8&<5?1^2>O]>AP%>H>8)0 4 % !0 4 % !0 4 % 'W]\>?'[^
MX;.^7)1=1C691GYHFAG#KC<H8@?,H8[=ZJ3TJB3AOVF?AO'X[T^/7K#YY(H%
M<DL4#VNUI<A7 ^9=V\#Y25+@AFV*$,^8_A1_R%[#_K_M?_1R4#/??VX_^8=_
MV]_^T*!(X;X"? 1/&"-J>IL8=/A;/.$695#&3]X6!1%( 9@,$;E5E925!G?7
M/QE\&Z0?L\.G"9$5561;2!@P"CO.RRL1T)<9)!.3G)!%7XB?!#2O&MA+K/AC
M+.K$F"('8Y#$RJ(WVO&X#!E08!555(_G4T 9_P"R-_8WFI]H_P"0OY\WV?\
MU_\ J_(&?N_N>GF?>^;_ ,=H!FK^U!_PCW^F?]!O_1_^?G_IE_VP_P!1_G=0
M!U_PD\$IXX\(6^GRN8TE9]S* 6VI>M(0,\ D+@$Y )SAL8(!R'_"?>#/ O\
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M=^-BM(F0* /E37] G\/SO:7:&.:-MKHW4'KVX((P01D,"""00:11GT =_P#
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MF=J((F498*6C'[MUR06*'=C:I=<@4;AL?/.H>';C3[@V<L;"X#A/+QEBQQM
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M'))!<]P6XIA8P?B]\++&"PCUC1O^/?Y0X#%E*L2HDS(Q<,'(1DY.3R%*ME-
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M*NGAP"0&6UM]K '[PW,K8/49 /J >*=PL5?B'\,M+\1Z=)JVA8!B+NX0L$8
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M "8H$)3 ^L/!?_'C;?\ 7M#_ .BUKX2O_$E_B?YL^UH?!'_"OR-FN8W"@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * ,CQC_QY7/\ U[S?^@-73A_XD?\ %'\T<]?^
M'+_"_P CY:K[X^' T )0 4 &: $H Q\TAA0 4 % "4P"@ H 6D 4 % !0 E
M!0!Z!\#M1ALM143 9>-DC)QA7.".21@D J,<DL%[FO*S"+E2TZ--^G]:GIX&
M2C4UZII>O]:'TI/.MNI=R%50223@ #DDD\  =37QZ5W9'U;=M3XYURZCNYY9
M(5VQM*[(N NU2Q*C X&!Q@<#M7Z#33C%)ZM)7?G8^%FTY-K1-NQ1K0S"@ H
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M=[K322#+0VDKQG)&&+1Q$\'GY)&&#D<YQD @&SA?CEK3ZSK=]+( "MR\0VY
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MLMKM[7X?[HV*DJRDJ2#M:_*LO'8J2I'0@D'@TR3Y4I%'U+\>O^11TG_MP_\
M2.2F(U?V0-#\W2+V6W;RKF6=XA-C?MV0H8FV,=IVM*S8XW9PQQC A,RO^&'?
M^HC_ .2W_P!OHL.YT'@']DZ3P;?0:A#J&6AD!*_9@-RD%73)F;&Y"5S@E<Y'
M(%%A7/+/VQ-+CL]:62,8::TB>0Y)W,&DB!Y/'R1J,# XSC))*8T>&XH&>I_L
MP?\ (PV?_;Q_Z3RT(3-#X_ZT^A>*IKN( O#+9RJ&R5+)#"P!P0<9'."#CN*
M/?-2TKP]^T(D<BRD7$2Y(0K%=*N 61U=6W(&<?, RA\A'Y;<Q;'G>O?LB:AX
M>D^U:'>9=?-*@EK>=1C"HLB$JS,I*DGRE^@8[2P[GSIK^@S^'YWM+M#'-&VU
MT;J#U[<$$8((R&!!!((-(9GT :&@7=S:SHUDTBW!;;&8BPEW-\NU=GS9.=N!
MR<X[T >[ZI^SIXF^($AO=4DA6?A )I!G:H&-HMTDC5<D\#!W;F(R<EBN;_\
MPQQ9Z+_I&HZEMME^^?+2WZ_*O[R2615^8CJIST&"006"X?MP_P#,._[>_P#V
MA0P1\M4AGOG[&'_(7F_Z\)/_ $=!30F>;?&C4Y-3UJ^DF.YA=S(#@#Y8V,2#
M@#HB@9ZG&22<FD!0^'EWJ,%[$NCM(MV[!4$9P6Y#;6S\I3Y0SA_DP,O\H- S
MV+_AEC7O%\WVW4YX4EFDS-O<R3*,[<A8U,9PH^1%<*%VKE,8!85SM/"G[*EG
MX,O+>\O=0W;9XO)78EOOF#AXTR\DF_.TC8H#-V88Y8KG _MH?\A>'_KPC_\
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M%C 4 #+XD9\  9P[+QU*]J=@N:O[0UG%8Z':16[;XDFMUC?(;<@@D"ME< Y
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M7PM?^)+_ !/\V?:4/@C_ (5^1LUS&X4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!
MD>,?^/*Y_P"O>;_T!JZ</_$C_BC^:.>O_#E_A?Y'RT:^^/AP- !0 E !0 "@
M#&H&)2 6F 4@$I@%( H 6@ H 2@!:8"4@"@ H O76N7%W&L,DLC1KC:C.S(N
M!@8!.!@<#'0<5FJ<8NZ23>[LKFCFVK-NRZ7*-:&84 % !0 4 % !0 4 % !0
M!]H?MH_\@B'_ *_X_P#T3/3$CXTM+M[-UEB8HZ,&5E)5E8'(8$<@@\@CD&D,
M^[_A9XJMOB_IEN]RP:ZMIK=Y0-OF)-"X9).4 42!"?E&-K/&K9#8H1YC^W'_
M ,P[_M[_ /:%($6M-L/^%S^$XK.V=#?67E@1!M@S$'CC5MX/WX"2&R$,G\2A
M7  /EG5-*FTF1H+F-XI5QN1U9'&0",JP!&001[$&D,]M^$O[,A\364FI:I*;
M2 PLT!^4' &?/??P(0.0,J7'S!D7:SL1@?LU*B^)+41$L@:YVLRA&*_9YL$J
M&8*2.H#, >,GK0,/VIK1X/$%TSJ5#K R$@@,OD1KN&>HW*RY'&01U!H ]._Y
MI[_G_H(T"/EBD,^I_P!AS_F(_P#;I_[7IB9RO['OCF/0M0ELIW1$NXT"%L@F
M5&/EH#G:-RN_!^\P55.2 P#.!^+WPANOA[=2(\;FT,A\B?[R,K;BBLX55$FU
M3N7 .02 4()!E3X4_"JZ^(]T+:V&V-<&:8C*1J>YZ98X.Q,@L0>0H9E -7X\
M_#>S^'U\+.SG>;,:NRN$+1Y VJS(1EC@M@HFU&3[V<T >O?MQ_\ ,._[>_\
MVA0)'RR*0SZK^.EH\_@_2V12P1;!G(!(5?LKKN..@W,JY/&2!U(IB/+/V7_%
MP\.:W"'("7*M;L2&)!<@Q@;>A,JHN2" "<X^\ 9J?M.?">YT'49]1BA)LIV$
MOF)N=4=MHD$A.=A:5B5S\I# (<@JH!YMX$^'=[XYG%O8Q%SN4.^"(HP<G<[
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MO@_X/DMIPBW=UO1UR\BF2?*L,@X#+;J>0=F]."^?F9)E? 7_ )%'5O\ M_\
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MW/A<Y &<DX!H Q?CE\")_A].TENDDE@54K,?G*GY5992J*$.\_+D ," "6#
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M<R'E]RL I(PJY"\EF;$CR?PSX0O?'%QLMU:1V?,DK;BJELDO(_.,X)YR6((
M9N*DH]U_:%TC^QM#M+7=N\F:WCW8QG9!(N<9.,XSC)QZU3(1G?LDC_C]_P"W
M;_VM0AR/G@<U)0_I0!]"_!X_\4UJ/_;Y_P"DR52)>Y\\U)1[U^SEK$.IV]WH
MEPX3SPQ0#B1@\92;!.5RJJI QG[QP0#BD2SR+QAX(NO"4Q@NXRO)"O@^6X&#
MN1L ,,$9[C.& .14E'0?"7X2S>/)LG*6L9_>R]R>OEIG@N1U/(0')SE582$W
M8NQBW^&FOIY$OFQ03!9'9<[5<%9%_=L2S(C$$X4^8"-G&"]@W1U/[2'PRN/M
M3:I;HTD4B+YNWYC&R)C<0!D1[%!W'(#!MQ7*@C0DSQOP_P"';C7Y1!:1M+(<
M<*,X&0NXGHJY(RQP!GDBD4>X^)]!T[X27FG31,?M 91.22T?E;3'-.4W-(KM
MO)0*2GRL I(YK8G<S?VB/AW-<W']L68,UO-&C2,A\P*53A_E'$1C4'=DC.[)
M *@I@F>/Z+HTNM3);VZ&25SA5'4G^0 '))P  22 ":11Z5\4/@U!X%LH9I+@
MM=.=K1@*48]25R5=40<%B'W,5X3=PVA)W#P/\$U\7:7+>VTI>Z!*K#@1HK*V
M65F8'<6C*E2-JJQPQZX+"N>?1:E?>$W>)'GM9#MWH&DA;IE=P!4]&R,]CQUI
M%'T?'KEY>>&[N77DVR;)E3?'M9L@+"S(!\K>:<*=JX 5_P#;-=".IYAX&^":
M^+M+DO;:4O= E5AP(T5E;+(S,#N+1E2I&U58X8]<)(ILX"'4[[PH[Q(\]K(=
MN] TD+=,KN *GHV1GL>.M(9]'IK=W=^&[N77DVR;)E3?&%9L@+"S(!\K>:<*
M=JX 5_\ ;-$=3SG]E1LZG+_UYR?^C8:2*D>?_$8_\3.\_P"ORX_]&M2&CVCP
M2R^//#,]G(#)-:B3RP"))<J#)"0""R@Y,0 ZJK*I&<"NA.S*O[0-ROA33++1
M(6'0-(5(3(C&,M&,\22,7R3]]"?F/(&"/(?AIXG'AG4K>[8@(D@#DAF 1P4D
M;"\DA&)&,\@<'H913/3?VB?AW-=7']L6:F:WFB1I&0^8%*IP_P HXB,:@[LD
M9W9(!4%M$IGC&B:--K,R6ULADED;"J.I/\@ .23@  DD $U)1Z=\4?@U!X#L
M89I+@M=.=K1@*48]25R5=40<%B'W,4X3=Q35A)W/)5YJ2C0T75FTB>*YC +Q
M2)(H;)4E&# '!!QD<X(^M,1] _'SPBWC>"VU?2E^T+L*N8]S.R%LIA/]EBX<
M !U)^884[:9*T/ -#\/7'B&406D;2R''"C.!D+N)Z*N2,LV%&>2*@H^E_B%X
M4_X1/PJ]D3N:-(=QSD;VN$=\'"_+N8[<C.W&>:M[$+<YO]D(_P#']_V[?^UJ
M41R//O@M\-K?QY</#<3-'Y:!]B+\SKRK$.<JNUBG4$L#QC!(25QMV,#Q!X9O
M_A[<XD\R&12PCF0LJL,8+1N,9&UAG'(SA@#D4;#W/>/V;_$VK:QO%X9)+,1$
MQS2#+%_,QM5S\T@^_NSNV[5&5Z&D0SS7X7^.[;0/$,LR-''93RW$88J418V<
MO$0.-@W*@^8852<@8R)3U*:T#X\_#*XT"]FO41GM9G,OF#Y@C.PWJY  3YV^
M3/!4@!BP; T"9P7@[PG<>+KA;2T7<[<DGA54=78\X49^I.  6(!11VOQF^%M
MKX \A(9VDFD3+HRIQCAI.&RJL>$4JW1\R'&*IJQ*=SU_XWWU[H^FVZ:)N%H$
M^>6$LS+&B*8L.K%A&5!+/Z* 6 8AFR4?-$MW>>*IE5FFN9R-J@EYI,#+8'WF
MP.3@=.3ZU!H?3?ACP'-X*\.7L%R1YLEO=2LHY"%H-NS.<,0%Y(XR2!D ,;Z&
M=[L\?^$'PBA\?P7,GGE9XE*I$!M7<RYB=G(;*%@P957<,9R,@&4KE-V.+N8K
M_P #3LC>=:SX(."T;%=V.&4C<A9>""5.,@G% ]SZ3^"WB6^O].N)==4FT2)2
MDDL?S/%Y9,F1C,B; I#%27W-\S]!2(9YM^R[XN31[V2TF946Y10I;.3(C?(@
M/09#MUZL% .3@I%2.0^)WPVN/!-PZ.C&V+_NI?O*RG)12P 'F8!W+@'() VX
M)30)W*OPY^'=QX[N/(@^5%P992,JBGOVRQP=JYRQST4,P$-NQH?&/P-:^";P
M6MK,TOR!F5@A,>1PI92,L<%L%$PI3[V<T,2U.")S2*'KQ0(1FH 0/0 .U  C
MT !.:!B"@0IH 3:#0,01 T@N,DM@:!W*DEE0!]+>$EVV=N/^G>+_ - 6OA:_
M\27^)_FS[.C\$?\ "OR-:N<W"@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * ,CQC_Q
MY7/_ %[S?^@-73A_XD?\4?S1SU_X<O\ "_R/ENOOCX<3% !0 E !0 "@#&H&
M%( I@% !2 * #% !B@!* "@!: "@ H * $H * "@ H * "@!*  4 +0 4 %
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MQX'2&% '4_##QQ_P@NH0ZCY?F^5YGR;MF=\;Q_>VMC&[/0YQCWI@'Q0\<?\
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MR'[47"QC?%#XP#X@00QRVPCGA;/FK(Q4AEQ(H0J, L%(RS%=N,G))3&E8Q?
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M=81H;2-;973:6#,\P.3DJ_R!<CC[I8<D,#C"N.QX]MQ2&>F> ?V@K[PFJP2
M7%NJ@*CG:Z@!L!7 )QDCA@^%4*NT4[B:.PO_ -K*21"(+14DXPSRF11R,Y4)
M&3QG^(8//.,%W%8\.UK6)=;F>YN7+RN<LQZD_P @ . !@      5)1Z#X _:
M"O?"BK!*!<6Z*%5&.UU #8"N 3C)'#!\* J[13N)HZW4/VM99$(@LU23C#/*
M9%'(SE52,GC/\0P>><8+N+E/&_%WC"X\67#7=TVYVX '"JHZ(HYPHS]2<DDL
M23)5BWX!^(MUX(F,UH1AEPZ."8W'.,@$'()R""".1G!8$N#1[%_PUQ_TX_\
MD?\ ^TU5R>4\N^)7Q=N_'C 2XC@0DI$N=N23AF)^\X4XSP.NU5W-F6QI6*'P
M_P#B#=>")C-:L/F&'C;)C<<XR 0<@G((((Y&<%@0=KGL!_:XQ_RX_P#D?_[3
M57)Y3RWXE_%RZ\>,!-B.!&)2)<[>2<,Q/WG"G&> .=JKN;,ME)6(_A3\1?\
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M;BLQ52<<D Q,0,] 2<=,GK57(Y3@OB?\=;KQPOV?:(+;()C4EF8@#&]N-P#
MD *HZ9#%5(3925CSFUNVMF62-BKJP964D,"#D$$<@@\@CI2&>V>%_P!JN\T^
M,I>PK<L.CAA"W4D[MJ,IZ@#:JX YW$YJKD\I)X@_:PN[Q=MG;QP$JP+.QF8$
MCY67Y8U!')^8.#QQ@$$N'*>(7%P]TS22,6=B69F)+$DY))/))/))ZU!1%G%
M"[Z8$;24 +G- #LYH 13B@!2^* &"3- AV: $#8H 5)* )C0!&30,^BO"W_'
MI!_UPB_] %?"U_XDO\3_ #9]I0^"/^%?D:E<QN% !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 9'C'_CRN?^O>;_T!JZ</_$C_ (H_FCGK_P .7^%_D?+=??'PX4 )
M0 4 )0 4 8M Q: "D 4 &: #- !0 4 )0 4 ** "@!*!A0(* "@ H * "@ H
M * $H 6@ H * "@!* "@ H * "F M( H ,4 )3 7%( H *  T )0 4 % "T#
M T"$H * "@ H *!A0(*!BT )0 4""@ H ^DOA;XL\(:#:V]_<Q;-2ACW,G^D
MS$R)E0Z[OW&Y\!UZ+&S#Y@5W!B/)_C/\2C\1-1>] *Q!5CA1MNY8UR1G:.I8
MLY&6VEMH8@ TAG#"@84""@84 +0 E !0 M !0 4 % !0 4 % !0 8I +0 4
M)0 M !0,*!!0 4 % !0 4P"@ H * "@84"%Q0 8I +B@88H 7% !B@ H ,4
M&* %Q0 8H ,4 &* .I\%>.V\*1WB)$CO=VCV^]BX,:N1OP 0IRH[C(8*0<!E
M<$<OB@84  H 7% !B@  S0 _;0 ;: />?BS\3=/U[P[I^G6TV^Y@^R>8FR1=
MNRW>-_F9 IPQ X)SU&1S3$D># 5)1(B9H F6WW4ADJV&: )5T[- $J:8*!EA
M+ "@"5;0"@"1;<"@0X(*8#A'0(>!0 I% #: ' 9H 3;0 %: %'% #Q0 ,:
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M?!'_  K\C4KF-PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M* $H 6@ H * $H 7- "4 +0 4#$H$% !0 N:!A0 4 % !B@0E Q: "@ H *
M$H *!!0 4 % Q10 4""@84 % !0 4 % "T % !0 4 % !0 4 +2 * "@!*8"
MT@"@ H * "@ I@% "XH 3% !0 N* %Q2 3% !0 N* #% "T#% H 6@!* #%
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MPK\C5KF-PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M06*D94$MQGDX)Q@J2!<I>'-'_MJYAM=VWSIHX]V,XWL%SC(SC.<9&?6@#?\
MBK\.O^$!N4M?-\[="LF[9Y>,LZXQN;^[G.>_2AH$[G&[\4 /1Z (R] "1T
M.TYI#'!M],0C\&D,:AYH 69<4 1K\M $I.!FF!$K8% #D>@ QCDT@(GN!TH
M>C8H <>E,!F_ I &W-,!I<9 I ++-V%  )MO% ";M]  A'6@!LDF[I0,0L:
M&F/N: 'F@!K#(P*!"%MHQ0 @<#I0,D3F@ '% AAEV"@8UI,T )%%F@0,NV@
MB^;F@"4KLY- $3-NH&*7H$-S0 C-CK0 BRYH >)<]*  <T !''- $:RYX% $
MJ<4 /+X% %=SF@8^./ S0(#+VH <K9H&(TN*!"B7- $0CW'- R;[HH$-27%
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MC."V>2!W4>M85<#*E%R;C9=K]7;L;4L;&K)12=WWMVOW.>KRST@H * "@ H
M* "@ H * "@"2"W:X(5 68]  2?7H*N,7)V5V^RU)E)15WHO,+B V[%&&&4D
M$>X.#THE%Q;3W3U^01DI)-;,CJ"@H * "@ H * "@ H * "@ H * "@ H R/
M&'_'E<_]>\W_ * U=.'_ (D?\4?S1SU_X<O\+_(^7,5]\?#B8H * "@!* "@
M#%I#"@ H 3% "XH 2@ H 6@ H 2@!:8"4@"@ H * "@ H * "@ H * "@ H
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M#$#D@9(!&<;AE@<A0 4 >I_LP?\ (PV?_;Q_Z3RT(&=3^V?_ ,A>'_KPC_\
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MH?+,Q+IY<8<*5+.I93\K;MJ[G(#84E2 "N=3XC_90UG183,@BN-N<I"[-)@
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MW4 214"/I?PG_P >=O\ ]<(O_0!7PM?^)+_$_P V?:T/@C_A7Y&K7,;A0 4
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M"E5BI)JS[W[V[%3_ (65;_W9/R7_ .*K#^TX=I?<O\S;^SI]X_>_\CD_ _\
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M$ X SG[Q /I;]GZS_P"$.TC3HFBQ)?SR,YWY^]#--')CYAS#!&NT;<9R?F#
M@CY/^,_AK_A&M8O+8!%43LZ*@PBI)B6-0,#&$< @# ((&1@TAGN_Q=NW^&/A
M:ST9&*7%PNV5227"G,URH>/"8$CK'@DAHV(^;E@Q'(_L7?\ (7F_Z\)/_1T%
M"&SB_$7CR\\%:[J-SI\GE2M=W:%MJ/E3.6(PZL.JCG&>.O6@#Z'_ &J?BAJ'
M@7[%_9TWE>;]HW_)&^=GD[?]8C8QN/3&<\]J!(\"_9?_ .1AL_\ MX_])Y:!
ML]>_:=^/MUH-Q_9&F/Y3+&#<2J/W@+J<1J67Y<(P?>A+9*A60JV01XOX&_:
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M'@7['_9TWE>;]HW_ "1OG9Y.W_6(V,;CTQG//:FQ(^6OA2/^)O8?]?\ :_\
MHY*11ZG^VA_R%X?^O"/_ -'3T,2.N_9S5/B)H%YH%P3B-OD;:-J++F2(C:RL
MQ69'<AB 00N2O 8,^6[JT>S=HI5*.C%65@596!P5(/((/!!Y!J1GU+K5H_PL
M\&B!E,=U>L%DP"<-/EF5Q)@H?LR>6P495^G.7JA'RK4C#% 'J7[,/_(PV?\
MV\?^D\M,&?2'QG_9S_X67>)>?:O(V0+%M\GS,X=WW9\U/[^,8[=>:9-S@O\
MAA__ *B/_DM_]OHL.YXS\9_A7_PK2[2S\[S]\"R[MGEXR[IMQO?^YG.>_3BD
M,U?V8?\ D8+/_MX_])Y:$#.H_;.'_$WA_P"O&/\ ]'3T,2/!<4BCU+]F(?\
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M3CWQ3QU+VE)^6OW?\ 6"J>SJ+ST^_P#X)Y/7Q)]B% !0![/H/_'O%_URC_\
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M?4W[#O\ S$?^W3_VO30F<C^QK=I!K$BNP4O92J@) +-YD3;1GJ=JLV!S@$]
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M7"QO>.?&,WC/P9)?W"HLDNS<$!"?+>J@P&9CT49Y/-,.IXI^S.F-?M/^V_\
MZ3RU**99_:9TYTUZY9E(#K RD@@,!#&N1GJ-RD9'<$=0:&"/,$M,U)1]1?M
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M0X;!'B8-24?1<]LUOX+VNI4E5;!!!PUX&4\]BI!![@@C@U70CJ?.1:I+'@4
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M_P#$C_BC^:.>O_#E_A?Y'R[7WQ\.% !B@!* "@!* ,2D,,T % !0 E !0 4
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M%!(3EMVX;AYA  "Y 89)VDEM"3-,G=X)_P _\_U'074^>0=@S4FA]$?&!O\
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MB%IO@[3&T71&$CR I)(A#J P7S'9]I61W4[?E^[S@IL5:&-*Y@?LG<:G*/\
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MG':@98==O% $GF>5Q0!2=RQI *LI;B@"T"(EQWH C,GF<=J8",HS2 EC7>:
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M:^2Q_P#&E\O_ $E'U."_A1^?YLPJ\T] W? __'Y'_P #_P#0&KTL!_&C\_\
MTEGGXW^%+Y?FCTO6Y#'!*RG!$3D$<$':>:^NKNU.37\K_(^5HJ\XK^\OS/*(
M_$5S&01*_!SRS$?D3@_C7Q*Q,T[\TOO9]B\/!Z<L?N1WWA'Q<-5'E2\2@?0,
M/4>_J/Q'&0/IL'C/;+EE\7Y_\'NOZ7SF+PGLO>7P_E_7]><_BGPLFJH648E
M)!& 6./NGIG., GI],@ZXO"*M%M?%T??R?\ 6AGA<4Z32?P]5V\U_6IY7)&8
MR588(."#P0?2OBVK.S/KT[ZG5?#7_CX;_KDW_H2U[66?Q'_A?YH\C,?X:_Q+
M\F>DU]:?+%'7O^/>7_KE)_Z":YL1_#E_AE^3.BA_$C_B7YH\8KX ^Y"@#V?0
M?^/>+_KE'_Z"*^_P_P##C_AC^2/AJ_\ $E_B?YL\U\<?\?DG_ /_ $!:^2Q_
M\:7R_P#24?4X+^%'Y_FS"KS3T":TM&NV$<8W,QP /\__ *JTA!S:BM6R)S4%
M=Z)'JGACPPNBKD_-(P^9O_91[?SZGL!]GA<*J"[R>[_1>7YGR&)Q+KOM%;+]
M7_6AE^*_&_V$F&WP7&0S'D+[#U8=^PZ$$YQQXO'>S?)"S?5]O^#_ %Z=>%P7
MM%S2VZ+O_P  \[DD,A+,<DG))Y)/K7RK=W=GTR5M!M(84 % 'L^@_P#'O%_U
MRC_]!%??X?\ AQ_PQ_)'PU?^)+_$_P V<YXU\7&SS;P\/CYFZ;01G ]\=^W;
MGIY6.QG)^[COU?;T\_/IZ[>G@L)S^_+;HN_K_7X;\CX:UXZ-*'Y*'AU'<>O/
M<=1T],@$UX>%Q#H2OK;JOZ['M8F@JT;=>C/6I$6\0@_,CKC@\$$>H]O2OMVE
M.-MTU]Z9\:FX.^S3_%'D/B'1CI$QC/3JISG*DG&>G/&#[^V*^%Q-!T9N/3IZ
M'VF'K*M!2^_U+?@?_C\C_P"!_P#H#5O@/XT?G_Z2S'&_PI?+\T>JW$XMU+L<
M*H))]@,GI7VDI**;>R6OR/D(Q<FDMV8O_"<6?_/3_P =?_XFO/\ K]/O^$O\
MCN^I5.WXK_,/^$XL_P#GI_XZ_P#\31]?I]_PE_D'U*IV_%?YE35_&-K<0R(L
MF6:-P!M?J5('5:PK8VG*$DGJXNVCZKT-J6#J1G%M:)KJN_J>?Z+J']G3)+_=
M89Q@G'1AS[9%?,4*GLIJ79Z^G7\#Z2M3]I!Q[K\>GXGK^I6(OXGB/\2D9(S@
M]CCV/-?=5:?M(N/=>I\53G[.2EV9R_PYTHVZO*XPQ;: 5P0%Z\GWX(]5_+Q\
MMH\JE)[MVU7;?\?R/6S"KS-16UKZ/O\ \#\RI\3-0YC@'H7/3'=5]_[WY_EA
MFE36,/F_R7ZF^6T]Y_)?F_T.&KYP]\* "@#K/AK_ ,?#?]<F_P#0EKV\L_B/
M_"_S1X^8_P -?XE^3.P\8W#6]K(R$JPVX()!^^HZBO=QLG&E)JZ>FJTZH\3!
MQ4JJ3U6N_HSS+^WKC_GK)_WVW^-?(?6)_P TO_ G_F?5^PA_+'[E_D']O7'_
M #UD_P"^V_QH^L3_ )I?^!/_ ##V$/Y8_<O\BM<W;W1W2,6.,98DG'IS64IN
M;NVWZNYK&"AHDEZ*QJ>%_#AUMR,X1<%SWYZ >YQUZ#\@>S"X9UY=DMV<F)Q"
MH1[M[(]%AT*TTH;]B* 0=S<X/&/F;)'/3GK7U<:%.BKVBK/=]/FSYAUZE5VN
MW?HO\D17?C2UML@R;B!T4%L\9P"!M_7ZXK.>.IQOK>W:[_';\2X8.I+I;ULO
M^":UI<BZ19%Z,H89ZX(S7="7/%275)_><<X\C<>S:^X\L\<?\?DG_ /_ $!:
M^,Q_\:7R_P#24?78+^%'Y_FSTK0?^/>+_KE'_P"@BOK</_#C_AC^2/EJ_P#$
ME_B?YL\U\<?\?DG_  #_ - 6ODL?_&E\O_24?4X+^%'Y_FS"KS3T H * /=:
M_2#\^/&=>_X^)?\ KK)_Z$:^ Q'\27^*7YL^YH?PX_X5^2'Z#KSZ,^].0?O+
MV(_H?0]OID&L/B'0E=;=5W)KT%6C9_)]CT+2_'-O>@!F\MCV;@=,GYNF/3."
M?2OJ:6/A4W?*^S_SV_(^:JX*<-E==U_EN;T%PMP R$,IZ$$$>G45Z49*2NK-
M=UJ>?*+B[/1^92U;0(=5&)5R<<,.&'7O^.<'(SVKGK8>-9>\OGU_K\#>E7E2
MV?RZ?U^)Y3K>D-I,IB;G'(." 0>AY_(^^1DXKXJO1=&3B_D^Z/L*-55HJ2^[
ML4*YCH"@ H * "@ H * "@ H R/&'_'E<_\ 7O-_Z U=.'_B1_Q1_-'/7_AR
M_P +_(^7J^^/AQ* "@!* "@ H PZ0PQ0 4 %  10,,4 +B@0F* #%  * %Q0
M,2@08H 2@ H 7% PH 6@0AH&)0(7% Q* %H 2@08H *!BXH * %H *!!0,*
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MIIB()7+<TAC9'["F!"YW4ACX(NYH$*5W\"@"14\G@]:8$(E(/'>@"=XMO)-
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M #9YKXX_X_)/^ ?^@+7R6/\ XTOE_P"DH^IP7\*/S_-F%7FGH&[X'_X_(_\
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MFV3?P]EZFE/,.>2CR[M+?O\ (XROGSW H * /9]!_P"/>+_KE'_Z"*^_P_\
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M[."CY:^KU9G5RG2% !0!UGPU_P"/AO\ KDW_ *$M>WEG\1_X7^:/'S'^&O\
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M 8H 2@!: "@0E Q: "@ Q0 N* $Q0 4 &* $Q0 8H * "@!*!"B@8M !0 E
M!B@!<4@#% !0 4 % !B@!<4 &*!AB@!*8"BD M @H&&*!"T#"@ H 7% !B@
M"T +B@#M/!GQAU3P7"UOI\_E1-(7*^7$^6(52<NC'HHXSCCZT"L<MJ>JS:M(
M9[B1Y96QN=V9W.  ,LQ).  ![ "@95 H =B@ VT )MH <%I / H&.Q3 :10
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MF&>!0!,F(NE #)3^=,"..$EJ0"N^3S3 4(9.E("65A$,=Z *WFGH* %(+#-
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M8]!MO']K,,LQ3GHRDGZ_+N%?41S"G):MKU3_ $N?-RP%1=$_1K];%35OB+%
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M,!P6@  H 4&@!3S0 T)0 IH 51FF NVD 8H <HIB%49H <RT (HH ",4 .%
M !F@ >@!NZ@!30,*0"AZ8A93Q0 QAFD,<IIB%;VH 1QB@!<[:0Q-N>: &1R<
MT"'OZT#$1N* $08- $I; H J>:2<4 2;N: 'QOOH :AZF@!88^] #M_I0 S=
MDT@)13 B<[>*!@YVB@"-00*0#\[5YI@()=HR:!$:29Y]: )&4]!WH F?$7%
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M'>@0[;MRW>F USM'N:0!;PY/X4 1F8CD=*8 ^76@"RY$  '7 H C1MJESU-
M#"^ ,4@&N?-( Z=Z!@[F8[1TIB$*^6<4 2*I VK0 V0" 'UI 58?F(/O3 MR
MW04\4 / R>?K0!!,_G$XZ4 .LE+-QV% ,D:3R<\\F@"L[_G0!8BM\C<: &2D
M2'/84 5L[SQ0(GBQGF@9'--GCM2 <G8"@":4"#CO3 BC&_K2 /,!X% $R2\?
M+0!"Q*_4T .XC7'<T ,R9>.PI@!?/3I2 FA'F?2@ :4)F@"*$Y!;O3 7SC(<
M"D ]8ASF@!)+K;PM,"#=W-("7MF@ 63:,"@!%EQ0 Z$;CQ0! 8SDYH E'/%
MCZB\(#%E;_\ 7O#_ .@+7PM?^)+_ !/\V?:T/@C_ (5^1KUS&X4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M(8\)0 X1YH >MMF@"5;.D,G2UQ0!*+:@"18,4P)!'0(?Y>* #I0 X4 .(H
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M9PJ\=: (+B39]33 G5=F&;TH KB3S&]A2 #\IR:!CT&3D\T"&^8&) _&@!4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % &MH/B631-WEA3NQG<">F<="/6N[#XJ5"]K:
MVWOTOYKN<=?#*O:]]+[>?R?8OWOQ N;E=HVIGNH(/3&,DG'U&#Z&NF>8SFK:
M+S2U_%LYX8"$7?5^O_ 2.<DD,A+,<DG))Y)/K7DMW=V>FE;0;2&% !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % &1XO\ ^/*X_P"O>;_T!JZ</_$C_BC^:.>O_#E_A?Y'S :^^/AQ
M* "@!* "@ QF@#!I#%H 6@84"$Q0,,4 % !B@!* %% "T % %[388),_:'D3
MIMV1K)GKG.Z6/';'7/MCG.;DMDGZMK]&:12>[:]%?]47?LEA_P ]Y_\ P'C_
M /DFLN:?:/\ X$__ ) OEAWE_P" K_Y(/LEA_P ]Y_\ P'C_ /DFCFGVC_X$
M_P#Y +0[R_\  5_\D'V2P_Y[S_\ @/'_ /)-'-/M'_P)_P#R [0[R_\  5_\
MD'V2P_Y[S_\ @/'_ /)-'-/M'_P)_P#R 6AWE_X"O_D@^QV'_/>?_P !X_\
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M_P"2:+S[1_\  G_\@%H=Y?\ @*_^2$%I8?\ />?_ ,!X_P#Y)HYI]H_^!/\
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M'_\ )-'-/M'_ ,"?_P @%H=Y?^ K_P"2%%I8?\]I_P#P'C_^2:+S[1_\"?\
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M1_\  G_\@%H=Y?\ @*_^2&FTL/\ GO/_ . \?_R31S3[1_\  G_\@%H=Y?\
M@*_^2 6=A_SWG_\  >/_ .2:.:?:/_@3_P#D M#O+_P%?_)#OL=A_P ]Y_\
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M_ 5_\D*+*Q_Y[3_^ \?_ ,DT<T^T?_ G_P#(!:'>7_@*_P#DAWV*Q_Y[3_\
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MRG_Q^B\^T?\ P)__ " 6AWE_X"O_ )(7[/:?\]9?^_*?_'Z.:?:/_@3_ /D
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M+_WY3_X_1S3[1_\  G_\@%H=Y?\ @*_^2'^1:?\ /67_ +\I_P#'Z+S[1_\
M G_\@%H=Y?\ @*_^2!H+0?\ +67_ +\I_P#'Z.:?:/\ X$__ ) +0[R_\!7_
M ,D-CM+7KYLO_?E/_C]+FGVC_P"!/_Y .6'>7_@*_P#DB0VUH/\ EK+_ -^4
M_P#CU.\^T?\ P)__ " 6AWE_X"O_ )(;]GM/^>LO_?E/_C]'-/M'_P "?_R
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MO^_*?_'Z7-/M'_P)_P#R <L.\O\ P%?_ "1)Y5J>DLO_ 'Y3_P"/T^:?:/\
MX$__ ) +0[R_\!7_ ,D-,5I_SUE_[\I_\?HO/M'_ ,"?_P @%H=Y?^ K_P"2
M'I%:#_EI+_WY3_X_1S3[1_\  G_\@*T.\O\ P%?_ "0SRK3_ )ZR_P#?E/\
MX_1>?:/_ ($__D!VAWE_X"O_ )(>;>T'_+67_ORG_P ?HYI]H_\ @3_^0"T.
M\O\ P%?_ "0WR+4?\M9?^_*?_'Z.:?:/_@3_ /D M#O+_P !7_R0X6]HO_+6
M7_ORG_Q^B\^T?_ G_P#("M#O+_P%?_)"M#:'CS9?^_*?_'J+S[1_\"?_ ,@.
MT.\O_ 5_\D(J6GW1++_WY3_X_2O/M'_P)_\ R 6AWE_X"O\ Y(@:UM!QYLO_
M 'Y3_P"/T7GVC_X$_P#Y =H=Y?\ @*_^2'QP6D8VB67_ +\I_P#'Z+S[1_\
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M  )__("M#O+_ ,!7_P D(UM:*,M++_WY3_X_1S3[1_\  G_\@'+#O+_P%?\
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M [0[R_\  5_\D5)6LPVT33?]^$_^2*.:?:/_ ($__D!.,.\O_ 5_\D67CM%
M42RC_MBG_P ?IWGVC_X$_P#Y +0[R_\  5_\D,DALP.)9OKY"'_VN*7-/M'_
M ,"?_P @.T.\O_ 5_P#) B6G $LV<?\ /!/_ )(HYI]H_P#@3_\ D!<L.\O_
M  %?_)$?V"T.<S3'G_GBG_Q^CFGVC_X$_P#Y =H=Y?\ @*_^2));>SV[1+-C
M_KBG_P ?HYI]H_\ @3_^0"T.\O\ P%?_ "13\BS;@33#_M@G_P D4<T^T?\
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MTW_?A/\ Y(I\T^T?_ G_ /(!:'>7_@*_^2(MEEDMYTW_ 'X3_P"2*.:?:/\
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MDC[!GN:8B%Y?*&!R32&)L- $PBVK[T  AVC/>@!$DV4  EQ0!]0^#SFRMO\
MKWA_] 6OA:_\27^)_FS[2A\$?\*_(UZYC<* "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H R/%__'E<?]>\W_H#5TX?^)'_ !1_-'/7_AR_PO\ (^8*^^/AP- "4 (1
M0 4 % &%BD,4"@ H *!AF@04# 4 % "8H *  4 +0 4 % !0 4 % "B@!<4
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M("Q:Q@?6@!US.9CL7I3 K8R<=Z0QRW 4D]AQ3$(S8&?6@!EQEL4 ,1]G3K2
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M ,!7^0>WG_-+[V']@V__ #RC_P"^%_PH^KP_EC_X"O\ (/;S_FE][#^P;?\
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M . K_(/;S_FE][#^P;?_ )Y1_P#?"_X4?5X?RQ_\!7^0>WG_ #2^]A_8-O\
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MY1_]\+_A1]7A_+'_ ,!7^0>WG_-+[V']@V__ #RC_P"^%_PH^KP_EC_X"O\
M(/;S_FE][#^P;?\ YY1_]\+_ (4?5X?RQ_\  5_D'MY_S2^]A_8-O_SRC_[X
M7_"CZO#^6/\ X"O\@]O/^:7WL/[!M_\ GE'_ -\+_A1]7A_+'_P%?Y![>?\
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M+_A1]7A_+'_P%?Y![>?\TOO8?V#;_P#/*/\ [X7_  H^KP_EC_X"O\@]O/\
MFE][#^P;?_GE'_WPO^%'U>'\L?\ P%?Y![>?\TOO8?V#;_\ /*/_ +X7_"CZ
MO#^6/_@*_P @]O/^:7WL/[!M_P#GE'_WPO\ A1]7A_+'_P !7^0>WG_-+[V<
M7\1K".T\KRT5<[\[0%S]W'05X&94XPY;)+XMDEV/=R^HY\UVWMN[]SC*^?/<
M"@ H * "@ H * "@ H * "@ H * "@ H * ,CQ?_ ,>5Q_U[S?\ H#5TX?\
MB1_Q1_-'/7_AR_PO\CY@K[X^'$- "9H ,T )0 9H Q32&% PH$)0,0B@!0*
M%Q0 E "XH ,4 )B@!: $H ,T % !0 M "B@!0*  B@!I6@!=M !BD 4 %,
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M 0PJ6.30!*9,F@ C;90 DF6XH >QV#% #E7% !( ] $3$+0 ^,;N>U  T@H
M3&3F@")GRW- $C<T &\(/>@!DDW( ZT $@+4 .FD\K&*!B,V_GO0 DSYP!0
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M "#ZE4[?BO\ ,/\ A.+/_GI_XZ__ ,31]?I]_P )?Y!]2J=OQ7^8?\)Q9_\
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M?BO\P_X3BS_YZ?\ CK__ !-'U^GW_"7^0?4JG;\5_F'_  G%G_ST_P#'7_\
MB:/K]/O^$O\ (/J53M^*_P P_P"$XL_^>G_CK_\ Q-'U^GW_  E_D'U*IV_%
M?YA_PG%G_P ]/_'7_P#B:/K]/O\ A+_(/J53M^*_S#_A.+/_ )Z?^.O_ /$T
M?7Z??\)?Y!]2J=OQ7^8?\)Q9_P#/3_QU_P#XFCZ_3[_A+_(/J53M^*_S#_A.
M+/\ YZ?^.O\ _$T?7Z??\)?Y!]2J=OQ7^8?\)Q9_\]/_ !U__B:/K]/O^$O\
M@^I5.WXK_,/^$XL_^>G_ (Z__P 31]?I]_PE_D'U*IV_%?YA_P )Q9_\]/\
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M_/3_ ,=?_P")H^OT^_X2_P @^I5.WXK_ ##_ (3BS_YZ?^.O_P#$T?7Z??\
M"7^0?4JG;\5_F'_"<6?_ #T_\=?_ .)H^OT^_P"$O\@^I5.WXK_,/^$XL_\
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M_0&KIP_\2/\ BC^:.>O_  Y?X7^1\O9K[X^'$S0,0F@ S0 A-(!,T 9% P-
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M=,\4AD[2[ <>F!3 ,K:@9Y- #%^<EVH&$<P.7/0'@4"*Z1E@7/?I2 ?)D'%
M$+Y;@=* )P. HZXI@2,1:C'>@"!9_,RW:D 1Y8@]Z8#IB<[5ZT")$AY"CMR:
M!E:\)N7XZ4 3S,$4 <F@"L4.<FD!-<R>=\S=.U,"M+*9, =*!$J1",#/4F@"
M:-"[<] *!C'.>G04 1 &7D]* )V(1,#J30 PJ 1N[4 .DN/-P>PH +2/SFR>
M@H$37=SYW^Z*!E52"<F@1)DGYN@H&.1S+]!_.@01@RDXZ4 0+C))[4#%B7=E
MC0!(7"#)ZT"(5RP)/2@9);Q@#)I"'@DY;'TI@1#"?,>32&/,A(W'C-,1#PW
MH ?"Q+#'04 /D3G<U Q8%,Y('2@1'( G% 'U1X+_ ./&V_Z]H?\ T6M?"5_X
MDO\ $_S9]K0^"/\ A7Y&S7,;A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M$GL>*8"3SF8[5Z 4 %R0F M #'8)G'7% #H(A$,MR32 BA).2: !YB% 7K0
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MC;?]>T/_ * M?"5_XDO\3_-GVE#X(_X5^1L5S&X4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M<]J ))WR<"@ :3=\J]NIH&)%&3@+Z\F@1+*1&V2>@_6F!5\WS3@=.](9)'&
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MT?@C_A7Y&O7,;A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M=M "XH 7;F@ "XH 4"@!=M P"4 .$5("3R: %$% #U@H E6"@!WE8H <L>*
M'JM,1)LS0 FS% "H<T *!0 M #<T !6@!N,T 2+0 8H ,9H =0 A;% "CF@
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MC<* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M;$0?(.N.* (HX#"<=\')I#%L6&"1R?7T% @DO/*4D<L>!]* *]N-@Q_$3^5
M$HM_,RS'@4 -51(0"> *8 296P.%I 32R>2FT=?2F!1!Z _C0!,9RYVK]V@
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M1_PK\C7KF-PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@#%\;?\>-U_U[3?\ HMJZ
M</\ Q(_XH_FCGK_PY?X7^1\E9K[P^)#- "YH -U !F@!<T --, % #L4 (:
M"@!0M  %H 4"D N* %Q0 F*!AMH -M "T .% "&@!10 X4 &* ' 4 *: (F-
M "I0 \4 (U "** %H 4"@!<4 *!0 4 )MH 4+0!(J4AC@M !MH /+H <(Z )
M52@ V4 .VT /5: '[:8#,<T@)E-,0,: $2@"0'- "!<T (RT .6@!,YH D!Q
M0 E "J* %>@!C+F@ $%(8YH\4  YIB'*:  T (B4 *3MH ,[J '!<4 "\T ,
M!- "V] #]N>: $D&X4 $:[:0#I#3  =W2@!N,G- P3UH 7&!0 U 10(<ZYI#
M$"=Z &',OX4 3QL .>M,08VT ).>.* &P@H*!B8WBD  9H $/E_>H ?&F[FF
M(BNIMG%(8EG&3RU $T('- $$@W<#I0 ]Y<CB@!!-Y2X[F@"-(R/K0!8D;C;W
MH 6.0(,=Z &1-M'N:8ALET <4ACX5W'F@"%91N(6@ ;DCB@!\<F]CGH* (U(
ME+.>@X% Q8T^T@>E(!Y;S3CL*8AT4WE)DT 16D81=[=32 1&,I+'CTIC)RNW
MKUH ; /(8YZXH$1W;;B,GF@8Q(CDL>*0$CN,KGKUH AC7SG+=A0!/=2#9CO0
M!!.I8@(.!UH C5][\]J +EN#("3WH KQ-Y@('0$T "84KGH.: );XF9=QX7T
MI@4F8MA3]T"@"6T48 [9S0(FDD^T. .$7K]: (H8?M+L>@%(8A;[:X ^ZM $
MOV+(R/6@"MJ1,Q"KT H =:W&PY Z#'XTQ%TI]F0R,?FZ_P#UJ!E1Y#*H1>K=
M30!&\ @..NWK]:0"QM_RT;UH 7[3A=Q_ 4P%MYRB$]S0(@>,)E>II#'W-QY*
MJ@]B?K0 ]8_+8,W7&: (YI3(Q!ZF@"5P+9"J]3Q3 A$>&7/)]*0$JIYK'ZF@
M" SG:47\:8$\2"W4.>21P* *OG' '4YI#))5(P.K-^E,17F?:=HZ]*0$[9MH
M\'[Q- "RM^[VKTZDTP&2?N4"^O6D!7D1NH]* +L[F"(#U%,1 &\A,#[QY- Q
MT'R#'?J:!#+?G)/2@9*LHG)/0 4"(A)YGR_PY-(8\ON;_944 0[_ +02?RH&
M.=^< =J8#&N!$ !^- @6Y*@GN:0"V]N9\9Z4P'23CGT4<?6@""(X''4T@+"2
M&!3_ 'LT 0NN.#U/)H 6*,8)I@,E;.(QZT")[D!=J?G2&B$GS3@<"@"U;?Z.
MI;ZXI@0"0P=>M #Y!A1S\Q- $+,%&*0P8>4 HZFF2$L3%L>E Q/+^T.!2$3W
M#^0P'I3&1294Y/4T")Q9BW3<QZT#(!TP.] !''M/)X% B>-LAG]>!0!#.P3Y
M1VY- RL29.E(![*$8 FF!-'CDGKT H 5TQ\B]>IH BEY(4=J "9A']: ",%E
M)Z"@0QYMIP@[4 )$-A]30#)1"1EF_"@8U9,\"@"2:;("CL.: (X\GI^= A!A
M2=W2@8Y/E^;\J!"V\1N#ST[F@!SS!6PO:@!((L@LYXH 6*0*=YZ=A0 GF-=,
M6/2@8PDRF@0Z2YS\B4 1$<^IH&23#^]VZ"@!^!&,]Z!#3D@ _E0 Y?W>* '(
MXARQY8]*!D4$?F$D]AF@01OGYCT'2@ BC,S!FZ9H ?<7.]OE]:!D?$?S'DT"
M/JSP8<V-M_U[0_\ H"U\)B/XDO\ %+\V?:T/@C_A7Y&S7,;A0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M#RQ\8_:_MT7F>5Y&SYY$QN\W=]QESG:.N>G%-"9XL7[4ABD[10 BMF@  YH
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M?XG^;/M:'P1_PK\C9KF-PH * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#%\;?\>%U_
MU[3?^BVKIP_\2/\ BC^:.>O_  Y?X7^1\DU]Z?$A0 4 )2 *8"T@'!:8"[:
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M2+:7%^WVKY%9/.MT<NP&,1LC,-V057).".3U)85SSGXJ_ 2X\!QK<(_VBW.
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M+^;;2.4#'"R(WS,J, ?FRH^^H )!RJ_+D:L-.YYII=F;UQ'&I8DA54 EBQ.
M !R23P!WI#/?]!_9ECLXC=:Y<BWC 'RHR($+;0-\L@*9R2I4 @G!#GI56)N7
M3^SGHGB-6BT_4&>8+N&)8)P " 6*1A&(YQG<,$CKT)8+GB/Q(^&\W@>[:TN&
M#*%#QNO ="2%;&25.5(*GH0<$KAC.Q:U/K/P5\'SX9TNZTHW'F?:/._>>7MV
M^9$L7W=[;L;<]1GIQUJ[&5SY=^+WP[;X>W*6:R^<9(A)OV>7C+.N,;G_ +F<
MY[]*AFB=R_XT^"P\+:7;:KY_F?:/)S'Y>W;YD32?>WG.-N/NC.<\=*=A7.9\
M&^"+GQ9,MM9KF5L\GA$7N['!PHSUY).  6(!0[GMEC^S3I7AN)!K%_Y<\N3Q
M)% AP%W*OG*S/@G[WR\$91>]6)N4_$G[+JW, N?#]T)D(/RR,C[]N_=LEC 3
M.0%"D  Y)D'2BP7/%O#GAMK^^2P;,3/<1PN64[D+.$.5.#D$\CCICBH+/7[C
M]E6Y:\%G'/\ Z/Y(DDN3$0 2SJ(E3S#O;Y03\P"J<GDJ&JQ-S<M/V>O#NJDP
MV6H%YF5@BB>VE^8*3G8B!F QD@$< \CK3L*YX_\ $OX3W/PYE5+EDECEWF%T
MR-VTX(93RK8*DCYE^; 9L'$M6*3N<.'*JP[D]*10^ E?O'D_YQ3$2;0TA5>P
MYI 7M(T_^W;N#3U;;YT\49?&[;O<+G&1G&<XR,^HI@>PWW[*-S/?+9I-_HP@
M61[DQ8 8LZB)4\P[V^4$_, JG)Y*AW8GF-Z+]G'0M>W1:9J)>X"@C$MO<!0&
M )*1A&(YQG< "1UZ%V%<\3^('PWO? $HAO "7&4D3+1,.,[20IR"<," 1P<;
M2I,[%+4Z7X?? Z?QY827MK,/-2Y$0B9<*?\ 5%G+[N JR%B K$[<#)(%%KB;
ML>E1_LSZ.S?89=0+:AM;"!X5.=I=3Y!W28"X)&_) )!4'BK"N><_#3X*)\1I
MKM(;K9';.BH_DEO,5C(%?:9$*<)G!R><'IS*5RF['EL^8D"+P#C/N:0S?^''
M@H^+[Z'3?,\HR^9F3;OQMC:3[NY<YVXZCKFF@>@?$3P(/!.H2V)E\WR]GS[=
MF=R*_P!W<V,;L=3G&?:@6Y[2?V3S:W!:ZNP+*.)7>;:L;<,V] "[!0J+N,C<
M#<,*V&Q5B;G/_%'X/Z3X<T\ZCIEX9OWHBP6CN%=SAM@>(*L95 SG<#G@<$C*
M:&F<Z/@QMT(^(!<9/3R?+_Z>/(^_O_X%]WV]Z+#OJ>N_LK?##^S(EUHR[C/#
M+'Y6S&W$P&=^XY_U73:.O7CEI$MG"_M$_!O_ (119=6$_F&ZOG_=^7MVB7S9
M?O;VSC;C[HSUXZ4F-,YF3X*>7H/_  D#7'(Q^Y\O_IOY'W]__ ON^WO18+GG
M<, NQN;H!TJ1GH_P>^"I^)8G_P!(\CR?*_Y9^9G?O_VTQC9[YSVQ5) W8X+0
M(6NV2WA7?-+(L:+D#+,0JC)( Y(Y.!ZT@/H*']F73M"56US41&\@78JO%;J&
M _> --N,@!(P0J$#DCY@!5B>8A\2?LIP:I";S1+SSUV?(C&.19&5B&"S1E4'
M P 5(W##, <JK!S'SI*XD//112+(LC&3R:0#K=//R6Z4 *\XDX/W5Z#WI@=W
M\'/@_-\3)9%5Q%#$ 7D(W8+9V +E2Q)4]P  23G 9V$W8]BA_9V\/%EMIM29
MK@,(V19[9"9<[2H0HS EN A+,#QDFG8FYYI\8_@3-\/$2X:83VSG9N"^4ROA
MB%*[FR"HR&![$$#Y=R:&G<X#P5X0NO&MTEG9)ND(Y)R$10?F=C@X49Z]22%4
M%B 45<^@K3]F'2?#L2'6K_RYWR1B2&"/@+N5?-5F?:Q^]\N05RBGK5B+F-X_
M_95-K;O?:/.;F/:KI$0K.R;<EDD0[9"?O*H1<J<*68 ,K#3/#O#N@S:W,EO:
MH9)Y&VQH.I/<\\  9))P  22 ":0SZ#TW]E.QT>'SM?OA&S,%'EO'#&&^8[=
M\RG>2H! "H1AOO#D58FY<_X9AT?Q)&4TC42S(RER'ANE (; *Q>65)(X);&
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MK2*TF=^7.4 "A1DL,D*"P=B+G8ZG^SCH9@F"ZDQN;>)GG(:*4((L><Q@C D
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M,Y5<C[K@94%E()9L^6%!-%@N>4^&=&N/$,RVMLA>21L*B]3W^@ '))(  ))
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M_*F2!D*N%' X   '%(H]4_9/;.J2_P#7E)_Z-AIHEGG'Q*3_ (FE[_U^7/\
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MPUOV>=</_+K_ .1H/_CE*P[GN?PW\&:C=:3<:/K";04*02.T<V%92%&U6/\
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M! JA=3Y5#;SCH!4%GTM\*=<FU?PM?B9BXBCO(H\\D(+965<]2 6.,YP,*.
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MGW,QW22/:NS8 RS6TC$X  ')/  'I5,A;GRU).+?D\LW/TJ2R:T4;=[CITI
M06EV1N;]:8'3?"-/-U6S?TO+;_T:M"!GO/[6GCM[80Z3%D>8OG2'D C++&O#
M<C<K,P(ZA"#D&J9$3YITFY;3I Z,5=&#!P2&!!R"".0<\@BH+/I+XGSGX@>%
M8-5FPDT+*S-M5F;$AMG ("[ [8D( Q\H7!P&%/5$+1E_]F?5ET/0+RZ"[A#/
M<28SC=LMXFQG!QG&,X./2F@>Y\N76I/J,CRL2S$L2S$EB3R6)/))/))ZU)9]
M%_L7G)U#G/\ QZ?^UZI$2/FH3[V+GL3@5!9Z5^S:3)K]J3_TW/\ Y EIH3+'
M[1";=>NV]H,?^ \5#!'K_P"UYKSP6EO9)D+-*[NP8@;8@N$*X^8%I W)P"@.
M"<$4R8GRE#)L5I">IP*DL^DX"5\!@CDX_G?U70CJ<K^Q[$1JTQ)_Y<I/_1L-
M)#D>:_%5S_:MZ>B_;KG\?WKTF-'NEPW_ !0>6'<''_;_ %70GJ?,SS&,$>O)
M^E078^E_V+1Q?_\ ;K_[7JT1(\D^!NMP^'=6MKNY;$8E:,G@!?,1HPQ+$ *"
M^6.>%!//2I13/>?CE^SQ=^.KQ;RTG3!0*R3,X";1@>651_E/)*D##9;)W86F
MB$SR#3H_$'P;,TRV[1+) %9B/.A7<V$D+1L8A(&X7?G&X@J0W*V*W/+M8U)]
M0EDGF;=++([R-@#+,2S'   R3T  ]!2*(%.X8/2@!)9O.YZ 4@(5DW@TP/J?
M]DG5H=5TZ[TK>\<Q=WW(P20))&L>^,Y+;D*<G&%+)R2<52,V<1XL_93UBR!^
MS&*X3S"%5'\N3;SAV$H1!T&0'8@GC(R:5BKG*>*_'^L6>GQ:#?*T,"Q_<DC9
M99$$@>/)ERP5&3:FS:,#:<@<*X['J7[+ELGAW2]1ULJ'>,2 +@*VV&+SF ?D
M@.64$8P"@)W< 4B6?/.IZ]<>))Y;NY<R2R$EF;KV^@  P !@      5)1WGP
MK^.%Q\-4FABC69)D!569@J2 8$F!P01PX&UF"K\Z[>2]@:N9O@KXH-X0U$ZE
M';P.SL^8]I5$5V!818)\L[<HI^;:I((8<47"QH^*+/5_BQ?'44M)RDQ"0[5D
M:%54[%42,-@ .2[95=Y=B%R0#<6QV'PH_9ZUO2=2@NYHQ;I#*CLQE0EE# .@
M\IG.60D8.%(R"><%I V0?MAMMU>$]?\ 08__ $=/0PB=6<Q^ N>O^-_3Z"ZG
M+?L>#&K3_P#7C)_Z-AI()'+$^7XLXYSK?_MW2ZE=#TW]L'QO-"\.E1DK$T0F
MDP>')=E12,9PIC+8S@D@D9135,E'SC%=/IFUXF*R[E964E64@Y4@CD$'D$<@
MU)9],_M&:G)J/AG3KB<[I9)+1W; &7:UE9C@  9))P !Z53(6XWX4S'P!X4G
MU:+!GG9V#;55D_>"VC!)#;PC9D (QEBN!DL1 ]6?,EU*^H.]Q*Q9G9B68DLQ
M)R6)/))/4GK4E'TG^QQXTDD-QI4C.R(@EA!P40;MLH!SN&XNA"C*YW'@D[J1
M+/!?BR=VK7W8?;KH?^17J2CG8&"#)Z#GZT"';S)\YXSTIC&"3)PHXSUI ?6W
MA7Q2_AKP1]KCSO$4Z*58HRM)=/$'! )!4ON&.N,9'45T(ZGR))+N^7\:DL^N
MO@3H-SH?AJ6[TR,2WUT9&C'[N-E(;R$RTF58)M:4!L Y*@<DFD0SQR\_9S\1
MW3,[VQ=W8L[-/ 69B<DDF7))/))ZFE8JYZK^S?X#U_P'=M#>0%;&96W_ +Z!
ME20#*R!5=V).W80N,@@MG8,-$MF;X'^'4,'C*XA&TI;![E4\L!/G"%$ SA=A
MG!5AW0$!<C:=1WT/./CWXSG\4:O.DA/EVTDD,4><JH1MCL, <NR[B3DXPN2%
M6DQHYOX;^-I/!FH0W4;LJ+(OG!,$O%N'F)AL*<J.,]&PP((! AL]Q_;98C^S
MP._VO_VA39,3YD9! H]3UJ2QRS^6O Y)H$0O'CJ:!G5_"SQ^_@&]%_'%'*0I
M4B0'(4D;BA'W'*@J&PP 9@5(.*!-'2>,;75_BY=_VA%:3F.9E2+:LC0JH.P*
M)& 0 ')=LJN\NQ"Y(#W%L=A\+_V>M<TW4[>[E06T<$L;LQF0ED5E#QCRF<Y9
M"PP<*1D,1G!=A-D/[8B-)J\(7_GQC/\ Y&GI,$>F?$#QO-X/\*63VQ*RS6UG
M")%.&0&#>S#@\E4*@C!7=N!!44Q=3Y"V"3+MQCM4EGU-\'/$,VK^$M0^TN7$
M,5[%'GJL:VRL$SU(!8XSG PH^4 "D0]SF/V-M 34;VYOFQFWB1$4J"092WSA
MC]TA8RO R0Y&0,@B&SQ_XC^/9?&MY)>7!)W,=B$[@B9.R,8"C ![ ;CEC\S$
MTAK0ZG]FSQG)X=U:% SB"X=8947!#E\K$2#@?+(P.X?,%W 9#%2(3.I_;&?&
MK0@#G[#'_P"CIZ;!'@RI_$U246(U"#S&Z=A0!)!!]JS(QP,XH$5GN=K80<4#
M"%&W9ZG- "9(R,\YH 6(&9N!TH =)(8V/<T )"F07;H.GUH CB_>G)X H M;
MP5R?N@\#UH JG+_,?PH [WX5?!B^^($@\A=EN'"RSMC:O&XX&07;'\*]"5W%
M0VZFA-GV5\./@YI_P^!-DA,K+M>:0[Y67<6VYP%4=,A54-M4MD@&JL1<[2>=
M8%+N0JJ"22<  <DDG@#%,ENQP6O_ !ML-,RL1:=QN&$&$R.F6; P3T9=_'/I
MG94FSBGBHQVU]#B=0_:%N9&S!#&BXY#EI#GGG*F,8QCC'X^FRHHXWC'T2^>O
M^1S\_P 9M4D8L)@H))"B./ ]AN4G ]R3ZDU?LT8/%3[_ (((/C-JD;!C,& (
M)4QQX/L=J@X/L0?0BCV:!8J??\$='IW[0T\>?M$"/TV[&:/'7.=WF9[8Z8]\
M\0Z)T1QCZI?+3_,[W0_C'IVK':9#$Q) $HV#@9SN!* =AE@<\8Y&<'3:.V&)
MC+R]3MJR.PQ=>\*0ZP,L-K_WP!GI@9]1T]^, CFO/Q&$C7WT?=?KW.ZABI4?
M-=G^G8\TUK0I='<)*!R,AARI]<' Z=_\"*^2KX>5!VE\FMF?54:\:RNOFGN9
M]<ATA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0!B^-O^/"Z_Z]IO_1;5TX?^)'_%'\T<]?\ AR_P
MO\CY*%?>'Q(8H 2F F*0"T % $P% #@M #MM ";: ' 4 +B@!=M PVT *!0
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M^&?%/BKQ%9R:A#.HA3H9$MX]X'WV4O&%VI_$S,J\$ E@0&(\/T#6&TB>.ZB
M+PRI(H;.W*,& ."#C(YP1]:11]+?&3X?+XYNM-OK=BT5RT<+8(1O*(:X$BAU
MX(C$A.[G[@"DYILE'%_M5>)EOK^&S4@BVC);A@P>7#%23P1L5",>IR2> ,:.
MJ_9KU-[S3+VSM#LNE=G1V V!I8ML1Z-T:(E@5(QCKR*$)GEEU^T%K]K(T4EP
M596*LK00!@0<$$&+((/!!Z4KE6-CPC\6?$GBZZ6SM+C<S#))B@"J >78^4<*
M,CW)P "Q )<5BOJ$FHCQ%9IK$BR7$=Q;("ABQL\_<O$87&=Q8!PK[6!( (H
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M!:$ST_XKZLE[XKLT .89+&,YQ@L9?-R.3QMD YP<@\8P2WN2MCGOVO27U:!
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MW/H>APZ#"EK:H(X8UVJHZ ?CR23R2<DDDDDDFK,SG?'7Q-M_"B[>)9\@>4K
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M@8N*  B@  H =B@!0M "[: #% "XH 3;0 8H ,T . H 6@!<4 &* %% "E:
M%"T .Q0 +0 _% %_0];FT.9+FV<QRQME6'4'IWX((X(.002"""10!])V?Q0T
M3XM6Z6FM*+>Y53AR?+0.58,T<N2%&%#;)?E+;5Q(5!JB=BM;?"3PGI9\^6_$
MR(K$QFZA8,-I[0JLA/<!3DD 8/0@7.?^-7Q]CU2(:7HQV6FP*\BJ8]RXP(D4
MA2D8'#< M]T (#O5P2/)? VI1Z9?VMQ,=L<=U [M@G"K(K,< $G '0 GTI#.
MW_:*\:VGB^_CN+&3S(UM40MM=/F$DK$8=5/1ASC'--@CRXFD,]L^)_Q'L-;T
M"QL+>7?<0_9?,39(NW9;NC?,RA3AB!P3GJ,BF2:7PC^/%G#9KI.MIOA7A)&0
MSQE 2ZK(IW'Y2 $VJPQM&%";B7!HU/MW@BP_?(N]D^94Q>-N*\A<280Y(QA_
ME/1N,TP-OP=^T_I\\LD,\?V2U1%%OA6?(4L""(P=GR[-JJI5<-ES\HHN*QXI
M\*M:M/"FM1W$LV;6)YP)MCC<ICD1'V ,PW9'&"1GGH:115^-/B*#Q)JMQ=VC
M[X7\K:V&7.V)%/# $<@CD?I0",_X>>.)?!%Y'>PC=MR'3)4.AX93C\QD$!@K
M$'&* /?=8\>>$O&NVYOUVS'.=T<Z2]E&]K?(?A1MRS;1P,'(IDF1=_&+0OA^
MC+X?MA+,ZG]ZPD55R.A:7,S ,BDQC:ASD.&S0,Q_V@_B'IWCFWM9K.8F6,ON
MA:-U8"15))8C9E2@4A2V=V0<#D!'/?!SXXO\/]UO+'YMK(X8@85T;Y59U./F
M^4?<) ) PR_-E!8]#GU3P3JQ\^1!&[JI*!+J,*=H&W;#^[!'?;D$Y.3G)8'+
M_%GXYQ:C!_9>B)Y%I\PD95$6\%CE45?NQM]YL@,^=K!1N#JX)&1^S]\4X? D
M\J78/D3K&"RKN965B%8_,/DVNQ; 9N%VCJ"(;0OQI_L&Z1)]$<"4ROYL:I.J
MD,,AAY@"(%(P%4#._C 6A@CH/A=\?+:SM$TG6(?-MUPHD(\X;=X**\;YRJ<D
M%<D*JJL9(S1<5C;^V^";']ZB[V3YE3%XVXKR%Q)A#DC&'^4]&XS3 XOXR_'2
M3QQBUM0T5F,$JV \C=<OM) 4'[J@D9&XDG:$5QI%_P#9N^(ECX--W]OE\KS?
M(V?)(^=OF[ON*V,;AUQUXH0F>+8P<TBCU']GGQE:>$KZ2XO9/+C:V= =KO\
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M&S$G.[+,01D\8#)U,_Q#^T-I?@NR>Q\,Q$,S$K*RGR\N,O+^])D=QPH$B@#
MZHH5BX[7/FK^U)3-]H#OY^_S/-W-YF_=NW[L[MV[G=G.><YJ"SZ<TKX\Z/X]
MMO(\3P(DB;L2*DC1X+*0$9"TT;' W ':P7EOFV"[D6L0ZI\8?#GP^M9!X=CW
M7<L<BI*$?,9.T L]R"Y4$!@@#*67Y@N[=0%KG-?M1_$[3_&HL_[/E\WRO/W_
M "2)C=Y6W_6*N<[3TSTY[4F-:&;\*/"^D>(M)O\ [4F_48(+J:/YIEVQI"FQ
MOE(C.)">#DGN"M ,\>GE$AV1]!_G-(9!*PC^5?Q- 'HOP/\ BC)\.KOS]I>W
ME&V= 2#MSD.HR%+KSC=P067*[MP:$U<]JUSQ;X'\4/\ :;L!97&7 CNHFW$E
MFW^0 C/ECN;+9/\ $0!3%JC/A_:%T3P&RVF@6F83(GG3X*DH&#-CS")96"M(
MJ^8R!&QC<G%%Q6.%_::\::?XRNH;O3I_.(@,3KY<B;-KEE;,BKG=YA& .-O)
M^883*1K_ !<^)>GZQX>L-.MY=]S#]E\Q-DB[=ENZ-\S*%.&('!.>HR*8CP$_
M*,#J:DH]Y^$OQ,T_P_X=U#3[J;9<S_:O+39(V[?;I&GS*I498$<D8ZG YJD2
MT>/^&O$LWABYAN[4XEB=7') /JC;2"5(RK $94D=ZDH^DH_B_P"'/B' C>(8
M5CN8U0,VR7#$;^$>',NSDL4<@ MQO(W56Y&PZ7XY:!X'$-IH:;$DGMS/.(V
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M.5N6ZY5J^WS>O3M^' L54JI0C\6MWHN_W>O?\=2VTRRU>/=&B%"<95=IR.W
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MEU;M?9+HM>O]>O%/%3K6C&^B5[;M]=NG]>D'V"POKGR51#F/=N5R!D'&T*I
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M:75OI^AX214!;D J9#Z=PQ ].W7'>OH)QHX?1J*OW3D_U/"C*M7U3>G9\O\
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MO$?+7/S@=QR<KZ'MCH!R!Q@Y5LNC.2<?=5]5_EV_+]=*6/E"+3U?1_Y_U?\
M2QI@TZ9O(B6-F&>J[B<'G#,#N_ GCIP*UI>QD^2*BWKTO^+6OW_@9U?;17/)
MR2TZV_!;&+XW\)QVB?:(!M /SJ.G)^\,GCD@8''(P!@Y\_'8107/'375=->O
M_ ._!8IS?)+7L_3I_P $R?!&E1ZG,R3+N41DXR1SN4=B/6N' THU9M25UR^:
MZKL=F-JRI03B[._EV?<M^/-#ATOR_)7;NWYY8]-N.I/K6^84(T>7E5KWOJWM
M;NS' UY5>;F=[6MHO/L<G7B'L!0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M&FWY5G%]<1I;Q )E! S9GR2Q7YE7:<KN4[2A.YR@!P);REV]SR?\* &S. @
MZ]Z 'A&D ]!TI@A)+7RSM[U(R1(C(=J#CIF@02/Y*[!ZY)I@1LF3D]3T% #V
M';^$4 ,P =QZ=A0!+#)N)<].WUH (R6^8=<X'^- $7E#OR<T .E;G ZT -,F
MQ=J_G0 TVI'7K0!8DFRPP.%% $18G+M^'UH (H6F(/0$X)H EGN5!V1CCH*
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M_H37U^-DXTI-=E^+2_4^4P<5*K&_]639YEH/_'Q%_P!=8_\ T(5\AA_XD?\
M%'\T?5U_X<O\+_)GI/CC_CSD_P" ?^AK7UN/_@R^7_I2/EL%_%C\_P F>6VU
MV]J=T;%3C&5)!QZ<5\;&;@[IM>CL?72@IZ-)^JN+=7\EWCS'9L=-Q+8]>IIS
MJ2GNV_5MBC34-DEZ*Q!61H% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % &+XV_X\+K_ *]IO_1;5TX?^)'_ !1_-'/7_AR_PO\ (^2LU]X?$B4
M% "T % #D% %S% P H =MH 3% #E% #L4 &* $(H 4"@!<4 +B@  H ?B@!=
MM  5Q0 ** '@4 &*  "@!Q6@!",4 (.: 'B@!5% A_2F TBD **!CJ #;F@!
M-F* %S0 XTQ O-(8G2@!Q6@ 48H  >:! [;NE P"\4 +]V@ S0 B'G% B390
M !,4#%84 1YYH 4@T /1<<F@ )QTH :?F% #HVR.: %8\<4 "MCK0 KINZT
M-"AQ0 %L=* "'CD]: &MEC0 NS>>: %9R#@4 1RY/RT 22]@: !KCG H 6)]
MF<>M !,, ?6@!2/+Y/2@";(D'% BJJ@DD]J11-$GF?,:8B*=LL?04#$B8$9-
M #V3& .Y%(!SE1QWH KS-L''WCWH >;;&%H$2N _'8"@8TJ(U_D*!"6\N.#Q
M3 </FYI $K^0I84#*4;EUW=N] "K)G)'T ]Z )XH7/4X% #HIQ#],GF@!\)%
MUE_3@&@"J;@R$@\XX% !'( -HZYY/M0 R-_FWGD>_>@"12225&<]:!DCH"N/
M4T"&R0M.1'V';^M #[LBW 0?>)% "+F-2#Z4 1K^Z !/'?US0!*TA4?+QD]Z
M *NI1F0A1R?Y4#)%CW+D]1Q0(;;.;(X/4]!3 223NW+Y_"D KW/EO\W/RB@"
MQ:DG+/P/2@"O]H-Z^%Z#I0 FJY7:I.2>M R-8]CC/4C\J0#XU,C'' />@!8D
M"N1V"YH ALYS@Y[G\Z8B6[F.5!^\3P.PH&0^<?FSP,YSZT 1QSB-#@8+']*!
M$VE0[<R-VX%(9)J+-CLHQ^-,!]I$50;>OK2$0YW2$MT44#&VZF<';@ ')-,
MFD$,:GOGC_&@!%+$%FX)'/K0!8D5;6+IR?ZT@*T3GKZ#&: $M(?/;:>%ZGWH
M$22RB1@,85:!C;$;RSGKSB@!+0X[989P/3WH BV&X?!.<GD]O>@";4"%98EZ
M8YH ;'%E@HX]30 ##N5'3')]J  .%)=1P.![F@!-/9MQ9>M #YW(<DG)VXH
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MKQ#V H ])^&O_'NW_75O_05KZW+/X;_Q/\D?+9C_ !%_A7YLY/QQ_P ?DG_
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M=#OQMQ'NSC&/,;.<\8QUJ<;;V\+VM:-[[6YF5@[^PG;?WK6_PH[#78I9H76
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M2/\ BC^:.>O_  Y?X7^1\DU]X?$AF@!,T +0 N: %!Q0!?Q0,4"@!P% "[:
M "@ (S0  4 +0  4 ."T"$- "K0,>*!!NH =C-  !0 O2@89H$**  M0,4T
M"+0 X4 +G% @;FF @YI ;GA+P5=^+I3;V,?F2*A<C<B?*"JDY=E'5AQG/- &
M=J>GOIDKV\PVR1NR.N0<,I*L,@D'!'4$CTH KD8H 4-F@!IXH&=/HWP\OM;M
M);^WBWV\._S'WQKMV(';Y68,<*0> <]!DTQ',A<4@$Q0,?S0 F: ';<<T *A
M% !NS0 GWJ!'1M\.;X6/]J^5_HG_ #TWQ_\ /3RON[M_W^.GOTYH&<T#@YH
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M8]NM,!8R(8]HY9\_A0!7CZA5Y)(YH F',F,9*YS[FD UF &>I8]?\!3 ?;.
MS.., X^M BLLF1QUR2?;WI#+EI;I GF,?F/2F(KS3J%XY)[4 3VI,/)'S?R'
MI0!G.YE)8\Y.*!EB.#R@03@\<4"!!YS #[HH :ARQ8^M(9+:Q_:\@G"CDFF(
MCGN?/_=H/E&<?XT );2"W5N[$X_"@ L6"DR$<+_.@ ('^L?DMDX_K0 U'+#
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M)QR0^!GZ;3C\S7LK---8_C_P#R7EG][\/^"4-6^(4UV-L0\L8Y(.YN_? Q^
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M *]IO_1;5TX?^)'_ !1_-'/7_AR_PO\ (^2<U]X?$B4 % !F@!: %)H TMM
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M_P#$\NCV_<?^B(J&"/,(RTK$_P -2465D R!VIB.C\5^/+[QOY;7\OF^5O\
M+^2-,;MN[[BKG.T=<].*0+0YJ0Y)/4] *!FCI/A.^UU?,M[>:5 VTM'$[J"
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M!0!#DQC&<9ZT )N"#CTXH $0RX)^Z./ZT 33WAN<(HPHY_\ KT#*Y'/3/I2
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M'./0= .@Z# SWKYBM4=63D^K/I*5-4XJ*Z%2L#8* "@ H * "@ H * "@ H
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MV3X!66%V3ZM/'[[0,_@5A!'LTK#L!^Z-A;GSGK^LRZ]*T]PYDFD;+N>I/X<
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MMO,+88'4F@1-''O8EO3CVI#&S-O8#'RC^E,!D$_GDCU_+% !9VOFY"\@']:
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MCI]T'U]:!D=M.+4@XR<T@+$DXMOF/+L,_3/:F(J0JVH.!UH FD8([%N<#_\
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MD 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M%%N ^<+Y0#2\I@85MS9RN"0!0KE_P]KOA+2;J 6$7FW$L\42?),^QF8;9/\
M2"%7# ?,N7&?E&,T <-^URI.J0X_Y\H__1LU)C1T\8_XH;_/_/\ 4=!=3SK]
MGI,:Y:?]M_\ T1+0AL]I^(3^%6OY1JG_ !^?)YO_ !]_\\UV?ZKY/N;>GX\Y
MIDG. ^!W./3_ *_Z0Q/B3\1-#_L.72M*E_YY^7'LG_Y[K*_S2+_O'D^P["@
M9MW@;/\ G_C^HZ!U/G>-<C)]*11[7^R7>L=1GC#'RS:L2N3M++)&%)'0D!B
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M!B'YNIQ0,C0E\N: 1:M7.UF!VC./?Z4"(K.#[6V ..Y/I2&.N6^T2%5Z<#Z
M4P()CMPB^O7UI )M+,1Z\4Q#P=G ^F* 'FW\A2[=<X _K0 UHS.HQP .OK0
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M R25G.7_ "I@,>0W!QVI 6-P@P%Y.,_C0!'! 96P.6)I 6 ?L^1U8Y&?3M3
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M!<M#G<G#(W]Y&Y4_E^M.+NB:D.25ON,6K,0H * /I#X(Z>MKIJ.N<RO([9Z
MAO+XXZ80>O.?I7!5>I]!A5:'K?\ R_0N?%'_ (]D_P"NR_\ H+UX&9?PU_B7
MY,^DR_\ B/\ PO\ -'G2U\B?5"T@"@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M"F^"FF7-WJDJDR;&CMPYP) AP@(!'F.2%;:K *@8LRCY7L+<\?\ V>0(]=M
M.I\__P!$2U**8W]H=_\ B?7>.H\C/O\ N(J;$CTGX*>+[?X@6$GAO4CR$ B.
M]A(Z@E\ G(W1%05&<% !L*HV6)G@?BOPQ)X4NY;&Z \V,C.#N4@@,K ^A4@C
M.#S@@'(J2SWG]L>(2?8-QX_TK_VA39"' !_ W'3'_M]1T#J?-PE\F/'M2+/H
MO]C&+8+\D8S]E_\ :U-$L^=!,TP))PH_,U)1 DWD+M'5CG% %B\'EQ@GJ<"@
M!MQ+DJO<XH 6,&X.1P!WH 8H)8_W10!'("&!(XZX_E0,L&!FPS=2>G84"%O+
MC8NT'+&@!@M]_P @[8Q0 YX2/D3C^\:!C-.0-[J":!!?)YS!0< <T ,DM265
MB?E!% R:YF\SD<*._K0!63A@,\X_+VH$3>?Y>X=\\?E0!#;*8-Q8\\?K0!/9
MID%VYQR/;WH @$A#%WXR/EH M6MKN3<N,GUH JP0&3G.3DC/84ADG]GF(X4Y
M8]_;O0 ](0 =G!7OW-,!CXN,*.%'+$T %V"P#'A<C:/:@1(EV,EL851P/>@"
MD(?M8:23D#IB@9<LE$X#-PH[4"(UNO-RRX'8?2@ OBJ(#[_G0,ADE\M@3RY_
M' ]*!"*% .\'=0,KREFPF,#K_P#7I :,4*L_'.!UI@1?:-Y9B>%/!]_7WH ;
M%;!HVD;DG.":0#6E^TE4/0 $BF ^]MR!E^..%% #+R<1(L:'D\X%("6"/RE"
MK]]N30 DD0MY!N.=JY_&@"*-?/DR3USQ0!$S>>^!]T=>W'>@"S;1"9B%R$%
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M(HSC\Z!A$0YXX7UH >\@?YA]U>F?6@". ;^2<#UH 22;G Z 4 -MUSR1GT%
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M:WTSQU-?,YG/6,?G]^GZ,^ERZ&CE\OU_5''K7SA]"+2 * "@ H * "@ H *
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MWIZ4P%%QO;*C QT'-(#0O3Y$8!P?0#U]33 S0"Y"+T]>U &B0+4?)]\\#UH
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MB0L#$Q4 [CN^0$XVB0G<!G+1+/N.K(/D_P ;>&&\-74EL<[0<H3_ !(>5.<
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M!&U3U! Y!.6[]<9P*^)QE7VE1OHM%Z+^KGV.$I>S@EU>K^91%>:>@% !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % &/XS_P"/&Y_Z]IO_ $!JZ:'\2/\ B7YHYZ_\.7^%_D?*^<#/-?=GQ0Y;
MG/:@1('S0 QGYZ<T#&CCB@1.@WT .S5 &* #I0 H;- #B,T -*T *O% "9I
M.4XH 5GI@)UH 4"D IH 4-3 0_-0 @%( 8>E Q1D4 *ORT +0(5_FZ4P&XW4
M@% H <ORT ,>@8X+0!(QP* & &@!A8J: 'E=W% "A,=* !YME $1.>: )F(
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M/<T 1Q29RW4G@4P"&,R-AN!SGUQ2 CN+LN<#@= * -"/*+L1<]-WU[T 5'E
M+-WZ#';UI@+Y990/4\<\DT@)+B8+MB3L1GZT 1BXV@I'^+4P&2'< N>/\>]
M$T0&-Q.U0,#N2>] BN/W8W=,]/I0!,GR ,QQA?E'<GUH&1;-H7=]:0$H<1_/
M_$?NCT'K0!%'E>O7)^M $ENNQAS\Q//M3$),=Q91U)'X#O0!&^)"$7I_GFD,
MDN!M7V'3W]Z &/,47W8_IV%,!L ,0SGEAQ]/Z4"$A7RN_P V>*!B@X^9CECT
M']:!#IK? #9)/Z4AA,_E+M)Y[T ,53@$#B@"=X?(4*O+'KZ FF!!<.!\HZ#^
M?K0(18RZX7ZGTH $7@+U).:!EI(Q$5)' R30 V,F8[GX3.<>OM2 B+-<?*O
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M.[=G<0>FW'0#UKT<;A8T.6U];[VZ6\EW.#!XEU[WMI;;SOYOL<U7D'J!0 4
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M1P>*YJB49-+5)NS\KG13;<4WHVE<@K(T"@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#'\9?\>5S
M_P!>\W_H#5TX?^)'_%'\T<]?^'+_  O\CY6^9NU?=GQ0!=G:@!1D]Z )%&!D
MT -1,=: &F?8<4"+!J@%H =0 8Q0 H:@!"U( VT *13 "* %-(!5XH 4#- "
M,*  <4  .V@!QI@-W4@' 4 *: $89H&(OR4 *H)YH$.44 "-0 QWS0,<AVT
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MYS)F1NW"CMG_ .M2 B6#(W-R!VH&37*%47'?&*!%?R6($8'0DG_Z] $G^I0
M?>/?^E,!;9?(5G)]A0 RU@,V7[#O2$3WUUG]V@XQCZGN30,;9)Y() RW3Z>M
M,!('*L7QD\A?KZT 0W!V +GD\DT (\6U<=!ZGJ?_ *U $TD@@4*H^8@<]Z (
M9H=I"$]LG^M #W?>23PJX _I2 C$F1UY-,"S-"J#+<G P*0$&_:<]3T% Q$8
MH#V)/- $EHWD R'TPM B+RS&.>K]!WH >MH(V"DD8')H 5R+@X P@!_2@"-8
M_MC<\!1R?I0!)-(&^5?2F (1;)D_?/3V% AOD>4HD?DGH/ZF@!CSF1N><=J
M'*ZPDDC<V?PH&2VEX2Q=AD 8 [4"(QFZ8GL.?I0,A:(+C')-("69S$NWN>O^
M%,0_S1;X8C)P,?XT 0-,UT0/_K4 32%8>%^9N@/:@9 <@;/Q/^% A;4 ?,1T
M_4T (LI.2.I&*!D9R!Z"@"[#;!%RQ^8]!_4T"(5<R KG"CDT 1NV_IP!T% Q
MPA##<3QV]2: %7]^0HX'K2$6[MT7"1C)/>F!$B;%.WINP30,BN)/.(4<!10!
M"XW?=Z"@"Q)-Y&0/O'J:!$4DN0%].3]: &32D]L#TH MQP_9\2$\D<#VQUH
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M&+*#LE!;L"I4?F"W\J[)96[:23?FK?JSDCF2OK'3R=_T1R.H:;)IS>7*NUL
MXZ\>H(X/X?2O#J4I4GRR5F>S3J*HKQ=T7=/\-27T+W"E0J;L@DY^50QQ@$=#
MZUT4\+*I!S5K*]][Z*_8PJ8E4YJ#O=V_%V[FQI7PZENEWRMY>0"%QN;\1D8_
M7WP:[J66RFKR?+Y6N_GM8XJN81@[)<WG>R^6Y'JWP]FM!NB/F#'( VMW[9.?
MP.23TJ:V72@KQ][\']W]/R*I9A&>C]W\5_7X>9RM>*>N% !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &/XS_X\;G_K
MVF_] :NG#_Q(_P"*/YHPK_!+_"_R/E)9<'!-?=GQ!(6![T#"1LCB@!JH3WH
MD7)XH$(^%ZT#+.:H0TT@)%YI@*10 E ")S2 <>*8!0 XT &Z@!<4 (7H $YH
M 4C- !U%( - !BF 1&D K<=: &H-U "/'0,=OP<4"%W;:!DBTQ$9^8TAA]XT
M /\ ,VCB@!8WW?6@!A7- !TH D//TH :3NS0 @DV\=Z %*9XH %^:@ 5LY)Z
M4 )NP<]J $)4\B@ M[?^(]Z0Q"F\Y'W10(1,NI]* )H&! %,"&3#?,>W2@"3
M:"-S<GL* )(GXR: *\CX.V@ N'"#'KQB@!T\8< >G2D,3 8[AV_G3$/CCWG)
MZ>GK0!$7,A;;TQB@"33FWI@?G0!*Q\K@=: (9N%&.N: "9QQGD#^= "W*EDS
MVXH D6Y^4^@'6@"K;Y.64<GOZ4AD\4?D<D<GIZT 26/ .X\[C0!7EN%W;F V
MCI[FF \DJA<\9!X_E2 =+,451[#CI3$1*PMCM;@$9_'N*0Q]S.(E##_@(_K3
M$5Q$8R&/)Z_2D,'C;<)6SZ^U "S$W*ANV>30!(5VX8G'H* &7\GF\#I_,T 3
M6^;8;?09S[T 5X\W 9N<#GZGTH 651MWMR3T'I0,FNI-J*2<$#@4"(#.8%'=
MF.2*8#E<R-N;LN>.U("&Y?S/N@\#.: +;2^5%E>,CKU)H$0%59 ,8'&3W/KB
M@9;9A$F M %2S!&Y>] "2Q!\1C&1U/:D,EO7$:8(QZ>_O3 @F0LH).   H_K
M2 FOI>%B3J1S3$3V8 ^1<<#F@"JDF]V"] #GZ"@!MRP"_+^([4#$ED%N1M^]
M@;C2 NP1@#>Q^5>WJ:8%5IRX:0_>(X'H,B@"&.#<!(>3N'TI 7O/^QJ6;ES3
M 990"-?,;ECSCTS20%>WN6E+$'D\4P(%F\C..1GF@">WN3<#RQ_$?R'<T"%>
MZ W!1Z 8]J!B61#99OFQSCMF@1+<W"^7ECRQ/% %/3Y H8GIB@""SR7ST Y^
MF.<TAL>)MY9CGF@"R5$0"#EBO/U/;\* &S1^6%B'4C)QT^II@)".=O11W- $
M:'R,D'J< _SI#-"+_18MV>3T]30(S6E\O&.3@=: +XM2B!F(QU/UI@5K#_3)
M 6.%7GVI ,N+K[0Y/X "F &+*'/ 'ZF@!6 .2W0  #]*0"!@ &/88 ]??Z4
M)*3)M3IDY/;%,!UW)YS!1PHX]Z0$@C%OGZ9YH CRURX8].W;@4P$)+ACT I
M+Y7R*SGKT'MZT ,=3=$N?NC_ #B@":]G(497&: $\T6@/]]N?IGM0 V.Y*(>
MV6Z]^W%,!DJ[ $7[Q//^%(!9;86Y&XY?T[#% #(%4Y9NQH$/E?RSN7[YYQZ
M]/QIC$@B+-\O+8SGIBD ^6/ "$]\DTP((;<NV>W7\J0$MX_G,JKUH DF L1M
M!^8]3_2F! (P5#M] /4]3_.@!\3&X?<W1?RX[4 1F3S6+ <]O:D!9M; *"7.
M1Z"F!6DN-^?R'^%("S96;.-N<#J2>U,0RZ=&(2$''<GJ<4#*TAVD]SSSVH 3
MR_.Y)X&.:!$JMY8)7JW3U H 9&VP>](9/$HD^7G"J3_*F(KM* #CIGI0,M+
M+=0[<LW0=@*0$$D@'! R3^E,0^9<_,_4]![4#&V\PC))Y&T@#\J &1L7)?\
M 4 "1\[<Y)]*0%BXD%O^[4<XP3UY[T 13.8%V,.22?Z?TH ACB^T$*@.33 F
MN(RIV#J<9]Z (7.WY1TI"+,0&S+= .!ZGUI@,!$_).$ P?\ "@!WVS(\N(8&
M<Y[T (B!%..2<^U $:+N 4?4GL*!D<K]EZ#C_P"O0(>_RJH_']:!@N(_F[]O
M\: &19D8"@1+#;&9PH^IH 220R-M7KF@"18!$2/1>?K0!#%)MRW?I_\ 7H&-
MV%F&[N:!,L7BL3@\<\"@97";VV^E B:&,,3C[H&:0QJRE"6/T%,0AD\T!12
MN" *N6^Z/S)H&0^8L"Y/+-@_04Q$4DC2#'0$T -E7 P/NT 78(4BB+GKC _Q
MH J%=WS/T[#UH B9MYR>G:@!44,?04 6X(EG8#&U>I]<"@"&>\!;CH#P/Y4
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ML,<;>7SC[V3CLA5ON>/6PMM8Z^1Y+72>6% !0 4 % !0 4 /@@:=@B LS$
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MP]NU %A9?.&_HHZ#')]Z *,?W>XR22?:@!8) $+*,8.<_P!/>@8ZZ'GKO?\
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M>YI@%K<,S;SVZ=N>U #4S,Q9CV/- A;=<Y+GY1SCU]J )R?LZ^9@!VR1GL*
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MYX]J *V[9DGER<_3WH <XR09!DD<#^5,!QN?LH..'/'T'I0!6C=F)/<\#\:
M)O)6,[2<^OH*!#99Q+[*.@_E0,A=B^% X_SDT 6&M#&!VR/Q-(!9K<0C;G+>
MW:F!79@OR@\4")C:B-02?F/0>U #9<2$ =!Q0 JDD[5')X'>@"\Z)IZ$-S*<
M]^E R@)6487C/4T");*( %B> /UH A&#DG@9^I/M0 +-C.P8_6@!]G"7;)Z
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M3-WXE?\ 'PO_ %R7_P!":O2S/^(O\*_-GGY=_#?^)_DCDZ\0]@OZ#_Q\1?\
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M>: &]&YH$/+XH&1_>H$/1,4 $SXXH&0-\W!H G@&!DT -4;,L>] ".P&!WH
MF9=W3M0 22[L8_.@ D?;P* %W!* $0X/N: (DD\DD?K0 C';A>N: ',X0?TH
M 1WVC ZFD,2%>=J]>YH ]$\+? C5O%J*\,/EQ,>)9CY:8VAPP',C*00%9592
M3UP"11-SJ+W]E/5;)#(A@E88^1)&#GD#@R(B\=>6' XR< E@N>/7NF3::[0W
M,;QN#RCJ4<9 (RK $9!!'MS2&5I!]H;:.0* )S'W/X"D!&#M.#RU R&!,EB?
M7I3 +M\  ]SS]*!$CP>:0W84#!')<X^Z!S0(1W (;H.P_K0!))+@#;TR.:
MR#!.>.YH JR.-OR\9X%(9/YWDCRR/FQ0 J-]G&T_>_G3$0RMY?IU]><^M(8V
MXN1:M\O+,HY].U,":RLS!\S<L1S0(WM"^'E_X@@FU.WBW6T/F"23?&NW8@=_
ME9@QPI!X!]LGB@#GY)?LJJ1U/ZYH :B_9F+-SGD^Q-(9TTWPYOH[+^V?*S:$
M<R;X^/WGE8V[]_W^/N^_3FF(YXDW)"L,+_=SS0,2\?RF51VR<=O:D SR/M)W
MN3Q[4 12S?:&#G[H./KZ&@"R\:SYD?D+V[4 5Y;C[0JHHQW/\J &2G@X]>3W
M)_PH N+=[LK&I)[L:!%6"+R,D]3D>Y]?I043)&&4 #YNH']:!$#R80CN30!+
M90^4=O5ORP.^*  R@R$#N.3Z8ZT -<AANQQG\_IZ"@">YG\A.#DL.!Z4 4W+
M-&%/KT_K0!8E(B51@'!'X^U #KB)K(!R#AU+#(*@KN*DJ3U&Y2,CN".H- %2
M,;_WW^UP* +,-L"2S'/N>GY4 (Q^T'"YV"@94W;V*CN<#VI 7)8G,;)&I944
M,Y )P"P7)QT&YE&3QD@=2* &J@L@&/S.1QQT_P ^M,1N_$#X>:AX)$9U&/RS
M-NV_-&^=NW</D9L8W#KC.>*&%SG#;^4FYNA_#_\ 72&,MWW)\Q^4'./6@"S9
M)TD(X&2!_4T 1.[;\]WYSZ"F!,\8M6P#N) Y)XI 0LOD<J<L01F@!T\QB3RT
M[_>/]*8":EQA&P<#C% $OG><FT#8@'S'KGVH$08^V':G" <_U-(8@X3"]V.
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MAK'BJ!+RQMM\#A@C>;"N=K%&X>16'S*>H_2G8FYJ7'[,^O@!4M.G?SK?D_\
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MPJJH+,68@!0!R22< #F@#I_%OPGU#P*J27\(02,0F9869B!DX5'9L#NV, D
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MZT 1K;Y^=^GIZF@!NX3D]J %,@;"JO&>?4T :&/L0P8\'KDGF@"C<RM<G<W
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M]@/ZGU/?Z8 \+$8AUY7>W1=CV:%!48V7S?<Z'PS?QPV,Z,ZACYF%) )S& ,
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M5R".01N/->?7=ZDFOYG^9W45:$5_=7Y%*N<W"@ H * "@ H * "@ H * "@
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M<:X_EVL3RNHW;8T:1L @;B%!.,D<^I% %[6/"5WH@$U[!/"F=H:2*2-=Q!(
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M/\S*6&5 '!!'4<TQ6.-"^6IS_$>.](9IZ!82WI6*W1I)G+81%9W.!D@*H).
M"3CMSTHL(GUSPE?Z,#<7EK-"C$*K21O&NX@D#+*!G /'U]*8%".0>6!R?7%(
M95MVW;B?N@?C]*8'1?#RV&I:I8QR(&C:\MPRL-RLOFJ&4@\$8X(Z8XH$>F?M
M>1"UU2WAA4*JV$01% "@"68  #@  8 Z 4V)'5_L41^7_: [_P"B9_\ (_%-
M"D?/'AOP[/K!9+:&2>7&=L:ER%! +$*"<9(&>G(J"B76O"ESX8 -W!+$[[MI
ME1HQQC.W<!NQD9QTR/6F,Q8AM&X]3@+_ %-("[-:&X98(5+N[*%1068L>  !
MR23C ZTP-B]^&>IVREY+.Y554L[M!*J(H&2264  #DFBPKG.W 7?\AR .OT[
M_G0,DT^T27)))'MP,T@"9MR[5YR6..P&>*8%KPOHG]MW5M8@[3/-%&6QNV^8
MX7=MR,XSG&1GID4 SZ5_:/\ BE<^ OL^B:5F!/LJ$R*=T@C^>%8U+9*X"9W@
M[\[<,N#NILA*YX3!\5-8L&$HOKG*D%0T\CC(.1E69E8>H8$'H014E6/HKP?K
M9^/.A3V-WL%]"%^?&T;\$P3?<8)N*LD@3)V[\!0ZJ*W(V/D7_4C@\D?-Z^N*
MDT/KSXR>,[WX6Z1IUE:2;+H)'&\BJDD>V&%4D'[Q<\NRE?ER0#G'0T]#-:GB
M[?M,:YT6[)QR6\FW_EY5*Y5CKOA'^TQJ=U>PVU\ZW"7$\,0!1(W3>VS<IC51
MU8$A@V0N 5R33N)HYO\ :IT!-"UAVCP!<Q).5"[0&.Z-NG!+-&7+<$ECG)Y*
M8T=]\?W'A7PWI^EO^YG80^9$G"L8XLS[BGR-^^=6.2=S_.,D$AL2W,#]CS26
MOM1FNB@:.&V(WG:2LCLH7 /S E%D&X#ID$_-@I ST;XNM;_%+0)=0M5#O:RR
MO&59=P2-RK[BZJRAH,3&/Y6^Y][ R]Q+0^/Y6"#GAO3J?J?3Z5)9[[^QWX5-
MQ?SWCA"+> ( >65Y6^5EX('R(ZL<@X;'()Q2%(\@\=>)V\5WMS=(7*RSRNN\
M_,(RQ\M3R0-J8  )  P. *D:/?O$<8\+^"+>VN#N:X\HH4Y7]Y,;Q<YP1^[7
M!P#\W'(^:JZ$]3YNT30I_$4ZV]K&9)9&"HB]2>IZ\!0!EB< #)) !-06?56B
MPZ7^SQ:%KIUFU26$L57.YAD 1J<'RXMW5FP9"K-M8JL:WL9[GS-XS\<7?C2X
M>\NFW2.< #A$4=(T!/"C/UR2S$L23)9]%?"Z_?X=^$9]11MTDDDDB\ >6S.E
MJO4,&VE-_(P?N]/FJEL2]6>5#]I77U8E[K QD+Y-OWZ?\LLU-QV.<\6?%S4_
M&T0AU&?S(4DWJ/+B3YP"HY1%/1CWQ^.*!V.+-T> @ ^G4T .VY^:3)/I2&=%
MI7A*ZU:,M:V\L[#!811O)MW9VYV@X!P<>N#Z4Q&->:5-I#F.YC:*1,9213&R
MY 8$JP#<@@CCI@T#*T2>5^\;G/W?<^M #Q%@A2/F8\T =9=?#C58R?+T^Z_\
M!IO_ (B@5SDX;KRU)/WF_E2&A+*U:Z)QQZDT"-32_#TVK.8+&*29PI9A&CR-
MM! /"@G&2!Z9(IC&>(/#-YHVPWL$L"MD()8WC+;<;L;@,XR,^F1ZT",<'S"!
MT%(9;TS29=:F\FWC>5SG:D:L[G ).%4$G !)]J8C8UKP-J6GQ^;/:7,428!>
M2&1$&2 ,EE &20!GN<4 C"$6YLOPH."?Z4#(Y91*>.F:!#I&-Q]W[H&* $90
M.">@Z"@8_<RC"\#Z_K0(@B8@[B?7% #67?TY- #\K#SU/Z4P&@EAN-(#ZFL9
M-G@$'COUZ?\ (0-5T)ZGSEIG@Z_U]3-:6T\Z!BI:.*210V 2,JI&<$''7!%2
M45+W1YM)=H;I'BD7&4=2CC(!&0P!'!!Y['- "0W8A&(QESWZX^E '0>-/B;?
M^- AU.;S3%O$7R1IMW;=Y_=HN?NCKGIQWHW Y/<6X')H Z6T^&NJ3Q+)%9W+
M)(H8,L$K J1E2"$((/48ZT!<YQ)/LX./O$8^@H ^GOV(XB@U GO]DX_[_P!4
MB&?-VB^'[GQ'(4MHI)7"EBL:-(VW(&<("<9(&>G(]:DLL:YX9N_#P NK>6#?
MG9YL;Q%MN,XW@9QD9QTR/6@#-0M ..IX[Y%  T)C X.]C_\ JH 2Y5EQ'C'K
MTSF@#0T?PU+JQ,5I%)/*%W%(D:1@,@$D*"< D#/3)'K0!8UOP=?:*HDNK2>%
M"P56DBDC4M@D %E S@$XZX!]* ,Q8#$N]NN< >GO0!7C!D)([ \_6@#I- \*
M7>H(9;*UGN &*[XXI)%#  XRJD X(..N"*=A&1JNE3::Y@ND>.4$%HW4HXR
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MM^IV1I*.RMZ%F#3E3M7.Y7-U$MI&%K.Y=A](84 % !0 4 % !0 4 % !0 4
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M\K*"021CG<MLS1YY\-OVGKG6+^"SU&.%4G;RPT2R@J[?ZO.6DR"V%Z#&[<6
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M'[2)4MWVRR.&"%U!1QM4H[L"J@RLQ+%3PPPY+A:YN_"'X_1?$V5M)U:"(R2
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M #=G'&*EE(]Z^ '_ !3'AS4=57]S._G>7*_"MY<0$&T/\C?OG91@'<YV')
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M\>X G=A2"'-7$D7/A7\;;3XJW,-EJMI&+R-A+;RJ"5WHWFG:3EXB!&I/S%9
MK!B,A&+W$U8X']L--^L0;L[191Y_[^S_ .%)E1.L\ :'8?![28_$%[&)KR<
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MO(%.UANV*VW((W8SQDU)1]$?$OXX6?P>/]CZ-:QB5%0R9!6)&*IMW 8>9VC
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M  ,BX9<*00#AF=B$P3-O]DWPI#:6MUKLL9FFB9XXD5"\JA(P[^6-V"[AP@&
M1@J&P["F@9DK^V7J#2E_L]O]G#_<_>>85SG;OW[=VWC=LQGG9CBBX6+?QT\6
M:5\2-*MK]&6'4?X8O]9+M#;)(G*'"J"?,C:0 LH.Q5+L ,$?.KVZ@[$.2<#\
M:DHFN;$080_>[^PH&5I&,YVH.!T_"@1,J):9W<L1VZ T@$M8W8_*.2/R]33
MDMK,.Q,C9"@D_7M0#8EY=_;&]% &0*!C?-:9@1P%&!GVXH$1B58,\[F]^E $
M:%IN6.%_SQ0!8\U8EXZ_K0!&ESY (');J: $NXRN"W)(!^@/04#$53(-SG ]
M*!#HI%@0D?>;@?3K0,:5+X4G _SS0 \A8S^[Y],^M BOLV'YN:+@3QPFX!8X
M"@T#/JCP7;C[#;?]>T/_ * M?"UW^\E_B?YL^RH+W(_X5^1MB$"N>YT6'A<4
MABT@"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@#&\:'%C<_\ 7M-_Z+:NG#_Q(_XH_FCG
MK_PY?X7^1\G//CKBOO#XDB,N[IQ0,0CU/Y4A#T<#H#0!;AC)H 62,GH:8RT3
MFF2*] QOW: '%L4"%)W4# '8* (MNZD,EQ3$-*X%(!#\O- QX.: $4<4Q"EB
M.*0"(-HQWH&$?[O@T"'!O2@!"V:!AC!S0 UL+R:  OG@4"+0]!3 CE8)]:0#
M@P7ZTP&N_E]:0$&,@>YH&3^6!0 FW(/I0(ZSQ/,=$L[:QC)"RQ+<2$'&]G/R
MJ1SPH4#KAC@D BO,HKVE251[I\J\K;_?<]*L_9PC!=5S/SO_ )6./\P)]:],
M\XZ[X<3OJ<DFFN3Y-RC<<X1U&]9 .,D;>1D!N,YP!7FXM<B55;Q:^:>C7XGH
M85\S=-[23^36M_P.-="H]V->B<!,(?+!]<4"&D[ %'4]:8"@" \=QS]: %BN
M>23TH =(VWGN30!'$AAX[DT@)5_T49)SZ4P&LWRX[G^M !##M7![=J )F.WY
M@.>PH ^L_@<3XI\,26,7$H2\MR6X3?)N=3D;CMQ*N3C.0>#QFB6?(SS&;ITZ
M"I*'%_F ]L&@#IO#7PNU+Q)!)>:?"9(D=E<ADSE55B I8.QPPP%!SG R>* N
M4_"GAB7Q3=0V%L!YLC'&X[5& 69B?0*"3C).. 3@4 >\+^S=HOAXF+4]1VS-
M\RCS(+;Y#P/ED\QCR&^8$ ],9!)=B;B-K_@C0CY\,?G2)]V/9<R9SP?EN"(C
M@'/S'C&1\V*8:A^V5")#I^>WVO\ /]Q28(DCRO@7Y^#S_P"E]'0.I\U*QD)8
M\>E(H^COV-!\VHG_ *]/_:]-$L\5^&7CB7P3>1WD(W;<AU)*JR'AD)'YC((#
M!6(.,4BCZ1TSXL^&_B-QJ,<4=P4,9^T(H*C:6;9/C"KDL$.Z-]W(521FB;6*
M&N?LPZ;KL+7.BS[-^2@WB>V.%*E0W+C+CEMS[?F 4\ %@N</^R-$UIJL\,BE
M)%M)0ZL"K*PFA!4@\@@\$'D4D-G:>*)/!;7<Z7G_ !\^=(9O^/[_ %FX[_N?
M+][/3Y?3B@6IGF3P)%^/_7_0&IG?'?XCZ3KFEP:;I<Q;R9HL)LF&V-(I$'S2
M(,XRHZEOUH8(T?VR1C[ <XP+KG_OQG\:&"/FBT^<DI],GO4EGTY\%;Q[GPKJ
M2R,6""]5022%'V9&( /0;F)P.,DGJ35(A[GS'<M]I8(>,$GZ5)8UI?.)P<$\
M'T '6@#Z;L96MO G[MF0E67(R#M:^*L.,<,I((Z$$@\570CJ?.!'D_NP1G&2
M3V%(H]A_8_._5YV'3[%(/_(L--"9YO\ $T$:O?!.OVVY/_D5J0SZ ^*5NWQ$
M\+V^I %[B )(S&-=[%28;@_)]Q-V93CC:@RHQ\K)6Y2_9RT=?!6E7FOW 0[T
M;RMQ525BW# ?)*B27Y-N <HIPV5H0V?.-[J,FMS2RNW[R21WD? &2S%CP  ,
MDYX %245;F-;7:B]21DGTH 4RX^[P#U8]Z /I?\ ;+N_LWV GH?M7_M"J9"/
M#_A82VJV1)P3>VV1W_UJ\4BSTW]KE_*U6%S_ ,^48 [D^;-0R4<C^S=%GQ!:
M.3R?M''I_H\M"&]A/VFW,FNW2CH#!D_6"*A@CU*!0/ @"]/_ +OYI]!=3YBN
M9!,Q<?=48 J2CZ5_8J+$ZAN_Z=,?^1Z<29'B/PU3_B<6(/!^VVQ)/_75.*11
MZ?\ M?(#JL6>1]BC_P#1TU-DQ/.?AA\.IO'5TMG 0K$%W=ND<:L S[<@LV6
M"CJ2,E5RP13=CV^U^!OA[PEE-3U /<1_/*ADBB+ ?.%\H;YAE,<*Q9LY7&0!
M5B;EKPOXA\&Z1>0G38_-NIIXHD^2X?8SN-LG^DD*N& ^9<N,_*,9H%J<-^U^
MH_MBW)Z?8XN/^VTU)E1.JENC_P (&7'7/_N0I]!=3YLO9%A3'\3#.!_GI4EG
MT?\ MK$XL,?]/7_M"J9$2SHURUOX$#*Q7*N"02#M:^96&0>A4D$=""0>#1T#
MJ?+D\XG<$>OZ"I+/4?V9+]UU^V5"0'6</@D;E\EV"MZC<JG![@'J!0B6=/\
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MA[G*_L<6_E:M/GK]AD_]&PTD.1YI\28O.UB_]!>W.3[>:U(:'_#N,1ZKIX'
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!B^-N;&Z_Z]IO_ $6U=.'_ (D?\4?S
M1SU_X<O\+_(^30CCL*^\/B1?*D:D,5;9A]XTP&O&.@R: 'M:[>HI"%6(]EH
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M] >IZT -"%,MV_6@!9'^4'\J *ZQ>80O;J3[T 6",-QSCJ30 R.4[BQYR<4
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M@-C[RDD*<T^@/<^9/%'AJY\,S-972;+A=H=<J^,J&494L/ND'@_7FI*/H?\
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MSC'_ !^GC_KTCJUL0]SDOV.26U>=CWL9#^<T&*2!GG/Q(E\G5M0;_I^N0/\
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MZ4  87.3U/\ "H''UXH$"H;@_.>%'0?RXI -:(KRF .P[TQC4"P_>&6/J>*
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M?^!R_P P_MI_2/\ []1?_$4>W?\ =_\  (?_ "(>Q7][_P #E_F']M/Z1_\
M?J+_ .(H]N_[O_@$/_D0]BO[W_@<O\P_MI_2/_OU%_\ $4>W?]W_ , A_P#(
MA[%?WO\ P.7^8?VT_I'_ -^HO_B*/;O^[_X!#_Y$/8K^]_X'+_,/[:?TC_[]
M1?\ Q%'MW_=_\ A_\B'L5_>_\#E_F']M/Z1_]^HO_B*/;O\ N_\ @$/_ )$/
M8K^]_P"!R_S#^VG](_\ OU%_\11[=_W?_ (?_(A[%?WO_ Y?YA_;3^D?_?J+
M_P"(H]N_[O\ X!#_ .1#V*_O?^!R_P P_MI_2/\ []1?_$4>W?\ =_\  (?_
M "(>Q7][_P #E_F']M/Z1_\ ?J+_ .(H]N_[O_@$/_D0]BO[W_@<O\P_MI_2
M/_OU%_\ $4>W?]W_ , A_P#(A[%?WO\ P.7^8?VT_I'_ -^HO_B*/;O^[_X!
M#_Y$/8K^]_X'+_,/[:?TC_[]1?\ Q%'MW_=_\ A_\B'L5_>_\#E_F']M/Z1_
M]^HO_B*/;O\ N_\ @$/_ )$/8K^]_P"!R_S#^VG](_\ OU%_\11[=_W?_ (?
M_(A[%?WO_ Y?YA_;3^D?_?J+_P"(H]N_[O\ X!#_ .1#V*_O?^!R_P P_MI_
M2/\ []1?_$4>W?\ =_\  (?_ "(>Q7][_P #E_F']M/Z1_\ ?J+_ .(H]N_[
MO_@$/_D0]BO[W_@<O\P_MI_2/_OU%_\ $4>W?]W_ , A_P#(A[%?WO\ P.7^
M8?VT_I'_ -^HO_B*/;O^[_X!#_Y$/8K^]_X'+_,/[:?TC_[]1?\ Q%'MW_=_
M\ A_\B'L5_>_\#E_F']M/Z1_]^HO_B*/;O\ N_\ @$/_ )$/8K^]_P"!R_S#
M^VG](_\ OU%_\11[=_W?_ (?_(A[%?WO_ Y?YA_;3^D?_?J+_P"(H]N_[O\
MX!#_ .1#V*_O?^!R_P P_MI_2/\ []1?_$4>W?\ =_\  (?_ "(>Q7][_P #
ME_F']M/Z1_\ ?J+_ .(H]N_[O_@$/_D0]BO[W_@<O\P_MI_2/_OU%_\ $4>W
M?]W_ , A_P#(A[%?WO\ P.7^8?VT_I'_ -^HO_B*/;O^[_X!#_Y$/8K^]_X'
M+_,/[:?TC_[]1?\ Q%'MW_=_\ A_\B'L5_>_\#E_F']M/Z1_]^HO_B*/;O\
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M?^!R_P P_MI_2/\ []1?_$4>W?\ =_\  (?_ "(>Q7][_P #E_F']M/Z1_\
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MC4C?MW !%7/W1R<].,4!8YRWU1[,@VQ9&1E8.I*L&'(8$<@@C(QTI#/1+/\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!B^-_\ CPNO
M^O:?_P!%M73A_P")'_%'\T<]?^'+_"_R/DQ9,]J^\/B1_GXZ8% R-YL]3^0H
M$+&Q;@4 .)\ON/RH&!)D_P XH T68'@4Q#L@4 -+<4 .$P(P* (U;!R: )'D
MH C3)I .C4OR*8#\[..](!LB]N] "JWECF@8U)=_2@!4R3]* '#]WSZT /'!
MS[4 1DXYH 5"'Y- !<8"XH$,GFV@*.M,"<#'/M0 N_N: ()I-@SZTABB,1#(
M_.@"1XM^!0!'(?+_  H @3Y,L>IH FE&,$T ,0F0\_@* ))'PO- "QP$D$>E
M "S,?NCK0 K?N@ .QH&,$P<EV[4"!X3*G' Z^](8Y8PX 7I3$,N(3(1V&: '
M1W)3*J.!WH 9O\E2>[=* (F/E@*.O>D,N!0PY_/O0(J0IO')ZMBF!-.?+ C[
MDBD,DDB\D%NG'/J: &QOL*@<=2:8@1RSESTQ0!&3_%U.>/>@!INOM#J3T'7T
MH EO&)*A1WH $QR@/U_PI#(=V3G &3@>F!3 DO(]V$7IG]?2D V:<.1&O/K_
M %H 1N&ZY/OT^E %E<+R.,#D_P">] %>!?M&=O7=Q0 J9+[0,L%/T% #&C\A
M@@ZGJ?0=Z +<F3DG 4#C')H IPG))'0]^] %JQ'E\J,9[=\>M !%<B60D] /
MPI@4D3S&^7L>/7VI 70WD(4498CD9X'X]* *YGV#RT'SMU/\Z ([R(KM3O0!
M<:,9^;A4% "1$S,"Q^4<CW],T :W@[QF_A/4(]0BY:*0';P-RD%73)5L;E)7
M=@D9R.<4Q'K7Q!_:JGU^U:TAMU@$T;I)EC,Y5@ 0IV(JY&X$D-P>-I&:=Q6/
M G;:"S9R>GT__74ED]O$ IE)QZ>] B* ^6I<]3P/ZT 7M/\ W:;N%'<]Z8%2
M]4W66)X'W?<>O-(!EO"6P.@'7U^M #;MQ(V <J,9- %H,KN7Z[>?;CI0!61M
MVZ3.3T'U/7K0!=MI0BY'S/@8[ 4 48(VDR%&6SSZ ?C2&3PVGGC .5'+-[_C
M3 DN)5<!%^[G&3W]A_C0!0D?S2J]P<4A#Y!O8@#DDY8TP'1QFZ<$?=' S[4
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M !/\V?:4/@C_ (5^1M;JYSH%S2 * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0,58"-N!CG)/:@!#<@$J@R2>O7\J!#54W)"+P!U)X^I- Q?($K[<_*.IQV%
M"RR&X.1P!P*0$8@!Y).?2@"Q& JJJ_>/7N<4 6+Z[6-/+C 'K_>-,"O=2"("
M)/0;L<DGO0!$L&%)?C&,"D!;O+L.!$@VC(R>W3J: 17N&^41K]T=^F?>@"*6
M7($<8[]>Y-,"5;%2X5CZ;B> /;ZT )<NJ'+?,<]!TQ0 [!_UA7 /W<G 'TSU
MH$0)$UR<L?E'4]<4 /V!?]62?P_K0,DAMEA7S'/.?E7U]_I0(A61KAQD;CZ
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M&@"%(&D&XX[DY_7\:8$-F^6YR?Y?C[>M("PJB]?GGN3V_"A@/#_:7*KT]3V
M]!0!7NE%P<(?E7]3_C0!/<,0JC'?@4 3W#+:I@<,0<_Y]*8%!G\J,*?K^?\
M*D \W>$V#@ #ZG\>PH +<FX0@8')^G H ?'<M*P/=0?8#M0 R&3SI 3\Q'))
MH FN+@!PXY., >_K0!!!<&#<?XF.,]\]Z &R(8?O\;_SQFD,GGB\UP. /3OB
MF(BSYTFWHH.3]!UH&69)S<,5B ]VQP!0(I8,A,:^OT_$TAA<D-]W[JC'U-,"
M6"-IL.YPN?Z4 ,7]XYSP#GGV_P#U4"%ENP[$ ?+C&/4#I0 Z>1I5R>!TQT'T
M]Z %A8JFSG))P.] #%C^SLH7ENI_SZ4#&WCF1\$Y/<^W>@"6W;DLOW5Z#U-
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M$/G(CP@. .>/R_'K2 IBT[MQSWZT#+EI(#]U5X'&?YT@(ED+'S)"< \#U/\
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M..O4\TP*HNV9?+CZ DD_XT"&-F7"$Y/Z#UH FEOOLH,473/7'-(9&T1C7YL
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % &-XU_X\;K_ *]IO_1;5TX?^)'_ !1_-'/7_AR_PO\
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M#G\Z )!=#:".7/KVIB'_ &/R\'C_ 'N] RB7\]BY^Z#BD(GE;:A]QR:!BQD
M@@9.  /7WH 6(8?)(W;3[8YZ?6@");CSF.,@=,^GJ?K0!(%%L0YZ<X!^]]:
M&I!YGSMR3T&>E "W!,I"CD=3^']* &WDFP@]2W4=O:@"67]U\HQN8 'M^'TH
M AD(4;$.,?>;M0 Y7'0<*!@^IH$*9#(I*C )[<=*!E=I3,/E&-HR3F@"6ZPR
MC)R<=^M $1 3YF&3@ #MG_/ZT .NV"@+@<#GU_$T .C?RUQP/?\ I[T 1KA<
M[>Y"\]>>] $MP/LB@+US@GN?_K4 +<2?9@,8W'J?3V![4 ,B&Q,\9)],]^OU
MH 48GR<^V3R<]OQ_D* &PS>7F1AD;<#/J: &0_*,OP.I]6]OI0!>BE,498\9
MZ=@/I3 H1KM7.>6)Y]J0#R1O"C[H_4_2D!.S_,7( 'IVS[TP*T*%@S>IQG^>
M* !5"/@#G!^N:!BP1@99S@CH/6@0V M*20V.N2:!BP,SGY.F,9ZG\: '+'F0
M*G/8GU]:!"-+\VT':N><9H 2_E$A"ITQB@!D\6"$7H.OU]:0RP\.X!<[E'7'
M0?\ UZ )'R%+$8 &!C%,"G'"2JY[]!_4T@$W,7VI]!3$3[?X =H_B)/)/X4
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M][_K^NQY1K'B"XUIMUS(\ARQ&XD@;N3M'11QT  X'I72DD>9*;GN[F?5&84
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M#W(]:ZZ6&G55XJZOW2_-G+4Q$*3M)V?H_P!$6_\ A![S_GG_ ./)_P#%5O\
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MNH/LD8P>"P]R3@_I0(J0.85,G0D8 ^O>@!(+PQIL' /7U- #V0#:!Z9Q_C2
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MC_&F&XR&U=B(T& W5CU..3CVH CN(8H'V+EST);&W/<T#(6G RD7(/4XZ_\
MUJ!%@F7@#[Q4# ZXI#(8H&4D,,>OK0(GDMMJX52,CG!'ZTP(2?.(50  !ENO
M;FD&R"[OL 11\@'KW)H!#Y838KM;AR/JV/3V_G0&Y!,D<"@<ECUSPH_K0,GL
MW4C  &>&.,G'H/>@0QXS>$[%;:O QQQ^- QT<?D YPHSZY:F()I#>'YMJJHS
MT(SZ<=Z (=YN21N)'4GH/\^E BUI4:*267(&.M*P%:XO#*Q 'T H*+"0"/\
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M *Y2?^@FOO\ $?PY?X9?DSX:A_$C_B7YH\8KX ^Y"@#TOX>Z4L$'G]7<GGN
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M=D)NVI9GTB:W!9XW51U)5@/3J16TJ,HJ[4DN[31E&K&3LFF_)HJ5@;!0!?\
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M^WTH K;PX]!D]!0!)"0^0ORCCDG/XT +/(;O"+T4=0.U $[W(QN& J\#U/\
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M]Z8"7EUDA(@#S][OQP,$]!0,K_8B3F0]^<$$TK@:-P!:D*BJ&Z]2Q'U./QH
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M\-: -;D,9ECAPN[=(=JGD# ]^:B3L:PASNUTO4Z>#X4>>P1+RV+$@ !\DD]
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M7;1O(\0D7RRS+@LR@'<B'.5/;TYJ2T?0_P 2?"-WXK\,Z7:V432S%;,E00H
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MOT_3F@"Y/>2( %PHQA1U;% R.VM_F"OUSR3T'_UZ!%O4I_.;;$., 9'0>_%
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MK[_$?PY?X9?DSX:A_$C_ (E^:.3^%_\ RV_[9_\ L]>)E7V_^W?U/9S/[/\
MV]^A0^)7_'PO_7)?_0FKFS/^(O\ "OS9T9=_#?\ B?Y([O0?^/>+_KE'_P"@
MBOI,/_#C_AC^2/GJ_P#$E_B?YL\8KX ^Y"@#6\.>'FUMR@.U0,EL$X]!VY/U
M' )[5W8;#.O*VR2U=KG'B,0J$;[M[([6;PW8:*H:;L<@LQ)//]T<'&1G"].M
M?02PU&@DY?BWKKV6_P!WJ>"L15K-J/X):?-[?>:?A_5;>\WI:KA5*DD*%4EA
MU X/;!R!77AZL)W4%9*VRLG?_ACEQ%*<+.;U=]W=Z?\ #G&_$K_CX7_KDO\
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MDY.[NWW>IZ<8J*LM%Y';^%/^0?<?]M?_ $6*^APG^[S_ .WO_24>#BOX\/\
MMW_TIG"5\V?0'6?#7_CX;_KDW_H2U[>6?Q'_ (7^:/'S'^&O\2_)F7>Z>VHW
MDD4?WFFDQG@?>))_+G^5<<Z;JUI16[E+\V=<*BITE)[*,?R1T?\ P@UK9_+<
M3X;J.4CX^C;CUSS7J_4*<-)RU]5'3YW/,^NU)ZQCIZ.7Y6#[7I-I\Z+N(Z+B
M1L]NC_+^?X<T<^'AJE=]K2?_ *5H')B)Z-V\[Q7_ *3J'Q0_Y8_]M/\ V2C-
M?L?]O?H&6?:_[=_4K>&_&ZVT8M[E<I@C=][@]B#U !/3M@;:RPV.48JG-76U
M]]/-=OTTL:XG!.4N>#L][;:^3_K76YLMI.GZYCRRH8C V$(W!)/R_GU7I^%=
M[HT<1M9-[<KL]/+_ (&QP*K6H;WLM[ZK7S_X)R?BKPJ=$(93NC8G!QR#Z'MT
MZ'C.#P,5XF+PGL&FM4_P_K_/0]G"XKV]ULU^)W/BC['\GVS_ &MOW_;/W/PZ
MU]'BO9Z>T\[?%Y7V/G\-[37V?E?;SMN87_$H_P ^=7F_[-_7.>C_ +1_7(7M
M+US3M+SY+;=V,\2GIG'4'UKII5Z%&_*[7WTD]O5'-5H5JMN97MMK']#S:ODC
MZD* "@#N_"G_ "#[C_MK_P"BQ7TF$_W>?_;W_I*/G\5_'A_V[_Z4SA*^;/H#
MK/AK_P ?#?\ 7)O_ $):]O+/XC_PO\T>/F/\-?XE^3,3Q%(9+F4DY_>N.>>
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M84?90O\ Y'H02/%OBE\5KGXA7<DDCN+-)"88?NH%7<$8J&*F0@G<V2>2 0N
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MJ JYX I%GT1^S/\ $67QJEUH6J.]ROD.RNY)<QL?+F1I-V\\R#8?O %AN "
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MKB2UNN'CD93UPV#PXW!3L(Y4D#((..:@U1F:2A9CCJ >>P]S]*!!"BL6<G(
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MI#+!46ORC)?VZ?2F(AE;RL[A\W'T%(8Y(3+@]%[G^= B8R)&K;.AP!W)]30
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MX ZX.>.,QC\4H1=-;M:^2?\ G_P>Q>"PSG)3>RV\W_P/^ 4?A?\ \MO^V?\
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M<8R2#P"<Y/X^V.>W&8-UVI)J]K:[6.+"8M44XM:;Z%OPMX?&AJ49@9'Y...
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MSUXR0,<8X-7F5;EAR=9?DO\ @_J1E]+FES]%^;_X'Z#?AI.&A=,_,),D>Q4
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MJT[J]DK+_,[,)0=&&N[U?^1A5YIZ 4 % !0 4 % !0 4 8OC8XL+K_KVF_\
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MX]3Z#T% #"XC&U1DYI#'0YR$''<GO3$,E;!VXXS^E "B11@@'(/'TH ?=,0
M2><_E0 VWM\CGK[\?G2 EMXC*",\=SVI@13@,P0'"]_K0 ^:(0?=.>U(!HS8
MD@]2./\ "F R1=BJQZL>30 Z-#$/,/!R,?2D,E>3(XX8]?84Q $\X#8,>W0G
MZT ?2_P.D\SPIJN !_Q^CV_X](Z9+W/EY(S(=H.>>O:I+/IWX\*/^$3TO)X_
MT'_TDDJF2MSYD+;  ."?S^E24?4/P08+X4U0CH!>_C_HD?-4B'N4_P!C#4$2
M:^B)Q)(D#JN"?E0R*YSC'!D7C.3G@'!P(;,G6_VM-9TB:2WE@M5DB=HV4K*2
M&4E6&1/@X(QD$@]C1<+$<?[76L7,B10V]L[NRJ%$<S,23@  39))Z =:5PL<
MW^T3XHU?5I8(=9MEMS%YGEE%8*^X1EL,9)$? "_=/RDX// &"/+% CPO\6,D
MYH*+-CILVJR+!;*\TK9PJ*78X!)P%R3@ DX'0$TA'J&E_%W7?A+,=,F8/Y:J
M##.?.5,HA3:R/D (!A0^P GY=W1W%:Y[%X&_:DL_&DXT^]M3$)V6)/F%Q$^_
M*E'!1" 20H^5@=WS;0":JXK'*ZAX<M? 7C2T,>(X)TW*BJ0J/,DT"H "W#2#
M(P JAL8"KFD'0WOC)\?=4\!ZB]I'#;F QQO"SAR[*RX8G;* ,.KC& < >H)+
M@D<$G[8^JL&/DVO'3Y)O_CU%QV)?B)\4O$/B'2-U[911V5R%;SDCDX59$*,<
MROL#-MVEP X.4SUH"QTL!\KP%D<XSS_V_P#6CH+J?+<DI*CUZDU)9]2? N/'
MA35 #S_IN3[_ &2.J1+W)/V-%V?;QW_T7_VO0A,^8+A,XC7MZ?S-26>H_LX.
ML6O6:*!SY^3W_P"/>4TT)G=ZCJ$>F>/!+.VU3)%&O!.6DLUC0< ]78#/09R<
M $T^HNAN_&W]H+5?A]J#VD4-L82L;PLZNSLI7#,=DR@8D#J 0#@9Y')&Q)7.
M%;]L;5AC]S:<]/DF_#_EO2N.Q-\4/B?XAUW2/]-LHTL[E4;SDCDX"R(R$DRO
ML#-MVEP X.4SUI@CP22([=S<+T'J:DH#<&--J\9)Z'GTH ^JOVS]/D>&RG5<
MHLDT9;(X9U1E&,Y.1&QX&!MYQD9IDQ/E.%=I+=<#\,^M24?4'PIB'ASP;>W-
MRP"7(NRF-Q(+HMJBG"\$RKVR ""2.<5T)>XOP,D\SPGJG&/^/[IQ_P ND?-"
M$]SYD_UQ"HH '4]?QS4EGT_^S+"NO:%J6F1,/.=YQAMP4":!8XV) /!9&SC)
M&.G(S2(9\NSW/GL=H[8'H!W-26=G\#]).IZS90Q;2PN4D+-D#;%^^<# /.U#
MCW(R0.0T)G;?M>Z@M_K"Q1'+16L2.,'ABTD@&2.?DD4Y&1SC.00!B1V7[:_)
MTX>]UQ_WXIL(E;]B_4HX9[ZV9LRO' ZC!Y5#(KG(&.#(@P3DYXS@X$$C/U;]
MJ_6=*FE@F@M5>)VC<;)3AU)5AD3D<$$9!.>U%PL06_[7>L7CK%#;VSN[!541
MS$EB< #$W))/ ')Z47"QE?&?4M:\97EEINJVT=M*9?+B8*ZQ,TIB!^??*K ?
M+G825S@C/%)C1ZOXS\:Z3\ _(M;*S66[:+YF^6.4QECEGF\MBQ9UX0#:-O1
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MEO/!:++$[(R[)3AE8JPR)R#@@\C(/:E<=B&+]KK69F6)+>V:1RH5%CF9B6.
MH F)))(P!R:=Q6.;_:"\6ZQJK00ZW:I;O%YGEE%8(V\1E\.9)$?: N=I^4G!
MYZ)C1Y,I\E<G[QZ>P_QI#.I^%$7EZK8LW>^M0/\ O\E ,]1_;&R=4A4=[*,$
M_P#;:;BJ9*.@_;=./[/_ .WO_P!H4,$?,C.64;AP!P.<'WJ2CZAE0R> <*.3
MC@?]?]5T)ZCOV+81#]O7^+_1,_\ D>A!(^8O/\OY5&6/5CR?P]/K4%GI?[,"
MA=>M2>2?/ _\!Y235(EA^TK;@^(;ICTS!P.O_'O%0P1Z?^VHN3IY/0?:R?\
MR!38HEC3;&75? 16!=SA)9,9 ^6.]:1SR1T12?4XP,G HZ!U/E4L(QQRQZGT
M^G^-24?0O[%FCO->W5V"NR.W$;#G<3*ZLI'&,8A;/(.2, \X:)D<%H^I1:SX
MG2ZA.8I-81XVP1N#7093@@$9!S@@$4#.R_;$M#/J\)Z 6,>3_P!MIZ;$CI_C
MP/\ BD]+"]S8@?\ @))0]@6YQO[(5]'IVL/%*<22VLB1CDY8,DA' P/E1CDX
M'&,Y(!2&SAOC1HDFE:Y>Q28)-R\O!)&V7]\N<@<A7&[WS@D<E CBGV.2S$DD
MG@?7WH*/J7]I>#_A'] TW2Y&!N$: 87<5(@MS'(P) & SKC."0>!P<4R$1VX
M5O (W=/_ +X4= ZGS&9@!T'4_3K4%D<>9/G;H._]!0 DI).!^E $LZ&(A#C
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M!3 ^Q?VOU']E0%N0M_$<>N(IN/QJF9H^0M2U-I<+PH_NK_7%2:#75( JX!.
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MJ3Z8H&5[@.>7;'^R/\!Q0!.[I:Q@ ;BW)ST'X>M #;6U,B>82 N[ 7GG\!2
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M:>'A2=XJS]7^K*,%PUN0R$JPZ$$@^G45SQDXNZNGW6AT2BI*SU7F;$?C6[C
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M#DC'6FA/<^>D0H=B'/J?4_X5)9W/P7^+#_#2],I4R02 ).@)SC.0ZC(4NO\
M#NX(++E=VX-$M'N&J^'O"/Q&)OS<BSEE.95,J6TC,RJQW),&7/JT8VNQ8EG/
M-,G8ELO%/AKX*1G^SV^U73QXW(ZRNPR[*&D&(HUW !@@W$;&9'P#1L&Y\O\
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MN0$D .$#X/S;6I[D['S_ *XZ_#;5_,TR83?9Y@\4BOO1D/S*K-'LW90[)0I
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M=&FYF;:!P ,'/M0!";81\J&9L\#M[9P.30!/>)-&N96"@_PCK0!3LD&X,%)
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MKY_,OX:_Q+\F?39?_$?^%_FCSE:^1/JA:0!0 4 % !0 4 % !0 4 % !0 4
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MD#G& OOSUH$,2;R$P/XC0!-&/L_S=NW?'KGWI#&VUI]HRW."<^] #BP+;2,
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M6F$O$:D^I;_/%(!D&(<[CW[4 2VS#F3TZ?6F RS@,[&7K@G-("&ZN?/DX]:
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M>>3@8]\<TK ))?@?N[< #N0,G\/\BF PHT6 B8.?XNOU/7%(9 =TCG)W'U'
M'XG_  H 2VF%K]Q29#ZC@?3F@1*T;R#8^2.I P<YZGK3 F(2QCY W-Z8S0!7
MD(ERTF03R!P!CWYH&.:Z^SH%X&YMP[GL/PZ4"(Q=-.P^7S,= !QG\* +MOYK
MA@ %QZG&/P&:!6*,D0^_.Q9CT49Z4#+<DS,FV,!0/7[V/H*!(@^S!ES@<="Q
MP/R[F@9#$"HWDYSP !G\: $65MP);H<_,?\ #- $T4PG8L%+MZXX_#H*0!=/
MY;!I6Y&, =!]:8R))/MAX QU).<_I0(<QDF4XPJ#OC'X>M(5AJ1B1/XF8?\
M?(H&2:<40%ICQV H$0$BZ;(4E<_0>V2*!EG>L8)< L>%4<CZT ,>U>Y(#?*
MN>?3Z#O0,F;4%_U:;F8\9/;Z>E,12NA\VUN<= #Q^= $=Q._W!@#T'^>:+@3
MV-MY(WX4^YZ?A0 @N"Q))SD8 '^>E $B3[0<L .X4<_G0 7#H8P5X]<=: *L
M3J_R)U/<_P"- #Y8EBX=MQ_V<X_,XH &*1KM YSR<?XT ?<G[,XQH%I_VW]O
M^7B6M$9/<J_M#:=YD$%QG[DK)MQUWKNSG/;R^F.<]L<]5%ZM'DXR.B?G^?\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MN8CYL=O;/6@ED.NW*JWEQC 'IUS3*$,1@0!E)9CR3V'ISQGW[4")+S4N@B
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M^@3M Y#8P58?=92,JP]L?KD5I%W5S"<.1V-.WD;3--DSQ]JF0+[K#DL?^^G
M_ U.[]/U-%[L'_>?Y?\ #B?#NX-E=?:!TBAG<G_MDRC_ ,>843U5@HNTK]D_
MR.9)S6AS"4 % 'U/\,]._L_3K=,[LQ!\XQ_K"9,=3TW8SWQGCI7G3=VSZ6A'
ME@O3\]3.^*5UMCBBQ]YRV?3:,8_'?^E?.YG.T8Q[N_W+_@GT>71O)R[*WW_\
M,< *^6/IA:0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M"?\ "@"NH:<[S_>% #54RG'8GK0!;<!SL4X4#YCGK0!6N)#PO8=/Z4 *\90
M#J>O^%  PWG8!C/4]\4 .9L$JI^7-  )?+!V\#]: &06I;YW^[U^M "QKO\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * ,7QM_QX77_ %[3?^BV
MKIP_\2/^*/YHYZ_\.7^%_D?(Y.:^\/B@$9-(!=VRF WS"U #A%GJ:!"'Y>E
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M)WZ<]?J* (886=2^,\_C]: ((,N<9^OL* +/#MM7C\^?K0!$9CSM.,G)_I0
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M(R,=?QXZ=Z *D4)N2/XI'YYZ ?C[?E0,;+*(\J<$ G'IVY]Q3$/M@)SMW;5
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MV^M%A7,^:87C98_(O8=/H*"A\YR092,=HQT [9Z4A%NP7S'R", XPH&!]/\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MOQW(Q["@!CRXS&F<$_B?2@18DM?L) ;E@,D<<9_ YI#'6<@7,TA]AW)/?_\
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MDA54'T W'Z>E 6&+.[#"J%4\;CUQ_GT%*X%_3M+V)EOF!_!?_KTP*I R3*>
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M ;C/ _\ U4 7/,1"$1<%>K ]_?BJ$5+N1(LG[S'KD_RI#$CL2Q7/< \GC]*
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M;L7?_>P-W^MQUQGIQ]*]+V<?JO-97[V5_CMN>?[1_6>6[MVOI\)QE?/GN!0
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M) 2<]!CZ<4 /C0LP8_A_2D V3,K''.T?_KI@2IM1<KDDT -#K$ ISD@9QWH
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M"_A^G<T#(BQN#M!S[]J!#48*V3SCM0!(SD-D]<?Y'UH BC7<#GZF@"9=T)!
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M  ]>.] #;&$S9CBYR>6/'%(9/)(T6+>/ _O'_P"O3 @NXPJ9_AS@ $<GU/\
M^K\: (K6%(%WR#GJH]_IZ4@'7,1"AY#@'.%'6@!T<PC7RL$YY(7KTX!-,1;N
M-,=%!(VH/X>K9]30,N!TL02H/W>/J?ZT"*NGV(A/F2<$_=/!Q_\ 7]* %MK-
M9W,K$[!P=W4^O3% Q;BZ%RK&-=B X)QR: &6X\G:^%(Y"KR2??%("U=7N[&>
M6_A0=![GWH!&>C!,@@LQXR <8^O6@8(2Q Q@9]/_ -5(">YF:Z'EK\D0ZGU_
M'N:JXA$"V"[B.6SLSCCWH 2W9C&S@XS]YR>W]T>IH N161CB^48W#YF/I0,K
MWMX),16X)P,9%("NNG/,W[QLGIQD_A0(T;Z^_LV/R1]X_P C_6F!!+OCVJ#M
M! &!RWO[#\Z &F[%BI*##'C<3DGUI#'Z7;RA#(65%/4GD_A0!"(OM!VQ GU=
MO7U%("..P,#;G^8^@_STH TB&DC8YP3U]O850BGY"JHVYV@?,WK["D4,NI ^
MTMPF>G?'T']:!"W,S2G"@J.P)QQ]!F@!8083L7YV]><#\\4 +!IF&S+V],_K
MGB@"80+.W[E2IQRQ[>_4T ,6##[!\S 'GC'UH KLSH"L>!SRQX)^G>@+!;Z;
MTD<EN>G_ .O%(#1OH\X.%4<=,9H"Y,\?RAQ]T<DFBP%.]U![E?DPJ>IX)^E,
M 60*J[%Y"C+GIT]Z!$0C>\;83E1R0.GYT#+;XG;8ORHO))Z4 13WGF*4C3(]
M>WUYH&(L_P!BCV]&/]WK^M B 0FR^8]6_%N:!D>WR>N=W7CD_P" H$6X2$3?
MMYSP>K9H K3W 5M[G)QP,_\ UJ!A#:M?'?)D+Z=,TA%JQ<6I)4#G@8Y/UYQ3
M ;%*(LNYZGH.OYT 5/,^UMM3@=_I]1FAC+D"K'\N"<?P@ #Z]>:"2M+=E,Y)
MY[#^5*X[$#1/+W&!CCDG]!0!IW#HA5R >!@'%,"M-*%.]^#V4<X_6@">>62^
M7Y<[?4X4?UHN!4M;4I\W)![#C-(9$A:,G:OS>O84 6(?D4B1L GG;\Q/XTQ$
M0E=5^08!/#'J?:@"5X5M4'F,WNHXS^M,152X$K?(H&.@//\ C2&32.(S\S,2
M1T7 '\^E $]O T(PF,GDDDT"(I+QY?E4CWVCC]:!D7V"2(_+@9'4G)I#$C=D
M# L">.V33$7+-39(23U[=,_K0(CCN<)M0=3DGM]*!D"0M,2&/'MD?TI 61Y5
MN,#[WL.?S-,1%)I[3MM.0.IY)I 27#1#$:+DCK@9IC(71KEN1@#MR!_*F(;'
M*"V/O-Z <?KBD!%)'Y?+Y/\ L@C%,"Q=/)@$ */3/_UJ0%*=@G4EF- #Y+7@
M?*6)[YX'M3 &Q;=P/7'6@":(>?\ O,$@>IZFD!:TGQ!<Z'.EU;R>7-&V4*]0
M>G0\$$<$'(()!!!(I@?=?PH^)</CVT69&'GHJBXC VE),<X!+'82"4.3D<$[
ME8#1.YBU8U/&O@J'Q9#Y4O##)CD RR'^H/\ $O?V(!&D9<K.>K2516?R9\V>
M*/"%SX8D$=RF,YVL#E& .,@C\\'# $9 R*[XR4MCY^I3=-V9BU9B% !0 4 %
M !0 4 % '3^"OA]<^*W_ '0VQ!@'E/W5XR<#(+''8>HW%0<UG*:B=-*BZFVW
M5GTGX<\.0^'85M[=<*.23RS'NS'N3_@    .!OF=SZ"$%!610\9>)QH\>U#^
M^8?*,9P,\L?UQGJ>Q ->7B\3[&-E\3V_S_KK\SU,+A_;2N_A6_\ D>5Y+DLQ
M)).23R23U-?%MW=V?7I65A:DH* "@ H * /2?AK_ ,>[?]=6_P#05KZW+/X;
M_P 3_)'RV8_Q%_A7YLX70?\ CXB_ZZQ_^A"OF\/_ !(_XH_FCZ&O_#E_A?Y,
M]/U?7!IDT*N<1R"0$GH"-NT]/J.PYR>E?85J_LIQ3VES7_"W]>9\G1H>UA)K
M=6M^-_Z\CD_'_AW[.WVF,?*Q^? &%/&#QZ_S[\@5XN88;E?M%L]_)_\ !_/U
M/9P&(YE[-[K;S7_ _+T,KP/_ ,?D?_ __0&KBP'\:/S_ /26=>-_A2^7YHO_
M !*_X^%_ZY+_ .A-73F?\1?X5^;.?+OX;_Q/\D;NB_\ (+/_ %RF_F]>E0_W
M5_X9_P#MQYU;_>5_BA^AYM7R1]2.CD,9#*<$'((X(/K33L[H35]#T?4O^)]I
MPD/W@F[)X^9,ASQQR V.W(Z=OK*O^T8?FZI7UTUCOM\SY>G^XQ'+T;MIVEMO
M\CS:ODCZD* /2=%_Y!9_ZY3?S>OK:'^ZO_#/_P!N/EJW^\K_ !0_0\VKY(^I
M"@"SIEL+J5(VZ,ZJ<=<$@5M2CSS47U:7WLRJ2Y(N79-_<C3\7:&FC2B.,D@H
M&^;!.<L.P'I77C*"H345?:^OJ_)=CEPE=UHN3MO;3T7KW-__ )A'^?\ GM7I
M_P#,'_7\YYW_ #%_U_(<QX?\/OK3E$.  "S'. ,X[=_0<9P>:\C#X=UY66EM
MW_74]7$8A4%=ZWV1U4VFZ7IQ\N4[F&<G+L>IX.S@$=,<'UKV94L/2]V6K]9/
M_P!)T/(52O4]Y:+T2_\ 2M2#4_!D-[&9[)L@#.P98'@' _B#8[')R0.*SJX*
M-2+G3?3;?HM.Z?D_P-*>,E"2A47SV^?:WFOQ.,MX#<,$499B ![DX'6O C%R
M:2W;T^9[DI**;>R.YB\(6NC+OO7W$CID@=LX"_,V#W]#R!7T2P=.@KU'?RU7
M;:VK_K0\!XNI6=J:MYZ/OO?1?UJ#>&K+6E/V-ML@!P,MSTZAOFQVR/7OC%#P
MM*NOW;LUYORW3UMYK\06)JT7^\5T_)>>S6GR8WXH?\L?^VG_ +)2S7['_;WZ
M#RS[7_;OZG"5\V?0!0!TOC+PU'HGE^66.[=G<0>FW'0#UKU\;A8T.6U];[VZ
M6\EW/+P>)=>][:6V\[^;[&@O@!;J&)XF.YPA<D@J 5R2  ">< #/U]1U++U.
M$7%N[M>]K)-7[',\>XSDI)65[6O=M.Q-]DTFT^1VW$=6S(V>_5/E_+\>:ODP
M\-&[OO>3_P#2=".?$3U2MY6BO_2M2MXD\$+;1FXMFRF =OWN#W!'4 $=>V3N
MK+$X%1BZD'=;VWT\GV_36YKAL:Y2Y)JSVOMKYK^M=+'&UX![84 26\!N&"*,
MLQ  ]R<#K5QBY-);MZ?,F4E%-O9'>22IX-MS&#NN)!GC'!Q@'D?=';/4YX&3
MCZ5M8&GR[SE_7W+I?=_.WSR3QE3FV@OZ^]]>R_%GB^0R6$#,<DF(DGDD^6W-
M1C'?#P;_ +O_ *2RL(K5YK_%_P"E(Y_P38_:[I,C(7+'G&,=#_WUC_\ 5FO,
MP-/GJKLM7\MOQL>CC9\E-^>GW_\  N:/Q&U(RS"$-\J*"5[;CDY]_E(^F?K7
M5F56\^2^B2NO-_\  L<V74[0YK:M[^7_  YR->&>R:7AS5#IDZ29PN<-UQM/
M!X'7'4>X'%=>&J^RFI=+Z^CWV.7$4O:P<>O3U1U/Q-L?]7,!ZJQS^*C'_?7]
M>U>SFE/X9^J;_%?J>3EL_BC\TOP?Z&!?>*GO+9;8C&TKR"1E5& "._/.<XX'
M%>94Q;G35/M;5=4E;7\_T/1AA5"HZG>^C[MF'7G'>=[\.9#;132.<1@@^H!
M)8X'/3';G\*^ERU\L)R?PK]$V_T/GLP7-*,5\7^;T_4YSPUXF;0RV%#*V,@Y
M!XSC![=>>#^%>5A<4\.WHFGO\K_YGIXG#*NEK9K;YV_R,>20R$LQR2<DGDD^
MM<#=W=G:E;0TO"Z,]S$$Z[P>#C@<M_X[GZ]*[,*FZL;=U]W7\#EQ+2IROV_'
MI^)J?$6<27( /*QJ#[');^1%=F923JV[15_Q?ZG)E\6J?JW;\%^AR]>,>L%
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 8OC?_CPNO^O:?_T6U=.'_B1_Q1_-'/7_ (<O\+_(^1<U]X?%!G-
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MF4Y]: )GS;KS]X]O04 *\VU26Y)  'H* *[-L7 ZGD_X4P)+:,)\SX/M_C2
MEE3S' /0\X'\J!AJ+$X#9]AV _K0!/96YB^? ) SSC H J-,7RQZG@>E $SJ
M$ V@YQ]X\#\* (63 XR<_K2 L+,T**J]<D^] @1O(0D<NV1_D4#*]JFPEO0'
M\^U #Y)@%"C!8\D_7M3 UH-!G%L;E4*VXE6)I6& 9&4N$'<G:I/&<<9QN7((
MSIP(3M7);'7Z]L4ABSR>4N,Y<CGO@>GUH&5OLY&.@]O\?2@1;NWX4< *>!_,
MG_/- $:7'V<%NCM^8'^)I@26.GX'F28 [9[_ (=:D"U>W1NB'.?+7GTR?\,\
M50%%96"DYP6/7V]![4AC_(,94*,$CDDX//?F@!HL_/;8I^1>K=OK_A0(D:;S
M!MSB)3QTSGUH B$:AMV"/0>I[4 6+>(*WS8)[YXZ]OK2 2YE:7]V@SSD^N?Q
M[4QAN+*(8@2>K8Y&?P[4 -D3[.@"G+$XP* )+2':@!^\2?P'][ZT"(W3@A,A
M2>_&?<T 6KB[. D0P .6'?\ &@8ZWMA:J78Y!!_&D!51%8%I.%'"KWY[TP+L
M,"D&:3T.P' [<''\J *EM;B4&27)!X R 3[]^* );)VC!9!R.GH!ZF@#5EF"
M1@L?F..I'^- D4]4D>]*HJX';MFD4-N9EMXRF<L>I^\<^@]!^M,5BQ]EV1@2
MY"*.!T+'WST_G0(KI>[5VX^8L=J]< ]Z0RS$[J!MV@@<N>W^?UIC15CA: F1
M<OGC., >^>E(!\<W.9'S_LKR3[<4@.P;X279TK^W=T0MNT>Y_._UWD]-FW[W
M/WON^_%585];'$7;&X98E&<8X'ZT@9:N;,3R!<!FXR>P]J V+4]NKE8#C"#)
M &<GM_.@"K<JUZ<,=JCC:.H [GT%,+$8N_+'EP#/8D"D,N6Y^SCY/F;'/< _
MTH H*JA][$LPZ=\GT'K0!<MHGAW3R CY2!NZ\T 5K:/ #XW,3QGHOUI 6;>%
M)"?-?=CHJ_=IB)C=,Q^7"]L8R0/Z4#9V6@?"6Y\06$^I6\T0A@\WS=Q;S#Y<
M8D8* A'W3QR.:=A7.)N7\Q%CQM3/.>"?SI#*=X3*1M&(P1CCK_C0 ^"'[4P&
MW!'.X_\ UZ +"E8"S<ECG SDX]: &PS23=,+@=3U% "PVR*<Y,AQTP<"@0^T
MG6#(8#//0Y_E0!4@E*!G;@'MW(IC(K:$2G<1A!W8]:D#3CO_ #E(C7KQD\*/
MQI@B#9OX<@X]#Q^G)- #'D,Y /R1CJ",?SZT@([@B[YYV@<;N :8R2/3 B"2
M5OHM B1Y_L\8$0PS'TP?UH!$*0LJX()8GGT% ,EFF^RKL!#,1V[?E0 H20@,
MBA/]IL9H&BO96V]B\K9QV[GZ4@'W?F2XP"J9QS\O^?K0!/Y0C(4'CU_A'X]S
M3$BI(%!VIR2>3C)Q2 MW$QD7&X(H]_F-4)%<R^6@V GCDXS^M(8UX=BC>VWT
M4<D^] Q]I:.F3&A&>K'TI"-7P]H$E_,MM IDGE.%5?O$_P @ .23@* 22 ":
M8,Q% ER/+R2>#STI6'<]'F^%LT>C_P!LAH_LP'W 6\S_ %OD] NW[W^UT]^*
MJVA-]3SF*!KCD#"CN?Z5)1/! &R5[=23BF2.\\,FP?-DXZ\ =Z $DS<80, @
M_3\:!E.X*SDB,X4?CF@8)$[C"+@#UXI"+<3F !G'0<*.OUI@4IKEKUOF&U10
M!6E?S3A#BD,T[>V 7;&I;U;I]>:9*(;EBIQPS?CQ[47*);"-E^:7 0>O% AD
MMT9LLN=O3 _STIL";3K9L$[-N?XC_2D(ZOQG\'[GPW8V^JS-&\-P8M@5G,@\
MR-I%R"@4#"\X)YZ9'--H+G&)"Z_,V%'8<5(R9K@)_JA]6/2F!UOPY^$-U\0C
M-]B>(&'R]S2LZYW[\;=J/G[ASG';K32N)NQQ"6SCYW?CV[T@+$$PMA\I!R.@
MZ_\ ZZ ("67*E67/L<T#(R?+&Q0.>Y/- # @AY/S/VP<@?E3$&R6[;#?+]>*
M0#XXE=L [0._'- R"ZA8]-Y'KB@!UA +7+R?@#U_*@DL&[?:<?*#_GI0,BCQ
M'W!)ZDD4 ;?@?QA>>$+I;RT;:XX.[.QU)&48<94X]B" P(8 @N#1]O\ PV^*
MUGX\A5X'59]I,D!8&1,8#''!9,L,.!@Y .&RHU3N8M6.FU?18=8C,5PBR(>S
M#.#@C(/4'!.",$=C5)V,Y14E9ZGC/BKX!RVV7L'\Q?\ GFY"R=APW"MW)SLP
M!@;C77&KW/)J8-KX=?)GEEY926+F.561QC*L"K#(R,@X/0YKH3N>8U;1D%,0
M4 % !0!=TC19M8D$5NC2.>RC.!D#)/0#)&2< =S4MV+C%R=EJ>K^#/@.9 )=
M1)7G_4J1G@C&YP2,$9R%YP0=P.0.>57L>G2PG67W'L=G91V*".)51!G"J JC
M)R< 8'4YKE;N>LE;1&+XH\7QZ,I52&FZ!,].,Y;'0<].I[<9(\W$XM45WEV_
MS_K4]##X5UGVCW_R_K0\LN+A[MS)(2SL<DG_ #^0Z <"OC9S<VY/5L^NA!05
MEHD-K(T"@ H * "@ H ])^&O_'NW_75O_05KZW+/X;_Q/\D?+9C_ !%_A7YL
MX70?^/B+_KK'_P"A"OF\/_$C_BC^:/H:_P##E_A?Y,ZSXH?\L?\ MI_[)7MY
MK]C_ +>_0\?+/M?]N_J7O"6KKKT+6\_S,HP<D?,N>#ZY' )ZYP<Y-=.#K+$0
M=.6K2UOU7_ _R=[G-BZ3H34XZ)[6Z/\ X/\ FK&%H6D-I.HI$W.-Q!P0""C8
M//Y'WR,G%>;AZ+HXA1?G9]URL]&O55;#N2\M.WO(/B5_Q\+_ -<E_P#0FHS/
M^(O\*_-AEW\-_P")_DC=T7_D%G_KE-_-Z]*A_NK_ ,,__;CSJW^\K_%#]#S:
MODCZD* /2=%_Y!9_ZY3?S>OK:'^ZO_#/_P!N/EJW^\K_ !0_0\VKY(^I"@#U
M'PM*L.GAG&5"2EA@'(#,2,'@\5]EA&HX=-ZI*5UY79\EBDW7:6C;C;[D9/\
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M%N[MKMC)(=S,<DG_ #_^JOFYS<VY/5L^@A!05EHD0UF6% !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 8OC?\
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MVI#"&/<<C/'3Z_TH =;L8R<'D]Z +$SY 0=<<^@I@,@(5.>G]:0%>)CN/<T
M?97['2;-)F[_ .G29_[]0U2(9\OQ_%35DZW]V2!_S\3=?^^Z11<T/XRZQ8/Y
MRWUP67.-\C2IR"/N2%D/!XR#@\CD"BX6/ISQ-??\+6\)O>S*D4GD23#C>%>W
M=MQ7."N\1LN<DJKD9;G=1.S/C%_E&!W]N:@LZ3P=\+]1\8K_ *!;O*%)W/\
M*D>1MRN]RJ;L,#MSNP<XQS3%<UO$7P)UCP[ UU=VKJBYRR,DNT %BS")V*J
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MG ).%4$G@$GV!-(9LV'@2_U"X-BEM*USQ^Y,;*Z@E0&8,!L7YERS84 @D@4
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MX=N-!<1W4,D,S ,JR(T;;22 <, 2,@\^Q% %_P .>!;_ ,8R_9["!IG7[Q7
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M#H2=V$WHS)N^4G;G=CG&,&BP7N8FCZ3)J+"*VB>65L[$12[' ))PH)/ )XZ
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M$<_> QG(SD'#L*YA^+O 5_X0#"^MY(@75=Y&8B2NX*'7*,<9X#'&".H.$4C
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ML <9!Y]:11!HVA7NN%WMH)9GPH/EHS[ V=N[:#C.#C/H: ,"&W <(!ER>O\
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MMUSVKZ;'25*DJ?>R7I&W_ ^\^<P474JN?:[?K*YYO7R9]0% 'I.B_P#(+/\
MURF_F]?6T/\ =7_AG_[<?+5O]Y7^*'Z'FU?)'U(4 7]!_P"/B+_KK'_Z$*Z<
M/_$C_BC^:.>O_#E_A?Y,W?B5_P ?"_\ 7)?_ $)J]+,_XB_PK\V>?EW\-_XG
M^2+_ /S"/\_\]JZ?^8/^OYSG_P"8O^OY"7PU(VH6#0PMMD0D#!PQYWCN,9Y7
MKZGVK3"MU<.X1=I*]K/7?F\K7V(Q*5.NI2UB[7NM-K>=[;G(2:W<QDJTL@(.
M""[ @^G6O!=>HG9RE][/:5&#UY8_<C7\.6UYK9.)I%0=7+,>?0#(R?7T'X ]
M^&C4KOXI)+=W?^9Q8B5.@OABV]E9?Y$WA>Z:QOBDS;V8-&7+'J,'JP!/*[?Y
M9XS>%FZ==J3NW=-W>_S]+$8F*J4$XJR5FE9;?+UN9WC32S8W#G!VN2RD]\\M
MT]">G7&/7)Y<;2=.HWK9NZ?KO^)TX.JITUW6C7IM^!GZ/I3:I*L2=SR>N!W8
M].GZ].IKEHTG6DHKY^2[G36JJE%R?R\WV.N^*'_+'_MI_P"R5[F:_8_[>_0\
M;+/M?]N_J<)7S9] % '=_%#_ )8_]M/_ &2OI,U^Q_V]^A\_EGVO^W?U#Q7_
M ,@^W_[9?^BS1B_]WA_V[_Z2PPO\>?\ V]_Z4CA*^;/H#N_"G_(/N/\ MK_Z
M+%?283_=Y_\ ;W_I*/G\5_'A_P!N_P#I3.$KYL^@"@#N_P#A:'_3'_Q__P"P
MKZ3^U?[O_DW_  #Y_P#LS^]_Y+_P0_X6A_TQ_P#'_P#["C^U?[O_ )-_P _L
MS^]_Y+_P3=U;Q1_9]O'<[,[]GR[L8W*6ZX.>GI7I5L5[.G&I:_-;2_=7['G4
ML-[2I*%[6OK;L[=S@=*UL0W@N6&%,C$C.<!L@]!SC.>G.*^9I5U&M[1[.3OY
M7O\ E<^CJT7*E[-;I+YVM^=CH_B3I);;<KS@;&]ADE3T]2023Z8KU<SHWM47
MH_T_KT/,RZK:\/FOU_KU.1T33!J<HB+! >YQ^  )&23@8'/?M7AT*7M9*-TK
M]?Z:N>S6J^RBY6OY?TF;^F^#)K6\12/D1@^\#Y2 <COP21C'4=>1S7ITL%*%
M9+HG?FZ:?KY?H>=4QD9TF^K5N7KK_6_ZA\1=56ZE6).?+#;B/4XROX8_7'44
M9E54Y**^S>_J^GRL&7TG"+D_M6MZ+K^)6\*^%?[1_?3?+ N22>-V.O/91W/X
M#G)&6$PGM??EI%?*]OT[O^EKBL5[/W(ZR?X?\'LOZ<OB#Q:KQBULQLB ()Z$
MCT'?!ZDGDYYQSF\1C$X^SIZ1Z^?_  ._5]?.,/A&I>TGK+\OZ^Y?ERM>*>N6
M]+TM]3<11#)/Y =R?0?_ *AS6]*DZLN6._Y&-6JJ4>9G9SW=OX/!CB&^X*<M
M^O// [[1R0!D]&KWY3A@ERQUG;5_Y]O1>5^YX<83QCN](7T7^7?U?R['#W=V
MUVQDD.YF.23_ )__ %5\[.;FW)ZMGOP@H*RT2(:S+"@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#%\;_\
M'A=?]>T__HMJZ</_ !(_XH_FCGK_ ,.7^%_D?(P%?>'Q0A)H$+SZT )F@ H
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M'QD$D-$JD-@$ G<HSDH>*5QV*_[1WC/2_%UZEWI^]FV;)7*"-), %&7($A8
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M@>5MH5U8<J,9)XZY/-6V2D?-7@/PU)\4=9,<^4%Q-+-.T2DA%.Z1\9R%!8A
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M") X)1F<-\P3HR$L=[&DQK8].N_BQI_PTTB"'1GBN)F/.0ZDD#][/(A(=2S
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MR058D+A=I.:29;B</\7_ !#:>(=1DGTX,D+\R$JJ;I 2&90O.U@ WSX<L6+
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M*S8VIY8Y+9 8 EMQ"A2)@XG(_';X;1^#M29X1^XG4RIE J*Q9M\:D#:0O!
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MBTU]]K>COJ=^$]Z7(]I)I_=>_J<BJA20.3W->@<)"&W$MG\?\*!")W(^GO0
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M+^]D&1G/RMB/:5('&]QG)( P1V7[+FH0Z?X=O9KE-\$<]RTB8#;D6WB+KAB
MV5!&#P>AXH0F9J_'7PE(0O\ 974_\^=G_P#'*+CL3P?'WPK9N)8],*NC JZV
MMH&#*<AE(DR"",@CD47%8\@^/7Q+M_B1?QW=FDB(ELD9\T*K9$DC$_*[C&''
M?.<\4F4D>K_MM#=_9P]?M?\ [0IL43YHM[1KMU@A4NSL%10"6+,0  !U))P
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MJ!P/:@"*-MQSZ<T *7WMNZ@4 2R2ENG>@!L" 9]?6@"#=U]2:0$I8#GT&/\
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M3T!R.Y_D!4%EG1-1?29DNHCMEC=7C. 0K*=RL0P(."!P00>],1]F3+#^T%H
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M]>:E*Y;=CF-:TG^P[B6UF92T,KQL5R<E&*DC('&1QD#Z4AD=G<-<$B,?B<4
MR>PN#I,R2NJR,CJVUQNC;!!VL.,J<8(XR#B@#ZC\8_#.P^--I#?:9*(9(HO*
M48P@"@E8'13^[*LW!4'"G(#J4(TM<R3L<3X>_9"O'E OKB)(!@GR=[R'D94;
MT0+E<_-\V#CY",U/*5S&7^T?\0(?%=W$EN5>"U5P'[,[D;\')#( BA3@9.X@
MLI4T-W'%6.N^-C!O"^FL3@?Z&>/^O63BF]B5N>*_"KQ_)X+OTO(>8ON3 @,6
MB+*7 R1AN 5Y'S  _*2#*=BVKGI7[2GPZBE6/Q#88^S3K&90J.,F0%EG/90X
M(5LA?GVD[F<X;74F+Z&Y^QN01?8&!_HO_M:G$4CS+]G$^;KUJW)/[_GM_P >
M\M2MRI;$_P"T?:&36[HEN/W&!_VPCIL(GF-O$MJ-QR&SQCKBI*/I3]LAV46.
MW&3]J_\ :-7(SB?,PMUB&YVRW85!H-AM3<'+-@>W- KDK6Z9P!P.YH'<21$D
M; R0/2F(LO<>6NT?*/IS0!7ACR"0"3_>- #9"J\L<GWI /BDV?,,$?7_ .M0
M ]+QIL[1@>W2F!$Z!CM'S']* %FE,0VY _6D U468\DG^5 $EW'GIP/:@9%;
M6W?I[F@1]0>$3FSM_P#KWB_] 6OAJ_\ $E_B?YL^SH_!'_"OR-:N8W"@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * ,3QQ_P >%U_U[3_^BVKIP_\ $C_BC^:.>O\
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MGM0!"K;.O6@!JL3SCZ4 *KY;!Z=_ZTADHC\T\?**!$;+N;CD"F,;R!N]>O\
MC0(6)LDX_/VI#-W0?&%[HB&*TN9X8V8L5BEDC!. -V%8#. !GK@#TIB,N5@@
MV(.?S-(9"X\OY..<9/?Z4 :FE^++O02XLIYH-^T-Y4CQ[MN<9V,,XR<9Z9/K
M3$5=6U&;5F\V=WEG8@M([%W. % +,23@  >@ %(99T/Q!/H1,MI-) ^T@F-V
MC8C@[25()&0#CIQ0(GOO&M[KD>R]N9YT# A))9) &P1N 9B,X)&>N"?6F!CP
MP#.X]^@I#+-GJTVGS++;2/$Z9Q(C%'&00<,I!'!(XZ@D4 :UU\3M3O-T<M[<
MM&RE61IY65E(P5(+8((X(/!'6F(YV12QR>.^*!BPKOY;@?EGZ4@.DD^)6J7J
MM')>73HP(9&GE96!&"I!;!!!P0>#3%8H:/XIN]!9S9SRP!@"PAE>,-C.W.PC
M.,G&>F3ZT 4]'U";3)!/!(\4@SMD1F1QD8."I!Y!(..Q- Q]]K<]\SS3R-+(
MV-TDC%W. %&68DG   SV&.U %W0/&=_H49CM;F>%68L5CED1<X +85@,X &>
MN *!&9J5])=L9)6+.[%F9B68DG)8D\DD\DGDFD,U=*\?:CH\2V]O=W$48R0B
M32(HR23@*P R22<=2<TQ&;J^OW.O/YMW-),X4*'D=I&"@DA06).,DG'3DT#*
MHD\SY0..](!)</UZ"@#4\.^([W0]WV.>: /MWF*1X]V,[<[",XR<9Z9/K3$1
MV>K2Z(PEMG>&09VNC%'&00<%2",@XX[<4#(-4U.757,UQ(\LK8+N[%W. %&6
M8DG   R>  *0"(A1=RG*X_+ZT 6M7\5WFOX^UW$LVW.TRR/)MSC.-Y.,X&<=
M<#TIB,O.1@#CN:0R6-S$..I[^@H ?INKS:9(LUM(T4JYVR(Q1QD$'#*01D$@
M^QQ0!LZCXYU'58VBNKRXEB.-R/-(Z-@@C(9B#R ?J,T",2-1MYX[^_\ ^J@8
MR(;\G]: -:V\:WUI;FTCN9U@(9?)$L@CVMG<-@;;AB3D8P<G/4TP,=QGY5_&
MD!,Z*.IR>OH/I0!JZ#XQOM&0QVES/#&6+%8I9(U)P!G"L!G  SUP!0 S5?$=
MSJQ\V[FDFDVA5:1VD8*"2%!8D@9)/XD]Z ,Q9?LX]6/X_P"30!?UKQ1>:]M-
M[<2S[-VSS9'DVYQG&XG&<#..N!Z4 9WD'JW [ ]Z -+2O%EYH1865Q+ &V[O
M*D>/=C.,[",XR<9]3ZT"+6I>-[[5X]EY<SS(&#*))9) & (! 9B,X)&>N":!
MD%EXMO-.A:"*>9(I"V^-9'6-@P"MN4$*V0,'(Y Q0!EP$*<^WI0!L:+XTOM%
M4I:W,\,18L1'+)&I; !.%8 G  SUP!Z4 5-7\1W.O2>==RR3,JA0TCM(P&20
M,L2<9)./<T 9B)YS#/0F@#I+KQ_J+)]F6ZN/($?E^4)I?+V8V[-N[;MV\8QC
M''2F(J^'O%5WH>\VMQ+#O W>5*\>[;G&=C#.,G&?4^M(90@N_+7 '/0>M $^
M@ZW<Z"[36LTD,A4J6C=HV()!()4@XR 2.F0* &W^J3:LYFG=YIWQN=R9'.
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MN7!XZU2Y1UN+NY,;J00TTI!!&"I!;!!'!%*X6,FTB 4LH.>Q- QL9%OR?O\
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MZ=>>M C-@'F9'W!_.@9H:9KUWHN5LYI8 Q&XQR/&6QG&=I&<9./3)H"Q/?\
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M(X#(,*O'K3 GNSO 0,#CTI 03-Y8VH.>_I3&,MTQ]XX^AH$.C19'&5XSWS2
MV9Y8K=<#'X4["1@RZD6/ R*10F3=<8VCWX% 'U)X/3996PZXMX?_ $!:^%K_
M ,27^)_FS[*C\$?\*_(UZYS<* "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H Q?&_\
MQX77_7M/_P"BVKIP_P#$C_BC^:.>O_#E_A?Y'R*.:^\/B1<&@8FV@!.E A=V
M* $+4 7PX7CKF@",0[3SU_I0 Q@9.@Y- Q)7P .^* 'D^2-O<B@!03& O<T
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M6D!&B8Y]0:8%@R>6N!WI 1!L#8.>:8"OD<=?04 -$1SM[Y'TI#+;1[#\I^M
M%>.],&0.],06I*\]2:0QQE*OA .: &CAMH_$TQ#KQ@1C@8_7ZF@8PJ44?2D
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M 3R6?YF.!0!]3^#1BQMO^O:'_P! 6OAJ_P#$E_B?YL^RH_!'_"OR-BN8W"@
MH * "@ H * "@ H * "@">U2-L^8S+Z;5#?7JZX_6M8*+W;7HD_U1G)M;)/U
M=OT98\FW_P">DG_?M?\ X[6G+#O+_P !7_R9G>?:/_@3_P#D \FW_P">DG_?
MM?\ X[1RP[R_\!7_ ,F%Y]H_^!/_ .0#R;?_ )Z2?]^U_P#CM'+#O+_P%?\
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MY]H_^!/_ .0#R;?_ )Z2?]^U_P#CM'+#O+_P%?\ R87GVC_X$_\ Y /)M_\
MGI)_W[7_ ..T<L.\O_ 5_P#)A>?:/_@3_P#D \FW_P">DG_?M?\ X[1RP[R_
M\!7_ ,F%Y]H_^!/_ .0#R;?_ )Z2?]^U_P#CM'+#O+_P%?\ R87GVC_X$_\
MY /)M_\ GI)_W[7_ ..T<L.\O_ 5_P#)A>?:/_@3_P#D \FW_P">DG_?M?\
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MM?\ X[1RP[R_\!7_ ,F%Y]H_^!/_ .0#R;?_ )Z2?]^U_P#CM'+#O+_P%?\
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MY]H_^!/_ .0#R;?_ )Z2?]^U_P#CM'+#O+_P%?\ R87GVC_X$_\ Y /)M_\
MGI)_W[7_ ..T<L.\O_ 5_P#)A>?:/_@3_P#D \FW_P">DG_?M?\ X[1RP[R_
M\!7_ ,F%Y]H_^!/_ .0#R;?_ )Z2?]^U_P#CM'+#O+_P%?\ R87GVC_X$_\
MY /)M_\ GI)_W[7_ ..T<L.\O_ 5_P#)A>?:/_@3_P#D \FW_P">DG_?M?\
MX[1RP[R_\!7_ ,F%Y]H_^!/_ .0#R;?_ )Z2?]^U_P#CM'+#O+_P%?\ R87G
MVC_X$_\ Y /)M_\ GI)_W[7_ ..T<L.\O_ 5_P#)A>?:/_@3_P#D \FW_P">
MDG_?M?\ X[1RP[R_\!7_ ,F%Y]H_^!/_ .0#R;?_ )Z2?]^U_P#CM'+#O+_P
M%?\ R87GVC_X$_\ Y CGBA4'8[ENP**H_,2-_*IDHVT<F_.*7_MS*BY7U2MY
M2;_]M14K V"@ H * "@ H Q?&_\ QX77_7M/_P"BVKIP_P#$C_BC^:.>O_#E
M_A?Y'R+OQ7WA\2!;- "&F,3-(0HYH =MH N3%8_N]3ZT !4(ON>,T 11G8?Y
M4##9N;'?J?\ "@!\9V$L><=Z $!S\Q_"@". Y)H <Q,I]@.: '1]-Q'T]:!"
M6[[NO<]>] P5O))V_A0 Y, $GDXZT (B?)N[Y_2@!4CW<^G3_&@!8GZ\\^M
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M7^(\^U "3R>8<TQ!=-O:D,=>.#\JC@4 +Z 9Z9-,!H5KD]>!WI /CD\D<=:
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M1U/<TP);659?EY\M>>?7TH$30?,=[<#.%SR*0QD\7VF3)&%&"3ZTP(+N8SN
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % &)XX_P"/"Z_Z]I__ $6U=.'_ (D?\4?S
M1SU_X<O\+_(^0\5]Z?$C@*0"T &* $S0 4 6GF6/@<GUI@-8D8![4@#[GS4
M.5 I/N!^M "I^\.6^Z* ))I=HW#GZT#*\2D<_P"?K0(<R;!@=Z!C7DP #T]J
M 'H/*P!WYH (HE9B">.M "3RG&.@_G0 KY?ITX&: )'0Q<+CG\Z (Y&&0!T
M_K3$([!^.@%(8X?-]W@8Y^E $3MO(]* 'Y#9]N10 ,^X[VZ4 ';<?7@4 $2[
MNIX]/\]J &F8RG':@"5VSA?KGZT ))A>">W;^5  RB%<CJ>H_P#U4  ^0 ]Q
M^0H 8^9OF;\* "8?EVH 5.23V'^<4 -+GJ.I% $F1#T.3WH 5X?+PW&?3TH
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M B:>?RNGS,?RH J*Z1<D9:@"02/.>>![4@& #<0IIW E6(CYN: +".$'OZ4
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MPK\C6KG-PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M[L'\*!$=^03SRWZ"@:+D;^4F2<$BF(JVP:\)5"=G<F@&/OL#")TR*!EQYQ$
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M9]G1^"/^%?D:]<YN% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MSC'7B@!@C68EF8!0?S- #XW%RQ9\!0.!ZTAD9N-S[F' Z#I3 ;.WF$L_7L*
M+>DV:@&20X';G% B'4;KSW^7A10,D@B5>G<<BD,@C(#A5Z YSBF(E@G^9FZD
MCKUI ,5L+M )8\X% %B"(VZY&-YZ>OY?UH&165N5?K\W)/H* +,H2!=JD%VZ
MF@"J\I7Y(QD],]: '6J?9W 49(ZF@1;LH/MTI+9('7TH MW[",8!&[/0= *
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M$EF*T6T7(ZXZT C(2U\U]S\#\J0RU)&OWF.?04#)['# EOE&>G2F2R)9O.D
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MX[R>/>F(IR2Y;/7Z4#)(%D?G&/<T@&2P%^K9^E(8\0[,9X'ZT ,GNVE.!T%
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M-6W$';D,Q.P@ =\;BHY E<;=C&2!;=3(W4?=]/:@1Z!;>"-+70O[2-S_ ,3
M]8/-B_Y[[/\ 5[?,_P!7\W7_ &NG%,5]3S*"+[<Y9ONCH/7%247;MO(7:HYQ
MW[4QD&AR"!6<]<\TD)B6\[:C(2.!Z^PH8WH2P2%F**:!%B%!99!P6]:!E*&)
MIF+#@^IH GAB^S D'@]6/\J ,V.Z\^0*.F?SH T+V+:-G<_E0!#;Q&X811\
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MOB2:58WR&W(&(5LK@'( .1P>U RJ\GV-,L<DCI2 @M$^T<MT]*8Q)"%)""D
MIR/O?E0!:M+,@;GZ>E,17EG$YX'0_A2&5I;MEX7CVH&/61(ERW+4Q%0.TAS0
M GE@,"W)H O27?E]!0(=);@C?(>: *-S+YW'0"@"6WMB>1T[T )*HSQVH&5)
M,%LL<TQ$[@SCT%(">UM\<GH* $O+DS<#H* *8D53W)HN,MP61G/S<"D(?<G9
M\@Z4 0R0F7"@8^M RUY(M5QQGVH$58F\H[F_*F!'(YN3ENG:@!/LS2#T6@!\
M!6U3U- #%NFF]A0!*MVJG &: &G-PV6Z4AC;V<)\J"@!%4LOS'\*!#XK+.2_
M3%4(IO<8.U*DHU],C,(RP'UIB(I8UE)+=* *ZMC(C'/K2 $LB?FD/X4P&L=W
M3@4 .@L_..30!).ZJ<+0 R4YZ<T 12QKZYH BD)/ XI#&*#G'>@#06R5!EN3
M0(A>(+R.* $6-3RU,!A4GM@4 -=@> : 'Q?N^@R:0#I#W-,#T#P/\ =4\8IY
MT48AB*Y62<M&K9"D;0%9R"&R&"[" ?FSQ56)O8]R\-?LBZ;8;'O));EQNW+D
M11-G('RKF08!'23DC/0[:KE(YCT#2/@SH^DH8X[*$J6S^\03-G 'WI=[ <=
M<=3C)-.Q-SH-%\,6FA;OLD$4._&[RXTCW8SC.T#.,G&>F3ZTQ%JYTR*Z.Z1%
M8XQEE!./3D5C*E&;NTGZI,UC4E#1-KT;12NO"EK<XW1*,?W?D_\ 0<9_&L)X
M2G/>*^6GY6-XXJ<=I/YZ_G<Q-1^&T4@)A8JV20&Y7OQTR/KSQV->=4RR+7NM
MI^>J]._YG?3S&2^))KRT?^7Y'*ZIX0N-.!9EW*/XE^8=,DXZ@#N2 *\6K@YT
MM6KKNM?/U_ ]BEBX5-$[/L]/^ 8M>>=P4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MO9R7R7T;K"I9EDC, V@' 5@\F7+;552 &+8W X!=A7/ VRYR.<"I*$8'UYH
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MB;$%LR@H[_,[*0V&2,$$C('+E 58,NX4TA.1V>H_L;O(I,=\"P4[5: JI;'
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MR$R,RK@,J_PJQSEAV]>:E*Y;=CF-5TV70II;5L&2*5XV*Y*DHQ4D$@'&1QD
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MH)(D08S0,ALK<2/TXI 6]0EQ\JBF(CMI=JG=U]Z (_LCR\G@4AD5F?(8C&:
M-"1W?&>!Z4Q ]RL/.: *Z737;<<"@"Y)$L:ECUQ0(RE7S"3U^M!1)YWD]>?:
M@0UY&F'4@4 .,B@;: (V5I/E6D,(K3RCU% #D)<D9_&@!N5C/3)H E6,GGI0
M V2,RG!;- $_]GK;X.:!#+NY:3Y5IC1%: (?F-(3+%Q=JO"?I3 I2EI*!A!
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@#%\;_\>%U_U[3_ /HMJZ</_$C_ (H_FCGK_P .7^%_D?(Q-?>'
MQ0!J  M0(0O0 TL30 H% %B/CGM0 R67>?ZT $K9Y'3I]: %'OTH&)G9R!QT
MH <!N/X?A0("OECIUH&2N J^XH A7@C^\?R]J '%O+R.I]: $C 09[Y_S^M
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M(50%&> *DH^E?V9/B3-XWCN=$U1GN%,#NK.27,3'RY8VDW;S_K%V'[P!8;@
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MYE55&X(S( R^9M8[FR3DD A   $+\(Y_$'@"ZC9;2]^R;\S0BWF9&5MH=@I
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M5;!I#/I/]KC4X]5T.UN(6W12W<#HV",JT$S*<$ C(/< ^HJF2C,^ &D-X/\
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M!U&5W(J.K$G</E7Y@HVMDHVK#66^#OA*&X@ %U=LK*XS(H>8%U<AR "L" 8
M*^8!E6!8D#=GR\_B"XN9OMDLTC7&Y6$I=C+E<;6WDELC P<Y&!CI2+/8[_\
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M:DL]6^,O[1,GBR"*"Q$MNA0^>NX?,S#:4RN"T8&>I ?=\R#:*;=R4K'(>$?
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MBBY_X1#[9YTAN/\ GKO;S/\ C\V?>SN^[QUZ<=*?0GJ?.&KZO<:W*)+N1YG
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M+1VB-^]D'4GKY:9X+D=3R$!W-G*JS2N2W8^T/#OAFV\-Q"WLXDBC&/E48R0
MNYCU9L 99B6..2:U,C/\9^.[?PK&6E8-)CY(@1O;.<''4+D'+$8&.,G .D8.
M1S5:JIK7?L>"^,_BC=>* 8V(C@)SY:]#@DKN8\L>1GHI(!V@BNR,%$\6KB'4
MTV78X^M3D"@ H * "@ H [KP5\7;KPV/*?\ ?0\85V.Y0%P K<[1TX((XX )
M)K&5-2.VEB73TW1[UX7\7VWB>,R6SYQC<I&'4D9P1^F1E20<$X-<<HN.Y[5.
MHJBNBYJNCQ:HNR5<\'!_B'N#VZ?CWR*Y*M&-96DOGU7H=M*M*D[I_+H_4\IU
M[07T9]C\@_=;L1_0^H[?3!/Q6(P[H2L]NC[GV%"NJT;KYKL9M<AU!0 4 % !
M0 4 ='X8\'-K'[QSLCSUQRW/('^///8\X];"X)U_>>D?S]/\SS,3C%1T6LOR
M]?\ ([&#P%:1@ H6/J6;)_[Y('Z5[T<OII6LWYMO]+'ARQU1N][>22_6XRZ^
M'UK-C:&3']ULY_[ZW?IBIGEU.6UUZ/\ SN5''SCO9^J_RL<-X@\,2Z*1N^9"
M3AAT^A]#CG'Y$X-?.8C"RH/75/9K^MSZ##XF-?;1K=,D\(Z&FLRF.0D (6^7
M .<J.X/K58.@J\W%WVOIZKR?<G%UW1BI*V]M?1^G8L^,O#4>B>7Y98[MV=Q!
MZ;<= /6ML;A8T.6U];[VZ6\EW,L'B77O>VEMO._F^QS5>0>H% !0 4 =OX<\
M$0ZG DSLX9MV<%<<,1W4^E?18; QJTU)N5W?:W1M=CP<1C94IN*2LK;W[)]S
MD=3MA:RO&O1791GK@$BO#JQY)N*Z-K[F>S3ESQ4NZ3^]%:L34* "@ H * -S
MPCH::S*8Y"0 A;Y< YRH[@^M>C@Z"KS<7?:^GJO)]S@Q==T8J2MO;7T?IV+/
MC+PU'HGE^66.[=G<0>FW'0#UK;&X6-#EM?6^]NEO)=S+!XEU[WMI;;SOYOL<
MU7D'J!0!V_ASP1#J<"3.SAFW9P5QPQ'=3Z5]%AL#&K34FY7=]K=&UV/!Q&-E
M2FXI*RMO?LGW-+_A6MO_ 'I/S7_XFNO^S(=Y?>O\CD_M&?:/W/\ S&3_  TA
M8'8[ANQ.UA^0"_SJ997&VCDGYV?Z(J.92OJE;RNOU9Q&LZ,^D/Y<F,X!!!R"
M#^1Z@CFOG:]!T9<KMMT/?HUE6CS+\2A7,= 4 % !0 4 % !0 4 % !0 4 %
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MH9]3YU8^>1$IV@<^M0:#%LEC)(.XTK ?1_[5< U>SL=1A(:'<P!Y#$3(LB,
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M''6K*FO/HCYLU/4Y-4D:>=B\CG+,>I_H!C@ < <#BN]*Q\_*3D[LJTR0H *
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MTN_TT."OCHTGRI7?7HOU-*3X8$ [9<G' *8&?KN./R-=;RO327X?\$Y5F?\
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M+NTM^_R(/AK_ ,?#?]<F_P#0EK++/XC_ ,+_ #1IF/\ #7^)?DR_\4/^6/\
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MG% $0.WYJ "4X _.@!T;;.3U[>U $L8)_G0!%C<V!]: $7YFR>U #MIR#W-
M#T<-["@!+AB1[9X% #4(C&.] "[3#P>M(9$J[FP*8A\Q ( [4@!8N[=/YT 2
M2R;?E'3M3 B)VX44 /0>9UZ"@!J_/Q0 H.["B@![C9\H_$T 0O*6X%(8_P P
M$8%,"-WW<4")W3RL+WI 1O\ W10,?;/Y.?6@0Q%WG)I@)*A8XH ?(I?"BD,9
M(>V* )BWE\CKBF R%2PSZ]32 D7D[!^= $,CX&!TS0 @&_GM0!.RD#/3^5,"
M.,;!D<DT $,1.?6D KCS&I@/B8%LGH*0#9<SM0 7$V?D7I[=Z !AY0 '4]:
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MW<:Q@*G4FF(;#&(R-U #M0?[20BTAF@D:VZ_A3$9<3A<GN3Q0,M/9C;N;K2
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M%0/KS^0/I73ET'*JGT2=_FK?J<^/FHTVNKM;Y.YO_$RY"Q1Q]V<L/3"@@_\
MH0KT\TE:$8]W?[E_P3S<MC>3EV5OO?\ P#4\#_\ 'G'_ ,#_ /0VKLP'\&/S
M_P#2F<F-_BR^7Y(\]\5636ES(&_B<L.N"&.1U_(^X(KY?%P<*LK]6VO1ZGTN
M%FITXVZ)+[M#:^&D!:9WQ\HCP3[E@1_Z":[\KB^=OHH_FU_D<.927(EUO^2?
M^9/\3IPS1)GY@')'L2 /_036N:25XKJD_P ;?Y&>6Q=I/II^%_\ ,ZJRL(M
M@)4?<3+D#YFV@DGD_7 )XS@<5[4*<<-#1;+5I:NVIX\ZDL1/U>B>RN<9=?$.
MXNCLA4+D@+@%WSQQSP<G_9[^O-?/SS&<W:*2O:W5_P!?(]V.7PAK)MVWZ+^O
MF=SKW_'O+_URD_\ 037T>(_AR_PR_)GS]#^)'_$OS1PGPU_X^&_ZY-_Z$M?-
MY9_$?^%_FCZ',?X:_P 2_)E_XH?\L?\ MI_[)73FOV/^WOT.?+/M?]N_J<)7
MS9] % 'K'@?_ (\X_P#@?_H;5]M@/X,?G_Z4SX[&_P 67R_)'!ZWK<\<\JK*
MX E< !V  W'CK7S5>O-5))2E\3ZON?14:,'"+Y8_"NB[&9<ZG+=#;([,,YPS
M$C/KR:Y)5935FV_5MG5&G&&J27HDBM6)J>D_#7_CW;_KJW_H*U];EG\-_P")
M_DCY;,?XB_PK\V<GXX_X_)/^ ?\ H"UXF/\ XTOE_P"DH]G!?PH_/\V,\&SB
M"[C+' R1^)4J/U(J<%)1JQ;[O\4U^I6,BY4I6_JS3/1/%6JRZ7#YL0!PPW;N
M@!XSP1WP*^IQ=65&'-&SU5[]OO76Q\SA:4:L^65UH[6[_<^AR=IX_N[MA'&B
M,S'  #?_ !?_ .JO%AF%2;44HMOR?^9[,\!3@KMR27FO\@\2ZO?-$T5Q$%0A
M264$@?,,?,&91R._]11BJU5Q<9Q23M=I/OWNT&&I4E)2C)MJ^C:[=K)F+X3U
M7^S;A&_A8[6S@#!(YR>F#@_AC->?A*OLJB?1Z/T?^6YW8JE[2FUU6J]5_5CT
M+7M,%W-;.3C;*W ]=I<<_5/QSVKZC$4N>=-]I/\ +F_]M/FJ%7DA-=XK\[?^
MW&7\1]4$,2P _,YR1Q]T>O<9;&/7!YKCS*KRQ4.K>OHO^#^1UY=2O)SZ+;U?
M_ _,XOPWIPU&X2)ONDY/N "Q'!'7&,]NM?/X:FJM2,7LWK\M?T/=Q%1TZ;DM
M_P#/0],US54\.PAE3C<%55PHR<D]N.A[=?SKZZO66&A=+K9):;W9\K0I/$3L
MWTNV]?(Y[P[XON-7N$C8 )ABP53TVG!))..<=,=<&O+PV,G6J*+M;6]EY>=^
MIZ>(PD*--O6^EKOS\K="Y\2O^/=?^NJ_^@M71F?\-?XE^3.?+OXC_P +_-!\
M-?\ CW;_ *ZM_P"@K1EG\-_XG^2#,?XB_P *_-G)^./^/R3_ (!_Z M>)C_X
MTOE_Z2CV<%_"C\_S9Z?)<F6(R0_,2FY,\ DC*]<=?PK[!RO#FCK=77GIIV/D
MU&TN66FMGY:Z]SS_ /X65<?W8_R;_P"*KYC^TY]H_<_\SZ3^SH=Y?>O\C6EU
M[4HE#F!<''16)Y&>0')'XCCH:[GB*Z5^1?<V_N4KG$J%%NW,_O2_%JQD_#7_
M (^&_P"N3?\ H2UPY9_$?^%_FCMS'^&O\2_)E_XH?\L?^VG_ +)73FOV/^WO
MT.?+/M?]N_J8/@?_ (_(_P#@?_H#5YN _C1^?_I+/0QO\*7R_-'6?$K_ (]U
M_P"NJ_\ H+5[>9_PU_B7Y,\;+OXC_P +_-%OP%.)+1 #RI8'V.XM_(BM\ODG
M22[-W^^_ZF..BU5?G:WW6_0\]\2P&"YE##!\QC^!.X?H17RV*BXU9)_S/\=?
MU/I<-)2IQMV7X:%K2?!\^J1&:/&,D $D$X].,=>.O7-;4<'.K'F5NN^E[=M#
M*KBXTI<KO\NGXDOAN Z5?(DPVL#@CKRRD+TSUR/ZU>&BZ->*EH[^NZTV]2,1
M)5:+<=5]VSUW]#O?%6JRZ7#YL0!PPW;N@!XSP1WP*^EQ=65&'-&SU5[]OO76
MQ\[A:4:L^65UH[6[_<^AR=IX_N[MA'&B,S'  #?_ !?_ .JO%AF%2;44HMOR
M?^9[,\!3@KMR27FO\@\2ZO?-$T5Q$%0A264$@?,,?,&91R._]11BJU5Q<9Q2
M3M=I/OWNT&&I4E)2C)MJ^C:[=K)G&UX![84 % !0!-=W;7;&20[F8Y)/^?\
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M\F2W>@ 50IS[=* $BC,YP*!AC<V!T'% "H,?49XH 5OF/TY_+F@1'"A<D^E
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M(ACO0!"9O*!8=>U $=K 9,N] R33X?-8^E F/N9EAX'44 0-,77)H @A/F'
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M<\&O8S&K&=-)-/WELT^C/*P%.4)MM->Z]TUU1SWA+Q/_ &*Q#Y,;#E1C@]F
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M$:_CN_*\MU;&_.TAL?=QT-=&95(SY;-/XMFGV,,OIN'-=-;;JW<XROGSW H
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M5C.FDFG[RV:?1GSF IRA-MIKW7NFNJ//Z^7/HSH_!WB?^QV*2?ZMR,]?E/\
M>Q_/OP/3!];!8KV#L_A?X>?^9YF,PWME=?$OQ\O\BSXWL89&^T0/&<_?567.
M<_> SSGOCZ\Y)&N.IQ;YXN/FDU>_??[_ +^YE@IR2Y)*7DVG]VWW?=V.3KQ#
MV"_::Y-:1M"C81L[AA3G(P>2,]*Z85Y0BX)Z.]U9=5;L<\Z$9R4FM5:SN^FI
M0KF.@* "@ H Q?&W_'A=?]>TW_HMJZ</_$C_ (H_FCGK_P .7^%_D?)!:OO#
MXH3.: $P: #;0 ;: %VT"!I..>M,![,!A>O^>M(  +-B@8\C8"*!#?\ 4X![
M\T#&X,9)/UH$+]T'/4_UH 6 &/)_*@!D;;,G\J!CU)ZT ([XZ]: !#QF@"5&
MV GUH @' ]Z %1-_';K0 ?>&!0 ^'H6/7M0 @. #0 P$$_YZT 2.Y4X'4T 1
MN>M #X_D ;TH 5UXW'\J &9VG/KTH DD/.U>_P"E "L!&.>: (3\U $LN5X]
MJ &(V[Z=Z ),"0XZ+0 D<F1\W*CM0!"#\U $S /P>OY"@!B^N* )8H\?7O0!
M')("?I0 HC(Y;N,XH :LGF')]* %7D&@"2#Y1D]: (8SN;)Z4 +(<FD I/'\
MJ8#L; #WI )&V26/:@ F?=S^5,!KR=%H ?.FSH>* &Q@Q\_Y^E "Q/D8YZT
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M8MI&6Z>O>F!-/,L7RIU_B:@ B(QC@#U/6@"NJ>821R.GO0!))&(0H Y/7Z4
M2'!.U#A<4 .@A#G X4?K2 M,CW"DYP@_#-,"B"+@@'A0*0!,2XPG"B@"QY@@
MCQTSW]:8!8V_F@L!^/I2 LQ7(7Y8Q@]VZTP*S7&T'Z_KZTAD4F4X/4\T 265
MMYAVGIW/]* +?G<[$X4=30!&)P,;!WZ^M #KRZ-P=O;O2&5[J$RXQPHI AT4
M'V48'WFXH G!-OM3OFJ$6W95Y;YC_*@"![TG!_(4 ),S2LJMUH F>'L#QW-
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MW5RH],,"3_Z"*^=S2-X1EV=OO7_ /I<ME:3CW5_N?_!/.Z^5/I@H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH Q?&_\ QX77_7M/_P"BVKIP_P#$C_BC^:.>O\$O\+_(^1L5]X?%"T &_% "
M;B: ';30 A6@"8P[@#QG'2@".%=_^?UH =CG% AI&6Q0 Y3YGY]:!@V';'IU
MH$-4%R?UH&.E8OSV'% ANW R>F:!CG;>1_G%,0R0[_IVI#%B;R_J: '3R9.!
M0 UVSQWH "P3IS0 1')^;I0!+*002.* $$C8XZ=/\B@!G Z=O\YH 1>A8]:!
M  #0,E8Y&!T_7Z4 -E(E.!Q0 S'(H ?CC/?/Z4 ,D?S.!T% "Q+G%  W[W-
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M-,G &*0"QVVWEC0!.C!NG:F!!/EJ &11-)]* )EB"G(H$)*XSSTH >)ST04
M.B0L<O2 AN)/,/%,"N9 E %FW8@\< T 1W(W,">U #OMF!@=:!C&M=_+4@+#
M( .*!%(1@')YI@2,^: $ACW<FF I(4\4 !M]YR:0%IKK:-JB@+%9K(R\M^5
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M?RH&6;MR!@?>/:@01Z<(@6?DXH"Y45V;/9:11-;2F7)]!Q3 ;9KO!STW<T"
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M(-N?6@"(DH* (/,V]*!DD<I8<T"%=S0,2)-QS2 ;>7.S@TP)H/N\4"*HX.:
M&"0NW/2@99\G(S0(<L)DH >TOEC ZT 5&@W'=2&36X\SK0(+J4)P*!E828H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * ,7QO_ ,>%U_U[3_\ HMJZ</\ Q(_XH_FCGK_!+_"_R/D;.:^[/BA0F: #
M9BF E "&@ H <[<T"'+P/<T#$D&XT &>1Z4"&NV[Z4P',OEK]:0"*O'X4 !
M3@TP'H<TAC%7=GO0 #C'KF@0Y4W<F@8KKY8QW- "$_PCKTH E51&.?\ Z] $
M2KD$T (IVCV[_P"% #7Y/UH >S;N/2@!81SCO0 ]''.>F,"@"+J>: !&YP.O
MK0 LK=10 CC:,?G0!)'^[&?6@0TM@4#)%0 9SSZ4 ,ACQ\Q_ 4 *#C)- #$;
M</\ /Y4 .; ''4<__6H CB;=G- A\;[/F_*@8-P-W8F@!JC:N?PH 3MB@!58
MOQVH G:3:* (8^Y- "$%CF@#T[X9_L_WWQ$MVN[22!$25HR)&D5MP5&)^6-Q
MC#COGKQ185SS*/CDT# ';0!Z;X>^ -]JFEMKB20"W$,\FUFD\W$1<,,",KD[
M#CYL=,D=BPKG"^'M&?6[J&UC*AYY4C4MD*"[!03@$XR>< GV- S?^)_PSN?A
M_<K:W;1LS0B4&(LRX+.H'S*ASE#VQC'- ''D[C[4 #N >* 'M+OZ_A0!U/PR
M^&5Q\1;EK2U:-9%B:4F0LJ[0R+@%4<YRX[8QGF@#"\1Z4VAW,MI)@O!+)$Q4
MDJ61BI() .,CC(''84 4"2,#UH 23U/X4 -(W?04 3)B5L=J0 <*2!0,9&-G
M- #XH]QW&@!;I,$#UH )!L'TH ;&N1DT /! ' _$T )"<F@!DZE#B@!53R_Q
MH <1@Y["@"[K>ASZ),;>[C,4JJC%&X8!T5UR.QVL"0>0>" 010!2DN"@Q0 0
MC9R>IH &CWG'YT *QW$ =J .[^*7P<N_AN8?MCPOY_F;?*9VQLV;L[T3^^,8
MSWZ4[ G<7P;\';OQ-I]QJ\+Q""V\W>KLXD/EQK*VT!&4_*V!EASUP.:+!<X/
M[Q+&D!>UK0I] E:"[1HY0J$HW##>BNN1V.U@2#R#P0""* *L:F,9Z ]Z (W'
M\(Y)H M@@C'H* *>WS#0,L3*'.WL!2 (ESTZ#K3 +AR1CN: "=_+7;0 ELID
M&P=SDT@)@ C8 SQQ3 >D9E;YCSZ>E("9KMIOE0X I@%S<93'I^M %6#<W;KQ
M2 [GPW\%KOQ%I\^J0O%Y5MYN]79PY\N,2-M 1@?E/&2.>N!S3L*YQ4<1(&>!
M2&,N2<C/6@!SQ",Y;J: +%K#N.6Z]J!%FZ80KCJQH*(UMQ#&2>I% B&PT_SU
M+$XQTH ';[2<'@"@8D%H;P_+PJT 23RDL%7MUH$2SRXQ&O4]30,FN\6Z[."3
M0(BNT\E0!UH [/XG_".X^'@A-X\3F7?M\MF.-FS.=R)_?&.O?I3:L"=SC65I
MAO;MTI#)%<]3T% &[\/OA[<_$:X:VM61"D1D)D+*I 95Q\JL<Y8=NF>:+7!N
MQ4US17TB66UD(W0R/&Q4G:2C%21D XR.,@?2D",FS8-GTH&313B$$C\J8CL_
M$7PMNO"]A!JLSQ-%<>5L56<R#S(S(N04 ' YP3STR.:=B;D7P^^$-Y\1GE:V
M>)?)\O=YC.N=^[&-J/\ W#G..W6DE<;=CCIH QPW7TI%&G?:))I0C-PA198A
M+'GC<A+*&QU )4XSC(PPX()!&=*/M'"]!0,6ZN2J8H J\*.O6@"W.QD4(.G%
M B:'$0QWH @B)W$MZ4QC%;>>:0RZ+7R1US[4@!3L&1UH ID&,%CU- #]-QRQ
MH$3!]YW=A3&/$OF^] A))"@P: *NXKP*8$I8G&:0RP)B%.>E BE;1;\O0,>!
MD=>:0BQ:N0,>M QKZ?@Y- $.23MH #-]GH JVR%SN- &G!\HR:8BO#RV:!EB
M>?=P*!%4VX3ZTAD5V^>!0 D*;10!<MI1 ,T"%>Y\SFF,KVZ;SFD!%< YH ;%
M#N.30!.:  KO'M3$1#*<"@9-%\M("2X0 9[T 58V'6@"8Q>8,FF!)#IPD&:!
M$4LW.WTH 8X,A"T 6)(@G2D!5N&(H B,IQ@T#-6R80)S3$4407+DF@9/(<?*
M*!%21?+SF@802\=*!$"AI&]LT :4[B!>* 17L1OR30#$DD+G:M  D!BZT@(I
M#MH&-1-W)H L1XC%,175O,- %R*814 5WNB[4 1W$V/K2!!;*7I@1RQY8"@9
M<:W"C H)'^5Y(S0,AB(?DT 0S-N/'2@",?-Q2&3*F.* +=GB+DTQ$&HS>?P.
ME %$0"/D4@'0*6.3VI@77N>R]:!%:5,]:8#3<;!Q0,=;P&;DT@"3@@4 79(5
M H$58W].*!DC$]Z8%2>?;TI")[" -R: );B14XH&4P=W- "ROG@4 -B4FF!(
M7$=("$9D-(#0AD$0IB*DEQN- Q@'FGVH ]M_9<\8)H&HFTD;;'=($'W0#*IS
M'DM@C(+JH&=S,HP>"*B1(^O9X%G4HX#*P(((R"#P00>",5H8M7/DCQ-H+Z!<
MR6K\F-L9XY!Y5L G&5(.,\9P>:].+NKGR]2'))Q[&95&9K>$O^/RW_Z^(O\
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M>O3_ &LG\?PKXC&U/:57Y:+Y?\&Y]E@Z?)37GJ_G_P "QAUYQWA0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0!B^-?\ CQNO^O:;_P!%M73A_P")'_%'\T85_@E_A?Y'R;N%?>'Q)&S4 -S0
M  T *: $H (EWGVH$.=LGV% $:\\T //J>E #UX&??BF QR9#DT@#;GYNPH
M3&X^V:8$DWR<=S2&,7Y!D4 ')R:!#PV_IT% R)GWF@"1,9_G0 228_H* &OS
M@=^] ".=V!3$*Y_2D!(S>5TZ_G0,4_NAGN: (E? S[T (<_G0(<J9X[^M P1
M"YSZ=: %DPW/;TH 5G+#;^0H 15WT $(#'':@![\-M'2@!DR]!TH 5UV_2@"
M-&SGWH$"#=P*8!,><#H*0#RN[O0,:S9'M0  \4 +'\O!H$.*^8<=J!@QXP*
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MQ ZG- %NUTB74IEM[:-I)&Z(BL[' ). H). "3[#- 'I0_9IUW_GU_'SH/\
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MCZUK[.5N:SMWL[=MS/VBORW5^U]2"LC0* "@ H * "@ H * "@ H * "@ H
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M<LA0J3V)W<XZ=AUZ=17OY;2C-N35W&UOQ/$S&HXI).R=[_@<;7@'MA0 4 %
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M"8@GC;NNV$@X4' ^7G(Y+4!9G<:7\18?'/A_49[>'[/!##=PQID?<2W!4[5
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MQF;/,UP?EZ5(Q]Q.%  H$-C3><TQBW$OF':M B,HP&*0R_98QBF(9?7 B'%
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MLU+VV"Q&<M'Z@Y.67G((R0 =W3<>V%2^CW/#KX9PU6WY'FM=!YX4 % !0 4
M% !0 4 >M> /@D][^^U(,B?*5B! =NA^;&2HQQMX?.?NX&>:=6VQZE'"WUEI
MY'N$$"P*$0!54   8  X  ' &*XSV$K'%^.?%84-:Q')/#L#T]5&.I['L!QU
MSCYW'XM6=.._VGV\O\_N]/H,%A7=5)?)?K_E]_KP-?,GT04 % !0 4 7]!_X
M^(O^NL?_ *$*Z</_ !(_XH_FCGK_ ,.7^%_DSK/BA_RQ_P"VG_LE>WFOV/\
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MV_X\+K_KVF_]%M73A_XD?\4?S1A7^"7^%_D?).*^[/B1*8!0 ;:  *:0#MM
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M=!P3\TD;QH. >KL!GH,Y.!DU**9ZA^T;\#[J>YN=>A='A\N)FC ?S5VJL38
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M9I%#9VDK.S '!!QD<X(^M25T/;/$/A:Q^/4"7UE,([R&-4D0[F4$J7$3 A2
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M."C3=]WY_P!?YF!'&9"%49). !R2?2O,2N[(]%NVIV=O\/)[L SRXPJA1RY
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MQ*D)G1<\"($#MDLV3^@_*L\S?[Q+^[^K+RU>XW_>_1'(UX9[)W?BO_D'V_\
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MU[3?^BVKIP_\2/\ BC^:.>O\$O\ "_R/DNONSXH:10 @.*8#P] "F2@!IDI
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M[P^Y#M0E,J)-OW@V36R(W9\W1KL&*@T( Q4\4#+';- B2S7?]Z@"2Z&P8]:
M)0ZQ+@4"*%RF.30,KXYI#+L"D]:H1/$=QI ,N[C'2@"J1OYH&,;]X?84@"0E
M\**8%V*W$"\T@*,\Q)H ;)<%%P/2@"QIZF09- #S\QQ3$6%C[F@"NS$FD40O
M(10(2*,DY-,"65\T"(YG"CB@8MA%DY/6D(T[A%0<=:8&>#NH&306Y0;C2$49
MKH[J"A_D--0 C-Y/% AT,N!S0!%&/..33 M!0* *S=: &2#% !%Q2 NV@R<T
MQ$5^^>!0!"%QTH&6;9-QR:!":A)LX% RF!V%("_8VV.3021:G<>E,976/UH
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M1S[=3 J=.,J>OJ]7?\+H\>&,<)N-33T6BM^.I@6.A78<>7'(K<X."F..?F.
M./?VKS*>'J7T4D^^J_'0]&=>G;5Q:[:/\-3I_B!=^7!%!(<RY5FQC'"D$]NI
M/''8^E>OF,[4XP>LM&_DK?BWH>5@(7G*:TCJE\W?\EJ<%7S1]"% !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MNV,DAW,QR2?\_P#ZJ\F<W-N3U;/4A!05EHD0UF6% !0 4 % !0 4 % !0 4
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M!]PFP "@"(_,1F@"V\ID'/ % %=Y !B@8R-* )4A!XH =&^T'UH$*,(,=30
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 8OC7_CQNO\ KVF_]%M73A_XD?\ %'\T<]?X)?X7^1\ED5]X?%"$T )F
M@ W4 &Z@!* %+<Y'2@0P<\FF JG'2D KMMX'>@!J''UI@.9]I'M0 *-IR:0$
M6:8$I?< !0 \?(OO2&1CY>M A5^3GOVH :Z8P/6F F<4 /7Y>M( 4;>M QJK
MS0(>WR<GK0,3=B@0T&F!*GH:0$2X!^E, 7+F@ 89I .V[NE Q!P<"@0^4[.G
M6@8U%W#)ZT )(V>!0 ]&V#/>@!I^;DT +&0W6@!JMC)H 56*_C0!(<(..M
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M39DT 26D189Z"@!%DQSVH <)3C@<4 /\LA,B@"($A>: &KE!Q0!8E 0 #J:
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M&.E "B&F YWVT@%M8/-.3TH T)BJT 94[;CQ3 2WAYRW2D!<D<8P*!"QDH*
M*SR9-,8]7SUH D%QMZTA%>:4ST#)K:R)ZT"$G&.!3&1QQ;C0!;D4**!%..0%
MJ0RU+* .*!%&1LTQDMK@TA$TR$=*8#%39R:0R.68GB@!BQ>M $>0#0!/!!NH
M$7';RA@4P*6\L:!DYC/>D SRJ (VCH =C%,!CMBD!$U #D:@!^P'FF(^H_!W
M_'E;?]>\/_H"U\+7_B2_Q/\ -GV='X(_X5^1KUS&X4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M1'J: &D;N!0!)%Q0 !=QI *R;S@4 6?LXB&3UH&1#Y#N/>@!\3=30!  9#0
M.<GB@"=R,4P&1#8=QH ;YAD.: )E&.32 &;;S0 V!=AR>] "RGS6Q0 LORC%
M #X";?IWH&),>>>M AS2"+IR: %BCR"6ZT#$BE\O)- $,2&9O:D!,XWG:.E
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MYH$:4<?DBD!GSW!)IC&Q?-0(L+\U(9,BA.30 UYLBF!5:39]: &H^:0#I&H
MDMUS0(N27(48%,"B\N:!CEDV4"',Y<4 0I%MYI#&22T -5-W6@#3LH HS0(D
MN)0E,#.EN,T 20H#0 V9O2@"%(\&D!:20)3 0MNZT /7"<T 1FXS0 [S* &/
M)0!"7S0,D$0 H$-6/=2&*R[: & AN*!'U+X/_P"/*V_Z]X?_ $!:^&K_ ,27
M^)_FS[.C\$?\*_(UZYC<* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H QO&O\ QXW7
M_7M-_P"BVKIH?Q(_XH_FC"O\$O\ "_R/DLK7W9\2(: &YI@% !B@!*0"1/CK
MR,4Q"*<@YI@"=/>@!0FX^U "/R?:@!'Y- "RGM0 AYXH ?&,G%( ;C)I@)&,
MT@$(SS3 :5R: '.-QQ0 ]SZ4@%9-@X[T 1=* '/P* $9L4##'%,0X#S.!T%(
M!",TP%4?G2 ;*,<4P$;FD!([;1B@8UA@8'>@"2&/ H C3@DT +NW<^E AF[/
M- Q[-L% #,[: '(,T 2W4F<** $D&: (XSDT .E.30 ^&4*<D9H <QST[T ,
MQY5 # Q;DT .1L<4 !XH =LW<4@&DYXH&.D4(/>F(8%W#% "%L\4 +@CB@!T
MJ^5Q0 B#UH D27R>.M(";;QN- RJ&QS0!*#GB@!COM.!0!(3L%,!(%"\F@!D
MDF[-(!\2$CVH D)+G':@!D@WG H =/+VH D@41KGO0!!GG- #U/E\F@9$3DY
MH$6K>, \=: )KA<-^% RO(GFL!VI 695VC:M PL45#S0 VXE\TYH$10C'- #
M[=N: %N9<G% #!$!RWX4 *P(%,!1$9.E %F.3"[>] $<($62: $A?S<GM0 L
M#ACB@!S\_+2 CG_<# ZT#&"7 H F*9%("2YVC"BF(OP@0)SUI@4G?S&!-(99
MFN0?E% B&6Y\H8% RQIXXR:8B&64RMA>@I#%D'DC/>D!4MT\XY-,"Q@$T (3
MYA^E ""3@DT )ID7F,<T@-61504P*OF[!FD,H]\T""1"^!3 O11B(<4AALH
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M)BWKYX% Q+,;.M B2XNMU %9CMI#*;.93Q0!I(GEK3$4\<YH E,VV@"6!^]
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M8^09Y[4Q!(2.: '10XY[T -D/F'V% #A&KC/>@"Q$HB&>] $62YYH&&-W I
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M_)H :/2@!\<>?H*  ON/% "#D4 .,FT8H  0HS0 X_O.: (U.!0 Z-MO ZT
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M .A7!R: &3+SS2&2&X &*8B!L=: %CE+<"@"16VT 1R28X% Q0.YH +ACVH
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * ,7QM_QX77_ %[3?^BV
MKIP_\2/^*/YHPK_!+_"_R/DDU]X?$@#FD N* #%, H ,T 0@4Q#@<_2@!2.U
M #"N[I0 /SB@!TG'6@ 3B@!P._@4 ,:@!5QF@ S0 B#- &M:Z[%$H4VL+$
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MNA_\B'M%_+'_ ,F_^2 :]#_SYP?]]7/_ ,D4>S?\TONA_P#(A[1?RQ_\F_\
MDALOB"'/_'G!_P!]7/\ \D4>S?\ -+[H?_(B]HOY8_\ DW_R0#7X?^?.#_OJ
MY_\ DBCV;_FE]T/_ )$?M%_+'_R;_P"2%?7H>@M(/^^KG_Y(H]F_YI?=#_Y$
M/:+^6/\ Y-_\D.?785_Y=(/^^KG_ .2*/9O^:7W0_P#D0]HOY8_^3?\ R0L>
MMQ'G['!C_>N?_DBCV;_FE]T/_D0]HOY8_P#DW_R0QO$,&<BT@_[ZN?\ Y(H]
MF_YI?=#_ .1#VB_EC_Y-_P#)"QZY#U^R0?\ ?5U_\D4>S?\ -+[H?_(B]HOY
M8_\ DW_R0G_"00L>+2#_ +ZN?_DBCV;_ )I?=#_Y$?M%_+'_ ,F_^2%;7H6.
M/LD'_?5S_P#)%'LW_-+[H?\ R(>T7\L?_)O_ )(?_;\ X^R0?]]7/_Q^CV;_
M )I?='_Y$/:+^6/_ )-_\D.3Q#"H_P"/2 ?\"N?_ (_1[-_S2^Z'_P B'M%_
M+'_R;_Y(B378I#Q9P?\ ?5S_ /)%'LW_ #2^Z'_R(>T7\L?_ ";_ .2'-KD*
M<?9(/^^KG_Y(H]F_YI?=#_Y$/:+^6/\ Y-_\D!UR%NEG!_WU<_\ R11[-_S2
M^Z/_ ,B'M%_+'_R;_P"2)#X@A0<6D'_?5S_\?H]F_P":7W0_^1#VB_EC_P"3
M?_)#6U^(#_CT@_[ZN?\ Y(H]F_YI?='_ .1'[1?RQ_\ )O\ Y(:VNP@?\>D'
M_?5S_P#)%+V;_FE]T?\ Y$/:+^6/_DW_ ,D2+K<)_P"72#'^]<__ !^CV;_F
ME]T?_D0]HOY8_P#DW_R1'+XAA8X^R0?]]7/_ ,?I^S?\TONA_P#(A[1?RQ_\
MF_\ DA[Z[ !_QZ0?]]7/_P ?H]F_YI?=#_Y$7M%_+'_R;_Y(1-?A8 ?9(/\
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M_?5S_P#'Z7LW_-+[H_\ R(>T7\L?_)O_ )(1O$$4Q_X](?\ OJY_^/T>S?\
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M/_R(>T7\L?\ R;_Y(@37(6)Q:P_]]7'_ ,?H]F_YI?='_P"1#VB_EC_Y-_\
M)#H=<A!YM8?SN/\ X_1[-_S2^Z/_ ,B'M%_+'_R;_P"2$F\21,<?98?SN/\
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M_P#DW_R0C:Q#T^RP_P#?5Q_\?H]F_P":7W1_^1#VB_EC_P"3?_)%PZK'"O\
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M^2&+K,7:UA_[ZN/_ (]1[-_S2^Z/_P B'M%_+'_R;_Y(L/JD0'_'M#_WU/\
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MS0_]]7'_ ,>H]F_YI?='_P"1#VB_EC_Y-_\ )%J+68D&3;0_G/\ _'J/9O\
MFE]T?_D0YU_+'_R;_P"2*YUR.0_\>T/_ 'U<?_'J/9O^:7W1_P#D1\Z_EC_Y
M-_\ )#FUF+_GVA_[ZN/_ (]2]F_YI?\ DO\ \B'M%_+'_P F_P#DBNVLQ9Q]
MEA_[ZN/_ (_1[-_S2^Z/_P B'M%_+'_R;_Y(F.LQ ?\ 'M#^=Q_\>I^S?\TO
MNC_\B'M%_+'_ ,F_^2$76HO^?:'_ +ZN/_CU'LW_ #2^Z/\ \B'.OY8_^3?_
M "1$=?B[VT/YW'_QZE[-_P TONC_ /(ASK^6/_DW_P D!U>%O^76'_OJX_\
MC]'LW_-+[H__ "(O:+^6/_DW_P D/77(4Z6T/_?5Q_\ 'J/9O^:7W1_^1'[1
M?RQ_\F_^2&G6XG_Y=8?^^KC_ ./4>S?\TONC_P#(A[1?RQ_\F_\ DAT6KPL?
M^/6'_OJX_P#CU/V;_FE]T?\ Y$7M%_+'_P F_P#DAUUKD*\?9H3^-Q_\>H]F
M_P":7W1_^1#VB_EC_P"3?_)$ UR$#_CUA_[ZN/\ X]1[-_S2^Z/_ ,B/VB_E
MC_Y-_P#)$MKKL1/_ ![0_G<?_'J/9O\ FE]T?_D1>T7\L?\ R;_Y(FFU:,_\
MNL/YS_\ QZE[-_S2^Z/_ ,B'M%_+'_R;_P"2)(]1B R;:'_OJ?\ ^/4>S?\
M-+_R7_Y$?M%_+'_R;_Y(C_MN)CC[-#^<_P#\>H]F_P":7W1_^1#VB_EC_P"3
M?_)!)K,2_P#+M#^<_P#\>I^S?\TONC_\B+VB_EC_ .3?_)$3>(8?^?:'\Y__
M (]1[-_S2^Z/_P B'.OY8_\ DW_R0Q=:BF/_ !ZP_P#?5Q_\>I>S?\TONC_\
MB'M%_+'_ ,F_^2+9U6*,?\>T/YS_ /QZG[-_S2^Z/_R(_:+^6/\ Y-_\D5TU
MB*0\6L/_ 'U<?_'J7LW_ #2^Z/\ \B'M%_+'_P F_P#DBZFJ1(/^/:'\Y_\
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M2(_[>B;_ )=H?^^KC_X]3]F_YI?='_Y$.=?RQ_\ )O\ Y(BDU^)!_P >L/\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M,7QM_P >-U_U[3?^BVKIH?Q(_P"*/YHPK_!+_"_R/DK;7W9\2*!0 Z@!"*8"
M8H 2@",C IB$' H <G/6@!-VT&@!%&.:  G>:  MNH >AP*0!&<=?I3 13@4
M (Z[?ZT .W8% #(XR10 ^/)XI (1S3 0MDT@'.,\T ,SFF H!?BD _V[T#$)
MV\4"(P<FF J#/]:0!]XTP%<[NE(!&;.!0 [&#B@8]5 Y_*@!$3/- !,<\4 ,
M09- AR_(:!C/O&@!QY.* %"Y/% !&.U "LG- "!=QP* %9L4 , W\T +WXH
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MH&2O%0!;@@"C)IB*]RVSB@ AYYH ?(<]* &JNVD,8QQ3 ?:1;FR: +%VHC%
MBLK#% RLB^8<T 23?+2 K)F0XI#+\8&,"J)(W&V@"$#<>: &SI0,NZ=;XYH)
M+ERX04#,Y[DXI#&V[TP)9GH$4Y#F@"]8X'- !<W&^@"O!-LI#+KR_+3$9Q&3
MS0,D/2@0V"+)R: )?*H ;(VV@8V(;C2 5Y-E #8)30 RXGSQ0 JK@8IB(PGF
MF@98$&P4@&+QUI@2,^10(K2$M2&-BMN: +#/LIB(TDW<F@8KG% ARL5%,1$[
MYH&-#9XI 6X$V4Q#)9<T 5,8ZU(R8'=3 :[8I@$<NZD!*TV* (/-S0 N<T )
MMH 4MCB@"&1\]* );>/UH O!Q'S3$1"XW&@8,^:!%9AO- QQXI .C7?]*!"N
M^VF! S;NE(9/$GE\F@ >6@"#RR: +41V"F(BDFSTH FBMP!DT 12QYH ;%#D
M\T 32+M% $4#<T@+3S8I@4)#YIH L6Y\LT 337>>* *Z<T /R%H 3S,\T 5Y
M&\R@ H 51F@"56Q0 PR;^!0!]2>#_P#CRMO^O>'_ - 6OA:_\27^)_FS[.C\
M$?\ "OR->N8W"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H QO&O_'C<_\
M7M-_Z+:NG#_Q(_XH_FC"O\$O\+_(^3#7W9\2)B@!#0 F:8!F@ Q0 Q?EX'6@
M0,V/K3 $.>30 F_ Q0 T#B@!Y3:,]Z $49Y- "R^E #<X/%  >M #F.V@!"<
M4 *1M% ";=O/K2 '&>:8"J,"D W/>@!5SWI@$:9Y- #LE1[T@&NNT8H %&V@
M 0;LTP%R0* !1CBD N !Q0!$.: 'Q+O- "T#'*<<F@!R<#- $*\\T .?/>@
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MI@5)I=_%(8Z&$T #G9TH %-,0TMMH  #C)H <B#J:0PDGVB@!JOFF(<T^P4
M,\W/- "._'- #(AFD,M% !S3$-"YI /VYZ4P(S0 QVQ0,C5">32 G04"'!MO
M2F QGH C4;^M  :0#0N:!EB%,4Q"R<T 5P.>* +2D+UH KRR[OI0!]3>#?\
MCRMO^O>'_P! 6OA:_P#$E_B?YL^SH_!'_"OR-BN8W"@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * ,7QK_ ,>-U_U[3?\ HMJZ</\ Q(_XH_FC"O\ !+_"_P CY,K[
ML^)%Q0 A6F F* "@ S0!">M,0X#=R: !VXQVI ,QFF =: %4[N#0 ;L_A0 G
M4T 2*, T 1H>]  %SUH <#0 2OVH <J_CFD DJX^6F "3/%(!%&: !SGI3 =
M&V*0"._FFF C?,<4 &<F@!-VT\4 /5<_-2 :&[T "MQ3 !$6&:0!&?2@ )V4
M#',_<T (S\4 ( 10 I&: %9=U !*U #(SMYH D5-WS4 1YW4 .BYXH 7&#0
MH3F@!['=Q0 @ >@ :; Q0 *VT8H C1LT 21O0,53DT"&;>: 'LV>.] PC?;2
M $&?FH E+;^M $)CW4 #]A3 L%,"D V3Y1Q0 ^% !DT ->3/- "/'D9- #X<
M'K0 V9?6@!Z1E^*!C95\OY:0#D Z&@!I'F'':F!9MY=O% $<K;S[4 1P'YLT
M 27+\YH 5'WCTI 1QOM.* ) * )4F$8I@*7\\YH :B>::0$W^KZ=: (KAMM
MQN_ H FLQN% #)!VH DMTVGFD!/)<'I3$4HN2:0R3'>F ZW^4YH +V7S.!0!
M*L.5YH$2Q1$C- RE,NYN32&60W&*!#8GVFF K?,<T 12/N- "#DYI#)HP#0
ML0'6@!LMQSQ0 PM0 ]1OYH L/-Y:\TQ%5?WM(8^&';UH ).N*8B_!%L7-(#/
MNISF@8R-M_% %O=L&!0!#$"QH$3E,T#*SKM_&@"2%<T -<;C0 /+LXH (N*
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@#%\;?\>-U_P!>TW_HMJZ</_$C
M_BC^:,*_P2_PO\CY+!K[L^)%W4 +3 0F@!I- "&@"/;S3$.8YH 21N *0!C
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M QS2X'- %1CGF@1+!S0!*30 T4#"20#I2 0)3  ^.*!"R9- $:OVH L10]Z
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M>_\ )?\ @A_:/]W\?^  _: S_P NO_D7_P"UT?V9_>_\E_X(?VC_ '?Q_P"
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M1_N_C_P /[0W_3K_ .1?_M=']F?WO_)?^"']H_W?Q_X J_M";O\ EU_\B_\
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M?[OX_P# &']H?'_+K_Y%_P#M=']F?WO_ "7_ ((?VC_=_'_@#3^T3C_EU_\
M(W_VNC^S/[W_ )+_ ,$7]H_W?Q_X ]?VAL_\NO\ Y&_^UT?V9_>_\E_X(?VC
M_=_'_@#Q^T#G_EV_\B__ &NC^R_[W_DO_!#^T?[OX_\   _M!8_Y=O\ R+_]
MKH_LO^]_Y+_P0_M'^[^/_ (V_:'Q_P NO_D7_P"UT?V9_>_\E_X(_P"T?[OX
M_P#  ?M#?].O_D;_ .UT?V9_>_\ )?\ @B_M'^[^/_ #_AH;_IU_\B__ &NC
M^R_[W_DO_!#^T?[OX_\   _M#_\ 3K_Y%_\ M=']F?WO_)?^"']H_P!W\?\
M@#?^&B?^G7_R-_\ :J/[,_O?^2_\$/[1_N_C_P  /^&BO^G7_P C?_:J/[,_
MO?\ DO\ P0_M'^[^/_ %'[1.?^77_P C?_:Z/[,_O?\ DO\ P0_M'^[^/_ %
M_P"&A_\ IU_\C?\ VNC^S/[W_DO_  0_M'^[^/\ P!1^T-_TZ_\ D;_[71_9
MG][_ ,E_X(?VC_=_'_@!_P -"_\ 3K_Y%_\ M=']F?WO_)?^"']H_P!W\?\
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M^1?_ +71_9?][_R7_@A_:/\ =_'_ ( A_:)_Z=?_ "-_]JH_LO\ O?\ DO\
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MC_=_'_@"_P##17_3K_Y&_P#M5']E_P![_P E_P""']H_W?Q_X ?\-$_].O\
MY&_^U4?V7_>_\E_X(?VC_=_'_@!_PT5_TZ_^1O\ [51_9?\ >_\ )?\ @A_:
M/]W\?^ '_#17_3K_ .1O_M5']E_WO_)?^"']H_W?Q_X O_#1'_3K_P"1O_M5
M']E_WO\ R7_@A_:/]W\?^ )_PT3_ -.O_D;_ .U4?V7_ 'O_ "7_ ((?VC_=
M_'_@"?\ #17_ $Z_^1O_ +51_9?][_R7_@A_:/\ =_'_ ( ?\-%_].O_ )&_
M^U4?V7_>_P#)?^"']H_W?Q_X ?\ #17_ $Z_^1O_ +51_9?][_R7_@A_:/\
M=_'_ ( ?\-%?].O_ )&_^U4?V7_>_P#)?^"']H_W?Q_X O\ PT5_TZ_^1O\
M[51_9?\ >_\ )?\ @A_:/]W\?^ '_#17_3K_ .1O_M5']E_WO_)?^"']H_W?
MQ_X A_:+_P"G7_R-_P#:J/[+_O?^2_\ !#^T?[OX_P# $_X:,_Z=?_(W_P!J
MH_LO^]_Y+_P0_M'^[^/_  !?^&B_^G7_ ,C?_:J/[+_O?^2_\$/[1_N_C_P
M_P"&B_\ IU_\C?\ VJC^R_[W_DO_  0_M'^[^/\ P '[1?\ TZ_^1O\ [51_
M9?\ >_\ )?\ @A_:7]W\?^ '_#1?_3K_ .1O_M5']E_WO_)?^"']I?W?Q_X
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M@!F=QYH D"9^E $7WC0!,1D4 1[2XH >[Y 6@"<$(,=Z %BM\#)H&0!-W)H
M-F:0"Q/MXH D1MAI@/D/<T"& 8H&"R'M2 =&F.: &'YS0,?(V!@4")+5=JYH
M ;&N[)H ,T  .>: &#+4#)&&* "8\4@$MX\\TP+YQCB@!JONH @G.XT *H\L
MT 2W+<9H A@DW4 2O-NXI -N%,0^M #;*/;R: )[V7=Q3 CBM-PS0 KH4XH
MA)VT &TKS0!/;P;SFD!-(VWK3 B9@1B@"$OLI#)K7YAQ0(;/[T#'(^Z@!CC/
M% %A5V4"(%^<T 6G? H J*V*!DL9&: &R29H 1\M3 0+L%(!48M0,AZF@19V
M[:  \<T 1[MWTH 1QNH GV8&*8$J2[!0!3=2YS2 ?&,4 -F^>@ AXH E;@4
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MX[4 .4[!0 6W)S0!+U- #[O"B@"K%\U $D')H 6XFV4 1HV10 R:3%  IS0
MA.^@"Q$,4 *P\SB@"%CL-,1/#( ,T 0S/NH&0Q-S2 L.F* (>E $Z)@9H 11
MM^M,0V9L=*0QJ?+0 2&@!PDP* *V[)H ?NS0 N_% %BW2@!]U)CB@$01OF@9
M%))0 UCF@0(V>* +"I0 U5H 29J0R2$[:8AL\F>* ""/% #Y&H ;MH&,+T 0
MLV:0!G-,":,;:!"RG:* *C2=A0!9MH-U(98D?RABF!2DFW4 +"F:0%DG8*8B
M%5SS0 \C;0,@D:D D9Q3$.+]J &N* &$]J +44>V@!LLF>M,"N9O2D J)YAH
M D=-M #(UYS0!*6W4 ,#8.: %:7=S3$5F;)I#')0!,R;10!7*ES0!;B3 Q0(
M2>3;P*!D:G'UH 0K0 %L4 (TF*8!T%  %)H <HH DVXH$ EVT 1,W>@"!CFD
M!8M+4MR: +CKMI@4W;)I#(R-QH N6\06@0Z3GK3 K!LF@!_ YI 5Y&W&@9+&
MN*8A7- $&W;2 <#BF 8SUH <HS0 [&: ) ^R@".27- $1H 8#2&.VXIB)$YH
M )'VT -7/>@"13MH E23- $<DE $&Z@1)OQ0!"QW4 *!F@!&H 3&*!CDH <3
MF@!QXZ4"&F@8P+OH =MQ0(-M,8P\TA#PV* '>7GDTP(WYXH 15H ?G% #&.:
M &@4@'@9H D"T -=L4 ,H 7;BF P\4@ 4 2HM,!2: &&@!M $JIF@0U^*!E<
MG- $T9Q0(D#XH C9MU "[* #90 QN*!C@,T"%)Q0,CW9H =B@0A;%  IH =N
MH "^* (RU ##S0 H6@!RB@!V* $- #30  4 .5: '8H :30 R@!": #K0 4
M% !MH 7I0 #F@!Q% #"* #% "$T (30  4 +0(6@ S0,#0(;MS3&&W%( !H$
M+F@!* $S0 9H * $H 7% "T )FF 9H 44 &:0"4P$Q0! *8AP7% "!>U #B<
MT "B@ ;!- "8H <BY.30 DG)H -N: !.* &]: '+2 1O2F H..* %(VT , R
M: '2-@X% "YQSWH 1!O- "RC;P* &[MM #HVW<F@ C;:<T@$/S<T#"-J %;G
MF@!5'>@!J^M #5.*!#]M R1WP,"@!F !0 !: (V'.* )%':@!6&_I0 TCB@"
M1/EZ4 -E&.* $"YZT (JXYH 5FS0 -R:0$T8 YH&,QYAIB&NW:@!$.#0,D*=
MZ %P.M A[#S3@4 *L.1BD,:[ <"@ QOH EB3=UZ4 1R/@X'2@!Z/MZ=: &*F
MXT  ZXH&/*[#0(2,X- $YXH BR&- %EE""D,9&N3FF C2ECDT"(PY<^U "R
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M>,+0!&5% #30,!Q0 A:@!K'- "J?2@0\,%H :7W4 &* )HH\4 #\TP(F8+0
MT<T .P* '&.@"-EQ0 L9H$*TE QFW- $B1T@%>F!7DXI $:9H E)I@,+8H 8
M6H  : )1)0(:: (* '@TABDYI@.08H$2%J &NV: &K0 %J &$9H <!B@!>M
MQK"@0S=0 $XH&)F@0@YH =C% "T .#4 *: &L: &4 2QK0!(33 C:@"+-( Z
MT !XH ;NH 4"@!PH ,T"$S0 ;\4#%!S0 ;J $ZT )B@ Q0 4 % @H ,4#"@
MS3$% "4AB4"#% !BF E( H * %ZT +B@ (I@-H * #- !0 4 0J:8@% "K0
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M A'?;0,(ALY- #U4R<T .SM% $2+OI 63%Y8H JFF!-'"<4@)=VR@"(C<,T
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MVXT *IH  ,T !.: %3F@">-* $GPM %/9NH 3I0,E1N,4 .(Q0 P\4"'1'-
M#)FQ0 T#CWH :BY- %O;@4 59!0!8MH\<T"">7% RIG=0!8MUQ0!)--F@" F
M@!N>: )]PQ0! 1NH C9<T .B7- %@QYZT 1228X% $3OF@"/:30!>M80O)H
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MH&)]WF@!H;<: !GW4 ,^\:!$H&30,:6S0 ]5P,T -5,C-  _I0 F-HH 5.:
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M^@!XH 1C0 N_% "(=YH N'Y: *TIS0 U3BF FS=2&,=]M "AZ!#<;J 'AMM
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M\_W?E?ZS_GFN_P#UOS_?W=?PXQ0P1S428I#$W4@)%'%,!%?;Q0 HYH )?FH
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M* 'JFV@!2,4 1M0,90!8MOEH$/D?- $$C^E  %R:8%HI@4@*;C)H&*U A5H
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M C% AH&32&2!*!!Y>ZF DAH K2M0 Z)J0$Q:F!&6S0!(GRT ("7H =F@ )H
MCH >#MH 3% "XS0 W;B@!<9H 'XH @+4 /0XH 7S: %W4 "\4  7=0 [..!0
M( ^*8#3+NH <:0R,B@!HH >#0(:[8H C49H L(^* 'F6F!"6S2 :: #.* $-
M "J,TP%8XH 9G- "EJ $"T@'@XI@.+4 1,V: (PM("0<T 2!-M,!NV@!K-B@
M!5- #LT"&'B@! M QP% A2: &.U QJC- A_2@8E A#0 FW=0,,;:!#2<T --
M "4 ."YH 7;B@!V,4 )F@ #4 &<T .!Q0 M "$TP&%J0#"<TP "D [% "$4
M&*8!BD 4 .S3$)B@8$8H 2@ Q0(,T &: #-(!:8!G% "4 %(!#0 F:8#AS0
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M+GSYX4T+^WKRWL]VSSYXHMV-VW>X3=C(SC.<9&?44BCW"7]CVZ.H"T2XS;"
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M(VS?M\MEDPS!2NYL@JI(8$]""%^7=+12=SS?1]%GU^X2UM4,DTC81!U)Z]^
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M\N0&(#'R]NX#!+ AE#L2V:'BG]EV/481=:%<B=-IPKNC!RN[.R6,!,Y 4*0
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MBO\  FY^'069I$FMW<(L@&QPVW=AD).,X;!5F&%RVTD"DU8I.YG_  D^&/\
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M^%;1*9XYH]MX@^"9FF%N\:RP;7<CSH%RV$D+1LT0D5N%#YQN(*D/RMA[G,>
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M!"J"H.-MO8A:,Y#]CM<:M-_UXR?^C8:2!GE_Q2&=6OO^OZY_]&O292.>88%
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M[HSV91_8P_YB'_;K_P"UZ41R/$?'WC6;QE=R7MP3EF.Q2=PC3)*1C 48 /7
MW'+'YB34E+0[+]F'7)K+68H(W*Q3K*)4_A8)%(Z9![AAD$<C)&<,P+0F9O[2
M4NW7[O\ [8?^D\5#!;'FAR>:DHL6>#R: %N'#&F!Z)^S=_R'[3_MO_Z3RTT3
M+8F_:4DVZY=8_P"F'_HB*A@MCU>^OS\-_",!MG*SW2QD2QJJL&GS,Q8YSD1
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MF-<M?^V__HB6I1I+87]I-\:[=_\ ;#_T1%0PCL>8K4E'TU^QL<_;_P#MU_\
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MN>1W/[//B"Z=I)+8L[,69FG@+$DY)),N22>23UJ;%<R/5OV>_!&N>"+IHKN
MK92JV\>="RHX&5D"JS,2<;"%QG(+9V"J2L0W<\)^-'AI/#FKW=M'C8)=ZA5"
M*HD42A H) "A]HQUQG Z"&:+8]I_;)'_ !X?]O7_ +0JY$1-KP=XMD\)^#1>
MPC]XB3!#Q\K/=/&K\A@=I;=@C!Q@XSFGT$]6?)EQ>O=.TDK%G=BS,Q+,23DD
MD\DD\DGK69H?4O['NNS7<-W;2.6AA:$QJ>0ID\TOCN 2H..F<D#+,3HC.1\Q
M38' J#0KQ<FD,^G/V.VS]N_[=?\ VM5Q,Y'SMXR\3OXHO)KU\@S2N^"Q<J"?
ME3<0,A5PHX' & !Q4EGM/['OAM+R\N+UL$P1(B J"092WSAB?E(6,KP,D.1D
M#(-(B17\=?"KQ'XPNY+R>V.78[%,]N1&F3LC&)%& #U &XY8_,2:+#32*_@;
MX3^)?!UY'>V]L?D8;U$]NHD3(WQG,C## =2#M.&'S*#18&TR_P#MA>'%LKRV
MO4P#/$Z, H!+1%<.6!^8E9 O(R @&2, $@B>C^+?&[^$?"UK)%D336=K#&PR
M-I> $OD,I!"*Q4C.'V\8S3OH2E=GR&R5F:GTU^S_ *D_Q TB]T6Z.Y8T5(Y'
M DV+(K",!2!GRWCW(2V1D*NT(M6M3-Z.YR'[((_XFDW_ %Y2?^C8:41R.%\=
M:C_9^LW4VU'V:A.VQQN1MLS':PXRIQ@CN.*3W&MCHOB#\1=2^,*11P6LA2W4
M&18%EE4R,,;V"@A1A2(P<E<O\[9X;U$E8HZ5^SCK=_L/V;8K[?F>2)=H;'++
MN,@P#DKMW#D;<\46'S'KO[2]A+8^'[*&Y;?,D]LLCY+;G6WE#MEL$Y()R>3U
M/--[$QW*'PSN3\/_  I<:M!@SS,Q5MJAE/F"VCR2&WA&S( 1CYBN!DL1:('J
MSYHNK][QFDD8L[,2S,2S$DY))/))/))ZU!H>D^ /C[<>#K"73?)CN$=B4\XL
MR*&XEC*9PR,,D*"F&9F.[.*:9+5STW]DW0S9V5[J<2":<L8HX_E1B8T$FP2-
MG:)&=0> !L#'/&*B3(\^USX$^)->F>ZNK<R32-EF,UODGIVEP !P ,
M"E8JZ.N^"WPU\0^!=0CE:W(MI&"7"^?!M*'(#D!V)*$[Q@;B 5! 8Y:5A-IE
M3XI>&TT7Q?:/'@"XN+*;:JA0I,PC;H>2S1ERW!)8YR>2GN"V+?[8OB9VN+;3
MQD(D1F/S':Q=BBY7&,J(VPW/WR!CG+D$3C?V8M2DM-<@2,X65)D<8!RHC:0#
MD<?.BG(P>,="04ARV+'[4GB&74M8>V<_N[9(UC4$X^=%D9B"2-Q+8) &550>
MF:&$=C<_9!G:/4IXPQ"-:,Q7)VDK+&%)'0D!F /;)QU-$12/,/B@/^)K??\
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M0 \)0 M,!KM0 P/0 A.: $VT .44@)-VVF(83F@"/K0,<*!$HXH 7K0!'(U
M#,4 .5: 'XQ0 K&@"-VH 8HH ?0 9H 8QH :!F@!V* 'K0 X&@!6- #: &$4
M &W- "[* &E: &$8H 0<T /5* '[<4 )UH 7I0 A;- #2: &YH =NH ,T (:
M8"9H$% "$T -S0 X"@!0*0"GBF VD M PH$% #30 "F 4 **  FD F:8"4 )
MF@!:0!3 *0!0 4P#% "&@ H 4"@!: $H ,T 11BF(:QR: 'MQ0 A&: !/6@
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MC/.!BB?.K)V%24?4?@:S_P"$.\&W4\X?_2DG8+MVLOG!;:+[Q&5.%DW<?*W
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MW_"2:99:O '\L8.TKDA+A$968@D+@HJ]P6< 'IFF9Q/EUG+&I-3Z?_9>M/\
MA&=+OM7G#>6<G:%P2ENCLS*20&R79>P#(06ZXI&<CRK]FTYUZU_[;_\ HB6D
MBI;"_M(K_P 3VZ/_ %P_]$14,(['L/PGUJZN_"CKI1*7=LTR@E0^XB03L$7#
M[BT;[5!7ESCCAJ:V(>YY(/VBM='6[_\ (-O_ /&J5R^4ZCX>_$3Q1X]F,%G<
MCY5R\CQ0+&@YV[B(6.21A0 2>3C:&(=[B:2/)?']Q>75_,VIL&NPP64J8B,J
MH4+^Y^3(  ('(((;Y@:EE(]W_;,;:+'_ +>O_:%5(B)&3GP%_G_G_HZ!U/F9
M4Q4&A]._L9K@7_\ VZ_^UZN)G(^9YG)J#0(4H ^F/V-#DW__ &Z_^UZN)G(^
M8HANJ2SZ-_8XU=(;B\M"#ODBBD!XVXC9E8'G.<RKCCL<D<9I$2.4\5?'+Q'X
M;N9;.>YQ)$Y5OW,(!QT8;H02K##*<#*D'O2N.R*^@?'?Q+KTZ6MM<&2:1L(@
MAM\D]?\ GE@ #DDX  )) !-%QV1'\=8]9MYHK?7)HYBBLT)C\H##;=QVHB.!
ME0H+J,E6VY )H8(]>^)WAV75_"EDT0SY$%G*XP2=@@V,0 #TW[CG "AB3Q3>
MQ"W/EBY?'%0:GTG^S,J>#]*O=9NB5A8C ("[A"&P49F 8L\AC4<?.NW))P+6
MAG+4Y7]D$_\ $UF_Z\I/_1L-*(Y&'8^%8_%GBF6RF/[M]1NRXY^94>21DX*D
M;@I7(.1G(SC%'4>R/4OC!^T3+X#O/[+TV"(+ B!S(IV<HK(L:QNFU50@<]3P
M% 7+4V0E<\GN/VA-?UQVBCG(\YBJQQ11AAO. B$(9,\X4AB_3YMW-3<JQZQ^
MT5;36WAVQCNLF=9;42[FWMO%O*'RV3N.[.3DY/.35/8F.Y2\'VC^,?!DUE:J
M3-"TBD$$[BDRW15 NXDE&"J, E^.G-+H-Z,^82F*@T.^^$?P>F^(SSK$XC$,
M6[<PRI=CB.,X(8!L,2P#;=O0D@%I7$W8]R_9Q,D.GZEIEI(OVJ&:0QS AX"S
MQ^7$ZG!W+OA+<K@J0<') M&<CR"X_:(\0VKM')<E'5BK*T$"L"#@@@Q9!!X(
M/(J;EV1M>#?B[XG\8W*V=G<;I&Y),, 1%&,NQ\HX49^I)  +$ EV*R14U5]3
M_P"$DLH]9D22YCNK1 R&+&SSPR\1!<9W%@'"OM8$@ BEU'T-3]KV/=JT)_Z<
MH_\ T;-3D*)S7[-__(>M/^V__I/+26Y4MB/]I,XU^[_[8?\ I/%0]Q1V.I_8
M_?=JDW_7E)_Z-AJHBD>;?$S+:M??]?MS_P"C7J64CZ=^-WC[4;#3K35M(<QP
M2*K2@QH[@2JK1%MR.J@<J3N'S,H&[(Q;,TCP=_VDM='2[_\ (-O_ /&JFY?*
MCM?#'BOQ?XDLI=2@N$6"/H9$M8MX!^=E+Q!-J8RS,RKP0"6! -1-(R?V.Q_Q
M-IO^O&3_ -&PT1"1YO\ $L;=6OC_ -/UU_Z->DRD+\,W_P")K8_]?UK_ .C4
MH0,]'_;"&=6A_P"O&/\ ]'3U3)B=5\;ACPII?_;E_P"DDE#V$MSYH,FVH-!H
M;;0!V^C?"K4I+!M=@&R&'$B,K'S3MD*LZ!,LOELNYBVS &X$@'#L*_0W_#7[
M4FLZ,OEN\=P JJOG(2RA01]Z-HV8GC<7+$D9SDG)<7*>V:KXIM_C'X;O+F2$
MQ&%9F"Y5RLD*"565BO0J0K':K89U''S&]T1LSR[]CX_\368?].,G_HV&E$J1
MY?\ %-L:M??]?UU_Z->I92/=?@5_R*FJ?]OO_I)'5+8A[GS,S5)9](_LNZ';
M:79W?B"X7>UOYBJ N718XA)(5RP7<ZN%[$ $;L.PJD1+L8&N?M;ZI>AT@2"
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M &.]  !NH$2;: &.U Q@% $J)NH$/;Y: (&/K0 @.: %/RT -SFF UFQ2&"
MF@1.AQ0 22YH KL] "H* '&@!"<4 .09H 5CB@"+K0!*!0 XBF!&S4 1M0
M4 . H ,9H <3MH ;UH :U  JYH =]* $+4"#=0 *M Q3S0(,XH  ] ",VZ@!
M-M !F@ S0 TF@!#0 9H <* %)H 04 +F@!"U #<T /5J '%J (V:F!'UI 2
M8H >&I@-9J #-(!I- #2: #.: $QFF O2D "F M( I@-- "8H$."XH * #-
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M"HC9E2/:!G!RP^3"H&#JX)'D/@GQ;-X1NH[ZU($L3$KN&Y2""K*1Z%20<$$
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M-?$>,-KEOY,R8P2)')&7PJRP 2%0#DJP5=S<!B-U7<BS1!<_&/PY\.8'/A^
M27,BN%;9* I.SAY)\2;. P1"02O.PG=1<+7/GZ+QC<R7RZM,WFW*SI-N?D%D
M8,H(4C"_* %7 "C"X &)*/HWQK\0O"OQ(@\V]<PW/E2)&SQ3^9&3D*6\C*.
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M?+VY_@V[<<8QQ3T%J<1\6OVA%\6VW]F:=#Y%G\@.X*'94VE$"KE8U5A_"6)
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MYOV?9\DCYV^;N_U:MC&X=<=>*I,F2N>'I'LI%&AX:\03>';J*\MSB2)PR\D
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MH F [TP(2VXT@&J] "@T#)(VYH$-E.\T /QBF R9L#%(!;<;10,E+4 1*<T
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M;L?05U9V?[/FEW"0W EU*X5=N2%<DEUC<1?O J("[9;(=@5+<JJWL1N?*!;
MJ#0C*YYH 8PH 4'%  @H E#4 -/'- "4# G?P*0"M#MH$*GRTP%3GF@!2V:
M$!S0!)OQ0! YH :M "YQ2 <HH =G=3 CD:@",<4 2+Q0 Y30 H?- "/)0!#N
MW4 3Q_**0 S4P(>M !G- $B#% #^M #": )$&Z@!9"!0(KL:!BAL\4 3;]HH
M$0EJ!C ,T 3CY: %)IB(';-(8SI0 ]4H$2 4  %, +T@%#8H 1I-U QFV@ 4
M4Q"EZ (Q\U("4"F A6@!C'-(! F*8#NE(!AH 0T "INI@65CQ0(",4#(2: &
MEL4 (!F@"9>* $>@!IH %H ?G% #6>@"/=0 AYH 7I0(7- #2U #<T .4T /
MW4 )UH ;C- "XH ,8H :: %S0 #F@!V,4 )3 :32 4"@!2: &DT ,Q0 4 .3
MBF I- "&D  4 +0(7-,8A:@0T\T#'A:!"YH 0B@!M Q*0!3$&: "@!,T % P
MQ2$&* $(I@)B@ H * "@ H 0F@!,T +0 HH ,T &: $H * $- !F@ H 6@!"
M: (S\U,0K<"@!,8H  =U  3@T .5LT -QVH &ZT (!F@!7ZXH 7Z4 *PV4 (
M!0 B]: %8YI (O%, I  XH 5>* %0YH 9GM0!*6P,4#$C% A<8YH&-5\4 (5
MH$'6@ (H&.Z4 -8T *G% $B_)0!']XT #T #KGI0!(R\4 "\4 'WJ &AJ ']
M* #.*0$D29&: &8YS0, ,T $@I@.(P* $Z4 .B&^@0LC8XI#&GGB@"5/DH C
MQ0 Y%VT# C<: )F&R@ CYZTA$/WS0,L[-M,1$3F@!)#MH&*G/- A%7<:0RQ*
M,"F(@5*0R7;NH 15\PXH L.FP8I@532 6),4#%/- ABFF!+"@H DD-("-XZ
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M3 7&: &,] #<YH 2@!JG<: )TYH 'H B<[N*0R:(;: 'GYNM,1$[9-  S9H
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M\TQ#V7% #&;=Q0 K+MH 1>* $% #L8H 1AVH <* &=: 'H* &D[C0 -S0 4
M*?2@!* %7FD N.:8 PQ2 5N!0 Q:8#E-(!&&V@8K4 -(H 4G- #@,4 -84 .
M;D4 -48H >W'(H 4\B@ C&T9H ;G)H %Y- #FX- "$YH 44 !&* '+S0 A]*
M0"[L&@8YCF@ W;: $)W\T .- "9XH <IVB@ C3/)H </F-,!9.M(!Y&10 QN
ME R6W''- "%LF@!96XH$0Q+WH&2++F@0W!)H D:+(H 8>.* )DAQS2 @FDR<
M4#)10!*5VB@!D'!R* '37!:F U5I /9: (YAMZ4P!5Q0 ]&Q2 DV T 124
MB[T /*T#&JVV@!RKF@ D/% @A;;0,GDDXH JXW4@'CY:8$4KYH 0$T 3)'B@
M !Q0!([9XH ($S0!'-P: %C7'- $T0V\T 17,F:0$=N,T 3D[: &,<TP&[J0
M"XXH&!3- A<[:8$<9WFD!:/ I@0.N:0$JMBF!&[ T ,CBYS2&6'/%,1704@+
M6[B@"O*V.*!C ,F@0X#)H&2"@ 0=S0 $=Z %7I0 UVQ0!&IIB)(6Q0 Z=NU(
M96(H E@BSS0 ^=MM #8TH$)(<<4#&;J 'CYJ )%04 ,84 "C% $ZM@4Q$4GS
M4#&.NVD T#% "O+0!".: ),T .6@"5FP* (6.:0!NH <.:8"-Q0 $8H @(H
M>IH E6@ :@"%J '0BF(D8YH :5I#().* %CH <U "!L4 (/FH F"XH @E.:
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M&: %/% #0,T *>*  4 **! : $H 7.* &DYH 7I0,:%S0("N* %"YH E Q0
M%J (V- #"U "[J #- "%J  4 .Q0 8Q0!&QH  : %S0 4 % !0 9H 0FF AH
M ;0 H6D(<* %S3&!- AM "%J &XS0 X"@ - !0 9H ,T (30 F: "@!: "@
M- !0 H% "F@!#0 TF@ S0 9H * $H ,T &: "@ H * "@",'-,0-[4 (.M "
ML^:  G- "H: #.3F@!,T !XH 1: '+0 A%  W'2@!R#'- #1SS0 'F@!Z* ,
M]Z0" YI@(>:0",W% "(<TP'+2&*QW4 (QS0 2''% "XH <XVT !/% !G-  >
M30 4 *>: %+8% $8XH <G'- "GYS0 $;: %H 5TH 4+B@!IXYI#$'- $F,4
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M-("0'% %>0Y- #2,4 68J %\S%,!A:D HH$.=L4P&H<4 ,=\TAC-^: $QNH
M#Q0 X4"')Q0,:QS0 TMBD )S3 L$8H BI@.-("-^: &J: )^@H B:7- !3$.
M#8H <K;J %?B@9 /FI 3J@%  \= %=A0(:.#0,G3)IB&%<T ,88I (33 :U
M$B#-( D?% $8;=0!.#B@")VS0,0'-,0,<T  .*0$A.*8"%J !&H G#4 0R24
M 1(NZ@"=:!B.<T )C-(0XQ8H :1G@4 2*NR@ SMI@,!W\T )0 T#O0 Y* )5
M;% $;OF@"(G)I 6$?;0 R23-,!@3- Q2,4"$S0 Y6QQ0 \CB@"+% #MM "A:
M %H :1F@!-M "XQ0 B\T .:@!* $5=U $F,4 -/RT (* $H <M #B<4 1EZ
M#=0 HH C)W4 2*E B3[M #"<T#$(H 7&: $=L4"&@4  :@ VT &* $)H :3B
M@!4YH G7B@!^<4P(9): (<YI 2+0 ^@!A-,!I:@!,YI )3 =MH F4;: %+9H
M C?B@"+K0 AXH 0-0 Z@ - "*FZ@!^,4@% Q3 3%  30 W% "'B@0 YH =0
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ME(!7; H :@S3 L9H :PH C8YH 5%Q0 KF@"/=B@!XH =G% "$T -,E #PM
M5W4 2+#B@!KKB@"(F@!ZG;0 ;L4 -^]0 N* $- "@T (: $VT )B@ 9Z $7B
M@"0/B@0C-NH 3=B@8]%S0 $T"$"T (XS0 T#;0 Y>: !FH&1DT -QNH$2KQ0
M ]:8"224 0XS0 H6D \"@!"<T -8T ,ZT / H <%I@*/EH 0M0 %\4 )]Z@!
M"<4 ,ZT  .* % I !%,!ZG% #@,T (QQ0 S- "4"%)S0 TB@!<4 "T .VXH
M,4 -+4 )G% !NS0 X'% !F@ +4 1L<T *IVT &<T +TH 9UH <!0 O2@!C'-
M  HH D H 0B@!C&@!5XH 5C3 :10 S&:0#P* '"@!&- AM,8F:!!F@!,T#"@
M04 *#0 N: $- "8H 0T )0 M(!0:8"YH 0F@!* "@ H 6@!": $H *  T )0
M 8H 7% "A: #% "4 (: $H 7- $03!Q3$*1@T (PS0 #B@!6&* $!Q0 HYH
M"V:  F@ :@!* %)P,4 .48% "$=Z $Z4@'>] "+0 ** $6@!: $V]Z '(G-
M#I1LH 3&!0,;'0(>QP* (PG>@!T?% Q4- "%2*  T .88%  O H 6*/?0 LO
M'% #LX%  O(- $:C%("4':*8$8&WF@ SFD!-%Q3&*B9I 1MUH <&YH <!N-
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M2(N*8$ZOB@"M,VZ@"/- "J<4 /C7- #R:0QN* )EEVT"()Y/,H&-5<4 *4H
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M"&[:8#UXI #/B@ !P*8"9QS0 F:0QP.:!#10,<%I ,<4P% Q0 +Q3 <S9XH
M<BXI"%=L4#(,9H >IQ0 ;Z ) <"@1"1DT#''B@!F: 'K+0 H.: '@8% $;F@
M!J<4")2:8%=SFD BT#+*O0!&3F@!RT"&N^* (33 6%,GFD!?1<"F!!,P6@"
M-2&(%SS0 JK0(D%, DDH @8T (* '1Q[CF@"7[M ")S0 IYH BD;%(!J"@"=
M5H 5>: )3Q0!7D:F!"5S0!+&-M $N^@"-Y,T@(B: )(Q0 I% #"<T 6 ^.*
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MFF F<T *!0(4"@!2: &YH&)0(4"@!2* $Q0 AH 2@!: "@!<4 (: $H 0T
MH =0 F: %H 2@ - "&@!* "@!: %H 2@ )H :3F@!:  T )0 4"(U6F(3% Q
MQ.: %#8H 04 #&@ - "4 .44 (BYH 7.* &8S0 J&@!RG- "#K0 M  *0"A:
M $/'- !F@ /2@!Q.!0 U>.E,8*,TA"CDT#'&@!HZT *[8H 6,4 (_)H <O-
M"XW&@!NW- #V-  AVT (OK0 F.] #]N>: %6@!K<F@!S"@"6'@4@(V.Z@8Y1
M0 X&@"$&@!V: %C.* )'.^@!B#%  6S0 H3% #@@- #^E $,[T .MQ0 CMS0
M ]>* '[^*!D3'- $L2=Z0#2W- $\LN13$1JV>*!@Z;:  -BD HH B";J )#%
MM% "1I3 >U #$I#'@4 ,D>@"2W^3F@1+)<[A0!"7H&")FD!*U,1%C% #EX-
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M0"LV*!A%S0!,QQ0(KN^:8#E&: )E7%(!YDQTH @8;Z &[<T *1B@!<XH 3-
M!B@!C"F *,T 3*-M $;&@ 4XH ?NH A;F@!4% $Q.* !6H$#/0,A8[C0 !:
M%+4 (7S0 TF@! N: )U&!2 ": &*,4 (.: !UH =##FF!8,>V@!A;% $3'%
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MA0 O2@!": $ZTP%/%(!M !0 9I@)0 4 (: "@  H 7I0 WK2 <!B@ S3 ,T
M-)H$)F@!P% "T &*  T -- #: ' 4 +B@ S0 AH :10 8H * "@ H 44 +0
M4 -Q0 8H ,4 +0 F: $)H 2@!:!!0,#0 E "4"&(U,! <T .44 )UH =MQ0
MG4T (.30(#Q0,?T% "1T #C%  J]J $V[:  <4 */F-  W!I .=MU  W Q0
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M=3 )#F@ 4T -)H &;% A>U QRG% #9#DT -#YH D/(H <LG% $:#)H ED?%
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MZD  T *3F@")FS3 D1J '-0!$6S0 X&@ 9J &[LT 2+Q0!&[T .C.: '.<T
M1*<4@) ,TP&.,4 ,49H E"YH F6'% ".*0$3-F@!I&* )HTVT #"F ^-MM !
M++0! I+T #"@!%&:0$C"F W9B@!56D!.K;!0!&7SS3 C)Q0 T4 *.: ';L4
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M 0T )0 8H 7I0 "@!>E !TH 3K0 =*  C- !TH 0F@ S3 ;0 N* "@ H ,T
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M !B@0X)0!(J4#'I+MH$1RR;J $0T#&JIS2 E. *8#0E("5VS0!'MQ0 IDQ0
M(^*8 YW4 -0[: )AS2 C=Z $"9H&/0YH 21L4 !/% " 4@%QMI@*JYH ?C%
M#-N:!#'/- QU  C4 #\T "1YH 5FH :KYI 3*,<T 1GGBF ;.] "D9H  N>:
M )$&* %<[J (5&*0".<T 21<<4 .FH C3K3 DWYH 8JT *QQ0!&30 @YXH E
M44@)-HI@5I3FD,(QF@0,,T .S0,4+W-,0A6@!0* 'J,T@(Y3B@","@!\<>:8
M#I1MH A09I#),8I@(KYI"'[: &2/B@ 04 /SB@"/?F@!Z&@!&DS3 1'W&@"1
MJ $1J "0YH CW[: '+)F@8UFH$-4T 2;\4 ,8YH C5>: +*OB@"*1LT ,Q0
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M10(::!AF@0[>%H B9LT *)-HH %7=0,<>* $ Q0 C-F@"-J  <T 2 XH$ H
M8>: %Q0  T *&Q0 UGS3 <#0 X'-( W9H 4<4P(VYH 3% #J0 * !GH 9C-
M"A<4 *$I@!XH :6S0 W&:0$H&VF(6@!C-0,:#0!(!F@!6- $1- @ S0 M #A
M0 C<T -Q0,*! * &MS0 !<4 *30 #F@!V* #% "&@!.M  30 F* %Q0 =*
M&@!2: &EJ %S0 9H$,)H&*!0 4P%Q0 E "@9H 0C% @Q0 HH&*30 F: $+4"
M$ZT &* $)H  : "@ H 44 % "8H * #- "%J $S0 HH 7-  30 E !F@ S0
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MJL64J20.CJVWECLVY8MFDQIGG)7-(8XKB@"2,X% $:G- ##DT (10!(%VC-
M#TH 1GH C'K0 ].:!G0>"O!LWC.\CL+<HLLN_:7)"?*C.<E58]%..#SB@1?^
M*7@I/!>H2Z?&YD$2PY=@ 69H4=C@=!N8X') P"2>2".0)YH*) : %DH C;FD
M @&* )UQ0 S&XTP)@,4 -)H$>K_LW>![/QCJ$EO?Q^;&MJ[A=SIAA)$H.493
MT8\9QS30F<#X^TN/2]1N[>$;8XKJ=$7).%61E49)). .I)/K2*1A$4 .<X%
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MJY9L;H8V/+%F/+$\G]*&",/P=X+N?&5REE9KN=N23PB*,;G8\X49^I)"J"Q
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M789H D7B@!).:8$:C%(!V<4 ,8TP%CXH ?G- #TXH 1J (#S0 +0 $XH 5:
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M0 N[% @'% #30 G6@!* $"YH&2 T .QB@!IYH$-Q0 ;<T##% "XH$!-  HH
M:>: %VXH :PI@ 3%(!0* '=* $S0 N<4 ,)H 3-,!U( )Q0 TT *O% $BC-,
M!6.* (B=U !B@!P7% !0(:S4 ,SF@8]5H$2T 1L<T#(VH$&[%  IS0!)0 G6
M@!#0,2@0X"@! M  10 W% #@: "@!: &&@!#0 @H =0 4 % "9I@(30  4@#
M% "&F H6D H% "T (33 3- !NQ0 #F@0^@!,T#&DT -S0(* %S0,0F@0@H <
M!0 $T )0 H% !F@!": $H 0T )0 4 ** "@!: $H * "@ H * %H 2@!,4 %
M "4 % A* "@84"%H *!A0(C)I@#<T "\4 )0 K4 +GM0  4 '2@!N: %8YH
M* %'!H '.: %/ I  XH 0&@!2V: %#]J8"#I2& .* '9Q0 BG% "** '9Q0
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MSWSGMBM&KF:=CQ']D#_D*3?]>4G_ *-AJ45(Z+4OV;%O[R[U/6;E+6T>ZG<
M,H<J\KA"TC_NX\DH0/G)#;3L:BPKC9OV8=)U^)_[$U#S)DP3F2&XCY#;5;R5
M4IEA][YL -A&/0L%SY]\8^%I_"=W+8W0 EB8 [3N4@@,K ^A4@C." <$ Y D
MT1V'PB^!UU\1B9580VJLRM,<.=X53L"!E8GY@<G"@9^8D!2TKB;L>N?\,]>&
M?.^S?VB_G;]GE_:;7S-^=NS;Y>[=NXQC.>,9IV)NSRGXO? BY^'06=I$FMG<
M(L@&QPVW=AD).,X;!5F&%RVTD"DU8:=SS$U)0TT =9\._AC>?$"<V]DHPB[G
MD<E8D'.W<0&.6(PH )/)QM5B':XF['NLO[-6@Z %AU/42DY7<<RV]N""Q"D)
M('8#C&=QR0>G058GF.>\?_LKR6<1O=%E^U0; XC.&E*X4@QL@V2YRS  (<8"
M[V/)8%(\P^%O@E/&U\E@\IA,BOL<1B0952^""Z8&U3R,\X&,$D)%-V*7Q$\&
MOX,OIM/D<2&)EPX! (90ZG!Z':PR.<'(!(Y*!:F3H.C/K=Q%:1D!YI8XU+9"
M@NP4$X!.,GG )QV- SL/C+\+D^&]Q':"<SN\7F$^4(E +,J@?O').5;/  &,
M$Y.&U82=SH/@Y^SE<>/%6\N'\BR/*L-KR28<HZJ,_)C:PW..#MPC@G D)NQZ
M#;?LZ^&]7/D66I%[AE;RU6XMI3D*3G8B!F QD@$' /(ZT["NSQKXL?"&Z^&\
MJ1SLDD<N\Q2(<;@I (93RK8*DCE?FP&;!Q+5BD[EWX3_  =D^(,-V\,FV2V1
M"D>T-YK,)"J;BZ!.4QDY'.3TY:5P;L>K:;^S%I.F^7;:K?XO)-I6-)(8<[L*
M%595=W^<, P"[N!L!!IV)YCPW7O #PZH^D6#&[D67RE*H8RS@?O!M8G:%8,"
MQ.W"E\[>:DJY[3I?[*=CH4'G:_?"(LP5?+>.&('YCMWSJ=Y*@$#:A&&^\.:J
MQ/,6U_9=T;Q&A&D:B7=&7>=\%TH!#8!6+RRI)'!+8P",'J"PN8^=/%_A.?PE
M=RV-T )8F .T[E((#*P/H5((R 0#@@'($EGK7PF_9HNO%\<=Y>/]GM7Y48S,
MZY7D _*JLN=KG)X#!&4@FDA-V.RB_9KT'Q"&ATS4B]P%W#$MO<  , S%(PC$
M<XSN !(Z]"6)N>1^)/@G<^&=4@TNX.([B>-(;@+E&5W5-V,CYEW#<F<@XY*E
M6*L7<^IO^%+_ /$A_P"$?^T?]MO+_P"GCS_N;_\ @/WO?VJ[&=];GQS\3_!G
M_"$ZA-IWF>;Y7E_/MV9WQK)]W<V,;L=3TS[5FS1.YTWQL^"?_"LOL_\ I'G^
M?YO_ "S\K;Y?E_\ 31\YW^V,=\TVK"3N'Q%^"?\ PB.GVNK0W'G0W/EX5H_*
MD7S(S*G DD4_*"&^88.,;@20- F>:AL5)1Z78_!3S-"?Q!-<;5&[9$L>]C^]
M\E=S&1 N9.N V%^89/RBK$WUL<GX%^'UWXYN/LEDH9]NYBS!55-RJ7.>2 6&
M0H9L=%-(;=CZ E_9HT'P^%AU/4BEP5W',MO;@@L0I"2!V XQG<02#TZ"K$7.
M;^)7[,1TBV?4=*G$]JL1E*N5W^6%5BZNH"2#&Y^B?* %WDT-#4CP-QBH+&)0
M!ZE\%/@M_P +-^T?Z1Y'D>5_RS\W=OW_ /31,8V>^<]L525R6['8>!_V:8(;
M9;[Q#<_8UDX2(M'$X)P4WO+D!BH8^7MW 8)8$,@=A7-/Q3^RM'?P"ZT"Z$Z;
M3A7=&#E=^[9+& F<@*%( !R6D'2BP<Q\WWMN]F[12*5=6*LK JRD'!4@\@@\
M$'D5)9]%+^Q\;.X)N;P"QCB622;8L;$[FWH 9&"!47<9&. 6&$;#8JQ',87Q
M:^#&D>'=/_M'3+XS 2B+;NCN%>0X;8'A"B,J@9SN!R,#@D9&@3(?A+^S%<^,
M(X[R\?[/:ORHQF>1<KR ?E167.USD\!A&RL"1(;=CN;;]G;PYJY\BRU(O.RM
MY:BXMI3D*3G8B!F QD@$' /(ZT[$W9XW\6/@M>?#IU,V)+=V81S)G:2"<*P/
MW'*C=MR01G:S;6Q+12=SW#]E'X7?V=&FN>=N^T031>3LQMQ.!NW[SG_5=-HZ
M]>.:2)DSAOVB_@M_PBOF:O\ :/,^TWS_ +KR]NWS?-E^]YC9QMQ]T9Z\=*30
MTSSWX7_":[^(TYBML+%&R>=*Q&(U;<0=N0SD[" !QG&XJ#N"2N4W8]KN/V<O
M#>CGR+W4BEPJKYBM<6L1W%0<['0LH.<@$DX(Y/4NQ%V</\8/V;9O T3WUO*)
MK167.[Y9D#.57(^ZX&5!92"6;/EA032:&G<\JT30Y]>F2UM4,DTC;40=2>O?
M@ #DDX  )) !-(H^A=,_94L=#@\[7[X1%F"KY;QPQ _,=N^=3O)4 @;4(PWW
MAS56)YBRG[+>C>(T(TC42[HR[SO@NE (; *Q>65)(X);& 1@]06#F/G;Q?X5
MG\)7<MC= "6)@#M.Y2" RL#Z%2",@$ X(!R!)9ZE\)OV=SXMM/[3O;@6UH&)
M!PI9HT)$K%BP6(#:0&8-T+%=H&YI$MG=0_LUZ#KX:'3-1+SA=PQ+;W  # ,Q
M2,(Q'.,[@ 2.O0U8FYX/\4/AS/\ #^\:RG(8;0\;C@/&20K8R2IRI!4]"#@L
MN&,LM.YN?"#X$W7Q&)E5A#:JS*\QPYWA5;8$#*Q)W Y.% S\Q("D2N)NQ[#_
M ,,\^&1+]F_M%_.W^7Y?VFU\S?G;LV^7G=NXQC.>,9IV)NSR7XP? >Y^&ZK.
MTB36SN$60#8X;;NPR$G&<-@JS#"Y;:2!2:L6G<XWP9X2F\5W45C:@&65B!N.
MU0 "S,3Z!02<9) P 3@% ?09_9KT3P]^ZU74]LQ^91YD%K\AX!V2^8Q^8-\V
M<'IC()-6)N8'Q)_9=72K234M+N?/@1!*$;;N,03<\BRJ0C_W@ JY7H68 ,-
MI'@(2H+ F@!KFF BC% "@YH 1A0 PG% $JT !H$-!H&2(V* &.V: &4 2HM
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M.:8"8H * %7I0 =: $H 5C0 $8% #L<8H 8>* %% "A: %Z4@$(W4 .9=HH
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M88 A(&=Y^U[:)#J\;*H!>SC9B  6/F2KN..IVJ!D\X '0"FQ1.N'R^ O\_\
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M?VUAG^S_ /M[_P#:%7(B):^!07X@>&[K1&V&2+>J [U WDS02.PSG$P;[O\
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M !0(<.*!A0 AH ,T .!H =0(830 A- "XH 0F@ SB@!* "@!30 F*  4P%H
M:QS2 3I0 E !G%  !F@"4<4 . I@,<YH :* "@ H 7;0 F*!#E- $;'- QN,
MT .5:!#\8H :: $H 2@ Q0 J<T /(H #\M $;/F@!10 =: #% !0 E "4 %
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M4?G^;.W&.]67R_)'&XKO.(:J[J!$RTP(7;F@"5#B@8JT@#;B@!&H  * '9H
M^S-$F'P1\+K<!0;IU20I+NC+3S;1L*DDYC3 95VEA$Q^0DD7L1N>4#]LS5_^
M>-I_WQ-_\?I7'8Z#P=^UO?7UW!%>Q6RV\DJ)(R^9&5#';OW/(Z@+G<<C! (R
MN=P+BL4OVP_! T^ZAU2,'%PI27ABHDC "$L20"R<!0!Q&6Y); QHWO@!:/>>
M%=3BC4N[M>JJJ"S,3:1@* .22> !R30A/<^7&-26?0?[&F@SM?3WNP_9Q;-$
M9.B^8TD3A!ZG:I)QG:,9QN7-(EGDWQ4YU:^_Z_KK_P!&O2*1[I\$_"-M\+K
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M<1L"\$LPP>-I:8FCS7]IWP2/#6K--&"(KI?.!PVT2%B)5#$G<=WSD#&T2 8
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M-PR^6[INY'SA=P93R#3V%N=WX5_;!O+1T3488Y8@JJS1@QS9RH,G+%&.,G:
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ML0,D#.!QDCZU!9]0?M+>.]8\%2P3V$WEVDB%#B.-\2J23N+QMC<A&T;N=CG
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MW%( Q0 A7% #-N:8$@&* %% ",^* &9S0  YH ?B@ - "$XH 0F@!A>@!,T
M2(F:!$F-M #2: &4 +0 E #3S0!(G% "DXH C8YH ;0  T .% "T (: $H *
M #% "4 )F@!: #- !F@!": "@!*8#AQ2 4F@ H :QI@ H #0 =: #&*!"CF@
M!<4#&F@0@H #0 W%( H <!3 44 +0 F:!C2: $H$% "T (: #% "T )0 HH
M* "@!#0 E !0 4 % !0 E "T % "4 &* "@!*8@H&%( H$)0 M !0 4 1^],
M  S0 'F@ 4YH <: $/%  BYH 3&30 [;0 8S0 "D T"F _H* &KS2 7I0 4
M(#F@!Y&^@8A.>*  T"%<;:!BJ,4 "KNH :#0 N<&@"1AF@"+;B@#I/!OB5-$
M=EG3S;:9=DT>3R,Y##D#>IY4]N0"I.X<E>DZB33M):Q?]='U.FC5]F]5>+T:
M_KJC3'@2VU']Y9WL C/\-PWDRJ>NTC!#8! +K\I.<#BL?K$H:2A*_>*YD_\
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M!>"268DLJJ7"QY1H5UI.KZY<W^I7(2S%Y+,BF*20S@RLZ*5$; )C!<. 2#M
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M.7MH(L*2FP&1SF1AN ?& B_,!RIP,'+#8)'DT8I#+%AJ<FES1W$!VR1.KHV
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MQ[$$$@C.UE:=A-7/9]1\8>"?%[?;+V/RYGW;E,=Q&^=S$L_V;,;,2<[LLQ!
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M.[@O-.N/.Q 8G7RY(]NUV=6S(J[MWF$8 XV\GYAA,:T.E^&7[2%M#:QZ3KD
MEMU5(UDV+(NQ2@C$D1&&" 9W+EL*OR,V6+3$T;=OK/@31S]HB02.BL51DNY0
MQVD;=LX\HD]!OP <'(QD&@:GE'QG^-4_Q&GVKF.SC8^5%W)Z>8^."Y'0<A =
MJY)9F3=QI6/0/@W\9=*BTHZ)K@Q$/- )C=XV1F#@$H6<2!V8JP50H52&#CEI
MB:/)/BO;Z9'>EM$??:-&A"[95V-C:R9F^=NF_/3YMH^[4LI'H_[3_P 2]/\
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M+0 N* $8T , S0 [- !G% @S0 "@",T &*!CQ0(#0,3.* $!S0 UCF@!0=M
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M !UH 3[U #B>* %3@4 1B@!ZC- #XSB@!#R:  <T (1B@ 88H <>!0 ]1Q2
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M@ S0 E Q:!"4 &* #% !0 A- !0 8H 6@!,T &: $S0 4 % !0 8H ,4 +0
M4"$S0,0F@!!0(=F@!#0 8H * "@ H 2@ S3 2D S&:8!0 &@"0<"@!HXH 2@
M!Y:@!.@H 0&@!<[J $- ""@!32 =G% #5- #\[: &J*  #% QZ\4 #MF@!(V
MH 0<T *YQ0(2,4#%Q0 ]A@4 -C- $C';0 T<T *5S0 C#% "Y(H <D1;FD Y
MJ!B)Q0 DAYI@2#Y1Q0(9NS0,1.#2 >W- #.M $B4 +.^: & \4 (HH =''0
M]CF@!5H ;)0 1<4#'2G(H$+#Q0 YQ0 PMF@8_;B@!CFD S- #QS0 J?+0 I;
M=0 DB[10 V,T /+8H 83FF ^(T@''UH :#B@! W- $DDE,!B+FD CT .CH <
M>* $)R* (B=M "YS0,FBH$.D:@"N:!CE- A: %9J $S0 ]!0 DQS0 V#Y>:!
MDA;-,0QN!2 :AH&2,<T (U $;M0 (NZ@"4KB@",T *HH ": !FH$-S0,>C4
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MH 1:!#LT .SBF A;-( +XH ;FF =:0"TP$Q2 8[4P%49H 4T )B@!PH 7K0
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MN6K/]G+7+M%DCM@R.H966>V96!&001+@@CD$<$46"Y,/V:M?'_+I_P"1K?\
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MF@!V_- #6- #%% $@XH 4MB@!NZ@ QF@!": '1KF@!Q&: &-0 +Q0 M @)H
M2@8W- AU QK&@0F* '*M  QS0 JT +UH ": &XH 4)F@ QB@!#Q0,9B@0HH
M44 (30 $XH :30 4 /'% "XI@#4@(PN:8#^E(!,4P T  -  30 E  !0 =:
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M^V_PNY@,M@<#.<#@570CJ>(?"W_D+6'_ %_6O_HY*13/4/VQO^0M#_UXQ_\
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MO7_M"J9$3P2T^&VIWBK)'97+(RAE98)65@1D$$+@@CD$=12*N<VQQ2&/!S0
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MBD A%,!",T /08I //% $)-  M #CQ3 0"@!] #<XH$+NH&,W9H <IH ,YH
M<1F@"-A0 V@ Q0 HH D44 '2@!C#- "(M $AH 4+0 QA0 BIF@!2M(!@6@"0
M4P$=J (NM %B-,4 *S4 1$[J  K0 UN*  #% $J<4 .+4 1#YJ !A0!&10 H
M6@ VT  H$(QH %YH DQ0 UJ!C3S0 X14 .Z4 *.: )5&* &,* (S0 !: ' T
M !.* (\[J ']* #I0 PG- AO6@"1?EH 4>M #.M QX6@!C'- @5<T ."T /"
M8H <S4 12R4#&@4 *#0(0MF@!ZB@!=U #&:@8@- AVZ@ H E'% Q<4 ,8XH
M;NH 7- @S0,0M0 "@09H 4+0  9H 4C% #*!CLYH *! 6H !S0 XM0 F: &'
MF@8&@0O2@!.M "8I@)0 8H ,4@' 4 +NQ3 8: 'KQ2 "* $-,!HH ,T@$S0
MH% #P,TP _+0 PT  &* &F@08H ,T#%H >.*!#@<T #-B@"(G- #2* %Q0 4
M )F@!5H =G% "B@!KO0 S- #@* %S0 F:  M0 F* %H * $)H 0<TP%H$(:!
MB T@'!J8"CF@0I&*!C": &YI +0(3- Q<4P%% @H ,T % "$T )F@ H * "@
M!<4 )0 M "]* #- !0 9Q0 TG- !0 4 -S0 4 +0 4 )0 8H 2@!10 4 &:!
M#<TP#-(8M !0 M @S0,0F@0F* #% !0 E !0 4 +G% "T 1YI@+0 A&* '4
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M=8Y?*VAVD#_+$B'(6)AU4XY/%-H29R*?L?:LO_+:T_[[F_\ C-*P^8Y#XF_
M:^^'UNMW=R0.CRB,"-I&;)5F!^:-!C"'OG..*+#3N>I_L5'/]H?]NG_M>FB9
M&IX*_9Y_M?5KS5-43]Q]NN6@@8?ZS]\Y$C@_\L^ZJ?\ 6=3^[P)"P7*O[5WQ
M,O=,VZ7"CPP3)EY^/WPZ-$A!.%&0) <,V0"!&<R#"*/EEJ@L:: /=_V.A_Q-
MIO\ KQD_]&P52)D<S^TJV-?N_P#MA_Z3Q4F-;'E^[-(9]B?$89\%)_UXZ=_Z
M%;U?0S6Y\?H*@T&/0!]=>';F/X-^&H]0MH/.N+A(G=PI"[I5+1F4[B1&@8(
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MH^Y<,SW)V/C$FH-1 ,T /^[2 ": $ H 2F G6@!<T .!S0 CM0!&PS0 Y!0
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M3S0,-N*0"=: %"TQ"F@ H 2@ H * $H * $H * %H 6@!<4 &<4 -+4 *.:
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M1#W/EN,5)9UOPGN7M=7L6C8J3>6ZDJ2#M:159<CL5)!'0@D'@T"9Z5^V,?\
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MF1U.&/\ P@7^?[0HT'J;?@[QUX-\&S-<6$GE2LA0MMO7^4E6(PZL.JCG&>*
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MI? +X$'P%*+[4WC^U2+Y<,0*ML+)O?YB.9=JL,1D@('.YPWRM(ENYX=^TO\
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M!B-S0(D1>* $(H "<4 (.: $H <3B@!!S0 M "8S0 IH 0B@!HH 4&@!2^*
M$!H ':@!R+0 \T#&L<4"&"@!RMB@!I^>@ (H 510 ]10,1N: &L<4"$6@!P-
M #E% #B: (V.* & YH DS0 E "B@!0<4 -+;J %Q0 F,T *!B@!Z\4 -9J &
MB@!10 X<4 (: &F@ !Q0 N,T !- !F@!,T  H ": %%  O- #B: $!Q3 :32
M !Q0 +S3 DSB@"/-  30 F,T *QH 2@ Q0 4 -H !0(,T  - "B@!^: #- "
M4 -QF@!,4 !H 04 !% "T  H =F@!&- $9- "B@!V: $- !0 E "T &* "F
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M&4AE.""#@CH01ZTAFGXO\<7GC69;B_D\V14"!MJ)\H+,!A%4=6/.,\T 8X%
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M@*!@PH 9B@"0'% #"^: 'J* &NV*!#!S0 J)S0!90XH CE>@9$.: '** #%
M#T%  QH$,)H 3- QRMB@!2V: &8H$-<T#&D4"%5<4 +0 +S0 Z@8H% ".:!#
M* '@T (3B@9'UH$2*N* %(H&-% B0-0 CM3 C- "BD 4#$)H$*: $S0 ]!F@
M!V*!C9#0(90 4 )C% "@T  &: )A0 $XH AZT !- "@4 /'% #<4 +F@8_I0
M PF@1'G- #J 'J*  G% " T -/S4 2!,4 (>* &T /% #7H 0<4P'"D _I0
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M  : &DT +F@!M(!5.*8 #WH 0>M(!V*8"*.*  F@ 44 /DXI -5: %S0 +0
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M(4B@!A- #EH <*!BDT 1M0(;0 \"@!IYH&.04 /H 8[4 -% A0: %- " 9H
M7% "&@8"@0IYH :!F@"8<4 (QH AS0  YH ?C% #30 E $D8S0 ]N*!D;&@!
M *!!TH  <T /H 0T  XH 4F@",G-  * ' 4 2'B@!N,T (1F@!RC% #J &,:
M &CF@!V<4 (!FF $9H ,XI .2@!Q:@"-C0 V@!V: '9Q0 PMF@!,T ** %H
M2F TFD JB@"8'% #: &L<T (!BF C4@!10 [% #2*8!TH 4#% !F@!": $S0
M 4  YH #0 'B@ % !0(6@!!0,,4"'8H 2@ ZT +G% !NH 830 4 % #Q0 TF
M@!* &DT *!B@!: %% #2:  4 )0 X+0 IH 3-, H 832 !S0 \4P"@ - "$T
M -ZT@';: $-,!* %% @)H 3- "YH 44 !H 0T -H 6@ H #0 F: "@ S0 F:
M %H 6@ H 3K0 8H !0 M "$T )0 AH 2@!: #- !0 4 % "B@ S0(3- !FF
ME(!10 Z@!* $I@)0 E !0 4@%%, S0 E "&@ H 7;MH 0"@ :@!#0 ]%]:0
M_%,!BF@ ;B@"4K@9H C8YH >&XH ;FD J"@!#S0,4#FF(>1MI#&MS0 "@!IY
MH <!VH$."8H&.V8H 3[U "@4 ,9<&@!QH 530 [I0 A% "XH <.: %;I0 R*
M@!S#-(8BKB@"1FXH 8!0 H6@!5H ':@!BC- $JF@!Q:@"5%XH @E.* &I\U(
M8X\4 (.: '8S3 0C% "F@!*!#0*0#R:8P7F@!Q&*0$;4P$SB@ -("6-L4Q#'
MI#'!N*8$9% B1'VT -+9I#&DT .H  M,  Q0 ]#2 :YS0 PT - S0!/MP* (
MR] #0* )4XH 5C0 P&@8I&* $S0(3.30 X4 (S4 /BXH 663/% $ % "MQ0!
M)&N* $84  XH :#F@981=HH :W- $3&@0J4 /H 8R\T#$ Q2 E6F V@!ZMB@
M!)),4 0 9H FCXH$#MB@!J>M $A:@9"S4 .0XH >*!#'.: &=:0R0<4 +NH
M&:@!E "$T (.: )%-  [4P(Z "@!,T"$S0!(M Q2: &$4 )G% @% Q5.:!",
M:!CHQB@!7:@"NPR: '!<4 2+0 C&@!@- #L4 &,T +C% "YQ0 QAF@!N<4")
M5- "LU #5H&%  HH$.S0 QVQ0 P<T 2#B@ S0 F: &$YH 51B@!] !B@8Y%H
M$#'% $0&: 'XH 1AB@8W=0(5>: 'D4 ,(H !0 A:@!4- $@:@"-VH ;B@!0,
M4 !- "$TP$1<T@+*+M% #7- R+.: '9H$-8T +'S0 \T -8XH !S0 &@!IH
M!0 \'% "[LT +NH&(* %%  QH$1DYH 4&F M(!: #-,!M(!=U !F@!N<T **
M 'A: &M0 WI0 @H <.* %S0 A-,! M(!X% #@* &GF@ VTP$-(!M "@T .%
M QQ3 90 N: &&@ H$% Q1S0 4 % "[<T &,T" \4#$ZT +0(44 (30 8S0 8
MH 0T --  * %S0  4 +F@!* !FH 110 IH  * $)H 0#- "DT *!0 I-,!,T
M@$- #2:8" 4A#A0,44"%IC$)H ;UI .'% @)I@)0 AH&&:!!0 4  H 7- "T
M (: $ H ,4 % "&@ H * $H 6@ H * "@!: "@!* "@ H 3- "4 % !0 8H
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M #2:8 30 9H !0 G2D A- #E6@!^RF G2@!&;%(!M "$T 20K0!*PH KL.:
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M $Q0!(!0 HH 5FH :#0 I:F TF@!M !0 H- "9S0 4 '6D X)0 A6F T\T
MXH * #% "YS0 N: &T % "9H 4'% A!S0!(.* $H :30 W% !0 "@!2: $H
M,T (* '4 % !0 WK0 O2@ H 44 (33 4<4@&DT -Q0 X#% "T %, )I -ZT
M**8!0(,T (: "@8E @Q0 IH 2@ % #J $S0 HH ": $H 3K0 =* "@!* %H
M2@ H 6@!:  T )0 A- "4 % !0 4 +0 M "4 )0 4 % @H&&*!"4P"@ H 7-
M !F@!M( H * "F 4 )0 4 % !0 4 (:  &@ Z4 +0 HH 5DH 810 Y!B@ 84
M (!2 <30 P&@"0"@ 9LT *%Q0 @XH&.49H =]V@",4 .08H 4<T )C% #S0
MR@ S0 ^,9H >1B@ % "+0 TKDT@';<4P!QB@8+2 5!NH >HQ0(208H&1CF@"
M2@!V<4 1'F@!V: '1\4 (U "DT ($S0!+C% #*  K0 _9F@8UAMH ;&W- #W
M% AC"@!F:!D@&*0 HW4P%,>* $84 (@I /=: (L4 .ZT % #0:  \T &* )D
MI@*\F* (MV: $- ""D 4P)$:D!([4 0&@!.E,!10 J\4@'YS3 B8T )0 JT
M2&D @XH <&H 3.:  F@!VV@",B@ % #@: !3B@!V<T (3B@8TT (10 Z.@![
M&D *,4Q#&-  M P/% ##0 X4"&L: !: )5H #0,CH 0<T@%(H  *8#AQ0 A%
M #,4@'!: )0N* &L* $S0 UFH :.:8#C0 W% AV* %6@8XF@",T"$+4 (.:
M)!0 A.*!BJ:! 30,C(S0!(O%  30 PF@0V@!ZG- #B<4#&%Z!"[Z &]:!BYH
M #0(2@!!S0 Z@!2U  #0 QN:8"HE("<+B@")VH :M #A0 UCFF 8I ** $H
M3=0 AH 0\4 '6@!X&*  +F@!Q.*!B9S0 TF@0A- "@4 . Q0 G6@ Q0 [I0!
M&3F@!I%,!Z+0!-NI -9L4 0T#"@09H >BYH D8XH 830 JB@!PH&,=J8AM(!
M>E "&@ % #\4#$/% "4 !H$&*8"F@!!0 O6D IXH ;B@ Q0 H7% #E% "$T
M-S0 &@!5% !0 &@!* %44 .H 3- #2] !G%  #FF M "4 % AI- Q0* %H <
MM #MU #"U AA;% P'- #A0 $T -!H$+F@!.M  30,* #% A1Q0 N: #=0!&S
M9H ,T **  F@!* $S0  9H =C%  30 "@!2:8!2 :: #.: %I@%( I@-I **
M %H 44 (33 832 44 +3 0T"$S0 M !B@8H% @- #: "@ H ":  4 &: #-
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M- A10 N: #=F@!30 9Q0 @.: %- #3S0 Y4H &.* & YH =F@!<4#$ H ,T
M(30 F:!"&@!5XH * &F@!P% #F%(8VF 9S0(,9H&/"XH 0B@!A- @!H 0&@"
M5#0 ]I* *S'- #A0 N<4 (* '4 !.*!C"U #1S0(>* $- #A0 X4 #&@!AH
M;F@!<T *JYH =C% !0 TF@!RG% #7;- #10 X#-,"2@ )Q0!"QS0 **0"YH
M:!F@"RM #6% $= #@: ';J & 9H #0 $4 )0 J\4 *6H ,T  H 7&* $- "4
M &* '+Q0 AYH #0 ]1B@!.M  QH 9F@!: %5<T /;B@!@% "&@ % "YH * &
MDT -% "T **8"F@!#Q0 W- "B@!W2@!,4 .Z4 ,+9H 0F@!H&:0#J8"DT )U
MH ,XH$)UH 7- "4 ** %H * $)Q0 AYH 3% "4 +0 M #<4 *!0 ^@!#0 AI
M@)2 <* "F TT@"@!!S0 Z@!":8"4 +2$%,8&@!": $Q0 [% @H 0T (!0 M
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M ,T )F@!PH <!B@!": $)I@*!2 4+0 ,: $!H 5: %)H 4<4 ,8T -H  <T
M2*<4 (6S3 ":0#<4 +G% !0 C-0 @% "T % !3$)0 AYH&+C% @Z4#%H ,T
M(3F@!,4 &* '8H 3&*  "@ (H$&* #&* $- " 4 +F@!10 $T )C-  : $H
M2@!0* #% !B@ H 4&@ )H ;F@ % "DT (30 "@ QF@!<8I@(30 E(04P%% P
M)H ;F@!0* '"@04#$- A* "@!10 AH  * %Q0 E "4 +TH 2@!: &F@ S0 E
M "@4 *30 V@!<4 &* "@ Q0 4 )0 4 % !F@!: $S0 M !F@!* $S0 F: %H
M *8@S2 *8"@4 &: $H *0!3 ,T (: $Q0 N* $H 7% !0 E "XH * $H 0T
M+G- !0 N[% "CF@!&- !G-  !B@![<T ,Q0 \<4@!A0,9MH E6@!"* !6Q0
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M &YS0 X"@ (H&.44 #'% B$F@!5YH EVXH 0F@",M0 4 % !0 X"@ *T )0
MM QAH$*M #LXH ;0 Y:  F@!-U  #F@!QXH 81F@ H 6@!M  !0 \4 (6H ;
MUH #0 9I@.1<T .(I -;BF P'- AXH&*!0 A;-(!,9H D Q0 AI@1YS0 \<4
M .I (*  F@!A-  #0 OWJ %Q3 -M(!0* %+4 ,S0 @YI@/%(!Y.*8$3'-(!"
M<4P'*: %S2 "<T (: $ZT +0 $T (#0 M "T !H 3- !BF 4 )FD 9H 7-,!
M* $/%  #0 HYH$.H&,)H !0 O6@!1S0 M "'F@!30 @H$.Q0,:30(;B@ -
M!0 M "4 !XH 3- !0 4 ** %%,!": #% "4@$Q0 "@!>E AI:@!* %S0,<M,
M ZT"$- "=* "@!: $- Q * '4"%%  : &YH *  4 *: &YH 44 &: "@!.E
M"$T % "YH 3- "4 % "YH * % H #Q0 E !0 9H * "@ Q0 8H 0T )0 4""
M@!: $H 2@  H&+3 *0""@0M !FF 4 % !0 E "4 +2 *8 : #% "T )0 4@"
MF F: "@ /-  M "MQ0 )UH 7&: &GF@!_2@ 44 *_% ")2 <* $9LT#' \4
M*HQ0 UN: %H :@YH E*XH :* !AF@!IH ,9H <1B@!XXH 0K0 TK2 ?'Q3 >
M[9H B%(!0*!CU^6F(4&@"1DI#(L4 /!H$-W8H&(.: $H ?TH !0 H&* !ES0
M TC;0 BG- !0 $T#'J:!"L: &!J  "@!QXH 8: !10!)C% #&.:!BHN* '-0
M!&6Q0 X"D A:F F:0#&H 6F BB@1(*0PQ0 ?=H -U "$9H  * &XH =3 44
M,)H$+2&.48H &% " 4 '2@"1#BF UCNH 8!BD [K0 FZ@"56Q3 1FS0!'B@
M6D H% "F@!M "L: &B@!^,T (10 Y1B@![M@4 0-0 ]1B@ )H 1A0 F,4 .H
M&-Q0 J\T 2=: &NU AA- #AQ0, ,4 (QH 8!0!*!B@!#0(44#$8T"$% P- A
MJT .S0,;F@0HH <QH 3K0 M #: % H .E #* )$.* 'L] $9.: '"@9&U AI
MXH 510 _-  : $5:!CR* &-0( U Q'- B/&: +$2T .?F@"!SB@!@H ?B@!<
M4 )0 9H 7- ""@!: &D4  H ": "@!0: $)H ;0 ^/B@!QH 8QQ0 +0 $T
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MH ,T &: $)H  * "@!* "@!: "@ Q0 HH 7- "4 (: $H 44 )0 N: "@ -
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M4 -/- "4@ "@!: &F@ - "@4 &: %H 44P F@!K-2 9FF X4@"F &@!,8H$
M% #Q0,,T (30 @H 6@!I- A* %S0 @YH 4\4 )0 N<4 )F@!10 $T  XH 0F
MF E  :!"@4#%I &: &FF A-  * %'%(!<T &:8#3S0(*0"@4#'8H$--,!*
MF@ % #@* $H&&* "D(*8"9H ;0 4 &: #K0 \"@ )H ;0 M "$T )B@!PH *
M $Q0 4 )UH <!0 &@!,T % !0 9H 2@!,T +3 *0!0 "@0M "9H 2@ - !3
M*0!3 *0PH$+3 ": $S0 M #2: "@ I % !3 2@ H * #- !0 4 (: "@ H 2
M@"0KB@!#2 3.*8"4 +UH 7I0 X"D *: $!YH &.30 K"@!%H 4B@"7% QA%
M"=: .E^&UHEWJEE%*H='O;965@&5E,J@J0>""."#P10(^^?^%5Z3_P ^%I_X
M#P__ !%60'_"J](_Y\+3_P !X?\ XB@8?\*LTG_GPM/_  'A_P#B*!&-XF^
M.B^(4VO:1Q$*X5X (&!8 ;OW>%8C *[PP![8)!5AW/DGXV?!.?X;S[ES)9R,
M?*EQR#U\M\<!P.AX#@;EP0RHBDSS$-4C/T=_X57I'_/A:?\ @/#_ /$5H0?%
MG[0VE0Z3KEU!;QI%$OD;410B#,$1.%4 #)))]SFH92/.0*11(&S0 PT *!0
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M4 /Q0 TT#%S0(.M Q<T -S0 V@":(4@&R4 1@T !I@-H <.: $ZT .I /8T
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MQ2  *8#L4@"F E !0(44 !- P% !B@!: &F@!*! : &XH 4<4 '6@!<4 (:
M "@ )H * "@ -,!* %Q0 M "4@"@!*8"8I . H *8!0(0T##I0(2@!PH&!-
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MJJ@#)8DK@ #DD\ 4 <TXH&)G% #1S0 XT &*!#E;% QCMFD B4")L<4P(^E
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M 44 (: $H 4"@!<T -)H =&* '$4 -(H 3% "4 . H 0F@!1Q0 AH !0 _-
M#": '+0 I- $1YH <HH 5J &YH 3=0(4<4P%49H &H&-/% A!0!(M ".<T -
M% #U.* '%J (SS0 HH #2&,H 44Q"T#'@T@%S0 PF@!: "@!* $H <*8 * $
M- "4"%%(8[% ""@ Q0 =*8"4 *!0 C4 *.* "D F* %Z4P$S0 A- "K2 =0
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MB6>G_M,?\@"[_P"W?_THBILE'PB!4&A^BWPM_P"038?]>-K_ .B4K0S9\O\
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M /%(!&YH 1A0 8IB$H >@H <S4 0LV:!BJ,T /H 5:0#6.: $H * %I@.2@
M<T@&$8H 6@ :@ 5: ),8H C8YI@- I /'% !NH 0&@!] #30 E QXI (QQ0
MS% "@4Q#EYH <*!ANQ0 PMF@0I.: $Z4 % #>M "B@!] #2* $W8I@.+9I#&
MF@0V@!5H >#0 TG- "=* ' T (QS0 E "4 +F@ % "T (: #K0 \<4 &: &,
M<T (10 !:  B@! ,4 . H &H :* '9H ;TH %7=0!)C% @S0,:30 C4 *HH
M7K0 TC% !F@!* %Z4 )G-, S2 7- "9H !S0 \#% "-0!&:8@ H <!0 XG%
M"9H :QS0 JB@9(!BD TBF FV@0N* &DT  H&*: $- A* %H *!BYI )G-  *
M %S3 !0 &D  8H *8!FD W-,!P% "@8H 0M2  <4 +F@ /-, Z4@#- "4 +0
M 4 *>* &T (:8 !0 X<4  H 6D F: &DTP%% #LT +G% #:  T -H$*!0 F:
M!B9Q0 H- "@T"#=0 F: "@!10 &@! * #% "8S0 [I0 AH 0T )F@ H 7- "
M4Q"YH 3- !F@ H 7-(84 *33 ;0 A% @Q2 44 *33 2@!* &YH <* %SB@!"
M: #- #: % H 6@ H 2@ - "4 +0 AH !0 M "B@!,T (30 4 % #A0 M !0
MAH 2@!": $H *!!0 4 +0 9H *  F@!O6@!:8PH$)2 7%, I#"@0E, I )F@
M I@+0 9H 2D 8I@% !0 M( I@% !F@ H 3- "&@ H #0(2@ H 6@!* )*0Q!
M0 X'%, !I #&@ S0 9I@*J]Z0P8TQ"%J %5:0$BC% QK&@!": %6@!P- '5?
M"Q?^)M8?]?UK_P"CDH$?HQ5D'G&J_L[Z'JTTEQ/:[I99'=V\Z<99B68X$H R
M3T  ]*5AW([3]FW0+1UD6S!*L& :2=UR#D95I"K#U!!!'!!%%@N>@Z9I4.E1
MB&WC2*)<[410B#)).%4 #)))]SFF(\,_:B^,B:%;MI%HX-U,NV<8#>7"RG<I
M).%=P1@8)"$M\I,;%,I(^/<8J"C]/ZT,SX/_ &F_^1@N_P#MW_\ 2>*I9:/4
M/V)?^8A_VZ?^UZ$)GT%X[\71^#[&>_E&5AC)"\C<Q(5$R%;&YR%S@@9R> :H
MD_.S7=>GU^=[JZ<R32-N=VZD].W  &  ,!0    !69H=G\#_ (F/X"U".5G(
MM9&"7"Y.TH<@.0%8DH3O&!N(!0$!SEH&??U69GY[?$;X?OH^M3:5;*"6N56!
M%8D8E*M"FZ3'(5U4ECC.?F(YJ#0^^M T9-#MX;2(DI#%'&I;!8JBA03@ 9P.
M< #/859F?%'[2'Q'F\4:G-;!G6VMI/*6/)"EXRRO(5W,I;<S!6 !\O:" <U#
M+1Y99W#VCK+$Q1U8,K*2K*P.0P(Y!!Y!'(- S]$OAEXQ_P"$STZWORNUI4^<
M8P-ZL4DP-S?+O4[<DG;C/.:L@^5OVN/#G]FZN+E0^VY@C<L1\F],Q,JG Z(J
M$C)(+9X! J64CLOV*#_R$/\ MT_]KT(&>H?M+_\ ( N_^V'_ *414V2CX18U
M!H?HK\+/^038?]>-K_Z)2M#-GS!^V-_R%X?^O&/_ -'3U#*0_P#8Z_Y"TW_7
MC)_Z.@IH&?7.JZG'I4,EQ,=L44;.[8)PJ@LQP 2< = "?2J(/SJ\;>.;GQG<
MM>7C;I&X '"(HSM1!DX49]R22S$L23F:G0_ /Q.^@:U:.F2)95@=0Q4$2GR^
M< Y"L0^T\$J.AP0T)GW]5F9^='Q2/_$WO_\ K^NO_1SUF:(^Z_A/X3/A/2[6
MR<$.D0,@8JQ$CDR2+E>" [$#&> .3U-D,^;_ -K7XBS7M[_9,3.D,"+YJ@E5
MD=PDHW -M=54(5RH*OOZC!I,I(^?L]JDH^\_V>?'K^,])CEFR9H6,$C')WLB
MJ0^2S%B492Q."7W< 8JT9L\?_;2\-[)K2_4.=R/"YQ^[78=\8SCAFWR=3R%X
M'RG*92/FS-241DT 2(,T *XQ0!'0 Z@!&- "9H :!F@"3% !NQ2 ;0 M,8UJ
M!""@!X% "YH :3BD,!0 F: '[J8#>E #A2 3.* %'- @(I@,ZT /!Q0 UC0
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M"&F@8HH * "@0E !0 4 .H !0 M #30 HXH 0T % #30  4 +0 AH *8A#0
M"@!": %% "TABTP$)H ,T""@ H *0!FF F: $-  !0 M !F@!* $- "@4 .Z
M4 )0 E !0 E "T !- #: %H !0 N: &DTP"D G6@!10 Z@ S0 9H ,T (30
ME !3 44A!B@ Q0 &@!M "T % !3 *!B4""D N:8"4@%H *8"4@$H * "F 4
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M''$_4G\Q_A18=R[#9P'J7_-?\*+!<N1Z3;/_ !/^:_X4!<D'AN&3[KG\2/\
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M'2@/7]/\*+!<:=-7U/Z?X46"XG]FJ.Y_S^%(+BG3E/K^G^% 7&G35]3^G^%
M7$.GJ/7_ #^% KB&P [F@+B&Q7U- 7$^Q@>M.P7'1V"N<<_Y_"BP7+JZ&A[G
M]/\ "BP[B_V$GJWZ?X46"XW^PD/=OT_PHL*X+H*-T+?I_A3L%RU#X2$G<_I_
MA18+E@>"4/\ $?S'_P 318=Q3X(4=&/YC_XFBP7&'P:HZEOS'^%*P7&'PI&.
MI;\Q_A18+@/"L7JWYC_"BP7'#PK%ZM^8_P *+!<7_A$XCW;\Q_A18+CO^$0B
M]7_,?_$T[!<<O@^+U?\ ,?\ Q-%A7 ^#HO[S_F/_ (FE8+B#P=%_>?\ ,?\
MQ-%@N+_PAL/]Y_S'_P 33L%P'@V$?Q/^8_\ B:+!<=_PB$0_B?\ ,?\ Q-%@
MN(?!\1_B?\Q_\32L%Q/^$+A_O/\ FO\ \318+A_PAD/]Y_S7_P")HL%Q1X-A
M'=_S'_Q-%@N(?"$7J_YC_P")I#N5KKPO''T+?F/\*FXR&/PW&>[?F/\ "E<9
M(/#$9[M^8_PHN(7_ (1:+U;\Q_A3N ?\(O$.[?F/\*+@+_PB\7JWYC_"BX"#
MPK$>[?F/\*+@5KGP_'%($!;!QW&>OTI7 N3^$8XQD%OS'^%4!!_PC\2CDO\
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M/V,?^0O-_P!>,G_HZ"@#ZD^*W_((O_\ KPNO_1+T#/S?H$=3\*O^0O8?]?\
M:_\ HY* /T@H&?F_\5A_Q-[_ /Z_[K_T<] C[H^"?B]/%>D6LZN7=8DCE+,&
MD\V-0KEOF8Y8C>-QW%65B!F@9X[^U7\%;K6YEU;3X_-/EI'-%&F9B03MEPN3
M)P0AXW*JJ>5SL /EO2])FU:006T;RRMG:B*SN< DX502< $GV!- CZIT']C*
MUGLD-W/.EZT67"F(Q)(1G;M"L6"D@'$@WX)!4$8!GA/QD^&L/P[NELH[G[3+
MY8>3$:QA,_<4XED.XCYB"%PI0C.[@$<$: "@ S0 4 %(!3\M  6Q0,<)B.]
M$GVLT .6\(H D6^QUH >+P&@"6.Z% $\>)#G- %U+,'D&@9:MILG%,0R^N=I
MI,:(?/$G&*0P^P9YH 3[.:0$<T?E"@8WS/6@0C2K0!I6S;(_\^E,1 ;C% %:
MYD#B@"L]L.M B&2V5NU $(TX/TIA8ECT#=_%^G_UZ!V&2Z%+%T.?R_QH'8C,
M$T70?RI"$749(OO T6 L0^(2GK_G\*5@+T/B@KW_ ,_E18"]#XF#=0#_ )^E
M*P%D:M#+]X?Y_*C48-;6\_M^=.X$3>'HW^X^/P/^-%P(9?#L@'RD'\O\:8B!
M],EBZK^HH"Q ^4Z@B@+$1?-(!RC-*P",:!#HADT#)I7[4QD6V@!K4  - A^*
M0QK"@! * &M0!**0"T % QZ(7Z4[ 7H-):3KQ_GZT[ 7HM& ZT["+B6"IT%%
M@)E@ [4[ 2! .U.P#@HH 4"@!=HI &P4 (8Q2 0VRMVI@0OIB-VI 5WT%&H
MJ3>'/[I_S^=("G-HLD7O^7^- %&2 IU% $1- "9S0(0T /M^M &HM QV<4P'
M16YEI@:EK9"/K0!<7 Z4 2** ';*!@%H C>+=2 @>US0!&8"M "$8H >*8AX
MH 0T  - "YH 44 %  * %I (: $- #2:3&4+YJS91#$:D9,#3$.I@% "9H >
MG6F!FW9S<#\/YBH W3S@50"M;YZT7 <EN!3 >R8J@$2.@ *4"(VCH&QH.*8(
MI:[%YL?^?45FSHINS.'88J#O!>!5HY*J"K/-84R@H * "@!<T % "YH * "@
M H * "@ ZT *%S5"'B&F(L(,4")5?% QZO0!*CT#)T.:0RRD):@9*+,T@'_8
MZ!C?LE %2\TWS1BF(YK4=&-N<C_/ZT",PC'6@0C4Q#TX- B=!0,T[.//)J2C
M8BN0G2D43"])H&2)*30 \(6H <L1- $BV] $BP 4 /$0H$.$= #A'0 [RZ8P
M\N@!?+H /+H$(8<T )Y0%( \H4 1RP <T#(DMMW)I -\CG)_*@"N]RP!(_"@
M#(";3N<\Y-,16_M@Q@A>I[_Y%,1D2R%CD]:!# V,BF @;- @!S2 E24]*!C^
M&H&(.*0QZINZ4 0O(T)H$*+C?UIB'+,4Z4"+$=X5J2T7H=04]:EHJYHV[1OW
MI6&:"*%Z4 2#!Z4[B"@!* "@!* &F@".@"&<X%" Y/5#EJU1FRB:9)-;]:0(
MT M06."T#$/% A,T (30,:3B@0T/0!*C4 24AC30 HH 1A0!"RTQ#2N*8#30
M(0<4 +0,0F@!0*!"XH >*  F@8TR@4 -,] AA<F@ \LF@!P@H >$"T !D H
MC>7-,",M0 W- @W4P$S0!$YH 9FF(7=0 M !B@! :0QP8T6 D68BE8=R9+PB
ME8+EA+ZBP[DRW>:07'^<&H 3K0 F*8Q=N: '*M("0+0 \"F!(.:  QT ,:.@
M!ABH 88\4 -)Q0 A- "4"$Q0 ;: ' 4 % PH$8560% !0 E !0 4 +0 4 )0
M 4 % "T % "4 +0 4 =+\,KM+/5;&65@B)>VS,S$*JJ)4)8D\  <DG@"@#]
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M^T)^TR/$B'3='<BV9?WT^&1I 1S$H8!E3LY(!<Y7A,^8"/G*@#V[]GO]H1_
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M0,^ Z!'2_#2[2SU2REE8(B7MLS,Q"JJB526)/  '))X H ^^_P#A:ND?\_\
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M*0RW&P%,"Q&^: '4 *& H <)E% A/M*BF OVL4 'VT4 'VL4 +]K% "_;!0
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M>?%,3(&FH$-,F:8";J8!NH 3- !G- !0!$],!,T""@ S2 6@ Q3 6@!10 M
M!G%(8HEQ2 >MSB@"=+N@9.MT#2&3+,#2&2JP- $BT@)!3&/ H =B@0F*8!0
MA3- $;09H C:"@!C1XH 9TH$**!A0(,4 )B@#"JR H * $H * "@ H * "@
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M@B1]IQ3:$7(7SUJ;%HN1Q!NM0:"-;X]Q2N(;L,?(- %VRU8IPU &Q#<"7D4
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M9I -,0I@-,5 ##'2 ;MH$-(H P:L@* "@!* "@ H * "@ H 6@ H 2@ H *
M%H * "@ H * "@ H * "@ -  * /?_V5/BCIW@7[;_:4WE>;]G\OY)'SL\[=
M_JT;&-PZXSGCO0!W_P >?CSHWBG1KFSL[GS)Y/)VKY4ZYVS1NW+QJH^52>3^
MM SY!- A: $H 6@ H * "@ H * "@ H * "@ H * %% !0 NZ@!1)0 >90 H
MDH 7?0 [=0 9H *  F@ S0 Y&QUH 5"O>@!P42D#I0 DL*IWR<T 1XQR: %Q
MQF@!$>@!,T &: %Q0 JC/6@ (Q0 E "T &* "@ S0  T &: "@!: "@!:0"A
MB* '"<CO0!/'J+)0,M0ZV4[?Y_*D.Y9375;J* N68]61Z0[EN"\4]#2"XYI0
M>] "-R*!BK+CB@"0B@ % %:['% &..33$6 .*0B,+B@8YEH 4#% #"F^G<!Z
M6RGJ*+@,GT^(]OY_XT7$5I-(3M_G]:=P(QHI/(-,0QK&6/H?Y4 -$\L74?Y_
M*D!-%K+Q]<C_ #]*.4=R]!XJ9._\O\*5@N:$/B\]\?I_A2L.Y:'B..7[RC\Z
M N.WVUSU&/Q/^-.X#3H<$GW&Q_GZT 2PZ6T'W6!'X"@9.!)'U7\CF@1(EWCJ
M#^1I@2+.IIW E#@]Z=QCPV:0KA0%Q<4!<<&H 6@!: #% #A0 8H * "@0M!0
ME(04 )F@8AH BE7?P:0S&N8/+/M0(H1:EOE\L=,?UQ5$&S'^E,99C- $PH$)
M2*%S0 N:0Q,T#%I"&L<4#&EZ8#@U,1(LN*0$J3^M $@<-3 -E A"M  5H ;L
MS0  YI#%*YH"Y') &H#F()+<BE89EWW7%0T,9$*D9*!0 [I3$)0 HH D@ZT"
M,FU^:X/U_P *0S=NXB.E,HA%RT'2HL5<T=)N XR?O?\ ZJU1FRU%*6)JT0/)
MS3 *10E!+$Z4 C.U:7:N#2&<7>PCTJT0S(ECV]* !34@.S2&&: "@!:!!0,6
MF 4@$H *8@- QZ"F(D!Q5"%7GB@$;MIHX<9-067(],5.U R=;95[4P'A0.E(
M8X4 +0!+$:!%I30 X<T (\(;K0!0N]*#\K2 S9K8Q]: &++0!*DNZ@8^1!)D
M&@#D=8T_R&R.AIDF8RXIDV)8/EH T89]U(9=BBW4AER*VH&6DMZ )TMZ )DA
MQ3 E2*D!)Y5 Q0N*8APC% "E*  B@!A8(.30,HS:S'#GGD4A&==Z^L>"M &;
M+KCR'(X_+_"@1#=ZH\@P3_+_  H S=^:HD-V* &MQ0 Y#FD,9G!IB%!SUI *
MIQ0,?GB@1&YR*!@%W4"&2BJ :E("1,KTI#+,$H/T-(HD:+RSQT-24.#TACI(
M?,&:=Q6(&C,=,0.JW'L::$R)$(&.GI3$7;*Y_"H9:--0!T[U!:%6WW4 1368
MDY%,"NI:V.10(UK2^$PYIB+8;-(0UJH95NSQ21+.2O#EC6IFRO3$6+;K4,9H
MK)@4BB)ES0 T14 +Y5 $BQT#'A<4 !I -VT *%Q0,D0T +)+B@5RN]P*!7(6
MN">E4 P@O0 HMR: '?9\4 +L I **0!F@ H 7% "%L4P()+C%,17>8M5"(\T
MP"D(6@ Q0,4+0(=LH&.QB@!"^* &F4T -+T  >F(?YU $3'- !0 "@8E "K0
M IH 2@!<T )B@!*!"YH * $Z4 +F@!P-(!ZR8H F2[(J;%%B+4,4K#+*7P-*
MP[EA+D&@"7S,TP%W9I@% !0 9H ,T % #67-,!ABH YJJ,PH * $H *  T %
M !0 4 % !0 4 +0 4 % !0 4 % !0 4 % !0 4 %  * %H * $- "T )0 M
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M2L!8COR*5AW+*:AFD.Y82[#4ADJR@TP'AJ #-, !H ,TP#- '+U1F% "4 %
M!0 4 % !0 4 % !0 M !0 4 % !0 4 % !0 4 % !0 4  H *  T  - "T %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
MM, S2  U "[J %W4 *&H 7?0 H:@!V: $H ?F@!* #% !0 IH ;0 M !0 4
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MS0 N:!"8H&.V4 .6.@ :.@!A3% A* %H 2@ H ,T +F@ S0,3- !0 9H$&:
M%WXI6 >LY%%ADT=Z14V'<LQW^:!W+"7F:0R=)@: 'AQ3 7.: .8JS,* "@ H
M * "@ H * %H 2@!: $H * %H * /;OV1O#UMKNJS17D,<Z"RD8+*BR*&$L(
M# ,",X)&>N"?6@#ZX_X5/H__ $#[3_P&A_\ B*!A_P *GT?_ *!]I_X#0_\
MQ% !_P *GT?_ *!]I_X#0_\ Q% !_P *GT?_ *!]I_X#0_\ Q% !_P *GT?_
M *!]I_X#0_\ Q% !_P *HT?_ *!]I_X#0_\ Q% !_P *GT?_ *!]I_X#0_\
MQ% !_P *HT?_ *!]I_X#0_\ Q% !_P *HT?_ *!]I_X#0_\ Q% !_P *HT?_
M *!]I_X#0_\ Q% !_P *GT?_ *!]I_X#0_\ Q% !_P *HT?_ *!]I_X#0_\
MQ% !_P *HT?_ *!]I_X#0_\ Q% !_P *HT?_ *!]I_X#0_\ Q% !_P *HT?_
M *!]I_X#0_\ Q% !_P *HT?_ *!]I_X#0_\ Q% !_P *HTC_ *!]I_X#0_\
MQ% !_P *HTC_ *!]I_X#0_\ Q% !_P *HTC_ *!]I_X#0_\ Q% !_P *HTC_
M *!]I_X#0_\ Q% !_P *HTC_ *!]I_X#0_\ Q% !_P *HTC_ *!]I_X#0_\
MQ% !_P *HTC_ *!]I_X#0_\ Q% !_P *HTC_ *!]I_X#0_\ Q% !_P *HTC_
M *!]I_X#0_\ Q% !_P *HTC_ *!]I_X#0_\ Q% !_P *HTC_ *!]I_X#0_\
MQ% !_P *HTC_ *!]I_X#0_\ Q% !_P *HTC_ *!]I_X#0_\ Q% !_P *HTC_
M *!]I_X#0_\ Q% !_P *HTC_ *!]I_X#0_\ Q% !_P *HTC_ *!]I_X#0_\
MQ% !_P *HTC_ *!]I_X#0_\ Q% !_P *HTC_ *!]I_X#0_\ Q% !_P *HTC_
M *!]I_X#0_\ Q% !_P *HTC_ *!]I_X#0_\ Q% !_P *HTC_ *!]I_X#0_\
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M_"JM(_Y\+3_P'A_^(H /^%5:1_SX6G_@/#_\10 ?\*JTC_GPM/\ P'A_^(H
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M?_$4 +_PK;2_^?*U_P"_$7_Q- #U^'>FKTL[;_OQ%_\ $T .'@'3A_RZ6_\
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M#IW_ #Z6_P#WYC_^)H&1)\-],0Y%E; ^H@BS_P"@TK")1X"TX=+2W_[\Q_\
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M_P!^(O\ XF@!1\/M-'_+G;?]^8O_ (F@!?\ A -._P"?2W_[\Q__ !- "_\
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M72WZV5J?^V$7_P 30!$?A9I)_P"7"T_\!X?_ (B@ _X59I)_Y<+3_P !X?\
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M:?\ @/#_ /$4 *?AAI1ZV-K_ . \/_Q%(!/^%6Z3_P ^%I_X#P__ !%,!/\
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M?^?"T_\  >'_ .(H /\ A5ND_P#/A:?^ \/_ ,10 H^&&E#_ )<;7_P'A_\
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M^%4Z1_SX6G_@/#_\10 ?\*ITC_GPM/\ P'A_^(H 3_A5&D?] ^T_\!H?_B*
M#_A5&C_] ^T_\!H?_B* #_A4^C_] ^T_\!H?_B* #_A4^C_] ^T_\!H?_B*
M#_A4^C_] ^T_\!H?_B* #_A4^C_] ^T_\!H?_B* #_A5&C_] ^T_\!H?_B*
M#_A4^C_] ^T_\!H?_B* #_A4^C_] ^T_\!H?_B* #_A4^C_] ^T_\!H?_B*
M#_A4^C_] ^T_\!H?_B* /S]^)MHEGJM]%$H1$O;E550%55$K@* .  . !P!0
M!S5 @% #@V*0QXDQ18"1;DBE8=R>.^Q2L.Y86]H"YC9JR1: "@04 % !0,*
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M,J# ^K"@#R[_ (:^T/\ O3?]^C_C0 ?\-?:'_>F_[]'_ !H /^&OM#_O3?\
M?H_XT >J>%?%,/BB!;JVR8VQC<-IY /3Z&@#7H H:[K<>B0M<39V+C.!D\G'
M2@#S[P;^T;I7B^X%I:M*9&!(W1E1QUYS0!ZA0 4 %  3B@#RK7?VE](T2Z:R
MF:7S595.(R1E@".<^XH ],TW4%U&-9H\[6&1G@T 6: "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * /S8^+'_ "&-0_Z_[K_T<] '*XH
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MY!/J/3UH _.G4X;CQG>7$T0:0F1WX#,0K.2!P#ZT >N?LB^-O[&OWL)20)\
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MXN[>(YQAYHT.>>/F8>AH BLOB+IM^=L-Y;.WHL\3'\@QH Z$'=R* "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M>*)_&VC,LS9D"&+<Q)))C'))+$\F@#Y4^.7PPG\#WK^>Z/YS-*NS=P'=\ Y
MY^7F@#L_@K^SI=ZYY.J)-"(PY^4[]_ ]E([^M '7?M0?&:?2G72K*0HRJ/-=
M696Y$;K@JP/J#D=* //O"W[,NJ^+[<7K2*F02%E\PR'!(X^4_P!WU]* *'@O
MQQJ7PNU%;:X=]@D5'1V<I@LNXA2P&0.A- 'VEK7C>.PTQ]4'W1;&51Z_(7 Z
M_P!: /A;4]=U+XL7YB1Y&$CG:FYRBJ22/EW,!P<<4 =]/^SUKO@"+[;:W&2H
MR8X6F#<X7D +_>]?6@#R'X??\?T6?[] 'Z84 % 'SI^VU_R#K;_K[_\ :;T
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MP!?J< T ?4?P8T?4=(LQ%JDGF.,X)+L_4\$OSTQB@#T"@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@#\V/BQ_R&-0_Z_[K_P!'/0!RX7- !LH
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M=IH \Y^.WA34-"E@?4Y?,DE1R!R-H! (Y8]>#Q0!]'?L@_\ (+?_ *ZC_P!
M6@#S+]M/_C\A_P"N,?\ Z%-0![7^S+_R!H_]]OY+0!\B?'B9Y=8G,GWOW?\
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M%"@#XG^'/_(?B_Z^I/\ V>@#ZG_:I_Y <OTC_P#1L5 'D/[&: WDIQR .?\
M@#T >V?M1(&T9\_\]%_]!>@#PO\ 8IN#_:LZ?P_8I#^/FP"@#T#]MS_CPM/^
MOEO_ $6U %#]BG_5W/T3_P!">@#P7XHN9-9D+<GS(?\ T7'0!^@_AU0MN@'
MQ_4T 3C280QD\M-Y.2VU=Q/KG&: .9^*'Q'A^']H;J89ZA%'!9L$@#@CM0!\
MY:?\<O$/Q$E:+2XP$')^5"5!SC)ROI0!YU\=/"FH:')"^IR^8\F_ Y&W:$SU
M8CD$=/2@#Z1_9(_Y!8_#_P!">@#Q?]L3_D)Q_P#7$_\ H;4 ?0_[-?\ R!X?
MHG_HJ.@#U*@ H @O_P#5O_N-_*@#\])O^1AC_P"OZ#_T-* /T2H ^(/VR?\
MD-+_ ->D7_H4E 'T;^S5 L.C1;1CYY/YT ='\6O^0;-]%_\ 0A0!\9?LQ?\
M(9C_ .N;_P!* /JGXW_&^/X<1J@7?/(,JH., [@&.1@@%>E 'C>@^/?$_P 3
M<M:A4M\E=X5>.AQPP/1A0!XC\5- N-#OFAO)/,EVJQ;GOGCDGI0!]Z?";_D&
M0_1O_0C0!\1?%S_D/3?]=H?_ $".@#['U3P(GCC18[.0XS'E3Z-M8*?P)H ^
M;9?@[X@^'$A:P#2)D\J0J'GK@N.RC\* +UG^TSK?A9@FHHI4'&-JAOSR?2@#
MZ.^$WQ=M_B-"9(1M= -Z$Y(R2 <X YP: .]H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M94_VMJ/A>64#)/4]/2@#Y,^&'Q;O/A-/)$T>]0S*\657Y@P#?-L?^YCCCN*
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MQQT')ZLN>!VH _07P[H::#;QVL7W(T"CKT'U)/ZT ?GOX^_Y#]W_ -A*X_\
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MTQ)KZ8;4E"!!QSM,@/1L]^X% 'TU0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MNM/(C/J)L_\ H4AH Z__ (2RS_Y^(?\ OXG^- !_PEEG_P _$/\ W\3_ !H
MY#Q+X.\/^)FWWGD2-ZF;'_H,@H CT#P-X>\/-OM1;QMZB8GU]9#ZF@#L_P#A
M++/_ )^(?^_B?XT 177B*QND:-YX2K*58>:G((P1][TH XO2?AYX;TB<7<"V
MZS*P8/YY)R"&!P9".H!Z4 =S_P )99_\_$/_ '\3_&@ _P"$LL_^?B'_ +^)
M_C0!Q_B3P9X?\3/YEX()&/<S8[ ?PR#T% #?#W@CP]X=;?:""-O43$_^A2&@
M#LO^$LL_^?B'_OXG^- '#^(OA[X<\1RFXNUMY)3U8SD=R?X9 .I- '7:9K&G
MZ7&L,,T*HH 4>:IP ,#JQ- $>LW^FZRGE7$L+H>QE4=P>S#N!0!Q,?PF\+QO
MY@CM]WKY[?\ QV@#N].UG3]-01PS0JHZ#S5/\V- '-?%_P 2VL^CWR)/$S&S
MG  D0DG8>  : /C_ /9QN4M]7A:5@J[QDL0H[]S0!]9ZE\-_#6IRF>9;=I#U
M;SR/Y2 4 =CINL:?IJ".&:%4'0>:I[D]V/<T 9OBRST?Q='Y-\\$J @X,P'(
MZ?=<&@"KX0T'0_!V[[ 8(MV<XFW9SC/WG/\ ='Y4 /\ &&C:)XQ"K?M!*%.5
M!F"X."/X7'K0!)X2T[1O""&.P:")3U F!]_XG- $'C/0=#\:^7_:)@F\K=LS
M-MQNV[ONNO7:.OI0!9\)66C^$4,5@\$2,02!,#G&<?><^M &M?:[87Z&.6>%
MD8$$>:G((P>C>AH X*Z^$WA>Z<R/';EB<D^>WKG_ )ZT =;X=72?#B[+22"-
M<8P)0?\ T)S0!>U'6M/U*,Q330LC8R/-49P01T8'J* ./\/?#OPWX=F%S:+;
MQRJ" PG)(SP>LA% '97^NV&H1O#+/"T<B,K#S4Y5@01PV>0: .+T+X;^&M!E
M6XMEMTE0@JPG)P001UD(Z@4 =TWBJS;@W$/_ '\3_P"*H X76OAOX:UMS+<+
M;NYZDSD?RD% '5:#<Z9H$8AM9840=A*I[D]V)ZDT :/_  EEG_S\0_\ ?Q/\
M: #_ (2RS_Y^(?\ OXG^- &;K=SIFN)Y=S+"Z^AE4?R84 <6GPB\+1MO$=ON
MSG/GM_\ ': .VT6\TS1$\NWEA1?02J>Y/=CZF@#0_P"$LL_^?B'_ +^)_C0!
MP>J_#;PUJT[7<ZV[3.^]G\\@ENN<"0#]* .PCU33HX!:B:'R0@0+YJXV@8 S
MNST_&@#C[#X:^&M/G%U$ENLP8L'\\YR<Y.#)COZ4 =+XF72O$\)MKR2"2(XR
MIE '!##E7!Z@4 97A+PKH/A!S)8>1$QZD39[$?Q.?4T ;'B272_$L1M[R2&2
M(G)4RJ.>1_"P/>@#$\(>$- \'2FXL/(BD9"A83;LJ2K$?-(1U4'\* -#QCIN
MC>,T6+4&@F1&W*#,%P<8S\KCM0!'X0T;1?!P86#01!\;L3!LXR1]YSZT ;\_
MB2RN%*M/"0>H\Q/_ (J@#@;[X5>&+]O,ECMV;U\]OZ2T =+X9LM'\,#;9O!&
M,8XF!XX_O.?04 ;4WB:RF!5IX2".1YB?_%4 <'?_  P\,W\AGE2W:0]6\\_T
MDQ0!JW_AG0M0M_L<I@:#^YYW'W@W4/GJ,]: )?!VAZ)X,#C3S!#O(+8FW9QD
M#[SGUH J>*_!OA_Q;()K[R)9 ,!C-CC.?X9 .M &]X>N-,\.Q"WM)88XEQA1
M*IZ */O,3T H TO^$LL_^?B'_OXG^- !_P )99_\_$/_ '\3_&@!'\4V;@@W
M$.",']XG_P 50!PA^&OAHSB[V6_G!U</YYSN4@@X\S'4#M0!WG_"66?_ #\0
M_P#?Q/\ &@#CO%G@OP_XNF^TWP@EE"A=QFP=H)('RR =S0!T'A^ZTSP]$+>U
MEACB7.%$JGKUZL30!/JFKZ?JL9AFFA9&ZCS5&>_9@: .1\.?#[PYX;F%Q:+;
MQR@$!A.2<'K]Z0B@#KM3UC3]30Q330LC @CS5'4$'HP[&@#B8/A;X8@D,RI;
MAR<Y\]NN<Y_UF.M &CXA\'>'_$2HEWY$BI]T&;&.,?PR#M0!L>&!I7A:$6UE
M)!'$N<*)01R2QY9R>I- '-:I\-O#6JSFZG6W:9B"6\\@D@  X$@'0#M0!VMK
MKMA:((DGA" 8 \U.G_?5 '(Z_P"!/#OB!B]T+>1B<DF<CGGGB0>IH AT?X;^
M&M&<26ZVZ,.A$Y/\Y#0!W2>*;-!@7$.!_P!-$_\ BJ -:@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M9]I4 ?,?QW_9QU+QUJCWUH81$T<:C>[*V57!X"'^= 'GO_#&NM?WK;_OX_\
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MH /^&-=:_O6W_?Q__C= !_PQKK7]ZV_[^/\ _&Z #_AC76O[UM_W\?\ ^-T
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M\?\ ^-T '_#&NM?WK;_OX_\ \;H /^&-=:_O6W_?Q_\ XW0 ?\,:ZU_>MO\
MOX__ ,;H /\ AC76O[UM_P!_'_\ C= !_P ,:ZU_>MO^_C__ !N@ _X8UUK^
M];?]_'_^-T '_#&NM?WK;_OX_P#\;H /^&-=:_O6W_?Q_P#XW0 ?\,:ZU_>M
MO^_C_P#QN@ _X8UUK^];?]_'_P#C= !_PQKK7]ZV_P"_C_\ QN@ _P"&-=:_
MO6W_ '\?_P"-T '_  QKK7]ZV_[^/_\ &Z #_AC76O[UM_W\?_XW0 ?\,:ZU
M_>MO^_C_ /QN@ _X8UUK^];?]_'_ /C= !_PQKK7]ZV_[^/_ /&Z #_AC76O
M[UM_W\?_ .-T '_#&NM?WK;_ +^/_P#&Z #_ (8UUK^];?\ ?Q__ (W0 ?\
M#&NM?WK;_OX__P ;H /^&-=:_O6W_?Q__C= !_PQKK7]ZV_[^/\ _&Z #_AC
M76O[UM_W\?\ ^-T '_#&NM?WK;_OX_\ \;H /^&-=:_O6W_?Q_\ XW0 ?\,:
MZU_>MO\ OX__ ,;H /\ AC76O[UM_P!_'_\ C= !_P ,:ZU_>MO^_C__ !N@
M _X8UUK^];?]_'_^-T '_#&NM?WK;_OX_P#\;H /^&-=:_O6W_?Q_P#XW0 ?
M\,:ZU_>MO^_C_P#QN@ _X8UUK^];?]_'_P#C= !_PQKK7]ZV_P"_C_\ QN@
M_P"&-=:_O6W_ '\?_P"-T '_  QKK7]ZV_[^/_\ &Z #_AC76O[UM_W\?_XW
M0 ?\,:ZU_>MO^_C_ /QN@ _X8UUK^];?]_'_ /C= !_PQKK7]ZV_[^/_ /&Z
M #_AC76O[UM_W\?_ .-T '_#&NM?WK;_ +^/_P#&Z #_ (8UUK^];?\ ?Q__
M (W0 ?\ #&NM?WK;_OX__P ;H /^&-=:_O6W_?Q__C= !_PQKK7]ZV_[^/\
M_&Z #_AC76O[UM_W\?\ ^-T '_#&NM?WK;_OX_\ \;H /^&-=:_O6W_?Q_\
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MZV_[^/\ _&Z #_AC76O[UM_W\?\ ^-T '_#&NM?WK;_OX_\ \;H ^WAQ0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /S9^+ _P")QJ'_ %_W
M7_HYZ .5Q0(* %W4##?0 F\T &XT""@![C% %FPEVG% (GOX\\TBC/(Q3)'K
M0,?2 6@!: %H 6@ I +0,4&F X-0 H>@#WG]CA\ZM-_UXR?^CH* /L6F(* "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H _-CXL'_B<:A_U_P!U_P"CGH Y6@08H&&* %"T
M ."T . Q0 N10 LG- AD;;3F@#3D/F+2**,R8- AJTP'BD M "T##- #J0!0
M(44#%H$ I@+0,]Y_8V_Y"TW_ %XR?^CH* /L>F(* "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H _-GXKC_ (G&H?\ 7_=?^CGH Y6@04##=0 ;J $W4 &: $H L'I0(BH
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MCD?9_<'.NZ^\/L;_ -UOR-'(^S^X.==U]X?8W_NM^1HY'V?W!SKNOO#[&_\
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M(T<C[/[@YUW7WA]C?^ZWY&CD?9_<'.NZ^\/L;_W6_(T<C[/[@YUW7WA]C?\
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M(T<C[/[@YUW7WA]C?^ZWY&CD?9_<'.NZ^\/L;_W6_(T<C[/[@YUW7WA]C?\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MU1T?@WQGY6(9SQV/YFO7P..Y?<E\G]YY>,P5_>C\U]QZ&K!N17UB=SY?86F
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % %#6-
M&354V./H?2N6O05:-F=%&LZ3NCR;5]'DT23![=#VZ#_&OA:U"6'E^3_KU/M*
M-:->/Z'H_@GQP-1 BF.''0GO7UV S!55RRW[]SY;'8'V;YH[':5]&> % !0
M4 % !0 4 ?FY\6HL:O?_ /7]=?\ HYZ8CD:0"YH&)F@ S0 9H *!!B@9+MQ0
M(6F AXH MVD_EU+&@N)O--(9%3$% "B@!10 4 +0 M P% "T""@9[S^QM_R%
MIO\ KQD_]'04"/LBF 4 >;?&'K!_VT_]DKX_._L?]O?^VGU>3_;_ .W?U&_"
MW_5R_P"\O\JG*/AEZK\AYI\4?1G<5]*?/A0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M:BZ3LR]72<X4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M?6)W/F&K"TQ!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 4-9T9-538X^AXR.GJ#Z5RUZ"K1L_O.FC6=)W1Y/JND2Z%)SD8/##
M./SP*^%K498:7Y/7_@'V=*M'$1_-?U<]%\$>.!J($,QQ(.A/?H.[9)R:^NP&
M8*JN26_?OMW>Y\MCL"Z;YH[?E]RV.UKZ,\ * "@ H * "@#\[OBQ;^9JM]_U
M^W7_ *->BX6.$F@*4Q$6*0PQ0 4 % !F@!=U #RU @H 44 .% QP%(!U PI"
M%I@** "@!10 4 % "T +0![S^QK_ ,A:;_KQD_\ 1T% 'V13 * /-OC#U@_[
M:?\ LE?'YW]C_M[_ -M/J\G^W_V[^HWX6_ZN7_>7^53E'PR]5^0\T^*/HSN*
M^E/GPH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M ,O7M 35TVL.>QXSU'?'M7#B,,JZL]^YV4,0Z+NON/)[_3Y=%DPV01T(R,]/
M\:^&J4Y8>5GH^Y]G3J1KQONNQZ#X0\7C40(Y#AQ^M?5X+&JJN66Y\SC,'[-\
MRV.KKW#Q@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M<4JZ\^Q\=B<,Z+\NYLUZ)P!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!2U72
M8]30I(,^_&1R#P<<=*YZU%5H\K-Z59TG='DFNZ!)HS[6Z=F['I_C7P>(PSH2
ML_DS[6AB%75U\T=)X-\9&+$,QXZ G_ZYKU\#CK>Y+Y,\O&8*_OQ^:/0U8.,C
MI7UB=SYAJPM,04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!E:]H
M":LA5ASV-<.)PRKQL]SLP^(=%W1Y1?V$FBRX/!!X/KC\:^&J4Y8>5NJV/LZ=
M2->-ST'P?XN&H@12<.!^?0>GJ:^KP.-]JN5[_P##'S.,PGLGS+;_ (<ZNO</
M&"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@"*YMUN5*L,@C%1**DK,N,G%W1Y
M?XN\*-I;>8G,9/Y=3CKZ"OBL;@W1?,MG_P $^OPF+55<KW_X8L^#O&)LB(IC
M\AZ'T_F:VP..]G[LMN_8QQF#Y_>CO^9Z4CAQD=#7V*=]3Y1JPZF(* "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H 1E##!Z4FKC3L>=^-/!OD9GA'R]6'I[]:^3QV!
MY??CMU1]/@L9S>Y+?HSG-!U]]'?<O([C\_\ &O(P^)="5UMV/5KX=5E9_>>N
M:7JJ:D@DC.1_]<C^E?>4:RJQYD?$U:3I.S+E=!@% !0 4 % !0 4 % !0 4
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MX+\8^41!,>. I_( 5Z^!QUO<E\G]R/+QN#O[\?FOO9Z&K;AD5]8G<^7>@M,
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * ,_6=
M&35$*..<<'T.#C^=<M>@JT;/Y'31K.E*Z/*-7TJ30I<=,'*GVR<'K[5\+6HR
MPT_R?S_X!]G1JQQ$?S1Z-X'\;#40(9>)!P#Z_I7U^7X_VJY);]/,^6QV"]D^
M>.QVE?1'@!0 4 % 'YX?% _\3:^_Z_KK_P!&O2 YL-0,CFA$E,1ESV^RF(AH
M&)2$+0,* ) *!!0  T /44#'T@%- "T % !0 M !0 HH * "@!U 'O'[&O\
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M0R<5!9 =1B'&]<_[P_QH F1P_(.: $EG6+EB!]3B@!D5ZDO"LI/L0: )B<4
M5VU"->"ZY_WA_C0!,D@<9!R* &QW*R$A6!(Z@$$B@!Y..M #(IUFY4@_0@T
M,DO8XN&91]2!0!)%.LOW2#]#F@!)+A8SAB 3TR0* &&_C!QO7/U% #XIUFY4
M@_0@T .DD$8RQ 'OQ0 1R"094@CU'(H =0 4 % !0 4 % !0 4 % !0 4 %
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M>O\ WT/\: %NW#1L1S\K?RH ^>O@+*6UW4 2<;KC_P!&15M+8RCN?1M8FH4
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M\?6M8Q,Y2-C]EYR^CPDG/W__ $;)2GN$-CUVLS0* "@ H * "@ H * "@ H
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MQEY6()CQ_"?Z<"O7P..Y?<E\G_2/+QN#O[\?FOZ9Z&K;AD5]8G<^8:L+3$%
M!0!Q?Q8^(\?@.T-RPW.<K&O(W-@D#(5L=.I&*J*N2W8\K\._##4?B2GVO5[@
MK&YRL(1/NGE?GC9#TQU&:MNQ"5P\2_ :X\'1F[T:<B5,?(5#;LD+UED8# +'
MI_2A2ON#C;8]#^"/Q0_X3ZT\QQB:/ D^I+8_A4=!VJ9*Q47<]!EG6'[Q ^I
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MT/\ &D,='?QR'"NI/H"#_6@"5Y!'R2 /?B@"$:C$>-Z_]]#_ !H E>=4&XD
M>N>* /#O@3XREUJ^OC=2AMLCJF=B_*LC!1P!GCO6LD9Q9V7B3X9KJ^IP:C]I
MV&+S/W6W.[='LZ[QC'7H?ZU*>EAM:GH)..M060'48QQO7/\ O#_&@"=7#\CD
M4 ,^TKDC<,CKR.* (UU"-C@.N?\ >'^- %B@ H * "@ H * "@ H H:SHZ:J
MA1_P//!]>"*Y:]!5H\K.FC6=&5T>3:QI$FBR8/KP>/\ $U\+7HRP\K?<S[.C
M65>/YGH_@?QN-2 AF.)!T/KU/8 # %?7Y?F'M5R2^+\]_)=CY;'8'V7O1V_+
M;S.TKZ(\ * "@#\[_BA_R%K[_K^NO_1KT@.9H&.4XH CN(MXIDF3*NTTP&4@
M"@ H F9,4 ,)H 4<T 3 4ABT +0 4@"F 4 ** "@ H 6@ H 6@#WG]C7_D+3
M?]>,G_HZ"@#[)I@% 'FWQAZP?]M/_9*^/SO['_;W_MI]7D_V_P#MW]1OPM_U
M<O\ O+_*IRCX9>J_(>:?%'T9W%?2GSX4 % !0 4 % !0 4 % !0 4 % !0 4
M % %35O]3)_US?\ ]!- CP']G#_D(7W_ %UE_P#:=:RV,XGT361J?-G[8</V
M%+2Z3AS*XS]$'^-;0,9DO[5;;K&R/L?YP40',[+]HWQ7<:%9J+=BF]U#. #@
M%U!Z@CH34Q5QR9R6A_ G2]<@687*O.RY#Y7<&[' ;&<X[53DT+E.\^$?AO4?
M":31:A('@5W,394G8 @3( &. :B3N4E8\RA2Z^,VI3P/(T=G S+M !#;7*GJ
M >F.AJ_A1'Q,L>/O@U)\/(?[1T9W\R/[R*N2V2$''S'^(G@4*5]P<;&W\6_B
MS<V5I;00 QW-T7'NNQU!ZCNI[BE&)38:?^R[#<Q[[V5GN2,E]H^4]L8(![&C
MG%R&;X!\077@+5O[$O)#+!(O[DD 'F18DX ] >]-JZN"T=B.PC_X5_XG* 8C
MO><]MTDK,>?^ T;H-F>E_'/Q?_PC6ERRH?WA4;/<[ES^AJ(J[*D[(X+P]<GX
M3^'?M)'^D,>1TSF<@?D)/2J?O,E:(Q_ _P ((_&D"W^L7(>609"DIQR5[%?0
M&FY6V$HW$\R3X0ZC!%!,);.=T0KE?E+R!<\9/"KW/>CXD'PB_M073S36<EL<
M.6A:,^Y\PJ>]$ F=1X7_ &=+>58KNYD9YF =\J.=RYV\$< FI<BE$Q/V?;EO
M">HW6CS'J4,8/'42R-^A%5+57%'1V.A_:7\1&.WBTZ+_ %EQ(N,<G"NF[]#4
MP0Y,]+\"^&AX9LXK0?\ +- M0W<M*QO4AA0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % &5XAT)-6C*MU X/H<''\ZX<3AU7C9_)_?_F=F'KNC*Z^:/([J%M-
ME(!Y5C@CGH<5\%.+I2MV>Y]M%JK&_='I7@[Q,=47:X.X=\<?G^%?8X'%^V5G
MNNI\GC,-[)W6QT]>T>2% !0 4 % !0!\E:AXQ@\(>,KF[NMWEJ"#M4NV6@0#
M@5O:\3"]F>K-^U)I&.//S_UQ:HY&7SH\VUS69_B]JUL;:)UM8FB8LRLOW9&R
M>1UVN.,U?PHGXF3_ +244MG=V:VQQ*NP(>.H0C/.:4 D>@>#O@#;Z3)%?22E
MI@"S$@#=N4C!YQQNXJ7(I1/.M)N)?C7>2M//Y5E&4PGR\Y3WP?O)Z]ZOX2?B
M-3QA\*(_ L7V_2+@*\9#,@*891\Q&26/08XI)WW&U8]C^%?C7_A,;&.Z/WRJ
MAQZ-M5C_ #K-JQ:=SKZDH\+^._CJZ>YBT;3VVS2D[B,9QM#CJ#Z&M8KJ9R?0
MCE_99MEA+"5OM&,^9M&[(.>F<=..E'.+D*WA+7K^YTB[MM25M\*,%=@1N!1F
M)Z >W%#6H+8M_LP?\@>;_>/_ **6B>XX;#/V=?\ C\U'_K\NO_1B42Z"B<+X
M3\/7/BK5KRSBE,4.XF4@*25+M@8/N*INR)6K-GXI_ ]/ =HVJ:;(R2P[<X4?
M-O=(^Y/9CVI*5]!N-M3TC3/$S^*/#PO)?OR12D_@SK_2HM9EWNCG/@=KHT'0
M'N3_ ,LXF8>Y6,L!^E5+5BCL<SX"\"3?&,R:CJ4K>3YK"./ ( ^5U_NG&)"*
M;?+H2ES%W4/!5U\*+V"33B\EM+)M>,+D#@DYP&(' YHOS#M8V_B]>ZCXAO+;
M2[4O#%*&,D@7*_ZM9 "67 P1@<CDTHZ:C>NA2UG]G'3+:)G%P$E52=_RYR.1
MP6Q[4<PN4E_9K\83ZK:W%M</O\D[4/'382>@]31-!%F5\ _^0]J/^]<?^C(J
M<M@CN?2%8FH4 % !0 4 % !0 4 % !0 4 1W%NMPI5AD'J*B45)6>Q49.+NC
MRCQAX>&DO\I!5N@[CIV_&OAL;AO82TV9]G@\1[:.NZ-+P3XK:V(@<%D[8&2.
MI[>YKLP&,<'R.[73RW9RXW"*2YUH^OGL>DU]@?*!0 4 % !0 4 % !0 4 ?,
MO[:IPEA_O7'\HJVIF,SO/^&I-(_Z;_\ ?EJGD97.CAOBI\:U\<6_V#2XI6:1
MU!9HW7 .5/8CO5*-B7*YTNK^%F\,^%G@D^_]E8L/0_9R"/TI7NRK61R7P?\
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M'F.5+/R"?W@(XR1QN-7>Y%K%7]ES_D#0_P# _P#T;)3GN*&QZ]69H% !0 4
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MZ'U=2FJL;/J>M^'=;_M6,-@@XYX..@K[S"U_;1N?$XFA[&5C6KN.,* "@ H
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M-?5GS(4 % 'S=^T=*=1U.RLF_P!67B;GID^8*VCL92W/H;28?)AC0=!&@_(
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M=?\ C\U'_K\NO_1B42Z"B5/@'_R&]3_W1_Z->B6R".[/2?CE_P @BY_[9?\
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M?\,='7KGEA0 4 % !0 4 % !0 4 ?,W[:OW;#_>N/Y15M3,9GN?_  K+3?\
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M6QXOX7G&@^+9UN#M$@^5FX4XA4=3C/)QQ6CU1FM&?1>J:DFF1//*<(BLQZ=
M"3U('05B:GF?BCX@V_C70]1FM ^Q(+A"6  )$8)P59@1AA5I69+=T<S\-?%Y
M\)>&6O%&YD+$ ],X3K@BJ:NR4[(R/ O@C4_B1!]ON;Z5(Y&;:D<G VL1T9#Z
M#O3;L)*YQWQS^'5MX-DM4CG>:5G.3(4+C#Q_W0#T/Y8JHNXI*QZ%^TA_R#+?
M_KM#_P"A-40W*EL:/Q&_Y%>+_KV7_P!$/26XWL=A\--8BT?1H)YV"HMO$220
M/^6:>I J7N-;'E$27'QPO]S!ETZ$GJ"%?@J=O#HWS*">:T^%$?$?2%E9)IZ"
M.-0J*. .!ZFL38^>?%/BS4/'NL/I%E,;>.+.65F1F 56_P!H$\GM6R5E<R;N
M[%[Q+\!H].M)[F]O9Y"D$K!7="A(0L.J YX/X4E('$/V15"VDX7[OVF7'TQ%
MBB80(_V:?^/W4?\ KM+_ .CFHF$1WQ(_Y&:R_P"V_P#Z3"A; ]RI\4)AHGB*
MVN9P!&PD +<+TC7J<#K[TUL#W/HI)ED&X$%<9R#D?G6)J?.#RC7_ !8&MSN$
M,8#E>1E;D[@<9]1G.*VV1CU-#P'_ ,C-=?\ 7(?^C6I/8:W/7_B)_P >,OT3
M_P!#6LT:,X/]EO\ Y \7_ __ $;+5SW(AL>OUF:!0 4 % !0 4 % !0!R'C#
MQD+(&*$Y?N0>GY'K7@8W'>S7+'?OV_$]S!X/G]Z6W]>1Q6A:!+K\F%SCNQS@
M<'O@^E?.8?#2Q,K+YO7S\O(]ZOB(X>.OR1[/HNB1Z0GEQCZGN>3UQ]:_1*&'
MC0CRQ/@J]=UI79H5UG,% 'YW_%'_ )"U]_U_77_HUZ .:% Q12 <* ,^_2K)
M*%2P"@ H M4 +0 =* $I#%H * "@!:  4 !H 44 % !0 M !0![U^QI_R%IO
M^O&3_P!'04 ?9-, H \V^,/6#_MI_P"R5\?G?V/^WO\ VT^KR?[?_;OZC?A;
M_JY?]Y?Y5.4?#+U7Y#S3XH^C.XKZ4^?"@ H * "@ H * "@ H * "@ H * "
M@ H @O8#<1L@ZLK#\QB@#YT3]GO6]-N9I[*\BB$KLV \ZGG'78H]!6W,C'E9
M<?X,^);KY9-2 7OLFN0WZBES(?*SN_AE\$+;P:QN'+37+=9'(?!]5)0,#R><
MU+E<I1L1_'/X5S_$&**.W>-#&6)W[L')C/&U3_=-$78)*YT_Q!\ 0>-;<V\^
M0<@JRX# @Y&"5;'(YQ23L-JYY=:_"/Q!IR>1!?IY.,9>2X,@'3@@  ^G'6KY
MD19G:?"WX01^#&>YE<RW4N[?(QWD[MK,,E0WWESR3U]:ERN4E8QO&_P,:\N?
M[0TN4V]R?O88QQMR3DB-=Q.3SDTU(3B8EQ\"M4\3D)K%X'@&?DADE&?J)%8'
MD T^9+87+<]*\6?#"T\16@LG0*B_<*A5*_-NX^4XR1S@<U"=BVKGFEM\'->T
MM?L]K?KY'0;Y;@R =\%0 #U[=:OF1'*SL?AE\&(O"$C7<KM-=.#ND=A)U*DX
M+*&^\N>3^M2Y7*4;';>)=#77;:2V< K(A4YY'/U!J5H4SRWX-? J3P1<S7-S
M(DA? CVY)4 MC[RC'!QQ5RE<B,;'J^MZ+%K<+6\ZAXVQD$!AP<C@@CJ,UF6>
M(P_ G5?#3%=(O=D'9)I)L#Z"-54<DUKS)[F?+8V?!GP(D@NEU#5IC<W"XV_,
M9(U(8,"!*I(P1Q@\9I.78:B:/Q7^%$_C&XMYX'C187C8AMV2%WYQA3_>I*5A
MM7/2["W-M&B'JJ*#^  J"SSG]HFS@N=(G^T'&/+VG@'_ %L><$@^U7'<B6Q1
M_9L\%G0-.$T@_>S\OG[WRNZC/ /3U)IS=V$59'K=9EA0 4 % !0 4 % !0 4
M % !0 4 % !0 4 !.* .'\9>,_)S#">>Y';\C7S6.QW+[D=^K_IGT.#P7-[\
MODOZ1R6@Z%)K<G?&?F8Y]1GGGGFO!P^'EB)>75_=_F>U7KJA'\D>L:3I*:8@
M1 !QR>,G\@*^ZHT51C9'QE6LZKNR[72<X4 % !0 4 % !0!Y'I?P=N+/Q'+K
MIDC,#J0$&[S.8E3^[MZCUZ5IS:6,^76YZY69H% 'E?Q/^$MQXMO+>ZADC58F
M!(;=D\$<84CO5J5B&KGJ%O'Y2A3V 'Y"H+/'O&GP$>XN3?:1.;6=L9 <QQ\!
M5Z1(#T![]ZT4C-Q,N3X&ZKXC=1K%XKP*P)CBDFP<'N)%93WI\R6PN6Y[5H>B
M1:)"EM ,)&H4< < 8&< #/'I66YH7Z!G%?$SX6V_CN()+E9%SL==H89QGDJQ
MZ#'%4G8EJYYU_P *C\0F/[,;]/)_O>;<>=C.?O8Q[=.G%7S(BS.PT7X,Q:!I
M\ME;'][*I#2/@DG# $D*">O?-3S797+8D^$'PTF\$V#V<[H[L204W;?N!>X!
MZBB3N$589\+/AE/X0GNIIG1A//-(H7=D!V5@#D#GCG%#=P2L0_#7X5S^%=0N
M[Z5XV2X "A=VX?.S<Y4#H>Q-#=T"5CJ_B)X9?Q/8RV<3*KR;,%L[1M=6.< G
MH*E.Q35S"\*?#F;1]$327=#*L<BEANV99G8=0#_%Z53>MR4M+$GPJ^'3^$[#
M[#=,DF5VMMR5((P1\P'\J3=V-*QQNH_ >\T:X>XT.Y\@2,S-&[NL>6;)PL2J
M!T4#V&/2JYNY/+V)=!^!-S?7*7FM7'GM&0517=HL\]5E4^IZ&AR[!R]RQ\2O
M@0^MW(U#39OL]T !N#&-<!0@QY:[ONY[]_2A2!Q*J?"#5];'EZG??N_2WEF7
M/UW@@\@?AFCF069I?"OX-S>!9;@!XS!*24 W;Q\N!GY5'7TH<KC4;$GPU^$=
MQX5U*ZOY9(V2<RE57=N&]T89RH'\/8TG*Z!*S/5J@L* "@ H * "@ H * "@
M H QO$?B--'3)Y<C@?@<'J.,BO/Q6*5"/GT7W_Y'=AL,ZS\NK/++FYEUN7NS
M$\#D_AWKXB<Y8B?5M[(^QC&-"/9(])\*>$UTE=[@&0]^#CZ9&1UYK[#!X-45
M=ZR_+\#Y3%XMUG9:+^O,Z.O7/+"@ H * "@ H * "@ H * /(_C_ /!VX^)
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MXH_Z"4?_ ']NJGF0[,]B\!Z/=:3;+%?2B688RX+L#\H!Y?GJ":S9HCHJ0PH
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M@\#[Y=S2W,A)DE<AV);:6^8J&QN7/)/)SUJ7*Y:5BCX;^%D^EZO-J;NACD0
M*-V\?.6YRN.A]:&]+"2U.Y\4:2VKVSP(0&;;@G..&![9]*E%,YOX.^ I? ]@
MEG.R.Z[LE,[>7=OX@#T:G)W%%6.YJ2@H * "@ H * "@#C_&/C$60,41RYX)
M';J.Q!!R*\#'8[V:Y([_ );^9[F#P?/[TMOSV.,T/0I?$$F!GD\L<\?CS7SN
M'P\L3+\V>]7KQP\?R1[-HFAQZ0@2,?4X&3^( ]:_0\/AXT(\J^\^#KUW6E=_
M<:%=9RA0 4 ?GC\4U_XFU]_U^W/_ *->D,Y<4"'"@8X4@*UZF15HDR328!0
M4 6J %H #0 E(8M !0 M !0 4 %  * %H *  4 +0![S^QI_R%YO^O&3_P!'
M04 ?95, H \V^,/6#_MI_P"R5\?G?V/^WO\ VT^KR?[?_;OZC?A;_JY?]Y?Y
M5.4?#+U7Y#S3XH^C.XKZ4^?"@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#PO4OV>+G7+G??7ADM
M<D^4"X/(XZDC[P!Z=JUYK&?*>X6]NMNH5  !T X%9&A)0 4 % !0 4 % !0
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M]C&,:$>R2/2?"GA1=*4._,A'Y=./K7V&#P:HJ[W?X'RN+Q;K.RV.CKUSR@H
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MYNUZAYP4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * ,?Q'XB31TR>6/0<_P"!KS\5B50C?KT7])G=AL.ZS\NIY5<7,FM2
MY/+,?;O^0KX>4Y8B?=MGV,8QH1\D>E>$_"BZ2N]^9".?;IQU(ZCK7V.#P:H*
M[^)_AMIN^Q\IB\6ZSLME_P 'R.CKUSRPH * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MZP#:HP!7V\8J*LCXZ4G)W9)5DA0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!R
MOB_Q@-,'E1<R'].A[@@Y'Y5X>-QOL?=C\7Y;>1[.#P?M?>>WY[^9YM:VSZBX
M5>6/^>]?(0@ZLK+5L^JE)4HW>B1ZMX9\,+HZ>KGJ?\DU]QA,(J"\^O\ 5V?&
MXK%.L_(W:],\X* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H Y#QCXP%B##%]\]3Z?F,5X&.QOL_<COU_JQ[>#P?M/>EM_7F<
M5H&A2:_+M'3.6/'3(SW'K7SF&P\L3.WWO^FCW\17CAXW^Y?U<]GT/1$TB,1H
M.PR?4X )YSZ=*_1,/AU0BHKY_<?!UZ[K2YG\C0KK.4* "@ H * /S[^*"YU6
M^_Z_;G_T:](9RACQ0 FR@!&&* &L,BF@,BZ7!IDD%(84 6J!!0 M Q*0"B@
MH * %H * "@!: "@ H * %H ]Y_8T_Y"\W_7C)_Z.@H ^RJ8!0!YM\8>L'_;
M3_V2OC\[^Q_V]_[:?5Y/]O\ [=_4;\+?]7+_ +R_RJ<H^&7JOR'FGQ1]&=Q7
MTI\^% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 (3B@
M#B/&7C+R<PPGGN?3]*^:QV.Y?<COU9]#@\'S>]+;HCD-"T!]9? Z=S^?^%>!
MA\.Z\K+YL]NOB%0C?[D>MZ7I:::@CC&!_P#7)_K7WE&BJ4>5'Q56JZKNRY70
M8!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!C^(O$::.F3RQZ#\1_C7GXG%*@
MK]>B^X[L/AG6?EW/*KBXEUF7)^9B?_K=J^'E*6(E?=L^RC&-"/9(]*\)^%%T
MA=S<R$<^WMUQ7V.#P:H*[^(^3Q>+=9V6QT=>N>6% !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % %+5M633$+N?H.]<U:LJ,>9G12I.J[(\DU[77UF3<W3^$>GMT
MKX3$8AUY7?R1]K0H*C&R^;.E\%^#O-Q/,.."H_(@]:]? X&_OR^2^YGDXW&6
M]R/S?WH]"5=HP*^L2L?,/46F 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M-WHD>K>&?#*Z.OJYZG\_?TK[C"814%Y]6?&8G%.L_(W*],\\* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M_P $\K^S:GE]_P#P _X63:_[?_?(_P :/[4I_P![[O\ @A_9M3R^_P#X ?\
M"R;7_;_[Y'^-']J4_P"]]W_!#^S:GE]__ #_ (63:_[?_?(_QH_M2G_>^[_@
MA_9M3R^__@!_PLFU_P!O_OD?XT?VI3_O?=_P0_LVIY??_P  /^%DVO\ M_\
M?(_QH_M2G_>^[_@A_9M3R^__ ( ?\+)M?]O_ +Y'^-']J4_[WW?\$/[-J>7W
M_P# #_A9-K_M_P#?(_QH_M2G_>^[_@A_9M3R^_\ X ?\+)M?]O\ [Y'^-']J
M4_[WW?\ !#^S:GE]_P#P _X63:_[?_?(_P :/[4I_P![[O\ @A_9M3R^_P#X
M ?\ "R;7_;_[Y'^-']J4_P"]]W_!#^S:GE]__ #_ (63:_[?_?(_QH_M2G_>
M^[_@A_9M3R^__@!_PLFU_P!O_OD?XT?VI3_O?=_P0_LVIY??_P  /^%DVO\
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M$/[-J>7W_P# #_A9-K_M_P#?(_QH_M2G_>^[_@A_9M3R^_\ X ?\+)M?]O\
M[Y'^-']J4_[WW?\ !#^S:GE]_P#P _X63:_[?_?(_P :/[4I_P![[O\ @A_9
MM3R^_P#X ?\ "R;7_;_[Y'^-']J4_P"]]W_!#^S:GE]__ #_ (63:_[?_?(_
MQH_M2G_>^[_@A_9M3R^__@!_PLFU_P!O_OD?XT?VI3_O?=_P0_LVIY??_P
M/^%DVO\ M_\ ?(_QH_M2G_>^[_@A_9M3R^__ ( ?\+)M?]O_ +Y'^-']J4_[
MWW?\$/[-J>7W_P# #_A9-K_M_P#?(_QH_M2G_>^[_@A_9M3R^_\ X ?\+)M?
M]O\ [Y'^-']J4_[WW?\ !#^S:GE]_P#P _X63:_[?_?(_P :/[4I_P![[O\
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M^-']J4_[WW?\$/[-J>7W_P# #_A9-K_M_P#?(_QH_M2G_>^[_@A_9M3R^_\
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M^[_@A_9M3R^__@!_PLFU_P!O_OD?XT?VI3_O?=_P0_LVIY??_P  /^%DVO\
MM_\ ?(_QH_M2G_>^[_@A_9M3R^__ ( ?\+)M?]O_ +Y'^-']J4_[WW?\$/[-
MJ>7W_P# #_A9-K_M_P#?(_QH_M2G_>^[_@A_9M3R^_\ X ?\+)M?]O\ [Y'^
M-']J4_[WW?\ !#^S:GE]_P#P _X63:_[?_?(_P :/[4I_P![[O\ @A_9M3R^
M_P#X ?\ "R;7_;_[Y'^-']J4_P"]]W_!#^S:GE]__ #_ (63:_[?_?(_QH_M
M2G_>^[_@A_9M3R^__@!_PLFU_P!O_OD?XT?VI3_O?=_P0_LVIY??_P  /^%D
MVO\ M_\ ?(_QH_M2G_>^[_@A_9M3R^__ ( ?\+)M?]O_ +Y'^-']J4_[WW?\
M$/[-J>7W_P# #_A9-K_M_P#?(_QH_M2G_>^[_@A_9M3R^_\ X ?\+)M?]O\
M[Y'^-']J4_[WW?\ !#^S:GE]_P#P _X63:_[?_?(_P :/[4I_P![[O\ @A_9
MM3R^_P#X ?\ "R;7_;_[Y'^-']J4_P"]]W_!#^S:GE]__ #_ (63:_[?_?(_
MQH_M2G_>^[_@A_9M3R^__@!_PLFU_P!O_OD?XT?VI3_O?=_P0_LVIY??_P
M/^%DVO\ M_\ ?(_QH_M2G_>^[_@A_9M3R^__ ( ?\+)M?]O_ +Y'^-']J4_[
MWW?\$/[-J>7W_P# #_A9-K_M_P#?(_QH_M2G_>^[_@A_9M3R^_\ X ?\+)M?
M]O\ [Y'^-']J4_[WW?\ !#^S:GE]_P#P _X63:_[?_?(_P :/[4I_P![[O\
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M^-']J4_[WW?\$/[-J>7W_P# #_A9-K_M_P#?(_QH_M2G_>^[_@A_9M3R^_\
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M/\:/[4I_WON_X(?V;4\OO_X ?\+)M?\ ;_[Y'^-']J4_[WW?\$/[-J>7W_\
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M_"R;7_;_ .^1_C1_:E/^]]W_  0_LVIY??\ \ /^%DVO^W_WR/\ &C^U*?\
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M*?\ >^[_ ((?V;4\OO\ ^ '_  LFU_V_^^1_C1_:E/\ O?=_P0_LVIY??_P
M_P"%DVO^W_WR/\:/[4I_WON_X(?V;4\OO_X ?\+)M?\ ;_[Y'^-']J4_[WW?
M\$/[-J>7W_\  #_A9-K_ +?_ 'R/\:/[4I_WON_X(?V;4\OO_P" '_"R;7_;
M_P"^1_C1_:E/^]]W_!#^S:GE]_\ P _X63:_[?\ WR/\:/[4I_WON_X(?V;4
M\OO_ . '_"R;7_;_ .^1_C1_:E/^]]W_  0_LVIY??\ \ /^%DVO^W_WR/\
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M^[_@A_9M3R^__@!_PLFU_P!O_OD?XT?VI3_O?=_P0_LVIY??_P  /^%DVO\
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M$/[-J>7W_P# #_A9-K_M_P#?(_QH_M2G_>^[_@A_9M3R^_\ X ?\+)M?]O\
M[Y'^-']J4_[WW?\ !#^S:GE]_P#P _X63:_[?_?(_P :/[4I_P![[O\ @A_9
MM3R^_P#X ?\ "R;7_;_[Y'^-']J4_P"]]W_!#^S:GE]__ #_ (63:_[?_?(_
MQH_M2G_>^[_@A_9M3R^__@!_PLFU_P!O_OD?XT?VI3_O?=_P0_LVIY??_P
M/^%DVO\ M_\ ?(_QH_M2G_>^[_@A_9M3R^__ ( ?\+)M?]O_ +Y'^-']J4_[
MWW?\$/[-J>7W_P# #_A9-K_M_P#?(_QH_M2G_>^[_@A_9M3R^_\ X ?\+)M?
M]O\ [Y'^-']J4_[WW?\ !#^S:GE]_P#P _X63:_[?_?(_P :/[4I_P![[O\
M@A_9M3R^_P#X ?\ "R;7_;_[Y'^-']J4_P"]]W_!#^S:GE]__ #_ (63:_[?
M_?(_QH_M2G_>^[_@A_9M3R^__@!_PLFU_P!O_OD?XT?VI3_O?=_P0_LVIY??
M_P  /^%DVO\ M_\ ?(_QH_M2G_>^[_@A_9M3R^__ ( ?\+)M?]O_ +Y'^-']
MJ4_[WW?\$/[-J>7W_P# #_A9-K_M_P#?(_QH_M2G_>^[_@A_9M3R^_\ X ?\
M+)M?]O\ [Y'^-']J4_[WW?\ !#^S:GE]_P#P _X63:_[?_?(_P :/[4I_P![
M[O\ @A_9M3R^_P#X ?\ "R;7_;_[Y'^-']J4_P"]]W_!#^S:GE]__ #_ (63
M:_[?_?(_QH_M2G_>^[_@A_9M3R^__@!_PLFU_P!O_OD?XT?VI3_O?=_P0_LV
MIY??_P  /^%DVO\ M_\ ?(_QH_M2G_>^[_@A_9M3R^__ ( ?\+)M?]O_ +Y'
M^-']J4_[WW?\$/[-J>7W_P# #_A9-K_M_P#?(_QH_M2G_>^[_@A_9M3R^_\
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M-K_M_P#?(_QH_M2G_>^[_@A_9M3R^_\ X ?\+)M?]O\ [Y'^-']J4_[WW?\
M!#^S:GE]_P#P _X63:_[?_?(_P :/[4I_P![[O\ @A_9M3R^_P#X ?\ "R;7
M_;_[Y'^-']J4_P"]]W_!#^S:GE]__ #_ (63:_[?_?(_QH_M2G_>^[_@A_9M
M3R^__@!_PLFU_P!O_OD?XT?VI3_O?=_P0_LVIY??_P  /^%DVO\ M_\ ?(_Q
MH_M2G_>^[_@A_9M3R^__ ( ?\+)M?]O_ +Y'^-']J4_[WW?\$/[-J>7W_P#
M#_A9-K_M_P#?(_QH_M2G_>^[_@A_9M3R^_\ X ?\+)M?]O\ [Y'^-']J4_[W
MW?\ !#^S:GE]_P#P _X63:_[?_?(_P :/[4I_P![[O\ @A_9M3R^_P#X ?\
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M]^/\V_\ B:/[&J=X_>__ )$/[7AVE]R_S#_A4ES_ 'X_S;_XFC^QJG>/WO\
M^1#^UX=I?<O\P_X5)<_WX_S;_P")H_L:IWC][_\ D0_M>':7W+_,/^%27/\
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M=I?<O\P_X5)<_P!^/\V_^)H_L:IWC][_ /D0_M>':7W+_,/^%27/]^/\V_\
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M 'X_S;_XFC^QJG>/WO\ ^1#^UX=I?<O\P_X5)<_WX_S;_P")H_L:IWC][_\
MD0_M>':7W+_,/^%27/\ ?C_-O_B:/[&J=X_>_P#Y$/[7AVE]R_S#_A4ES_?C
M_-O_ (FC^QJG>/WO_P"1#^UX=I?<O\P_X5)<_P!^/\V_^)H_L:IWC][_ /D0
M_M>':7W+_,/^%27/]^/\V_\ B:/[&J=X_>__ )$/[7AVE]R_S#_A4ES_ 'X_
MS;_XFC^QJG>/WO\ ^1#^UX=I?<O\P_X5)<_WX_S;_P")H_L:IWC][_\ D0_M
M>':7W+_,/^%27/\ ?C_-O_B:/[&J=X_>_P#Y$/[7AVE]R_S#_A4ES_?C_-O_
M (FC^QJG>/WO_P"1#^UX=I?<O\P_X5)<_P!^/\V_^)H_L:IWC][_ /D0_M>'
M:7W+_,/^%27/]^/\V_\ B:/[&J=X_>__ )$/[7AVE]R_S#_A4ES_ 'X_S;_X
MFC^QJG>/WO\ ^1#^UX=I?<O\P_X5)<_WX_S;_P")H_L:IWC][_\ D0_M>':7
MW+_,/^%27/\ ?C_-O_B:/[&J=X_>_P#Y$/[7AVE]R_S#_A4ES_?C_-O_ (FC
M^QJG>/WO_P"1#^UX=I?<O\P_X5)<_P!^/\V_^)H_L:IWC][_ /D0_M>':7W+
M_,/^%27/]^/\V_\ B:/[&J=X_>__ )$/[7AVE]R_S#_A4ES_ 'X_S;_XFC^Q
MJG>/WO\ ^1#^UX=I?<O\P_X5)<_WX_S;_P")H_L:IWC][_\ D0_M>':7W+_,
M/^%27/\ ?C_-O_B:/[&J=X_>_P#Y$/[7AVE]R_S#_A4ES_?C_-O_ (FC^QJG
M>/WO_P"1#^UX=I?<O\P_X5)<_P!^/\V_^)H_L:IWC][_ /D0_M>':7W+_,/^
M%27/]^/\V_\ B:/[&J=X_>__ )$/[7AVE]R_S#_A4ES_ 'X_S;_XFC^QJG>/
MWO\ ^1#^UX=I?<O\P_X5)<_WX_S;_P")H_L:IWC][_\ D0_M>':7W+_,/^%2
M7/\ ?C_-O_B:/[&J=X_>_P#Y$/[7AVE]R_S#_A4ES_?C_-O_ (FC^QJG>/WO
M_P"1#^UX=I?<O\P_X5)<_P!^/\V_^)H_L:IWC][_ /D0_M>':7W+_,/^%27/
M]^/\V_\ B:/[&J=X_>__ )$/[7AVE]R_S#_A4ES_ 'X_S;_XFC^QJG>/WO\
M^1#^UX=I?<O\P_X5)<_WX_S;_P")H_L:IWC][_\ D0_M>':7W+_,/^%27/\
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M=I?<O\P_X5)<_P!^/\V_^)H_L:IWC][_ /D0_M>':7W+_,/^%27/]^/\V_\
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M 'X_S;_XFC^QJG>/WO\ ^1#^UX=I?<O\P_X5)<_WX_S;_P")H_L:IWC][_\
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M]^/\V_\ B:/[&J=X_>__ )$/[7AVE]R_S#_A4ES_ 'X_S;_XFC^QJG>/WO\
M^1#^UX=I?<O\P_X5)<_WX_S;_P")H_L:IWC][_\ D0_M>':7W+_,/^%27/\
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M=I?<O\P_X5)<_P!^/\V_^)H_L:IWC][_ /D0_M>':7W+_,/^%27/]^/\V_\
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M 'X_S;_XFC^QJG>/WO\ ^1#^UX=I?<O\P_X5)<_WX_S;_P")H_L:IWC][_\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?GQ\3A_P 3
M6^_Z_;G_ -&O2*.:H ,4@%ZT" )0,9(PH B Q4C T 9=:&84#%H ,4@"@!:
M"@ H * "@ - !0 4 ** &M)BF(]X_8P;.KS?]>,G_HZ"@#[.H&% !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 ?GU\3A_Q-;[_ *_;G_T:]24<Q3 7&: %)VT@('GW<"@!
M,8J1A0 4 419-6IE<7["U [A]B8=J N(;9O2D WR6':@8A0CM0 W% !0 4
MI !H ,T +0 (OF' IB)C8BF(]S_8TA\K6)Q_TX2?^CH*!H^RZ0PH * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@#\^_B:?^)K??]?MS_P"C7J2CF<4 ,EG$5 BF93.?:D,F
M1-M(8Z@!* "@!PDVUJ9B*2>: )8F(H"X_I0 QI">*0Q_E>M $<@!Z 4 *MN'
MZ@4 120(>U ##:(?7]* &G3U/0T ,;33V(_S^% $4E@_^<T ,$;H,;<?A3$-
M$Y3L:!'N_P"QF^[5YO\ KPD_]'04 C[,I%!0 4 >2?&SQ9=:'+"MM*T89&)
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ME/6%H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % "@[>12 ]E^%OQ7Q
MBUO6_P!V1C]3ABS=. !@5RU*?5'K8?$?9?WGLX.:Y3UPH * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H _-KXKC.KW_P#U_P!U_P"CGH$8-K;9YJ2C01-M24-DDQ3$-23- $H.
M:0Q: $- # >:T()XAGFF22XS04*S8I"*[7'84#&P)MH ?<3]NM #(D[F@ 9J
M %5N,4 $?% #XSS0!*.:!D;'<<TA#NM,H]O_ &0O^0K-_P!>4G_HV&@1]>4"
M"@ H \._:'_UUO\ ]<W_ /0A771ZGC8W=>AY'74>6% !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 H..E(#V7X6?%?I:WC?[KD_[Q.XDDGL
M!7+4I]4>MA\1]E_>>S@YKE/7"@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 *K
M%3D4@/9?A5\5,;;2[/LC'^1X)))/6N6I3ZH];#XC[+/9P<URGKA0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 ?GE\38\:M??]?UU_P"CGK-EG,NV* *SMNJB1\:4ADX&*0PH 2@
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M/K0 )$7Z GZ4 .^S-_=/Y&@+#",4Q"4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 JMMY%(#V7X4?%/&VRNCZ+&W_?*JF%7Z
MG)/UKEJ4^J/6P^(^R_D>S*V[D5RGKBT % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M< _>8]/QK.$TD=-:A*4KJWWG*WOPCO;-#(_E[5&3B136BJ)G,\-)*^GWG5?
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M-=4=CR:GQ/U9F51F% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 *#MYI >R_"GXIXVV=V?0(Q_ !3T   ZURU*?5'K8?$?9?
MR/9D<.,CD&N4]<6@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M#^8S0!+0 4 % !0 4 !.* .>MO'MG=W/V.*19)>X1D8#@GG#$CH>U '0T %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &?XCU(Z7;37"@%HX9' /0E5+
M'VXH \0^ ?[15W\2+Y[.XABC1;=Y 4W[LAXUQ\S$8PYH ]_H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#\[/B@F=6O_\
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M=<:P(_,2(-'(CA@K!R5S@$ECD<\BH4$C:==RM>VC*>I>.I]0N8[QPGF1*H4
M';A22,C<3W]134;*Q,JKE)2TT*'B/Q#)X@E,\H4,0!\H(''U)JHJVAG.;F[L
MMCQG-]C_ +.PGE9ZX._[^_KG'7VZ5/+K<OVKY>3I_P &YV&D#4O"]LLD.R>&
M3D*1)(JX)'3*@<Y-9NTGV.J/-3C=6:?JSJ/!/B"[O1+/=(L,"0R?*JLBDX!!
MP21TS6<DEHCII3D[MZ*S\CQ;7;@7-Q*Z]&E<CZ%B174MCR)N[;\RC5$!0 4
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M7OV@M3\ :C]G,4+6K!=K;)"Y^12>?,53AF].E 'OZ:JDL)N%.4"LV?IG/\J
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M.P.!O8]<]: /5* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MZ]#R.NH\L* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .GT+
MXBW6BIY494KZ.NX?J?>LW!,Z85G!6_,76OB/=ZNGE.553U"+LSU'8^]"@D$J
M[DK?D<O6AS!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M/>;Y0B. X;".#D,0#A,D<\8H ]/\>67B_P <0?9KRQ!3(.52-6&#G@[SCWH
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MY\$>1#)J$H^=FPA/=2JD_J* /-?CE )_$D:,,@R*"/8SR4 ?56O:1$VBF':
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MUUW1]9CO+FT>..28M,PV! "2QX#=,]J /L:@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * /SS^*'_(6OO\ K^NO_1KUF6<Q0 4 % !0 &F E( Q0!.Y(YK0S(F.
M[Z4#)81BF(24TBB)1BD!83BF(AD&30 !:!D@..M( .&H 3&V@!TB9H D5>*8
MB-GH&+'&&'- CVC]CB/R]5G'_3D__HV&@#[#H * "@#P[]H?_76__7-__0A7
M71ZGC8W=>AY'74>6% &CX?T9M:G2W3AG.!^1/<CTJ6[*YI"/.['JT_A+0_#F
M(+]R9A]X@3#KR.$W#H1WKFYI2V_0]-TZ<-);_,@U?X;6&N0&XTEL! 2P(<Y_
M[^%<=#34VG9DRH1FKP_7]3DOA]X*77?,EF/[N-6)'/. #C@@]*TG*QRT:7/=
MO9'+ZM&B32"(80.VT<],G'7GI6B.>6[L5MA]*9 VF [8:0"$8I@=]X/\(V^H
M:=<W<RDO&)0AR1AA&&7@'GGUK"4K-([J=-2@Y/I>WW' [#6QP@!F@!*8&QX5
MT3^U[A(3P"1GZ9&1U%1)V1K3CS.QK?$S1+?1KKR;52J@'(R6YR1WJ8.ZU-:\
M5&5D<GL/I6ARC:8"A2:0 1B@ "DT !&*8 !F@ *D4@$ S3 =L/I2 0#-, (Q
M0 $8I +L- "$8I@)0!Z;\-/!UEJ-K)=WX.R-G!(+C  4YPAR>I[5SSDT[(]&
MA2C*+E+H:OD>&/[Q_P#)G_"I][^K&MJ7]<QB>,8]#6W;[ 29^-O^N_O+G[XQ
M]W-7'FOK^AA5]G;W=_G^IYSM-;' !7% '3^#8K B1K\GA&V >9RWR[>4!]^O
M%1*_0Z:7+KS?+?\ 0YVZ"L[>7]W<=O7IGC]*LYWN:/A;21JES' _1B?T4GV]
M*F3LC2G'FDD:_P 3M'MM&NVMK52H3&<LS=45AU^IJ8-M79K7BHRLCD]A]*T.
M4;3 7::0!M- !L-  %)H ? H+ -P,C/TSS0-'3>+4T^.*(663)L3S#^\'.#N
M&'&.N.GX5G&_4Z*G+9<N_7<Y;8:T.8]#\.^$[4Z9)?W"EF7;CYF7'[S8>A_I
M6+D^:QWPIKD<G_6MC&1-.2PW')O,CC]X!]XY[;/NX_\ UU6M_(R]WD_O?,Y4
M*36AR@1BF E %[1=(?6)5@B&7;..G8$]R!VJ6[%QCS.R.VUKPM:+.NG6ZDS#
M)>3<V.@?[I./NY'!]_:LE)VN=DJ<;\BW[_B/O/#-C;^;.5(AB^0#+G>S#*MG
MJN#Q@CFES/8;IQ5WT7KJ1> ?A_%K"/>W1VV\>2PY)VJ QY4[ONY[4YSMHMR:
M-%23D]D=+;:?X:NF"(Q+,< ?Z0.?Q%9WE_5CI4:3T_S.)^(7@ ^%V5U;=%(3
ML.,8'7'WB> >IK:$^8XZU'V?HSMM,\":7I%G'-J>0[;LMF3GYL#A">Q%8N3;
MT.N-*$8IR_7]"+R/#']X_P#DS_A3][^K!:E_7,8.JVNCW%U#%:9,3%0[9EZE
ML;<, >1W%6N:VIA)0<DEM\SI)/!>DB:2(*<K"SA=TO9L Y_I6?,SH]E"[7EY
MG-77A&VNM/DNX4*/'+(#\S-E00!U( ZUIS.]CG=-.#DNC9YY6YP!0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % #D0N<#K2 ]X^%OPM&F 7-T,R'[J_W?O ]&(.00?:N.<[Z
M(]O#X?EU>YZG7.>D% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MPS[R23EO*8?WF_0T >"?L5(5U6?(_P"7%_\ T;#0!]>^)--.IV\D*\%UP/\
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M@C)8-GY7(Y!Z$#% 'TI0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M?P;EB&^R=9TV@DY52/;&XGT_.A5.X2PS^SJ<W>ZC=ZPT=E<,2$)"J5 QQCL
M3P*M)+4YW*4K1?0]O\:^!XO$,<,3SB$1@\84YW;3W8>GZUR1E8]FK24TE>UC
MD#\#;4?\OH_[Y7_XNM?:OL<GU1?S?U]YY]OC\,7CC:)Q&2$.2OS @J_&>A[<
M@UM\2.'2G+O;863QDYCF55VR3R.TDF<DHXYCP1C&><C![4<H>UT?=MW?KT.X
M^'<'VK2[B-OND'^:UE/XD=M%7@T>42KM)'H370>8,IB"@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@!\,)F(51DGM2&E<]W^%GPO&F@75R,R'E1Z>_!]#W%<=2=]#VL/0Y?>>YZG
M7.>D% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Y'\;OC
M!=> 3&EM:FX\W?R"PV[0A[(W7=W]* /'/@)\,KSQ+J7]K7ZD)SG< I)VE5X&
MT_PCM0!]?T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 ?GE\4/^0M??]?UU_Z->H*.9I#"@ H 0T %
M !0 4 /+;>:T('[1+S0 PS"/BF(5COI#'H,4# OQ0 P<T !H ,T@%+4 ,Q0
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M[SW/5 ,5SGI!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M#GK2;LBH0YW8['XG>(458]/@;*Q* Q!&"P&U@<'U'H*R@NIUUY[170\[K<X
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@"2"!IV"J,DD  <FD-*Y[K\+?A8-. NKH9D."JD?=^Z02
M&4$,".QKCG4OHCVL/A^7WGN>J 8KG/2"@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M?"_X6C3@+FZ7,AZ*1T^H(Z\5QSG?1'M4,/RZO<]4 Q7.>D% !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0!^>'Q./_ !-K[_K^NO\ T<]04<\* "@8F* "@!,4 % "9H <DFTU9!-D
M&@0T'L: &9QQ0,"*8A$8KTI#)PP>@ VTA@8<T (+<4 .P%I@0ELTADB1]Z8A
MDUP 0*!#&C+&@#W?]D- NJS>OV*3_P!&PT#/KJ@04 % 'AW[0_\ KK?_ *YO
M_P"A"NNCU/&QNZ]#R.NH\L* "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@!R(7.!2 ]X^%WPL&F 7-T,R'HO]W[P/0D'(P?:N.<[Z(]NAA^7
M5[GJ8&*YST@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M4\;&[KT/(ZZCRPH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M?%$93M49)I#W/=_A9\+AI@%U<C,A^Z/[O49X;!R#W'%<<YWT/:P^'Y?>>YZG
M7.>D% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MZ5T4YJ)YV)HNHU8X'_A1FH^D?_??_P!:MO:HX?JDO+[P_P"%&:CZ1_\ ??\
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MFH^D?_??_P!:CVJ#ZI+R^\/^%&:CZ1_]]_\ UJ/:H/JDO+[P_P"%&:CZ1_\
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MH^D?_??_ -:CVJ#ZI+R^\/\ A1FH^D?_ 'W_ /6H]J@^J2\OO#_A1FH^D?\
MWW_]:CVJ#ZI+R^\/^%&:CZ1_]]__ %J/:H/JDO+[P_X49J/I'_WW_P#6H]J@
M^J2\OO#_ (49J/I'_P!]_P#UJ/:H/JDO+[P_X49J/I'_ -]__6H]J@^J2\OO
M#_A1FH^D?_??_P!:CVJ#ZI+R^\/^%&:CZ1_]]_\ UJ/:H/JDO+[P_P"%&:CZ
M1_\ ??\ ]:CVJ#ZI+R^\[WX<?"7^Q#Y]U@R@_* <@>^>*QG4OL=U##\FKW/3
M@,5SGHA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?GK\3_\ D*WW_7[<_P#HUZ@HYF@
MH&(30!%(] B'&ZF!,B4@'T -9,U9!&AV=* )Q<9ZT .:X4#- %*74CT6@"H\
MADZF@9'L% "[: %Z4@"@!PH 2@!*8$F: $)H ]Z_8P_Y"\W_ %XR?^CH* /L
MV@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@#\]/B?\ \A6^_P"OVY_]&O4%G,T !.*
M(9)*8B(?-0!,B8I /H *!D;7:BK(*\E[Z"@")[@M0(C9B>]  !2 ;3&)0 M
M!0 4 **0 : $%,!XH 4B@#WG]C#_ )"\W_7A)_Z.@H ^S: "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * /SO^*DF-6OO^OZZ_]&O4E')#YJ!$Z1TADE !0 E
MQ*!!0!EXJR1*!"B@ - R3M0!&:0""@ -, Q0 E(!PH * !: 'F@!* />OV,O
M^0O-_P!>,G_HZ"@#[,I@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?G5\4ANU:__P"O
MZZ_]'/4C.>CCQ2&24#"@04 )0 E !0!EU9(4 "B@!6%(!YH 8: $H *8!0 8
MI *!0 8H %H <: "@#WG]C+_ )"\W_7C)_Z.@H ^S*8!0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % 'YX?$Y/^)M??]?UU_Z.>I*.=Z4AB4 % A#0 4 )0,*!&95DB4 *
M* %:D XT ,- "4 % !3 6D X"@!"* $7B@!30 HH ]Z_8S_Y"\W_ %XR?^CH
M* /LNF 4 % 'G'Q5^(UQX2DB2!8R'5B=X8G@@<89:WIP4CS\17=-JUOF<+_P
MO^__ +D'_?+_ /QRMO9+S./ZY+R_'_,/^%_W_P#<@_[Y?_XY1[)>8?7)>7X_
MYA_PO^__ +D'_?+_ /QRCV2\P^N2\OQ_S#_A?]__ '(/^^7_ /CE'LEYA]<E
MY?C_ )A_PO\ O_[D'_?+_P#QRCV2\P^N2\OQ_P P_P"%_P!__<@_[Y?_ ..4
M>R7F'UR7E^/^8?\ "_[_ /N0?]\O_P#'*/9+S#ZY+R_'_,/^%_W_ /<@_P"^
M7_\ CE'LEYA]<EY?C_F'_"_[_P#N0?\ ?+__ !RCV2\P^N2\OQ_S#_A?]_\
MW(/^^7_^.4>R7F'UR7E^/^8?\+_O_P"Y!_WR_P#\<H]DO,/KDO+\?\P_X7_?
M_P!R#_OE_P#XY1[)>8?7)>7X_P"8?\+_ +_^Y!_WR_\ \<H]DO,/KDO+\?\
M,/\ A?\ ?_W(/^^7_P#CE'LEYA]<EY?C_F'_  O^_P#[D'_?+_\ QRCV2\P^
MN2\OQ_S#_A?]_P#W(/\ OE__ (Y1[)>8?7)>7X_YA_PO^_\ [D'_ 'R__P <
MH]DO,/KDO+\?\P_X7_?_ -R#_OE__CE'LEYA]<EY?C_F'_"_[_\ N0?]\O\
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MKDO+\?\ ,/\ A?\ ?_W(/^^7_P#CE'LEYA]<EY?C_F'_  O^_P#[D'_?+_\
MQRCV2\P^N2\OQ_S#_A?]_P#W(/\ OE__ (Y1[)>8?7)>7X_YA_PO^_\ [D'_
M 'R__P <H]DO,/KDO+\?\SN?AU\6QX@/DW6U)2?EQ\JG[H &6)+9)_"L9T[;
M'91Q//H]STBL#T H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /ST
M^)__ "%;[_K]NO\ T:]04<P:!A0(* $)H 2@ H * ,RK)"@!: $-(!YH 8:
M$H * %I@%("04 )B@! *  T  H ]Z_8S_P"0O-_UXR?^CH* /LNF 4 % 'AW
M[0_^NM_^N;_^A"NNCU/&QNZ]#R.NH\L* "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M)+>X:W8.A(8'((X-(:=CWKX6_% :L!:W!Q*  I_O=@._/&2:XYPMJ>WAZ_-H
M]ST^N<]$* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /ST^*'_(5OO^
MOVY_]&O4%',4 % Q*  B@04 )0 4 9E62** %Q0 AI *: $- #: %H !0 4
M2"@!*  4 (: %H ]Y_8R_P"0O-_UXR?^CH* /LNF 4 % 'AW[0_^NM_^N;_^
MA"NNCU/&QNZ]#R.NH\L* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@!\,QA.Y3@C
MO2&G8]]^%OQ0&L 6MP<3#[I_O=3V7 P!W/-<<X6U/;P]?F]U[GIM<YZ(4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0!^>GQ0_Y"M]_P!?US_Z->H*.8)Q
M0!&[XI@(LE $@.:0"&@ H * ,VK)%% "T@&F@!QH :: $H 2@!U !0!(* $H
M 04 )0 Z@#WC]C/_ )"\W_7C)_Z.@H ^RZ8!0 4 >'?M#_ZZW_ZYO_Z$*ZZ/
M4\;&[KT/(ZZCRPH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@!R.4.12 ]]^&'
MQ3&L 6]T<3#HW][[Q/0 # P/>N.<+:H]RAB.;1[GIU<YZ(4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % 'YY_%#_ )"M]_U^W/\ Z->H*.5=Z8$).Z@"1$I
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M-T,.K,0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H ?#,82&4X(/%(:=CWOX7_%(:L!;71Q*.C$XW?4D]<G@"N.<+:H]NAB.;
M1[GI]<YZ(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M\YJSL0TQ!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 26]PUNP="0P(((X.12&G8]Z^%OQ2755%K='$H "L3@-]U0,LQ)<DGH.:XY
MPMJCV\/B.;W7N>GUSGHA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MJNQEA?B^7^1R7BK_ (^Y_P#KO+_Z&:UCLCEJ?$_5_F9=49A0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % $EO<-;L'0D,"""#@@C
MGM2&G8]Z^%OQ0&JJMK<G$H "G^]P !U)+=2:XYPMJ>WAZ_-H]ST^N<]$* "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M-^(NI)K%E$]ARL#*3C(VJJ'GG'3(Z40T=F*M[T%*.R?Y(E-S;>,+%7O?W7E
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M\*^!?$'BR+S[$3RQ_P!X3!>Y'\4@/8T ;7_"D_%?_/&X_P# A/\ X[0!]3?
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M1+F41ILA3< "02<;2#G />@#UN@ H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /SR^*'_ "%K[_K^NO\
MT:]04<QF@ H * $H&% "4""@"G%S5").M  %I )B@!Q% #=M !MH 3;0 NV@
M!K<4 0LU4(8!3$.VXH <H ZT@(WP* />OV+3_P 3>;_KPD_]'04 ?:% PH *
M /#OVA_]=;_]<W_]"%=='J>-C=UZ'D==1Y84 % !0 4 % !0 4 % !0 4 %
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M_=W<;JZ[ VNW#3"Y+_O1T;:O\L;>_I1]6TO?WN__  +V#^V5S<BC:D]X7O\
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MEK!<-UDAC<_5E#>@]: -*@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M2(N;H8C'13WZCGH?0US3G;1'I4,/S:O8]WCC$8P.@KC/;'4 % !0 4 % !0
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M &E0!\X?M>>.[G1XHK:W8H';YB,<@JW'(/I0!D?"C]GW3+JS74;^02!LE@V
MHY]0P[F@#S#]EL!?$5N!TQ<?^B9* /HCXR_"+3/',N7N8X;D<8WIN).."&88
M[=J /&]8^!VL?#:-[VQG411AG+;DW$*"QP"#DX7I0!ZM^S;\:I?&Z26M[R\4
M98R'H5&Q>> !R2: ,#QY^S9IWB>=Y=/NHQ*S$F)70\DY/\1/K0!YUKVDZ[\$
MRDGG 0MG:%9"3C .1M)',E 'I_CSQ;+\2_"S3JF)2\;,!DC D;IQSPM %3]B
MC6(HK6YMV8"1IPP4D9("*,_G0!=_;5U:)]/@MPP,@NT<KD9V^7,N<=>O% '%
M:?X<GM_!S[EZ32R=_NLJ8- '9_L::E&UK)#N&\8RN1GEG/2@#TWQK\=],\'3
MK:W3OYC'&$7?CA2,X/'WA0!Y-^U_?+?64$J9"L5(R,'[Q[4 6O!GB63P[X4>
M>'A_*8*?0_9\AOP(H \V^!WPQC^*DTEUJ,Q+*22,+S\P//(X^8T <5\>O#UI
MX?U1[>PVB%8X_NG(W;?F[GG- 'T[^U7_ ,@,_2+_ -&14 97[('S:;./]I1^
MCT > >*_#"ZKXBFL[EC$LEYLWX'&YPN><#'.?PH ]+\9_LQ:3X/@^U75_+Y9
MZ%8T8G@MP-W/ H Z+X;^#K1=&O&TJ::=9$VCS8O+Y#J3C!.: .2_8]U&.RO[
MB*1@K.4"@D#.U9B: /2/VPM1C33?)+#>S*0N1GAUSQUH F_8]_Y!LG_71?\
MT$4 >\T ?#'[1<"W&OA&&043(_X$] 'VUH:[;>(#_GDG_H(H ^'M=U2;XJ:W
M]DNI2D3'@<87$:DCG'4K0!TO[07PCT[P'9*+?!G+KST;&3GC<?Y4 >F?LPPQ
M7&A31W! B=F5RQPNTPH&R21QC- ''^)_V6;76I7ETFZ1R26\M6C(&23U#$]P
M* .,OO$6N_!29(YY5:,](PRD$8XSA<CK0![;\=?$8\1^%)[H# <P\?2Y1>_T
MH Y?]A[_ (][W_KK#_Z"U '*?MKN4U*U(ZBUR/\ OZ] 'T[\*9#)I%@QZFQM
M2?\ OTE '4T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M9^'8=-U!4N&=;A&.Q> IX8?Q8;ISQ2F[H=""C/7<7QYH-G>7NU))/-?[X^3
MPJXQWZ>M$&T@K0BY=;_(DUKX8Z?H3LMS.XS]P!H\GCG.X#OZ4*;8Y4(PW;\M
MC,T;X:PW :YN)?+M<X1BRJS<9'WAM/&>AJG/IU,XT$]6[(N)\-++5U8:?.6E
M4'"NR<X]D!.,D4N=K<KV$9?"]?.WZ&/X#^'RZ_/+;SED,8_AP.<D'[P/'%5.
M=E<RHT>=M/H;<OP]TNU?R);EA)ZAXM@[\DC/3]:CG?8V]C!.S>OJCFO$'@Y_
M"]W'&_*F1=IYYP5SV ZGM6BES(YYTO9R2\STSXE>&+.[G$M[,8^#M560,1GK
MAJYX2:6AZ->G%N\G;[CAO%GPXBLK87EE(98\@')#$?*6.=@P.,=^];1G=V9Q
M5*"4>:.J//ZW.$* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H 4#- 'J?PN^%AU$BYNEQ&.54@C=T/(*\J0>QK
MFG.VB/2P^'YM7L>[0PB$!5& !@"N,]I*P^@84 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % 'F/Q\^&MSX_LQ;6C1J_P#TT+*/OQM_"K=E/:@#
MYT_X8PUG_GI:_P#?R3_XS0 ?\,8:S_STM?\ OY)_\9H ^A_V=OAA=?#FPDM+
MQHV=[EI 8V9EVF.-1RRJ<Y0]O3F@"K\7?V>;7QX?.7]W/C[R[1GKP3M8]\T
M>$WW[%^JACY,MN4[;I)-WZ18H ]!\!?L>P:<PEU!_,8?P*5:,]>NZ,'T_&@#
MU_Q[X'.K:<VGV02/Y2$!RJ#@^@/<^E '!_L[?!:]^'7F?;&B;?NQY;,W79_>
M1?[IH ]NH Y#XM^$I?%VEW%A;E1+*BA2Y(7AU;D@$]!Z&@#@?V:_@O>_#3[7
M]M:)O/\ (V>6S-]SS=V=R+C[XQU[T >K>*_#<?B2V>UF 974]><'!P><]#0!
M\Y^ _P!F_6? ^HBZM);?R-X!#22;S'N4MPL8&<+TSB@#ZABS@;L9P,XZ9[T
M>??'#X?W'CFQ-K:E YSRY*KV]%8_I0!F_ 'X777P_M6M[MHV8]/+9F'WG/\
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MLT:[XF8#6;U98UZ8E=R,]?OQ8ZA?RH ^A?#/P^MO#]D-.C7=$%8'<!DY+'G
M _B/:@#PSQ%^RS=Z9<-=:#<"!F)P"YC"CT&R,\<"@"/0OV7;_6+E+C7[D3[2
M#A9#)D YVG?&..6S]: /H9_"MN]K]A*#R-@0K@8(  Z=.U 'SGJ?[+NIZ#<-
M-H-T(0QR2TC(WT^2(^I_"@#3\$?LO7#W0OM=F%Q*.2 QD4D# )WQ@\ +CZ4
M=?\ M!?"*Z^($"161B4J1_K&91U)_A5J +O@SX0O::*VD7Q0LT97<A+ $Q>7
MD%E'(YQQ0!Y#:?LNZWX=G8Z7=I%"V03YKK(1G.#MBQT _&@"'Q9^QU>W05[:
M='E))E,SGKQT*Q9/.>M 'O7C3X>/XSTHZ?=E1*P7YE/ VN&&"RD\A1GB@#QG
MP%^SQK_A2=1'=QI:^8C.B2R L >X\H ]Z .V^,W[.:>-)1>VC^5<CW"H3EFW
M$A&;.2/PH X!/V8]<UPI!JEXKVJ$;565V8 <# :+'W210!]'^#O!T'A:U2S@
M'R*!G@<G R3@#DXH \$\<?LKW,5U]LT*987))^9S'MR #MV1GKEL_6@#/\2?
MLO:OXCM]]W=B:[!&WS)6:,#/S<^5NZ ?C0!ZW\ _AK<^ +-K:[:-G9P1Y99A
MC;C^)5H ]-H ^;?BI^SIJ/BO51J%N\ B"J,.[A^"QZ",COZT ?16G6YMXT0]
M510?3@ 4 ?-_Q(_98N;R\-]H\J1,V.'<H%PJK\NR,]<$GF@"GJ?[+6I^(H3)
MJ-WYUV!A=TC-'[\F+=UQ0!Z!\'?@Y=>'M-GTO5#$Z3%\&,L^%:-8_P"-5&>O
M:@#@+[]F'5?#\[2:%=B%68_>D9#@DG'R1'VH ;:_LLZGXBE#ZY=^8!W21G;I
M_MQ?2@#V'XJ_#1_$6BRZ38;$9O*V;R53Y95D;.U2>@/;K0!@?LW_  AN_AM%
M<QWK1,97C9?+9F&%# YW(OK[T 87[1GP%O\ XCW<-Q9-"J1P;#YC.ISO9N-J
M-Q@T >R^!=%?0K"UM)2#)#;01L5)*[DC53@D XR..!]* -N@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H _/+XH?\A:^_P"OZZ_]&O4%'+YH 6@!* $H * "@!*
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M54HW5C*E52G=[%LR6&E:A#<P3AD+N7^]\N5/J/4]J6K5BO=C--/O<1?$UO\
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MM=;O\CSVMSA"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ ZT >J?"SX7G42+JY&(Q@J/7N#].*YJD[:'I8>AS>\]C
MW:"!8 %4  #  XKC/:2L/H&% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M;AYJ#=SBKIQ([$="Q(_.M3C9%3$% !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'J?PM^%QU,BZN1B,?='][
MJ.S9&".XYKFG.VAZ6'P_-[SV/>(HA$,*, 5QGM#J!A0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0!^>/Q1_P"0M??]?UU_Z->I*.8I % "4 % "4P%Q0 E(#&J
MR H * "@ H * "@ H 6@ H * $H * %H * /?OV+/^0O-_UX2?\ HZ"@#[1H
M&% !0!X=^T/_ *ZW_P"N;_\ H0KKH]3QL;NO0\CKJ/+"@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H  ,T >I_"_X6'4R+FZ&(^RG^+[P.>01V/O7-.I;1'I4,/S
M:O8]Y1 @P*XSVQ: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _/'XH?\
M(6OO^OZZ_P#1KU)1S!I )0 4 (QI@1EZ '*^: %H QZH@,T % !F@ H * "@
M H 6@ H 2@!<4 % !0 4 >_?L6?\A>;_ *\)/_1T% 'VC0,* "@#P[]H?_76
M_P#US?\ ]"%=='J>-C=UZ'D==1Y84 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 *!F
M@#U/X7_"TZB1<W2XC'12,9^H(Z8/:N:<[:(]*AA^;5['NT,0A 51@#I7&>UL
M/H&% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M_P *.==P]C+L_N#_ (0&_P#^?:;_ +]M_A1SKN'L9=G]P?\ " W_ /S[3?\
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M!_P@-_\ \^TW_?MO\*.==P]C+L_N#_A ;_\ Y]IO^_;?X4<Z[A[&79_<'_"
MW_\ S[3?]^V_PHYUW#V,NS^X/^$!O_\ GVF_[]M_A1SKN'L9=G]P?\(#?_\
M/M-_W[;_  HYUW#V,NS^X/\ A ;_ /Y]IO\ OVW^%'.NX>QEV?W!_P (#?\
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M%8SJ=CLH8>[O+[CW&"!8%"J     .!7&>RE8?0,* "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * /SP^*/_(6OO\ K^NO_1KU)1S- #2<4@(G>F P#-,1
M*JXI#'4 %("MN/I5"$W>U !D>E !\OI0 ;5]*+@'EKZ4!83RDH"P>0E%P$^S
M)1<0GV1?6G< ^R#UI7 /L0]:8"?8O>D ?83ZBF GV$^U 'O7[&-L8M7F)_Y\
M9/\ T=!0!]FT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?GA\4?^0M??\ 7]=?^C7J
M2CF"V* ('>@!JKNH$2JF* '4AA3 * &"=:8A?-6@!0ZT +E30 H H 78#0 G
MD@T 'D"D,/LX- !]E% "&U% !]D% !]CH /LE !]E]Z /=?V.X=FK3?]>,G_
M *.@IH3/L.F(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H _._P"*38U:^_Z_KK_T:]24
M<D\F: &*,T")U7% Q:0!0 4 )F@"+RA5DAY(H 3[.* #[.* #[,* #[.* %^
MS"@!/L] !Y'O0 [R3ZT 'E'UH -C#O0 N&]: %R_K2 7>XH ]V_8Z=CJTV?^
M?&3_ -'04P/L2@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * /SI^**9U>_P#^OZZ_]'/4C.=5,4#%I )0 M "4 % #:8"50@H *!"T %
M"T % !0 M !0 M !0 4 +F@ H ]T_8\_Y"TW_7C)_P"C8: /L*@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@#\[OB@O_$VO_P#K^NO_ $<]24<R:0!0 E  : "@ H ;
M0 VK)%H * %H * "@!: "@!: "@ H *!BT % A0:!GNG['G_ "%IO^O&3_T;
M#0(^PJ "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M)71?I%A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M>M:'+HLAAG7:XZC(/Z@D4)W%*#@[,H51 4 % !0 4 % !0 4 % !0 4 =9X
M\>2>%Y1WB8C<..A*Y/W2>@Z"LIPYCJHUG3?D?26AZW'K,2S1'((![\9 ..0/
M6N!JQ]!"2DKHOTBPH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M1WM@U\96#+"S[=HQPA;&<U+J6=C2.'3AS7Z'FU=!YX4 % !0 4 % !0 4 %
M!0 4 =9X"\>2>&)!WB)^9?RR>F>U93AS'51K.F_(^DM$UN/6(Q+$001^5<+5
MCZ"$U)71?J2PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * /SO^*7_(6OO^OZZ_\ 1KU)1RY% #<T@%!S0 &F E(
MH 2F @JB0H * %H 6@!* %H * "@!: "@ H 6@ H * /=OV//^0M-_UXR?\
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MJ-9TWY'TEHNN1:S&)86# ^A!(Y([$^E<+5CZ",U)71?J2PH * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 ?GA\4?^0M??]?UU_Z->I*.8'% !MH C9* & [: '9S2 2@
M!: &59(9H 6@ H 7- !0 4 +0 4 &: #- "T#"@09H 6@#W;]CK_ )"TW_7C
M)_Z.@H ^PZ "@"&]_P!6W^ZW\J:$]CXXKU#Y,* "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .L\!^/9/#,@
MY)C)Y6LIPYCJHUG3?D?26B:W'K,0FB.5(K@:L?00DI*Z+](L* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M $9MO)H %D#]#F@!: "@ H * "@ H *  MMZT (L@;H<T +0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MC6X+8XDE13Z%U'\S0 ^UU6&[XCD1O]UE;^1H M4 1W%RMLI:1@JCJ20!^9H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M$?.L1W>N?+?Z4 <G^Q3]R?\ WI/Y04 <Q^V7_P A!/\ KDG_ +-0!ZS\5_\
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M^1)O#=\DO=BTJ \=,>6K>^: /I[P?%=16L:W^TW 4;RI+*3]2!0!LT % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M "@ H * "@ H * /DS]N/_6V'^Y<?SBH Z2]TI]2\%VRQC)6$.>O11(3T!H
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MR5?MIZ7DJ<LL#$?]])]* .0\ :,OQ/UAX=3GD*^8^!O&?X^!O#],#\* -/\
M:D\*Z;X8:TMM."!U\_SMH0/SY31[M@'8G&1TZ4 >A3?\B1;_ .[_ .U9* (O
MV*(AY-PV!GS2,]\;8^* /5_VAO\ D#7/_7&3_P! :@#Q_P#8NE$0N68X 0<G
MI]Z@#6\7?!OP]X[N";&\C%P2<QQ2P@$@<_*L;-T4D_C0!YEXU\!:O\&0MQ'>
MC9GA$EER>0#D;4&,GUZ4 ?3GP,^($OC:P6XG7$@P&(! )QG(RS$T >B4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % 'YV_%+_D+7W_7]=?^CGI#.8%  : &XH :
MW%(8PF@!K4 *IH MU1(4 % "T %( Q3 44 &* #% "B@88H 7%( I@+0(,4
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MZ>FGHL40 50 , #H,=N_%<3=SW4N5618I%!0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 >,_M!? N?XGO;/!-'%Y*R@[PQSO*$8V_[M '=^ _!']@:7
M#IEP5D\N$QN0/E;.<\'V/>@#QSQ7^R?(;AKG1[DVI=B3\SK@$DD#RP,#[N![
M4 6_!'[+!LKA;O59_M4BD$99F!QV/F Y'7B@#IOCY\%)?B3%;16TJ1"!G/S@
MD$,%  VCMMH ZSX0^"'\#:9!ITKK(\7FY9<A3OE>08SST;% 'DOC#]F&ZUW6
MFU=+B)8VN(I=A#[L)MR.!C/RT >J?%SX91_$.S^R.=K!]ZMZ,%=1G@G&6Y%
M'EWPS_9NU'P?=QS-?;K>.0/Y*M*%.".H^Z>!B@ M?V9+J'6%U4W$6P2N^S#[
MN=W'3'>@#V+XA^%'\4V$ME&P1G"88YP-KJW;G^&@#@/@)\#9_AH9C/-'+YA4
MC8&&, CO]: (/VKH[:;2LS$!O,4IZD[9,#IZT >>?L8^"/,:75'&0-\(STR/
M)D!^O- 'U9-"LP*N 0>H(R#^!H ^?_&W[*@NYFN=*G-M(><[F4 \ X\L#'&?
MSH H:#^R;-<3++J]V;G:<CYW)_\ (@/' S]* /;]=\ 6FL69T]XU$.TA0 H
MX(!'&!C/84 >!W'[)U_ISD:7J!@B))V[Y0?QV8&< ?E0!M>"_P!E/['<+=ZI
M.;F1""/F9@?KO!R.M ';?&_X1R?$&UBMK>1(O+S]X$C!VX'R_P"[0!-\+_A)
M_P (OI8TN\9)A\V2H^4YD=QPP_VA^(H \OU+]DJYL)&;2+UK=3VWR!OQ* 4
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M->-?V4_M4YN=)N#;2$YSN88X ./+ QQN_.@#&M_V3;_46']IWYGC!Z;Y2?\
MQ_(H ^A?!_A&#PG;):6PPB #)QN/N2 ,F@#:H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * /SL^*1_XFU__ -?UU_Z.>D,Y?=2&)NH 4&@!"* &&@!N,T ."T 6
M*H0M !0 4 ** "@ H 4&@!: "@ % "T % "B@ H ]S_8_P#^0K-_UY2?^C8:
M!'U]0 4 0WO^K;_=;^5-">Q\<5ZA\F% !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '>_#3X</XB<2R<0J1S
MZ_D0>U83GRG=0H<[OT/HBPL$L$$<8PH& *XF[GNI65BQ2*"@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'YT_%,_\3:__P"OZZ_]'/4E'+T
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MSKB;N>^E;0FI#"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M(XQA1T'ZUQ-W/=2MH3TB@H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M6\L"C[L[\'<>-JC[@;^Z>]3"7+HRZ]/VGO1U_KR.?D^&,6DVSS7TNR7'R(K
M$\'&0Z@]?2M.>[T,/8*,;R>O3^F:T?\ R C_ +__ +1-3]K^NYK_ ,NOZ[!J
M/_($3_>_]IBA?$$OX7]=C'^"7_'Z/\]FJJNQEA?B.5\7_P#'U)]5_P#016D=
MCEJ?$S&JS(* "@ H * "@ H * "@ H * "@ H [_ .&WPT?Q XEE!6$'N",]
M.F5(/!K"<['=0H<[N]CZ&L+!+!!'& % Z#BN)NY[J7*K(L4B@H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 ?G7\4_\ D+7_ /U_77_HYZDHY>@ H 3- "4
M%  30 E $U42+0 4 +0 M !0 4 +0 4 % "T % !0 Z@ H ]S_8^_P"0K-_U
MXR?^C8: /K^@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@#\Z?BFW_$VO_\ K^NO_1SU
M)1R^Z@ W4 )NH -U  6H 3=0 ;J )ZHD* %H * %H 6@ H * %H * "@!: "
M@ H =0![G^Q]_P A6;_KQD_]&PT ?7] !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'Y
MN_%:7&KW_P#U_P!U_P"CGI%G*^<:0P\TT 'FF@0>:: #S30 ><: #SC0!IU1
M 4 % "T % "T +0 4 % "T % !0 M !0 M 'NG['W_(5F_Z\9/\ T;#0!]?T
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 ?FU\5_P#D+ZA_U_W7_HYZ11RM PH$% !0
M 4 % !0!J@TR1: "@ H 6@ H 6@!: "@ H 6@ H * %H * /=/V/O^0M-_UX
MR?\ HV&@#[ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H _-KXK_P#(7U#_ *_[K_T<
M](9RM 7"F(6D 4 )3 *0!0!JTP &@!: "@ % "T % "B@!: "@ H 6@ H *
M%H ]T_8^_P"0M-_UXR?^C8: /L"@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#\VOBO
M_P A?4/^O^Z_]'/0!RU !0 E !0 4 %( I@:M !0  T +0 4 ** "@ H 44
M+0 4  H 6@ H * /=?V/?^0M-_UXR?\ HV&@#[ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H _-KXK_P#(7U#_ *_[K_T<] '*T % !0 4""@ H&% &H#0 M !0  T
M +0 4 +F@ H * %!H 6@ H  : %H * /=/V/?^0M-_UXR?\ HV&@#[!H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H _-OXKC_B;ZA_U_P!U_P"CGH Y7% !B@ Q0 8H
M ,4 )B@!<4 :5 "B@!: "@ !H 6@ H 44 % !0 HH 6@ H !0 M 'NG['O\
MR%IO^O&3_P!&PT ?8- !0!SOBOX@V7A5<W4JJ?[NY=_;L6![C\* /-I_VO-%
MA?83.3G&1&I'Y[Z .]\&_%6P\7#_ $64;O[K%0_;^$,3W'XT ==0 4 % !0
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ME.D?M1:3JMW'8Q^=YLDRQ+F,!=S,%&3NZ9- 'KM !0 4 % !0!'<W MU+MT
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M[_\ &, ?^AT >B>#OBA8>+A_HLJEO[I90_?^$,3_  D_2@#JZ "@ H * "@
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@#\W?BM_R%[_\ Z_[K_P!'/0!RM !B@!<4
M (: "@ (H :30!I4 % "B@!: "@ !H 6@ H 4&@ H * %!H 6@ H  : /=?V
M/?\ D+3?]>,G_HV&@#[!H Y/XH>/4\#64EXPW%0,+P<_,JGC<N>OK0!\#7]_
MJ'Q-N\GS)I6/"C>^,* <#YB.%R?I0!Z-%^QUJ[Q^9YEN."=I:;?],>3UH \X
MFMM0^&-ZI;?#,C!A]] X5@?]DE25Y]: /O'X/^.QXVTZ*Z_C"HDF.F\(A?\
MB8]6[G/K0!V<LHB&YC@#N>!0!S-Y\4M*LFVRWMLC>C31@_JU &QI'B*VUD;K
M:6.4>J,KC]": -"@#G&^).F+,;4WEOYX<H8_-3?O!P5VYSNSQCKF@"?5O'5A
MH_%S<PQ<9^>1$_F10!-HOBZSUW_CTGBF_P"N;J__ *"3Z4 :U &+K'C>QT0[
M;JYAB/H\B(?U(H H6?Q4TJ];9%>VSMZ+-&3Z= U '30S+. R$$$9!'(- &;K
M_BVT\.A6O9XH Y(4R.L8)'4#<1GK0 N@^*K3Q "UG/',%QDQNK@9SC.TGT/Y
M&@!FO>+[/P]C[9/%#NZ>8ZIGZ;B* )-!\3VOB%3)9S1SHK;2T;JX!QG!*D\X
M- %'6?B'IVB/Y5U=P128SM>5$;&2,X8@]01^% %K4O&%GI:"6>XBC1@"K.ZJ
MI!&002<$8- #-#\;6.O';:7,,Q':.1'/?^Z3Z'\J )=:\66FA#-W/%"/^FCJ
MG_H1% #=$\86>O<6EQ%-C_GFZO\ ^@DT :] &?J_B&WT8;KF5(E]794'ZD4
M9-E\3]+OFV17MN[>BS1D_D&H Z56#<B@#)U[QA9^'L?;+B*'=T\QU3/TW$4
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M_P#NF@#\VKO1WUG49+>,@,]Q* 6R!]YCS@$]O2@#UU/V+-7< B>TY&?OS?\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M7)"C)..[?SH ]5_94^,$VN%M.O'+N/\ 5L22Q'[QVR6))[ >@H S/VUNMO\
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M,[WX73H)9,L^[;(A9<[0I//!_CQ0!]@?LY^+Y?$>EQO<$LZ Y8DDG+/W))/
MH \+_:5^,5SJ=Z=,LG941MC;"RLSY(QE6'!!Z$4 8^D_LJ:IJ]J+\RJ'9 XC
M;>9#E0PYZ9YQUZT 4?A+\3KWX?ZB+2Z=S%O*.KLQ  R,@%L#D>E 'T%^T;\*
M)OB1;VTL$B1B#S&.\,<^9Y8&, ]-O- 'QQX"\&/XRNTLHF5&<,0S9QP,]N:
M/L?X7_"";X9Z5?P3RI*94D<% P  B(P=P% 'RG\._P#D8+3_ +",'_HY: /M
M+XZ_$G_A [!ID_UKY6//3=C//(]* /C_ ,&>"-4^,$[_ +UB,Y9Y&=D&<^YP
M,C'Y4 6O'WP2U+X9/&R2;]^<-"77&-O7H?XL?G0!]2?L[^(;_5;(KJ,;J\9
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M3( #.Z@'..?DH ]4^"/[-]U<26VK">+RU8-LP^[[OTQWH ^P8UV #T H =0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M=6M[EFT- \^T;@1&<#/'^L('6@#V75[GQUJ\3036ZE&QD8M1T((_C]10!D_
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M'\#O$WB*=KJXLR9&ZE7@4=2>@D]Z /LIXY(]."SC#A$!''8@=N* /B']F_\
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MC^#[+$?QWRT >_?LR1*FC1;1_&_\Q0!;_:0BC?0[GS?N@P\^G[Z/^M 'SO\
ML=.1J1&>-C\?\!- %W]MO_D(VO\ UZ?^U'H ]J_9;$8T=/+_ +XW?[WE19H
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M%Q9?]<IO_0DH ]%_9$G,NEL#VD '_? H \=_;4_Y#$/_ %X1_P#HZ>@#Z2^
MG_()A^@_]!6@#T.@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MW\J +?P._:.EM/L^D&WSE\>;OQ@;>/E\OV]: /KN)MX!]0* '4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % 'YL_%C_D+ZA_U_P!U_P"CGH Y8&@ (H ,T +NH 1CF@!* 'A\
M4K%7+3\T"$IB 4 !:@ S0 N*!A0 N* %4D4")E-  S;:0">=3 :;C% $BONH
M =F@#W;]CL_\3:;_ *\9/_1L- 'V%0!FWWB>TT]O+FGBC<8^5I$5N>G!(- &
M5JNOZ7JR>7//;NI[&9/KV;VH XI_AOX4=MY2TW9SGSQ_\<H Z[0]2TC0EV6T
MUO&OH)D_JY]* -3_ (3BP_Y^H/\ O['_ /%4 ,E\9:?*"K7,!!_Z;1__ !5
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M6N+D6CR.268S#))))/$@[DT =C9>*]-LD6*.YMU1%55'G1X  P!][T% $_\
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MHS!<3V[QMU4S)@]NS"@#G/#7ACPWX8E^T69M8I,8W"9<XR#CESW _*@#L?\
MA.+#_GZ@_P"_L?\ \50!RGB+1/#WB-MUVUK(?4S+_1Q0 GAS0?#OAMM]FUK&
MWJ)E]_5SZF@#K/\ A.+#_GZ@_P"_L?\ \50!\C_ME:O#J=_;-!(D@%K@E&5P
M#YC<94GF@#T7]GS^S-2T7[-J+PD&8_))(J'_ %48Z;@?44 >B^'O#WAWPX_F
M6AM8V]1,O]7- '6_\)O8?\_4'_?V/_XJ@#B-4\%>&-5F-S.+1Y6()8S#)(
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@#\W?BLF=7O_\ K_NO_1ST <MLI &* $I@+0 4 (<4
M )MH M,II#$Q3 * #- A=U( W4##=0 ;J %!IB)A0 .>*0RN:8AK&@"='XH
ME!S0![O^QW_R%IO^O&3_ -'04 ?8= 'S/\=/V;=1\>:F]]:O L;1QJ!([JV5
M7!X6-A^M 'GW_#%^L_\ /6U_[^2__&: #_AB_6?^>MK_ -_)?_C- !_PQ?K/
M_/6U_P"_DO\ \9H /^&+]9_YZVO_ '\E_P#C- !_PQ?K/_/6U_[^2_\ QF@
M_P"&+]9_YZVO_?R7_P",T '_  Q?K/\ SUM?^_DO_P 9H /^&+]9_P">MK_W
M\E_^,T '_#%^L_\ /6U_[^2__&: #_AB_6?^>MK_ -_)?_C- !_PQ?K/_/6U
M_P"_DO\ \9H /^&+]9_YZVO_ '\E_P#C- !_PQ?K/_/6U_[^2_\ QF@ _P"&
M+]9_YZVO_?R7_P",T '_  Q?K/\ SUM?^_DO_P 9H /^&+]9_P">MK_W\E_^
M,T '_#%^L_\ /6U_[^2__&: #_AB_6?^>MK_ -_)?_C- !_PQ?K/_/6U_P"_
MDO\ \9H /^&+]9_YZVO_ '\E_P#C- !_PQ?K/_/6U_[^2_\ QF@ _P"&+]9_
MYZVO_?R7_P",T '_  Q?K/\ SUM?^_DO_P 9H /^&+]9_P">MK_W\E_^,T '
M_#%^L_\ /6U_[^2__&: #_AB_6?^>MK_ -_)?_C- !_PQ?K/_/6U_P"_DO\
M\9H /^&+]9_YZVO_ '\E_P#C- !_PQ?K/_/6U_[^2_\ QF@ _P"&+]9_YZVO
M_?R7_P",T '_  Q?K/\ SUM?^_DO_P 9H /^&+]9_P">MK_W\E_^,T '_#%^
ML_\ /6U_[^2__&: #_AB_6?^>MK_ -_)?_C- !_PQ?K/_/6U_P"_DO\ \9H
M/^&+]9_YZVO_ '\E_P#C- !_PQ?K/_/6U_[^2_\ QF@ _P"&+]9_YZVO_?R7
M_P",T '_  Q?K/\ SUM?^_DO_P 9H /^&+]9_P">MK_W\E_^,T '_#%^L_\
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MK/\ SUM?^_DO_P 9H /^&+]9_P">MK_W\E_^,T '_#%^L_\ /6U_[^2__&:
M#_AB_6?^>MK_ -_)?_C- !_PQ?K/_/6U_P"_DO\ \9H /^&+]9_YZVO_ '\E
M_P#C- !_PQ?K/_/6U_[^2_\ QF@ _P"&+]9_YZVO_?R7_P",T '_  Q?K/\
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MQ?K/_/6U_P"_DO\ \9H /^&+]9_YZVO_ '\E_P#C- !_PQ?K/_/6U_[^2_\
MQF@ _P"&+]9_YZVO_?R7_P",T '_  Q?K/\ SUM?^_DO_P 9H /^&+]9_P">
MMK_W\E_^,T '_#%^L_\ /6U_[^2__&: #_AB_6?^>MK_ -_)?_C- !_PQ?K/
M_/6U_P"_DO\ \9H /^&+]9_YZVO_ '\E_P#C- !_PQ?K/_/6U_[^2_\ QF@
M_P"&+]9_YZVO_?R7_P",T '_  Q?K/\ SUM?^_DO_P 9H /^&+]9_P">MK_W
M\E_^,T ?:&EVQM8HXVZJBJ<=,@ &@"S0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?G'\4U_
MXF]__P!?UU_Z.>D,Y@K0 TI0 A2@!I2@"%^*8AFZ@ W4 := !0 M !B@ Q0
M;10 >6* $\H4  AQ0 _% ",*0$:1^M,"*1.>* '[>* )HWS0![S^QU_R%IO^
MO&3_ -'04 ?8= !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'YS?%/\ Y"U__P!?UU_Z
M.>D,Y>@!IH ;F@!* (9:8B$B@ Q0!J4 % !0 M !0 "@!: "@!: %H 0T 1>
M;MH ;]H [4 .6?/.* )%.>: />?V.S_Q-IO^O&3_ -'04 ?8= !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?G+\5/^0O
M?_\ 7]=?^CGI#.6)H :: "@"*4XH KDYIB'+0 IH OT +0 M !0 4#%H$+0
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M_P"%'LY=G]S#VD>Z^]!_9\G]QO\ OD_X4>SEV?W,/:1[K[T']GR?W&_[Y/\
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M_P"%'LY=G]S#VD>Z^]!_9\G]QO\ OD_X4>SEV?W,/:1[K[T']GR?W&_[Y/\
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M^=Q^!YO?COU1Z<CAQD<BOLT[GR+5A:8@H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _.;X
MJ?\ (6O_ /K^NO\ T<](9RM !0 4 -9<T 0R18IB(>E !0!I4 % !0 M !0
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M;QF#=-\T=CK:]X\4* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * (YX%G!5AD'J
M*F45)6>Q49.+NCR_Q;X0;33YD8)0_IT]!ZFOBL;@G2?,M5_PQ]?A,8JJL]_^
M')O!_C$V)$4IRG;VZ^X[FM,#CO9^[+;\C/&8/VGO1W_,],BE$HW*00>A'(K[
M%--71\FU;1CJH04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % $5U:K=*4<9![5G."FK/8N$W!W1Y7XH\*-I+;DR4['T^O&*^(Q>
M#=!W6Q]CA<6JRL]S>\">.O((@G/R\!2>W0 <GI7J9?F'+:$]NC^Y'FX_ \WO
MQWZK[STU'$@!!R",@]J^S3OJ?)-6T%IB"@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M_>7^53E'PR]5^0\T^*/HSN*^E/GPH * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@"&[M%NU*.
M0?7!_G6<X*:L]2X3<'='EGBGPJVD-O3)0G@^G7V [5\3C,&Z#NMOZ\D?8X7%
M*LK/?^O,WO GCLP8@N#\O 5B>G0 9+=,>U>GE^8\ON3VZ/[EU>QYN/P'-[\=
M^J^]]$>FHX<9'(-?9IWU/DFK:"TQ!0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?G-\4S_Q-[__
M *_KK_T<]24<N30 E,!* "@"&1,T"$$6* %VT 3[Q3$'F4 &^@!-Q- !S0 N
MPT 'ET (8\4 /W&@!A/<T 19)]: 'HAH E$= #ME #@* /=_V.?^0M-_UXR?
M^CH* /L6@ H \V^,/6#_ +:?^R5\?G?V/^WO_;3ZO)_M_P#;OZC?A;_JY?\
M>7^53E'PR]5^0\T^*/HSN*^E/GPH * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * ,S7-!35DVN.>Q[]1_A7%B,.JZL_O.NA7=%W7W
M'DVHZ=+HLF&R".A'&>A_K7PM6E+#RL_O/M*=2->-U]QZ!X0\7C4 (Y#AQ^M?
M58+&^U7++<^:QF#]F^9;'65[IXH4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M1W%NMP"K#(-1**DK,J,G%W1Y?XM\)-IC>9'RA/Y5\7C<$Z+YEL?7X3%JJN5[
MD_@[QB;$B*4Y0G@^G0?E@=*TP..]F^26WY;(SQF#]HN:._Y[GI<4@E 8<@C(
MK[%.ZNCY-JSL.JA!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 0W=HMVI1QD$$?TK.<%-69<)N#NCRSQ7X6;2'WK]PG@^G)X_(
M5\3C,(Z#NMO^'/L<)BE65GO_ ,,;O@;QUY&()S\O9CVKT\OS#E]R>W1GFX[
M<WOQWZH].5MW(K[-:GR6PM,04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?G-\5/^0O?_ /7]=?\
MHYZ0SEJ0Q* "@!,T ,+T &^@!-U $^VJ)#% "T +0 4  H ": #.: $QF@!2
MN: %VT *!0 M !B@!* />/V./^0M-_UXR?\ HZ"@#[%H * /-OC#U@_[:?\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M2-WU6QZ5X-\2MJ:[7!W#O@X_/\*^QP.*=96:=UU/E,;AE2=U:SZ'3U[1Y 4
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MMY;C7_#=WV>YX^88-?&K+N>E5]B?)A0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?G-\5#_P 3:_\ ^OZZ
M_P#1STAG*F@ H 2F C4@*C]:8@H -U %^@ H 44 % !0 M !0,*!!F@8M !0
M(*!BYH$% !0![O\ L<?\A:;_ *\9/_1T% 'V-0 4 >;?&'K!_P!M/_9*^/SO
M['_;W_MI]7D_V_\ MW]1OPM_U<O^\O\ *IRCX9>J_(>:?%'T9W%?2GSX4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!\Q_M"Q";Q)I*L,@M; @]"#<G(K:.S
M,9;H]^O_  )8WR&.2WB*L,$;%/\ ,5E<UL?.M]/<? [4Q@L=/F;..2HZL0O^
MK3CCUK;XD9?"STG]HE#KVA2RVQWKB(X7YB<S1=,9SC'/I41T94MCB?A+\&K3
MQ9817"7UVK$-N1)8P%^=@!C8Q&0,\FJE*S)4;D?Q ^%FD>&'ACO;N_E=Y$V(
M)('.2V <,JG&>N*$VP:2.[\<7VE6]M9Z5?QR,DJPI$[+$2A96168L0%( .2
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M\1]&:-HT6C1+! H2-1A5   YST&!WK$U/!?B-XPO_%6K#1;&4VZ+_K'#/&Q
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MVS.S,1O9$R23C$:CCIQ[5JIF3B9Z? /6K["7>I$Q]PDLZD_7.0:.9!RL];\
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M#CU#[@>"1^5/FL'+<]'\3_#R+6-..F+\J>4$4\#H ,G ZX'I4)ZW*:TL<O\
M"GX:ZGX/81W%RDMN"=J@R%N=W][CJ1^5.3N)*Q/\'_A1-X&:[::1'^T&+;MW
M<;%8'.0/[W:B3N"5B7P)\+9O#FH7-])(C).^0HW;A\H'.1CM0W= E8Z?XA>&
M'\3V4UI&P5I(Y%!;. 61E!..>]2G8IJYB>'/#</@O2OLNI21F)4 D8_<P%4'
M[PZ<>E-N[$E9'G6E_!NZ@)N/#]\JV\C$[7>0IR<G:$"@<FKYNY'+V/._C-X
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M>!;?QC;FWN![JPQN!P0""0<=:E.Q35SRB#X)ZUIJFWM;]1;\A0SS&15Z  C
M& !C ZUIS(SY6=I\-/@U#X/9KB1FEN7^\['?WSP67<.<]ZERN4HV(#\*ICKY
MUKS$\HJ@V?-OXB,?ICJ<]>E%]+!;6YZ+J%L;J-XQP61E_,$5!9P7P3^&<OP_
MMGMYY$D+,#E,XX&.X%7)W(BK'HM06% !0 4 % !0 4 8/BCQ0ND+@<N>@KR\
M7BU07F>EA<*ZS\CS***;7I<#+,?J>W^ KXU*6)GU;?\ 7Z'UC<</'LD>P>%O
M"B:&G8N>K?GTXST-??X3!K#KN^K/A\5BW7?EV-ZO4/-"@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /S
MC^*G_(7O_P#K^NO_ $<](9R^: $H "<4 )NH AE.:8B*@ H OT +0 4 % "T
M % !0 4 +0 4 % "YH&% !0 9H ]X_8X_P"0M-_UXR?^CH*!'V-0 4 >;?&'
MK!_VT_\ 9*^/SO['_;W_ +:?5Y/]O_MW]1OPM_U<O^\O\JG*/AEZK\AYI\4?
M1G<5]*?/A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0!@^*?$ZZ.N!RY' _/!Z>U>7B\6J"\^AZ6%PKK/R/
M,HHI==EP/F9C_GK7QJ4L3.V[9]8W'#P[)'L'A7PJFB)ZN>I_/_&OO\'@UAX^
M?5_UZGP^*Q;KORZ(WJ]0\T* "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * /SA^*9_XF]_\ ]?\ =?\
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MAL,Z\K=.K/:Q&(5%7Z]$>M:7I::<@C0<#Z_U)K[NC15*/*CXNK5=5W9<KH,
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H QO$GB--'3)Y8]!_D&O/Q6*5"/GT
M7]7._#89UGY=3RN::36I<GEF/MW_ "%?#RE+$3[ML^Q48T(]DCTSPGX572%W
M-S(1R?3...I'4=:^RP>#5!7?Q/?\--_(^2Q>*=9V6R_X.NQT->L>8% !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@#\W_BK_P A>_\ ^O\ NO\ T<](
M9S(H 4F@""0TQ$>* '"@ - "H<4 6Z "@ H 6@ H *  4 +0 4 % "T % !0
M 9H&+0(]W_8W_P"0M-_UXR?^CH* /L>@ H \V^,/6#_MI_[)7Q^=_8_[>_\
M;3ZO)_M_]N_J-^%O^KE_WE_E4Y1\,O5?D/-/BCZ,[BOI3Y\* "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H 0G% '#>,O&7E9AA//<U\S
MCL=;W(_-GT6#P5_?E\D<GH/A]]9? X7N?S_PKPL/AG7EY=7]Y[.(Q"H+SZ(]
M;TS3$TY D8P/_KY_K7W=*DJ2Y4?%5:KJN[+==!B% !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % &-XC\2)HZ9/+'H/Q']#7GXK%*@O/HON._#89UGY=SRN::76I
M<G+,?_U=J^'E*6(EW;/L4HT(]DCTSPIX572%W-S(1R?3VK[+!X-4%=_$?)8O
M%.L[+8Z&O6/,"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * ,#Q1XH725P.7/05Y>+Q:H+S/2PN%=9^1YI!!+KTV!DLQY/U/_
M ->OC8QEB9]VV?62E'#P[)(]?\)^%DT-!W<@;C^ R/S%??X/!K#Q\WN_N/A\
M7BG7EY=%]YO5ZAYH4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MP8K,E.-H77KI^3.W#Y?R.\[/T_X8XJ)@[9D)P3R1U_6OG%9O6_F>^[I:?(]
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MLR?]W[W_ )!_PLNV])/R7_XJC^U:?:7W+_,/[,G_ '?O?^0?\++MO23\E_\
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M5I]I?<O\P_LR?]W[W_D'_"R[;TD_)?\ XJC^U:?:7W+_ ##^S)_W?O?^0?\
M"R[;TD_)?_BJ/[5I]I?<O\P_LR?]W[W_ )!_PLNV])/R7_XJC^U:?:7W+_,/
M[,G_ '?O?^0?\++MO23\E_\ BJ/[5I]I?<O\P_LR?]W[W_D'_"R[;TD_)?\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M:7X?YA_PJ.X_YZ1_^/?_ !-']BS[Q_'_ "#^UX=I?A_F'_"H[C_GI'_X]_\
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MYZ1_^/?_ !-']BS[Q_'_ "#^UX=I?A_F'_"H[C_GI'_X]_\ $T?V+/O'\?\
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M:7X?YA_PJ.X_YZ1_^/?_ !-']BS[Q_'_ "#^UX=I?A_F'_"H[C_GI'_X]_\
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MYZ1_^/?_ !-']BS[Q_'_ "#^UX=I?A_F'_"H[C_GI'_X]_\ $T?V+/O'\?\
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M:7X?YA_PJ.X_YZ1_^/?_ !-']BS[Q_'_ "#^UX=I?A_F'_"H[C_GI'_X]_\
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MYZ1_^/?_ !-']BS[Q_'_ "#^UX=I?A_F'_"H[C_GI'_X]_\ $T?V+/O'\?\
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M:7X?YA_PJ.X_YZ1_^/?_ !-']BS[Q_'_ "#^UX=I?A_F'_"H[C_GI'_X]_\
M$T?V+/O'\?\ (/[7AVE^'^8O_"H[C_GI'_X]_P#$T?V+/O'\?\A?VO#M+\/\
MSM_"WA./0TZ N>K<'\C@&OI<)@UAUW?5_P!(^?Q6+==]ET7],WJ]0\T* "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@#\X?BI_R%[_ /Z_[K_T<](9R] #3Q0 9S0 UZ8%
M=J!"4 % %Z@84""@!<T % !0 M "T % !0 M !0 4 % "T >\?L;?\A:;_KQ
MD_\ 1T% 'V10 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!^;_Q4;_B;W_\ U_W7_HYZ
M0',;J!B'F@! : !Z8BL: $H$% %V@8M !0 4  - "T % !0 M "T % !F@!:
M "@ H ]Y_8V_Y"TW_7C)_P"CH* /LB@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#\V
M?BO_ ,AC4/\ K_NO_1ST <KF@!=] "^90 &3- $9H 2@04 7:!A0 N: "@ H
M ,T +0 4 % "YH 6@ H ,T +0 4 >\_L:_\ (6F_Z\9/_1T% 'V10 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0!^:_Q8/\ Q.-0_P"O^Z_]'/0!RN: #- !F@!* "@
MH$% %V@84 % !F@!: "@ H 6@ H * %!H 6@ H * %H ]Y_8U_Y"TW_7C)_Z
M.@H ^R* "@ H SM?UZ/0XO.ESMR!P,GG\132N)NQS/\ PN"R])/^^1_\55\C
M(YT'_"X++TD_[Y'_ ,51R,.=!_PN"R])/^^1_P#%4<C#G0?\+@LO23_OD?\
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M=!KPS"3D=FP&_+)]*EJQ2E<VJDH* "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H _-?XL?\ (8U#_K_N_P#T<] '*4""@ H * "@ H * +E P!H 6@ H
M ,T +0 4 % "@T % !0 N: %H * "@#WG]C7_D+3?]>,G_HZ"@#[)H * "@#
MC/BW_P >)_ZZ)6D-S.>QX?70<P4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!=TG
M6)-*<21'!'N0#P1S@CUI-7&G8]V\)>,(_$"9!PXZKQGJ<<9)Z"N9QL=,97.@
MJ2PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /S7^+'_ "&-0_Z_[O\
M]'/0!RE !0 4 % !0 4""@"W0,6@ S0 M !0 4 +0 4 % "YH * "@!: %H
M* />?V-/^0O-_P!>,G_HZ"@#[)H * "@#C/BW_QXG_KHE:0W,Y['A]=!S!0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!>TC6)-*<21D@CZX-)JXT['NOA'Q='
MKZ9'#CJ*YFK'3&5SH*DL* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /S7^
M+'_(8U#_ *_[O_T<] '*T &* #% !B@!* "@04 6Z!BT % !F@!: "@ H 6@
M H *  &@!: "@ H 7- 'O7[&G_(7F_Z\9/\ T=!0!]DT % !0!QGQ;_X\3_U
MT2M(;F<]CP^N@Y@H [#X?^"?[>??+_JEZC^]U&,@Y%1*5C2,;GI=UX@T[1F\
MB1E5EQP48GD9'(4^M8V;-KI%'Q?X.@U^ S0X#@$JP! P.HQQZ4XRL*4;GB\=
MJTCB,#YB0 /<\ 5T'.= ?AS?@;O).,9^\G_Q53S(KE9SLT1A8JW!!(/U'6J(
M-R;P)>0J':(A2,@[D_\ BJGF1?*Q]Q\/KZV4N\1 '4[D_P#BJ.9!RLP[2T:[
M8(@RQ. /_P!=42= WPVOUY\D_P#?2?\ Q53S(KE9A)ITCR>0!^\W%<9'4<8S
MTJKDV+>L>&;C1@IN$VANG*G/Y$TD[C:L2:7X1NM53S(8]R^N5'KZD>AH;L"C
M<;I7A6YU7=Y*;MIYY48_,BANP)7+=OX O;C(6(G:<'YDX/\ WU2YD/E95@\)
MW,\IMUCS(HR5ROKCKG'6G<5ANL^%[C10#<)L#' Y4_R)H3N#5B#2=%FU9MD"
M[F],@=B>Y'I0W825R[JO@R[TI/-GCVH"!G<IZ].A)I*28W%HKZ/X<GUG/V=-
MV.O*C^9%-NP)7+\7P]OI<[8C\I(/S)U'7^*ES(?*S!GA,#%&&&4D$>XX-40>
MM_"2U26 EE!Y[@'N:PF=$#S'Q NV=P/;^0K9&+/4_"-JCZ:Q*@GRGYP,]&K%
M[FRV/(+6U:[=8T&69@JCU). .?>MS W;KX?WUJID>(A5&2=R?T:IYD5RLYXC
M'%40='%\.KZ8;EA)!_VD_P#BJGF1?*S+U#19=)<).NUL],@_R)IIW):L>N7=
MDATP$*-QA/.!G[IK#J='0H_#CP8+> S31_O7SMR004(4J<9(ZY]Z<I"C$RO"
M_AR73[\^>@"LY*YVD8))'0GM5-W1*5F6/B-X8EU28+:Q@D=0-J]0,=2/0THN
MPY*YP>L>&+C1L&X39GIRI_D36J=S)JQE4R0H * "@ H O:/J[Z5()(S@@TFK
MC3L>Z^$/%J>((\CAP/F'/H,]@.]<TE8Z8NYT%26% !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 ?FQ\6/^0QJ'_7_=?^CGH Y6@ H * "@!* $H$% %J@8N: %
MH 2@!: %H * "@ S0 M !0 4 +0 4 % 'O7[&G_(7F_Z\9/_ $=!0!]E4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MD]2_XN\)7&LW 8R8M^."0,<+TX[L*E.PY1N.^*2[K4$<C>G/XT0W'/8FOO\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H "<4
M<]KWB]-/^5/F;]/TKQL5CXTM%JSGG543B+K49]9..2/0#./T]Z^5G6J8E]7Y
M'$Y.9I:?X$EN!E^!C\:[:662GJ]#2-%L9XEL;/PFBRW;L Q(& #R!]17KPRB
M+ZLT=)1W,3_A8NBOP'8?@/\ XJNS^R8=B;1.IMO!T&I1B2WEWJ>A!4CKCMGT
MK@EE,5U?W#=&^QE:GX0FL>0,CVY/Z"O-J97..L=3FG!P_P" )IGB:;2V"MG
M_A/'I_A6%/%5,,[2O;S_ *\BH56O\CO-%\11ZH.#ANX/%?5X?%QKK3?L>A":
MD:M>@:A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MCZX/Y4FKC3L>Z^$?&$>OID$!QU7@'OVR3T&:YG&QTQE<Z"I+"@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % %[2-8DTIQ)$2"/<X/!'."/6DU<:=CW7PEXOCU],CAQU7OW^M<S5CIC*Y
MT%26% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M$MO/?]#UK2=2748PZ]_\2/Z5Z%"LJT5)?UJ?61ES*Y<KI+"@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M*Y#J_AZ?1\"="F<XR0>GT)]:$[B:L5[#3WU!Q'$-S'H./ZT[V!*YI7W@N[L
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MDL* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M_P 7)K\8(X< ;A[X&>P'4US25CIC*YT%26% !0 4 % !0 4 % !0 4 % !0
M4 >1_''X^?\ "K9((_LWG^<KMGS?*V[2HQ_JWSG/M0!WW@+Q3_PEEC!?[/+\
MZ,/LW;MN>V<+G\A0!O4 % &;XCU@Z/ \X7?MQ\N<9RP'7!]?2@#S+X._'Y_B
M),T+69M]N/F,A?/#'H8D]/UH ]?H * "@#.U[Q%!H,9FN7"(O4\D]0.@R>]
M&@K;AD4 +0!\^?$?]K'_ (0R\DLOL7F^6S#?Y^S."1T\EL?G0!S'_#<__4._
M\F?_ +10!Z1\-/VF;'QG((''D3-]U,NX)ZXW>6H'2@#V('- !0 4 % !0 4
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M#*)0&'0UX\9<RN?I ^K&% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 ?FQ\6/^0QJ'_7_=?^CGH Y6@ H * $- "4""@ H
M L4##- Q:!!0 4 +F@84""@!0: "@!: "@8N:!!0 4 >]?L9?\A>;_KQD_\
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M"]H^KOI,@EC.""/QYSBDU<:=CW3PCXNCUZ,$'#@<BN9JQTQE<Z&I+"@ H *
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M^+MK\0(RT!PZ_>0\'OTSR>!0!YY\4OVFI/ ]^++[.CQY^9R[ @;BI. /09H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@#\V/BQ_R&-0_P"O^Z_]'/0!RM !0 4 (10 E !0 4 6* "@
M84"%H * "@ !H 6@ H 6@84"%H * #- "T >]?L9?\A>;_KQD_\ 1T% 'V90
M 4 % '&?%O\ X\3_ -=$K2&YG/8\/KH.8* -'3_$5QIPVPR,@] <4FKC3L49
M93*=S')/>F(90!I#Q)<"/R?,;RP,;<\8]*5BKF;3)-+3_$=QIR[(9&1<YP#@
M4FKE)V(M2UJ;4\><[/CIDYH2L)NYU?PZ\/0ZJ2WG-%,O0*5!.<YQG)/ YJ).
MQI%7.F?P1?3S#SI]\"NK ,Q+<$'D;<5',B^5F=\6/$*%DAB;+HRMD$'!&X8X
M/!]J<$3-G!:AKT^HJ$FD9U4\ G(':M4K&3=RK:W36C!XR58=".HI@7[WQ3=7
MJ[)979>."<C@Y'ZTK#N-N_$MS> "25F ((R>A'(-%@N-U#Q#<:BNR:1G4'."
M<BA*PF[CK;Q+<VR>6DK!/[H/'I18=R"QUB:P8O$[*QZD'!-%KBO8CO=0DOG,
MDK%G.,D\GC@4PO<TU\:WJ\"=_P ZGE0^9F9>ZA)?-OE8LWJ>356%>Y:_X22X
M\OR?,;R\8VYXQC&/RI6'<S:9)/97KV3B2)BKCH1P1QC^5 R4ZO*9//WGS/[V
M>>F/Y46"Y#=W;WC&20EF/4GJ: );G5I;E%B=R47&U2>!CIC\Z+!<(-6EMT:)
M'(1L[E!X.>M%@N=YHUPUMI#NA(8$X(Z_?%9/<U6QQUQXLNKD;7E<CT)K2QG=
ME&QU"2P;?$Q5L$9'!P>M,5[$<\[3L68Y).23UH$6].UZ?31B&1D&<\''^>E)
MJXT["W^OSZ@,32,X]SFBU@;N4*8BYJ.L3:E@S.S[<XR<XSUI)6&W<K03M 0R
M'!'0BF(U3XRO"-OG/CTS2Y45S,R99C,2S')/4TR1E !0 4 % !0 4 % !0 4
M % %[2-8DTEQ)$<$?K2:N-.Q[IX1\7QZ\@((#CJO&>_;)/:N9JQTQE<Z&I+"
M@ H * "@ H * "@ H J:OJBZ5$T\F=JC)QR>N/:@#A_AS\=+#X@2O!:"57CQ
MGS%5<Y#'C#MG[AS^% 'A?[<7^OL?^N4__H24 >@6>K/IG@Z%X^IL67\XWH \
M^_8Z\-PZE-->3*'D7> 2 <$&)@WUR30!WG[6WAF"XT\7!0"1"<-CGIT_6@#G
M_@;K<E]X=FBD.0A&#WYF/^% ')_L9_\ 'Y+^'_H$E '/_'2W6Y\1^6XRK7,8
M(]064$4 ?5'BCPU!'H,]NJ (ME+M '0B)@"/?% 'SK^Q]-]AU6YC'(,6W\I!
M_A0!S?[6_P#R'I?^N,'_ *!0!]TVGW%_W1_*@"6@#X9^)_\ R-2?]?\ %_Z.
M% 'V[I?^JC_W%_D* /FK]MV]1X+2($;EED)'&<%1CWH X3Q5<S:5X2LK8Y42
M/<[QR,[;E&7^= $/PD^)NK^%[01Z?I?GQL.91#.^_ENI3@]2/PH S=(TW6+O
M68M0_L^>#?<Q%PD$RH%\Q2W5>F!SDT >P_M=^"FU6TBU*-?WB;%?@Y"!97/8
MD<GOQ0!@77QD\[PKMWXF8&!>0&^14P1\V?\ /2@#JOV0?!)TZT?4)%(><X^8
M8/R,XSR!US0!\Z77B2XGUIKM8?M4Q(_=E6DW8C SA?F. ,_A0!WWQ'\=:]X]
MMOLMQH[J 00RVUSN&,\#.1WH [WX&VU[IWA_4+>^AEB(CN"@E1XSM$"@ ;@.
M,Y_6@#A/V4?^0S<?[I_]&B@#)^+DI\4^(O(G)V'"X^B'U^E 'V9_PC%LMK]F
M$:^5L^[CCUZ?7F@#XT^$MPWACQ$8;<X3E<=!RJ^GUH M?M!6:WWB&&)_NO,B
MG/3#38/Z&@#ZHB\(6R:2+/8OE?9E&,#!_=A<_D* /E3]GBY.F^('ABX1IW0@
M=,!GP/TH R/C':K=>(I$<9!$>1_VR!H ^G?VBM'A71)4"+M5DVC' ^?/\Z /
M)/V,-!AN6FN74&1&VJ2.0"%/\Z .6_:6MUM=?B*#:2J,<=R9I>?K0!UW[4>K
MR1Z3I\2L0K)%N]\P]#0!S'PO^*FL^&K,06&E>;$2?W@@N&W<D]4X.#0!E>!M
M)U6#6$O_ .S[B $X*K!,J+\FSNO?J>>IH ZS]M__ (^[/_KA)_Z&* /<_@=X
M7MX=#ME5 //M4,F!]XL@#$^N10!\N> I1I7BPPH/E_M*5![ 3-C^5 'H/[;'
M_+M_OO\ ^@K0![7\ ?\ D#6__;7_ -&O0!Z%0!\B_ME>-?M,T6GQG*JH=QGH
MX9U['T/?F@";X;_M Z'X9TM=-ECN,O&/.VQQE2YC1'(S(,\KW% 'F/PG\>1^
M'M;%Q$=MO),^=V%(3+%<\X].] 'TG^U9K;P:.RQG"RA2?PDB84 8_P"QYX>A
MALGN0H\QRN3CG@R+_*@#S+]L?P_%I6H0O$ #-"SO[G=C^5 '<_%'_D3M/_ZX
MV_\ Z324 ,_8Q\/H(9;L@;B63/?@J?ZT 6?VT=1;3;2U@B^5)7FW@=#CRV'Z
MT >=?"CXH:QX:L$@L-*\^([_ -\(+A_,^=SRR?*=I8KQTQ@\T 9?A;3M7&LI
MJ']GW$ DF0,%MYEC525#=5X&!DY- !^T#K4MSK^2OFF*4*D9!8-B4D)@<G)X
MP.N>* .GUOXGZ]K=B=/;1B(3$$4BVN>!MV@CJ,XH Z3]D;2M0T2>XBN[>>&)
MD7;YD4D:@[F)QN % 'E/@O3H]1\2)%*H9"TF0>1Q"Q'ZB@#WC]L&PC_LP/M&
MY74*>X!<9% %?]COP]"MA+.5!D:3&XCG!1<CZ4 >.>)H%M?%B[!M_P")@3QZ
M^>U '2?M@:M)+/!;D_(L<; >Y4@F@"7PS\7M<TVT6U@T;=!CM;W)#<YSQP>>
M: ,_]G'0=3T+6$DEM+B&%E?=NAE2/.Q@N2R@=30!E?'.W6Y\1^6XRK7,8(]0
M64$4 ?5'BGPU!'H,]NJ (ME)M '0B(@$>^* /G;]CV?[#JMS&.08MOY2"@#F
MOVM_^0]+_P!<8/\ T 4 ?=-I]Q?]T?RH DD0."#T(Q0!\7>+K5OA]XJCF'"7
M%RC'/&(VG ..G9?I0!F_%J1_BEKGEVYW*B^7D<X"RN,\;O[PH U_@K\0!X0L
M]1MW;!MQE03@D^;M.,D9/TH W_V/O"QG>ZU"0<';Y9^OG*_;W[&@#@?@G_R,
M2_[K_P#H H [[]M;_66__7,?^A-0![#\'/\ D 0?]>L?_HE* /EOX5Z/%JGB
M0I,H9?MDO!Y!^=Z /H#]J_1HFTAI-HW1@;#CIF2(''X4 4?V.KX3Z<\?]PK^
MKRF@#W^@ H XWXFOMBC]Y/\ V4UY.84N>DW_ "ZGFXN?+RKO+]"OX8E#6TB]
MP!_.N+*)>ZT;4=CYO^':V9$OVJZF@.X8$9C /+YSO]./S-?9RN80MU9O>&&B
MBUF(V<LEPN&!9]K$?=_N<5+^'4M?%IJ=3\>?%,FLW,>FVJM*$97D5 7/RLRD
M$+GL>X[UG35E<TJRN[(Y'Q7?W2_9[B.REA-JL8+F&1!MC!ZD_7VK2/:^YG)O
M1VV/H30+N#QW8+Y@#JZ!7'!Y &>Y[UR/W6=B]Y'@_@7P,FHZK]AF8O;PDD(V
M"/G1VZ8Q]X UU2E97..,;RL>R_&V(1:5(JC !3C_ (%7/3W.JI\)X9X)\-QW
M=JCMJ*0D@?NS/&A'M@C(KID]=CDC&ZW_ !/8_A/HZ:>)-EVMSD-TD23'W/[O
MT_6N>;OTL=--6ZW/'/"'@F?Q1J-ZMO*8BLLIX.,_O2,=#70Y62.:,>9LV/A'
MIB6FJLFJ,_VE#^ZWX /RN#][!^[CI_*IF]-"J:M+7<[SXKW ><*.J]?Q"D5]
M#ET?<]?\V?#9Y*]5+M_E$]"\"MNLH2?[G]37SN)@H5)16R9]IETN:A!OM^K-
MVN0]0* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M,4#+Q\579_Y;R_\ ?Q_\:5D.[,Z64S$LQ)8G)).23ZYIDC* "@ H * "@ H
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MN87>U)=20K$$;Q\R[BBY*Q\&@"_\4OC%<?&!4LM,MY=F?FROS'(Y^X[#'X4
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M4 ><_"[]HX_#JT_L_4()"R%MN%&>6).=T@]L8% &]\!H=;\7WYOKV>Z2T7^
MRS"-LHRC:K%E.&7GW/K0!C?MO_\ 'W9_]<)/_0Q0!]$_!/\ Y MA_P!>D/\
MZ"* /D'PW_R./_<7F_\ 1ST >M?MF>&I[V*WGB4LJN^[ )V\*,GTYH T/V;/
MC5!J4=OHRQ2"5?.W.0OE_P#+20<[L]!CIUH ]_U2^%A$\IZ(C-^0)H ^$;+3
M#\8-?D5F/E/(7.T\B/>H;;G>!PW';- 'OG_#%VC?\];O_OY%_P#&: /%OVA/
M@9!\-A%-9-*T;L1EV#$$#)Y5$% 'L-K#_P +C\-;$.;@8 SR1MF7K]\\JG%
M'E?P5^-,GPK\RRU""4ABNU%7YP?F/1W4#)8=!TH Y?\ :"\677BBZCN;F)XH
MVC)A5P5;9N]V8=?3B@#V7XH_\B=I_P#UQM__ $FDH U?V,_^0<__ %VD_DE
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MZD[7R#@@=^* /)_C5_R,R_\ 7W%_Z&E 'UOXL_Y ]Q_UY2_^BS0!\N_LG_\
M(8N/]T_^C!0!5_:\\,3QZJU[M/DO'& V#C*J ><8ZF@#Z-^#WQJ@^(HD6&*2
M,1",9<*,Y#=-K-TV4 >F4 ?-'[97A<F&'48QAT=(]PX8?ZQ\Y R.1GK0!RW[
M''A@W]W/?2_,OELH)Y.\/&Q)R#Z^N: /+_CCX?;PMJD\"EE$GSD9P"'8L,@
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M * "@ H * "@ H * .M\">&HM:$QFS\@0K@XZD@U$G8TBKG)D8JS,2@ H *
M"@ H * "@!\49E(5>2>E 'KOP^^'XLP)YQECR >W\ZPE(Z(Q/0P,5D:A0 4
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M<[_+3?GUSC.: -.@""\T^.]&V5%<>C*&'Z@T 4K3PI9V9W16\*-ZK&BG\P*
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MDJ*Z^C ,/R.: *=GX8M+([HH(D/JL:*?T H 6W\,VML_FQP1+)G.X1H&SZY
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M%?"U@VLW2AN>Y/T&?Z5]GB)^RIL_+L%2>(K*_P _DO\ @'O &*^%/UP* "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MQ/0P,5D:A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!7ET^.4[F12?4J"?Y4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M.P/;([UE\1M\)L>#_$,FLI*63RU5>!G.<AO4#TJ9*Q47<Y?X>?\ 'I<_0_\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M*0 [(D5CU8%L_P ZKD%SD'PZN6N+X.YRQ1LG\*<MA1W-;7?B,]G/)&8D?8Y
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!^:_P 6/^0QJ'_7_=_^CGH Y6@ H * % H 7% !B@!=M "T
M % "9H 6@ H * "@!:  T )0 ;J %#4 +UH 4"@!30![W^Q?_P A>;_KPD_]
M'04 ?9] !0 4 <9\6_\ CQ/_ %T2M(;F<]CP^N@Y@H * "@ H * "@ H * "
M@ H * "@#9MO%4EO;/9@+L?J2#NZ[N.<?I4VUN5?2QC51)HZ%K;Z++YT8!8
MC#9(Y^A%)JXT[%?4K]M0D:5L!F8DXZ<_7--: ]2M0(* "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ='&93A1DGL* /7O
MA_\ #P60$]P,N>BD=/O#H5!Z$5A*1T1B>AUD:A0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M/S7^+'_(8U#_ *_[K_T<] '*T %  * 'K0 N: #- "9H * %H ;0 4 .%  :
M "@ S0 E  * #% "@4 .Q0 F: ' T >^_L8?\A>;_KPD_P#1T% 'V=0 4 %
M'&?%O_CQ/_71*TAN9SV/#ZZ#F"@#J?"_A1-4ADF<GY , ''?'I4-V+2N<PXP
M2*L@;0 4 % !0!U'B[PNFBQQ,I)+[L\\= 1_.H3N7)6.7JR H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H ?%$92%49)Z4 >N_#_ .'PLP)[@98] >WYCWK"4CHC$]#Z5D:A0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 (R
M!^",TT[":N59=(AE^]&A^JJ?Z5HJLELW][,)4(2WC%^J7^1'_8%O_P \8_\
MOA?\*KVT_P":7WLCZK3_ )8_^ K_ ")HM,BB^ZB#Z*!_2H=23W;^]FD:,8[*
M*]$BR!BLS<* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@#\U_BQ_R&-0_Z_[O_P!'/0!RM !0 4 (: $H * "@"4T )0 4 *#0 M
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M[9P5:&04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % #XHC*0J\DF@#U[X>> !8@7$X^<X*CTZ$'AO4=Q6$I'1&)Z%61J% !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 ?FO\ %C_D,:A_U_W?_HYZ .5H * "
M@!#0 E !0 4 24  H #0 4  - #J "@ H  : #K0 4 % "XH 6@ SB@#WW]B
MXYU>;_KPD_\ 1T% 'V?0 4 % '&?%O\ X\3_ -=$K2&YG/8\/KH.8* -_P +
M>+W\/EMJAU8#*DX'Z5+C<M2L,E\5.+DW4($9./E!R/N[>]%M+"OK<WC\4F8[
MS A?^]N;-3R%\YD2^-'N+D74JAROW5).!SD=*KETL3S:W*GB3Q*^NR^:XQ@8
M '( R2/YTTK";N7M2\;MJ-NMM)&IV@!6R<C@#Z4E&PW*Z+0^(K20B&6)7QT)
M)SU]OI2Y1\Q7\.^/9-&C\DJ)$[*20!R3V]S0XW$I6-"'XIR0'Y(U5-I&T$XY
M[^M+D*YS,TSQL]@TS! ?-WYY/&['^%4XW)4K'/3R^:Q;U)/YU1!UMA\298(Q
M%*@E Z;B1_*H<33F(-=^($NIQ^2JB-.X4Y!Y![^XH4;"<KG*U9 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 /BB,IVJ,DT
M>O?#[X?"R GG'S]AZ5A*1T1B>A5D:A0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MS(<*"3Z#DT >O^ /AX+$">X&7[*1T^\.A ([&L)2N=$8V/0JR-0H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * /S7^+'_ "&-0_Z_[O\ ]'/0!RM !0 4
M -H * "@ H ?0 HH * "@!: $S0 9H 7- !0 4 % !0 4 *: #- 'OW[%O\
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M'_X]_A1SAR!_PI:X_P">L?\ X]_A1SAR!_PI:X_YZQ_^/?X4<X<@?\*6N/\
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M8Y7N/XA[U$I7+C"QW=9FH4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0!^:_P 6/^0QJ'_7_=_^CGH Y6@ H * &T % !0 4 /% "T % !0 4 % !0
M4 '6@!<4 +0 E "T +0 F* /?OV+A_Q-YO\ KPD_]'04 ?:% !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % 'YK_%C_D,:A_U_P!W_P"CGH Y6@ H 2@!* "@ H * '9H
M 6@ S0 9H * "@!: "@ H 7- !0 M "4 +0 "@#W[]B[_D+S?]>$G_HZ"@#[
M0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M!_S]_P#D&W_^-4 +_P --^(/^?O_ ,@V_P#\:H /^&FO$'_/W_Y!M_\ XU0
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MVEM?/_+W_P"0;?\ ^-4 +_PTMK__ #]_^0;?_P"-4 ,E_:7U\=+O_P @V_\
M\:J6-$'_  TSXA/_ "^?^0;?_P"-5-RK#A^TSX@ YO/_ "#;?_&J=R!8_P!I
MO7SUN_\ R#;_ /QJE<=A_P#PTSK_ /S]_P#D&W_^-4KL=@_X:8U__G[_ /(-
MO_\ &J7,%@_X:8U__G[_ /(-O_\ &J.8+!_PTQK_ /S]_P#D&W_^-4<P6%'[
M2^O_ //W_P"0;?\ ^-4TPL+_ ,-+Z_\ \_?_ )!M_P#XU57%83_AI?7_ /G[
M_P#(-O\ _&J5PL)_PTQK_P#S]_\ D&W_ /C5%QV%_P"&F-?_ .?O_P @V_\
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MW_\ C5 !_P -*:]_S]_^0;?_ .-4 '_#2FO_ //W_P"0;?\ ^-4 '_#2FO\
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M ,:H 3_AI;7_ /G[_P#(-O\ _&J8!_PTMK__ #]_^0;?_P"-4"#_ (:6U_\
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M_P#XU3 /^&E]?_Y^_P#R#;__ !J@ _X:7U__ )^__(-O_P#&J #_ (:7U_\
MY^__ "#;_P#QJ@ _X:7U_P#Y^_\ R#;_ /QJ@ _X:7U__G[_ /(-O_\ &J #
M_AI?7_\ G[_\@V__ ,:I '_#2^O_ //W_P"0;?\ ^-4"#_AI?7_^?O\ \@V_
M_P :H /^&E]?_P"?O_R#;_\ QJF ?\-+Z_\ \_?_ )!M_P#XU0,/^&E]?_Y^
M_P#R#;__ !J@ _X:8U__ )^__(-O_P#&J!"?\-,:_P#\_?\ Y!M__C5 !_PT
MQK__ #]_^0;?_P"-4 '_  TOK_\ S]_^0;?_ .-4##_AI?7_ /G[_P#(-O\
M_&J!!_PTOK__ #]_^0;?_P"-4##_ (:7U_\ Y^__ "#;_P#QJD ']IC7_P#G
M[_\ (-O_ /&J!"?\-,:__P _?_D&W_\ C5, _P"&F-?_ .?O_P @V_\ \:H
M/^&F-?\ ^?O_ ,@V_P#\:H /^&F-?_Y^_P#R#;__ !JD,/\ AIC7_P#G[_\
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M#;?_ !J@!1^TYX@_Y_/_ "#;?_&J %_X:<\0?\_G_D&W_P#C5 "_\--^(/\
MG\_\@V__ ,:H /\ AISQ!_S]_P#D&W_^-4 '_#3GB#_G\_\ (-O_ /&J #_A
MISQ!_P _?_D&W_\ C5 !_P --^(/^?O_ ,@V_P#\:H 7_AIKQ!_S]_\ D&W_
M /C5 "C]IKQ!_P _?_D&W_\ C5 "_P##3/B#_G[_ /(-O_\ &J #_AIKQ!_S
M]_\ D&W_ /C5 !_PTUX@_P"?O_R#;_\ QJ@ _P"&F?$'_/W_ .0;?_XU0 ?\
M-,^(/^?O_P @V_\ \:H 7_AIGQ!_S]_^0;?_ .-4 '_#3.O_ //W_P"0;?\
M^-4 (?VFM?\ ^?O_ ,@V_P#\:H 3_AIKQ!_S]_\ D&W_ /C5 "?\-->(/^?O
M_P @V_\ \:H /^&F_$'_ #]_^0;?_P"-4 )_PTWX@_Y^_P#R#;__ !J@!#^T
MYX@_Y_/_ "#;_P#QJ@!#^T[X@_Y_/_(-O_\ &J $_P"&G?$'_/Y_Y!MO_C5
M!_PT[X@_Y_/_ "#;?_&J #_AIWQ!_P _G_D&V_\ C5 !_P -.^(/^?S_ ,@V
MW_QJ@ _X:>\0?\_G_D&V_P#C5 !_PT[X@_Y_/_(-M_\ &J #_AIWQ!_S^?\
MD&V_^-4 +_PT[X@_Y_/_ "#;?_&J %_X:<\0?\_G_D&W_P#C5 "_\-.>(/\
MG\_\@V__ ,:H 3_AISQ!_P _G_D&W_\ C5 Q/^&G/$'_ #^?^0;?_P"-4 '_
M  TYX@_Y_/\ R#;_ /QJ@ _X:<\0?\_G_D&W_P#C5 !_PT[X@_Y_/_(-M_\
M&J $_P"&G?$'_/Y_Y!MO_C5 "?\ #3WB#_G\_P#(-M_\:H 3_AI_Q#_S^?\
MD&V_^-4 '_#3_B'_ )_/_(-M_P#&J!"?\-0>(?\ G\_\@VW_ ,:H /\ AI_Q
M#_S^?^0;;_XU0 #]I_Q#_P _G_D&V_\ C5 QP_:>\0_\_G_D&V_^-4"%_P"&
MG?$'_/Y_Y!MO_C5 "_\ #3OB#_G\_P#(-M_\:H 3_AIWQ!_S^?\ D&V_^-4
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M-4 '_#4?B+_G\_\ (%M_\:H /^&H_$7_ #^?^0+;_P"-4 '_  U'XB_Y_/\
MR!;?_&J /-=6U235YI+F=MTLLCR.V ,LQ+,<  #)).  /04 5: "@!#0 E !
M0 4 % "F@ !H 6@ H 2@!10 X4 % !0 4 % !0 O6@!: "@!I- "4 % #EH
M=F@!: "@ Q0 V@!<T 1&@ H * "@ H *8!0 4@%H$2Q4#): #- ",* (GH 1
M* )TXH ?F@!* #- "9H 7- !0 4 % !0 N* "@ H * %H * "@ H 6@ H *
M"@ H * %H * "@ H * %H * %H 2@!: "@!: "@ H ,4 +0 4 +G% $#/NH&
M5I(C0(9Y9H <(": 'BV]: %^5* $:Y]* (FD+4 )0(*!CPE #2:! O/% R8Y
MAH A;F@0E !0 4 % "YH GMH-_)H&7@,<4 (_2@"A#UJ"T6VI%$>:0"&F FW
M- %J 8%6B&24R1@/- "$XH&(&R* $?I0 UANP:8$ZFD V1-_% $?D4 3*: %
MH ;+TJ&4BL#FLRR)Y#G%4B&31TACZ0Q:!!0 9H <IIH!<U0A,TAA0 AI --
M"B@ I &: "@"6,ULB&/IB"@!M !0 4 +0 4 +0 TF@ I@&:0!0 E #EH =F@
M S0 4 &: #- !0 A- !0 4 % "4 %,!*0@S0 9I@&:0"9H *8PS0 9H ,T@"
M@ IB"@ S0 9H * "@ H&+2 *8"4A"4P"@ H * "@!,T &:0!FF 4 % "4 %
M!0 4 % !0 4 % !0 4@"@!* "F 4 +0,*0@H *!AF@!,TP#- "4@"@!IH :3
M0 PT )0 M !F@ H <* &/0 E !0 HH 6@ H * "@!P% "@4 +B@ H 6@ Q0
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M &* #% "T &V@ VT +MH ,4 &* #% !MH 7;0 8H ,4 +B@ Q0 8H ,4 '-
M!S0 AW>E #?F]* $=6(X_I0! 8'/7^E $@@8=J $\IO3^5 "B)O3^5 "/$Y[
M?RH C-LY[?RH 3[(WI_*@ ^QMZ?RH /LC>G\J #[&WI_*@"9+0B@!LEN[=OY
M4 1_8W]/Y4 6+>U*<GK0 R>!G/3^5 $7V-_3]10 OV-O3^5  +-_3]10(/L;
M^GZB@8?8W]/U% "_8W]/Y4 788RHP: ),4 (PR* *D=LP/2IL7<G,1I6"XPP
M'TI6'<0V[>E.P7%2!AVIV%<L*N*HD7% A/+H -E "[: %VT )LH 7% !B@8F
MV@!"#2 AE#]A_*@8V.)S][^E2T-,<T+5'*5S$!M6]/U%:6)N6A"14V"X>4:G
ME"X>4:=@N'E&ERA</*-.P7%$1II!<7RS3L*XGE&E8+AY1HL.X>4:+!<3RC18
M+B^4:+!<3RCZ4K!</*/I18+BB(T6"X]$(JT)C\51(%: &[#0 ;#0 NR@ VT
M+MH 3:: $V&@ V&@ V&@ V&@ V&@!0AH 7;0 ;: #;0 ;: #;0 ;: $VT &T
MT &V@ VT &TT &PT )L- !L-, V&@0;#0 ;#2&)Y9H /+- !Y9H -AH 78:
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MH 3;0 %: $V4@ +B@ Q3 -M !MH 0K0 !<4 &VD FV@ VT &* #%, VT &*
M$VT &* #% !B@!,4 )B@!&7- #=AH -AH -AH -AH -AH 3;0 ;: #;0 ;:
M$VT &V@ VT &: %H * #- "T % !0 N: "@ H 6@!: "@ H ,T +0 4 % "Y
MH * "@ H 7- "T % !0 4 +F@ H * "@!<T % !0 4 +F@!: "@ H ,T +0
M4 % !F@!: "@ H 6@ H 6@ H * #- "T % !0 4 &: %S0 4 % !0 M !F@!
M: "@ H * #- "T % !0 4 +F@ H * "@ H 7- !F@!: "@ H * #- !F@!:
M"@ H * "@ H 7- !F@ H * "@ H * %S0 9H 6@ H * "@ H ,T +F@ H *
M"@ H * "@ H * #- "YH ,T % !0 4 % !0 4 % !0 N: #- !F@ S0 M !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 &: #- !F@ S0 9H ,T +F@ S0 9H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * #- !F@ S0 9H ,T
M&: $S0 9H ,T % !0 4 % !0 4 % !0 4 % !0 F: #- !F@ S0 9H 2@ H
M* "@ H * "@ H * "@ S0 F: "@ H * "@ H * #- "9H * "@ H * "@ H
M3- !F@ H 2@ H * "@ H * #- "9H * "@ H * #- "4 % !0 4 % "9H *
M$H * "@ H ,T )0 4 % !0 9H 3- !0 4 % !0 F: "@!* "@ H ,T )0 4
M% !0 F: "@ H * $S0 E !0 4 % "9H * "@ H 3- !0 4 % "4 &: $H *
M"@ S0 E !0 4 &: $H * "@!* $H * "@ S0 E !0 4 )F@ H * $S0 E !0
M 4 &: (Z %% "T % !0 M !0 4 ** "@ H * '4 % !0 4 +0 4 % !0 M !
M0 4 % "B@!: "@ H !0 M !0 4 ** "@ H * %% "T % !0 4 +0 4 % !0
MM !0 4 % "B@!: "@ H *  4 +0 4 % !0 4 +0 4 % !0 M !0 M !0 4 %
M "B@ H * "@ H 44 % !0 4 % "T +0 4 % !0 4 % !0 M !0 4 % !0 4
M% "B@ H * "@ H * "@!<T +0 4 % !0 4 % !F@!: "@ H * "@ H * "@
MH * "@ S0 M !0 4 % !0 4 % !0 4 % "T &: %H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ S0 9H ,T % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 F: #- "
M4 % !0 4 % !0 4 % !0 4 % !0 4 !H 3- !0 4 % !0 4 % !0 &@!,T %
M !0 4 % !0 4 % "9H 2@ H * "@ H * "@ - "4 % !0 4 % !0 &@!* "@
M H * "@!#0 E !0 4 % !0 E !0 4 % !0 4 )0 4 % !0 4 (: $H * "@
MH *  T )0 4 %  : $H * "@ H 2@!* "@ H #0 E !0 4 % "4 % !0 4 (
M: $H * "@ H 2@ H * "@!#0 4 % !0 AH 2@ H *  T )0 4 % "4 % !0
..AH 2@ H *  T )0!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form424b4_010.jpg
<TEXT>
begin 644 form424b4_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $G IT# 2(  A$! Q$!_\0
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M=:.S\BI]D3_GDO\ X_\ XT?9$_YY+_X__C5SR_?]/_KT>7[_ *?_ %Z7LO\
MIW5^Y?\ SP+T_DI?^ +_ "*?V1/^>2_^/_XT?9$_YY+_ ./_ .-7/+]_T_\
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M !JYY?O^G_UZ/+]_T_\ KT>R_P"G=7[E_P#/ -/Y*7_@"_R*?V1/^>2_^/\
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M+WPYX>UPZM)JVIZE932.;F8Z!;Z3+';SSZ=J>H6_D2W'\]WP]_9)^.MKXO\
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M?(W"DI.%VG#9NS=M.FJW^\J?9$_YY+_X_P#XT?9$_P">2_\ C_\ C5SR_?\
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MW)<O(K)N5B*M*C5I5(5:5.<+1?+%<C;4XV?,E=6W\]B[']UO\]UJPGW1^/\
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M7;R+7O"-E?:'>:M=K,FE6=KI\6G^7_1R]KO=F\U@KL6="JR+)N01M&PF\T)
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M\-_"<6D:YXL\-0:+I-QX \,Z7:VT.M:YHYU76M:N/%E]KUY!J5N;A _ZD?\
M!0S]L7X[?L=>$K[XF>&_V9/"OQD^!6D:-HH\?>,M8^-6G^ =1TC7_$GC+3_"
M>F:):>";WP7XCDUNS:35[&[N]:EU"PM[E;U; Z6T5LMU-XO\2O\ @HA^T_\
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M']?N?%6M6&HZS>A=:8RS*GG_ .W!^PA^UW\1/VH_B%\6?V;?"V@^#=1^(/\
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MR8N,IMT%1CO3TO[39J]T]-[9G[1/["?[67CCQ+_P4^T;P=X/^''B3PS^V?\
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MIX.1USUYQCOZ>W2J]M:Q6L$-M JQPP1K%$BJ JQHH2-0,\!% '?.,\584;0
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M0/#'QF^,/[1?[8GA+P?_ ,(%XN\9:Q\3_P!H/2-0,?BBP\)?%Q-4^&_C_4O
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M+^/?B1\'?'(USQAX+GL--U.U2'7+GPW$+>TU77[6XL[F]A*:A-J=G.5'V/\
M\$P/V>_B=\,O'7[1'Q-\9?#/XI_!W2_B7;_#'1-+\(_$B[^#^G#Q#K/@7PW>
M:1J?BFP\ ?!K3D\/>&$L$,&DQ:J-0BN?%UN(]=OH(=4N-0C3GKY;AN7VE/,'
M-K_EU[\;;N^L5#UMT=]+:]F%XESBMF6%IXC+52PDY..*Q*H3DXTU%JZBH2FU
MS\NBB]=5LF?IH?VA/@;!\1(/A#-\7/AM'\3]S1K\.7^(&@CQT)Y81>0V(\*'
M4VUF2]-DQN7TZ2U%Y;Q*)8K>2REAF'@_P@_X*#?LL?&6/XM:CH/Q7\)Z#I7P
MB^+-_P#"76]6\7^+?"FA:;KFNZ39)=OK?ARYN-?N(;OPMJ:VFJPZ)?2BQGU&
M70]3D-G;RPS1I^-WB#]CW]J7PU^WQ>?$#X2?L^^)+'0M:_;"L/C#K]Q\3Q\%
MOBM^SY-X"U!X1XJ^,W@[X@ZG;:!\9_AA\7(M%ENK32/ ]DNL:?I5X%BMWU.V
MM+:2ZY'Q%^P+\8==N?BG\''_ &0;>3PEJW_!6OX7_M"?\+ M4\ R>#O&_P"R
M]?W>L-<>'K=)KYO$":%X&L+EWGM+F!F-QKNH:;'#;VMNEW?[0P6&C&-L5&3?
M+S)NW*GK)OFTTVM&3>]D]SBQ7$&?^TS"G# <U'ZS6I9>_J]3]]2E0:IRMR*5
M)N<5?G4&K^]9:G[N>'_VQ_ACKOQ&\5>&(]1\+P?"_P *_"7P5\6;/X_3_$OP
M!_PKGQ'9^-M?U3PW;:?IK+KAU"U@M+^Q*)K6KQZ=I>HSNUAI;W,\.&]AT#]H
MKX%>(]$\5>(]!^+_ ,,-;\.^![VWL_&?B#1/B!X5U?1?"EU?S1QVUOXDU/3=
M2NK+0[B>>=5CAU">#:A7SV@F$MO#_.A_P5!_9S\2_#71O^"C7Q)TKX<:%X/^
M VK_ +%/[-'PL^'UWI4.A^&O",OBGPU\>K?4]?\ !&G:/I[VUI8Z0+#4[*S2
M)[-X+:2ZN&L%L[RUEOKSQ[]ICX$_$.R^!W[?G[1FH?LM:=^Q]\%T_8/\"_ R
MY\"+J7A^]@^)?Q&TGXJ>%-?U3XB2:5X/EN+:Y\-Z?X>MH=!L_%VNRG7=4M;J
M2^OV1X+UI*CEV%J6F\0KR2U=NO)[NF[NY:)7NKVY;"J<4YK0Q-6A4PM2M5_V
MFJJ$,-7CRTWF&)G3FYNDJ5EAY4;1Y^=\]K<T96_J=\)_'[X*>/H/%%UX#^*O
MPZ\:VW@II%\7W'A7QQX:UVW\+""RDU*XE\17.FZA<VFC6T=C&TXO-0N+>T)#
MI)/%Y4C+2\._M&? WQ?X4\0>/?"?Q@^%WB;P3X2N)K3Q3XM\/?$+PCK?AGPQ
M<6\B_:8/$6OZ;J\^DZ+-;*)1=#4KNWCA=&C620C)_FIO?V'_ -I3X^Z!\8=9
M^$_[,MK^R!IVJ_\ !/?P=^SO:Z/!XH^'NF6O[0?Q.M/$VE>,;G5+3_A7NJMI
MEYH-QX3M[O1;#Q-XIL9+K58]4C348M/-I=6*\S#_ ,$^/VH?'_P9_:(U32/@
M5\0O"&M:GX<_96L;GX-?$76_@IX-TKX_V'P)\56WB7QKX-L? _PNTNW\*V6F
MF'S+;P[XT\6/>ZIXHDM[>VU73I9KR=UM99@U=O%16JT>K2N[IVNM;*S6R=I:
MW2RK\69S[.JJ.48B4_JV+=)JG*/-75&F\-%72Y>>JZD&Y62Y>9M1<6_V5\9_
M\%6_A)H&M_M(P>#_  KJ/Q5\&?LT> ?@E\4_%GQ$^'GBKPWXB\.ZW\/?BQK1
MT_7]>\,_V7)?27UU\-=)2[US7M*D>*2Z2QN;3[1IP3[8?U&T35;+7=&TK6]-
MNK>^T[5].LM3L+VTE$]I>6=];QW-M=6LX51/;7$,J303JH6:)TD4;6%?RY>(
M_AWXQ^&&D?\ !6?]I3QS^R;<?LL?!SXV?LE> ?"'PY^'DC> 4_MGQG<Z=KG@
M2#2KC1O ]Q-#8^)M5\7W^EL?#MM$L>HP:_I<+SVE]<97^B']D_PAX@^'_P"R
M_P#L[^!?%BRQ^*/!WP3^&/ACQ%#-(\SVVMZ'X-T?3=3LQ+(JR216=[;36L+R
M#S###&7+-ECPXS#4:-&$Z=12DYQBXZ-I.ES.[C>-X27*[-IO57O<]O(\TQN/
MS+&4Z]*K3P\:..G0=2G."DEG^+AA?CC%ISREX6M9I22GR22J1G"/T!1117F'
MUH4444 %%%% !1110 5DW?\ KF_#_P!!6M:LF[_US?A_Z"M>+G__ "+I?]A&
M&_\ 2ZH/X*G^%?\ I<2Y']UO\]UJPGW1^/\ ,U7C^ZW^>ZU83[H_'^9KT*7Q
M4_\ #5_](P1<_BGZQ_(=111740%%%% !1110 4444 %%%% !1110 4444 %>
M3_&SXV?#O]G?X3?$SXX_%S6G\,_"_P"$7@SQ!X_\>^)H=/U+6_[#\,>&-._M
M75KN32-#M-0UN[N(K)99XK33M-O)9HXPPPSJE>L5\5_\%#_@+XP_:I_8B_:Q
M_9I\!ZCH.C>,/CE\"/'OPP\*ZMXHN+J#P]9ZYXN\/:GIL$NLRZ?97]];:>AE
MB\ZX@MI),N/+V,@<'JTMM6TDKZ7;>B7F]%U&DY2C!:RF^6*[NS=E\DW\CP?X
M(_\ !8W]B?X^_&#X7? KP;JOQQT#XB?&A]=C^&%K\4_V8/VB?A#X?\9R>&O#
M5_XPU=- \7?$KX9^&/#>IM'X:TR^U>U^R:E*MU:1*X:,R +^I$,GG1I(%9 X
MW!6:)SMR=K;H9)8V###*5D8;2,X.0/Y^_!'[.O\ P5!^,/[3W_!/'QI^TW\.
M/V//A7\*/V)/$_CWQ1=7OP9^-OQ(^(?CWQ9+XD_9X\6_!;3].AT/Q;\*/"FB
MVUBMUK]C=W-VFHQ2.X?;I\.\3)_0% =T2G:$!+X1>BC>V%/) 91@, =H8$+A
M0!4PJ4ZCJ>SJ4ZJI3]G-TJD*D8SM?EYH-Q;2WLVD]'KH2KZWC*+3:Y9QE"3M
MI=1FE)Q[22<6K--IH^3/B7^W%^SI\(OVF/AK^R/X]\87.A_'#XO_  W\;_%'
MX;>&I=$U26V\7Z!\/DEG\2:?HFJ0VTEG>>)8;*UO]0M-"607-[::=?&W9YX1
M;OT_P7_:T^!'QZ^'/P9^)W@'QYHK:#^T#X T7XF?"32O$-]:^&_&?B_PEKUH
M+^ROM.\%:M-;^);F1+5XVN8K+3;P1REX4DE:-C7Y7?\ !2W_ ())^,/V]/VF
M8/CIHWQ"\._#._\ AQ^Q9XX^&?P$^(5O/KB?$;X3_M90?&[X>?%CX6_$RQM[
M/1OLC?#F'0O#_BSPAX_%EKTVLZ]HWBC4O#\6A^1YEU+^=G@'_@@?^U?X2E^
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MV *B.'V;5.YMHPOV>/.\$"0@J9/+C+LAQA&<J\A484\L3N Y"X46]O\ N_\
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M%0JTYMJFU&;M&3:4922;:2NTKW)****DH**** "BBB@ HHHH **** "BBB@
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M?A7PU;:;IZV=DOP>DU'QEK_@[4[W7!J^@Z?+JLU]]GUDQZ?^J?Q;_96^(O[
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MJ,9_IY;7&;97\AD<N0R#/!68PMN5L,K!@0X90RLI#*K#:-F"821[F 4^9,I
MR?N2N@.<#[P7/U-?GS:>)?C#^RM$EIXPGUOX\_ R%52'QWI-G-=?%/X=Z>C%
MHV\6Z)&]Y>>.]"TZ O"VN:,Q\416=O;->Z+K5REYJUW]B^"_B3X5^(/AVV\5
M>"]7TWQ-X?O]AL-3TJ]BDAG:09>&<2I!]DNK>;?;75K+_I=M<1O%=V]M<+)!
M%^C\/\08/'UIY56PW]A9Q"I64N&\9.A#%8/V=:I"<Z%>,W0Q\,PD_KL/JE;$
M2HTF_;QI3C7A3_%<XX8Q&2X6&:4<?0XCX<Q?LJ66\7X&498#-71HU*LIUZ+E
M[?*,?4I22EEN:PR_%OZO.5'ZU1E0K5_1RZ_7V _QP/UI0<C.,9SP?K[5\5?%
MCX]_&_P3\8O!OPS\(_!KPOXHL/B!-J<7A76]4^(T_AR2^;PWH<.M>)5N[7_A
M#=5CM&L8/M LC]JE6_$<(1XC+\OV!87MQ,@6XMEA</*I>-YGA9%E=8Y [VT0
M!DC"R.A+>4[-%YDFS>WI99GV6YOB\[P6!J8B5?AW&4\OS1XC X[ T(8JK1]O
M&&#Q>-P^'PN:05+6I6RRMBZ-*35.I.%3W%&;</9ADN#R/'8OZA4H<0X&>8Y>
MLNS3+<UKT\)3=.,I9IALNQ-:ODU252;I4\/F<:.(JU:.*IPI.>%KJ.M7R=^U
M=\4?BC\'/ &J>/OA[X8\'>(K+1#%+XA@\3^(M5T&[$<\VG6.F'2DL-!UN&^%
MQ>WIM[LSRZ:+18EDC%\TC1Q?4OVOYF7R\[<=&.><?>S& /8 MD?6OCK]N?4(
MK;]F?XK22F",3V&BPHUY<-';R2R>(]!C$$7F20%IM@:=(XVB*F.6<*^QV;S>
M,\=3P7"O$..ACZ6$EEF5U\PJ5_;PC&C2PWLY5*E67-RQI14TYRES175;N/J>
M'N%P^8\>\%99BLOPV9T,VXIR/**F&QM&M/#5(YICHX*:;A[*49^SJ3M-2@J:
MO4E448N_T!X U#QC=^&=&N?'FE^&=(\2W,=V^OVOA;4[W5]"MI%N9C;165_J
M&GZ9=R/_ &>UHUZKV<*1ZB]U! TT$44S^DVH"P*%144-(%522N/-?# GGYQ\
MW_ JX733YND6"6;PW2S6ML09+L;K@2VMLK.LR)+'(8T1)T=&8SB7:QB<'/<V
M>[R!NV\23A=K;AY8GD$7)5>?*V;ACY6RN6QN/MY6I1RC)HU<12K8AX"'M^7$
M4:TJE14Z%1U$Z56<:T4J]/EK4N>DZ52C.,^6K%R^/JSA/'XN-/!83#4Z7M7&
M>%HU*=+GJYKF\)T*%2:<)1HT\+15>E"I.>&J\M&N_:1+-%%%=XPHHJK-<-&Q
M5(O,(5S]_;\ZQ^8J$;&P7&,'MG.#2;LKV;_PQ<G]T4W;S$VHVOHG*$$^G-.2
MA&[V2<I).3M%7NVD6J*H1WI9 9(A'+M5WB\S<8PS;1N;RU]0<;1P15N)VD0,
MR;#N<%<[N%=E!S@9W !NG&<9/4U).,E&2:;3:TNFDTOB7N]597NUJKI,.:-W
M%2C)QG5IMP:G%3HN*J1<HMQO%SBM];NU[.TE%%%(84444 %%%% !1110 444
M4 %%%% !7X8?\' Z^'KW]A>P\/>*/CS<?LXZ/XI_:$^!VD7?C_6_#7Q$UKX+
M:TD'B*>[M?AS^TMJOPVU31?%'@WX">-;^2*P\=>+]*U.%K&W2"*6*=$D4?N?
M6'K/AO1/$=CJ.E>(=+TW7=(U>%;35-(UG3=/U/2]2T]58?V;J%C>6LUO?V'F
M/+<+!>QSA)YI61A&WE@ _@F_9]^.OCKPUHW[%G@KX1_&W1OV9?A%X3_X+?S_
M  G^)6M_"3XN?$#]H?\ 8J^(VJ>*O@DOBFRT[]G'QY\3W\,^+[#X"7>NZ1JO
M@>V^$GB:[\2^'--^)/C:Z\0'Q"%M(-!D^G=-_;0_;7^*O@/]@G]JWX]?$GX;
M>/?^%@_M_P#[47@WX2_#G2OA?;^%)/A'I'P#^$O[6FB:;XDU'Q!I?CRTM/'?
MB7QCJ_A#2[E]-UVP7P?IVEQ:7$FF7-U>;[?^Q&'X1?#&W\-:9X*M_A[X%M_!
MFC:E8ZOI7A.W\):-#X>TW4],F%YINJ:?I"VW]G6.L6.HJE_;:M:VL5]%.B.D
MRRKYIRO%'P2^'?C#P3J/@'6/#&@PZ!J>B>*-%,&C:/9Z3_8O_":Z5JFD>*-4
M\)K 'C\,ZSJ-KJ]_LU6P0WT<EW=R3W%W+>74DH!_$OH__!>3]O#3?V9?$GQ5
M\/\ [2?[/7[0GBW7O^"?_A_]K#Q;%X.^">E^%M*_8P^+ND?M _#CX;7/PN^)
M:Z1K^H3>+(/B9X2U3Q-)!!KLFA>(9-5TV^\0>#-.N_"6HZ!!;>Q?$?\ X+-_
MMN^%-$^)OPQ^'G[0'P0_:!\%V7[:?[.7P'T#_@I)\//AE\+_  /\./#7@[XS
M? +5?C?XZ\'S^&OB!\4-(^ FG>._A[XLMM,\$>%/$7Q ^(&CZ9H+7MQ9?$34
MH/%T]JES_2M??\$O_P!DF[_8GD_8#MO".K:-\ [SP3\.? .L-H>J6VF?$#Q!
MH?PJUC0M<\%3:_XX@TW^T=5U?2K[PYI?EZK=1/="!)X49%G;'V&_PA^&<GA'
M4OA^_@'P._@36?M"ZMX*D\(Z%+X2U-+V\-]J U#PY/9RZ1>RWUZ(=1N[FXM)
M+BZU2W@O;N2X$,,$8!_#I^V)_P %9?VQ_CO^QOK_ (.^+_Q[_9Z_96T?QE_P
M2T^*GQOEU;2_!UMXWTS]NKXA:E\5OB!\#QX#^!GC#4/$=FO@?6[3P/X>\/\
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M/B'/HNK:98V^HM/+JEO8QV6D:?(JZA<W$M]*TTDSPWTLMS:F%FC6+R;2-?\
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M?V3JX>JHZM%48[U9 O"!B<%?,8 ?7S(HW'XQ@'G!.*F%P"<;2!ZG/^'\B?\
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MUXY\7?'S2K_6=9U*?XC_  4TQ]"\#_#GX)>'KV^;5O -KI_B"-]!T"6^^Q
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MOXE?!^\^U>*VURXTZ'1X/B7H6@G78[6'1;L:@^BSWMOI<OD6;B'?!$?N522
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M8_+*V2Y=CLVR/Z[@,PQ^!P&.GF=7A_V6!PV5S='VF8Y?BI4<>X5LIPN)Q?\
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MO"5<NKU<'C,EQ. Q&&PN<Y'Q7EN38WZE3Q/]L>PJTL-BJE/+)5:.'J3HM/\
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M!<?9&N:58ZK::CINI6EIJ5A?:=/:WUEJ5I]LL[JSFB>.:"YB;$$L4Q;]_%<
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M\4Z_\2)C="0NUQ';>)[Z\L;5F;[L=G:V\$**D4$4<2)&/I'1/#&C^&K1=/\
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M%X(=="CTC7/&O@KQ'<W-O\2-&N)K"UT/5;2]L[?4=02,7DO]5'\T']=L;B1
MXQABV-K*X(#$ [E)4D@ D D*25R<9+ZAMP1#'EMQQDN&9E<DDET+R2MY3DEH
ME:1BL95<\8$U !1110 5DW?^N;\/_05K6K)N_P#7-^'_ *"M>+G_ /R+I?\
M81AO_2ZH/X*G^%?^EQ+D?W6_SW6K"?='X_S-5X_NM_GNM6$^Z/Q_F:]"E\5/
M_#5_](P1<_BGZQ_(IS.&D>,Q[R &02(S#<OEI(R(ZPQ/"B7*;W%R26:5 N8B
M#_"E^T7\<_V!]<_;O^+NC>)/V)7C\#?"W]N77=5\2:YH7[;.O>!/BI\7_B[=
M?M4?LX?";XRZCJ'[+J7]I::W\-V^+LOP^^,6C_">*YTF'XM6_P -[SXFV<NE
MQ/?>(-7_ +KI5VN[$<,ZR8D>:2%M@AC 9=YC@7+MD+&4#A;MU9HV#?QYZ3\(
M?BG\+O\ @HO\8?C1X[^"?_!)C]HC5-7_ ."BVI>!/A5^TE\;_C[IFA?M-_#&
MX\=V.F^+?A[\%+W1](^&UUX5_P"%U:;\*K)=5^&6AZX]EXKO(+W0M L];$D5
MGJ4O40?N!_P5;\0W5Y^S?XC^!$O[%?[3/[:7@7]H_0?%_@#X@Z5^S-J'@C3_
M !7\/;#RM-G@\4SZIXN\4Z UCKFEZBT%_P"$I[<7D-CK6E+'-;2Z?$;&+\Z_
M^"//PD^-I_:F^)/QC_:J^%O_  4GOOBCI_P!T_X,_#;XV_MX:=^S]H'AWPS\
M(;3XA6^HK\*/ MO\#;EM0U7Q]K^HWMIKWBGQ]XFAAO/$L/A]#;6NDR7EQ=77
M[7?MR>)OVB?"'[)7Q_\ %7[)>D6FO_M*>&?ASK&K?!K0[K0].\31:WXTM&C_
M +,T>[TG6-3TG39X=39;C37GU#7-,M+19[G4+FY%MIK_ &GYG_X)_P#[>WQK
M_:YUO4O#OQ._82^-?[-">'?!=OJNJ_$?QCXS^#WB[X?ZYXF@U.T\/:MX0\,7
MOP\\5ZYJOF_VF-4U+2WO+>.U.E:-J2+>1W5E]@H _4ZT!%O&6W;WW22*RQ*R
M22NTDD;"$"/=%([1DY=R5)EDEE+R/^)G_!QI_P H:OVV_P#L0_#7_J?>&:_;
M>W8/!$P*L&C1@4D,R$%004E94:5,$;)64-(N'/)-?B1_P<:?\H:OVV_^Q#\-
M?^I]X9KR,^_Y%&-_Z]TO_4S+3ULA_P"1WE?_ &%_^ZN8'^7%_P $F_\ E)Q^
MPS_V<C\+/_3]:5_MI6W_ ![Q?[@K_$M_X)-_\I./V&?^SD?A9_Z?K2O]M*V_
MX]XO]P5UU?\ DH,?_P!@&&_]3\6<G_,IP/\ V&XS_P!0L"3U_,)_P69;X?\
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MP@K]B:_';_@N]_RCE\<?]ES_ &1/_6J/A!0!^PZ]#_O/_P"AM3J:O0_[S_\
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MRTSX0?"7QUX]UK]F/]IW0?$'AG2+;4]/T+X@_"GQ7X;\+7,]UJEEH]K;:O\
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M3]KK_DW+XX?]B!JW_H%O7C\7_P#)*<4?]DUQ#_ZI<P/;X:_Y*7AG_LI>'O\
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M_P *-&UG0O#&J_$C5],TV:XTWP;9>)?%"QZ#I+ZQ=,;5+R^>6&UEG,A\TO\
M8Y/Y!O"/P+_;XOOVJ=9^+NC?L-_\%DOV>-%^-W[3-E\</BGX1\ _\%.OV7M
M^!UIJOB?QEHK>,-8U[X<>#=%DU[4/#<>E6,%SJ7AVWNVOM;TS3FTH7A^V_VF
M.H@_>K_@L9\5/@5\//\ @GO^TEX+^-/[3GA[]E>V^+OPG\<?#3P?\1M7O-4>
MY/BF_P##-T4\/Z+I&@:E8>(_$6I:KIMM+!-X;T"]N/%VHZ(VM2:%9WUU:2X_
M"7_@WS\&^!O 7[</Q*T:R^.W[">M^)+']F/X@7GAGX,?\$\?&_Q#^+_P\E\
M>,/VFX?'$_B'XG>-=;=?!_A'Q!\-M4UV;PQX&^&5Q;GXB)X:\6ZQJEY=(L$V
ME'^@G_@K7X3NO&W_  3L_:R30/@+X#_:2\9:'\)_$OB/P5\-?'?P]LOBUI5[
MXFT?2;B>QUBP\$744@UKQ/X8TF[UK6_#.EP3VEW<ZTEGIL%[##K$UU7XL_\
M!$37?VK_  S^W1\>?@-\=!+>Z'X-^!^JWGB&/0/V!?@A^QOX2TS6;7XI:/IW
MPDUF_P#%/PY\,:?-\2A\4/@YKUGXI_X1+3?%&LVOPRU*W?PEJ^E:MJ'AZYUN
M@#^M*!UDC#!HW.^17\N3S466.1TFB$AY)AE5XF!"%&0H8XRIC7\2/^#C3_E#
M5^VW_P!B'X:_]3[PS7[;6Z[(E7>\A!<L\C^8Y<R,T@9@2H*N679&$BBQY<,4
M42)$GXD_\'&G_*&K]MO_ +$/PU_ZGWAFO(S[_D48W_KW2_\ 4S+3ULA_Y'>5
M_P#87_[JY@?Y<7_!)O\ Y2<?L,_]G(_"S_T_6E?[:5M_Q[Q?[@K_ !+?^"3?
M_*3C]AG_ +.1^%G_ *?K2O\ ;2MO^/>+_<%==7_DH,?_ -@&&_\ 4_%G)_S*
M<#_V&XS_ -0L"3U^<O[7_P"RQ^UI\4O&EC\3?V1OV[_&G[,7C"#PW'X3\0?#
M/QO\+?!GQ_\ V:_'6CPM?W$=_J/PU\61:-K'ASQB\FI/;WWB?PAXXTIM4TZQ
MTS3]3TR>.UE>Y_1JOS%_;._X*+^)OV2_BQX<^%/AG]@K]MK]K:Y\1^!+/QU/
MXD_98\#^#_'.C>'X;KQ!J_A[^Q]=M=5\?>'-:T_48FTC[>\@TPZ>]G>0NEVT
MPE0=AR'(_LY_L?\ [>6B_$GPEXY_:R_X*,3_ !+\,^ ;X7GAO]GO]F[]GOP!
M^SG\'=1@?3[G2]+MOB)J5SJ7Q!^(_BS0]+:.>6R\*Z1XS\,Z$)+#2;:]L=1L
M].@LV_5V&'C<9)"=[N Q<F.4O)YR1M*-QMR2$BC*!%C163(*%?PT_P""67Q
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MG&,&XNI&7\>/_!17]O?]M/X6_M@>'K/7;?X=_#?Q3\#=.M_$G@+0=#@A\?\
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M6'X=P-&MA\&HUZN)<I4JDDY7450FIMRFW57M)5%:<DWSMRE^7<%<'9Y1XO\
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MN^./&&B>%-/\7^'O$7C2YTVZTV:]U_6=8CT:WO!=-)#_ #O]$&__ !"['?\
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MNXD<.X!9RFY\MY6YO))\H,0F:FH **** "LF[_US?A_Z"M:U9-W_ *YOP_\
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M ,I./V&?^SD?A9_Z?K2O]M*V_P"/>+_<%==7_DH,?_V 8;_U/Q9R?\RG _\
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MROZ&6N/(A#O$0B(1^Z4E2X=(XHH8U!D<2LV(V"!2 "0H8 ?C/_P3+\)_LJ_
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MK6GZ;H.L>&=;TZWU?2=<LK_4I[2)M.OM,N[>]@N)C"KP2I(H9&5C_#)\;O\
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M/@WXJR_LH>'OBA\-O"'Q%\(/J.H#Q/IFF33:;8:4VGWTNN:O/=3W+_K'\/\
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M_P $A+E0T?\ P4/_ &70/F)\[XE:9;X10<N1<+$X7<-F2HRW0$8)_ SXT_\
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MG> _#&F>%[*1E>WM6"M;Z7'Y>;>+,6PA<$$^N4 %%%% !1110 4444 %%%%
M!1SS^G'\^>?THHH ;@Y!R-O)(*Y.[H"&R ,#C&TD^HYS^?O[77_!+3]A']N;
M6=-\5?M)?L]^$?&/CO1[6/3M-^)>C7&O>!/B9::1$XD71QX[\#:QX?\ $5WI
M;'=#)IVIWM_I[6<US:I:1K.[5^@E% 'P#^R;_P $N_V$OV'M5U#Q-^S+^SMX
M(\!>.M8L9-*UOXEZE_;7COXG:OI$BR;](NOB'X[U?Q%XOATB65H&N-)T_5[+
M3)X+2SLVLUM;6VBA^^XHUB18U"A5SC:BH.223M0!0Q)RQ55!8DA5!P'UD:OK
MFG:#I^I:MJUQ%8Z7I%I-J&IZA=30VMI8:?;P27%Q>W5S=O;P);P10S/,Z2R>
M6L9+ '( !;N+U+=MI7<>-QWI&J*W_+1GF:-'6/K,D+37"*\3"!Q*M?C_ /\
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MQ3_PO?\ :X_Z,D7_ ,21^'?_ ,S],;X]?M;J#C]B+>0LI"I^TG\- 6>-8G2
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MN[ZE01*, %@JJ=GSS,0V" 6+S$.H7'RD9W#<&!/%J,;4 R6Z\D 'DD]!QQG
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M@YX>E7:?+*5)-/1Z?#IK9W?8_)?XS?\ !3OQS?>(?@!I7P/T^'X=67Q)U/\
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M@ K)N_\ 7-^'_H*UK5DW?^N;\/\ T%:\7/\ _D72_P"PC#?^EU0?P5/\*_\
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MVG3Q9_PCIE-_I>D-J<S3WL1F@>.ZG /VV63<H)5ESG *EN,G:<IN7YAA@,Y
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M?XB_%/\ :Q^$-Q^T7!?^+O&7C#]D?]LO_@N?XD^&_A?Q!9:_XJM]2_9@^/\
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M.I2VUT]QY.E2QH&K]&S#RY# ;\*0$D :(E-P?$@+3;?,"3AEVF0%D?9AGB,
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M,;8S;S;EP"8/+( &!5JHX@1&,G+$L6.) -S,2VT2EG5=Q.Q22%7"I\@45)0
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MXXXXTBCBC08CBBCC54CBB0+'$@'RQJH)8@L9: "BBB@ HHHH **** "BBB@
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M8"Z$PSSQE9G /RO_ .&A?^"U_P#TC2_8^_\ %A.N?_0K4O\ PT-_P6J'+_\
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M-+70=.;]_O\ @GK^PUJ/PL^&7PY^+G[5VA>"_B3^W4?#GC#0?$G[0WB7PWX
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M;Q?XEG2^T@R60A^*OVL_^")GQH^!O['W[0OP8_9WT#Q'^U!\>?VQ_CS^S?\
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M:.?^Y5_\%R_^2"WFO_ H_P#R1-14/FO_ ,\F_7_XFCS7_P">3?K_ /$T<_\
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M;S7_ (%'_P"2)J*A\U_^>3?K_P#$T>:__/)OU_\ B:.?^Y5_\%R_^2"WFO\
MP*/_ ,D345#YK_\ /)OU_P#B:/-?_GDWZ_\ Q-'/_<J_^"Y?_)!;S7_@4?\
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M>.O%:Z%I&DZ)K7CCQ/J22ZWXD\0RZ*LVK:Q>7UZ\2/=REA\T;<U.LK]Z4O\
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M%'L:/_/JG_X#'_Y$/JU'^3_R:7_R0;D_N-^8_P#BJ-R?W&_,?_%444>QH_\
M/JG_ . Q_P#D0^K4?Y/_ ":7_P D&Y/[C?F/_BJ-R?W&_,?_ !5%%'L:/_/J
MG_X#'_Y$/JU'^3_R:7_R0;D_N-^8_P#BJ-R?W&_,?_%444>QH_\ /JG_ . Q
M_P#D0^K4?Y/_ ":7_P D&Y/[C?F/_BJ-R?W&_,?_ !5%%'L:/_/JG_X#'_Y$
M/JU'^3_R:7_R0;D_N-^8_P#BJ-R?W&_,?_%444>QH_\ /JG_ . Q_P#D0^K4
M?Y/_ ":7_P D&Y/[C?F/_BJ-R?W&_,?_ !5%%'L:/_/JG_X#'_Y$/JU'^3_R
M:7_R0;D_N-^8_P#BJ-R?W&_,?_%444>QH_\ /JG_ . Q_P#D0^K4?Y/_ ":7
M_P D&Y/[C?F/_BJ-R?W&_,?_ !5%%'L:/_/JG_X#'_Y$/JU'^3_R:7_R0;D_
MN-^8_P#BJ-R?W&_,?_%444>QH_\ /JG_ . Q_P#D0^K4?Y/_ ":7_P D&Y/[
MC?F/_BJ-R?W&_,?_ !5%%'L:/_/JG_X#'_Y$/JU'^3_R:7_R0;D_N-^8_P#B
MJ-R?W&_,?_%444>QH_\ /JG_ . Q_P#D0^K4?Y/_ ":7_P D&Y/[C?F/_BJ^
M4?VPOV-?@E^V]\(=4^$/QFTO6(H#J.D>)_ _C[PAJ*>'_B9\(_B)X8N'O_!_
MQ.^%WB^.&XO?"_C;PGJACU'2+Y$N++SHWAO;"[M+J]@N2BCV-'_GU3^<(O\
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M/_R(?5J/\G_DTO\ Y(-R?W&_,?\ Q5&Y/[C?F/\ XJBBCV-'_GU3_P# 8_\
MR(?5J/\ )_Y-+_Y(-R?W&_,?_%4;D_N-^8_^*HHH]C1_Y]4__ 8__(A]6H_R
M?^32_P#D@W)_<;\Q_P#%4;D_N-^8_P#BJ**/8T?^?5/_ ,!C_P#(A]6H_P G
M_DTO_D@W)_<;\Q_\51N3^XWYC_XJBBCV-'_GU3_\!C_\B'U:C_)_Y-+_ .2#
M<G]QOS'_ ,51N3^XWYC_ .*HHH]C1_Y]4_\ P&/_ ,B'U:C_ "?^32_^2#<G
M]QOS'_Q5&Y/[C?F/_BJ**/8T?^?5/_P&/_R(?5J/\G_DTO\ Y(-R?W&_,?\
MQ59-](%D!\J9ARH$)BR,*C$N)98QR7PNUGX4[@O&XHKY_B>-*EE%6?L*4[8C
J"+EDI*.M6HKOV4Z4M-TN>U]T]+9UJ4*5&I*FN65HJ]V]'.-])-K7T/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>form424b4_016.jpg
<TEXT>
begin 644 form424b4_016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &E NX# 2(  A$! Q$!_\0
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MHK\4?^(B3_@C[_T==K'_ (C/^UM_\XFC_B(D_P""/O\ T==K'_B,_P"UM_\
M.)H]G4_Y]S_\ E_\B'M:?_/R'_@2_P S]KJ*_%'_ (B)/^"/O_1UVL?^(S_M
M;?\ SB:/^(B3_@C[_P!'7:Q_XC/^UM_\XFCV=3_GW/\ \ E_\B'M:?\ S\A_
MX$O\S]KJ*_%'_B(D_P""/O\ T==K'_B,_P"UM_\ .)H_XB)/^"/O_1UVL?\
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MW/\ \ E_\B'M:?\ S\A_X$O\S]KJ*_%'_B(D_P""/O\ T==K'_B,_P"UM_\
M.)H_XB)/^"/O_1UVL?\ B,_[6W_SB:/9U/\ GW/_ , E_P#(A[6G_P _(?\
M@2_S/VNHK\4?^(B3_@C[_P!'7:Q_XC/^UM_\XFC_ (B)/^"/O_1UVL?^(S_M
M;?\ SB:/9U/^?<__  "7_P B'M:?_/R'_@2_S/VNHK\4?^(B3_@C[_T==K'_
M (C/^UM_\XFC_B(D_P""/O\ T==K'_B,_P"UM_\ .)H]G4_Y]S_\ E_\B'M:
M?_/R'_@2_P S]KJ*_%'_ (B)/^"/O_1UVL?^(S_M;?\ SB:/^(B3_@C[_P!'
M7:Q_XC/^UM_\XFCV=3_GW/\ \ E_\B'M:?\ S\A_X$O\S]KJ*_%'_B(D_P""
M/O\ T==K'_B,_P"UM_\ .)H_XB)/^"/O_1UVL?\ B,_[6W_SB:/9U/\ GW/_
M , E_P#(A[6G_P _(?\ @2_S/VNHK\4?^(B3_@C[_P!'7:Q_XC/^UM_\XFC_
M (B)/^"/O_1UVL?^(S_M;?\ SB:/9U/^?<__  "7_P B'M:?_/R'_@2_S/VN
MHK\4?^(B3_@C[_T==K'_ (C/^UM_\XFC_B(D_P""/O\ T==K'_B,_P"UM_\
M.)H]G4_Y]S_\ E_\B'M:?_/R'_@2_P S]KJ*_%'_ (B)/^"/O_1UVL?^(S_M
M;?\ SB:/^(B3_@C[_P!'7:Q_XC/^UM_\XFCV=3_GW/\ \ E_\B'M:?\ S\A_
MX$O\S]KJ*_%'_B(D_P""/O\ T==K'_B,_P"UM_\ .)H_XB)/^"/O_1UVL?\
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MW/\ \ E_\B'M:?\ S\A_X$O\S]KJ*_%'_B(D_P""/O\ T==K'_B,_P"UM_\
M.)H_XB)/^"/O_1UVL?\ B,_[6W_SB:/9U/\ GW/_ , E_P#(A[6G_P _(?\
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MHK\4?^(B3_@C[_T==K'_ (C/^UM_\XFC_B(D_P""/O\ T==K'_B,_P"UM_\
M.)H]G4_Y]S_\ E_\B'M:?_/R'_@2_P S]KJ*_%'_ (B)/^"/O_1UVL?^(S_M
M;?\ SB:/^(B3_@C[_P!'7:Q_XC/^UM_\XFCV=3_GW/\ \ E_\B'M:?\ S\A_
MX$O\S]KJ*_%'_B(D_P""/O\ T==K'_B,_P"UM_\ .)H_XB)/^"/O_1UVL?\
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MW/\ \ E_\B'M:?\ S\A_X$O\S]KJ*_%'_B(D_P""/O\ T==K'_B,_P"UM_\
M.)H_XB)/^"/O_1UVL?\ B,_[6W_SB:/9U/\ GW/_ , E_P#(A[6G_P _(?\
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MHK\4?^(B3_@C[_T==K'_ (C/^UM_\XFC_B(D_P""/O\ T==K'_B,_P"UM_\
M.)H]G4_Y]S_\ E_\B'M:?_/R'_@2_P S]KJ*_%'_ (B)/^"/O_1UVL?^(S_M
M;?\ SB:/^(B3_@C[_P!'7:Q_XC/^UM_\XFCV=3_GW/\ \ E_\B'M:?\ S\A_
MX$O\S]KJ*_%'_B(D_P""/O\ T==K'_B,_P"UM_\ .)JO=?\ !Q;_ ,$>+.VG
MNY_VK]:$%M#+/.Z_LR_M;-Y<,*-)(Y4? G<VU5.%4%V.%168@%JE4;LJ<[_X
M)?Y('5I)7=2%O\2_2_?L?MM12 A@&'0@$=N",CBEK/\ X*^:T?XF@5\2?MZD
MCX0^&<'&?B9HH/N/^$8\89'XU]MU\1_MZ_\ )(?#'_93-%_]1CQC7Y5XX_\
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M?X48/J?T_P *6BC7O+_P*7^8679?^ Q_^1$P?4_I_A1@^I_3_"EHHU[R_P#
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M_P# I?YA9=E_X#'_ .1$P?4_I_A1@^I_3_"EHHU[R_\  I?YA9=E_P" Q_\
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MHU[R_P# I?YA9=E_X#'_ .1$P?4_I_A1@^I_3_"EHHU[R_\  I?YA9=E_P"
MQ_\ D1,'U/Z?X48/J?T_PI:*->\O_ I?YA9=E_X#'_Y$3!]3^G^%&#ZG]/\
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M7M\-^,_C)^V7_P )MX2_:7^!WP#_ &BO"GP>\+_![Q;^RGXR\$67[5/P$D^
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MH *Q?$G_ "+VN_\ 8'U+_P!(YJVJQ?$G_(O:[_V!]2_](YJ'L_1_DQQ^*/\
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MIU*E6K5G.I4J5)SG.<Y2G.4I2E+\>O\ AP;_ ,$E/^C/M _\.I\?/_GJT?\
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ME;1.VB;&J%-\S5&DU!1<GR4_=4Y^SC>\%K*?NI*^K5[718_X<&_\$E/^C/M
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M9M1A-V3;?++3W9-*5*E!2<J5)**YI7IP32;BDW>"T<IP3;LESQ=WS14O /\
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M<&_\$E/^C/M _P##J?'S_P">K1_PX-_X)*?]&?:!_P"'4^/G_P ]6O?O O\
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M *,^T#_PZGQ\_P#GJU^PM%'M:O\ S\J?^!S_ /D@]C2_Y]4O_!</_D#\>O\
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MX^?_ #U:_86BCVM7_GY4_P# Y_\ R0>QI?\ /JE_X+A_\@?CU_PX-_X)*?\
M1GV@?^'4^/G_ ,]6C_AP;_P24_Z,^T#_ ,.I\?/_ )ZM?L+11[6K_P _*G_@
M<_\ Y(/8TO\ GU2_\%P_^0/QZ_X<&_\ !)3_ *,^T#_PZGQ\_P#GJT?\.#?^
M"2G_ $9]H'_AU/CY_P#/5K]A:*/:U?\ GY4_\#G_ /)![&E_SZI?^"X?_('X
M]?\ #@W_ ()*?]&?:!_X=3X^?_/5H_X<&_\ !)3_ *,^T#_PZGQ\_P#GJU^P
MM%'M:O\ S\J?^!S_ /D@]C2_Y]4O_!</_D#\>O\ AP;_ ,$E/^C/M _\.I\?
M/_GJT?\ #@W_ ()*?]&?:!_X=3X^?_/5K]A:*/:U?^?E3_P.?_R0>QI?\^J7
M_@N'_P @?CU_PX-_X)*?]&?:!_X=3X^?_/5J"Y_X("_\$C[N"2VG_8[\/R03
MH\,\9^*WQ^420R(R2)E/BNK?.C%>HQG=R0!7[&44>UJ_\_*G_@<__D@]E2_Y
M]4__  7#_P"0 9P,\G'/UHHHK,T"BBB@ HHHH **** (Y"!M/IDXXR0,$]2!
MP!SDBOYQ_$?_  2^\%?M;_\ !7[]O;XI?M._"CXZQ_""[_9Y_8OT?X+?$#P9
M\7_C[\!?"WBWQ%IFE?$NU^).E6GB/X*_$#P%!XWN_#>SPY%J&F:[-K \.R7B
M26D%@=6EEN_Z.BN2#TQGZ\C!P>Q]Z_*3XJ_\$3_^"77QC^)/CCXL_$[]D_P[
MXL^(OQ+\4:OXU\;^)+CXA?&;3[G7O%'B&\GU#6-6EL-&^(UAI5K)>W<DT[VV
MG6%E9P[BD%O%&%00TE)3?13BK-J_M*3HK7I.//)T[.TI.*E?2,FI.,:L5M55
M*,VU>RIUHUM/*4HQ@[IM?96MU\%_M#:W\5OV)/\ @LYH?[27AK]A_P#;A_:F
M^ #_ /!)/X:_LI:/K?[+'PTT_P",>IZ+X]\/_M3^/_'HTGQ5K?Q#^)/@@75Q
M8>"]+TRYU*^NO$6M>)+JYU[1[R]M[G^T+B^3XL\;_L&?M_?$7]B?XV_L\/\
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M07]I[XP_L67>@^%X_&WQ=^%'Q2U3XEZ%\'_CY\._ 7Q0U3P]X4^)FN?"R_\
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M)_=3\VH]I3_F7_@-3_Y6%_+\8?\ R9;HJIY\G]U/S:CSY/[J?FU'M*?\R_\
M :G_ ,K"_E^,/_DRW153SY/[J?FU'GR?W4_-J/:4_P"9?^ U/_E87\OQA_\
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M/X:KNKFF 6-R*M6>!W?^&8?BG_T>U^TO_P"#H?\ RWH_X9A^*?\ T>U^TO\
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M/A]\5]5^*UW\2]$\)6_Q U;P58? O2_ E[\;M3UZR^'5Y8_%"2UT[X>7:/\
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M(^N"03W/!+L#W_,_XU@_#+@M-KZCGVC:O_K]XC:[:_\ )?NV^UW9IZO<Z/\
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MT76-9A^*=P9="\3^'?!MWX/F^&7QDM?BO=^(/%^@>(_%OA*U\._!*[^'=O\
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MPS6][7<O#6*5TG9RE%:-WLFU@?\ #,/Q3_Z/:_:7_P#!T/\ Y;T?\,P_%/\
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M]3QU!%?%/_#>WP>_Z$KX\_\ AI[W_P"6U>=?$[_@H)H%IX3U5/A3\.OBA?\
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M/^&]O@]_T)7QY_\ #3WO_P MJ_4J?BYX:TIJ<..>'U)*:3]OF%USTZE-M?\
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M?'6M>"_ [?MQ?MH_M=>"-8^$>E>(M1O? &O^.(_"G[:/C?X4>*-'^*_A#7O
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MP',P7DD =R>!Z#\?R_&OBC_AO;X/?]"5\>?_  T][_\ +:JUU^WU\'88F?\
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M $)7QY_\-/>__+:OUK_B+/AG_P!%SP__ .#\P_\ H>/R_P#XA'XG?]$-G_\
MX*RS_P"B0ZW]J']ESPE^U'??L[:?\0M$\'^+?A_\'_CGJGQ>\7^!_&NCOK>E
M^-+-_P!GKX\?"+1-(MK4_P"B0ZEI?BWXM:!XPAO+\&VAMO"UW$BM?7-B\?/6
MW['_ (0\%?%7X3>*O@KH/P[^$/PW^%W[./[7'P3MOAOX+\)6WANSG\1?M-^/
M?V:O':^,K6+0[:VTW-GJ/P-\0W?C*ZU"*?7_ !3K?BRPUBYOKJ\M]1N7I_\
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MBYHWA^Z2[9GFU3P[IOBZVT?5+N#%G=WUG/<6:);R1HOE'_#>WP>_Z$KX\_\
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MK4+R:6ZNIG/4U\3?\-Z_!T=/!7QY]?\ DD][U/)_YBWK1_PWM\'O^A*^//\
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M^'] O=&\ ^"/A]X$TWI?^&]O@]_T)7QY_P##3WO_ ,MJ/^&]O@]_T)7QY_\
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MMS=W++NE)?K:^)O^&]O@]_T)7QY_\-/>_P#RVH_X;V^#W_0E?'G_ ,-/>_\
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MAZGI_ANYTNW6)[N!:^A/^&]O@]_T)7QY_P##3WO_ ,MJ/^&]O@]_T)7QY_\
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M (AY#_H<2_\ "!?_ #:/_B8NI_T2,/\ P^O_ .=)_I>?VUHG_09TK_P;6O\
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M >Q#MD>XSD9'49!'J#4M%%E_3?\ F'*NQ7CMQ&Q;S)')=W^<IU<8()5%) '
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MU[_@E9\5M5^/.H_M+^'OV5/ASX"^*\7_  6-_8:_:$\$>,++7/@_;>/?AO\
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ML[7DD[J,I1O:U^5V;7E?;O9O:P1;<8MJS<4W\[O35Z-6:UZ_<4444AA1110
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MC6R\=ZK>>#O'_P /[GQ[JFE?$R 6'C_2;+Q1XHU3Q+\2/%'C#Q#I'CVS\6>
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MB#/VD_\ HA'P+_\  GQ__P#-'0/^#@[]I9<A?@5\"UR.OVCQ^W//;_A) /\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^TM^S_X'^-'_  4MT/X+> /VM?@1\&/!]O\ LH?\$V_V4OVC/V;/ /A3QO\
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M9)P"0/< J< DX(.!3MP[D=0.O<]!VY/85^#_ .W]_P %.?&/["G[1OQA^R^
M/'/QF\-_#']A[]G[XV6OP@M?B7\+O ?@GQ1XN^,_[>FC?LL->:9/>_L_:_\
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M=X7FU._L? G_ (*S>-_VQ/%O@RU_8X_9&U'XQ_#F'X4?L>?&#X^>(/&OQO\
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M\8_%_COP]::K;17>FZ?8O&M?0M]^R;\!M3\.?LR>$[OP0\^A_L=^)/!_B_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM.IAO94ZF88VK3ITZ:J1CR8:C7HX-RC2I1D\-37L,,H4Z=8"@=!_.O7O@/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD_X<C?\ !.OK_P *F\7YQC/_  N;XM^N<_\ (X]1QCMQTZY_6:BG_;><WO\
MVKF%^_UJKS?^!7YTO)32MI:UTX7 G!2VX3X?6^JRO#)ZKE=FFFKIM.S3:;NW
M=M_DU_PY(_X)V?\ 1)O%_P#X>;XM_P#S8_\ UO3 H_X<D?\ !.S_ *)-XO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%M96GB?XV_L__MW?L_\ ["G@GXI^%?@#_P %$?V%_P!F_1/ >N?L[? CP?\
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M/VFO'B: OAWX/:_X@;2_%']I^+;73;WP?X7U\W=M%I?@_P <^,K36M%G\&^
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M%#WZF%C5DHPJU9TZ]11G'V4:'U>E5GRSORJM5J5L3A82G4E+#THTJLZ<W5G
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^?M2?^'3@_\ E!1_PPYX;_Z+[^U)_P"'3@_^4%'_ !$SQ)_Z-+@O_%N\'_\
MT-"_XAUX:_\ 1XL9T_YM-Q7T7_94G:'_ ()"?\$JN,?\$V/V&./^K6/@Y_\
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M_P!%\_:D_P##IP?_ "@I?\1,\2?^C2X+_P 6[P?_ /0T'_$._#7_ */%C/\
MQ4W%7_T4G:#_ ()"?\$JA_SC8_88)_[-8^#G\O\ A#L?YS1_PZ(_X)2KP_\
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M<_\ AT)_P2J//_#MC]AC!Y_Y-8^#@X(XZ>#\ ^M!_P""0G_!*H_\XV/V&/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\3^#OC8_@CX@1^!O%_B/]M+XD_$KX4?#[P+?#4/!FEOX%UBS\>^"_#O@MO\
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M6/V=OB%XH^"W[*7@+]C_ ,0>*OVG?V'_ (:?M1Z7K'@#X=W&L:AX=^(/P?\
M!?Q#^(-C9? OXPZ?J7BOQG(FJ:AK'Q?^&OB"QUG2=.^)'PI^(4?@SPM/I^5&
M67TZN+HUYJI15:<<-BZ4:W/4C3IXJG.I2<_WN$I8R>&PDZ4YTGB*5*K2C5A"
MM*LJ:K5,TJ3PU>E"K&$\+.56A4C3<XU95L/[.G4Y9RA*I2P\J[G"$IT9XCFC
M&I4P\8RG]2?%'_@H3\$? 7@S]I7Q+X4TCXF?$[4/V;?AW\>_&6HCP]\*/BQ;
M_#'QWXJ_9X\/W^K_ !%^%7@_X\)X U7X7:EXWT#4K)]$\0Z=I>L:S?:1+:>)
M[JPTK7D\">-K?0H+7_@H'\%[&YBT_P 467Q+7Q9X@\36'A;P;\+?!/P(^/GC
MSXN3:]!^RY\%_P!J/Q%X4\2?#_0/AO>:YIWBOP_X'^,NGZO>Q65M=Z-::0+7
M2]2U.T\<V/B+PQI7C'C/_@EQI?C7XH_&WQG/\6=$\%^&/C)\/?CC\.=7MOA#
M\"?#7PA^+WBWPO\ &[X/^*/@U;^!OVAOB?X!\;:+\,_VE?A9\$](\3Q>(_@1
MX>\;?LY:-\1_ ^O^"?ANE]\8_$EAX;UJW\6>S?"C]BO7_ GQR\)?'[Q9\7]'
M\8^+]%\<:]\0/$6D>&OA1?> /#&NZWXC_8[_ &9_V2M2M-"M]6^+7Q(U?POI
M"C]G1?B+90:AK'C"]@7QB?!<]_=MX<'C'7R4<KC&\*]9V@I**G5C)N%/%)4Y
M<JY(NO4I8=U5",O9J2=.4N=!*IFLISDZ+?+"4:>B:E5<L*XMV:DZ<(3Q48U)
M.+E]I14-='7?^"CW[(NA:9X+\0+X[\9>)/"?CSP;\!O'VE>./ _P/^-GC7P-
MH7AK]J#7]*\-_L^/\0?%_AOX?ZAH/PQUCXKZEK-A_P ([X:^(5[X;\2:?9W-
ME?>*M(\/6FKZ#/J_W3@JS1N%$B$JX4JPW*2K[64LK -D JS J5.?F%?SX:S^
MP3^UO\+K7P7^R1\%8E\0?L\>)?!/_!._1?BW\=;K3OA5'::_X@_8YUWX9:#X
MP\::AI/B/X\>&_BI\"]2\1?"KX2^'O#[^!? 'P<_;*T+XI-I_A:QL?B7^S-X
M@G\=>-+K^@TL2[2'C<S$ 8P"Q7(&!C ((&"1C&.",\^,HX6GAJ4Z5?VCJ.;D
MJF(]HU2<8MJM2ERTZ7O3]E&[ESQIMS3N[]>$K8NIB:\*T%[*"M"2I>S;G[6<
M8WNW=RHJ%6I%.4:<YRBI)1T\M^,7PA\#_&_P5J/@'Q]I8OM'O2;FROX3%'J_
MAS64AGCLM?T&ZFCF6#4[4S2HR.DMK>VLD]AJ%O=6-U/;R_(GPC^+_C7]G[QI
MIO[-O[3.J+/97!%O\%OCC=F2#0_%VC121167ASQ)J5](ZV=_:^=;V$<^H7#7
MNF7;V^E:O=7EE>^']<OOK#XV?&GP7\"/ U]XZ\:WA2(;['0-#MV0ZQXGUTQ/
M+;:1I$#$;I''[R]O7(L]*LU:\OI(T,*3_-'P6^"OCKXJ^--/_:7_ &G;('Q.
ML<<WPC^$4P8Z%\+-$,K7-AJ&IZ9<%E;Q6^Y+Z&WO(A>:?>_\3O5PGB(:=IOA
M?\"XT4I^(?#=/@&:AXE499>N)JM.:_U>H>'$Z\IXRCXB1HNG*;E*.)EP%A</
M.7%$<ZG6Q&2UL-P_4SZ5;]WX.E[/@#B5\<N_AQ568OA>E4<O[>K^(T,+".#J
M^'CFI0HJC-T*7'V*Q"?"M3(X0P>;4L5Q LA>&^Z=3O[#1].U#5M5NH=.TS2;
M&\U/5+ZY#""PT_3K>6\O[N<*"XCM;6&::3"D@(>#7Q!\*OVE_CQXVT/X8?&W
MQA\"/AKX'_98^+O@^3XDV_C-_CRR?%GX%?"N_P#AIX@^+'@[XF?M#^#/&'P^
M\%?#W3]'UOPUI6D:5\0= ^&WQ2\:ZU\&_%OBG3+;SOB?X)TKQA\0/"_W)>6E
MKJ%I=6&H6EOJ%A?VUQ97]C=H);6_L[N%[>[L[J,Y$EM=0R207"$$-%(X(()!
M_.2S_8-\=ZM\+-&_9<^)'[3VM^*/V./"/PP\2_!CP]\*_!WPXN_AE\:_&/PN
MUCX1>+?@CX>\!_M ?M$V?Q6\2Z-\5?"W@;P/XM2XTJU\&? OX+ZOXK\7^#?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]1?(C_VO^^F_QH\B/_:_[Z;_ !H_XA;X@_\ 1Y<3_P"*L\/O_GT'_$3> _\
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M?V=?$OQTCUZU\Q%T>>SOI= ;3]?N=;O;"TTC1C<ZDD[20^6WWJZY&1G*@D
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M$J]&T3QA\#_$^H?&;7]5B^#O[8O_  4)_:TET^+P/8::WB>7]OG2/CUHVK^
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M6-<N_BCK-EX-T_3[S5&ECBO:O_P6,_8UT?P_\--2,/[1FK^+_BIXQ^+OPO\
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M:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KS;XO_"SPW\:_AKXP^%GBZ;5K?PYXVTG^QM7GT.[M['5XK7[3
M!=!["[NK/4+>"=9;>,AYK*Y0KN4Q-GCTFBFFXRC*+:E"2E&2T<91=XR3Z-/5
M,4HJ491DDXR3C*+U4HM6::ZIIV:['Y.G_@CA^RJ3G_A(/C7_ .%GX8_^88_S
MQ2?\.</V5/\ H8/C7_X6?AC_ .86OUCHKM_M/,?^@[$_^!K_ .0./^S<O_Z
ML/\ ^ /])GY.?\.</V5/^A@^-?\ X6?AC_YA:/\ ASA^RI_T,'QK_P#"S\,?
M_,+7ZQT4?VGF/_0=B?\ P./_ ,K#^SLO_P"@+#_^ 2_^6'Y.?\.</V5/^A@^
M-?\ X6?AC_YA:/\ ASA^RI_T,'QK_P#"S\,?_,+7ZQT4?VGF/_0=B?\ P./_
M ,K#^SLO_P"@+#_^ 2_^6'Y.?\.</V5/^A@^-?\ X6?AC_YA:/\ ASA^RI_T
M,'QK_P#"S\,?_,+7ZQT4?VGF/_0=B?\ P./_ ,K#^SLO_P"@+#_^ 2_^6'Y.
M?\.</V5/^A@^-?\ X6?AC_YA:/\ ASA^RI_T,'QK_P#"S\,?_,+7ZQT4?VGF
M/_0=B?\ P./_ ,K#^SLO_P"@+#_^ 2_^6'Y.?\.</V5!G_BH/C6<@@C_ (3/
MPR,@@@_\R,.Q/<?45]]_ CX"?#7]G+P#8?#KX8:(=+T:VEDOM2U&\FCO?$'B
M?6ITBCNM?\3ZJL%N^J:O<QQ0P>:8H;:RL[>UTS3+2QTNSM+*#VBBLJV,Q>(B
MH5\36JP4N;DG.\>:UDVE&-VM;7;2;;M?4TI8/"4)NI0PU&E-KEYX0M+EO=QN
MW*R?6UFTM^@4445S'2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
A%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>form424b4_017.jpg
<TEXT>
begin 644 form424b4_017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #O DT# 2(  A$! Q$!_\0
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MK)"^ PW*>S*58'H0016I7B>@B[?]L3Q;)8DG1_\ A"M+74-OW/MGVR\,.?\
M;\G?^!6O;* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /,M4_:,\#Z+J/
MBFSO+S4(6\*LBZY/_9-T8=/#QB57ED$>T(8V#[@2 IR2!79:=XRTC5=633;:
M\26YEM%O[?:<I<V[8_>Q,.'4%E!(Z;ES]X9^-_'<,VJ>-OVI[2/Q-KOAI=:2
MPM[--/T=KC^TBNE1Q2)%F$N^7#1'RF!&3@@\UZ#;V^N1ZK^R?$^@+X4UN""X
M34M#MV9DT^S7266:#)).U)?LJ\D\A>2>: /J*BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH SM)T&QT62]EM8=L][-]HN9F)9YGP%!9CR<* H'0  "M&BB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ K/CT&RCUR36/)WZB\(MA.Y)*19!*+
M_=!(!..I SG QH44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 445X5H_[1-SKG[5VH?"Z*Q2VT>RT.:Z6XN()DN+J\CEAW>62 GDJDN-W
M.YPW3 R >ZT5XI\._CSXH\0?&"7X>^,/AS)X)U!]&FUNSN1K4.H)<0QW$<+
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M6C7SQ^W5\.?"GBC]G+XA>(-9\,Z1JVNZ+X=O9--U*^LHYKBR81E@T3LI*'<
M>#U KWK0Y&FT33W=BSM;QLS'J25'- %ZBBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HC;0M<+<
M&)#.J&,2[1N"D@E<]<$@<>PJ6B@#P34_^3[/#_\ V3J__P#3E:U[W7@FI_\
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M1\3KCX5>%[;5;;2O[7>:Z6W,.\I@%6.[(!_N_K7B_P#PV;JW_0D'_P "7_\
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M8(XV3A.2&XXKZOK^6'2V9-3M"I*L)D(*G!'S"OZF+/\ X\X/]Q?Y4 34444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHKRC]I"U\'W'@:WD\<>%-5\6:#;W:RR1Z2KLUH0C#SY DB-L )!QN/S#CT
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M]%CTP6<0U&US&51W\S)P=Q(QCIS7RS_P7(_X^_@__N:I_.UK[?U/_D^SP_\
M]DZO_P#TY6M?$'_!<C_C[^#_ /N:I_.UH _+&OU'_P""97_)EWQO_P"PHO\
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M'9;2CC:[AR>[&T5;7EU=E&*U:>NYZ31117WI^;A1110 4444 %%%% !1110
M4444 %4=<F>WT34)8F*21V\C*PZ@A20:O5!?6JWUG<6SEE2:-HV*]0",''YT
M 9/@2\GU+P/X>N[J5I[F?3K>665NKNT2DD^Y)-;M4=#TF+0=%T_3(&=X+*WC
MMHVD(+%44*"<=\"KU !1110 5E^)]-L=4T*[AU&QCU&T51.;:1=P=HR'7C'4
M,H(]P*U*AO)I+>UFEBA:XE1&985(!<@9"@GIGI0!\6?LH_%7P/+\3-,T7PQ\
M*?#/A)M>LDN&U#POKT=_Y+^3/*L-U&D2>7(JQR@JQW(9%!'SU]LUX#^R_P#%
M#Q#\1;KQ"FMZ!I^G+ L-T\VG:-=Z<+:[E+^?8S"X&9IHMB;IH_E;>.!QGWZ@
M=V]PHHHH$%%%% !1110!XS^V=_R:?\6_^Q:OO_1+5ZMX?_Y .F_]>T7_ * *
M\I_;._Y-/^+?_8M7W_HEJ]6\/_\ (!TW_KVB_P#0!0!H4444 %%%% !1110
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MQZ_"_3?^0E:?]=4_]"%?NA^V'_R/6@?]@A/_ $8]?!\;?\B>7^*/YGZ1X?\
M_(]A_AE^1X-7W#^R/_R1NU_Z_+C_ -"KX>K[A_9'_P"2-VO_ %^7'_H5?G7
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MUX;N)+JS6[CDO<117!B5I))Q;I&B%0H;=\QR ?K18T7!"*".F!0(4"@!% &
M!CICI0!\CZ'^V]XCUK0M%U5/A]"MM/#+>7K?VFS?Z.EY96V8 L1W29ON4?9@
MPMV(-8GB/]O/Q++\/_$6HV'@B+0+V&6^MK2^U>\/D6\D-I/,D4RK&6%R6A55
MB("N6P&XK[3\F,# 1<>F!ZY_G1Y:<C8N&.3QU/K0!\J?M@>)OB%?_LGZY-I>
M@Z+J.BZEX.FFU[4+[49+6XM-]N"[0P+$XD."QVEUY %?4&AA5T33PC%D^SQ[
M688)&T8.*\G_ &S./V3OBV!_T+-]_P"B6KU;P_\ \@'3?^O:+_T 4 :%%%%
M!1110 5Y!^TQK_BSP_X-TZ?PFUU%=/?*DTME'YDH38Y V[3\I(Y/; ]:]?HK
MAQV'EB\/.A";@Y+=;H]'+\5' XJGB9TU447?E>S]3XLUCXB?%R+PCX;FBN=:
M2ZF-WY\D=J6D?;(H7>OE_+@9QZC-3>)_B%\6[?7]+CM[C68X7LK%Y%AM2Z,S
M1(7+'R^&))+#L21VK[-HKY&7#.)DO]^J?9_!6[]=_P#,^YCQ=A8M/^SJ?VNB
M^T[_ ,O39?A8^2_!?CKXGW?QIL[#4)]6.BMJDD<L,EL1 (@S<;_+'R@ 8/?
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M ->Y_P#I+/O&OYAOC%_R5SQO_P!AR^_]*'K^GFOYAOC%_P E<\;_ /8<OO\
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MV%6&:<XRC?F6EU;L?0E?S#?&+CXN>. ?^@Y??^E#U_01_P ,7_"[_GT\2_\
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MQHI49W9(SECSP*XG3_V=_C3XSCOI_%,AU>YLM0N]/L9-3:WMV6QBF9;?:(U
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6OT- $U%0_:HO[WZ&C[5%_>_0T ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>logo_002.jpg
<TEXT>
begin 644 logo_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #Y!#P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ?*'Q^_P"2H2_]>D/\C7E]>H?'[_DJ$O\ UZ0_R->7T %%%% !
M7O?[-/\ Q\^(/]R'^;5X)7O?[-/_ !\^(/\ <A_FU 'T)1110 4444 >;ZO\
M;_".B:O=Z9=C4/M%K(8I-D *Y'H=U4O^&@_!/IJ?_@,/_BJ^?/B-_P E&\0?
M]?LG\ZYB@#ZJ_P"&@_!/IJ?_ (##_P"*H_X:#\$^FI_^ P_^*KY5HH ^JO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGG_DG<O_ %^R?R6OEJOJ7]GG_DG<O_7[)_): /6J*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH 9-*L$#RN<*BEC7FM]=O?7LMQ(>7/
M]!V%=/XLU$QPK8QG!D^:3Z=A6!HNGG4=1CC(_=K\SGV%>#F%1U:JH0_I_P#
M/>R^FJ5)UY_TO^"7[7PK<W-K'.9HX]XW;6!R*F_X0ZY_Y^HOR-=> %4 # '
MI:[EEV'2LU^)PO,<0W=/\#C_ /A#KG_GZB_(T?\ "'7/_/U%^1KL**?]G8?^
M7\6+^T,1_-^"./\ ^$.N?^?J+\C1_P (=<_\_47Y&NPHH_L[#_R_BP_M#$?S
M?@CC_P#A#KG_ )^HOR-'_"'7/_/U%^1KL**/[.P_\OXL/[0Q'\WX(X__ (0Z
MY_Y^HOR-'_"'7/\ S]1?D:["BC^SL/\ R_BP_M#$?S?@CC_^$.N?^?J+\C56
M_P##5Q86C7!E20+U"@YQZUW5,EC2:)HY%W(PP14RRZ@XM15GZE1S&NI)R=UZ
M'G>DWQT_48I\_+G:_N#7HP(8 @Y!Y!KS74;)K"_EMSDA3\I/<=JZWPM?FYL#
M;NV7@X&?[O:N/+:KA-T)_P!/J=>94E."KP_I=#>HHHKW3PPHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BJ]U?6=BF^[NH+=/[TT@0?K6--X\\(VYQ)XFT@'T%XC']#0!T-%<J?B5X*
M!Q_PDVF_]_A4L?Q"\'2_=\3Z5_P*Z1?YF@#I:*S;3Q!HM^0+/6-/N">GDW*/
MG\C6E0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/_GGIO\ WX/_ ,51_P -"^,_^>>F_P#?@_\ Q5>3T4 >L?\ #0OC/_GGIO\
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MMJN$W0G_ $^IZV8TE."KP_I=#=HHHKW3PPHHHH **** "BBB@ HHHH ****
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M0QK_ /U[Q?\ H35X77NG[-/_ "&-?_Z]XO\ T)J /HNBBB@#Y0^/W_)4)?\
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M@/\ A)-3_P">X_*C_A)-3_Y[C\J/[4H]F']EUNZ._HK@/^$DU/\ Y[C\J/\
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MP'_T#)O_  (?_&O1J* /.?\ A1O@/_H&3?\ @0_^-'_"C? ?_0,F_P# A_\
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M **** /E#X_?\E0E_P"O2'^1KR^O4/C]_P E0E_Z](?Y&O+Z "BBB@ KWO\
M9I_X^?$'^Y#_ #:O!*][_9I_X^?$'^Y#_-J /H2BBB@ HHHH ^)_B-_R4;Q!
M_P!?LG\ZYBNG^(W_ "4;Q!_U^R?SKF* "BBB@ KZE_9Y_P"2=R_]?LG\EKY:
MKZE_9Y_Y)W+_ -?LG\EH ]:HHHH **** .2^)_\ R3'Q%_UY/7Q;7VE\3_\
MDF/B+_KR>OBV@ HHHH **** "BBMGPQX6U;Q=K$>F:1;^;,W+.QPD:_WF/84
M 8U;VC^"?$VO*K:9HEY/&W(D$1"G\3Q7TOX*^"WASPO'%<7T*:IJ0 )EG3,:
M'_90\?B>:]) "@   #L* /DBW^!?CVX0,=,@B!_YZ72 _D":FD^ GCM%RMI9
MR'T6Z7^N*^LJ* /CB]^$'CNQ!,F@3R =?)=9/Y&OL6,8C4'K@4ZB@#Y0^/6N
M-JGQ%ELE?,.G1+"!V#$;F_F/RKR^MCQ9J!U7QAK-^3G[1>S2#Z%S@?EBL>@
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M\@>K5\O5D\7B;1VV^1]/2BL)AKRWW^9HQ>$;<Q(9)WW[1NP._>G_ /"(6O\
MSWD_*NBHKW5@\.OL(\)XRN_MLYW_ (1"U_Y[R?E1_P (A:_\]Y/RKHJ*?U/#
M_P B#ZY7_G9SO_"(6O\ SWD_*C_A$+7_ )[R?E7144?4\/\ R(/KE?\ G9SO
M_"(6O_/>3\J/^$0M?^>\GY5T5%'U/#_R(/KE?^=G._\ "(6O_/>3\J/^$0M?
M^>\GY5T5%'U/#_R(/KE?^=G._P#"(6O_ #WD_*LS6O#R:=:"X@=G ;# CH*[
M6HYX([F!X95RCC!%9U,#1E!J,4F:4\=6C-.4FT>?Z+?&PU..0MB-CM?Z&O1
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M^_Y*A+_UZ0_R->7UZA\?O^2H2_\ 7I#_ "->7T %%%% !7O?[-/_ !\^(/\
M<A_FU>"5[W^S3_Q\^(/]R'^;4 ?0E%%% !1110!\3_$;_DHWB#_K]D_G7,5T
M_P 1O^2C>(/^OV3^=<Q0 4444 %?4O[//_).Y?\ K]D_DM?+5?4O[//_ "3N
M7_K]D_DM 'K5%%% !1110!R7Q/\ ^28^(O\ KR>OBVOM+XG_ /),?$7_ %Y/
M7Q;0 4444 %%%% %G3M/NM5U&WT^RA::ZN)!'%&O5F/2OLSP#X)LO WAR*PM
MU1KIP'NK@#F1\>OH.@'^)KQ?]G;PP+W6[[Q%/'F.R40P$C_EHPY(^B_^A5])
M4 %%%% !1110 4444 <D?A?X(9BQ\,V!).2=G_UZ3_A5W@?_ *%G3_\ OW_]
M>NNHH Y'_A5W@?\ Z%G3_P#OW_\ 7H_X5=X'_P"A9T__ +]__7KKJ* .1_X5
M=X'_ .A9T_\ []__ %ZZ/3-,LM&T^+3].MH[:TAR(X8QA5R23C\235NB@ HH
MHH **:\B1J6D=44=2QP*Q=0\8^&M*4F^UW3X<=0TZY_(&@#<K)\2Z]9^&O#M
M[JUZX6*WB9@,\NV.%'N3Q7G7B+]H'PMIBM'I$=QJUQV**8X@?=FY/X#\:\(\
M;?$37?'5TK:C,([2,YBM(>(T]SZGW- '*S2M//),_P!Z1BQ^I.:9110 4444
M %?8/P7_ .25:/\ 23_T,U\?5]@_!?\ Y)5H_P!)/_0S0!WU%%% !1110!'<
M0)<V\D,@RKJ0:\VO;5[*\EMY!\R-CZCL:]-KF/%NG%XTOHQDI\LGT[&O+S*A
M[2GSK>/Y'IY;7Y*G(]G^9>\.:B;W3A'(<RP_*?<=C6S7GFAZ@=/U)')_=O\
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M_FU 'T)1110 4444 ?$_Q&_Y*-X@_P"OV3^=<Q73_$;_ )*-X@_Z_9/YUS%
M!1110 5]2_L\_P#).Y?^OV3^2U\M5]2_L\_\D[E_Z_9/Y+0!ZU1110 4444
M<E\3_P#DF/B+_KR>OBVOM+XG_P#),?$7_7D]?%M !1110 4444 ?7WP5TI=*
M^%^F';MDNR]RY]2QX/\ WR%'X5Z#6-X1M19>#M&MU& EE$,?\!!K9H ****
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M->T*7'#6LB_DW_UZ^CJ\1_:1TEI_#FCZL@R+2Y>%\=A(H(/YI^M 'S=1110
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M9"I_2JE% '?67QH\>6*A5ULS*.T\*/G\2,UH_P#"_?'6W'VBQSZ_91FO,**
M.]OOC-X\OU*MKC0J>T$21_J!FN,U#4[[5;DW&H7D]U,?XYG+']:JT4 %%%=5
MX5\ :SXKL=0U"VB,5A8P22R7#K\K,JEMB^I./PS0!RM%%% !1110!J^&9A;^
M*M)F/1+R(_\ CPK[J!R,U\"VTQM[J&8=8W#_ )'-?>=E,MQ8V\R'*R1*X/J"
M,T 8'Q$_Y)QXC_[!TW_H!KXFK[9^(G_)./$?_8.F_P#0#7Q-0 4444 %%%%
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MN?\ P+D_QH ^2J*^M?\ A0_@+_H'7/\ X%R?XT?\*'\!?] ZY_\  N3_ !H
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MJ<G^L7ZBOK/_ (4/X"_Z!US_ .!<G^-*/@1X"!!&GW.1_P!/<G^- 'H&G?\
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M?_"7ZC_SRM?^^&_^*H_X2_4?^>5K_P!\-_\ %5<_X0S_ *?_ /R#_P#94?\
M"&?]/_\ Y!_^RHY,P[O[T'-E_9?<RG_PE^H_\\K7_OAO_BJI:CKEWJD2QSB)
M54YQ&",_7)-;/_"&?]/_ /Y!_P#LJ/\ A#/^G_\ \@__ &53.ECYQ<9;>J*A
M5P$)<T=_1F=X:T\W>HB9E_=0?,3[]A7=U3TW3XM,M!!$2><ECU)JY7K8/#^P
MI*+WZGE8NO[>JY+;H%%%%=9R!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
G!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
